<SEC-DOCUMENT>0001711279-22-000016.txt : 20220509
<SEC-HEADER>0001711279-22-000016.hdr.sgml : 20220509
<ACCEPTANCE-DATETIME>20220509160703
ACCESSION NUMBER:		0001711279-22-000016
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220509
DATE AS OF CHANGE:		20220509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Krystal Biotech, Inc.
		CENTRAL INDEX KEY:			0001711279
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				821080209
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38210
		FILM NUMBER:		22904907

	BUSINESS ADDRESS:	
		STREET 1:		2100 WHARTON STREET
		STREET 2:		SUITE 701
		CITY:			PITTSBURGH
		STATE:			PA
		ZIP:			15203
		BUSINESS PHONE:		(412) 586-5830

	MAIL ADDRESS:	
		STREET 1:		2100 WHARTON STREET
		STREET 2:		SUITE 701
		CITY:			PITTSBURGH
		STATE:			PA
		ZIP:			15203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>krys-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:27464c84-a11a-4d8c-aabe-cd82bfdc0a8a,g:c7af04d0-bbfe-49f0-8ddd-58863f20a4c2,d:1d18f2ca829a4240ba3639a9ab04fa9c--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:krys="http://www.krystalbio.com/20220331" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>krys-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180L2ZyYWc6NGQ3MTE0NmFhOWMzNGIyMDgwMzBjODRkNTY1ZjY3ZGYvdGFibGU6ZDgwODY0N2Q3ZWEyNGM5MTg3MzE4YTliZDZjMTI1YTYvdGFibGVyYW5nZTpkODA4NjQ3ZDdlYTI0YzkxODczMThhOWJkNmMxMjVhNl8zLTEtMS0xLTIwOTc3_b569c529-9686-499f-b144-9516b391f4b3">false</ix:nonNumeric><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180L2ZyYWc6NGQ3MTE0NmFhOWMzNGIyMDgwMzBjODRkNTY1ZjY3ZGYvdGFibGU6ZDgwODY0N2Q3ZWEyNGM5MTg3MzE4YTliZDZjMTI1YTYvdGFibGVyYW5nZTpkODA4NjQ3ZDdlYTI0YzkxODczMThhOWJkNmMxMjVhNl81LTEtMS0xLTIwOTc3_753ee795-433d-4c66-b68b-b6a7fff3907c">2022</ix:nonNumeric><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180L2ZyYWc6NGQ3MTE0NmFhOWMzNGIyMDgwMzBjODRkNTY1ZjY3ZGYvdGFibGU6ZDgwODY0N2Q3ZWEyNGM5MTg3MzE4YTliZDZjMTI1YTYvdGFibGVyYW5nZTpkODA4NjQ3ZDdlYTI0YzkxODczMThhOWJkNmMxMjVhNl82LTEtMS0xLTIwOTc3_46449e69-e462-4b36-bb6e-3a3d35f74182">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180L2ZyYWc6NGQ3MTE0NmFhOWMzNGIyMDgwMzBjODRkNTY1ZjY3ZGYvdGFibGU6ZDgwODY0N2Q3ZWEyNGM5MTg3MzE4YTliZDZjMTI1YTYvdGFibGVyYW5nZTpkODA4NjQ3ZDdlYTI0YzkxODczMThhOWJkNmMxMjVhNl85LTEtMS0xLTIwOTc3_8c434271-55ab-41ea-8dcd-48efcfd7ebc5">0001711279</ix:nonNumeric><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180L2ZyYWc6NGQ3MTE0NmFhOWMzNGIyMDgwMzBjODRkNTY1ZjY3ZGYvdGFibGU6ZDgwODY0N2Q3ZWEyNGM5MTg3MzE4YTliZDZjMTI1YTYvdGFibGVyYW5nZTpkODA4NjQ3ZDdlYTI0YzkxODczMThhOWJkNmMxMjVhNl8xMC0xLTEtMS0yMDk3Nw_ab4dff3f-d256-4ad0-bbb5-682fc56a1d34">--12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="krys-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92219a3d65e04e42ae2386983e67244f_I20220429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i905c5a481a8b4f42a9009703d3ecf075_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i99c92e6ca8634fd79257a600a35f3f21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86b8575463f64b2a97e77aaf2dd5e8b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cccc0f95b584f8db0533775037f4666_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8b763ffc1fc42a380e6da94773832ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a174e96b10748d3b41c69212ebe2cc6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03e20359e3ba42acaec22a55b3fabb99_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d3866220aae469d99c8d6687e42ce45_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie46a796ec4c446038a3653b810fcbd77_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57267989876b466d9ebc59f49913b75f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e52f1591d1347c4bb2558fb1f9ee147_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65beb9114acd4ee1adef1dde5c44ba5c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87c8b8e1430a4c708d973ff2e25ae17b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ddceeccd7914fa1bc3f31fd69e6830a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6ffefd397c440af90b9447cc5a238f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica68c43f75604a03a077b382685b1a41_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib67facf3d8f849e2b66fd1c7f68989ad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67063c7c5279465183dd7e83d8f84145_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i381f9df67cae40a4b3c35dfa60c3546f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic12c80c1247f4acaa167064b8bb02705_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77370fc21ec5473987c50059d5cab0bc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f9b5535cbbc4e22af9f06fe59eaa400_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c06fb3b4ad5401d80b059fc7e9e1d3d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i861f0c6362bd4446bef9d197ad8a4835_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17fb83d3cf56449095121eab4cdd43b7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8440da614aa3444894a316404ee33125_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i395b8e2070414f429d49289ac92db97b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf458d33964c41e09d92634f029b4c61_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>krys:segment</xbrli:measure></xbrli:unit><xbrli:context id="ie8265b62d98547d1b612aa5059737994_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff7c8222f2ec4030bb73e073b01cc801_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8526152bbd814c19af8798ebbf6df780_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b7a2cb4937f4539b4d97203dc50610f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1ef4419eb8c470d85aacefec56909e5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41aa2659a9d349aca4310c4ac210e321_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee85b21ece4849119c1efceb43453fde_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice1e26d5975d48f7995f61e80667d911_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63849f9dca98492397cffbdb5ad8bc0a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71df1d506a1d42f59d5769c25d50de0d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b56a800b1dc4d59b0579103fb3856e3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5e3ccafd6e7408e8d72c7ed3d59aa1d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0718e9e6a304faa99a8d0ba4d170a50_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63e06177b3b947ed827f1ae04d3f6c24_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91af162b5ce24bcca39b1802458f9c63_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12453054567d425ebb3db8321c10080c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0605bcc794c8466488458ac6a40a567a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fc83aec7ccf4e56b6000b187c116bc9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac939cd950c94172a39585927ae3707b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52a9c36697194609ac56e04b9aa3d9a8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c95f3dd9aa1471889572b02d7094b9d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2740425fee244d2f922f4b25973e349b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdbc6dddacb448d9ad60106137194932_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebe00a10a2724634b1c0118d2d67a4a8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeaaf7239b4345778bad76871b818c5a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3140340b83cb4218b934f3877760f87c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icba6d511515a4acf97d285fa1677f2cb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a3729b490084ba89c9abadcac13b833_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23a4767bf6e240bda02a5dbd7afc4ff7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d1b20d4b556453996c9073c1c2716ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f0e12c30bc84334939e2e4bf442dfac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49e8debc5cb94ea6a469f4196d724fa5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46c951025fce41ab952849ce6a3ab2e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf8f54899b4a4148a67b60622acaf77b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ba725ffee7e42e6a8128c65b3a212bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf6969542ce14c959f3e2e0e56bcb784_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1502ff476f7844a8b66df5fd7220258e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bad5e70d1fb436897da83e0b8eeee55_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa7daa0072cb419cb2dbaaf3afff522e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c36492a3b734099aac3b58956194853_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc7984fa6b0c43debd86bc7ec5c8ddef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbf78e0869994741ae4e6b2efdb39bc9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f5b030412564955be828db44eb6b956_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b8b8c8c466f413999e0992ec12716e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63e50181337f4deda50f8a1ec567dd37_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if60f2e99fb10489cb879593621b5e8bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a8a378d87ac477fa9eb1f74361e0f3a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd44f57ba38a4bbfb2f25ef586c2f644_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbf226c7773f451cb39f05cc616016f9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie70bd060e96749a89eccb6ac7c4aa94e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8144f7ab623b4afca039c1cbdf57e750_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c8d6050468f4d63a79e15bdcd8ec20b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a8d28f658e64c9cb72dab709adfb297_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ce87c71085b42e9b14d17fca3b617ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16934897395943d38eb471fd6a4ab451_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c5891e652c44560a9dfb628c66faca5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4980d8ad41eb414591647b2b42093a20_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95c8dea3eb594cc3900cf46e3694ed5b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbf36e2c49fc42d9a41ee8670488e982_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:TwoThousandSixteenLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i259ce76551454123911c8f7e6cf9cd6d_I20200121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-01-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5b58230696440249bca1a1906cb63f3_D20201015-20201015"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-15</xbrli:startDate><xbrli:endDate>2020-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2384fef03d174e7293ac35a6c188c7cf_I20201005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1f1bacd274b4e44b1a1f8151a2b5097_I20201015"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i6642a4976dcc4bbb8b89924a05835ed9_I20211215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:BostonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib888a32279a646d6bc98bb4650978ad1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9ac354f7bd046949c8c5c9a884f44b6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab4cf6bacbe94549a3840f7cc0180c4d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea664a78d9854e7982861ce146a3ba39_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib712ea82a3604445a0cc14028e0d6896_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b26ab4e640a459f8745fdfc687a4c41_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if89acc13e6c64c308c9dfc70390e2d45_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ASTRAFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7f4b2c43112444b9e122e360545adab_I20210913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic40bbdf109724a63a017b7987802289f_D20220312-20220312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-12</xbrli:startDate><xbrli:endDate>2022-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e9524e5aa5c470a884b1e3b3fd4d2fc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>krys:milestone</xbrli:measure></xbrli:unit><xbrli:context id="ic24584a607d040f58ee27bb2c65542e0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbc91ac07e524baca470f06f672c1d2c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36d06bb51d1041f08406992557a842ec_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic65f36fa2aab4beabcc772980cf0f956_D20220312-20220312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-12</xbrli:startDate><xbrli:endDate>2022-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5edf1309bf4c4394b9c48237c6eb3b9e_D20220312-20220312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-12</xbrli:startDate><xbrli:endDate>2022-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4203d07f57134f55a0643e1e7a9ea003_D20220312-20220312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-12</xbrli:startDate><xbrli:endDate>2022-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5afc353e283647ec9083f64e9ed8c939_D20211203-20211203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-03</xbrli:startDate><xbrli:endDate>2021-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60ec291ee12943d1a98627ef006017cc_D20211203-20211203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-03</xbrli:startDate><xbrli:endDate>2021-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08fed205929d4c55ae8e914a0a90a14b_I20211203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c1f8e7fe2fa45fd8b4dff23e6288333_D20211203-20211203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-03</xbrli:startDate><xbrli:endDate>2021-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if01cbed47b8d4cc3bfbc1d974a9fed3d_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ff87f18f6694c9ea3a6fef4996ab07c_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica2c921cbe27424bb2a3e6cab5b07128_I20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i289cb50e19984c88a48c5a07e1b8a29a_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida8733e7f8b54da6ada1a0ab22fe829f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PlacementSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krys:StockSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fbd96b4612a4a66b26fde342c7e05ba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PlacementSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krys:StockSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c9fb5f61e014e0d8958ffdb2f7baa47_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia295d7f2365647ae8d0fe3f1f16d1308_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i286d68b1d6d2436481fb4a0d8428bca6_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80af56866df1412e92048fc6c85f5bc4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic542a3c28cfa40a79269e8998b92ebd4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecc1050fb75f4c92929ea53bb5db6e2e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea276893239144509596b8ab8da16fc9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bd1d3ebc2374d15b477f6f17769c8b5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1df3a737f254e1890366151309871c2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice42d3e965264766b589d5585c17eea5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c01f855c0c84b0e9b660ee225b9ec6f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4351d78dc27b42ba8f8b3dc0f50aab47_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i728d1afbbec24034b661de93f72a65fb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a13b8bd5de345f7816207b985555ac2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5ef3f34ff534130b14863a9e62343c7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i159a69784f534b459befa6407a0a7b31_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95cf472c8b2540888dd2f36a876d9c9c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9e66ec8312f4f8c9a9dff635bd641f1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcde6861ff0841f797527708e897648a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2f80cb0be8e44f88a74d836902c06d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34ffbc56d9c943f2b61272f256499cfb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2d9d3e6725f41cbba150ba4c1a85196_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i383ec6469caa4edeaa4b2d6d77e7fba4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29cc8ebc55e7487dac7291d42222cb41_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krys:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28da46ff21b84b0aa5a790183dfad270_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:IncentiveStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7448456091a9407bba292044857bb844_D20220429-20220429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-29</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id610a4a750eb45a88b570c32459f3956_D20220405-20220405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-05</xbrli:startDate><xbrli:endDate>2022-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec19ce2f98484127826acb386e5ebf55_I20220405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001711279</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-05</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_1"></div><div style="min-height:27pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDU4_1d710e49-0351-49af-bfe6-fa0d8c88c277">10-Q</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGFibGU6N2M2MWJiNGIzOWRhNDgyZTg4ZTVmNjEyMmU0Y2I0NmEvdGFibGVyYW5nZTo3YzYxYmI0YjM5ZGE0ODJlODhlNWY2MTIyZTRjYjQ2YV8wLTAtMS0xLTIwOTc3_77c653fa-35dd-4840-b915-cae8e6b19bd7">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDI_70cc69f3-997a-45e0-b746-a1f9eb8ee2e2">March&#160;31, 2022</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGFibGU6YTgxODFhYmUxYzQ4NGNkMWJlNmRiNzg3YTNlNjJlMDEvdGFibGVyYW5nZTphODE4MWFiZTFjNDg0Y2QxYmU2ZGI3ODdhM2U2MmUwMV8wLTAtMS0xLTIwOTc3_65f2bde9-8489-49b9-892b-dcea3f062935">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDU5_ed53a6cd-a307-47c7-9242-ca65ace93864">001-38210</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="margin-top:3pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDcw_384278c1-fde5-46a6-b338-afa3df3e55fd">Krystal Biotech, Inc.</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="text-align:center;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGFibGU6ZGVhZTgxNThhYjJmNGYxNmI4MTlmZmNmODc4ZjdkZWYvdGFibGVyYW5nZTpkZWFlODE1OGFiMmY0ZjE2YjgxOWZmY2Y4NzhmN2RlZl8wLTAtMS0xLTIwOTc3_6e7a5021-c4c6-443b-8e68-da08c1a357fa">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGFibGU6ZGVhZTgxNThhYjJmNGYxNmI4MTlmZmNmODc4ZjdkZWYvdGFibGVyYW5nZTpkZWFlODE1OGFiMmY0ZjE2YjgxOWZmY2Y4NzhmN2RlZl8wLTItMS0xLTIwOTc3_9299777a-7526-4c73-b2a3-dd73b77ec47b">82-1080209</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDcx_0cf5fc8f-b60e-471d-9618-cec25cea929b">2100 Wharton Street</ix:nonNumeric>, <ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDYz_706263bf-7f1b-4660-b6eb-54d95df5221c">Suite 701</ix:nonNumeric></span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDY2_c856342a-d3e8-42a8-8ef0-eff7cd1bd3b0">Pittsburgh</ix:nonNumeric>, <ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDYx_6a522abd-92d7-4f81-8d0f-dc38cefba765">Pennsylvania</ix:nonNumeric> <ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM181OTk_736cbe42-2983-4efe-9207-7b057a0d01f5">15203</ix:nonNumeric></span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDcy_001351e7-e136-4476-9377-a13db0f7e93c">412</ix:nonNumeric>) <ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDYy_fcbceee5-d05d-43d4-8745-9e6c121f81a6">586-5830</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%;text-decoration:underline">_____________________________________________________</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGFibGU6ODgwY2VmMzE5ZmNhNDEyM2EwNjJhMDMzZDE5YWU1MTIvdGFibGVyYW5nZTo4ODBjZWYzMTlmY2E0MTIzYTA2MmEwMzNkMTlhZTUxMl8xLTAtMS0xLTIwOTc3_0a2f5e49-5fc1-4f16-bd05-ebdbe9f4328a">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGFibGU6ODgwY2VmMzE5ZmNhNDEyM2EwNjJhMDMzZDE5YWU1MTIvdGFibGVyYW5nZTo4ODBjZWYzMTlmY2E0MTIzYTA2MmEwMzNkMTlhZTUxMl8xLTEtMS0xLTIwOTc3_ac552ddc-574b-4c6e-91ed-70bfa6481617">KRYS</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGFibGU6ODgwY2VmMzE5ZmNhNDEyM2EwNjJhMDMzZDE5YWU1MTIvdGFibGVyYW5nZTo4ODBjZWYzMTlmY2E0MTIzYTA2MmEwMzNkMTlhZTUxMl8xLTItMS0xLTIwOTc3L3RleHRyZWdpb246MDEyZDM4NjllOGExNDVjMTljODc4YzJlODMyODNjYTlfMTY0OTI2NzQ0MTY5Ng_88ba4eae-0ac4-47ef-9e5f-8cdebe307acc">NASDAQ</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     <ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDcz_ab45d3b5-ef7b-4e53-aa1e-8cd3c1928c41">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDY1_7e0f3dce-3a17-4b7c-a98e-0a8e14d6a836">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:21.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGFibGU6NmNlNzRiMWQ0NDQxNGY5ZGE1ZDQ0NzY5ZGI3NmU0YzMvdGFibGVyYW5nZTo2Y2U3NGIxZDQ0NDE0ZjlkYTVkNDQ3NjlkYjc2ZTRjM18wLTAtMS0xLTIxNTY3_c7410ef4-cc2f-4ed2-b057-6773b2c8234b">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGFibGU6NmNlNzRiMWQ0NDQxNGY5ZGE1ZDQ0NzY5ZGI3NmU0YzMvdGFibGVyYW5nZTo2Y2U3NGIxZDQ0NDE0ZjlkYTVkNDQ3NjlkYjc2ZTRjM18xLTYtMS0xLTIwOTc3_0af5a414-1031-4b1b-a2fb-c63a76d5dbe8">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;&#160;&#160;            </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDY3_6549b1b2-c22a-4931-a341-60ad0a17984d">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM180OTQ3ODAyMzI3NDcw_e7a221a8-d1fd-4822-9df0-4a88785f17ae">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of April&#160;29, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i92219a3d65e04e42ae2386983e67244f_I20220429" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM183MTQ2ODI1NTgzMDcy_ced74b7c-5428-4ef3-a57e-8c31e929f6d9">25,635,138</ix:nonFraction> shares of the registrant&#8217;s common stock issued and outstanding.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.134%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page No.</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_13">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_16">Condensed Consolidated Balance Sheets as of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_16">March 31, 2022</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_16"> and December 31, 20</a>21</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_19">Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_19">Months Ended </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_19">March</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_19"> 3</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_19">1</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_19">, 202</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_19">2</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_19"> and 20</a>21</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_22">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_22"> Months Ended </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_22">March</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_22"> 3</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_22">1</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_22">, 202</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_22">2</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_22"> and 20</a>21</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_25">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_25">Three </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_25">Months Ended </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_25">March</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_25"> 3</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_25">1</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_25">, 202</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_25">2</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_25">  and 20</a>21</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_28">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_61">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_61">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_61">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_85">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_85">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_85">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_88">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_88">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_88">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_91">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_94">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_94">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_94">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_97">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_97">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_97">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_100">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_100">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_100">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_103">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_103">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_103">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_106">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_106">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_106">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_109">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_109">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_109">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_112">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_112">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_112">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_115">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1d18f2ca829a4240ba3639a9ab04fa9c_115">33</a></span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS (UNAUDITED)</span></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_16"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:72.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.676%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except shares and per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfNC0xLTEtMS0yMDk3Nw_b2777597-182c-4342-9623-2f5198cd1a43">269,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfNC0zLTEtMS0yMDk3Nw_74409a17-79ac-49de-959c-52cf652946e0">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfNS0xLTEtMS0yMDk3Nw_be6e653d-ce0c-48b1-abba-33e4b2c116cd">165,329</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfNS0zLTEtMS0yMDk3Nw_c8e21cb4-fbc1-4540-bebf-f40e6df492b6">96,850</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfNi0xLTEtMS0yMDk3Nw_94fb84fd-628f-4b19-808b-0968f9629115">3,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfNi0zLTEtMS0yMDk3Nw_cd6365a6-5efd-443d-9b58-817d01e34460">4,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfNy0xLTEtMS0yMDk3Nw_ca29c2a5-9f2b-41eb-a99b-d5817ebb5dc2">437,998</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfNy0zLTEtMS0yMDk3Nw_5e374c27-6124-4f0c-af47-6c1ceed23ada">442,267</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfOC0xLTEtMS0yMDk3Nw_3125ba51-4ce1-4a2f-b526-baf7c3045759">136,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfOC0zLTEtMS0yMDk3Nw_d2b20c5b-56e5-4847-9759-e7a9c3500849">112,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfOS0xLTEtMS0yMDk3Nw_55fae7f5-737e-4a0b-b0cd-a97ee493d7b3">33,339</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfOS0zLTEtMS0yMDk3Nw_c3d40d36-8fdc-4390-a489-869cb55c80b6">64,371</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTAtMS0xLTEtMjA5Nzc_9be160d2-77cd-4bea-8f7b-28f26b3211e7">8,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTAtMy0xLTEtMjA5Nzc_42ecb77f-1e80-4b65-b574-b7ac5e987703">7,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTEtMS0xLTEtMjA5Nzc_f1d33a11-6446-47d9-b2ae-b784699450b9">157</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTEtMy0xLTEtMjA5Nzc_81ca7916-bc14-448d-8859-635cd1f9f130">74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTItMS0xLTEtMjA5Nzc_5d96ec78-1db0-43b6-8c29-8fda22adde3a">616,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTItMy0xLTEtMjA5Nzc_bfc41976-4202-4a4c-a0f4-701b48507ca3">626,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTUtMS0xLTEtMjA5Nzc_ecb9b2bb-6ccb-4fdb-80eb-48dded202b11">8,209</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTUtMy0xLTEtMjA5Nzc_774e1b5b-d8da-44ea-8beb-0424bb1b33ad">8,398</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTYtMS0xLTEtMjA5Nzc_bf4688ec-1de6-4595-a3ef-36c9e2aaf708">1,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTYtMy0xLTEtMjA5Nzc_2bb5083a-dbec-404e-98e3-5c317eb6a0ac">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTctMS0xLTEtMjA5Nzc_e2bb2d08-d437-4c04-b472-2c3ca2880db3">50,817</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTctMy0xLTEtMjA5Nzc_ef3efcff-9258-4135-b3c3-6f7504f35427">16,297</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTktMS0xLTEtMjA5Nzc_2236fa40-c481-4c09-a35f-3a9a8b137b76">60,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTktMy0xLTEtMjA5Nzc_2704f0cc-318b-4da7-af00-e27b2f3dd547">25,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjAtMS0xLTEtMjA5Nzc_d1a71b0f-298a-46ad-844a-03bee9e10485">7,883</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjAtMy0xLTEtMjA5Nzc_30e56a55-5037-4c1f-9971-03343f957c9c">6,983</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjEtMS0xLTEtMjA5Nzc_ef290029-3d44-4c85-abf3-301cd00ed679">68,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjEtMy0xLTEtMjA5Nzc_a8a5fdbf-2d3a-47e0-8949-7af78f9ed2e5">32,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 6)</span></td><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjItMS0xLTEtMjA5Nzc_a47b453f-596d-45b3-bbf6-c6bd44792c18"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjItMy0xLTEtMjA5Nzc_83c69032-bfd3-4ee8-895b-762ddb5677f5"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock; $<ix:nonFraction unitRef="usdPerShare" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjQtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjpiZTliM2E0ZTYxNjY0NTU1YWEwYWU4NzlmZjBhN2Q3Nl8yMQ_6914fa46-6ec1-4a26-8f9e-3fdd976fd3c8"><ix:nonFraction unitRef="usdPerShare" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjQtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjpiZTliM2E0ZTYxNjY0NTU1YWEwYWU4NzlmZjBhN2Q3Nl8yMQ_dcbc01ee-e93c-4fb3-b90b-aa4aa958662c">0.00001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjQtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjpiZTliM2E0ZTYxNjY0NTU1YWEwYWU4NzlmZjBhN2Q3Nl8zNQ_521dafba-a542-4852-bd6b-7c027826f4a4"><ix:nonFraction unitRef="shares" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjQtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjpiZTliM2E0ZTYxNjY0NTU1YWEwYWU4NzlmZjBhN2Q3Nl8zNQ_ea5ef308-78a2-470b-96ce-16195ae6cca3">20,000,000</ix:nonFraction></ix:nonFraction> shares authorized at</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; March&#160;31, 2022 (unaudited) and December&#160;31, 2021; <ix:nonFraction unitRef="shares" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjQtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjpiZTliM2E0ZTYxNjY0NTU1YWEwYWU4NzlmZjBhN2Q3Nl84NQ_1cb2cb07-d1a5-4849-b96c-4ac2f8d576af"><ix:nonFraction unitRef="shares" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjQtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjpiZTliM2E0ZTYxNjY0NTU1YWEwYWU4NzlmZjBhN2Q3Nl84NQ_5dfe611f-99ef-438e-9e5b-3bdf0522f868">2,061,773</ix:nonFraction></ix:nonFraction></span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; shares issued, and <ix:nonFraction unitRef="shares" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjQtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjpiZTliM2E0ZTYxNjY0NTU1YWEwYWU4NzlmZjBhN2Q3Nl8xMTA_53d970a3-7516-4234-b1ae-8ee9c9fb8908"><ix:nonFraction unitRef="shares" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjQtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjpiZTliM2E0ZTYxNjY0NTU1YWEwYWU4NzlmZjBhN2Q3Nl8xMTA_99ea9136-99fb-4ed7-a40d-337c07046d36">no</ix:nonFraction></ix:nonFraction> shares outstanding at March&#160;31, 2022</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; (unaudited) and December&#160;31, 2021</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjQtMS0xLTEtMjA5Nzc_88a47e4a-7655-4b31-ae28-6b7ca4b4fde6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjQtMy0xLTEtMjA5Nzc_a7ff7e66-063c-46f4-9e25-a6ef5371f0dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock; $<ix:nonFraction unitRef="usdPerShare" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjUtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjo2ZTZiYzFlODVhMGI0YjA0YWU0ODcyMTVkNzk4OTVlMl8xOA_44ed94c2-2065-4b64-99ef-db3f724635b4"><ix:nonFraction unitRef="usdPerShare" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjUtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjo2ZTZiYzFlODVhMGI0YjA0YWU0ODcyMTVkNzk4OTVlMl8xOA_b8401fbf-7989-4ef9-b0a4-6e9b1bd76b62">0.00001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjUtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjo2ZTZiYzFlODVhMGI0YjA0YWU0ODcyMTVkNzk4OTVlMl8zMg_a6f7d203-d08c-4616-a419-1ed93920751e"><ix:nonFraction unitRef="shares" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjUtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjo2ZTZiYzFlODVhMGI0YjA0YWU0ODcyMTVkNzk4OTVlMl8zMg_c954c2ad-eeca-4018-a669-5ac65c57a9d0">80,000,000</ix:nonFraction></ix:nonFraction> shares authorized at</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; March&#160;31, 2022 (unaudited) and December&#160;31, 2021; <ix:nonFraction unitRef="shares" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjUtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjo2ZTZiYzFlODVhMGI0YjA0YWU0ODcyMTVkNzk4OTVlMl84Mg_51f52c6d-6518-40b6-ac53-5b35df873fb7">25,199,081</ix:nonFraction></span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; shares issued and outstanding at March&#160;31, 2022</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; (unaudited); and <ix:nonFraction unitRef="shares" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjUtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjo2ZTZiYzFlODVhMGI0YjA0YWU0ODcyMTVkNzk4OTVlMl83MTQ2ODI1NTgwODA2_3e2e51fa-9eb7-489f-8e3e-5592788dae2c"><ix:nonFraction unitRef="shares" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjUtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjo2ZTZiYzFlODVhMGI0YjA0YWU0ODcyMTVkNzk4OTVlMl83MTQ2ODI1NTgwODA2_641fbf0a-74a4-450b-810e-a148af1689a8">25,207,985</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjUtMS0xLTEtMjA5Nzc_749292f7-5616-4ea4-a65c-a97a985d66df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjUtMy0xLTEtMjA5Nzc_c8e662a4-0dd1-4e9b-b382-0dbf63ba8826">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjYtMS0xLTEtMjA5Nzc_3b384da6-1b68-426d-8f65-6051eadc7012">740,500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjYtMy0xLTEtMjA5Nzc_e27b5a2a-732f-4219-8be1-3e3b499fadfb">734,523</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjctMS0xLTEtMjA5Nzc_9fc95ad5-e517-4581-83ec-8eadc722449c">1,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjctMy0xLTEtMjA5Nzc_16e18088-920b-46ce-8122-4c1c1d59ae90">163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjgtMS0xLTEtMjA5Nzc_5506f84d-afb8-41a3-ab0e-b428891e9eb6">190,749</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjgtMy0xLTEtMjA5Nzc_3da070fa-26d9-42c3-91a9-e01e91dfd31f">140,784</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjktMS0xLTEtMjA5Nzc_ca5075a5-27e3-4723-b267-bf7be63f98ce">548,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjktMy0xLTEtMjA5Nzc_74a4ad7a-100e-4283-a272-60c0e3b8caf0">593,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMzAtMS0xLTEtMjA5Nzc_d114a3ee-36e2-4aed-a63e-2ee42c778f15">616,874</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMzAtMy0xLTEtMjA5Nzc_ae9006b4-d156-494f-96b8-9bb452fbe83b">626,295</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:2pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.836%"><tr><td style="width:1.0%"></td><td style="width:51.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.877%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.178%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMy0xLTEtMS0yMDk3Nw_0df25442-2b89-473d-af7b-7c408e757e1d">9,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMy0zLTEtMS0yMDk3Nw_64d88426-c062-4eed-99dd-8c26f5f0f526">6,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfNC0xLTEtMS0yMDk3Nw_de334658-942d-422f-bc12-e732737f0c86">15,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfNC0zLTEtMS0yMDk3Nw_4b9ffe80-1e25-400b-81ba-d051284b3b26">8,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfNS0xLTEtMS0yMjE1Mw_5c4f7e1f-2bf1-41ce-8370-144b289add0c">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfNS0zLTEtMS0yMjE1NQ_6e80ec8a-2e48-4496-b7b7-c2244b0e9fbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfNS0xLTEtMS0yMDk3Nw_a1c0e289-871b-4b65-aa26-5c771641116c">50,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfNS0zLTEtMS0yMDk3Nw_55ef8264-2d60-4f84-8bd3-3400b8e662f3">14,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfNi0xLTEtMS0yMDk3Nw_df28a5f6-4f60-4968-a9f7-5e1615872495">50,222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfNi0zLTEtMS0yMDk3Nw_e4189390-1416-4676-a9b9-8d91e85115dd">14,353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Income (Expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="krys:InterestIncomeExpenseAndOtherNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfOC0xLTEtMS0yMDk3Nw_813bf024-83bc-46c4-8de4-327266f06236">257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="krys:InterestIncomeExpenseAndOtherNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfOC0zLTEtMS0yMDk3Nw_8c3d5ee2-19fe-4671-be29-f5ca8606ab73">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTAtMS0xLTEtMjI4NDg_74bc790f-209b-4299-8a5d-8a858b1f7738">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTAtMy0xLTEtMjI4NDg_b9cd0a43-4f07-4170-8d7b-25eef6b68cc0">1,492</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTAtMS0xLTEtMjA5Nzc_74ae9e1e-a076-4ee1-b856-11c60919134d">49,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTAtMy0xLTEtMjA5Nzc_7a05d9a5-c7f2-4017-a5b0-154ae7292421">15,812</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on available-for-sale securities and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTEtMS0xLTEtMjA5Nzc_8f0d13bb-e856-46be-a4c5-72c235e5f01b">1,034</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTEtMy0xLTEtMjA5Nzc_d9e3e145-cc9c-4093-a526-f3e7297e310e">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTItMS0xLTEtMjA5Nzc_bfb21e2a-eee6-4f2d-8025-761a2ad3b1c4">50,999</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTItMy0xLTEtMjA5Nzc_3a2cc527-f034-4b01-8828-fa9448e51526">15,815</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share:<br/>&#160;&#160; Basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTQtMS0xLTEtMjA5Nzc_31b8a3b8-a84f-459a-9425-9ded64e21cd7"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTQtMS0xLTEtMjA5Nzc_6ffb17c6-07c9-4f17-a605-5de9f282777a">1.99</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTQtMy0xLTEtMjA5Nzc_1f64faac-6641-47cd-9a11-9bae3a720f69"><ix:nonFraction unitRef="usdPerShare" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTQtMy0xLTEtMjA5Nzc_95d2af5b-742d-4c3f-b820-19d65e6bbd06">0.74</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:<br/>&#160;&#160; Basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTYtMS0xLTEtMjA5Nzc_71f784e6-efaa-44fd-b340-d116bae46d07"><ix:nonFraction unitRef="shares" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTYtMS0xLTEtMjA5Nzc_7ea6455c-e31e-4a49-b1b3-e61a9705cbd1">25,114,453</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTYtMy0xLTEtMjA5Nzc_308e3098-fbb6-4ef5-a3e3-c4df6681c01a"><ix:nonFraction unitRef="shares" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTYtMy0xLTEtMjA5Nzc_b79e100b-0d2a-48e5-9380-1ccaf1929300">21,253,508</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:2pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:27.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.022%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except shares)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at January 1, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86b8575463f64b2a97e77aaf2dd5e8b8_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfMy0xLTEtMS0yMDk3Nw_dd24c72a-99ce-4f74-bdec-116678439d59">25,207,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b8575463f64b2a97e77aaf2dd5e8b8_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfMy0zLTEtMS0yMDk3Nw_6525a887-5f69-4212-9457-0bd428856401">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cccc0f95b584f8db0533775037f4666_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfMy01LTEtMS0yMDk3Nw_e2137c54-8a47-4a50-b098-eb87bcf4866a">734,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8b763ffc1fc42a380e6da94773832ed_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfMy03LTEtMS0yMDk3Nw_83183d1a-4aca-44d3-8c08-61190a3ac32a">163</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a174e96b10748d3b41c69212ebe2cc6_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfMy05LTEtMS0yMDk3Nw_4b862be7-c07f-48d6-8961-0a90bbdcb1d8">140,784</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfMy0xMS0xLTEtMjA5Nzc_fb01ca27-f119-4e25-a4c2-c8ae901b126d">593,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03e20359e3ba42acaec22a55b3fabb99_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNC0xLTEtMS0yNDIxMg_36695cbd-06eb-4615-826e-0b1a2fa9d186">1,475</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d3866220aae469d99c8d6687e42ce45_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNC01LTEtMS0yNDIxMg_fdcc7078-40bc-4310-9f69-00f135111ad1">55</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNC0xMS0xLTEtMjQyMTI_21a1a6ff-70da-4816-a732-2e62d29e9e25">55</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock surrendered for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i03e20359e3ba42acaec22a55b3fabb99_D20220101-20220331" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNC0xLTEtMS0yMDk3Nw_bb36a795-da1e-4636-97b4-0997ca9a579b">10,379</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d3866220aae469d99c8d6687e42ce45_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNC01LTEtMS0yMDk3Nw_6ae8b7de-cd85-4d5d-b506-9ddece65ce2d">649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNC0xMS0xLTEtMjA5Nzc_520ea695-86e2-46c4-a416-5dbae557cb4f">649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d3866220aae469d99c8d6687e42ce45_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNS01LTEtMS0yMDk3Nw_d09a5226-75c7-4c7b-af4d-a1e736c685bc">6,571</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNS0xMS0xLTEtMjA5Nzc_e60bf288-2651-481f-b98d-557c075ded6a">6,571</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on investments and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie46a796ec4c446038a3653b810fcbd77_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNi03LTEtMS0yMDk3Nw_3a1b74e3-c51d-461d-9346-47e16aca28a4">1,034</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNi0xMS0xLTEtMjA5Nzc_0001ecff-3392-4cb9-97ae-3d6b9e3d740a">1,034</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57267989876b466d9ebc59f49913b75f_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNy05LTEtMS0yMDk3Nw_c4966300-e718-473e-b8b5-22a60a613ecd">49,965</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNy0xMS0xLTEtMjA5Nzc_115f06c9-8788-43bc-88c7-aa6ba1ec3e7e">49,965</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at March 31, 2022</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e52f1591d1347c4bb2558fb1f9ee147_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfOC0xLTEtMS0yMDk3Nw_acd31267-83f4-43b8-bfc4-066634d5ce1d">25,199,081</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e52f1591d1347c4bb2558fb1f9ee147_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfOC0zLTEtMS0yMDk3Nw_dd68c464-af8c-4093-b12b-afe640e35f67">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65beb9114acd4ee1adef1dde5c44ba5c_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfOC01LTEtMS0yMDk3Nw_fbf4b4c7-efee-4eb1-a196-4dca1cdea47a">740,500</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87c8b8e1430a4c708d973ff2e25ae17b_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfOC03LTEtMS0yMDk3Nw_89c6a142-3f38-447e-acaf-7d9869760732">1,197</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ddceeccd7914fa1bc3f31fd69e6830a_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfOC05LTEtMS0yMDk3Nw_bf465440-f338-4ab4-9f52-1d7156bf06f3">190,749</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfOC0xMS0xLTEtMjA5Nzc_e89ee3eb-aa7f-43eb-a969-bc4eef6ac839">548,554</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:27.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.022%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except shares)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at January 1, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6ffefd397c440af90b9447cc5a238f5_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfMy0xLTEtMS0yMDk3Nw_b5e5ab06-9336-4692-9cf7-9d5c1153b61c">19,714,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ffefd397c440af90b9447cc5a238f5_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfMy0zLTEtMS0yMDk3Nw_c0dc5dda-51fc-4909-ba2b-e9641e14059f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica68c43f75604a03a077b382685b1a41_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfMy01LTEtMS0yMDk3Nw_3e4d0f03-ad85-4dd2-9a40-1e5851efad67">363,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67facf3d8f849e2b66fd1c7f68989ad_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfMy03LTEtMS0yMDk3Nw_e955fb62-f955-465e-9564-2a687505daa3">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67063c7c5279465183dd7e83d8f84145_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfMy05LTEtMS0yMDk3Nw_1860fcd9-8c7d-4004-bad8-bb572286255a">71,214</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i381f9df67cae40a4b3c35dfa60c3546f_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfMy0xMS0xLTEtMjA5Nzc_addf437d-d951-488b-935f-29385a23203f">292,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic12c80c1247f4acaa167064b8bb02705_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfNC0xLTEtMS0yMDk3Nw_ed81c41f-ffec-4bac-acc6-0b3438683952">2,489,837</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77370fc21ec5473987c50059d5cab0bc_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfNC01LTEtMS0yMDk3Nw_be53a5b0-0475-4ecc-9ace-b0a9dd2f38d9">152,033</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfNC0xMS0xLTEtMjA5Nzc_d165c443-8da4-43eb-9a9f-120dd4055dcf">152,033</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77370fc21ec5473987c50059d5cab0bc_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfNS01LTEtMS0yMDk3Nw_458c6173-3190-4d41-82a1-5bc6e06e4f63">2,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfNS0xMS0xLTEtMjA5Nzc_12e20228-6ce6-4c45-b7c4-c2193280168a">2,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on investments and other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f9b5535cbbc4e22af9f06fe59eaa400_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfNi03LTEtMS0yMDk3Nw_53494e29-75a0-472e-af4d-a63c87c8d2f4">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfNi0xMS0xLTEtMjA5Nzc_682d212c-151f-48b3-8e1c-9d4d11d804ea">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c06fb3b4ad5401d80b059fc7e9e1d3d_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfNy05LTEtMS0yMDk3Nw_cfe6d0c3-ff5f-4ccb-bd05-ef92d4c7b236">15,812</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfNy0xMS0xLTEtMjA5Nzc_8d0fee8b-ee70-4a8d-8d4f-b51866b823d1">15,812</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balances at March 31, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i861f0c6362bd4446bef9d197ad8a4835_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfOC0xLTEtMS0yMDk3Nw_9591c853-69fa-47a6-a902-298435f13883">22,204,057</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i861f0c6362bd4446bef9d197ad8a4835_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfOC0zLTEtMS0yMDk3Nw_45e8136a-282e-4ede-b9c7-8e0d3b46951f">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17fb83d3cf56449095121eab4cdd43b7_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfOC01LTEtMS0yMDk3Nw_bd72ea4a-f14a-44ac-90bc-ca7eae5eab9d">517,675</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8440da614aa3444894a316404ee33125_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfOC03LTEtMS0yMDk3Nw_1bd35400-d86d-496d-b8c1-ef8c874214cf">3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i395b8e2070414f429d49289ac92db97b_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfOC05LTEtMS0yMDk3Nw_eafb007b-85f3-4e8c-8904-c76999ffbd49">87,026</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf458d33964c41e09d92634f029b4c61_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfOC0xMS0xLTEtMjA5Nzc_cc3fcc86-7f05-4d6a-9186-bce2b0a2a26c">430,652</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMy0xLTEtMS0yMDk3Nw_86362dc3-627f-41e2-bec7-b1db97bfa301">49,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMy0zLTEtMS0yMDk3Nw_efc9c9a2-8781-4449-b9a1-a55d007c1181">15,812</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfNS0xLTEtMS0yMDk3Nw_72b0de6d-b459-4bc2-83bc-d38b35425655">1,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfNS0zLTEtMS0yMDk3Nw_47b2e5dd-3ad5-4b4f-9b20-f102c2915e0c">536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfNi0xLTEtMS0yMDk3Nw_1f6db0c2-8660-4f38-8f6f-b03774f655e0">6,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfNi0zLTEtMS0yMDk3Nw_4268f7f8-7441-42b8-92ac-0061c0aa87e3">2,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:OtherNoncashExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfOC0xLTEtMS0yMDk3Nw_ebeed404-1502-40b7-ac39-acc90f216df8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:OtherNoncashExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfOC0zLTEtMS0yMDk3Nw_712c55c1-3481-4434-b460-d682352fc61a">1,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTAtMS0xLTEtMjQ2OTc_10ed003d-407b-459a-976e-e8b82876a41f">135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTAtMy0xLTEtMjQ4NTI_85873ae4-aff0-40fd-9426-7498fae7e502">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTEtMS0xLTEtMjA5Nzc_6d568b0e-f615-448a-a030-b3929c8e99af">820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTEtMy0xLTEtMjA5Nzc_7cb0663c-5572-4e80-9cec-cf47a57b10c9">1,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTQtMS0xLTEtMjQ3NDY_8cfcdd43-3ff8-4840-9642-c6cb80d5ab39">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTQtMy0xLTEtMjU3MDM_6eaa176c-6228-46e0-91b2-204340c401d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" sign="-" name="krys:IncreaseDecreaseInLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTMtMS0xLTEtMjA5Nzc_78c077ae-c28a-41f0-9f1f-be288d361af6">126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" sign="-" name="krys:IncreaseDecreaseInLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTMtMy0xLTEtMjA5Nzc_4de9ea09-cc41-4ca3-ab46-b7ed4421e073">77</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTQtMS0xLTEtMjA5Nzc_3d878ccb-66a9-40e9-b23f-4218f9e4212f">554</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTQtMy0xLTEtMjA5Nzc_32b1ca68-43b7-4da1-a5ee-e40b7ede816b">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTUtMS0xLTEtMjA5Nzc_8dcaee6b-96e7-4772-bfcd-66e500055b4a">2,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTUtMy0xLTEtMjA5Nzc_8bff05fe-31f9-45a5-b810-41103f60f2b4">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="krys:IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTgtMS0xLTEtMjQ3NTQ_49ac598c-9947-4eb0-bc28-baa08eba5cd9">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="krys:IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTgtMy0xLTEtMjU3MDk_c0ea259a-d6d8-49c7-ad4e-a017904bf2de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTYtMS0xLTEtMjA5Nzc_8679e61b-16f7-4e8f-9231-33fbe66f02e1">15,493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTYtMy0xLTEtMjA5Nzc_084b889d-77fc-4d68-b7ad-e2390f7d1729"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTYtMy0xLTEtMjA5Nzc_a2b09f27-3e20-4a2b-afb0-7a87d264c6ee">9,654</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTktMS0xLTEtMjA5Nzc_007b2f4c-8ee1-42b2-beee-9b4991963c79">17,191</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTktMy0xLTEtMjA5Nzc_2e931167-7881-41e9-8fcf-8ad88a92167a">2,473</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjEtMS0xLTEtMjA5Nzc_3bfebe76-c480-42f1-87b0-1b0b43655d58">62,754</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjEtMy0xLTEtMjA5Nzc_d01c8c27-b754-4c7a-a988-2dd9fdc72487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjItMS0xLTEtMjA5Nzc_406a0ce2-f1e3-474b-a4cc-22bee967a5a6">24,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjItMy0xLTEtMjA5Nzc_f1f4ca40-4e43-4765-9478-8e44303fe40b">1,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjQtMS0xLTEtMjA5Nzc_1fb166db-7360-42b3-a612-b8de8b6ac299">55,908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjQtMy0xLTEtMjA5Nzc_ca1fe9b1-c014-4464-9556-638f0037627c">747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjctMS0xLTEtMjA5Nzc_aaa268ee-bdfc-4562-ad00-e0e8535bbf51">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjctMy0xLTEtMjA5Nzc_7942a2d6-60f2-40ac-b085-30f027a54b21">152,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to settlement of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzAtMS0xLTEtMjQ3OTE_83495cdc-e06f-4c09-9718-ee2b83ba6c15">649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzAtMy0xLTEtMjU3MTU_0bb2cabf-d900-429f-9a12-4a45aca4d2c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of ASTRA build to suit liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="krys:PaymentsForSuitLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjgtMS0xLTEtMjA5Nzc_89d23893-c522-4770-baa4-20f75fc35899">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="krys:PaymentsForSuitLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjgtMy0xLTEtMjA5Nzc_7e092476-ec5c-46af-986a-d7023aa65876">7,960</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjktMS0xLTEtMjA5Nzc_28c4aa92-4ff3-41a0-bf57-b2bb05ff3c97">542</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjktMy0xLTEtMjA5Nzc_5d72bb34-ad69-461f-b754-29063af9edd8">144,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzEtMS0xLTEtMjA5Nzc_15a14535-b3bb-46d7-90a8-c4e5587cdca8">71,943</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzEtMy0xLTEtMjA5Nzc_e603e63b-6993-41f0-b680-b1f3d559ecea">133,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzMtMS0xLTEtMjA5Nzc_35bd3314-6d13-480b-ab11-d8f099550164">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i381f9df67cae40a4b3c35dfa60c3546f_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzMtMy0xLTEtMjA5Nzc_0082ecaa-8981-4f58-9656-0905708ba652">268,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzQtMS0xLTEtMjA5Nzc_8ad413bf-d554-4cdc-b613-c1ab166d4077">269,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf458d33964c41e09d92634f029b4c61_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzQtMy0xLTEtMjA5Nzc_fa491bf2-d6b3-4306-933d-17e96e9172c0">402,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures of Non-Cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid purchases of property and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzctMS0xLTEtMjA5Nzc_7bc29c4f-09a2-4400-8145-c765be751343">14,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzctMy0xLTEtMjA5Nzc_453bca85-e8c3-49ea-82c2-a6946efd6bbe">2,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial recognition of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzgtMS0xLTEtMjA5Nzc_ded70b03-2966-40fc-82c5-f3fb043a7269">1,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzgtMy0xLTEtMjA5Nzc_163cf058-c430-45a2-90fa-9ae9062eafb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid offering costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="krys:OfferingCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzktMS0xLTEtMjA5Nzc_f8337501-a686-4cc0-9f52-ef5f08a8a492">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="krys:OfferingCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzktMy0xLTEtMjA5Nzc_fb5d53da-e87a-4ce2-aa87-9c3deccc426c">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Krystal Biotech, Inc.&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zMS9mcmFnOmU2OGMyOTAxMzFkYTQ5Mjk4NjYxOGI3Mjg3ZjE0OGMyL3RleHRyZWdpb246ZTY4YzI5MDEzMWRhNDkyOTg2NjE4YjcyODdmMTQ4YzJfMzM2NQ_a314f5ee-7361-48de-9b27-99087de35fb1" continuedAt="i1c2eecfc5de143ac93161d8307cd35ee" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="i1c2eecfc5de143ac93161d8307cd35ee"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Krystal Biotech, Inc. (the&#160;&#8220;Company,&#8221;&#160;or&#160;&#8220;we&#8221;&#160;or other similar pronouns) commenced operations on April 15, 2016. On March 31, 2017, the Company converted from a California limited liability company to a Delaware C-corporation, and changed its name from Krystal Biotech LLC to Krystal Biotech, Inc. On June 19, 2018, the Company incorporated Krystal Australia Pty Ltd., an Australian proprietary limited company, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies in Australia. On April 24, 2019, the Company incorporated Jeune Aesthetics, Inc., formerly known as Jeune, Inc. ("Jeune"), in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions. On January 7, 2022, the Company incorporated Krystal Biotech Switzerland GmbH, for the purpose of establishing initial operations in Europe for the development and commercialization of Krystal's pipeline.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biotechnology company leading the field of redosable gene delivery. Using our patented platform that is based on engineered herpes simplex virus type 1 ("HSV-1"), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#8217;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a doctor&#8217;s office or potentially in the patient&#8217;s home by a healthcare professional. Our goal is to develop easy to use medicines to dramatically improve the lives of patients living with debilitating diseases.  Our innovative technology platform is supported by in-house, commercial scale current good manufacturing practices ("cGMP") manufacturing capabilities.  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zMS9mcmFnOmU2OGMyOTAxMzFkYTQ5Mjk4NjYxOGI3Mjg3ZjE0OGMyL3RleHRyZWdpb246ZTY4YzI5MDEzMWRhNDkyOTg2NjE4YjcyODdmMTQ4YzJfMTc0Ng_6da58673-2158-44a7-bdcc-e36f0b73c8a3">190.7</ix:nonFraction> million. With the net proceeds raised from its public and private securities offerings the Company believes that its cash, cash equivalents and short-term investments of approximately $<ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zMS9mcmFnOmU2OGMyOTAxMzFkYTQ5Mjk4NjYxOGI3Mjg3ZjE0OGMyL3RleHRyZWdpb246ZTY4YzI5MDEzMWRhNDkyOTg2NjE4YjcyODdmMTQ4YzJfMjAwNw_9cbeaa0c-dd06-42d9-9938-7692865babcb">434.6</ix:nonFraction> million as of March&#160;31, 2022 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q. As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company&#8217;s cost structure. The Company may never achieve profitability and unless and until it does, the Company will continue to need to raise additional capital or obtain financing from other sources. Management intends to fund future operations through the sale of equity and debt financings and may also seek additional capital through arrangements with strategic partners or other sources. There can be no assurance that additional funding will be available on terms acceptable to the Company, if at all.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to the failure of product candidates in clinical and preclinical studies, the development of competing product candidates or other technological innovations by competitors, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to c</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ommercialize product candidates.</span></div></ix:continuation><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_34"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNjg_4c9f2907-7b35-40c8-b50b-93d60d82bd2f" continuedAt="i2b849cd1a08c48ddb54f852a29bd7ea2" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i2b849cd1a08c48ddb54f852a29bd7ea2" continuedAt="i50224214897e4fca875d6c16ca02d9d3"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNjI_1ccb6aae-d803-4bd5-b454-c4120bdd6302" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;), as found in the Accounting Standards Codification (&#8220;ASC&#8221;), the Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;), and the rules and regulations of the US Securities and Exchange Commission (&#8220;SEC&#8221;).  In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods ended March&#160;31, 2022 and 2021, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation.  Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company&#8217;s previously reported financial position or results of operation.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, as filed with the SEC on February 28, 2022.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i50224214897e4fca875d6c16ca02d9d3" continuedAt="i36bef04346ee44609b8da085bb4927f9"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="krys:RisksAndUncertaintiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNzQ_d025514e-24bb-4cb3-9162-b24b23544724" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The novel coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect our business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. However, the full extent, consequences, and duration of the&#160;COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that these events could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2022.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNjM_cc268b34-c9bd-45e6-b3b9-9e8c42fc40a2" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</span></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNjk_016b908d-dc0c-4c03-a1fb-617771b5e101" continuedAt="iad7ab6499c6545d7b9276ace239ef974" escape="true">Segment and Geographical Information</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iad7ab6499c6545d7b9276ace239ef974">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#8217;s chief operating decision maker view the Company&#8217;s operations and manage its business in <ix:nonFraction unitRef="segment" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMzk2Ng_6199d66d-3327-4fad-a529-7725202d18dd">one</ix:nonFraction> operating segment, which is the business of developing and commercializing pharmaceuticals.</ix:continuation> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNzU_8bcc9031-7589-480c-9a59-3177dfadbe01" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#8217;s policy is to invest its cash, cash equivalents and investments in money market funds, certificates of deposit, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNzY_6d798cb8-08c8-470c-8b11-2cdcb26a13d1" continuedAt="i4a8f44bf80f94fc1a2508e22fd0b9edd" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Investments</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments with maturities of greater than 90 days but less than one year are classified as short-term investments on the consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4a8f44bf80f94fc1a2508e22fd0b9edd">As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity in the consolidated balance sheets.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i36bef04346ee44609b8da085bb4927f9" continuedAt="i6c77b2f7ad244df689f813a69eca5cc1"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNzA_4a1a7db5-bb9e-4bf6-a349-14f61d57564f" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#8217;s financial statements, are reasonable estimates of fair value, primarily due to their short maturities. Marketable securities are classified as long-term investments if the Company has the ability and intent to hold them and such holding period is longer than one year. The Company classifies all of its investments as available-for-sale.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale, short-term and long-term investments, which consist of, commercial paper, corporate bonds, and government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNjQ_241a2bb4-b7c8-435d-b6e8-055f283e34f2" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. <ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="krys:EstimatedUsefulLivesOfAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNzc_98c52112-459c-49d8-ac18-c6620c6e6c2c" continuedAt="i5e8677ecf18749cc994104c208fe189a" escape="true">Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i5e8677ecf18749cc994104c208fe189a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"></td><td style="width:51.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie8265b62d98547d1b612aa5059737994_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RhYmxlOjJkZGY0YmJhZjc3NzQzYzdiZGM5ODMyY2M1YTNjNDdmL3RhYmxlcmFuZ2U6MmRkZjRiYmFmNzc3NDNjN2JkYzk4MzJjYzVhM2M0N2ZfMC0xLTEtMS0yMDk3Ny90ZXh0cmVnaW9uOmM3NTU3NjY3ZjZiZTRlZDFhMmIyOTg0ZDg5YTRmOWYwXzE2NDkyNjc0NDE2ODY_8d6fed03-0e76-4a97-b173-b373528f899f">3</ix:nonNumeric> - <ix:nonNumeric contextRef="iff7c8222f2ec4030bb73e073b01cc801_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RhYmxlOjJkZGY0YmJhZjc3NzQzYzdiZGM5ODMyY2M1YTNjNDdmL3RhYmxlcmFuZ2U6MmRkZjRiYmFmNzc3NDNjN2JkYzk4MzJjYzVhM2M0N2ZfMC0xLTEtMS0yMDk3Ny90ZXh0cmVnaW9uOmM3NTU3NjY3ZjZiZTRlZDFhMmIyOTg0ZDg5YTRmOWYwXzE2NDkyNjc0NDE2OTE_338c6e2a-a889-4f8a-a02b-8883a3d26137">7</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8526152bbd814c19af8798ebbf6df780_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RhYmxlOjJkZGY0YmJhZjc3NzQzYzdiZGM5ODMyY2M1YTNjNDdmL3RhYmxlcmFuZ2U6MmRkZjRiYmFmNzc3NDNjN2JkYzk4MzJjYzVhM2M0N2ZfMS0xLTEtMS0yMDk3Ny90ZXh0cmVnaW9uOmI2ZjE0YzBiZDI3ODQwNmRhYzczOGY0NmY1ZWI2ODU0XzQ_ac05c603-a920-450b-b918-fff748ec9920">3</ix:nonNumeric> - <ix:nonNumeric contextRef="i5b7a2cb4937f4539b4d97203dc50610f_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RhYmxlOjJkZGY0YmJhZjc3NzQzYzdiZGM5ODMyY2M1YTNjNDdmL3RhYmxlcmFuZ2U6MmRkZjRiYmFmNzc3NDNjN2JkYzk4MzJjYzVhM2M0N2ZfMS0xLTEtMS0yMDk3Ny90ZXh0cmVnaW9uOmI2ZjE0YzBiZDI3ODQwNmRhYzczOGY0NmY1ZWI2ODU0Xzg_eb661bb0-520e-4867-a319-a987b6f7705f">7</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1ef4419eb8c470d85aacefec56909e5_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RhYmxlOjJkZGY0YmJhZjc3NzQzYzdiZGM5ODMyY2M1YTNjNDdmL3RhYmxlcmFuZ2U6MmRkZjRiYmFmNzc3NDNjN2JkYzk4MzJjYzVhM2M0N2ZfMi0xLTEtMS0yMDk3Ny90ZXh0cmVnaW9uOjFjZjQ1OWVlN2JkMDQ5MjNhM2I2YjhmNThlMmZkZWE4XzE2NDkyNjc0NDE2ODY_212aad5d-26d8-4db6-8f21-a99f2944830d">3</ix:nonNumeric> - <ix:nonNumeric contextRef="i41aa2659a9d349aca4310c4ac210e321_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RhYmxlOjJkZGY0YmJhZjc3NzQzYzdiZGM5ODMyY2M1YTNjNDdmL3RhYmxlcmFuZ2U6MmRkZjRiYmFmNzc3NDNjN2JkYzk4MzJjYzVhM2M0N2ZfMi0xLTEtMS0yMDk3Ny90ZXh0cmVnaW9uOjFjZjQ1OWVlN2JkMDQ5MjNhM2I2YjhmNThlMmZkZWE4XzE2NDkyNjc0NDE2OTc_218a9644-894f-4f2c-b04b-57d999dfaafb">7</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of remaining useful life or remaining lease term</span></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress ("CIP") is not depreciated until the asset is placed in service.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNjU_14ff46ca-56ec-47bb-b239-ae719f8730f6" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has <ix:nonFraction unitRef="usd" contextRef="iee85b21ece4849119c1efceb43453fde_D20220101-20220331" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTAxMjE_5c3bf040-8c32-4598-9d43-bf282b4f6250"><ix:nonFraction unitRef="usd" contextRef="ice1e26d5975d48f7995f61e80667d911_D20210101-20210331" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTAxMjE_b6fdee0d-70d4-42d1-adf2-eb0fb410b7fa">no</ix:nonFraction></ix:nonFraction>t recognized any impairment losses for the three months ended March&#160;31, 2022 and 2021.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i6c77b2f7ad244df689f813a69eca5cc1" continuedAt="i8f045a699b694400b987322ae80821bc"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNzI_933d4a5d-b0fc-4a6a-8865-665a7ce7ce91" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, Leases ("ASC 842"). Right-of-use lease assets represent our right to use an underlying asset during the lease term and the lease obligations represent our commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#8217;s lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, we have used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain "sale-leaseback" criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on our assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNjY_8b7f5cf0-18a4-4a4c-917c-2b6029900a32" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, related clinical manufacturing costs, contract management services, regulatory and other related costs.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#8217;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third party service providers and the Company&#8217;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNzM_4eda2160-269d-4f01-9b47-2b79b491ae3b" continuedAt="i1a5901684a0546edb2653462f6321e12" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value recognition provisions of Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 718"), to account for stock-based compensation. Compensation costs related to stock options granted is based on the estimated fair value of the awards on the date of grant. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Once the Company's own sufficient historical volatility data was obtained, the Company eliminated the use of a representative peer group and uses only its own historical volatility data in its estimate of expected volatility.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the expected term of its stock options using the &#8220;simplified&#8221; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i8f045a699b694400b987322ae80821bc"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1a5901684a0546edb2653462f6321e12">Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied.</ix:continuation> </span></div><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNzE_70514d37-fbc2-43cf-ad64-ac601e58cd88" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses and is presented net of taxes. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNjc_d41ee735-e5d8-4702-ab03-93e7393b3308" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU 2020-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2020-08") to provide further clarification and update the previously issued guidance in ASU 2017-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20: Premium Amortization on Purchased Callable Debt Securities) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2017-08").  ASU 2017-08 shortened the amortization period for certain callable debt securities purchased at a premium by requiring that the premium be amortized to the earliest call date. ASU 2020-08 requires that at each reporting period, to the extent that the amortized cost of an individual callable debt security exceeds the amount repayable by the issuer at the next call date, the excess premium shall be amortized to the next call date. The new standard was effective beginning January 1, 2021 and should be applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. The adoption of ASU 2020-08 did not have a material impact on the Company's financial position or results of operations upon adoption.</span></div></ix:nonNumeric></ix:continuation><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_37"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RleHRyZWdpb246OTYyOTcwYTU0NzhiNDAzMGFhZDczM2QwYTIwYmI3MjJfOTU4_458293c7-0ab5-4ea1-974c-9e7cd09c3280" continuedAt="ia4a17eab84044265982eb27778ff17b0" escape="true">Net Loss Per Share Attributable to Common Stockholders</ix:nonNumeric></span></div><ix:continuation id="ia4a17eab84044265982eb27778ff17b0"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of shares of common stock and common share equivalents outstanding for the period. Common share equivalents consist of common stock issuable upon exercise of stock options and vesting of restricted stock awards. There were <ix:nonFraction unitRef="shares" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RleHRyZWdpb246OTYyOTcwYTU0NzhiNDAzMGFhZDczM2QwYTIwYmI3MjJfNjYz_3c06cb58-6719-4327-833b-c02f69fff47d">3,226,962</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RleHRyZWdpb246OTYyOTcwYTU0NzhiNDAzMGFhZDczM2QwYTIwYmI3MjJfNjcw_251e7c2a-d1e8-4bb7-9dae-5030ebce206a">1,423,540</ix:nonFraction> common share equivalents outstanding as of March&#160;31, 2022 and 2021, respectively, in the form of stock options and unvested restricted stock awards, that have been excluded from the calculation of diluted net loss per common share as their effect would be anti-dilutive for all periods presented.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RleHRyZWdpb246OTYyOTcwYTU0NzhiNDAzMGFhZDczM2QwYTIwYmI3MjJfOTU5_023e22f5-a411-44fa-8ac6-547287e65ddd" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.596%"><tr><td style="width:1.0%"></td><td style="width:64.187%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.683%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except shares and per share data)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RhYmxlOjE1ZjMzY2I1MmU2MTQ3MGU4MzgzMDE1YTEwY2JmN2Y5L3RhYmxlcmFuZ2U6MTVmMzNjYjUyZTYxNDcwZTgzODMwMTVhMTBjYmY3ZjlfNC0xLTEtMS0yMDk3Nw_3fb312de-38c0-496b-9afe-e2c379714d3d">49,965</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RhYmxlOjE1ZjMzY2I1MmU2MTQ3MGU4MzgzMDE1YTEwY2JmN2Y5L3RhYmxlcmFuZ2U6MTVmMzNjYjUyZTYxNDcwZTgzODMwMTVhMTBjYmY3ZjlfNC0zLTEtMS0yMDk3Nw_2a48040f-5a78-4b64-a3c1-2ef683c38837">15,812</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; diluted common shares</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RhYmxlOjE1ZjMzY2I1MmU2MTQ3MGU4MzgzMDE1YTEwY2JmN2Y5L3RhYmxlcmFuZ2U6MTVmMzNjYjUyZTYxNDcwZTgzODMwMTVhMTBjYmY3ZjlfNi0xLTEtMS0yMDk3Nw_0f282d69-6a72-45cd-b0c8-1df2ed903a9a"><ix:nonFraction unitRef="shares" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RhYmxlOjE1ZjMzY2I1MmU2MTQ3MGU4MzgzMDE1YTEwY2JmN2Y5L3RhYmxlcmFuZ2U6MTVmMzNjYjUyZTYxNDcwZTgzODMwMTVhMTBjYmY3ZjlfNi0xLTEtMS0yMDk3Nw_70e843de-3670-4874-8a38-682b88d630e7">25,114,453</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RhYmxlOjE1ZjMzY2I1MmU2MTQ3MGU4MzgzMDE1YTEwY2JmN2Y5L3RhYmxlcmFuZ2U6MTVmMzNjYjUyZTYxNDcwZTgzODMwMTVhMTBjYmY3ZjlfNi0zLTEtMS0yMDk3Nw_697d879b-4bae-4a84-89f8-b31a847ddc24"><ix:nonFraction unitRef="shares" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RhYmxlOjE1ZjMzY2I1MmU2MTQ3MGU4MzgzMDE1YTEwY2JmN2Y5L3RhYmxlcmFuZ2U6MTVmMzNjYjUyZTYxNDcwZTgzODMwMTVhMTBjYmY3ZjlfNi0zLTEtMS0yMDk3Nw_fb3a1b13-0a4f-4827-8690-4c95539805bd">21,253,508</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per<br/>&#160;&#160; common share</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RhYmxlOjE1ZjMzY2I1MmU2MTQ3MGU4MzgzMDE1YTEwY2JmN2Y5L3RhYmxlcmFuZ2U6MTVmMzNjYjUyZTYxNDcwZTgzODMwMTVhMTBjYmY3ZjlfNy0xLTEtMS0yMDk3Nw_37c1b87e-e918-4cab-9353-bdcbace39cdf"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RhYmxlOjE1ZjMzY2I1MmU2MTQ3MGU4MzgzMDE1YTEwY2JmN2Y5L3RhYmxlcmFuZ2U6MTVmMzNjYjUyZTYxNDcwZTgzODMwMTVhMTBjYmY3ZjlfNy0xLTEtMS0yMDk3Nw_5371e751-8240-48ed-bca8-b26c81886b59">1.99</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RhYmxlOjE1ZjMzY2I1MmU2MTQ3MGU4MzgzMDE1YTEwY2JmN2Y5L3RhYmxlcmFuZ2U6MTVmMzNjYjUyZTYxNDcwZTgzODMwMTVhMTBjYmY3ZjlfNy0zLTEtMS0yMDk3Nw_425d00d4-8181-477b-a396-50c6e33d9bb2"><ix:nonFraction unitRef="usdPerShare" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RhYmxlOjE1ZjMzY2I1MmU2MTQ3MGU4MzgzMDE1YTEwY2JmN2Y5L3RhYmxlcmFuZ2U6MTVmMzNjYjUyZTYxNDcwZTgzODMwMTVhMTBjYmY3ZjlfNy0zLTEtMS0yMDk3Nw_5db1c0e4-ab68-4a6e-b758-fedee9ab4690">0.74</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt;text-align:center;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RleHRyZWdpb246MDNiYjNjZWZiMzlmNGM4Y2JhZTljZWNkYmY0MWQ2NzBfNTAz_b809b21f-c752-4ff8-88c9-494f7b3966a5" continuedAt="i797ea36a4e2749cebeb3faf631b6be22" escape="true">Fair Value Instruments</ix:nonNumeric></span></div><ix:continuation id="i797ea36a4e2749cebeb3faf631b6be22"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RleHRyZWdpb246MDNiYjNjZWZiMzlmNGM4Y2JhZTljZWNkYmY0MWQ2NzBfNTA0_c20e8ea6-6c48-4382-b7da-495605e7d9bb" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category as of March&#160;31, 2022 and December&#160;31, 2021, respectively (in thousands):</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63849f9dca98492397cffbdb5ad8bc0a_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfNC0xLTEtMS0yMDk3Nw_7e299ae6-f413-4297-8447-d8285edf93d5">269,303</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63849f9dca98492397cffbdb5ad8bc0a_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfNC03LTEtMS0yMDk3Nw_53cd8d61-ac4e-4a0e-ba7f-327836e6e945">269,303</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71df1d506a1d42f59d5769c25d50de0d_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfNC05LTEtMS0yMDk3Nw_1f75855d-e928-4485-b611-b1b3506b445e">269,303</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b56a800b1dc4d59b0579103fb3856e3_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfNS0xLTEtMS0yMDk3Nw_899d5e6a-6697-438d-92cf-635961172310">269,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b56a800b1dc4d59b0579103fb3856e3_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfNS03LTEtMS0yMDk3Nw_584bbe1b-b0f7-4c2b-aedf-54954e08c27e">269,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e3ccafd6e7408e8d72c7ed3d59aa1d_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfNS05LTEtMS0yMDk3Nw_dc28570d-32d3-458a-aa35-46ed3a1b0f89">269,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0718e9e6a304faa99a8d0ba4d170a50_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOC0xLTEtMS0yMDk3Nw_7d4683f3-b1a9-4c77-abec-1d6d480b675d">39,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0718e9e6a304faa99a8d0ba4d170a50_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOC0zLTEtMS0yMDk3Nw_9cc49d31-dac8-4098-bfbe-4af6b5cdbc7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0718e9e6a304faa99a8d0ba4d170a50_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOC01LTEtMS0yMDk3Nw_fa49547c-9b2d-4be4-b73d-ce4f80e97943">37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0718e9e6a304faa99a8d0ba4d170a50_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOC03LTEtMS0yMDk3Nw_cc82f3a4-adb5-4036-bf71-41ffaf07aafa">39,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e06177b3b947ed827f1ae04d3f6c24_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOC0xMS0xLTEtMjA5Nzc_d1448050-f763-4f6e-82b7-3378c5b655fe">39,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91af162b5ce24bcca39b1802458f9c63_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOC0xMy0xLTEtMjA5Nzc_64ca78ef-45d1-459f-a219-ccc327174dcf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12453054567d425ebb3db8321c10080c_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOS0xLTEtMS0yMDk3Nw_72b21390-43dc-411b-a338-8358e1353f12">106,741</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12453054567d425ebb3db8321c10080c_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOS0zLTEtMS0yMDk3Nw_7719a689-014f-471b-84e1-204f93998274">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12453054567d425ebb3db8321c10080c_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOS01LTEtMS0yMDk3Nw_0e2d8dd6-39d7-43f5-a97c-ef436e6bdd5e">724</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12453054567d425ebb3db8321c10080c_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOS03LTEtMS0yMDk3Nw_89842cc4-ac15-4bf3-ab6f-5c8abcf6e6e0">106,019</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0605bcc794c8466488458ac6a40a567a_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOS0xMS0xLTEtMjA5Nzc_5cefef93-b4cc-4cd8-a142-dae3554f3c0e">81,961</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fc83aec7ccf4e56b6000b187c116bc9_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOS0xMy0xLTEtMjA5Nzc_0a03ac45-548e-446e-9753-73a549036ba5">24,058</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac939cd950c94172a39585927ae3707b_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTAtMS0xLTEtMjA5Nzc_29c1793a-51b0-4897-ae03-1acc3e575660">53,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac939cd950c94172a39585927ae3707b_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTAtMy0xLTEtMjA5Nzc_a6f223f9-3f82-496e-a466-a5cefb8081ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac939cd950c94172a39585927ae3707b_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTAtNS0xLTEtMjA5Nzc_31839ecf-108e-4867-87b1-43e8ff4cdc19">440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac939cd950c94172a39585927ae3707b_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTAtNy0xLTEtMjA5Nzc_33f451dd-382c-4334-b199-1ea23e86d7d1">53,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52a9c36697194609ac56e04b9aa3d9a8_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTAtMTEtMS0xLTIwOTc3_a3ed5018-fb86-4a7c-b698-c81824d94a91">43,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c95f3dd9aa1471889572b02d7094b9d_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTAtMTMtMS0xLTIwOTc3_b2e0e303-4caf-4178-8efb-a16b59114495">9,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2740425fee244d2f922f4b25973e349b_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTEtMS0xLTEtMjA5Nzc_70cc1430-283f-4025-b2a2-6b461a784989">199,867</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2740425fee244d2f922f4b25973e349b_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTEtMy0xLTEtMjA5Nzc_a727258a-dc56-4da5-9f82-27b5717d1758">2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2740425fee244d2f922f4b25973e349b_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTEtNS0xLTEtMjA5Nzc_4fe4b0a4-b38c-4928-bf02-199fc244a686">1,201</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2740425fee244d2f922f4b25973e349b_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTEtNy0xLTEtMjA5Nzc_7fc839f1-fa35-46da-8c6a-6ae47fad0ff5">198,668</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdbc6dddacb448d9ad60106137194932_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTEtMTEtMS0xLTIwOTc3_888b22d0-a259-4cb1-a317-7375810a6bf4">165,329</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebe00a10a2724634b1c0118d2d67a4a8_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTEtMTMtMS0xLTIwOTc3_c1db0bac-ffa7-45e4-9ca2-c8de07e544c5">33,339</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTItMS0xLTEtMjA5Nzc_e680e2d2-871b-4dfb-a8b2-e51dcbcace49">469,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTItMy0xLTEtMjA5Nzc_2452b61d-e2b2-4fc3-b5e7-a2fa9e7a038f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTItNS0xLTEtMjA5Nzc_9466cf14-af55-4cd8-a657-4fc03ab40d52">1,201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTItNy0xLTEtMjA5Nzc_74f6a9a9-2e87-4746-aa61-cfb800751d5c">467,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeaaf7239b4345778bad76871b818c5a_I20220331" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTItOS0xLTEtMjA5Nzc_d9b9f35f-02a0-44a8-a4cf-0bed5f0b3300">269,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3140340b83cb4218b934f3877760f87c_I20220331" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTItMTEtMS0xLTIwOTc3_4eeb11e2-53da-4824-857c-b48ceb95dfce">165,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba6d511515a4acf97d285fa1677f2cb_I20220331" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTItMTMtMS0xLTIwOTc3_37de22da-3abd-45cd-93ed-1837983315a2">33,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:22.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a3729b490084ba89c9abadcac13b833_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMy0xLTEtMS0yMDk3Nw_1e58ff7e-c2b3-44e8-9bdf-f0f9c84c2417">341,246</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a3729b490084ba89c9abadcac13b833_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMy03LTEtMS0yMDk3Nw_1675de11-be89-4880-9429-e4abaf03172f">341,246</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23a4767bf6e240bda02a5dbd7afc4ff7_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMy05LTEtMS0yMDk3Nw_7bb6059a-5650-4e8f-bad6-787f0b6e6e35">341,246</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d1b20d4b556453996c9073c1c2716ee_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNS0xLTEtMS0yMDk3Nw_5b26db29-a21c-4333-b39b-bc153f0c0379">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d1b20d4b556453996c9073c1c2716ee_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNS03LTEtMS0yMDk3Nw_135d18be-957d-413f-8dba-c7aaa739eef7">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f0e12c30bc84334939e2e4bf442dfac_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNS05LTEtMS0yMDk3Nw_03512803-5c21-4dd3-83b1-e092dff4cdb6">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49e8debc5cb94ea6a469f4196d724fa5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy0xLTEtMS0yMjE2Ng_140df78c-af4f-4731-8ef9-861dfccc013d">40,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49e8debc5cb94ea6a469f4196d724fa5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy0zLTEtMS0yMjE2Ng_9ad908a1-598f-4f16-86d5-55009e723641">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49e8debc5cb94ea6a469f4196d724fa5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy01LTEtMS0yMjE2Ng_c5573c72-ced9-4038-9210-172b0505c4db">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49e8debc5cb94ea6a469f4196d724fa5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy03LTEtMS0yMjE2Ng_5854c516-e4d1-400d-b5e5-55a3f3b0592e">40,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46c951025fce41ab952849ce6a3ab2e4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy0xMS0xLTEtMjIxNjY_682321d5-8675-4d84-9611-68502fa25ddc">40,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8f54899b4a4148a67b60622acaf77b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy0xMy0xLTEtMjIxNjY_d1056f54-91d2-4531-bd0d-c9a2cf7515b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ba725ffee7e42e6a8128c65b3a212bd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy0xLTEtMS0yMDk3Nw_44ac8f70-3109-4403-88ce-d637ae7e6491">83,300</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ba725ffee7e42e6a8128c65b3a212bd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy0zLTEtMS0yMDk3Nw_051878d4-4c5d-4c42-9b05-84046a2c28e2">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ba725ffee7e42e6a8128c65b3a212bd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy01LTEtMS0yMDk3Nw_3fe88090-2599-49a0-a493-010ba3ebcffd">114</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ba725ffee7e42e6a8128c65b3a212bd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy03LTEtMS0yMDk3Nw_ce3fc119-7771-458c-81d3-47a0978092af">83,196</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf6969542ce14c959f3e2e0e56bcb784_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy0xMS0xLTEtMjA5Nzc_03056371-b1aa-4811-8040-ce3071dcc571">35,768</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1502ff476f7844a8b66df5fd7220258e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy0xMy0xLTEtMjA5Nzc_688c53d2-236b-4f29-b002-ac2d16019a92">47,428</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bad5e70d1fb436897da83e0b8eeee55_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfOS0xLTEtMS0yMjE2Ng_c3c08ed2-b2bf-4fcd-8a25-42b98b072a30">37,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bad5e70d1fb436897da83e0b8eeee55_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfOS0zLTEtMS0yMjE2Ng_427d84cb-1e76-4b83-888d-559945af9aed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3bad5e70d1fb436897da83e0b8eeee55_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfOS01LTEtMS0yMjE2Ng_2436ee8b-3441-4dcf-acba-e10048b1e500">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bad5e70d1fb436897da83e0b8eeee55_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfOS03LTEtMS0yMjE2Ng_cb7c1eba-8d23-48b6-b3b5-83c59454f3dc">37,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa7daa0072cb419cb2dbaaf3afff522e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfOS0xMS0xLTEtMjIxNjY_4690be64-881b-4579-94fb-f1b5335daf06">20,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c36492a3b734099aac3b58956194853_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfOS0xMy0xLTEtMjIxNjY_4b0a90c4-bd8a-4f06-8dd5-e83378c1b707">16,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7984fa6b0c43debd86bc7ec5c8ddef_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTEtMS0xLTEtMjA5Nzc_71b9a3da-3e75-4986-a10a-6687ec326547">161,390</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7984fa6b0c43debd86bc7ec5c8ddef_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTEtMy0xLTEtMjA5Nzc_f55353d9-adb1-48f9-899f-11325d7fe277">11</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc7984fa6b0c43debd86bc7ec5c8ddef_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTEtNS0xLTEtMjA5Nzc_c1ee533e-4bfe-4fcb-ad79-bb7799fb4445">180</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7984fa6b0c43debd86bc7ec5c8ddef_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTEtNy0xLTEtMjA5Nzc_5c3adbc5-d5c6-4888-bbd4-a76af96eb1f6">161,221</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbf78e0869994741ae4e6b2efdb39bc9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTEtMTEtMS0xLTIwOTc3_42b4c6c0-6a97-46a9-af29-c43189ac622c">96,850</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f5b030412564955be828db44eb6b956_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTEtMTMtMS0xLTIwOTc3_bc256a4d-c27b-423e-9fb2-607d65491334">64,371</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTItMS0xLTEtMjA5Nzc_96f61483-6175-4218-87d2-cc5ffe6486f5">502,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTItMy0xLTEtMjA5Nzc_e77abdb3-f82e-410c-bdc2-d5237380a628">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTItNS0xLTEtMjA5Nzc_6a202c0b-d35a-4176-944a-21b9409443f6">180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTItNy0xLTEtMjA5Nzc_8f9f52d1-030a-463d-90ca-7b5389fdfa76">502,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8b8c8c466f413999e0992ec12716e5_I20211231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTItOS0xLTEtMjA5Nzc_4cfc6c6f-b811-4fc5-8b57-12e7a2a9e60d">341,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e50181337f4deda50f8a1ec567dd37_I20211231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTItMTEtMS0xLTIwOTc3_cb556deb-ccd8-469a-a74f-d0b9af846ece">96,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if60f2e99fb10489cb879593621b5e8bc_I20211231" decimals="-3" name="krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTItMTMtMS0xLTIwOTc3_b65fcc62-602f-48f4-b1c7-9716907b7460">64,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company&#8217;s short-term marketable securities mature in <ix:nonNumeric contextRef="ifdbc6dddacb448d9ad60106137194932_I20220331" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RleHRyZWdpb246MDNiYjNjZWZiMzlmNGM4Y2JhZTljZWNkYmY0MWQ2NzBfMjcy_ef074a95-b03c-4418-9ad2-4e93d45f9bcb">one year</ix:nonNumeric> or less.</span></div><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company's long-term marketable securities mature between <ix:nonNumeric contextRef="i8a8a378d87ac477fa9eb1f74361e0f3a_I20220331" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RleHRyZWdpb246MDNiYjNjZWZiMzlmNGM4Y2JhZTljZWNkYmY0MWQ2NzBfMzQ1_9f7d578f-36e8-4975-8c7b-729edf62ef7b">one year</ix:nonNumeric> and <ix:nonNumeric contextRef="icd44f57ba38a4bbfb2f25ef586c2f644_I20220331" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RleHRyZWdpb246MDNiYjNjZWZiMzlmNGM4Y2JhZTljZWNkYmY0MWQ2NzBfMzUy_ab7751fa-6189-4b15-9b6d-4ba048df1863">two years</ix:nonNumeric>.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 to these unaudited condensed consolidated financial statements for additional discussion regarding the Company&#8217;s fair value measurements.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RleHRyZWdpb246MDI3MzNhNDY0YTg4NDY0NWEwOGZkZGU3ZGNlMGE0MzdfMzgw_01b569b1-103c-44b0-aa55-cc7c13a3a48a" continuedAt="i50d890ab09cf4dc59ff76f3151aaa426" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="i50d890ab09cf4dc59ff76f3151aaa426"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RleHRyZWdpb246MDI3MzNhNDY0YTg4NDY0NWEwOGZkZGU3ZGNlMGE0MzdfMzgx_c9b4b441-b165-4e9d-acd1-cdc7b1f4f064" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:67.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbf226c7773f451cb39f05cc616016f9_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfMi0xLTEtMS0yMDk3Nw_62319e15-18ef-4c15-b46c-0e2e3ea060a5">128,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70bd060e96749a89eccb6ac7c4aa94e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfMi0zLTEtMS0yMDk3Nw_d1414ec5-fdb3-486d-92d6-21f529559c6b">104,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8144f7ab623b4afca039c1cbdf57e750_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfMy0xLTEtMS0yMDk3Nw_be9eb413-3dac-4e70-96c0-37bd05aed9a8">5,736</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c8d6050468f4d63a79e15bdcd8ec20b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfMy0zLTEtMS0yMDk3Nw_e6895ef0-0207-4b4c-97f5-bf165f3e88e4">5,723</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a8d28f658e64c9cb72dab709adfb297_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfNC0xLTEtMS0yMDk3Nw_4887811e-f0d0-4952-808a-56be7cea29b3">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ce87c71085b42e9b14d17fca3b617ca_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfNC0zLTEtMS0yMDk3Nw_f43faff6-84a7-4c20-b3a9-3c27a0bd0d47">891</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16934897395943d38eb471fd6a4ab451_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfNS0xLTEtMS0yMDk3Nw_e54bffb0-3026-4604-afb7-6db2afca403d">96</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c5891e652c44560a9dfb628c66faca5_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfNS0zLTEtMS0yMDk3Nw_99100dc4-b9ec-4b27-a3b9-f9caa9524100">85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4980d8ad41eb414591647b2b42093a20_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfNi0xLTEtMS0yMDk3Nw_e6eec1f2-0cb5-4608-a073-83336b311c3d">5,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95c8dea3eb594cc3900cf46e3694ed5b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfNi0zLTEtMS0yMDk3Nw_eaf2b023-9e28-42ba-9859-4cde9dfa1aad">5,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfNy0xLTEtMS0yMDk3Nw_4dfdebc6-f7ad-44a2-86dc-b114dd95cdb4">141,603</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfNy0zLTEtMS0yMDk3Nw_3fd8fb25-75f0-48e3-91a5-6c8a6562e85a">116,569</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfOC0xLTEtMS0yMDk3Nw_8e354b87-34d9-4751-8543-ed12c9655fb9">4,676</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfOC0zLTEtMS0yMDk3Nw_6089690c-62cd-45ce-8354-218b1c5b9656">4,214</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfOS0xLTEtMS0yMDk3Nw_bd016f2b-778f-45cf-8fc5-60581c7e3e33">136,927</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfOS0zLTEtMS0yMDk3Nw_002cff31-d60b-45a6-83e4-e02b6790fe4a">112,355</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RleHRyZWdpb246MDI3MzNhNDY0YTg4NDY0NWEwOGZkZGU3ZGNlMGE0MzdfMTU3_76d997ad-f549-49b6-b38e-1aa8c737424f">462</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RleHRyZWdpb246MDI3MzNhNDY0YTg4NDY0NWEwOGZkZGU3ZGNlMGE0MzdfMTk4_c7829ca9-ff2d-4b4f-bc7f-8ce25c75ac60">438</ix:nonFraction> thousand for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RleHRyZWdpb246MDI3MzNhNDY0YTg4NDY0NWEwOGZkZGU3ZGNlMGE0MzdfMzgy_3030f2b7-ded3-4649-86ae-f3c601baf9ac" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-indent:29.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:67.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical and clinical expenses</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="krys:AccruedPreclinicalAndClinicalExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfMi0xLTEtMS0yMDk3Nw_2f48f532-5aef-4e82-a849-01b312d923b8">2,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="krys:AccruedPreclinicalAndClinicalExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfMi0zLTEtMS0yMDk3Nw_3102efc3-5c0b-4730-8d64-a0138d690fe4">1,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfMy0xLTEtMS0yMDk3Nw_b9a2d61d-b49a-44e1-86b4-04dd9e51063f">4,168</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfMy0zLTEtMS0yMDk3Nw_baa3ccf8-b3e5-403a-a353-4c771c93ec0f">2,011</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="krys:AccruedPayrollAndBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfNC0xLTEtMS0yMDk3Nw_5ecf65a1-723e-44d3-9ad8-2129a355bf89">1,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="krys:AccruedPayrollAndBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfNC0zLTEtMS0yMDk3Nw_2ed6d525-07df-4344-9385-3531f675ca63">2,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:AccruedIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfNS0xLTEtMS0yMDk3Nw_f1261bea-6558-4da1-b0cd-f5a66dff356a">149</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:AccruedIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfNS0zLTEtMS0yMDk3Nw_c1acc423-7f56-46d1-b279-1f50ecfe048a">83</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction in progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="krys:AccruedConstructionInProgressCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfNi0xLTEtMS0yMDk3Nw_905b2e15-17b9-4732-a8d6-f93d48e7d6eb">17,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="krys:AccruedConstructionInProgressCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfNi0zLTEtMS0yMDk3Nw_1f2f35cc-d36b-4a45-8654-0a82d57646df">9,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued financing costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="krys:AccruedFinancingFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfNy0xLTEtMS0yMDk3Nw_296ce04d-aaed-4cd2-868f-054f852c419c">54</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="krys:AccruedFinancingFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfNy0zLTEtMS0yMDk3Nw_50b0c3a2-ccc4-40b1-8ccd-c17e6d1cb115">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation settlement</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfOC0xLTEtMS0yMzYzNg_55c0cc5a-0f4c-42ae-9b24-74e19c9d0464">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:LitigationReserveCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfOC0zLTEtMS0yNTczMA_a53a3dbd-59f8-4de5-a800-86f07fa45c6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfOC0xLTEtMS0yMDk3Nw_7a1ff240-980c-4bcb-b1c1-3dd0be2019bd">142</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfOC0zLTEtMS0yMDk3Nw_402e26fd-ddfe-43ac-9755-c6846b306292">87</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="krys:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfOS0xLTEtMS0yMDk3Nw_9c26283b-7df1-462f-a2c1-b555137a7ce7">50,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="krys:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfOS0zLTEtMS0yMDk3Nw_33ff902d-6654-4635-bbcc-2f17576f56cf">16,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><span><br/></span></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_46"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTE3NjY_71b565c5-bd54-4348-810e-0963a18dde43" continuedAt="if6ce842541cf452b9a84d7d957bdc964" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="if6ce842541cf452b9a84d7d957bdc964" continuedAt="ibdff8b5083c147899ed25befa141130b"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Contracts and Agreements</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Agreements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2016, the Company signed an operating lease for laboratory and office space that commenced in June 2016 and expired on October 31, 2017 (the &#8220;2016 Lease&#8221;). The 2016 Lease has been amended several times to increase the area leased, which currently consists of approximately <ix:nonFraction unitRef="sqft" contextRef="idbf36e2c49fc42d9a41ee8670488e982_I20220331" decimals="-3" name="krys:AdditionalAreaOfRealEstatePropertyLeased" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMzYy_c1889a3a-8d4e-4474-8ddd-7ed4fdb0d591">47,000</ix:nonFraction> square feet and includes the commercial scale cGMP-compliant manufacturing facility, ANCORIS.  As a result of the lease amendments, the lease expiration date was extended to October 31, 2031. </span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 26, 2019, we entered into a lease agreement for our second commercial gene therapy facility ("ASTRA") in the Pittsburgh, Pennsylvania area ("ASTRA lease") with Northfield I, LLC (the "Landlord", "Northfield", or "Lessor") with </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="ibdff8b5083c147899ed25befa141130b" continuedAt="i0dbee69178be44deb708de5235e8a287"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an initial lease term that expired on October 31, 2035.  The ASTRA lease contained an option ("Purchase Option") to purchase the building, related improvements and take corresponding assignment of the Landlord's rights under its existing Ground Lease (the "Ground Lease"). A cash contribution in the amount of $<ix:nonFraction unitRef="usd" contextRef="i259ce76551454123911c8f7e6cf9cd6d_I20200121" decimals="-5" name="krys:PaymentToEscrowForReducingLeaseRentals" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTAxNg_a9741fba-c839-4eb4-9974-696ba4e3d644">2.4</ix:nonFraction>&#160;million was paid to escrow on January 21, 2020. The contribution was intended to reduce the amount of the building construction costs and had the effect of reducing the base rental rate of the lease and as such, was recorded as prepaid rent in the consolidated balance sheet at the time of payment.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2020, the Company was provided with notice that the initial delivery conditions of the building had been met, including completion of the building shell, interior slab, and exterior doors, and on October 15, 2020, the Company gave the Landlord notice of its intent to purchase ASTRA for approximately $<ix:nonFraction unitRef="usd" contextRef="ia5b58230696440249bca1a1906cb63f3_D20201015-20201015" decimals="-5" name="krys:PurchasePriceOfPotentialBuildingPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTYyNQ_d206f724-22b4-4d27-a0f6-5667ca2ea6f7">9.4</ix:nonFraction>&#160;million, subject to the parties entering into a commercially reasonable purchase and sale agreement. As a result of the Company's ability to exercise its option to purchase ASTRA, the Company obtained control over the construction in progress of ASTRA as of October 5, 2020.  The Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i2384fef03d174e7293ac35a6c188c7cf_I20201005" decimals="-5" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTkxOQ_8bd612a7-1897-4ac4-8797-b42a12e6dcf0"><ix:nonFraction unitRef="usd" contextRef="i2384fef03d174e7293ac35a6c188c7cf_I20201005" decimals="-5" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTkxOQ_af480ce4-72ea-4e08-906c-3288842b654d">10.0</ix:nonFraction></ix:nonFraction>&#160;million CIP asset and a corresponding build to suit lease liability related to the costs incurred by the Landlord, offset by the previous cash contribution of $<ix:nonFraction unitRef="usd" contextRef="i2384fef03d174e7293ac35a6c188c7cf_I20201005" decimals="-5" name="krys:PaymentToEscrowForReducingLeaseRentals" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjA3Mw_43b4ce40-e129-4965-9b20-b65157a34983">2.4</ix:nonFraction>&#160;million.  </span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2021, the Company entered into a Purchase and Sale Agreement ("PSA") for ASTRA with Northfield related to the purchase option exercised by the Company on October 15, 2020, for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="ia5b58230696440249bca1a1906cb63f3_D20201015-20201015" decimals="-5" name="krys:PurchasePriceOfPotentialBuildingPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjI5MA_8f85497f-cd31-4976-aa5c-b436abf38c7a">9.4</ix:nonFraction>&#160;million. The Company held approximately $<ix:nonFraction unitRef="usd" contextRef="ib1f1bacd274b4e44b1a1f8151a2b5097_I20201015" decimals="-5" name="us-gaap:EscrowDeposit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjMyNQ_1f7b7d74-4012-4b51-9901-e70622dc89b0">1.5</ix:nonFraction>&#160;million on deposit with Northfield under the existing lease agreement and applied this deposit as a credit against the purchase price at closing. On February 1, 2021, Northfield delivered the space as substantially complete and made the space available for access by the Company, thus triggering lease commencement.  As a result, the Company concluded that this transaction did not qualify for sale-leaseback accounting because it did not meet the definition of a sale.  As control did not transfer to the Lessor at lease commencement, the transaction continued to be accounted for as construction in progress and a financing obligation. On March 5, 2021, the purchase closed and the Company determined that reclassification of the construction in progress to buildings and leasehold improvements was not appropriate as the interior of the building was not yet ready for its intended use. The building continues to be held under construction in progress as of March&#160;31, 2022. The interior of the building is currently under construction and is expected to be completed and validated in 2022.  From construction completion to the closing of the purchase, the Company recognized interest expense to accrete the financial obligation to a balance that equaled the cash consideration that was paid upon the close of purchase. For more information about the expected construction costs associated with ASTRA, see "ASTRA Contractual Obligations" below.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the transaction, the Company also became the accounting owner of the Ground Lease, due to obtaining control over ASTRA, and recorded the applicable operating right-of-use asset and corresponding lease liability as of October 5, 2020. When the PSA was finalized, the Company took assignment of the Lessor's Ground Lease, in accordance with the Purchase Option, of which lease payments are based on annual payments of $<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="krys:LessorOperatingLeaseLiabilityAnnualLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNDE4MQ_223ef89f-0090-4301-9897-4c5e05c3f05d">82</ix:nonFraction>&#160;thousand, and are subject to a cumulative <ix:nonFraction unitRef="number" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="INF" name="krys:CumulativeEscalationClausePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNDIxNw_5bd5871a-2580-4fbe-b3bd-2dbb89e42d87">10</ix:nonFraction>% escalation clause every <ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="krys:CumulativeEscalationClauseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNDI0NA_638a1abf-6083-4c34-88c3-176e1b8d8a9b">5</ix:nonNumeric> years through 2071. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 15, 2021, the Company entered into a <ix:nonNumeric contextRef="i6642a4976dcc4bbb8b89924a05835ed9_I20211215" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTA5OTUxMTY0OTUzNw_843bba20-5221-4230-af7e-6bb5003863d8">3</ix:nonNumeric> year lease agreement for our Boston, Massachusetts office (the "Boston Lease") location that commenced in January 2022 and expires in January 2025.</span></div><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTE3Njc_7640c77c-32e7-4a1e-b313-5a1f3daa6468" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, future minimum commitments under the Company&#8217;s operating leases were as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"></td><td style="width:83.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.756%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining nine months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOjc5ZTE3YWUxY2VlZDRjNzdiNDc4ZGZjNjA2ZTgwMWNjL3RhYmxlcmFuZ2U6NzllMTdhZTFjZWVkNGM3N2I0NzhkZmM2MDZlODAxY2NfMS0xLTEtMS0yMDk3Nw_52956351-2638-46b2-be20-cba1a681b26a">1,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOjc5ZTE3YWUxY2VlZDRjNzdiNDc4ZGZjNjA2ZTgwMWNjL3RhYmxlcmFuZ2U6NzllMTdhZTFjZWVkNGM3N2I0NzhkZmM2MDZlODAxY2NfMi0xLTEtMS0yMDk3Nw_4536fb58-7075-4951-995e-a5905cc61c77">1,510</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOjc5ZTE3YWUxY2VlZDRjNzdiNDc4ZGZjNjA2ZTgwMWNjL3RhYmxlcmFuZ2U6NzllMTdhZTFjZWVkNGM3N2I0NzhkZmM2MDZlODAxY2NfMy0xLTEtMS0yMDk3Nw_2df4682c-25d1-4ff1-bf0f-d2b63c2b785a">1,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOjc5ZTE3YWUxY2VlZDRjNzdiNDc4ZGZjNjA2ZTgwMWNjL3RhYmxlcmFuZ2U6NzllMTdhZTFjZWVkNGM3N2I0NzhkZmM2MDZlODAxY2NfNC0xLTEtMS0yMDk3Nw_00de5a91-e11a-4422-b6ad-194d7271d379">1,277</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOjc5ZTE3YWUxY2VlZDRjNzdiNDc4ZGZjNjA2ZTgwMWNjL3RhYmxlcmFuZ2U6NzllMTdhZTFjZWVkNGM3N2I0NzhkZmM2MDZlODAxY2NfNS0xLTEtMS0yMDk3Nw_5dea588d-9078-457a-84b4-250c0bdca8d6">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="krys:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOjc5ZTE3YWUxY2VlZDRjNzdiNDc4ZGZjNjA2ZTgwMWNjL3RhYmxlcmFuZ2U6NzllMTdhZTFjZWVkNGM3N2I0NzhkZmM2MDZlODAxY2NfNi0xLTEtMS0yMDk3Nw_6ab8b030-c8dd-43a7-8822-4dde3c8a2347">12,063</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOjc5ZTE3YWUxY2VlZDRjNzdiNDc4ZGZjNjA2ZTgwMWNjL3RhYmxlcmFuZ2U6NzllMTdhZTFjZWVkNGM3N2I0NzhkZmM2MDZlODAxY2NfNy0xLTEtMS0yMDk3Nw_61df90aa-1b96-4c9f-ac59-0e1daeae7c8f">18,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOjc5ZTE3YWUxY2VlZDRjNzdiNDc4ZGZjNjA2ZTgwMWNjL3RhYmxlcmFuZ2U6NzllMTdhZTFjZWVkNGM3N2I0NzhkZmM2MDZlODAxY2NfOC0xLTEtMS0yMDk3Nw_e6b308cf-d1b7-4431-b589-3a88342da506">9,487</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOjc5ZTE3YWUxY2VlZDRjNzdiNDc4ZGZjNjA2ZTgwMWNjL3RhYmxlcmFuZ2U6NzllMTdhZTFjZWVkNGM3N2I0NzhkZmM2MDZlODAxY2NfOS0xLTEtMS0yMDk3Nw_d7731bb5-d893-46ff-bd86-3a67a904bb5b">9,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTE3Njg_94aa7965-c00f-4fdb-adca-b44230c41afa" continuedAt="ia970e78d893b4383bf0b6e8941227b09" escape="true">Supplemental condensed consolidated balance sheet information related to leases is as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i0dbee69178be44deb708de5235e8a287" continuedAt="i164fdbd1df2242318e667805262c4d5c"><div style="margin-top:2pt;text-indent:29.25pt"><ix:continuation id="ia970e78d893b4383bf0b6e8941227b09"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:67.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfMy0xLTEtMS0yMDk3Nw_57300471-89d3-4aaa-a1e8-968e1e81f482">8,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfMy0zLTEtMS0yMDk3Nw_aff7ef56-fc73-4eba-82e8-7d690287fcf4">7,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfNC0xLTEtMS0yMDk3Nw_6dbbab2b-7472-446b-9b80-f83e50278e8f">1,411</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfNC0zLTEtMS0yMDk3Nw_83fe68cc-4052-4bd6-8642-4445ae237447">1,041</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfNS0xLTEtMS0yMDk3Nw_5277a61a-aa82-4814-bd97-d1de30750f50">7,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfNS0zLTEtMS0yMDk3Nw_e0e165aa-2d33-4949-b732-57c38a7ebcbb">6,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfNi0xLTEtMS0yMDk3Nw_cf1b10d1-1b9e-4763-b060-4c0decd6f929">9,294</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfNi0zLTEtMS0yMDk3Nw_5612bf92-ed97-4a8c-bd8c-634d19b53a2a">8,024</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term, in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfNy0xLTEtMS0yMDk3Nw_9a070c8d-b44a-409e-a775-e7938b3e409f">13.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfNy0zLTEtMS0yMDk3Nw_ffe10a50-2b8c-4624-a7fd-18e43f3fc803">14.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfOC0xLTEtMS0yMDk3Nw_45b599ad-1e57-4dc2-8f75-9a7d60ff86e3">9.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfOC0zLTEtMS0yMDk3Nw_c9f89a16-3b9a-4869-b626-c97f26fa8e52">9.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-top:2pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded operating lease costs of $<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNDUxNQ_d71b1a86-32c8-44ec-9a80-a59ae169f207">409</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTA5OTUxMTY0ODI3NQ_6d7f2885-e929-490b-a8c2-af64d9d78798">218</ix:nonFraction> thousand for the three months ended March&#160;31, 2022 and 2021, respectively, and variable lease costs of $<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNDYzNg_083cdb59-ad82-4b93-9d45-eb17cee56e57">49</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTA5OTUxMTY0ODMxNg_91d8e9c6-d3a5-4e14-8bfd-a0034a3b6832">37</ix:nonFraction> thousand for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Agreements with Contract Manufacturing Organizations and Contract Research Organizations</span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various agreements in the normal course of business with Contract Research Organizations ("CROs"), Contract Manufacturing Organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. The agreements with CMOs relate to the manufacturing of sterile gel that is mixed with in-house produced vectors as part of the final drug product applied in certain of our clinical trials. These agreements may also include research and development activities, storage, packaging, labeling, and/or testing of our preclinical and clinical-stage products. The Company is obligated to make milestone payments under certain of these agreements. The estimated remaining commitment as of March&#160;31, 2022 under these agreements is approximately $<ix:nonFraction unitRef="usd" contextRef="ib888a32279a646d6bc98bb4650978ad1_I20220331" decimals="-5" name="krys:RemainingCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNTczMQ_90ee0831-82d6-452b-81a0-70fca86fa8d1">3.1</ix:nonFraction> million. The Company may also be responsible for the payment of a monthly service fee for project management services for the duration of any agreements. The Company has incurred expenses under these agreements of $<ix:nonFraction unitRef="usd" contextRef="ic9ac354f7bd046949c8c5c9a884f44b6_D20220101-20220331" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNTk0MA_ad645641-1b52-4b91-8070-afa2368a1046"><ix:nonFraction unitRef="usd" contextRef="iab4cf6bacbe94549a3840f7cc0180c4d_D20210101-20210331" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNTk0MA_bb1bd259-496d-4a90-8a19-aece20501e97">1.8</ix:nonFraction></ix:nonFraction> million for each of the three months ended March&#160;31, 2022 and 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Preparedness Activities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to facilitate, coordinate and perform agreed upon commercial preparedness and market research activities relating to our lead product candidate. These contracts typically call for the payment of fees for services upon the achievement of certain milestones. The estimated remaining commitment as of March&#160;31, 2022 is $<ix:nonFraction unitRef="usd" contextRef="iea664a78d9854e7982861ce146a3ba39_I20220331" decimals="-5" name="krys:RemainingCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNjQzNA_94839dc4-26b9-49ca-886d-63991dc50a2a">4.3</ix:nonFraction> million. The Company has incurred expenses under these activities of $<ix:nonFraction unitRef="usd" contextRef="ib712ea82a3604445a0cc14028e0d6896_D20220101-20220331" decimals="-5" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNjQ5OA_a9d727c4-cdb0-433c-bb9e-b07527a27208">3.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3b26ab4e640a459f8745fdfc687a4c41_D20210101-20210331" decimals="-3" name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTA5OTUxMTY0ODc0OA_510c0dd1-64e6-4bda-a472-7042aa2386bf">1.3</ix:nonFraction> million for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASTRA Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to construct our second cGMP facility, ASTRA. Additionally, we have entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. The estimated remaining commitment as of March&#160;31, 2022 is $<ix:nonFraction unitRef="usd" contextRef="if89acc13e6c64c308c9dfc70390e2d45_I20220331" decimals="-5" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTA5OTUxMTY0OTQxMQ_8f0e2369-83f0-466e-acd4-ea8db6b36fa3">20.2</ix:nonFraction> million. The Company has included costs incurred to-date associated with ASTRA within construction in progress as of March&#160;31, 2022.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On June 30, 2021, the Company entered into a Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction (collectively, the &#8220;Agreement&#8221;) with The Whiting-Turner Contracting Company (&#8220;Whiting-Turner&#8221;), pursuant to which Whiting-Turner is constructing and managing the construction of ASTRA. Subject to certain conditions in the Agreement, the Company will pay Whiting-Turner a contract price consisting of the cost of work plus a fee equal to <ix:nonFraction unitRef="number" contextRef="if89acc13e6c64c308c9dfc70390e2d45_I20220331" decimals="INF" name="krys:CostOfWorkPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNzY4MA_1810d878-d050-48ec-948d-66a3a16b8d22">1.75</ix:nonFraction>% of the cost of work. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective September 13, 2021, the Company entered into a guaranteed maximum price amendment (the "Amendment") to the Agreement to set forth the guaranteed maximum price, as well as the date by which Whiting-Turner is to achieve Substantial Completion (as defined in the Agreement). Under the Amendment, the guaranteed maximum price to be paid by the Company is $<ix:nonFraction unitRef="usd" contextRef="ia7f4b2c43112444b9e122e360545adab_I20210913" decimals="-5" name="krys:LossContingencyGuaranteedMaximumPriceToBePaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI3NzIyOA_d3d731f7-682b-45a5-8133-dc39b94051c8">82.3</ix:nonFraction>&#160;million, subject to certain additions and deductions by change orders as provided by the Agreement. Whiting-Turner&#8217;s work under the Agreement represents a portion of the work necessary to complete construction </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i164fdbd1df2242318e667805262c4d5c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the ASTRA facility and, therefore the date of Substantial Completion of Whiting-Turner&#8217;s work under the Agreement does not equate to the date of completion of ASTRA. The guaranteed maximum price under the Agreement constitutes only a portion of the total estimated cost of building and equipping ASTRA. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2020, a complaint was filed against us in the United States District Court for the Western District of Pennsylvania by PeriphaGen, Inc. ("PeriphaGen"), which also named our Chief Executive Officer and President, R&amp;D, Krish Krishnan and Suma Krishnan, respectively. The complaint alleged breach of contract and misappropriation of trade secrets, which secrets the plaintiff asserted were used to develop our product candidates, including the vector backbones, and our STAR-D platform. We answered the complaint on June 26, 2020 by denying the allegations and brought a counterclaim asking the court to declare that we did not misappropriate PeriphaGen&#8217;s trade secrets or confidential information, and to further declare that we are the rightful and sole owner of our product candidates and STAR-D platform. In addition, we filed a third-party complaint against two principals of PeriphaGen, James Wechuck and David Krisky, alleging breach of contract and seeking contribution and indemnification from them in the event PeriphaGen is awarded damages. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2022, the court officially ordered the parties to attend mediation on March 11, 2022.  During the course of the mediation process, the parties were able to exchange information, allowing the parties to value their positions.  On March 12, 2022, we entered into a binding term sheet.  In consideration of settling the dispute, the acquisition of certain PeriphaGen assets, and the grant of a license by PeriphaGen for dermatological applications, Krystal made a payment of $<ix:nonFraction unitRef="usd" contextRef="ic40bbdf109724a63a017b7987802289f_D20220312-20220312" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDI4Nw_e7a10e19-93a3-4148-97eb-ae7da7163459">25.0</ix:nonFraction>&#160;million on April 28, 2022.  Upon approval of Krystal&#8217;s first product by the U.S. Food and Drug Administration ("FDA"), Krystal will pay an additional $<ix:nonFraction unitRef="usd" contextRef="i2e9524e5aa5c470a884b1e3b3fd4d2fc_D20220101-20220331" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDMxNQ_23a4fd1d-04b1-4ddb-99f9-0ac7a86a83db">12.5</ix:nonFraction>&#160;million, followed by <ix:nonFraction unitRef="milestone" contextRef="i2e9524e5aa5c470a884b1e3b3fd4d2fc_D20220101-20220331" decimals="INF" name="krys:NumberOfMilestones" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDQyMQ_150964fa-79f3-472e-9bc6-b17f94790984">three</ix:nonFraction> additional $<ix:nonFraction unitRef="usd" contextRef="ic24584a607d040f58ee27bb2c65542e0_D20220101-20220331" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDMwMA_3247e999-f09f-4f50-bf18-cfc0d5e0f124"><ix:nonFraction unitRef="usd" contextRef="ifbc91ac07e524baca470f06f672c1d2c_D20220101-20220331" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDMwMA_cca55d7d-9c1e-45a6-bbaf-277f5c0775c3"><ix:nonFraction unitRef="usd" contextRef="i36d06bb51d1041f08406992557a842ec_D20220101-20220331" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDMwMA_f8d30c29-055e-45f2-a875-2f1ac6ef11d0">12.5</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million contingent milestone payments upon reaching $<ix:nonFraction unitRef="usd" contextRef="ic65f36fa2aab4beabcc772980cf0f956_D20220312-20220312" decimals="-5" name="krys:LitigationSettlementMilestonePaymentsSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDQwMQ_0f6a3b45-ffb4-4985-bd87-b63768b44114">100.0</ix:nonFraction>&#160;million in total cumulative sales, $<ix:nonFraction unitRef="usd" contextRef="i5edf1309bf4c4394b9c48237c6eb3b9e_D20220312-20220312" decimals="-5" name="krys:LitigationSettlementMilestonePaymentsSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDMzMA_9a1a29a2-2868-403e-b6e0-f017b0b4436f">200.0</ix:nonFraction>&#160;million in total cumulative sales and $<ix:nonFraction unitRef="usd" contextRef="i4203d07f57134f55a0643e1e7a9ea003_D20220312-20220312" decimals="-5" name="krys:LitigationSettlementMilestonePaymentsSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDM0NA_3ae2a2d6-fcb0-4adf-a83e-fb64588700b4">300.0</ix:nonFraction>&#160;million in total cumulative sales. As defined in the settlement agreement, cumulative sales shall include all revenue from sales of Krystal products by Krystal and its affiliates and licensees, as reported by Krystal in its annual Form 10-K filings. If all milestones are achieved, the total consideration for settling the dispute, acquiring certain assets, and granting of a license from PeriphaGen will be $<ix:nonFraction unitRef="usd" contextRef="ic40bbdf109724a63a017b7987802289f_D20220312-20220312" decimals="-5" name="krys:LitigationSettlementTotalConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDM1OA_4ad88b2c-4c1a-4035-89eb-efe5d080db05">75.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final settlement agreement was signed on April 28, 2022, and, because we deemed settlement to be probable as of the balance sheet date, we have recorded an accrued liability equal to the settlement of $<ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-5" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNDk0NzgwMjM2NjE4Ng_19b8c763-6cb7-4a24-b74d-e9518dd25eb1">25.0</ix:nonFraction>&#160;million under accrued expenses and other current liabilities on the condensed consolidated balance sheet and under litigation settlement expense on the condensed consolidated statements of operations.  The additional contingent milestone payments were not deemed probable due to uncertainty in the achievement of these milestones as of March 31, 2022, and therefore no additional accrual has been recorded.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received $<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDM3MQ_a58a8045-a321-48cd-8df7-f87a1ee07e1b">768</ix:nonFraction>&#160;thousand of insurance proceeds during the three months ended March&#160;31, 2022  and we have recorded an additional $<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDM4Ng_640772bc-0303-4c27-b7ff-56216c3f4aff">301</ix:nonFraction>&#160;thousand as a receivable within prepaid expenses and other current assets on the condensed consolidated balance sheet as management determined that the amount was probable of collection relating to legal defense costs and expenses associated with the PeriphaGen litigation. The reimbursements have been recorded as an offset to our legal fees included in general and administrative expenses on the condensed consolidated statements of operations and within operating activities on the condensed consolidated statements of cash flows.</span></div></ix:continuation><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTc0Mg_d67b1f71-2a9d-43f8-853c-aab9818a411f" continuedAt="ibcb27b51318e4367a1dd05e0cff87af8" escape="true">Capitalization</ix:nonNumeric></span></div><ix:continuation id="ibcb27b51318e4367a1dd05e0cff87af8" continuedAt="i33eb42b72b704f079bb4587b3ad66927"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2021, the Company completed a public offering of <ix:nonFraction unitRef="shares" contextRef="i5afc353e283647ec9083f64e9ed8c939_D20211203-20211203" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTY0OTI2NzQ0MzQ3NQ_40cb4ba3-825f-45bc-94f6-b93e070b6ac8">2,866,667</ix:nonFraction> shares of its common stock, including <ix:nonFraction unitRef="shares" contextRef="i60ec291ee12943d1a98627ef006017cc_D20211203-20211203" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTY0OTI2NzQ0MzUxNw_8affafee-cb06-4f6a-9f68-d4dbb767ba6e">200,000</ix:nonFraction> shares purchased by the underwriters, at $<ix:nonFraction unitRef="usdPerShare" contextRef="i08fed205929d4c55ae8e914a0a90a14b_I20211203" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTY0OTI2NzQ0MzU2Mg_4b522fad-c3ce-4dd9-a7db-f71d690e82a6">75.00</ix:nonFraction> per share.  Net proceeds to the Company from the offering were $<ix:nonFraction unitRef="usd" contextRef="i5afc353e283647ec9083f64e9ed8c939_D20211203-20211203" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTY0OTI2NzQ0MzYyOQ_8b56af83-71f0-496b-9557-76c8943cfe70">201.9</ix:nonFraction>&#160;million after deducting underwriting discounts and commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="i5afc353e283647ec9083f64e9ed8c939_D20211203-20211203" decimals="-5" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTY0OTI2NzQ0MzcwNQ_e4205800-850c-4a5b-8986-ec0a56fac9a0">12.9</ix:nonFraction>&#160;million, and other offering expenses payable by the Company of $<ix:nonFraction unitRef="usd" contextRef="i0c1f8e7fe2fa45fd8b4dff23e6288333_D20211203-20211203" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTY0OTI2NzQ0Mzc2NA_4a13d079-833c-4e1b-a6f2-66395042769b">227</ix:nonFraction>&#160;thousand.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2021, the Company completed a public offering of <ix:nonFraction unitRef="shares" contextRef="if01cbed47b8d4cc3bfbc1d974a9fed3d_D20210201-20210201" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTA4_dfb3bd23-39bc-42de-aa40-3c5b75ca8c83">2,211,538</ix:nonFraction> shares of its common stock, including <ix:nonFraction unitRef="shares" contextRef="i8ff87f18f6694c9ea3a6fef4996ab07c_D20210201-20210201" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTQ5_0a62d70b-5d0f-4b41-a695-e4d58b06cfbb">288,461</ix:nonFraction> shares purchased by the underwriters, at $<ix:nonFraction unitRef="usdPerShare" contextRef="ica2c921cbe27424bb2a3e6cab5b07128_I20210201" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTkz_f677ef14-86cd-4bae-a33a-72be231bbc75">65.00</ix:nonFraction> per share.  Net proceeds to the Company from the offering were $<ix:nonFraction unitRef="usd" contextRef="if01cbed47b8d4cc3bfbc1d974a9fed3d_D20210201-20210201" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMjU5_9e665bb0-513b-4781-9a0f-18edac6adb82">134.9</ix:nonFraction>&#160;million after deducting underwriting discounts and commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="if01cbed47b8d4cc3bfbc1d974a9fed3d_D20210201-20210201" decimals="-5" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMzM0_62def278-f226-4fce-a095-6e5a5b294f45">8.6</ix:nonFraction>&#160;million, and other offering expenses payable by the Company of $<ix:nonFraction unitRef="usd" contextRef="i289cb50e19984c88a48c5a07e1b8a29a_D20210201-20210201" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMzky_f3290a41-2268-483a-ab85-356601994978">198</ix:nonFraction>&#160;thousand.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company entered into a sales agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen") with respect to an at-the-market equity offering program ("ATM Program"), under which Cowen will act as the Company's agent and/or principal and may issue and sell from time to time, during the term of the Sales Agreement, shares of our common stock, having an aggregate offering price up to $<ix:nonFraction unitRef="usd" contextRef="ida8733e7f8b54da6ada1a0ab22fe829f_I20201231" decimals="-5" name="krys:SaleOfStockAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfODM5_7f264825-d281-4ea6-8a1d-334a80ba0428">150.0</ix:nonFraction>&#160;million ("Placement Shares").  Related offering expenses payable by the Company were $<ix:nonFraction unitRef="usd" contextRef="i9fbd96b4612a4a66b26fde342c7e05ba_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfOTE5_d1570228-2a35-4fc0-91af-da605ff9561b">172</ix:nonFraction> thousand.  The issuance and sale of the Placement Shares by the Company under the Sales Agreement will be made pursuant to the Company's effective "shelf" registration statement on Form </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i33eb42b72b704f079bb4587b3ad66927">S-3. During the three months ended March&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="i5c9fb5f61e014e0d8958ffdb2f7baa47_D20210101-20210331" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTEzNw_dcf91001-098f-4e60-9147-f575bb4606de">262,500</ix:nonFraction> shares of common stock were issued pursuant to the ATM Program at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia295d7f2365647ae8d0fe3f1f16d1308_I20210331" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTIzNA_4ce9dcec-ade0-41cc-a398-57fac7d107e5">66.50</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i286d68b1d6d2436481fb4a0d8428bca6_D20210201-20210201" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTI2Nw_8c2e12f6-b766-44fd-a54d-d4ac510f72e9">16.9</ix:nonFraction>&#160;million after deducting underwriting discounts and commissions of approximately $<ix:nonFraction unitRef="usd" contextRef="i286d68b1d6d2436481fb4a0d8428bca6_D20210201-20210201" decimals="-3" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTM0Mg_1fab4118-b1b9-423a-99c7-3fbe8a8c6c59">524</ix:nonFraction>&#160;thousand, resulting in a remaining $<ix:nonFraction unitRef="usd" contextRef="i5c9fb5f61e014e0d8958ffdb2f7baa47_D20210101-20210331" decimals="-5" name="krys:SaleOfStockRemainingAvailableIssuanceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTM3MQ_6b6313e9-b245-430f-8851-b9e2076eb4f8">132.5</ix:nonFraction>&#160;million available for issuance under the ATM Program.</ix:continuation></span></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMzc3NA_3f4e7267-0d1d-48df-81a9-b50252f2830b" continuedAt="i16feb99f818a48f98045b0404d287ada" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i16feb99f818a48f98045b0404d287ada" continuedAt="i8030c69b61a448a3b0ad75ad624367a4"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted to employees vest ratably over <ix:nonNumeric contextRef="i80af56866df1412e92048fc6c85f5bc4_D20220101-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMzc3NQ_3f54c038-ad5a-486a-989e-47bf2a6e9798">four-year</ix:nonNumeric> periods and stock options granted to directors of the company vest ratably over <ix:nonNumeric contextRef="ic542a3c28cfa40a79269e8998b92ebd4_D20220101-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMjA2_851ad44d-9eb7-4797-9a57-3511f6965179">one year</ix:nonNumeric> to <ix:nonNumeric contextRef="iecc1050fb75f4c92929ea53bb5db6e2e_D20220101-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMzc2OQ_f20b6002-973d-4ac2-bb6d-ef27c4dc36b5">four-year</ix:nonNumeric> periods. Stock options have a life of <ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMjU4_f4721150-b95f-4748-a16a-040ed85d0887">ten years</ix:nonNumeric>. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted <ix:nonFraction unitRef="shares" contextRef="iea276893239144509596b8ab8da16fc9_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMjgz_c23bbd6c-41a6-4aab-99f1-26e2bb7cf2ec">1,179,500</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7bd1d3ebc2374d15b477f6f17769c8b5_D20210101-20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjA2OA_06427162-4705-43c5-a8a0-fbfb57373829">502,450</ix:nonFraction> stock options to employees and directors of the Company during the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMzc3MA_04b1319c-1230-443b-950a-0865a89145be" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:38.740%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In&#160;thousands)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfMS0xLTEtMS0yMDk3Nw_0015d5ec-bfd0-404b-80ca-0f3bcfc16b9d">2,043,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfMS0zLTEtMS0yMDk3Nw_6d668754-44bc-4274-aa3e-a62e75085d59">57.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1df3a737f254e1890366151309871c2_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfMS01LTEtMS0yMDk3Nw_047234d3-d441-44af-b953-33048e7ecb78">9.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfMS03LTEtMS0yMDk3Nw_a31508b9-b6b9-4e10-9c12-3cc55fd9b046">31,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfMi0xLTEtMS0yMDk3Nw_a50aa2a7-55db-4a6b-8d7e-8dab19cf5c46">1,179,500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfMi0zLTEtMS0yMDk3Nw_b0657829-412c-4557-8447-6668a71e00a1">62.53</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfMy0xLTEtMS0yMDk3Nw_93f66360-9f40-47fa-bbc1-ab2781d53760">1,475</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfMy0zLTEtMS0yMDk3Nw_0be3ae40-2c88-485b-9bae-b9d77911b4fe">37.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNC0xLTEtMS0yMDk3Nw_448a03bf-3ae1-4a64-83be-2f95250d1f0d">68,342</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNC0zLTEtMS0yMDk3Nw_8e9b2ad7-7450-409b-b75a-0eef63332cb3">61.24</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNS0xLTEtMS0yMDk3Nw_13c083d6-999f-4cbe-9980-1b56caa465bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNS0zLTEtMS0yMDk3Nw_7bc91e54-f08d-4969-8aec-04aad2be3c2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNi0xLTEtMS0yMDk3Nw_203b3209-717f-4dca-909f-8d255ae1649c">3,152,862</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNi0zLTEtMS0yMDk3Nw_aee5c889-0828-4394-8bc3-98af7dff81f7">58.99</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNi01LTEtMS0yMDk3Nw_136e558b-788b-4e3a-af5d-593d5f6dc322">9.1</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNi03LTEtMS0yMDk3Nw_d0524399-d747-49a3-a983-f0a724164a18">30,364</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNy0xLTEtMS0yMDk3Nw_0bbcb1ad-8592-46de-b836-082416db6d06">439,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNy0zLTEtMS0yMDk3Nw_98cae8cf-b15f-4fcd-8bf6-11489a6064b6">44.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNy01LTEtMS0yMDk3Nw_ac993130-8005-4a12-aebf-52204320d2d8">7.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNy03LTEtMS0yMDk3Nw_603f43ec-927b-4471-98dd-c16b88a205c2">10,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Aggregate intrinsic value represents the difference between the closing stock price of our common stock on March&#160;31, 2022 and the exercise price of outstanding in-the-money options.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value (the amount by which the fair market value exceeds the exercise price) of stock options exercised during the three months ended March&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMTAyMQ_b00a1694-43ca-4087-b782-823514ea8647">36</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjE1MQ_40d00eca-02e3-4952-bc7b-e16a1ff6f83d">808</ix:nonFraction>&#160;thousand, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value per share of options granted to employees and directors during the three months ended March&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i80af56866df1412e92048fc6c85f5bc4_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMTI0Mg_4afc1e05-c092-4eb3-beec-95399f249e96">43.09</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ice42d3e965264766b589d5585c17eea5_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjE2OQ_04be9843-aca0-4d97-a50b-45c69f5bb577">50.04</ix:nonFraction>, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $<ix:nonFraction unitRef="usd" contextRef="i8c01f855c0c84b0e9b660ee225b9ec6f_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMTU0NA_97dad5df-6a01-4f4f-a91d-31131d8503d8">101.1</ix:nonFraction> million of unrecognized stock-based compensation expense related to employees' and directors&#8217; option awards that is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i4351d78dc27b42ba8f8b3dc0f50aab47_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMTcxNA_3c8615e6-976d-44ad-a669-69294d8e7b39">3.4</ix:nonNumeric> years as of March&#160;31, 2022.</span></div><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMzc3MQ_0f33028f-c5fb-4c7f-b7c3-0ac38780706a" continuedAt="i71d1729d7127437281e0e1b7e93b9ffc" escape="true"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three months ended March&#160;31, 2022 and 2021 as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.842%"><tr><td style="width:1.0%"></td><td style="width:53.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.982%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.887%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i728d1afbbec24034b661de93f72a65fb_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjFhMDY2Njc4OTgzMDRjNzk5NDU3MjdhNzYzNDQ3NTk5L3RhYmxlcmFuZ2U6MWEwNjY2Nzg5ODMwNGM3OTk0NTcyN2E3NjM0NDc1OTlfMy0xLTEtMS0yMDk3Nw_abe134ca-a5d5-4d17-93f3-9ae782130b3d">1,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a13b8bd5de345f7816207b985555ac2_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjFhMDY2Njc4OTgzMDRjNzk5NDU3MjdhNzYzNDQ3NTk5L3RhYmxlcmFuZ2U6MWEwNjY2Nzg5ODMwNGM3OTk0NTcyN2E3NjM0NDc1OTlfMy0zLTEtMS0yMDk3Nw_680dca92-8d43-401d-95a6-5b0b2bf9c0c1">516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5ef3f34ff534130b14863a9e62343c7_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjFhMDY2Njc4OTgzMDRjNzk5NDU3MjdhNzYzNDQ3NTk5L3RhYmxlcmFuZ2U6MWEwNjY2Nzg5ODMwNGM3OTk0NTcyN2E3NjM0NDc1OTlfNC0xLTEtMS0yMDk3Nw_28d31a1e-169d-4786-9fda-977cc7016498">4,582</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i159a69784f534b459befa6407a0a7b31_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjFhMDY2Njc4OTgzMDRjNzk5NDU3MjdhNzYzNDQ3NTk5L3RhYmxlcmFuZ2U6MWEwNjY2Nzg5ODMwNGM3OTk0NTcyN2E3NjM0NDc1OTlfNC0zLTEtMS0yMDk3Nw_c97d89e6-558e-42f3-aa29-855dba019be7">1,615</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80af56866df1412e92048fc6c85f5bc4_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjFhMDY2Njc4OTgzMDRjNzk5NDU3MjdhNzYzNDQ3NTk5L3RhYmxlcmFuZ2U6MWEwNjY2Nzg5ODMwNGM3OTk0NTcyN2E3NjM0NDc1OTlfNS0xLTEtMS0yMDk3Nw_0344f065-bc5a-4b19-bd1f-65d5b7eba493">5,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice42d3e965264766b589d5585c17eea5_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjFhMDY2Njc4OTgzMDRjNzk5NDU3MjdhNzYzNDQ3NTk5L3RhYmxlcmFuZ2U6MWEwNjY2Nzg5ODMwNGM3OTk0NTcyN2E3NjM0NDc1OTlfNS0zLTEtMS0yMDk3Nw_1f0fc897-ff23-41c0-8fad-7f5fa4b9fa35">2,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the portion of stock-based compensation that relates to work performed on the construction of new buildings. There was $<ix:nonFraction unitRef="usd" contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjE4OQ_ee56ed8c-8586-4b31-a20d-0e36dbfe3b5a">141</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjE5Nw_9812b281-319f-473e-9ab5-2c6286575bb5">37</ix:nonFraction>&#160;thousand of stock-based compensation that was capitalized in the three months ended March&#160;31, 2022 and 2021, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><ix:continuation id="i8030c69b61a448a3b0ad75ad624367a4"><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i80af56866df1412e92048fc6c85f5bc4_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjQ1MA_edc95c24-ec32-49a3-98ec-2aabf7c36b8d">6.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ice42d3e965264766b589d5585c17eea5_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjIxNQ_fd1b5b31-0632-43cd-b565-9dfadbd0077b">2.1</ix:nonFraction> million for the three months ended March&#160;31, 2022 and 2021, respectively. <ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMzc3Nw_37ec10c3-abe5-44c7-b63d-a5ebefed2e81" continuedAt="ic904f359c578478a947982f70d0b8199" escape="true">The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three months ended March&#160;31, 2022 and 2021:</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><ix:continuation id="ic904f359c578478a947982f70d0b8199"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.672%"><tr><td style="width:1.0%"></td><td style="width:54.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.004%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.348%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i80af56866df1412e92048fc6c85f5bc4_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmI1OTNlNTYwN2M3YjQxNDI5ZTVlMDE5MjU1YTdkMjU3L3RhYmxlcmFuZ2U6YjU5M2U1NjA3YzdiNDE0MjllNWUwMTkyNTVhN2QyNTdfMi0xLTEtMS0yMDk3Nw_3adf980f-1fab-4ae0-ad2a-238e7d262841">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice42d3e965264766b589d5585c17eea5_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmI1OTNlNTYwN2M3YjQxNDI5ZTVlMDE5MjU1YTdkMjU3L3RhYmxlcmFuZ2U6YjU5M2U1NjA3YzdiNDE0MjllNWUwMTkyNTVhN2QyNTdfMi0zLTEtMS0yMDk3Nw_fc394031-5ef9-4d06-afd9-44d4f68f82a8">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of the award (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmI1OTNlNTYwN2M3YjQxNDI5ZTVlMDE5MjU1YTdkMjU3L3RhYmxlcmFuZ2U6YjU5M2U1NjA3YzdiNDE0MjllNWUwMTkyNTVhN2QyNTdfMy0xLTEtMS0yMDk3Nw_0de1c2ef-7437-4322-ba6b-eb1f867b7b93">6.24</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmI1OTNlNTYwN2M3YjQxNDI5ZTVlMDE5MjU1YTdkMjU3L3RhYmxlcmFuZ2U6YjU5M2U1NjA3YzdiNDE0MjllNWUwMTkyNTVhN2QyNTdfMy0zLTEtMS0yMDk3Nw_7cb8f479-7601-4d41-a7fa-858047d72485">6.22</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i80af56866df1412e92048fc6c85f5bc4_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmI1OTNlNTYwN2M3YjQxNDI5ZTVlMDE5MjU1YTdkMjU3L3RhYmxlcmFuZ2U6YjU5M2U1NjA3YzdiNDE0MjllNWUwMTkyNTVhN2QyNTdfNC0xLTEtMS0yMDk3Nw_5529744a-14b2-40db-a8b7-9c1bc266a089">1.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice42d3e965264766b589d5585c17eea5_D20210101-20210331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmI1OTNlNTYwN2M3YjQxNDI5ZTVlMDE5MjU1YTdkMjU3L3RhYmxlcmFuZ2U6YjU5M2U1NjA3YzdiNDE0MjllNWUwMTkyNTVhN2QyNTdfNC0zLTEtMS0yMDk3Nw_a7ebc815-9a45-4b0b-9933-c0fc861379fd">1.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i80af56866df1412e92048fc6c85f5bc4_D20220101-20220331" decimals="2" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmI1OTNlNTYwN2M3YjQxNDI5ZTVlMDE5MjU1YTdkMjU3L3RhYmxlcmFuZ2U6YjU5M2U1NjA3YzdiNDE0MjllNWUwMTkyNTVhN2QyNTdfNS0xLTEtMS0yMDk3Nw_59a3a845-ffac-4d21-a679-486321271f42">62.53</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice42d3e965264766b589d5585c17eea5_D20210101-20210331" decimals="2" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmI1OTNlNTYwN2M3YjQxNDI5ZTVlMDE5MjU1YTdkMjU3L3RhYmxlcmFuZ2U6YjU5M2U1NjA3YzdiNDE0MjllNWUwMTkyNTVhN2QyNTdfNS0zLTEtMS0yMDk3Nw_3ac494b8-d93f-4897-933f-a7d8afee4738">77.46</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i80af56866df1412e92048fc6c85f5bc4_D20220101-20220331" decimals="4" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmI1OTNlNTYwN2M3YjQxNDI5ZTVlMDE5MjU1YTdkMjU3L3RhYmxlcmFuZ2U6YjU5M2U1NjA3YzdiNDE0MjllNWUwMTkyNTVhN2QyNTdfNi0xLTEtMS0yMDk3Nw_4c44a8a6-2e4f-42d1-838c-8a0a165daa37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice42d3e965264766b589d5585c17eea5_D20210101-20210331" decimals="4" name="krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmI1OTNlNTYwN2M3YjQxNDI5ZTVlMDE5MjU1YTdkMjU3L3RhYmxlcmFuZ2U6YjU5M2U1NjA3YzdiNDE0MjllNWUwMTkyNTVhN2QyNTdfNi0zLTEtMS0yMDk3Nw_48064962-7dd0-4339-9ce8-3bb8b707b4e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards ("RSAs") granted to employees vest ratably over a <ix:nonNumeric contextRef="i95cf472c8b2540888dd2f36a876d9c9c_D20220101-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMzc3Mg_4f37b107-d63d-434b-b824-ec348a2d0f89">four-year</ix:nonNumeric> period. The Company granted <ix:nonFraction unitRef="shares" contextRef="ic9e66ec8312f4f8c9a9dff635bd641f1_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjIzNw_53b1b7b6-48ce-4631-a8e5-adc8ed95a345">zero</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="idcde6861ff0841f797527708e897648a_D20210101-20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjI0MQ_1dd4e579-2071-4b42-ac5a-8b712ff9eb77">98,800</ix:nonFraction> RSAs to employees of the Company during the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMzc3Ng_64f48419-ea0e-45ac-b6a7-2113e8dda6fe" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"><tr><td style="width:1.0%"></td><td style="width:50.452%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.630%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2f80cb0be8e44f88a74d836902c06d0_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmEwYmU5NWNmYTVkYjQ1NmQ4MzA1NzlkOWQ0YTZkNzdiL3RhYmxlcmFuZ2U6YTBiZTk1Y2ZhNWRiNDU2ZDgzMDU3OWQ5ZDRhNmQ3N2JfMS0xLTEtMS0yMDk3Nw_9186eda8-034d-414a-bff6-1148cab84d76">98,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id2f80cb0be8e44f88a74d836902c06d0_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmEwYmU5NWNmYTVkYjQ1NmQ4MzA1NzlkOWQ0YTZkNzdiL3RhYmxlcmFuZ2U6YTBiZTk1Y2ZhNWRiNDU2ZDgzMDU3OWQ5ZDRhNmQ3N2JfMS0zLTEtMS0yMDk3Nw_a0a0f391-51cf-4f93-b0df-974f12034ceb">78.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9e66ec8312f4f8c9a9dff635bd641f1_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmEwYmU5NWNmYTVkYjQ1NmQ4MzA1NzlkOWQ0YTZkNzdiL3RhYmxlcmFuZ2U6YTBiZTk1Y2ZhNWRiNDU2ZDgzMDU3OWQ5ZDRhNmQ3N2JfMi0xLTEtMS0yMDk3Nw_2d2fa97f-76f6-4bdb-b271-0f4e048fba99">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic9e66ec8312f4f8c9a9dff635bd641f1_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmEwYmU5NWNmYTVkYjQ1NmQ4MzA1NzlkOWQ0YTZkNzdiL3RhYmxlcmFuZ2U6YTBiZTk1Y2ZhNWRiNDU2ZDgzMDU3OWQ5ZDRhNmQ3N2JfMi0zLTEtMS0yMDk3Nw_0501491f-4b34-4abb-b280-06c2456990ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic9e66ec8312f4f8c9a9dff635bd641f1_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmEwYmU5NWNmYTVkYjQ1NmQ4MzA1NzlkOWQ0YTZkNzdiL3RhYmxlcmFuZ2U6YTBiZTk1Y2ZhNWRiNDU2ZDgzMDU3OWQ5ZDRhNmQ3N2JfMy0xLTEtMS0yMDk3Nw_3a7d28ed-c26b-4d7f-910d-f52421c19587">14,321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic9e66ec8312f4f8c9a9dff635bd641f1_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmEwYmU5NWNmYTVkYjQ1NmQ4MzA1NzlkOWQ0YTZkNzdiL3RhYmxlcmFuZ2U6YTBiZTk1Y2ZhNWRiNDU2ZDgzMDU3OWQ5ZDRhNmQ3N2JfMy0zLTEtMS0yMDk3Nw_0a76298c-0d9b-42df-8e5f-f863a1a353ae">78.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic9e66ec8312f4f8c9a9dff635bd641f1_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmEwYmU5NWNmYTVkYjQ1NmQ4MzA1NzlkOWQ0YTZkNzdiL3RhYmxlcmFuZ2U6YTBiZTk1Y2ZhNWRiNDU2ZDgzMDU3OWQ5ZDRhNmQ3N2JfNC0xLTEtMS0yMDk3Nw_8a3683d1-d5ec-4138-b21c-4736591a536f">10,379</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic9e66ec8312f4f8c9a9dff635bd641f1_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmEwYmU5NWNmYTVkYjQ1NmQ4MzA1NzlkOWQ0YTZkNzdiL3RhYmxlcmFuZ2U6YTBiZTk1Y2ZhNWRiNDU2ZDgzMDU3OWQ5ZDRhNmQ3N2JfNC0zLTEtMS0yMDk3Nw_bbb68cfc-3b62-4bbf-b4b6-4327828765e8">78.89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34ffbc56d9c943f2b61272f256499cfb_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmEwYmU5NWNmYTVkYjQ1NmQ4MzA1NzlkOWQ0YTZkNzdiL3RhYmxlcmFuZ2U6YTBiZTk1Y2ZhNWRiNDU2ZDgzMDU3OWQ5ZDRhNmQ3N2JfNS0xLTEtMS0yMDk3Nw_c800cdd7-f50e-4207-8efe-5b52b87d5c45">74,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i34ffbc56d9c943f2b61272f256499cfb_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmEwYmU5NWNmYTVkYjQ1NmQ4MzA1NzlkOWQ0YTZkNzdiL3RhYmxlcmFuZ2U6YTBiZTk1Y2ZhNWRiNDU2ZDgzMDU3OWQ5ZDRhNmQ3N2JfNS0zLTEtMS0yMDk3Nw_2dd8c6be-371f-494e-8674-53220257002b">78.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $<ix:nonFraction unitRef="usd" contextRef="i34ffbc56d9c943f2b61272f256499cfb_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjI1Ng_5031a674-6c3e-4189-95ef-ac3e3a594448">5.7</ix:nonFraction> million of unrecognized stock-based compensation expense related to employees&#8217;&#160;awards that is expected to be recognized over a weighted-average period of&#160;<ix:nonNumeric contextRef="ic9e66ec8312f4f8c9a9dff635bd641f1_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjI2MQ_7f9d1d03-2009-466b-a19e-e7543ea08d86">2.9</ix:nonNumeric> years as of March&#160;31, 2022.</span></div><ix:continuation id="i71d1729d7127437281e0e1b7e93b9ffc"><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to RSAs of $<ix:nonFraction unitRef="usd" contextRef="ic9e66ec8312f4f8c9a9dff635bd641f1_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjI2OQ_33963d86-919c-406b-9dd5-3a598aac2378">480</ix:nonFraction> thousand and $<ix:nonFraction unitRef="usd" contextRef="idcde6861ff0841f797527708e897648a_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjI3Mw_b2dd3173-daaa-446c-84ed-8c03ec6c2df7">182</ix:nonFraction> thousand for the three months ended March&#160;31, 2022 and 2021, respectively, within general and administrative expenses in the accompanying condensed consolidated statements of operations (in thousands):</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.134%"><tr><td style="width:1.0%"></td><td style="width:53.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.783%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2d9d3e6725f41cbba150ba4c1a85196_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjZmZWMwNzNjM2YwMTQ2ZDQ5MWFlMDdlZWE5ZDUwNzhiL3RhYmxlcmFuZ2U6NmZlYzA3M2MzZjAxNDZkNDkxYWUwN2VlYTlkNTA3OGJfMy0xLTEtMS0yMDk3Nw_ab368b01-f047-493f-8410-4518a6568faa">480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i383ec6469caa4edeaa4b2d6d77e7fba4_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjZmZWMwNzNjM2YwMTQ2ZDQ5MWFlMDdlZWE5ZDUwNzhiL3RhYmxlcmFuZ2U6NmZlYzA3M2MzZjAxNDZkNDkxYWUwN2VlYTlkNTA3OGJfMy0zLTEtMS0yMDk3Nw_3ffee157-1ad3-4571-86b9-2ddd1ab5a8fd">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9e66ec8312f4f8c9a9dff635bd641f1_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjZmZWMwNzNjM2YwMTQ2ZDQ5MWFlMDdlZWE5ZDUwNzhiL3RhYmxlcmFuZ2U6NmZlYzA3M2MzZjAxNDZkNDkxYWUwN2VlYTlkNTA3OGJfNC0xLTEtMS0yMDk3Nw_a3cdb6ae-70cd-44cf-a5a2-08afc33ae192">480</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcde6861ff0841f797527708e897648a_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjZmZWMwNzNjM2YwMTQ2ZDQ5MWFlMDdlZWE5ZDUwNzhiL3RhYmxlcmFuZ2U6NmZlYzA3M2MzZjAxNDZkNDkxYWUwN2VlYTlkNTA3OGJfNC0zLTEtMS0yMDk3Nw_987c2ef7-3c38-488b-9233-99656f18f78a">182</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares remaining available for grant under the Company&#8217;s stock incentive plan were <ix:nonFraction unitRef="shares" contextRef="i29cc8ebc55e7487dac7291d42222cb41_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMzcwOQ_f376e5b8-22e4-46a9-9408-94f85e5cd4c0">1,028,815</ix:nonFraction>, with a sublimit for incentive stock options of <ix:nonFraction unitRef="shares" contextRef="i28da46ff21b84b0aa5a790183dfad270_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMzc2MA_644d538a-a3ef-4ca0-8a92-51e1222aee20">26,546</ix:nonFraction>, at March&#160;31, 2022.</span></div></ix:continuation><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181OC9mcmFnOmRlNGZjMWMxYWJmNDQ4M2ViZjI2YTkzMWU2ZjE3NzQ4L3RleHRyZWdpb246ZGU0ZmMxYzFhYmY0NDgzZWJmMjZhOTMxZTZmMTc3NDhfMzcw_49aef8cb-75eb-40e1-b886-3954992df5c4" continuedAt="i787c23ba84ff44b9bee7962d607533b4" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="i787c23ba84ff44b9bee7962d607533b4"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 28, 2022, the Company entered into a final settlement agreement and paid PeriphaGen an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i7448456091a9407bba292044857bb844_D20220429-20220429" decimals="-6" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181OC9mcmFnOmRlNGZjMWMxYWJmNDQ4M2ViZjI2YTkzMWU2ZjE3NzQ4L3RleHRyZWdpb246ZGU0ZmMxYzFhYmY0NDgzZWJmMjZhOTMxZTZmMTc3NDhfMjE5OTAyMzI1OTY3NA_be7afcf0-af1b-4bb3-8852-687642f1f11f">25.0</ix:nonFraction>&#160;million for: (i) the resolution of all claims in the trade secret litigation with PeriphaGen, Inc.; (ii) the acquisition of certain PeriphaGen assets, and (iii) the grant of a license by PeriphaGen for dermatological applications.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2022, pursuant to an inbound request, the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="id610a4a750eb45a88b570c32459f3956_D20220405-20220405" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181OC9mcmFnOmRlNGZjMWMxYWJmNDQ4M2ViZjI2YTkzMWU2ZjE3NzQ4L3RleHRyZWdpb246ZGU0ZmMxYzFhYmY0NDgzZWJmMjZhOTMxZTZmMTc3NDhfMjE5OTAyMzI1OTY4Nw_0a54fd3f-570e-4e95-acba-7cb7c42c3d03">434,782</ix:nonFraction> shares of common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iec19ce2f98484127826acb386e5ebf55_I20220405" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181OC9mcmFnOmRlNGZjMWMxYWJmNDQ4M2ViZjI2YTkzMWU2ZjE3NzQ4L3RleHRyZWdpb246ZGU0ZmMxYzFhYmY0NDgzZWJmMjZhOTMxZTZmMTc3NDhfMjE5OTAyMzI1OTY5Ng_df10760a-92f2-437e-8ded-8c628a75a7dc">69.00</ix:nonFraction> per share, under it's ATM Program, for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="id610a4a750eb45a88b570c32459f3956_D20220405-20220405" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181OC9mcmFnOmRlNGZjMWMxYWJmNDQ4M2ViZjI2YTkzMWU2ZjE3NzQ4L3RleHRyZWdpb246ZGU0ZmMxYzFhYmY0NDgzZWJmMjZhOTMxZTZmMTc3NDhfMjE5OTAyMzI1OTcwNA_fa68aa19-f000-4f0b-be8d-49252b494c2f">29.1</ix:nonFraction>&#160;million after deducting underwriting discounts and commissions.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and related notes included in Item 1 of Part I of this Quarterly Report on Form 10-Q and with the audited financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on February 28, 2022.</span></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or similar expressions and the negatives of those terms. These statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Some of such factors include, but are not limited to:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, timing, cost, progress and results, of our research and development activities, preclinical studies and clinical trials for B-VEC (previously &#8220;KB103&#8221; and now known as Vyjuvek</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), KB105, KB104, KB407, KB408, KB301, KB303, and any other product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continuing impact that the COVID-19 pandemic and measures implemented to prevent its spread may have on our business operations, access to capital, research and development activities, and preclinical and clinical trials for our product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, scope or results of regulatory filings and approvals, including timing of final US Food and Drug Administration (&#8220;FDA&#8221;), marketing and other regulatory approval of our product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve certain accelerated or orphan drug designations from the FDA;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our estimates regarding the potential market opportunity for B-VEC, KB105, KB104, KB407, KB408, KB301, KB303 and any other product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise capital to fund our operations;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased costs associated with our research and development programs for our product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our general and administrative expenses;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our ability to successfully develop and commercialize our product candidates, including B-VEC, KB105, KB104, KB407, KB408, KB301, KB303 and our other product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify and develop new product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify, recruit and retain key personnel;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to our marketing and manufacturing capabilities and strategy;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our business model, strategic plans for our business, product candidates and technology;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of building a medical affairs and commercial organization including a sales force in anticipation of commercialization of B-VEC and any additional product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our product candidates and gene therapy, in general;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitive position and the success of competing therapies;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intellectual property position and our ability to protect and enforce our intellectual property;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations or obtain additional funding;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and needs for or ability to obtain additional financing;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully avoid or resolve any litigation, intellectual property or other claims, that may be brought against us;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">global economic conditions; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of changes in laws and regulations.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and in other filings we make with the SEC from time to time. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management&#8217;s beliefs and assumptions only as of the date of this Quarterly Report. You should read this Quarterly Report completely and with the understanding that our actual future results may be materially different from what we expect.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this Form 10-Q, unless the context requires otherwise, all references to &#8220;Krystal,&#8221; &#8220;the Company,&#8221; we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or similar terms refer to Krystal Biotech, Inc., together with its consolidated subsidiaries.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biotechnology company leading the field of redosable gene delivery. Using our patented platform that is based on engineered HSV-1, we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#8217;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a healthcare professional&#8217;s office or potentially in the patient&#8217;s home by a healthcare professional. Our goal is to develop easy-to-use medicines to dramatically improve the lives of patients living with rare diseases and chronic conditions.  Our innovative technology platform is supported by in-house, commercial scale cGMP manufacturing capabilities.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Product Candidates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information regarding our product candidates in various stages of clinical and preclinical development:</span></div><div style="text-align:center;text-indent:31.5pt"><img src="krys-20220331_g1.jpg" alt="krys-20220331_g1.jpg" style="height:835px;margin-bottom:5pt;vertical-align:text-bottom;width:638px"/></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">There can be no assurance that the upcoming milestones will be met on the expected timeline or at all.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline Highlights and Recent Developments</span></div><div style="margin-top:3pt;padding-left:58.5pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B-VEC is a topical gel containing our novel vector designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COL7A1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene for the treatment of dystrophic epidermolysis bullosa ("dystrophic EB"), a serious rare skin disease caused by missing or mutated type VII collagen protein ("COL7"). Our randomized, double-blind, placebo-controlled GEM-3 pivotal study was designed to evaluate topical B-VEC as compared to placebo in dystrophic EB patients. Following public announcement of topline data from the GEM-3 study trial on November 29, 2021, we presented more detailed results at the 2022 American Academy of Dermatology Annual Meeting on March 26, 2022. We expect to file a BLA with the FDA in 2Q 2022, and an MAA with the EMA in 2H 2022. On March 28, 2022, we announced that detailed results from the Phase 1 and 2 study of B-VEC were published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During 2Q 2021, we began enrolling patients into an open label extension ("OLE") study, including patients who participated in the Phase 3 study, as well as new participants who meet all enrollment criteria.  Based on the feedback from the FDA following their review of our human factors validation study report, we announced on April 11, 2022 our plan to offer dystrophic EB patients enrolled in the GEM-3 OLE, the opportunity to be dosed in their homes by a healthcare professional. </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KB105 is a topical gel containing our novel vector designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TGM1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene for the treatment of TGM1-deficient autosomal recessive congenital ichthyosis ("TGM1-ARCI"), a serious rare skin disorder caused by missing or mutated TGM1 protein. A randomized, placebo-controlled Phase 1/2 study is ongoing. On July 1, 2021, we announced data from the fourth patient dosed in the trial, showing repeat topical KB105 dosing continued to be well tolerated with no adverse events or evidence of immune response. We plan to resume dosing in the KB105 Phase 2 study later this year.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KB407 is an inhaled (nebulized) formulation of our novel vector designed to deliver two copies of the full-length </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CFTR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene for the treatment of cystic fibrosis, a serious rare lung disease caused by missing or mutated cystic fibrosis transmembrane conductance regulator ("CFTR") protein. On September 29, 2021, we announced that the Bellberry Human Research Ethics Committee in Australia granted approval to conduct a Phase 1 clinical study of inhaled KB407 in patients with cystic fibrosis, and trial initiation is anticipated in 2Q 2022. We plan to submit an IND and initiate a Phase 1 trial in the U.S. in 2H 2022. </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KB104 is a topical gel formulation of our novel vector designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINK5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene for the treatment of Netherton Syndrome, a debilitating autosomal recessive skin disorder caused by missing or mutated SPINK5 protein. We expect to initiate a Phase 1 clinical study in 2022.  </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several other product candidates in various stages of preclinical development as reflected in the chart above.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also leveraging the ability of our platform to deliver proteins of interest to cells in the skin in the context of aesthetic medicine via our wholly-owned subsidiary Jeune Aesthetics, Inc ("Jeune").  A Summary description of Jeune&#8217;s key product candidate and its status is as follows: </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KB301 is a solution formulation of our novel vector for intradermal injection designed to deliver two copies of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COL3A1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transgene to address signs of aging or damaged skin caused by declining levels of, or damaged proteins within the extracellular matrix, including type III collagen. A Phase 1 study is currently ongoing. On March 22, 2022, we announced positive proof-of-concept efficacy data from Cohort 2 of the PEARL-1 study of KB301. We plan to initiate a Phase 2 trial in 4Q 2022 or early 2023. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeune has several other aesthetic medicine product candidates in various stages of preclinical development as reflected in the chart above.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Highlights and Recent Developments</span></div><div style="margin-top:3pt;padding-left:58.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">On January 18, 2022, we announced that Jing Marantz, MD, PhD, MBA had resigned from the Board of Directors to accept the position as Chief Business Officer with the Company and E. Rand Sutherland was appointed as a member of the Board of Directors to fill the vacancy.</span></div><div style="margin-top:3pt;padding-left:58.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">On March 15, 2022, we announced that we had reached a binding term sheet with PeriphaGen, Inc. ("PeriphaGen") to resolve all claims in the trade secret litigation filed by PeriphaGen on May 20, 2020.</span></div><div style="padding-left:22.5pt;text-indent:31.5pt"><span><br/></span></div><div style="padding-left:22.5pt;text-indent:31.5pt"><span><br/></span></div><div style="padding-left:22.5pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Update</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has prompted governments and businesses across the globe to take unprecedented measures, such as restrictions on travel and business operations, temporary closures of businesses, and quarantines. For example, in an effort to slow the spread of the virus, The Commonwealth of Pennsylvania where the Company&#8217;s primary offices, laboratory and manufacturing spaces are located, enacted stay-at-home orders, and sweeping restrictions to travel were initiated by corporations and governments. Although these restrictions have been lifted, it is not known at this time whether they will be reestablished or the extent to which the Company will be impacted. The degree of the pandemic&#8217;s effect on the Company&#8217;s clinical, operational and financial performance will depend on future developments, including additional protective measures that may be implemented by governmental authorities or the Company to protect its employees, or by investigators, caregivers or patients to minimize exposure, all of which are uncertain and difficult to predict. To date the impact of the pandemic on our business and clinical trials in the U.S. has been minimal and the increased vaccination rates in the U.S. are encouraging. We will continue to assess the potential impact of the pandemic on our business and operations, including our supply chain and preclinical and clinical trial activities. Outside of the U.S., we have experienced pandemic-related delays in clinical trial initiation in Australia, and we will continue to closely monitor this rapidly evolving situation. For additional information regarding the impact of the coronavirus pandemic, please see "Risk Factor - Business interruptions resulting from the COVID-19 outbreak or similar public health crises could cause a disruption of the development efforts of our product candidates and adversely impact our business." in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. </span></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_67"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no approved products for commercial marketing or sale and have not generated any revenue from the sale of products or other sources to date. In the future, we may generate revenue from product sales, royalties on product sales, or license fees, milestones, or other upfront payments if we enter into any collaborations or license agreements. We expect that our future revenue will fluctuate from quarter to quarter for many reasons, including the uncertain timing and amount of any such payments and sales.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred to advance our preclinical and clinical candidates, which include:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with contract manufacturing organizations, consultants and other vendors that conduct our preclinical activities;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of acquiring, developing and manufacturing clinical trial materials and lab supplies;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility costs, depreciation and other expenses, which include direct expenses for rent and maintenance of facilities and other supplies; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payroll related expenses, including stock-based compensation expense.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense internal research and development costs to operations as incurred. We expense third party costs for research and development activities, such as the manufacturing of preclinical and clinical materials, based on an evaluation of the progress to completion of specific tasks such as manufacturing of drug substance, fill/finish and stability testing, which is provided to us by our vendors.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses will increase as we continue the manufacturing of preclinical and clinical materials and manage the clinical trials of, and seek regulatory approval for, our product candidates and expand our product portfolio. In the near term, we expect that our research and development expenses will increase as we continue our open label extension ("OLE") study for B-VEC, resume dosing with KB105 Phase&#160;2 clinical trial, initiate Phase 2 trial for KB301, initiate Phase 1 trial for KB407, and incur preclinical expenses for our other product candidates. Due to the numerous risks and uncertainties associated with product development, we cannot determine with certainty the duration, costs and timing of clinical trials, and, as a result, the actual costs to complete clinical trials may exceed the expected costs.&#160;</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist principally of salaries and other related costs, including stock-based compensation for personnel in our executive, commercial, business development and other administrative functions. General </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and administrative expenses also include professional fees associated with corporate and intellectual property-related legal expenses, consulting and accounting services, facility-related costs and expenses associated with obtaining and maintaining patents. Other general and administrative costs include stock-based compensation and travel expenses.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase in the future to support the continued research and development of our product candidates and to operate as a public company. These increases will likely include increased costs for insurance, costs related to the hiring of additional personnel and payments to outside consultants, lawyers and accountants, among other expenses. Additionally, if and when we believe a regulatory approval of our first product candidate appears likely, we anticipate that we will increase our salary and personnel costs and other expenses as a result of our preparation for commercial operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASTRA Capital Expenditures</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2021, we closed on the purchase of the building that was constructed to house our second cGMP facility, ASTRA. We are currently in the process of constructing the interior build-out of this facility and we have entered into a contract with Whiting-Turner who will manage the construction of ASTRA.  Further, we have entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. We expect to continue to incur significant capital expenditures related to ASTRA as we construct and validate this facility, which is expected to be completed in 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income&#160;&#160;</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists primarily of income earned from our cash, cash equivalents and investments.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists primarily of non-cash interest expense recognized to accrete the build to suit financial obligation to a balance that equaled the cash consideration that was paid upon the close of the purchase of ASTRA.  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies, Significant Judgments and Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes during the three months ended March&#160;31, 2022 to our critical accounting policies, significant judgments and estimates as disclosed in our management&#8217;s discussion and analysis of financial condition and results of operations included in our Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended March&#160;31, 2022 and 2021</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.695%"><tr><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,222)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,353)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,869)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Income (Expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,492)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,965)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,812)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,153)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses&#160;</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and development expenses increased $3.1 million in the three months ended March&#160;31, 2022 compared to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March&#160;31, 2021. Higher research and development expenses were due to an increase in preclinical, clinical and pre-commercial manufacturing activities of $1.3 million, payroll related expenses of $1.6 million, which were primarily driven by an increase in headcount to support overall growth, and includes an $848 thousand increase in stock-based compensation, and other research and development expenses of $320 thousand, primarily due to software related costs and rent. These increases were partially offset by a decrease in travel related activities of approximately $86&#160;thousand.</span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased $7.8 million in the three months ended March&#160;31, 2022 as compared to the three months ended March&#160;31, 2021. Higher general and administrative spending was due largely to increases in payroll related expenses of approximately $5.9 million, which was primarily driven by an increase in headcount to personnel in our executive, commercial, business development and other administrative functions to support overall growth, and includes a $3.3 million increase in stock-based compensation, commercial preparedness expenses of approximately $1.0 million, medical affairs costs of $162 thousand, software related costs of $130 thousand, business development costs of $166 thousand, and other administrative expenses of $526 thousand, primarily due to rent and taxes. These increases were offset by a decrease in legal and professional fees of approximately $92 thousand, which includes $509 thousand of insurance proceeds.</span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation settlement </span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation settlement expenses increased $25.0 million in the three months ended March&#160;31, 2022 as compared to the three months ended March&#160;31, 2021 and consisted of the settlement of litigation with PeriphaGen. See "Legal Proceedings" in Note 6 of the notes to condensed consolidated financial statements included in this Form 10-Q for more information.</span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income for the three months ended March&#160;31, 2022 and 2021 was $257 thousand and $33 thousand, respectively, and consisted of interest and dividend income earned from our cash, cash equivalents and investments. </span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three months ended March&#160;31, 2022 and 2021 was zero and $1.5 million, respectively, and related to accretion of the financial obligation for the build to suit lease liability during the three months ended March&#160;31, 2021 to a balance that equaled the purchase consideration for ASTRA.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, our cash, cash equivalents and short-term investments balance was approximately $434.6 million. Since operations began, we have incurred operating losses. Our net losses were $50.0 million and $15.8 million for the three months ended March&#160;31, 2022 and 2021, respectively. At March&#160;31, 2022, we had an accumulated deficit of $190.7&#160;million. With the net proceeds raised from our previous public and private securities offerings and our ability to issue additional shares under our current ATM  program, the Company believes that our cash, cash equivalents and short-term investments as of March&#160;31, 2022 will be sufficient to allow the Company to fund operations for at least 12 months from the filing date of this Form 10-Q. </span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of our product candidates and the achievement of a level of revenues adequate to support the Company&#8217;s cost structure. Furthermore, we expect to incur increasing costs associated with operating as a public company, meeting financial controls, satisfying regulatory and quality standards, maintaining product and clinical trials, and furthering our efforts around our current and future product candidates. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional capital or obtain financing from other sources. </span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to clinical trials can be unpredictable and therefore there can be no guarantee that we will have sufficient capital to fund our continued clinical studies of B-VEC, KB105, KB301 or our planned preclinical studies for our other product candidates, or our operations.  Further, we do not expect to generate any product revenues until 4Q 2022, at the earliest, assuming we receive marketing approval for B-VEC on the schedule we currently contemplate. While we are in the process of building out our internal vector manufacturing capacity, some of our manufacturing activities will be contracted out to third parties. Additionally, we currently utilize third-party contract research organizations to carry out our clinical development activities. As we seek to obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses as we prepare for product sales, marketing, manufacturing, and distribution. Our funds may not be sufficient to enable us to conduct pivotal clinical trials for, seek marketing approval for or commercially launch B-VEC, KB105, KB301 or any other product candidate. Accordingly, to obtain marketing approval for and to commercialize these or any other product candidates, we may be required to obtain further funding through public or private equity offerings, debt financings, collaboration and licensing arrangements or other sources. Adequate additional financing may not be available to us on acceptable terms, if at all. Our failure to raise capital when needed could have a negative effect on our financial condition and our ability to pursue our business strategy.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Capital Requirements</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of capital are, and we expect will continue to be for the near future, compensation and related expenses, manufacturing costs for preclinical and clinical materials, third party clinical trial research and development services, laboratory and related supplies, clinical costs, legal and other regulatory expenses and general overhead costs.  In order to complete the process of obtaining regulatory approval for any of our product candidates and to build the sales, manufacturing, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we will require substantial additional funding.</span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect, and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timeline and cost of our OLE study for B-VEC;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, timing and costs of our ongoing Phase 1/2 clinical trials for KB105;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, results and costs of our Phase 2 clinical trials for KB301;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, timing and costs of manufacturing of B-VEC;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continued development and the filing on an IND application for future product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, scope, progress, timing, costs and results of drug discovery, laboratory testing, manufacturing, preclinical studies and clinical trials for any other product candidates that we may pursue in the future, if any;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of maintaining our own commercial-scale cGMP manufacturing facilities;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and costs of seeking regulatory approvals;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with the manufacturing process development and evaluation of third-party manufacturers;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, in the event we receive marketing approval for our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which the costs of our product candidates, if approved, will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payors;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of commercialization activities for our current and future product candidates if we receive marketing approval for such product candidates we may develop, including the costs and timing of establishing product sales, medical affairs, marketing, distribution and manufacturing capabilities;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subject to receipt of marketing approval, if any, revenue received from commercial sale of our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may establish;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, maintenance, defense and enforcement of any patents or other intellectual property rights, including milestone and royalty payments and patent prosecution fees that we are obligated to pay pursuant to our license agreements;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our current license agreements remaining in effect and our achievement of milestones under those agreements;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations and licenses on favorable terms, if at all; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we&#160;acquire or in-license other product candidates and technologies.</span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to obtain substantial additional funding in order to receive regulatory approval and to commercialize our product candidates. To the extent that we raise additional capital through the sale of common stock, convertible securities or other equity securities, the ownership interests of our existing stockholders may be materially diluted and the terms of these securities could include liquidation or other preferences that could adversely affect the rights of our existing stockholders. In addition, debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely affect our ability to conduct our business. If we are unable to raise capital when needed or on attractive terms, we could be forced to significantly delay, scale back or discontinue the development or commercialization of our product candidates, seek collaborators at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available, and relinquish or license, potentially on unfavorable terms, our rights to our product candidates that we otherwise would seek to develop or commercialize ourselves.&#160;</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources and Uses of Cash</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our sources and uses of cash (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"></td><td style="width:67.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,493)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,654)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,908)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(747)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided (used in) by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(542)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,943)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,903&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the three months ended March&#160;31, 2022 was $15.5&#160;million and consisted primarily of a net loss of $50.0&#160;million adjusted for non-cash items primarily of depreciation and amortization and stock-based compensation expense of $7.3&#160;million, and increases in net operating liabilities of approximately $27.2&#160;million which includes an increase in accrued legal settlement of $25.0&#160;million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the three months ended March&#160;31, 2021 was $9.7&#160;million and consisted primarily of a net loss of $15.8&#160;million adjusted for non-cash items primarily of depreciation and amortization and stock-based compensation expense of approximately $2.8&#160;million and build to suit interest expense of $1.5&#160;million, as well as decreases in net operating assets of approximately $1.8&#160;million. </span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the three months ended March&#160;31, 2022 was $55.9&#160;million and consisted primarily of expenditures of $17.2&#160;million on the build-out of our ASTRA facility, leasehold improvement of new office space, and purchases of computer and laboratory equipment, $62.8 million on the purchase of short-term and long-term investments, partially offset by proceeds of $24.0&#160;million received from the maturities of short-term investments.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the three months ended March&#160;31, 2021 was $747&#160;thousand and consisted primarily of expenditures of $2.5&#160;million on the build-out of our ASTRA facility, leasehold improvement of new office space, and purchase of computer and laboratory equipment, partially offset by proceeds of $1.7&#160;million received from the maturities of short-term investments.</span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used by financing activities for the three months ended March&#160;31, 2022 was $542&#160;thousand and consisted primarily of proceeds of $107&#160;thousand received from exercises of stock options and offset by $649&#160;thousand used for the employee tax withholding payment for settlement of vested restricted stock awards. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended March&#160;31, 2021 was $144.3&#160;million and consisted primarily of proceeds of $152.3&#160;million received from our ATM Program, a public offering, and exercises of stock options, partially offset by $8.0&#160;million used for the purchase of the ASTRA building. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2021 the Company completed a public offering of 2,211,538 shares of its common stock at $65.00 per share. Net proceeds to the Company from the offering were $134.9&#160;million after deducting underwriting discounts and commissions of approximately $8.6&#160;million and other offering expenses of approximately $198&#160;thousand.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, pursuant to the ATM Program the Company issued 262,500 shares of common stock at a weighted average price of $66.50 per share for net proceeds of $16.9&#160;million after deducting underwriting discounts and commissions of approximately $524&#160;thousand. The Company also incurred $172 thousand of other offering expenses related to the ATM Program. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021, the Company received proceeds of $346 thousand&#160;from the exercise of stock options.</span></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements&#160;as defined in the rules and regulations of the SEC.</span></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_79"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our contractual obligations as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 other than as described in Note 6 &#8220;Commitments and Contingencies&#8221; of our condensed consolidated financial statements on this Form 10-Q.</span></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_82"></div><div style="margin-top:18pt"><span><br/></span></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Qualitative and Quantitative Disclosures About Market Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash, cash equivalents and short-term investments of $434.6 million at March&#160;31, 2022, which consist primarily of money market, bank deposits, commercial paper, corporate bonds, and government agency securities. The investments in these financial instruments are made in accordance with an investment policy which specifies the categories, allocations and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. Some of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial instruments in which we invest could be subject to market risk. This means that a change in prevailing interest rates may cause the value of the instruments to fluctuate. For example, if we purchase a security that was issued with a fixed interest rate and the prevailing interest rate later rises, the value of that security will probably decline. To minimize this risk, we intend to maintain a portfolio which may include cash, cash equivalents and short and long-term investment securities available-for-sale in a variety of securities which may include money market funds, government and non-government debt securities and commercial paper, all with various maturity dates. Based on our current investment portfolio, we do not believe that our results of operations or our financial position would be materially affected by an immediate change of 10% in interest rates.</span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not hold or issue derivatives, derivative commodity instruments or other financial instruments for speculative trading purposes. Further, we do not believe our cash, cash equivalents and short-term investments have a significant risk of default or illiquidity. While we believe our cash, cash equivalents and short-term investments do not contain excessive risk, we cannot provide absolute assurance that any investments we make in the future will not be subject to adverse changes in market value. Our cash, cash equivalents and short and long-term investments are recorded at fair value.</span></div><div style="margin-top:12pt;text-indent:29.25pt"><span><br/></span></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer and our Chief Accounting Officer, with the participation of other members of the Company&#8217;s management, have evaluated the effectiveness of the Company&#8217;s &#8220;disclosure controls and procedures&#8221; (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;)) as of the end of the period covered by this quarterly report, and our Chief Executive Officer and our Chief Accounting Officer have concluded that our disclosure controls and procedures are effective based on their evaluation of these controls and procedures as required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we implemented a new enterprise resource planning software, Microsoft Dynamics D365 (&#8220;Dynamics&#8221;), as part of a plan to integrate and upgrade our systems and processes. The implementation of this software is scheduled to continue in phases over a number of years. As the phased implementation of this system occurs, we expect certain changes to our processes and procedures which, in turn, will result in changes to our internal control over financial reporting. We expect Dynamics to strengthen our internal financial controls by automating a number of accounting and reporting processes and activities, thereby decreasing the number of manual processes previously required. Management will continue to evaluate and monitor our internal controls as processes and procedures in each of the affected areas evolve.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as discussed above, no change in our internal control over financial reporting occurred during the quarter ended March&#160;31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_94"></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information set forth under the heading &#8220;Legal Proceedings&#8221; in Note 6 of the notes to condensed consolidated financial statements included in Item 1 of Part I of this Form 10-Q is incorporated by reference in response to this item.</span></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed in "Summary Risk Factors" and "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on February 28, 2022, there are a number of risks and uncertainties that may have a material effect on the operating results of our business and our financial condition. There have been no material changes from the risk factors previously disclosed in such filing.</span></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20220331ex311.htm">Certification of Periodic Report by Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20220331ex312.htm">Certification of Periodic Report by Chief Accounting Officer under Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="krys-20220331ex321.htm">Certification of Chief Executive Officer and Chief Accounting Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL (Extensible Business Reporting Language). The following materials from this Quarterly Report on Form 10-Q for the period ended March 31, 2022, formatted in Inline XBRL: (i) consolidated balance sheets of Krystal Biotech, Inc., (ii) consolidated statements of operations of Krystal Biotech, Inc., (iii) consolidated statements of comprehensive income/(loss) of Krystal Biotech, Inc., (iv) consolidated statements of changes in equity of Krystal Biotech, Inc., (v) consolidated statements of cash flows of Krystal Biotech, Inc. and (vi) notes to consolidated financial statements of Krystal Biotech, Inc. The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL </span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i1d18f2ca829a4240ba3639a9ab04fa9c_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.240%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KRYSTAL BIOTECH, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May&#160;9, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Krish S. Krishnan</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krish S. Krishnan</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal executive officer)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kathryn A. Romano</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathryn A. Romano</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal financial and accounting officer)</span></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>krys-20220331ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0264ede4fa1d45c187c1d1fbcfe765ef_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Krish S. Krishnan, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q&#160;of Krystal Biotech, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the Condensed financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and&#160;15d-15(e))&#160;for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;9, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:9pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>3
<FILENAME>krys-20220331ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i513117cf2ec7406cbb3d1a177a31cf54_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF ACCOUNTING OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Krish S. Krishnan, Chief Executive Officer, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the Quarterly Report on Form&#160;10-Q&#160;for the three months ended March&#160;31, 2022, (the &#8220;Periodic Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Krystal Biotech, Inc.</font></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;9, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Krish S. Krishnan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kathryn A. Romano, Chief Accounting Officer, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the Quarterly Report on Form&#160;10-Q&#160;for the three months ended March&#160;31, 2022, (the &#8220;Periodic Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Krystal Biotech, Inc.</font></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;9, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</font></td></tr></table></div><div style="margin-top:9pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>4
<FILENAME>krys-20220331ex312.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i56a8f71c3a7a4687897bc8ddcf92c600_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF ACCOUNTING OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kathryn A. Romano, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form&#160;10-Q&#160;of Krystal Biotech, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the Condensed financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;9, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathryn A. Romano</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:9pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>krys-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:27464c84-a11a-4d8c-aabe-cd82bfdc0a8a,g:c7af04d0-bbfe-49f0-8ddd-58863f20a4c2-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:krys="http://www.krystalbio.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.krystalbio.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="krys-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.krystalbio.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.krystalbio.com/role/Organization">
        <link:definition>2101101 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail">
        <link:definition>2402401 - Disclosure - Organization - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholders" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders">
        <link:definition>2108103 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholdersTables" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables">
        <link:definition>2309302 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail">
        <link:definition>2410404 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail">
        <link:definition>2411405 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstruments" roleURI="http://www.krystalbio.com/role/FairValueInstruments">
        <link:definition>2112104 - Disclosure - Fair Value Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstrumentsTables" roleURI="http://www.krystalbio.com/role/FairValueInstrumentsTables">
        <link:definition>2313303 - Disclosure - Fair Value Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail">
        <link:definition>2414406 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1">
        <link:definition>2414406 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://www.krystalbio.com/role/BalanceSheetComponents">
        <link:definition>2115105 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsTables">
        <link:definition>2316304 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail">
        <link:definition>2417407 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail">
        <link:definition>2418408 - Disclosure - Balance Sheet Components - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail">
        <link:definition>2419409 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.krystalbio.com/role/CommitmentsandContingencies">
        <link:definition>2120106 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesTables">
        <link:definition>2321305 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>2422410 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail">
        <link:definition>2423411 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1" roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1">
        <link:definition>2423411 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail">
        <link:definition>2424412 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Capitalization" roleURI="http://www.krystalbio.com/role/Capitalization">
        <link:definition>2125107 - Disclosure - Capitalization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalizationAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail">
        <link:definition>2426413 - Disclosure - Capitalization - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.krystalbio.com/role/StockBasedCompensation">
        <link:definition>2127108 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.krystalbio.com/role/StockBasedCompensationTables">
        <link:definition>2328306 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>2429414 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail">
        <link:definition>2430415 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail">
        <link:definition>2431416 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" roleURI="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail">
        <link:definition>2432417 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails">
        <link:definition>2433418 - Disclosure - Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.krystalbio.com/role/SubsequentEvents">
        <link:definition>2134109 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.krystalbio.com/role/SubsequentEventsDetails">
        <link:definition>2435419 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="krys_ATMProgramMember" abstract="true" name="ATMProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_SignificantAccountingPoliciesLineItems" abstract="true" name="SignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="krys_PeriphaGenMember" abstract="true" name="PeriphaGenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_InterestIncomeExpenseAndOtherNonoperatingNet" abstract="false" name="InterestIncomeExpenseAndOtherNonoperatingNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_AccruedConstructionInProgressCurrent" abstract="false" name="AccruedConstructionInProgressCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" abstract="false" name="LessorOperatingLeaseLiabilityAnnualLeasePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_LongTermMarketableSecuritiesMember" abstract="true" name="LongTermMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_ASTRAFacilityMember" abstract="true" name="ASTRAFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_PlacementSharesMember" abstract="true" name="PlacementSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_SignificantAccountingPoliciesTable" abstract="true" name="SignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="krys_ClinicalSupplyAgreementMember" abstract="true" name="ClinicalSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" abstract="false" name="ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" abstract="false" name="CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" abstract="false" name="CashCashEquivalentsAndDebtSecuritiesAvailableForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_NumberOfMilestones" abstract="false" name="NumberOfMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="krys_MilestoneThreeMember" abstract="true" name="MilestoneThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment" abstract="false" name="IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_PaymentsForSuitLiability" abstract="false" name="PaymentsForSuitLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_AccruedPreclinicalAndClinicalExpenses" abstract="false" name="AccruedPreclinicalAndClinicalExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_CumulativeEscalationClauseTerm" abstract="false" name="CumulativeEscalationClauseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="krys_SaleOfStockAggregateOfferingPrice" abstract="false" name="SaleOfStockAggregateOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_StockIncentivePlanMember" abstract="true" name="StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_PurchasePriceOfPotentialBuildingPurchase" abstract="false" name="PurchasePriceOfPotentialBuildingPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_RemainingCommitmentAmount" abstract="false" name="RemainingCommitmentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_MilestonesAxis" abstract="true" name="MilestonesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="krys_EstimatedUsefulLivesOfAssetsTableTextBlock" abstract="false" name="EstimatedUsefulLivesOfAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="krys_IncentiveStockOptionsMember" abstract="true" name="IncentiveStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_PaymentToEscrowForReducingLeaseRentals" abstract="false" name="PaymentToEscrowForReducingLeaseRentals" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_LabEquipmentMember" abstract="true" name="LabEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_LitigationSettlementTotalConsideration" abstract="false" name="LitigationSettlementTotalConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_AccruedPayrollAndBenefits" abstract="false" name="AccruedPayrollAndBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_AdditionalAreaOfRealEstatePropertyLeased" abstract="false" name="AdditionalAreaOfRealEstatePropertyLeased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="krys_MilestonesDomain" abstract="true" name="MilestonesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_TwoThousandSixteenLeaseAgreementMember" abstract="true" name="TwoThousandSixteenLeaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_NonEmployeeStockOptionMember" abstract="true" name="NonEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_LossContingencyGuaranteedMaximumPriceToBePaid" abstract="false" name="LossContingencyGuaranteedMaximumPriceToBePaid" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_BostonLeaseMember" abstract="true" name="BostonLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_CostOfWorkPercentage" abstract="false" name="CostOfWorkPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="krys_MilestoneTwoMember" abstract="true" name="MilestoneTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="krys_AccruedFinancingFeesCurrent" abstract="false" name="AccruedFinancingFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_MilestoneOneMember" abstract="true" name="MilestoneOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_LitigationSettlementMilestonePaymentsSalesThreshold" abstract="false" name="LitigationSettlementMilestonePaymentsSalesThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_OfferingCostsIncurredButNotYetPaid" abstract="false" name="OfferingCostsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_StockSaleAgreementMember" abstract="true" name="StockSaleAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_CumulativeEscalationClausePercent" abstract="false" name="CumulativeEscalationClausePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="krys_AccruedExpensesAndOtherCurrentLiabilities" abstract="false" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_RisksAndUncertaintiesPolicyTextBlock" abstract="false" name="RisksAndUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="krys_IncreaseDecreaseInLeaseLiability" abstract="false" name="IncreaseDecreaseInLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_SaleOfStockRemainingAvailableIssuanceAmount" abstract="false" name="SaleOfStockRemainingAvailableIssuanceAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="krys_OtherContractualObligationsMember" abstract="true" name="OtherContractualObligationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>krys-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:27464c84-a11a-4d8c-aabe-cd82bfdc0a8a,g:c7af04d0-bbfe-49f0-8ddd-58863f20a4c2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="krys-20220331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_aec30f06-3174-4657-90af-c90802ff8d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0bd6705a-77e4-42d6-94ae-69bc43cfb083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_aec30f06-3174-4657-90af-c90802ff8d3d" xlink:to="loc_us-gaap_AssetsCurrent_0bd6705a-77e4-42d6-94ae-69bc43cfb083" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_86c1cccc-89a4-41d7-8d4b-576e09cc2026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_aec30f06-3174-4657-90af-c90802ff8d3d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_86c1cccc-89a4-41d7-8d4b-576e09cc2026" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_793d39d9-5e81-4d4a-b557-3f2e69484c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_aec30f06-3174-4657-90af-c90802ff8d3d" xlink:to="loc_us-gaap_LongTermInvestments_793d39d9-5e81-4d4a-b557-3f2e69484c75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6804a959-715e-4fae-970c-450013c27482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_aec30f06-3174-4657-90af-c90802ff8d3d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6804a959-715e-4fae-970c-450013c27482" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ef428289-fd12-4405-aede-234397e91fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_aec30f06-3174-4657-90af-c90802ff8d3d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ef428289-fd12-4405-aede-234397e91fe7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3dc29998-fde0-4eac-96ff-f99b012c569d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c4c93d8f-275b-4e8d-98a8-ab1516ea2e63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3dc29998-fde0-4eac-96ff-f99b012c569d" xlink:to="loc_us-gaap_LiabilitiesCurrent_c4c93d8f-275b-4e8d-98a8-ab1516ea2e63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c435187c-eac0-4178-b50c-053f8a9ce588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3dc29998-fde0-4eac-96ff-f99b012c569d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c435187c-eac0-4178-b50c-053f8a9ce588" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ec4ce963-eb4c-4b6c-a34a-9eef90298b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8015a391-7343-4d46-a484-96efbd187319" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ec4ce963-eb4c-4b6c-a34a-9eef90298b99" xlink:to="loc_us-gaap_Liabilities_8015a391-7343-4d46-a484-96efbd187319" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_69327f06-23d7-4b9a-9280-c374d3b2334f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ec4ce963-eb4c-4b6c-a34a-9eef90298b99" xlink:to="loc_us-gaap_CommitmentsAndContingencies_69327f06-23d7-4b9a-9280-c374d3b2334f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a88e195d-a47a-425f-8f52-d89bcc2199d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ec4ce963-eb4c-4b6c-a34a-9eef90298b99" xlink:to="loc_us-gaap_StockholdersEquity_a88e195d-a47a-425f-8f52-d89bcc2199d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3b5bc842-21ed-4b54-97ef-48ff585658ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_76f3eec8-b0d5-4c53-902b-7e87969a3837" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b5bc842-21ed-4b54-97ef-48ff585658ff" xlink:to="loc_us-gaap_PreferredStockValue_76f3eec8-b0d5-4c53-902b-7e87969a3837" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e50767a0-b144-4b74-82ee-7b85c76ad216" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b5bc842-21ed-4b54-97ef-48ff585658ff" xlink:to="loc_us-gaap_CommonStockValue_e50767a0-b144-4b74-82ee-7b85c76ad216" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_223335cd-2ca9-49e2-971f-0e61c2ab6690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b5bc842-21ed-4b54-97ef-48ff585658ff" xlink:to="loc_us-gaap_AdditionalPaidInCapital_223335cd-2ca9-49e2-971f-0e61c2ab6690" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0f7996c9-9855-4559-94eb-9f086ae543d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b5bc842-21ed-4b54-97ef-48ff585658ff" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0f7996c9-9855-4559-94eb-9f086ae543d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c48eca8f-6f43-42de-af34-cfa60c4fb57a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3b5bc842-21ed-4b54-97ef-48ff585658ff" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c48eca8f-6f43-42de-af34-cfa60c4fb57a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_36c8d72f-f1ac-4d8e-b221-c3e88464d775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_61e5ac82-6f3c-4988-bb95-d366cae76de0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_36c8d72f-f1ac-4d8e-b221-c3e88464d775" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_61e5ac82-6f3c-4988-bb95-d366cae76de0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_df05a050-cd7f-422c-a658-6b4912ebaafd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_36c8d72f-f1ac-4d8e-b221-c3e88464d775" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_df05a050-cd7f-422c-a658-6b4912ebaafd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_40c2dff7-c547-4a47-a064-0046e7a3e6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_36c8d72f-f1ac-4d8e-b221-c3e88464d775" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_40c2dff7-c547-4a47-a064-0046e7a3e6f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_29885e6a-ebe3-4921-84a3-f03120efb29a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6894ad21-3971-4447-86c4-a55540cab73d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_29885e6a-ebe3-4921-84a3-f03120efb29a" xlink:to="loc_us-gaap_AccountsPayableCurrent_6894ad21-3971-4447-86c4-a55540cab73d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f7ba9b13-a115-49ec-8c7b-464b7f21c183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_29885e6a-ebe3-4921-84a3-f03120efb29a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f7ba9b13-a115-49ec-8c7b-464b7f21c183" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_db71c7ac-ff56-4a08-8a22-b6cd02f12101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_29885e6a-ebe3-4921-84a3-f03120efb29a" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_db71c7ac-ff56-4a08-8a22-b6cd02f12101" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="krys-20220331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e9527ece-1b6e-41c9-a952-eef57ce77e21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_294498da-8f6c-4063-b7f3-5cf9b1abde65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e9527ece-1b6e-41c9-a952-eef57ce77e21" xlink:to="loc_us-gaap_OperatingExpenses_294498da-8f6c-4063-b7f3-5cf9b1abde65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3b2d2668-3be5-4c6b-b765-94574d5729e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c52a72e9-1b83-481d-90b2-668ff54dbcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3b2d2668-3be5-4c6b-b765-94574d5729e3" xlink:to="loc_us-gaap_OperatingIncomeLoss_c52a72e9-1b83-481d-90b2-668ff54dbcbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_9b5c6bf5-33d5-4459-b80f-6117d402da03" xlink:href="krys-20220331.xsd#krys_InterestIncomeExpenseAndOtherNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3b2d2668-3be5-4c6b-b765-94574d5729e3" xlink:to="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_9b5c6bf5-33d5-4459-b80f-6117d402da03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_7143000e-9cef-48b5-aa22-56cd642a430f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3b2d2668-3be5-4c6b-b765-94574d5729e3" xlink:to="loc_us-gaap_InterestExpense_7143000e-9cef-48b5-aa22-56cd642a430f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cffecde9-6f79-43c9-9cc6-b215076ae2da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b36ce49b-78c6-40c2-a5ce-25dd77cf7d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cffecde9-6f79-43c9-9cc6-b215076ae2da" xlink:to="loc_us-gaap_NetIncomeLoss_b36ce49b-78c6-40c2-a5ce-25dd77cf7d98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_eaee1224-92da-4dc2-9dbc-abc18677c8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cffecde9-6f79-43c9-9cc6-b215076ae2da" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_eaee1224-92da-4dc2-9dbc-abc18677c8f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9ad4bc5d-913c-4e91-b7a1-a58a245b1c36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f9256000-b7de-43ff-9d07-80f85710dcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_9ad4bc5d-913c-4e91-b7a1-a58a245b1c36" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f9256000-b7de-43ff-9d07-80f85710dcd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_bbb54123-45db-4333-aae1-2ddef1e0987f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_9ad4bc5d-913c-4e91-b7a1-a58a245b1c36" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_bbb54123-45db-4333-aae1-2ddef1e0987f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_6275cd13-2d4d-413c-acc9-8603b81f80dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_9ad4bc5d-913c-4e91-b7a1-a58a245b1c36" xlink:to="loc_us-gaap_LitigationSettlementExpense_6275cd13-2d4d-413c-acc9-8603b81f80dd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="krys-20220331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5dd8746f-c835-42aa-8e14-95da50ab641f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_89985d42-a867-497c-9ebb-9633b7279dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5dd8746f-c835-42aa-8e14-95da50ab641f" xlink:to="loc_us-gaap_NetIncomeLoss_89985d42-a867-497c-9ebb-9633b7279dd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_58b8c068-dc8e-4446-b53b-77ec2a817c62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5dd8746f-c835-42aa-8e14-95da50ab641f" xlink:to="loc_us-gaap_DepreciationAndAmortization_58b8c068-dc8e-4446-b53b-77ec2a817c62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_23a18a0d-a2de-47e8-8a5a-687174d6c0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5dd8746f-c835-42aa-8e14-95da50ab641f" xlink:to="loc_us-gaap_ShareBasedCompensation_23a18a0d-a2de-47e8-8a5a-687174d6c0b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_71bfa876-5cf5-47f6-a9b5-67b0f2d0ef6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5dd8746f-c835-42aa-8e14-95da50ab641f" xlink:to="loc_us-gaap_OtherNoncashExpense_71bfa876-5cf5-47f6-a9b5-67b0f2d0ef6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8f627449-0725-400b-ae25-2d0bb89ca4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5dd8746f-c835-42aa-8e14-95da50ab641f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8f627449-0725-400b-ae25-2d0bb89ca4a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseInLeaseLiability_8b394f0c-1b21-413b-89c2-5ba428c5efe1" xlink:href="krys-20220331.xsd#krys_IncreaseDecreaseInLeaseLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5dd8746f-c835-42aa-8e14-95da50ab641f" xlink:to="loc_krys_IncreaseDecreaseInLeaseLiability_8b394f0c-1b21-413b-89c2-5ba428c5efe1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4f182e0d-c08a-442d-8190-bbe1aef53ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5dd8746f-c835-42aa-8e14-95da50ab641f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4f182e0d-c08a-442d-8190-bbe1aef53ee1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_14ec1970-bdf5-4d48-b356-ca30ccbd257e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5dd8746f-c835-42aa-8e14-95da50ab641f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_14ec1970-bdf5-4d48-b356-ca30ccbd257e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_deaa38bb-4e44-4918-bc0e-7a1291e52dae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5dd8746f-c835-42aa-8e14-95da50ab641f" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_deaa38bb-4e44-4918-bc0e-7a1291e52dae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_6070ee21-0446-4db2-9309-0ce3424106ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5dd8746f-c835-42aa-8e14-95da50ab641f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_6070ee21-0446-4db2-9309-0ce3424106ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment_3581b950-3c2d-4509-81d0-7a24238d0c33" xlink:href="krys-20220331.xsd#krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5dd8746f-c835-42aa-8e14-95da50ab641f" xlink:to="loc_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment_3581b950-3c2d-4509-81d0-7a24238d0c33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4d01ecd-c322-42ac-9c25-ed774e2b34b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ed9408f7-055e-4cf5-95d2-a9b691c66ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4d01ecd-c322-42ac-9c25-ed774e2b34b4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ed9408f7-055e-4cf5-95d2-a9b691c66ec5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentsForSuitLiability_4a0dcaf6-3326-4cd6-97a8-fef162f8d6b4" xlink:href="krys-20220331.xsd#krys_PaymentsForSuitLiability"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4d01ecd-c322-42ac-9c25-ed774e2b34b4" xlink:to="loc_krys_PaymentsForSuitLiability_4a0dcaf6-3326-4cd6-97a8-fef162f8d6b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_61bc61dd-57b1-4929-b60b-f59c23867efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4d01ecd-c322-42ac-9c25-ed774e2b34b4" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_61bc61dd-57b1-4929-b60b-f59c23867efd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7a37353-e38e-4739-bbb5-1ee7e57a82e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8f722ae0-5a86-4044-b329-419ce1127f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7a37353-e38e-4739-bbb5-1ee7e57a82e8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8f722ae0-5a86-4044-b329-419ce1127f08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_48ef722c-b6ad-4a19-a51c-76a9e0d50110" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7a37353-e38e-4739-bbb5-1ee7e57a82e8" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_48ef722c-b6ad-4a19-a51c-76a9e0d50110" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_c0b892f7-7866-4039-9229-efc09187aef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7a37353-e38e-4739-bbb5-1ee7e57a82e8" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_c0b892f7-7866-4039-9229-efc09187aef2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d47b74ac-31e3-42f4-ac9d-927240b7317f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2049c331-9194-41f4-9621-81c3f240eca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d47b74ac-31e3-42f4-ac9d-927240b7317f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2049c331-9194-41f4-9621-81c3f240eca5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_03d38d5a-f61a-4366-b417-0c214c6699b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d47b74ac-31e3-42f4-ac9d-927240b7317f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_03d38d5a-f61a-4366-b417-0c214c6699b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dcbe103f-8d73-4ccf-bbaa-c29161791dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d47b74ac-31e3-42f4-ac9d-927240b7317f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dcbe103f-8d73-4ccf-bbaa-c29161791dda" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_c293ae85-1072-495b-88c8-f7c38edcf0e5" xlink:href="krys-20220331.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_86bd5745-81bd-440d-845b-9354f059bfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_c293ae85-1072-495b-88c8-f7c38edcf0e5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_86bd5745-81bd-440d-845b-9354f059bfcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0fe854d8-d306-4d82-bb22-9dc2c6c089f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_c293ae85-1072-495b-88c8-f7c38edcf0e5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0fe854d8-d306-4d82-bb22-9dc2c6c089f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_dcfde0a2-0047-4c56-bb8d-be569c03ddd4" xlink:href="krys-20220331.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4a274380-55a9-4d14-bf12-79682f286791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_dcfde0a2-0047-4c56-bb8d-be569c03ddd4" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4a274380-55a9-4d14-bf12-79682f286791" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ab61a1dd-783e-42a9-8a5f-5f8b206ed8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_dcfde0a2-0047-4c56-bb8d-be569c03ddd4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ab61a1dd-783e-42a9-8a5f-5f8b206ed8f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d5fc6c1a-049a-4ac0-b62a-46b30fa3f599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e216e46d-4609-49cf-b750-2f25a56c43ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d5fc6c1a-049a-4ac0-b62a-46b30fa3f599" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e216e46d-4609-49cf-b750-2f25a56c43ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2e8325af-cef5-4f02-adeb-bc7fe24b1781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d5fc6c1a-049a-4ac0-b62a-46b30fa3f599" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2e8325af-cef5-4f02-adeb-bc7fe24b1781" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bded22e3-c03d-4b1a-a918-72ef76ee8f03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d5fc6c1a-049a-4ac0-b62a-46b30fa3f599" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bded22e3-c03d-4b1a-a918-72ef76ee8f03" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="simple" xlink:href="krys-20220331.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_9ccac56b-bf02-4c24-9d05-0aaf50828db3" xlink:href="krys-20220331.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2cbc2fc3-d3f2-43ed-a733-b2ce795fdea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_9ccac56b-bf02-4c24-9d05-0aaf50828db3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2cbc2fc3-d3f2-43ed-a733-b2ce795fdea0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_3dfc15ef-2aa9-4821-9be5-303b1dcc2656" xlink:href="krys-20220331.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_9ccac56b-bf02-4c24-9d05-0aaf50828db3" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_3dfc15ef-2aa9-4821-9be5-303b1dcc2656" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ec340b88-b368-458b-8284-be278a864af1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_9ccac56b-bf02-4c24-9d05-0aaf50828db3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ec340b88-b368-458b-8284-be278a864af1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9a157b74-9917-4f5d-94e6-15a67905b8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ae7b6290-6324-4ee4-acb3-7ec2e3956784" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_9a157b74-9917-4f5d-94e6-15a67905b8f5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ae7b6290-6324-4ee4-acb3-7ec2e3956784" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bc4bf20a-3c3b-483b-a90c-b6f25a8fb735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_9a157b74-9917-4f5d-94e6-15a67905b8f5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bc4bf20a-3c3b-483b-a90c-b6f25a8fb735" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_d7622e48-8dfb-4be6-87b6-c41e89506720" xlink:href="krys-20220331.xsd#krys_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPreclinicalAndClinicalExpenses_7440795a-4344-4c1e-a4b4-bb3afe7800cf" xlink:href="krys-20220331.xsd#krys_AccruedPreclinicalAndClinicalExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_d7622e48-8dfb-4be6-87b6-c41e89506720" xlink:to="loc_krys_AccruedPreclinicalAndClinicalExpenses_7440795a-4344-4c1e-a4b4-bb3afe7800cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_0431f8cc-ce0d-4289-af9e-8efefd3a395e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_d7622e48-8dfb-4be6-87b6-c41e89506720" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_0431f8cc-ce0d-4289-af9e-8efefd3a395e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPayrollAndBenefits_6ad8d78a-8b15-4a38-a261-b82df0216404" xlink:href="krys-20220331.xsd#krys_AccruedPayrollAndBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_d7622e48-8dfb-4be6-87b6-c41e89506720" xlink:to="loc_krys_AccruedPayrollAndBenefits_6ad8d78a-8b15-4a38-a261-b82df0216404" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes_e973389a-57bd-4e7a-862f-c7e1b8e5e1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_d7622e48-8dfb-4be6-87b6-c41e89506720" xlink:to="loc_us-gaap_AccruedIncomeTaxes_e973389a-57bd-4e7a-862f-c7e1b8e5e1b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedConstructionInProgressCurrent_f5e668f3-b111-468e-b2dd-aea686ff552e" xlink:href="krys-20220331.xsd#krys_AccruedConstructionInProgressCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_d7622e48-8dfb-4be6-87b6-c41e89506720" xlink:to="loc_krys_AccruedConstructionInProgressCurrent_f5e668f3-b111-468e-b2dd-aea686ff552e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedFinancingFeesCurrent_4b118659-e02d-4245-86aa-de8a27dcfbb7" xlink:href="krys-20220331.xsd#krys_AccruedFinancingFeesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_d7622e48-8dfb-4be6-87b6-c41e89506720" xlink:to="loc_krys_AccruedFinancingFeesCurrent_4b118659-e02d-4245-86aa-de8a27dcfbb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_25fa9c39-0032-474d-96bb-9c808948de73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_d7622e48-8dfb-4be6-87b6-c41e89506720" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_25fa9c39-0032-474d-96bb-9c808948de73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_435fbd95-0021-4e72-af6a-4b9f5edf3eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_d7622e48-8dfb-4be6-87b6-c41e89506720" xlink:to="loc_us-gaap_LitigationReserveCurrent_435fbd95-0021-4e72-af6a-4b9f5edf3eab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1d623a23-ecc0-47b0-b2c2-c709a41835da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ff8cef60-ac49-425c-a354-439080eec680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1d623a23-ecc0-47b0-b2c2-c709a41835da" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ff8cef60-ac49-425c-a354-439080eec680" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c428c06d-2587-424a-a671-03c1ac0613a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1d623a23-ecc0-47b0-b2c2-c709a41835da" xlink:to="loc_us-gaap_OperatingLeaseLiability_c428c06d-2587-424a-a671-03c1ac0613a9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1" xlink:type="simple" xlink:href="krys-20220331.xsd#CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2acbdfac-ad24-4307-87c8-77e379b2ef40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f0ef1242-0127-4f0d-a02b-d9fcb15d4509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2acbdfac-ad24-4307-87c8-77e379b2ef40" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f0ef1242-0127-4f0d-a02b-d9fcb15d4509" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6ca7bc9e-96a1-431c-9ca7-f7ce08f87477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2acbdfac-ad24-4307-87c8-77e379b2ef40" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6ca7bc9e-96a1-431c-9ca7-f7ce08f87477" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e9e9672f-0bfd-48dd-9152-aa91b51f5590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2acbdfac-ad24-4307-87c8-77e379b2ef40" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e9e9672f-0bfd-48dd-9152-aa91b51f5590" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fea77cb2-7295-4586-8021-b8dc8c90d66f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2acbdfac-ad24-4307-87c8-77e379b2ef40" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fea77cb2-7295-4586-8021-b8dc8c90d66f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3068ed43-2822-463c-af33-1891109e1654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2acbdfac-ad24-4307-87c8-77e379b2ef40" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3068ed43-2822-463c-af33-1891109e1654" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_06288a46-2691-4cac-99a6-4fbc8fed647c" xlink:href="krys-20220331.xsd#krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2acbdfac-ad24-4307-87c8-77e379b2ef40" xlink:to="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_06288a46-2691-4cac-99a6-4fbc8fed647c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"/>
  <link:calculationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_197ceed3-cb47-43b5-afcb-697c3f798a82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ac2d2568-2a63-4987-9317-94936fe14dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_197ceed3-cb47-43b5-afcb-697c3f798a82" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ac2d2568-2a63-4987-9317-94936fe14dfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c90149e4-9163-4640-995e-ffa569eb40f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_197ceed3-cb47-43b5-afcb-697c3f798a82" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c90149e4-9163-4640-995e-ffa569eb40f8" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>krys-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:27464c84-a11a-4d8c-aabe-cd82bfdc0a8a,g:c7af04d0-bbfe-49f0-8ddd-58863f20a4c2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="krys-20220331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="ibec7073f9e7243ac80493f1ab29e1cd1_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2e8858ad-de2f-4cbc-9c6d-0b0d6ca8c923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2e8858ad-de2f-4cbc-9c6d-0b0d6ca8c923" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d310cb93-96f5-40a4-84a8-7516363ed91e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:to="loc_us-gaap_SharesOutstanding_d310cb93-96f5-40a4-84a8-7516363ed91e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cefab358-e274-4815-a03a-69893bac03a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:to="loc_us-gaap_StockholdersEquity_cefab358-e274-4815-a03a-69893bac03a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b94b1600-5764-439f-ba0b-45bdc6af3c96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b94b1600-5764-439f-ba0b-45bdc6af3c96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c4702099-b3a7-48d7-9cbb-1768c2325b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c4702099-b3a7-48d7-9cbb-1768c2325b9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_7677d118-5f18-4d05-9150-46aa06fda177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_7677d118-5f18-4d05-9150-46aa06fda177" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_922f1ba1-7f95-4912-9412-f8d8acadec9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_922f1ba1-7f95-4912-9412-f8d8acadec9a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1a7ba20c-bc63-463a-9fe8-43b916d32cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1a7ba20c-bc63-463a-9fe8-43b916d32cd5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7352f125-4dfc-46d0-ad60-37ce01ec482f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7352f125-4dfc-46d0-ad60-37ce01ec482f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7a67e620-52bf-41c8-8240-d06edd23e94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:to="loc_us-gaap_NetIncomeLoss_7a67e620-52bf-41c8-8240-d06edd23e94f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_807d7222-5124-44ac-8ac7-dfd5fc8e51c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_88141a3e-3466-4886-9cb7-8eaf5ca13d66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6a31ab5c-15fc-4b02-914f-1ee7aaf0312a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2e8858ad-de2f-4cbc-9c6d-0b0d6ca8c923" xlink:to="loc_us-gaap_StatementTable_6a31ab5c-15fc-4b02-914f-1ee7aaf0312a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1697f7dc-c2e8-4e06-9c80-6000f7441ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6a31ab5c-15fc-4b02-914f-1ee7aaf0312a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1697f7dc-c2e8-4e06-9c80-6000f7441ccf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1697f7dc-c2e8-4e06-9c80-6000f7441ccf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1697f7dc-c2e8-4e06-9c80-6000f7441ccf" xlink:to="loc_us-gaap_EquityComponentDomain_1697f7dc-c2e8-4e06-9c80-6000f7441ccf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e721a25f-0587-4e4c-8ffc-ac5316e880d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1697f7dc-c2e8-4e06-9c80-6000f7441ccf" xlink:to="loc_us-gaap_EquityComponentDomain_e721a25f-0587-4e4c-8ffc-ac5316e880d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_106719c2-a164-41e8-82db-9a40477d5cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e721a25f-0587-4e4c-8ffc-ac5316e880d1" xlink:to="loc_us-gaap_CommonStockMember_106719c2-a164-41e8-82db-9a40477d5cd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_18bd1c02-fdac-4b1b-86bf-22eae7eb2e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e721a25f-0587-4e4c-8ffc-ac5316e880d1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_18bd1c02-fdac-4b1b-86bf-22eae7eb2e55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f460ec2a-a08a-4836-8867-d501afb8f992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e721a25f-0587-4e4c-8ffc-ac5316e880d1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f460ec2a-a08a-4836-8867-d501afb8f992" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e365005c-bbc8-4a02-b60b-b4fdada15279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e721a25f-0587-4e4c-8ffc-ac5316e880d1" xlink:to="loc_us-gaap_RetainedEarningsMember_e365005c-bbc8-4a02-b60b-b4fdada15279" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" id="ia1cad4f46eb74f3186daff1cf799a937_SummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesLineItems_6356de22-2d74-45bc-9d1f-be5da8b8fb81" xlink:href="krys-20220331.xsd#krys_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_bb0cf0cf-eca1-46c0-ac5c-527a333c006a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_6356de22-2d74-45bc-9d1f-be5da8b8fb81" xlink:to="loc_us-gaap_NumberOfOperatingSegments_bb0cf0cf-eca1-46c0-ac5c-527a333c006a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_3e215255-a6de-477d-ae61-b614685f4956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_6356de22-2d74-45bc-9d1f-be5da8b8fb81" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_3e215255-a6de-477d-ae61-b614685f4956" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesTable_8f563873-6def-4b43-be9e-91ea781d7965" xlink:href="krys-20220331.xsd#krys_SignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_6356de22-2d74-45bc-9d1f-be5da8b8fb81" xlink:to="loc_krys_SignificantAccountingPoliciesTable_8f563873-6def-4b43-be9e-91ea781d7965" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_93a376f1-bc6d-44c3-8a90-b6b7ea879e17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_krys_SignificantAccountingPoliciesTable_8f563873-6def-4b43-be9e-91ea781d7965" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_93a376f1-bc6d-44c3-8a90-b6b7ea879e17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_93a376f1-bc6d-44c3-8a90-b6b7ea879e17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_93a376f1-bc6d-44c3-8a90-b6b7ea879e17" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_93a376f1-bc6d-44c3-8a90-b6b7ea879e17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5fe9e3cd-dfe8-44c2-bc1e-a2e5e619b8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_93a376f1-bc6d-44c3-8a90-b6b7ea879e17" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5fe9e3cd-dfe8-44c2-bc1e-a2e5e619b8a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_3c4a99f6-4b24-4597-ba8e-d30a43217a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5fe9e3cd-dfe8-44c2-bc1e-a2e5e619b8a9" xlink:to="loc_us-gaap_EquipmentMember_3c4a99f6-4b24-4597-ba8e-d30a43217a90" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="extended" id="i3aa706691e9f47f0a75c1c7f91c6861c_SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f11039d6-8e4a-4b0c-b132-2c18cc4bfbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f6253465-4c3c-45c1-861f-d06c77219650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f11039d6-8e4a-4b0c-b132-2c18cc4bfbd5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f6253465-4c3c-45c1-861f-d06c77219650" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf3c2491-0c9f-4220-af38-d150cecaa2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f11039d6-8e4a-4b0c-b132-2c18cc4bfbd5" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf3c2491-0c9f-4220-af38-d150cecaa2a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_609ac055-0535-4a8b-89fa-a3fbd173e8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf3c2491-0c9f-4220-af38-d150cecaa2a0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_609ac055-0535-4a8b-89fa-a3fbd173e8c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_609ac055-0535-4a8b-89fa-a3fbd173e8c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_609ac055-0535-4a8b-89fa-a3fbd173e8c2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_609ac055-0535-4a8b-89fa-a3fbd173e8c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_edaab1b8-552f-4f1f-aec6-241a53a857e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_609ac055-0535-4a8b-89fa-a3fbd173e8c2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_edaab1b8-552f-4f1f-aec6-241a53a857e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d056e6e0-7cbe-4a99-93e4-49ce5b2406d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_edaab1b8-552f-4f1f-aec6-241a53a857e9" xlink:to="loc_us-gaap_ComputerEquipmentMember_d056e6e0-7cbe-4a99-93e4-49ce5b2406d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember_ee7231ab-fd05-44dd-9cbe-1eafff0072a0" xlink:href="krys-20220331.xsd#krys_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_edaab1b8-552f-4f1f-aec6-241a53a857e9" xlink:to="loc_krys_LabEquipmentMember_ee7231ab-fd05-44dd-9cbe-1eafff0072a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_7ec7fc5d-1d1a-4521-a38c-8b9677c72016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_edaab1b8-552f-4f1f-aec6-241a53a857e9" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_7ec7fc5d-1d1a-4521-a38c-8b9677c72016" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1044507a-5043-41ef-8f4a-14d6f989e74b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf3c2491-0c9f-4220-af38-d150cecaa2a0" xlink:to="loc_srt_RangeAxis_1044507a-5043-41ef-8f4a-14d6f989e74b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1044507a-5043-41ef-8f4a-14d6f989e74b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1044507a-5043-41ef-8f4a-14d6f989e74b" xlink:to="loc_srt_RangeMember_1044507a-5043-41ef-8f4a-14d6f989e74b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b716c844-a913-4be0-aa63-2ba6a29ef3ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1044507a-5043-41ef-8f4a-14d6f989e74b" xlink:to="loc_srt_RangeMember_b716c844-a913-4be0-aa63-2ba6a29ef3ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ec07f6cc-d2bb-4a0e-b2d3-75d35c047224" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b716c844-a913-4be0-aa63-2ba6a29ef3ab" xlink:to="loc_srt_MinimumMember_ec07f6cc-d2bb-4a0e-b2d3-75d35c047224" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4acacb39-30f4-4681-aae9-6012bf522bfe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b716c844-a913-4be0-aa63-2ba6a29ef3ab" xlink:to="loc_srt_MaximumMember_4acacb39-30f4-4681-aae9-6012bf522bfe" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended" id="if0417a7830b442988c1b2c5e2e9513a9_FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8c31221-df1c-4e2e-b767-beecbcf933df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a113c976-f3fd-4910-a28f-43b97981df2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8c31221-df1c-4e2e-b767-beecbcf933df" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a113c976-f3fd-4910-a28f-43b97981df2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_91f8eb9f-f7f0-4ef0-bd6f-293a1156a38d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8c31221-df1c-4e2e-b767-beecbcf933df" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_91f8eb9f-f7f0-4ef0-bd6f-293a1156a38d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4895cd4c-4d3d-4689-aaff-ff9b8e883f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8c31221-df1c-4e2e-b767-beecbcf933df" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4895cd4c-4d3d-4689-aaff-ff9b8e883f58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_13baef78-1b7a-4eda-80f6-bbaa5cf19790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8c31221-df1c-4e2e-b767-beecbcf933df" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_13baef78-1b7a-4eda-80f6-bbaa5cf19790" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ec500024-cc8c-4adb-9143-6963e6aa022f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8c31221-df1c-4e2e-b767-beecbcf933df" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ec500024-cc8c-4adb-9143-6963e6aa022f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_46462a2c-04ff-48ff-94ce-999d577ee32a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8c31221-df1c-4e2e-b767-beecbcf933df" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_46462a2c-04ff-48ff-94ce-999d577ee32a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_70d0e768-f44e-4f3a-afa6-d375309c4895" xlink:href="krys-20220331.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8c31221-df1c-4e2e-b767-beecbcf933df" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_70d0e768-f44e-4f3a-afa6-d375309c4895" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_a01c1ae7-05f0-4f64-9bfc-57c4f48dad2d" xlink:href="krys-20220331.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8c31221-df1c-4e2e-b767-beecbcf933df" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_a01c1ae7-05f0-4f64-9bfc-57c4f48dad2d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_76a6b189-96b8-4867-a499-57232117e50a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8c31221-df1c-4e2e-b767-beecbcf933df" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_76a6b189-96b8-4867-a499-57232117e50a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36aa45e4-a547-4f0f-90db-95c9681d9e85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8c31221-df1c-4e2e-b767-beecbcf933df" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36aa45e4-a547-4f0f-90db-95c9681d9e85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_30562123-7a38-4539-a0ef-66545916189f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36aa45e4-a547-4f0f-90db-95c9681d9e85" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_30562123-7a38-4539-a0ef-66545916189f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_30562123-7a38-4539-a0ef-66545916189f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_30562123-7a38-4539-a0ef-66545916189f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_30562123-7a38-4539-a0ef-66545916189f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f253f893-ea5b-4c56-896e-53671f881868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_30562123-7a38-4539-a0ef-66545916189f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f253f893-ea5b-4c56-896e-53671f881868" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_ba586aac-ae00-4728-9080-73eb105a8b00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f253f893-ea5b-4c56-896e-53671f881868" xlink:to="loc_us-gaap_CashMember_ba586aac-ae00-4728-9080-73eb105a8b00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_22e4fa92-d0ea-400d-bc34-e6de6952aa74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f253f893-ea5b-4c56-896e-53671f881868" xlink:to="loc_us-gaap_CommercialPaperMember_22e4fa92-d0ea-400d-bc34-e6de6952aa74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_23cdd73c-a93f-4278-85d6-c2e36f9a838c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f253f893-ea5b-4c56-896e-53671f881868" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_23cdd73c-a93f-4278-85d6-c2e36f9a838c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_2d0a5aa6-43d4-497c-a9ed-cda2e6c96789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f253f893-ea5b-4c56-896e-53671f881868" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_2d0a5aa6-43d4-497c-a9ed-cda2e6c96789" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b5d65cbb-6642-4a16-b534-a0418b433dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36aa45e4-a547-4f0f-90db-95c9681d9e85" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b5d65cbb-6642-4a16-b534-a0418b433dcf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b5d65cbb-6642-4a16-b534-a0418b433dcf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b5d65cbb-6642-4a16-b534-a0418b433dcf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b5d65cbb-6642-4a16-b534-a0418b433dcf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f3025b3-f1bf-42cd-9336-94d837b95f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b5d65cbb-6642-4a16-b534-a0418b433dcf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f3025b3-f1bf-42cd-9336-94d837b95f9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_82809ffd-4aa2-4bba-9bb9-b7b99a40d9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f3025b3-f1bf-42cd-9336-94d837b95f9d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_82809ffd-4aa2-4bba-9bb9-b7b99a40d9b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_cb32007f-3e8e-434a-807b-140be61091d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f3025b3-f1bf-42cd-9336-94d837b95f9d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_cb32007f-3e8e-434a-807b-140be61091d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b0b86a9f-f5af-446e-9410-e350a45c75ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36aa45e4-a547-4f0f-90db-95c9681d9e85" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b0b86a9f-f5af-446e-9410-e350a45c75ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b0b86a9f-f5af-446e-9410-e350a45c75ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b0b86a9f-f5af-446e-9410-e350a45c75ed" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b0b86a9f-f5af-446e-9410-e350a45c75ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2cd778a3-6d7f-4ed7-a533-3a9396e017bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b0b86a9f-f5af-446e-9410-e350a45c75ed" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2cd778a3-6d7f-4ed7-a533-3a9396e017bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_ce77a63c-071b-47f1-9d2b-398667236c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2cd778a3-6d7f-4ed7-a533-3a9396e017bc" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_ce77a63c-071b-47f1-9d2b-398667236c0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_4555842b-e148-4f10-ab5a-69c56929073a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2cd778a3-6d7f-4ed7-a533-3a9396e017bc" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_4555842b-e148-4f10-ab5a-69c56929073a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LongTermMarketableSecuritiesMember_1e1ba5c8-6302-4f22-8f87-bd5fbcf852a9" xlink:href="krys-20220331.xsd#krys_LongTermMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2cd778a3-6d7f-4ed7-a533-3a9396e017bc" xlink:to="loc_krys_LongTermMarketableSecuritiesMember_1e1ba5c8-6302-4f22-8f87-bd5fbcf852a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cf52ad41-6ee1-4536-b139-4bd590a2e599" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36aa45e4-a547-4f0f-90db-95c9681d9e85" xlink:to="loc_srt_RangeAxis_cf52ad41-6ee1-4536-b139-4bd590a2e599" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cf52ad41-6ee1-4536-b139-4bd590a2e599_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cf52ad41-6ee1-4536-b139-4bd590a2e599" xlink:to="loc_srt_RangeMember_cf52ad41-6ee1-4536-b139-4bd590a2e599_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6444d60c-ce85-45fa-b46d-d415f22ae1f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cf52ad41-6ee1-4536-b139-4bd590a2e599" xlink:to="loc_srt_RangeMember_6444d60c-ce85-45fa-b46d-d415f22ae1f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3a114078-c0dd-48ba-938c-124a4b43db5c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6444d60c-ce85-45fa-b46d-d415f22ae1f2" xlink:to="loc_srt_MinimumMember_3a114078-c0dd-48ba-938c-124a4b43db5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9ad155e8-eb5e-4b06-85d4-039df7719ea4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6444d60c-ce85-45fa-b46d-d415f22ae1f2" xlink:to="loc_srt_MaximumMember_9ad155e8-eb5e-4b06-85d4-039df7719ea4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended" id="i3ad646e302a64c8c873d9cd983d46f7b_BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_054937f1-8a38-4c29-a993-8f0deebeaec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8e2fef16-1f01-416d-b90e-ff240faffaa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_054937f1-8a38-4c29-a993-8f0deebeaec3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8e2fef16-1f01-416d-b90e-ff240faffaa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_374178c8-dc9b-4ee6-857e-a5de103c45c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_054937f1-8a38-4c29-a993-8f0deebeaec3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_374178c8-dc9b-4ee6-857e-a5de103c45c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fd5e8cc1-c897-4425-8155-bd3de8a49aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_054937f1-8a38-4c29-a993-8f0deebeaec3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fd5e8cc1-c897-4425-8155-bd3de8a49aa1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d8141fb9-3d8a-4b38-b26a-6dae8c5130ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_054937f1-8a38-4c29-a993-8f0deebeaec3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d8141fb9-3d8a-4b38-b26a-6dae8c5130ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8e89e9c1-7b25-440e-a1ea-2d15b615a625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d8141fb9-3d8a-4b38-b26a-6dae8c5130ad" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8e89e9c1-7b25-440e-a1ea-2d15b615a625" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8e89e9c1-7b25-440e-a1ea-2d15b615a625_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8e89e9c1-7b25-440e-a1ea-2d15b615a625" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8e89e9c1-7b25-440e-a1ea-2d15b615a625_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9e6c46b7-24c3-4cb4-872a-fa77a87d3d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8e89e9c1-7b25-440e-a1ea-2d15b615a625" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9e6c46b7-24c3-4cb4-872a-fa77a87d3d71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_480f3e80-b9be-4201-9108-e766c8c389a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9e6c46b7-24c3-4cb4-872a-fa77a87d3d71" xlink:to="loc_us-gaap_ConstructionInProgressMember_480f3e80-b9be-4201-9108-e766c8c389a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_394b526c-0e39-4a29-bcbf-868c4d08ca47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9e6c46b7-24c3-4cb4-872a-fa77a87d3d71" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_394b526c-0e39-4a29-bcbf-868c4d08ca47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_6a22ff6e-e6a2-46ec-9292-eb76f8b48f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9e6c46b7-24c3-4cb4-872a-fa77a87d3d71" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_6a22ff6e-e6a2-46ec-9292-eb76f8b48f72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_deec78e4-8cc9-4400-8e80-5639df707104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9e6c46b7-24c3-4cb4-872a-fa77a87d3d71" xlink:to="loc_us-gaap_ComputerEquipmentMember_deec78e4-8cc9-4400-8e80-5639df707104" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember_dd1aa5a7-79a2-4a20-9eb6-eb4721902e45" xlink:href="krys-20220331.xsd#krys_LabEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9e6c46b7-24c3-4cb4-872a-fa77a87d3d71" xlink:to="loc_krys_LabEquipmentMember_dd1aa5a7-79a2-4a20-9eb6-eb4721902e45" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended" id="i620c8f42918b4e2e9570a9024e471bd9_CommitmentsandContingenciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AdditionalAreaOfRealEstatePropertyLeased_4ced7a8a-aebc-49b6-959c-7dbff7dfd45f" xlink:href="krys-20220331.xsd#krys_AdditionalAreaOfRealEstatePropertyLeased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_AdditionalAreaOfRealEstatePropertyLeased_4ced7a8a-aebc-49b6-959c-7dbff7dfd45f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentToEscrowForReducingLeaseRentals_35f814bc-e121-483b-b830-304a921c8232" xlink:href="krys-20220331.xsd#krys_PaymentToEscrowForReducingLeaseRentals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_PaymentToEscrowForReducingLeaseRentals_35f814bc-e121-483b-b830-304a921c8232" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PurchasePriceOfPotentialBuildingPurchase_ef6a9367-e6de-4f5f-b270-62d3f5c1382c" xlink:href="krys-20220331.xsd#krys_PurchasePriceOfPotentialBuildingPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_PurchasePriceOfPotentialBuildingPurchase_ef6a9367-e6de-4f5f-b270-62d3f5c1382c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_d5d52df4-8d42-4050-b8e3-44a71dc03518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_FinanceLeaseLiability_d5d52df4-8d42-4050-b8e3-44a71dc03518" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_9117fbc2-baa9-4e1a-9c7f-bb4397b86613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_ConstructionInProgressGross_9117fbc2-baa9-4e1a-9c7f-bb4397b86613" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_6408cbd3-3517-4b48-a68c-7991de0f4ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_EscrowDeposit_6408cbd3-3517-4b48-a68c-7991de0f4ce9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_a0073e08-d26d-4d68-9d3a-97582b715a96" xlink:href="krys-20220331.xsd#krys_LessorOperatingLeaseLiabilityAnnualLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_a0073e08-d26d-4d68-9d3a-97582b715a96" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClausePercent_b0d29bc9-793d-40c6-9328-5c905a8169d1" xlink:href="krys-20220331.xsd#krys_CumulativeEscalationClausePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_CumulativeEscalationClausePercent_b0d29bc9-793d-40c6-9328-5c905a8169d1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClauseTerm_745ddde7-0f92-4e10-a67b-ca2270decef0" xlink:href="krys-20220331.xsd#krys_CumulativeEscalationClauseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_CumulativeEscalationClauseTerm_745ddde7-0f92-4e10-a67b-ca2270decef0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2eb1d6f3-ce4e-4de9-b04c-9519e85ac289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2eb1d6f3-ce4e-4de9-b04c-9519e85ac289" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0c4cc1e0-ac9c-4d1c-8e2f-c128360d8e34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0c4cc1e0-ac9c-4d1c-8e2f-c128360d8e34" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_19e80e00-7852-43ef-9ffd-aea8a9030169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_19e80e00-7852-43ef-9ffd-aea8a9030169" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_84fd3445-4ba5-4514-8d67-e93b4740445a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_84fd3445-4ba5-4514-8d67-e93b4740445a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_b70149cb-0fa3-464b-b346-bee3074437aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_OperatingLeaseCost_b70149cb-0fa3-464b-b346-bee3074437aa" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_8411b3f2-5b3f-4f7f-88ce-adcc5044c705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_VariableLeaseCost_8411b3f2-5b3f-4f7f-88ce-adcc5044c705" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RemainingCommitmentAmount_51e91b3b-56e7-4622-90a8-9c9e1c71fb73" xlink:href="krys-20220331.xsd#krys_RemainingCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_RemainingCommitmentAmount_51e91b3b-56e7-4622-90a8-9c9e1c71fb73" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_0c98ac22-0ccf-4a49-826f-6dea7cd7614e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_ProfessionalFees_0c98ac22-0ccf-4a49-826f-6dea7cd7614e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_d8bfd782-a493-4b77-8c26-ca07bc8619e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_ContractualObligation_d8bfd782-a493-4b77-8c26-ca07bc8619e5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CostOfWorkPercentage_cae8de34-dc7f-4c2b-a54a-79cfaa1bc339" xlink:href="krys-20220331.xsd#krys_CostOfWorkPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_CostOfWorkPercentage_cae8de34-dc7f-4c2b-a54a-79cfaa1bc339" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid_64569787-5edc-436a-9d52-2cb3871cd948" xlink:href="krys-20220331.xsd#krys_LossContingencyGuaranteedMaximumPriceToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid_64569787-5edc-436a-9d52-2cb3871cd948" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5ea0b478-0933-49a8-8c4c-4f7479d2e4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5ea0b478-0933-49a8-8c4c-4f7479d2e4f4" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_7da66a75-0528-4add-a7c5-26ddd8a7363e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_LitigationSettlementExpense_7da66a75-0528-4add-a7c5-26ddd8a7363e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_9de93873-e3ca-4c28-859e-048d93e038f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_9de93873-e3ca-4c28-859e-048d93e038f0" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NumberOfMilestones_61a02af4-e1de-462e-9bc5-b1bc71094baa" xlink:href="krys-20220331.xsd#krys_NumberOfMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_NumberOfMilestones_61a02af4-e1de-462e-9bc5-b1bc71094baa" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold_64cb34d0-2580-402e-9832-b64507220b58" xlink:href="krys-20220331.xsd#krys_LitigationSettlementMilestonePaymentsSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold_64cb34d0-2580-402e-9832-b64507220b58" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementTotalConsideration_5f034ded-4b9f-474f-a49b-8aa116511b83" xlink:href="krys-20220331.xsd#krys_LitigationSettlementTotalConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_LitigationSettlementTotalConsideration_5f034ded-4b9f-474f-a49b-8aa116511b83" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_4e920ea5-243a-4310-9cde-6e0c03a26d51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_4e920ea5-243a-4310-9cde-6e0c03a26d51" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_3800b107-97cc-439b-99ef-605e76d8fbec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_3800b107-97cc-439b-99ef-605e76d8fbec" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_0596278c-a88d-4102-a822-77f3ec0a7123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_LitigationReserveCurrent_0596278c-a88d-4102-a822-77f3ec0a7123" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7bf66faa-08ff-476f-a753-eb445b23d30d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7bf66faa-08ff-476f-a753-eb445b23d30d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_01bf0a3e-0759-47ae-a8a1-ce88fe50886a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7bf66faa-08ff-476f-a753-eb445b23d30d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_01bf0a3e-0759-47ae-a8a1-ce88fe50886a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_01bf0a3e-0759-47ae-a8a1-ce88fe50886a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_01bf0a3e-0759-47ae-a8a1-ce88fe50886a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_01bf0a3e-0759-47ae-a8a1-ce88fe50886a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_df502ed2-d150-4d1b-a515-a1ba29c3ac65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_01bf0a3e-0759-47ae-a8a1-ce88fe50886a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_df502ed2-d150-4d1b-a515-a1ba29c3ac65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_TwoThousandSixteenLeaseAgreementMember_4fc144fc-632c-4a0a-a596-608435f82501" xlink:href="krys-20220331.xsd#krys_TwoThousandSixteenLeaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_df502ed2-d150-4d1b-a515-a1ba29c3ac65" xlink:to="loc_krys_TwoThousandSixteenLeaseAgreementMember_4fc144fc-632c-4a0a-a596-608435f82501" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_BostonLeaseMember_8487e743-e671-491c-b1c3-a259d79673ef" xlink:href="krys-20220331.xsd#krys_BostonLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_df502ed2-d150-4d1b-a515-a1ba29c3ac65" xlink:to="loc_krys_BostonLeaseMember_8487e743-e671-491c-b1c3-a259d79673ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_9df0770a-b6b6-40e8-b419-d1eb6374bcf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7bf66faa-08ff-476f-a753-eb445b23d30d" xlink:to="loc_us-gaap_SupplyCommitmentAxis_9df0770a-b6b6-40e8-b419-d1eb6374bcf9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_9df0770a-b6b6-40e8-b419-d1eb6374bcf9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SupplyCommitmentAxis_9df0770a-b6b6-40e8-b419-d1eb6374bcf9" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_9df0770a-b6b6-40e8-b419-d1eb6374bcf9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_4b886e0b-697b-42d4-87ed-2e913befee2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SupplyCommitmentAxis_9df0770a-b6b6-40e8-b419-d1eb6374bcf9" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_4b886e0b-697b-42d4-87ed-2e913befee2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ClinicalSupplyAgreementMember_e65fd50e-f829-47a9-9b42-aad45ba08f96" xlink:href="krys-20220331.xsd#krys_ClinicalSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_4b886e0b-697b-42d4-87ed-2e913befee2f" xlink:to="loc_krys_ClinicalSupplyAgreementMember_e65fd50e-f829-47a9-9b42-aad45ba08f96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OtherContractualObligationsMember_1001f86e-3083-4e97-8da7-3bbe42f364a0" xlink:href="krys-20220331.xsd#krys_OtherContractualObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_4b886e0b-697b-42d4-87ed-2e913befee2f" xlink:to="loc_krys_OtherContractualObligationsMember_1001f86e-3083-4e97-8da7-3bbe42f364a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ASTRAFacilityMember_732ea2a7-4c80-4d15-a69f-95959d90f81e" xlink:href="krys-20220331.xsd#krys_ASTRAFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_4b886e0b-697b-42d4-87ed-2e913befee2f" xlink:to="loc_krys_ASTRAFacilityMember_732ea2a7-4c80-4d15-a69f-95959d90f81e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesAxis_d7803b45-c13a-40d6-b715-fbaa2db6089d" xlink:href="krys-20220331.xsd#krys_MilestonesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7bf66faa-08ff-476f-a753-eb445b23d30d" xlink:to="loc_krys_MilestonesAxis_d7803b45-c13a-40d6-b715-fbaa2db6089d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesDomain_d7803b45-c13a-40d6-b715-fbaa2db6089d_default" xlink:href="krys-20220331.xsd#krys_MilestonesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_krys_MilestonesAxis_d7803b45-c13a-40d6-b715-fbaa2db6089d" xlink:to="loc_krys_MilestonesDomain_d7803b45-c13a-40d6-b715-fbaa2db6089d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesDomain_6e386f40-1bde-4f19-9ac8-97031e31b301" xlink:href="krys-20220331.xsd#krys_MilestonesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_krys_MilestonesAxis_d7803b45-c13a-40d6-b715-fbaa2db6089d" xlink:to="loc_krys_MilestonesDomain_6e386f40-1bde-4f19-9ac8-97031e31b301" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneOneMember_bb58dc00-430a-497d-97e0-fc2079068ec8" xlink:href="krys-20220331.xsd#krys_MilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_MilestonesDomain_6e386f40-1bde-4f19-9ac8-97031e31b301" xlink:to="loc_krys_MilestoneOneMember_bb58dc00-430a-497d-97e0-fc2079068ec8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneTwoMember_56a52444-8e26-4f05-bba8-7edfbfd8e839" xlink:href="krys-20220331.xsd#krys_MilestoneTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_MilestonesDomain_6e386f40-1bde-4f19-9ac8-97031e31b301" xlink:to="loc_krys_MilestoneTwoMember_56a52444-8e26-4f05-bba8-7edfbfd8e839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneThreeMember_cf2001f6-d287-42cc-a28f-e4d03689bcb9" xlink:href="krys-20220331.xsd#krys_MilestoneThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_krys_MilestonesDomain_6e386f40-1bde-4f19-9ac8-97031e31b301" xlink:to="loc_krys_MilestoneThreeMember_cf2001f6-d287-42cc-a28f-e4d03689bcb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_4044a787-1612-4fa9-9d78-bfa2700b8e98" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7bf66faa-08ff-476f-a753-eb445b23d30d" xlink:to="loc_srt_LitigationCaseAxis_4044a787-1612-4fa9-9d78-bfa2700b8e98" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4044a787-1612-4fa9-9d78-bfa2700b8e98_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_4044a787-1612-4fa9-9d78-bfa2700b8e98" xlink:to="loc_srt_LitigationCaseTypeDomain_4044a787-1612-4fa9-9d78-bfa2700b8e98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_7e703e6f-19ef-49d5-ad9f-dd38b8b668e1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_4044a787-1612-4fa9-9d78-bfa2700b8e98" xlink:to="loc_srt_LitigationCaseTypeDomain_7e703e6f-19ef-49d5-ad9f-dd38b8b668e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PeriphaGenMember_7e8e7e8f-1652-46ea-b89e-aa7f8103cec8" xlink:href="krys-20220331.xsd#krys_PeriphaGenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_7e703e6f-19ef-49d5-ad9f-dd38b8b668e1" xlink:to="loc_krys_PeriphaGenMember_7e8e7e8f-1652-46ea-b89e-aa7f8103cec8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#CapitalizationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="extended" id="if7cb265aa2394cb2bc71cf80ac213327_CapitalizationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_9929e984-aa05-4a78-a0ad-b13db6b006a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14fa07c8-171b-4343-ab5d-42786b2ab2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_9929e984-aa05-4a78-a0ad-b13db6b006a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14fa07c8-171b-4343-ab5d-42786b2ab2b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_c27dca0d-eb7e-4de9-aebd-0a62e080fd5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_9929e984-aa05-4a78-a0ad-b13db6b006a6" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_c27dca0d-eb7e-4de9-aebd-0a62e080fd5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_62861cbe-3c12-492c-936e-2b4571e9e4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_9929e984-aa05-4a78-a0ad-b13db6b006a6" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_62861cbe-3c12-492c-936e-2b4571e9e4d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_94e79bd4-0b4b-4f47-9aaa-73915d09d74d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_9929e984-aa05-4a78-a0ad-b13db6b006a6" xlink:to="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_94e79bd4-0b4b-4f47-9aaa-73915d09d74d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_4eae2678-dbaa-4e3c-bcb7-1d11952f7992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_9929e984-aa05-4a78-a0ad-b13db6b006a6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_4eae2678-dbaa-4e3c-bcb7-1d11952f7992" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockAggregateOfferingPrice_68fa1a22-cb81-4afa-97f0-611f2f750e5b" xlink:href="krys-20220331.xsd#krys_SaleOfStockAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_9929e984-aa05-4a78-a0ad-b13db6b006a6" xlink:to="loc_krys_SaleOfStockAggregateOfferingPrice_68fa1a22-cb81-4afa-97f0-611f2f750e5b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a9d83a4d-3d76-4f15-99c9-88d53df624af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_9929e984-aa05-4a78-a0ad-b13db6b006a6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a9d83a4d-3d76-4f15-99c9-88d53df624af" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d22b258f-c7b9-4c40-b80a-ed9f0238fc65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_9929e984-aa05-4a78-a0ad-b13db6b006a6" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d22b258f-c7b9-4c40-b80a-ed9f0238fc65" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_77e884aa-6688-43da-938d-276db64ae4d9" xlink:href="krys-20220331.xsd#krys_SaleOfStockRemainingAvailableIssuanceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_9929e984-aa05-4a78-a0ad-b13db6b006a6" xlink:to="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_77e884aa-6688-43da-938d-276db64ae4d9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_f0e43315-3882-48d3-8277-cf0a3715b0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_9929e984-aa05-4a78-a0ad-b13db6b006a6" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityTable_f0e43315-3882-48d3-8277-cf0a3715b0d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_aec67af8-ad8b-4d32-aa19-dd540595cadc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_f0e43315-3882-48d3-8277-cf0a3715b0d4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_aec67af8-ad8b-4d32-aa19-dd540595cadc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aec67af8-ad8b-4d32-aa19-dd540595cadc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_aec67af8-ad8b-4d32-aa19-dd540595cadc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aec67af8-ad8b-4d32-aa19-dd540595cadc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4596c81f-0873-4c5c-8a8c-89cb2b480ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_aec67af8-ad8b-4d32-aa19-dd540595cadc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4596c81f-0873-4c5c-8a8c-89cb2b480ed2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockSaleAgreementMember_0d5b7353-9110-459b-a9f2-699c28b1c88e" xlink:href="krys-20220331.xsd#krys_StockSaleAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4596c81f-0873-4c5c-8a8c-89cb2b480ed2" xlink:to="loc_krys_StockSaleAgreementMember_0d5b7353-9110-459b-a9f2-699c28b1c88e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e18591c0-4cc8-4aab-94c2-53af56f41839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_f0e43315-3882-48d3-8277-cf0a3715b0d4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e18591c0-4cc8-4aab-94c2-53af56f41839" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e18591c0-4cc8-4aab-94c2-53af56f41839_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e18591c0-4cc8-4aab-94c2-53af56f41839" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e18591c0-4cc8-4aab-94c2-53af56f41839_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b08204bb-5a10-41de-8ca6-e5db7d461bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e18591c0-4cc8-4aab-94c2-53af56f41839" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b08204bb-5a10-41de-8ca6-e5db7d461bbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PublicOfferingMember_be0df882-539d-46ae-a390-7e700c883f47" xlink:href="krys-20220331.xsd#krys_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b08204bb-5a10-41de-8ca6-e5db7d461bbb" xlink:to="loc_krys_PublicOfferingMember_be0df882-539d-46ae-a390-7e700c883f47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_2ce536a6-ab92-47f4-96fe-dbf551a3ab97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b08204bb-5a10-41de-8ca6-e5db7d461bbb" xlink:to="loc_us-gaap_OverAllotmentOptionMember_2ce536a6-ab92-47f4-96fe-dbf551a3ab97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PlacementSharesMember_d4488fbd-a926-43ec-abbd-5f9ebc2a39ea" xlink:href="krys-20220331.xsd#krys_PlacementSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b08204bb-5a10-41de-8ca6-e5db7d461bbb" xlink:to="loc_krys_PlacementSharesMember_d4488fbd-a926-43ec-abbd-5f9ebc2a39ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ATMProgramMember_0a57bab5-2257-43fb-969f-c79b0df4d16b" xlink:href="krys-20220331.xsd#krys_ATMProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b08204bb-5a10-41de-8ca6-e5db7d461bbb" xlink:to="loc_krys_ATMProgramMember_0a57bab5-2257-43fb-969f-c79b0df4d16b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended" id="id064997acb994f1d972257e3a7e67d58_StockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_db2e001c-32a7-49e6-8462-ab5d65ae00a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_db2e001c-32a7-49e6-8462-ab5d65ae00a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_623fb5fb-918b-4d9a-a439-df57fa18913d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_623fb5fb-918b-4d9a-a439-df57fa18913d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f7d74a88-b21a-4d33-b21c-ae8dba6971b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f7d74a88-b21a-4d33-b21c-ae8dba6971b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e62c75a9-c5e7-43c7-96c4-925d27195fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e62c75a9-c5e7-43c7-96c4-925d27195fa9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4ccdd5f0-cb4c-4e44-b1e2-1e7b912e2bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4ccdd5f0-cb4c-4e44-b1e2-1e7b912e2bf8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_30dde037-581b-431c-94f2-a71ced1268bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_30dde037-581b-431c-94f2-a71ced1268bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa56c6f3-2986-4c12-9b85-27be3403db81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa56c6f3-2986-4c12-9b85-27be3403db81" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_128f1aee-19e4-497f-83de-25af074b5a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_128f1aee-19e4-497f-83de-25af074b5a8d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_04152f9a-eab8-44a6-99fd-beba787fada1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_04152f9a-eab8-44a6-99fd-beba787fada1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_501c8d29-3613-4b97-a966-67437f6d43dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_501c8d29-3613-4b97-a966-67437f6d43dd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_fe96c841-ba74-4914-8a72-69337e91bf64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_fe96c841-ba74-4914-8a72-69337e91bf64" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_06176094-d218-40cf-88d8-09ec09b52e46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3130db79-1b7b-4041-a0e1-4ad9fce0697a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3130db79-1b7b-4041-a0e1-4ad9fce0697a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4155296e-4342-41ff-8e7a-d02e3803bfbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4155296e-4342-41ff-8e7a-d02e3803bfbb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_034ab009-e079-4f69-90bc-156ddd131bef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4155296e-4342-41ff-8e7a-d02e3803bfbb" xlink:to="loc_us-gaap_AwardTypeAxis_034ab009-e079-4f69-90bc-156ddd131bef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_034ab009-e079-4f69-90bc-156ddd131bef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_034ab009-e079-4f69-90bc-156ddd131bef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_034ab009-e079-4f69-90bc-156ddd131bef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b97a840-ba6f-493f-83d9-ff7411c87f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_034ab009-e079-4f69-90bc-156ddd131bef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b97a840-ba6f-493f-83d9-ff7411c87f8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_306d0549-1ee1-4406-88ec-22919068f519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b97a840-ba6f-493f-83d9-ff7411c87f8b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_306d0549-1ee1-4406-88ec-22919068f519" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember_b408fcbe-37e6-4599-a5a3-b6dcb639c9ac" xlink:href="krys-20220331.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b97a840-ba6f-493f-83d9-ff7411c87f8b" xlink:to="loc_krys_NonEmployeeStockOptionMember_b408fcbe-37e6-4599-a5a3-b6dcb639c9ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_9b5bceb4-df70-4b83-928f-3606328e4bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b97a840-ba6f-493f-83d9-ff7411c87f8b" xlink:to="loc_us-gaap_RestrictedStockMember_9b5bceb4-df70-4b83-928f-3606328e4bf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncentiveStockOptionsMember_a3057e43-297c-4e46-808b-226cbe5baaba" xlink:href="krys-20220331.xsd#krys_IncentiveStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b97a840-ba6f-493f-83d9-ff7411c87f8b" xlink:to="loc_krys_IncentiveStockOptionsMember_a3057e43-297c-4e46-808b-226cbe5baaba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3c7ac54b-093a-491a-892c-e92f0da5c66a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4155296e-4342-41ff-8e7a-d02e3803bfbb" xlink:to="loc_srt_RangeAxis_3c7ac54b-093a-491a-892c-e92f0da5c66a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3c7ac54b-093a-491a-892c-e92f0da5c66a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3c7ac54b-093a-491a-892c-e92f0da5c66a" xlink:to="loc_srt_RangeMember_3c7ac54b-093a-491a-892c-e92f0da5c66a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c42d93ef-6b46-4c96-a3c9-484ca3026c3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3c7ac54b-093a-491a-892c-e92f0da5c66a" xlink:to="loc_srt_RangeMember_c42d93ef-6b46-4c96-a3c9-484ca3026c3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5cf8626e-e2b7-4558-94ef-f33f2af36fb7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c42d93ef-6b46-4c96-a3c9-484ca3026c3d" xlink:to="loc_srt_MinimumMember_5cf8626e-e2b7-4558-94ef-f33f2af36fb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_960c46ee-4cf4-4cb2-8293-b974fbe2d3a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c42d93ef-6b46-4c96-a3c9-484ca3026c3d" xlink:to="loc_srt_MaximumMember_960c46ee-4cf4-4cb2-8293-b974fbe2d3a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_52f19098-7540-4c60-91ab-2ebf2eac9331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4155296e-4342-41ff-8e7a-d02e3803bfbb" xlink:to="loc_us-gaap_PlanNameAxis_52f19098-7540-4c60-91ab-2ebf2eac9331" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_52f19098-7540-4c60-91ab-2ebf2eac9331_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_52f19098-7540-4c60-91ab-2ebf2eac9331" xlink:to="loc_us-gaap_PlanNameDomain_52f19098-7540-4c60-91ab-2ebf2eac9331_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d74754d0-a6a2-4d34-9622-2a21ba7cf915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_52f19098-7540-4c60-91ab-2ebf2eac9331" xlink:to="loc_us-gaap_PlanNameDomain_d74754d0-a6a2-4d34-9622-2a21ba7cf915" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockIncentivePlanMember_b3a3a827-c6d2-4421-b7ee-07176c3fe512" xlink:href="krys-20220331.xsd#krys_StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d74754d0-a6a2-4d34-9622-2a21ba7cf915" xlink:to="loc_krys_StockIncentivePlanMember_b3a3a827-c6d2-4421-b7ee-07176c3fe512" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_8f39e577-474d-4c9f-86c1-21397002198c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4155296e-4342-41ff-8e7a-d02e3803bfbb" xlink:to="loc_srt_TitleOfIndividualAxis_8f39e577-474d-4c9f-86c1-21397002198c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8f39e577-474d-4c9f-86c1-21397002198c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_8f39e577-474d-4c9f-86c1-21397002198c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8f39e577-474d-4c9f-86c1-21397002198c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_22acdbb0-69fa-49b2-9b36-c18266e29efa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_8f39e577-474d-4c9f-86c1-21397002198c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_22acdbb0-69fa-49b2-9b36-c18266e29efa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_5c1a6930-f629-4b6f-850b-a933bb88737c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_22acdbb0-69fa-49b2-9b36-c18266e29efa" xlink:to="loc_srt_DirectorMember_5c1a6930-f629-4b6f-850b-a933bb88737c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" xlink:type="extended" id="i21d8c3d763444ae1a0412d21c4d4b1e1_StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a594e843-9d49-4a8f-9b07-cf28d86f68c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bb549d53-2ea0-4c92-9e48-c5fe82e7f25b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a594e843-9d49-4a8f-9b07-cf28d86f68c7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bb549d53-2ea0-4c92-9e48-c5fe82e7f25b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0935a0ce-a47d-4678-9764-44fa37232331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a594e843-9d49-4a8f-9b07-cf28d86f68c7" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0935a0ce-a47d-4678-9764-44fa37232331" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_42855abf-c7f2-467f-a3e2-06ea6c724e12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0935a0ce-a47d-4678-9764-44fa37232331" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_42855abf-c7f2-467f-a3e2-06ea6c724e12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_42855abf-c7f2-467f-a3e2-06ea6c724e12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_42855abf-c7f2-467f-a3e2-06ea6c724e12" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_42855abf-c7f2-467f-a3e2-06ea6c724e12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_44e0473d-c776-476d-b733-7ad59a8f3538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_42855abf-c7f2-467f-a3e2-06ea6c724e12" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_44e0473d-c776-476d-b733-7ad59a8f3538" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5da8928f-0507-481e-aa2f-72948e89ac3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_44e0473d-c776-476d-b733-7ad59a8f3538" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5da8928f-0507-481e-aa2f-72948e89ac3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_22a3d6c3-43d1-48bf-a5c5-80722d1e637c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_44e0473d-c776-476d-b733-7ad59a8f3538" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_22a3d6c3-43d1-48bf-a5c5-80722d1e637c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f4c2397b-4f1f-4da5-9e2d-09b3fa68c1be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0935a0ce-a47d-4678-9764-44fa37232331" xlink:to="loc_us-gaap_AwardTypeAxis_f4c2397b-4f1f-4da5-9e2d-09b3fa68c1be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4c2397b-4f1f-4da5-9e2d-09b3fa68c1be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f4c2397b-4f1f-4da5-9e2d-09b3fa68c1be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4c2397b-4f1f-4da5-9e2d-09b3fa68c1be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60c5e557-63f8-44d0-ae79-8c41f5c3067f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f4c2397b-4f1f-4da5-9e2d-09b3fa68c1be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60c5e557-63f8-44d0-ae79-8c41f5c3067f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_48b240ac-3d6e-4c73-9dc5-add89bccc7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60c5e557-63f8-44d0-ae79-8c41f5c3067f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_48b240ac-3d6e-4c73-9dc5-add89bccc7cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_759b2c8a-7526-441e-bbdc-69c56dc2ba7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60c5e557-63f8-44d0-ae79-8c41f5c3067f" xlink:to="loc_us-gaap_RestrictedStockMember_759b2c8a-7526-441e-bbdc-69c56dc2ba7e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="extended" id="ic3539523b66e40be99ab60bee3c34a00_StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf465975-4a7c-49f3-a3d9-df34746fc58e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3c4e2923-2720-4166-a55c-b08bbf68c0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf465975-4a7c-49f3-a3d9-df34746fc58e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3c4e2923-2720-4166-a55c-b08bbf68c0f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_759082c5-1a6f-4c51-bd84-2af4aae2abda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf465975-4a7c-49f3-a3d9-df34746fc58e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_759082c5-1a6f-4c51-bd84-2af4aae2abda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3f74f6fd-5bd0-4ddd-95f0-aea5f0dd9022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf465975-4a7c-49f3-a3d9-df34746fc58e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3f74f6fd-5bd0-4ddd-95f0-aea5f0dd9022" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_6212a8a2-5590-409e-a70b-cc8dfe85f2da" xlink:href="krys-20220331.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf465975-4a7c-49f3-a3d9-df34746fc58e" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_6212a8a2-5590-409e-a70b-cc8dfe85f2da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_45a86ddd-6e66-4386-80af-cda8e19db706" xlink:href="krys-20220331.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf465975-4a7c-49f3-a3d9-df34746fc58e" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_45a86ddd-6e66-4386-80af-cda8e19db706" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_587159a5-c621-4005-a119-0facaf9159a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf465975-4a7c-49f3-a3d9-df34746fc58e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_587159a5-c621-4005-a119-0facaf9159a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_892ba498-142c-4ccd-8a51-3325484279db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_587159a5-c621-4005-a119-0facaf9159a3" xlink:to="loc_us-gaap_AwardTypeAxis_892ba498-142c-4ccd-8a51-3325484279db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_892ba498-142c-4ccd-8a51-3325484279db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_892ba498-142c-4ccd-8a51-3325484279db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_892ba498-142c-4ccd-8a51-3325484279db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10bbf469-256d-452d-88c1-bf580c480b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_892ba498-142c-4ccd-8a51-3325484279db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10bbf469-256d-452d-88c1-bf580c480b43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d316ac89-a597-4236-bf41-be251dd4cfe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10bbf469-256d-452d-88c1-bf580c480b43" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d316ac89-a597-4236-bf41-be251dd4cfe3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" xlink:type="simple" xlink:href="krys-20220331.xsd#StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" xlink:type="extended" id="i06034065c814447288c47454eba69e02_StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd183613-28c7-40cd-8dd5-5349e53e3bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1060f28-faf8-4b17-91ae-2ab8a80ea66d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd183613-28c7-40cd-8dd5-5349e53e3bb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1060f28-faf8-4b17-91ae-2ab8a80ea66d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_adcb04c9-1e3b-40ce-adcd-c4cf0ced8383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1060f28-faf8-4b17-91ae-2ab8a80ea66d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_adcb04c9-1e3b-40ce-adcd-c4cf0ced8383" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8d75fd2c-fd66-4706-ae3e-b14b5626265c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1060f28-faf8-4b17-91ae-2ab8a80ea66d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8d75fd2c-fd66-4706-ae3e-b14b5626265c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2775884f-ae4a-43d7-8b79-a272a9b27cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1060f28-faf8-4b17-91ae-2ab8a80ea66d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2775884f-ae4a-43d7-8b79-a272a9b27cf2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3299d78f-8725-4b52-a88f-22aef09ce322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1060f28-faf8-4b17-91ae-2ab8a80ea66d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3299d78f-8725-4b52-a88f-22aef09ce322" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9adce309-7fcc-499e-8f0e-2305f7b93093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_856e8133-4cfc-4177-abc8-2318c8e4d8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd183613-28c7-40cd-8dd5-5349e53e3bb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_856e8133-4cfc-4177-abc8-2318c8e4d8dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_55234392-c461-408c-acc7-1a33b77e6a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_856e8133-4cfc-4177-abc8-2318c8e4d8dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_55234392-c461-408c-acc7-1a33b77e6a1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_74fa3649-ec34-4dd9-a287-3f78c4b495a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_856e8133-4cfc-4177-abc8-2318c8e4d8dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_74fa3649-ec34-4dd9-a287-3f78c4b495a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_faae18ec-f6ca-4add-bc19-35ac84646bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_856e8133-4cfc-4177-abc8-2318c8e4d8dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_faae18ec-f6ca-4add-bc19-35ac84646bd8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9620e041-1150-4978-8b6e-48da4522f5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_856e8133-4cfc-4177-abc8-2318c8e4d8dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9620e041-1150-4978-8b6e-48da4522f5a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8435dbd7-d5f4-4499-81b7-11d51d252369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_87c14c9c-6d3d-4200-9121-04395d70528d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd183613-28c7-40cd-8dd5-5349e53e3bb3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_87c14c9c-6d3d-4200-9121-04395d70528d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2b9f02cb-a4df-4e54-9577-a229255e0c66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_87c14c9c-6d3d-4200-9121-04395d70528d" xlink:to="loc_us-gaap_AwardTypeAxis_2b9f02cb-a4df-4e54-9577-a229255e0c66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b9f02cb-a4df-4e54-9577-a229255e0c66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2b9f02cb-a4df-4e54-9577-a229255e0c66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b9f02cb-a4df-4e54-9577-a229255e0c66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_083ac05f-aa12-427a-9162-fbe36669c721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2b9f02cb-a4df-4e54-9577-a229255e0c66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_083ac05f-aa12-427a-9162-fbe36669c721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b736daad-44c9-4329-808f-80dfbd37a18d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_083ac05f-aa12-427a-9162-fbe36669c721" xlink:to="loc_us-gaap_RestrictedStockMember_b736daad-44c9-4329-808f-80dfbd37a18d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="krys-20220331.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.krystalbio.com/role/SubsequentEventsDetails" xlink:type="extended" id="i7594da7afa0f4e319f36972bf37622e7_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_89124079-5931-4db4-9a31-3d4db6e70dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_6a3222a4-0a66-4346-9c03-b06526632562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_89124079-5931-4db4-9a31-3d4db6e70dfc" xlink:to="loc_us-gaap_LitigationSettlementExpense_6a3222a4-0a66-4346-9c03-b06526632562" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5dfcf155-c801-4b4d-8196-15e0389c715e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_89124079-5931-4db4-9a31-3d4db6e70dfc" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5dfcf155-c801-4b4d-8196-15e0389c715e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2b008f1a-0e0f-4975-923a-6fd8b5e199bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_89124079-5931-4db4-9a31-3d4db6e70dfc" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2b008f1a-0e0f-4975-923a-6fd8b5e199bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ebb62854-801f-48a9-bd16-079e286d5cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_89124079-5931-4db4-9a31-3d4db6e70dfc" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ebb62854-801f-48a9-bd16-079e286d5cd8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_460dbf57-5070-425f-8bd5-7be978bac099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_89124079-5931-4db4-9a31-3d4db6e70dfc" xlink:to="loc_us-gaap_SubsequentEventTable_460dbf57-5070-425f-8bd5-7be978bac099" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_d384efdf-8f12-4b9d-8074-e64d51cb62c0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_460dbf57-5070-425f-8bd5-7be978bac099" xlink:to="loc_srt_LitigationCaseAxis_d384efdf-8f12-4b9d-8074-e64d51cb62c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d384efdf-8f12-4b9d-8074-e64d51cb62c0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_d384efdf-8f12-4b9d-8074-e64d51cb62c0" xlink:to="loc_srt_LitigationCaseTypeDomain_d384efdf-8f12-4b9d-8074-e64d51cb62c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ea3fa301-a0cd-48d0-b897-51a1fcfa75cb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_d384efdf-8f12-4b9d-8074-e64d51cb62c0" xlink:to="loc_srt_LitigationCaseTypeDomain_ea3fa301-a0cd-48d0-b897-51a1fcfa75cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PeriphaGenMember_563d0868-1047-46f3-ac3b-15e683266200" xlink:href="krys-20220331.xsd#krys_PeriphaGenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ea3fa301-a0cd-48d0-b897-51a1fcfa75cb" xlink:to="loc_krys_PeriphaGenMember_563d0868-1047-46f3-ac3b-15e683266200" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_28592ea3-e853-4e90-b6c6-bedbfcf49d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_460dbf57-5070-425f-8bd5-7be978bac099" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_28592ea3-e853-4e90-b6c6-bedbfcf49d09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_28592ea3-e853-4e90-b6c6-bedbfcf49d09_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_28592ea3-e853-4e90-b6c6-bedbfcf49d09" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_28592ea3-e853-4e90-b6c6-bedbfcf49d09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cfcb0a24-d67c-41d6-96ff-2e127f8a6088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_28592ea3-e853-4e90-b6c6-bedbfcf49d09" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cfcb0a24-d67c-41d6-96ff-2e127f8a6088" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PublicOfferingMember_6a0ee409-013f-481a-a705-109c536d136c" xlink:href="krys-20220331.xsd#krys_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cfcb0a24-d67c-41d6-96ff-2e127f8a6088" xlink:to="loc_krys_PublicOfferingMember_6a0ee409-013f-481a-a705-109c536d136c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2e805b59-53ba-456a-ab78-9a19c9aa2e45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_460dbf57-5070-425f-8bd5-7be978bac099" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2e805b59-53ba-456a-ab78-9a19c9aa2e45" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2e805b59-53ba-456a-ab78-9a19c9aa2e45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2e805b59-53ba-456a-ab78-9a19c9aa2e45" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2e805b59-53ba-456a-ab78-9a19c9aa2e45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c0997480-a408-4357-942c-1bfb36092474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2e805b59-53ba-456a-ab78-9a19c9aa2e45" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c0997480-a408-4357-942c-1bfb36092474" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_85bf1435-0e8b-4279-b980-25a3fdeda2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c0997480-a408-4357-942c-1bfb36092474" xlink:to="loc_us-gaap_SubsequentEventMember_85bf1435-0e8b-4279-b980-25a3fdeda2ce" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>krys-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:27464c84-a11a-4d8c-aabe-cd82bfdc0a8a,g:c7af04d0-bbfe-49f0-8ddd-58863f20a4c2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_krys_StockSaleAgreementMember_c2a4b4f7-7a4b-4e8f-9a68-40756cb5ddca_terseLabel_en-US" xlink:label="lab_krys_StockSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement</link:label>
    <link:label id="lab_krys_StockSaleAgreementMember_label_en-US" xlink:label="lab_krys_StockSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement [Member]</link:label>
    <link:label id="lab_krys_StockSaleAgreementMember_documentation_en-US" xlink:label="lab_krys_StockSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockSaleAgreementMember" xlink:href="krys-20220331.xsd#krys_StockSaleAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_StockSaleAgreementMember" xlink:to="lab_krys_StockSaleAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_b9f09b41-6dc8-449e-bc5a-121d33f76b7d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk and Off-Balance Sheet Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_5a0595cd-6940-4a72-8140-1ed5d7930601_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_25da74e8-cabc-4828-8578-bb351d7fa721_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_OfferingCostsIncurredButNotYetPaid_eb747aca-79bf-42e1-be2e-3457725779e9_terseLabel_en-US" xlink:label="lab_krys_OfferingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid offering costs</link:label>
    <link:label id="lab_krys_OfferingCostsIncurredButNotYetPaid_label_en-US" xlink:label="lab_krys_OfferingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_krys_OfferingCostsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_krys_OfferingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OfferingCostsIncurredButNotYetPaid" xlink:href="krys-20220331.xsd#krys_OfferingCostsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_OfferingCostsIncurredButNotYetPaid" xlink:to="lab_krys_OfferingCostsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ATMProgramMember_bc22d367-24af-494f-846c-b9b8896e9fea_terseLabel_en-US" xlink:label="lab_krys_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Program</link:label>
    <link:label id="lab_krys_ATMProgramMember_label_en-US" xlink:label="lab_krys_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Program [Member]</link:label>
    <link:label id="lab_krys_ATMProgramMember_documentation_en-US" xlink:label="lab_krys_ATMProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ATMProgramMember" xlink:href="krys-20220331.xsd#krys_ATMProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ATMProgramMember" xlink:to="lab_krys_ATMProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_04495f80-c5c5-4514-942c-54ac63ed5d70_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_75b82dd3-af45-4a6a-a813-86dd36204b8b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_c2411c59-27dc-43b5-9b61-5087fb9adff0_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_71df0ae6-76af-4b46-9170-77fdbd56de9c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_e010f731-4973-468e-8bf1-29ce8d18843f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_7109d983-06ff-4d05-9811-abc0def44bcb_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_bf97db76-4549-417e-9630-25ada1956582_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_76c7a4b4-8aca-4a1f-a79a-6f3ac48eb992_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ebb8fe23-d19c-48d5-8765-fc1be6a8fdd8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_462f9a9b-459d-424d-896b-63dff2a6e9d8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_032820a8-b093-4e7d-afa1-e95a11550ecf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_eae73b5d-73f8-4e01-98f2-e047be3840a3_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ab8640e7-ae91-47f3-a504-565862876a97_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b85eb469-c328-46f8-9c16-bf634d7c22a2_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_3a9860bb-8bfb-4342-abaf-d7855a6541c7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_917aa22d-880c-4901-acd8-f01da4b7d2c0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3baa4cad-d0b5-4099-8a58-5b20cd8f5b13_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_9c58e794-8c75-46ec-97d1-a493e75e76a3_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_cf46ff05-b2ae-4f97-877e-8bf94c49137a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d068ebaa-c765-4be0-a71f-4d109f0cc855_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_758562d1-59c9-4b3a-876e-1544bcdf231c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_5abaf571-40ae-46eb-a790-6a0a590cd114_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment and Geographical Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0466db60-0e27-4a91-925d-3f04f923a316_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0b7cc8f7-2e55-4a1a-abae-e774066bead6_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_be117017-e9b2-4bbf-9054-510a52a7ded9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_c3211eb7-7b39-41ca-8a7f-159ab4c031cf_terseLabel_en-US" xlink:label="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, operating lease, liability, annual lease payments</link:label>
    <link:label id="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_label_en-US" xlink:label="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Liability, Annual Lease Payments</link:label>
    <link:label id="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_documentation_en-US" xlink:label="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Liability, Annual Lease Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:href="krys-20220331.xsd#krys_LessorOperatingLeaseLiabilityAnnualLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:to="lab_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1efd29b8-7804-4de4-bf56-b9db4b89ce6f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ClinicalSupplyAgreementMember_78063d2c-aa47-4fd4-a803-be02aeae8a24_terseLabel_en-US" xlink:label="lab_krys_ClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Supply Agreements</link:label>
    <link:label id="lab_krys_ClinicalSupplyAgreementMember_label_en-US" xlink:label="lab_krys_ClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Supply Agreement [Member]</link:label>
    <link:label id="lab_krys_ClinicalSupplyAgreementMember_documentation_en-US" xlink:label="lab_krys_ClinicalSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical supply agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ClinicalSupplyAgreementMember" xlink:href="krys-20220331.xsd#krys_ClinicalSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ClinicalSupplyAgreementMember" xlink:to="lab_krys_ClinicalSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_bd5da451-8eb0-4e12-9f9b-9d5fa1de2864_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agency securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_bcd87184-175c-45ba-be24-58d4c4ad4b2b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_5f8482bc-1692-4a8b-a4d1-738809044d7a_terseLabel_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_label_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Exercise Price</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award fair value assumptions weighted average exercise price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:href="krys-20220331.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:to="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SignificantAccountingPoliciesLineItems_db251a6f-3402-4037-b57c-21bf9cf9e389_terseLabel_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_krys_SignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_krys_SignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesLineItems" xlink:href="krys-20220331.xsd#krys_SignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems" xlink:to="lab_krys_SignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_bdd66a82-eb14-40d7-84ba-f0d37c16e04c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8ccbe274-251e-4986-825f-d22271d6343d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term, in years</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_c73554bb-8abe-4242-bf37-191e072c8c7c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f9258a5f-c660-436a-8338-ac00c8b7a9de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_7ec782a4-efe9-4be0-a04e-ba70e6bc576d_terseLabel_en-US" xlink:label="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases</link:label>
    <link:label id="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_label_en-US" xlink:label="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Supplemental Condensed Consolidated Balance Sheet Information Related To Leases [Table Text Block]</link:label>
    <link:label id="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_documentation_en-US" xlink:label="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of supplemental condensed consolidated balance sheet information related to leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:href="krys-20220331.xsd#krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="lab_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a3866bdb-5458-4506-87aa-95ce834f67fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares remaining available for grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_610a9329-83e8-4aa0-8b71-5127c67a002e_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_728a5a66-ebf3-4848-97e4-451cc848a76b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cc2cdad0-0628-459c-886c-c58350675057_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d948e53d-7ddf-47f0-8261-cd3180e41d13_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_dd53e07d-3f67-48b7-a56f-1f7b62522d84_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f3bf5d52-0aa2-4d0e-b2e5-d8cd161e5aa2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestonesDomain_c698f2f1-87ac-4a56-8540-ce7e16e1d41e_terseLabel_en-US" xlink:label="lab_krys_MilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Domain]</link:label>
    <link:label id="lab_krys_MilestonesDomain_label_en-US" xlink:label="lab_krys_MilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Domain]</link:label>
    <link:label id="lab_krys_MilestonesDomain_documentation_en-US" xlink:label="lab_krys_MilestonesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesDomain" xlink:href="krys-20220331.xsd#krys_MilestonesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestonesDomain" xlink:to="lab_krys_MilestonesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8fe3390b-7695-4d6f-9372-290f7dcf684e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_de3d7f20-b1b6-454f-bbc2-3f8e850061d9_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_f5113db3-b5b9-40ca-a82d-7f16f8455d83_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedPayrollAndBenefits_223b8da1-589c-4ccf-9a22-adf9f4a7d1be_terseLabel_en-US" xlink:label="lab_krys_AccruedPayrollAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_krys_AccruedPayrollAndBenefits_label_en-US" xlink:label="lab_krys_AccruedPayrollAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Payroll And Benefits</link:label>
    <link:label id="lab_krys_AccruedPayrollAndBenefits_documentation_en-US" xlink:label="lab_krys_AccruedPayrollAndBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPayrollAndBenefits" xlink:href="krys-20220331.xsd#krys_AccruedPayrollAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedPayrollAndBenefits" xlink:to="lab_krys_AccruedPayrollAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_749256cb-0630-4de6-9ff7-e363940abf03_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_4d0b3723-e6c8-42dc-aacd-1870763c3a57_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_5a284f5c-bc74-4b2f-bbe3-375493495d26_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0a1f83f9-0e58-4b34-9178-dd46b86ef4b1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d1bf3fba-450a-49b7-b87b-957582080616_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b3ba2e74-184d-46d2-85e3-b8519c26fb0a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_5f4c479b-3d37-474c-b22d-0a4f45223f54_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_f00a30cc-aab6-4efe-81db-04de7ec76e91_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b4fa973f-65e9-4819-9a97-7c4a11676fdb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_IncreaseDecreaseInLeaseLiability_2b73e2fe-badc-4af9-be9f-ba350895aa37_terseLabel_en-US" xlink:label="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_krys_IncreaseDecreaseInLeaseLiability_label_en-US" xlink:label="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Lease Liability</link:label>
    <link:label id="lab_krys_IncreaseDecreaseInLeaseLiability_documentation_en-US" xlink:label="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in lease liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseInLeaseLiability" xlink:href="krys-20220331.xsd#krys_IncreaseDecreaseInLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_IncreaseDecreaseInLeaseLiability" xlink:to="lab_krys_IncreaseDecreaseInLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_702d4483-7cd6-4566-b590-0b2cf4f7bca6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_f4ee1c23-3250-4b5b-85ae-4d9ee79d1cea_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_85126d2e-9fa1-497e-bae9-06c46cd5e15c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_cceed07c-1969-4284-8e13-7d2dc3f753cc_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b8ca60ce-2bc9-4316-86dc-2e88d1c9a6b4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c4d5ef88-879d-436a-9b8f-9e8af0b986c9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common share equivalents outstanding, excluded from the calculation of diluted net loss per common share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_d755fec1-a300-4cf3-bc2f-ced4953851f3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e9b3182b-3b75-47c9-9bbe-42a94703b42a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_a833dc1b-a0f7-4aff-9ae4-f6d9e4b9aa3e_terseLabel_en-US" xlink:label="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriting discounts and commissions</link:label>
    <link:label id="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_label_en-US" xlink:label="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Related to Distribution or Servicing and Underwriting Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:to="lab_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_c610ac12-6679-4b46-8322-2a729ffdc85c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_58d1e3f0-eb9b-4634-9496-3ea02431b425_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_79d29a09-8bed-4dcd-a747-418b97a51603_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_98166465-661a-480c-8c50-32bda237321f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_581b78d0-b74d-41ae-9105-297cc59a6e12_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_77fa0c22-e169-4057-9ea5-c66ed2dc9b8f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value per share of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_f22afec9-dcf8-403b-9ee0-2badafc09e9b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0a002af8-331b-40b8-82db-b50b0d9d3809_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_df2acb42-e216-4f69-8749-b6ba9dd6cb6f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on available-for-sale securities and other</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1bb3daeb-160b-4f1a-b7ed-a33829591703_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on investments and other</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_79907c3e-4e77-42d5-8b56-290ee1aef63b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b1ab89d6-bab4-4cd3-8525-11cf616e3d30_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_503bb8a8-97ca-4b0f-bf73-4f0fb5d5700e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e98fa1b9-3c12-4628-bf31-8a02b432e4df_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_25c62eb5-6991-47dc-913d-78bccecf6269_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_702160e2-255d-4908-b0d0-6ed39adf9e95_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestoneThreeMember_1d5ae17e-91ae-4c30-8ba9-d698228e64f6_terseLabel_en-US" xlink:label="lab_krys_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:label id="lab_krys_MilestoneThreeMember_label_en-US" xlink:label="lab_krys_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three [Member]</link:label>
    <link:label id="lab_krys_MilestoneThreeMember_documentation_en-US" xlink:label="lab_krys_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneThreeMember" xlink:href="krys-20220331.xsd#krys_MilestoneThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestoneThreeMember" xlink:to="lab_krys_MilestoneThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7e49fc5a-889d-4833-a952-ae80743915cd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average Remaining Contractual Life (Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment_8becd7c9-662a-4c9b-96e8-8539f3e29b7b_terseLabel_en-US" xlink:label="lab_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued legal settlement</link:label>
    <link:label id="lab_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Accrued Legal Settlement And In-Process Research And Development</link:label>
    <link:label id="lab_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Accrued Legal Settlement And In-Process Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment" xlink:href="krys-20220331.xsd#krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment" xlink:to="lab_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_5570e3fb-e7ca-4d62-b17f-49213fbdf026_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d0066a37-5fd4-40d1-a573-0c72120bda74_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_0d2c2974-c439-4e1e-b136-3fc26574b486_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_ec772f0d-03b3-44ec-b340-cf7fde80097c_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_NumberOfMilestones_6b9f11df-f43a-42b1-a5cf-7c4fb7f02856_terseLabel_en-US" xlink:label="lab_krys_NumberOfMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of milestones</link:label>
    <link:label id="lab_krys_NumberOfMilestones_label_en-US" xlink:label="lab_krys_NumberOfMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Milestones</link:label>
    <link:label id="lab_krys_NumberOfMilestones_documentation_en-US" xlink:label="lab_krys_NumberOfMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NumberOfMilestones" xlink:href="krys-20220331.xsd#krys_NumberOfMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_NumberOfMilestones" xlink:to="lab_krys_NumberOfMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a270422b-3861-45b6-8e81-8f760f10fc99_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, amount awarded to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_64eb22d1-0e85-4d45-8faa-8a8e02df86fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock award granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_02189bff-d387-468d-9ef1-fbaccaf8da44_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_20d62649-1814-4c0d-8612-db46b59e9785_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_2603682d-c50a-4a11-b664-6e22e74a7f47_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock; $0.00001 par value; 20,000,000 shares authorized at &#160;&#160; March&#160;31, 2022 (unaudited) and December&#160;31, 2021; 2,061,773 &#160;&#160; shares issued, and no shares outstanding at March&#160;31, 2022 &#160;&#160; (unaudited) and December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_5bd3b605-65e9-4572-9d67-884cb732ad12_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a0597cbe-0c8c-4bc3-8ef7-4bcf135af207_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_158d1f70-9e26-470b-b917-800906c0c384_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_3ce4281f-bd5a-4fd9-b8fc-519d99021aa9_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_196eb87a-cb99-4011-b0fb-5f7a6ee4efa0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_dc4ea19d-9b1c-4a24-82a2-194417f3f01c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_1872fb98-76b3-446b-b427-0cf6a266cf62_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_76e4dbf9-f983-4fc7-b59f-b6cc687d6b7d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c4d07121-679b-47aa-aeb3-4e75e95224e7_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2abd9360-64fe-4a47-b4e0-7038dfbd3e01_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PaymentToEscrowForReducingLeaseRentals_1213b146-e727-4111-9a8e-93b7a46012f7_terseLabel_en-US" xlink:label="lab_krys_PaymentToEscrowForReducingLeaseRentals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash contribution</link:label>
    <link:label id="lab_krys_PaymentToEscrowForReducingLeaseRentals_label_en-US" xlink:label="lab_krys_PaymentToEscrowForReducingLeaseRentals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment To Escrow For Reducing Lease Rentals</link:label>
    <link:label id="lab_krys_PaymentToEscrowForReducingLeaseRentals_documentation_en-US" xlink:label="lab_krys_PaymentToEscrowForReducingLeaseRentals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to escrow for reducing lease rentals.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentToEscrowForReducingLeaseRentals" xlink:href="krys-20220331.xsd#krys_PaymentToEscrowForReducingLeaseRentals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PaymentToEscrowForReducingLeaseRentals" xlink:to="lab_krys_PaymentToEscrowForReducingLeaseRentals" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ASTRAFacilityMember_5ffdc4f8-386c-4e92-92db-e03f95a3736c_terseLabel_en-US" xlink:label="lab_krys_ASTRAFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASTRA Facility</link:label>
    <link:label id="lab_krys_ASTRAFacilityMember_label_en-US" xlink:label="lab_krys_ASTRAFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A S T R A Facility [Member]</link:label>
    <link:label id="lab_krys_ASTRAFacilityMember_documentation_en-US" xlink:label="lab_krys_ASTRAFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASTRA facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ASTRAFacilityMember" xlink:href="krys-20220331.xsd#krys_ASTRAFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ASTRAFacilityMember" xlink:to="lab_krys_ASTRAFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5767250b-104d-47b5-9128-cb247795be39_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_7f9fedf4-4760-4dc3-a3a0-44ed4b1f3c99_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_345769bf-7c3a-4aad-bcd8-d8d13548e38c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SaleOfStockAggregateOfferingPrice_8bcd205a-ccad-4371-8d2f-414ef7a12987_terseLabel_en-US" xlink:label="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, aggregate offering price</link:label>
    <link:label id="lab_krys_SaleOfStockAggregateOfferingPrice_label_en-US" xlink:label="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Price</link:label>
    <link:label id="lab_krys_SaleOfStockAggregateOfferingPrice_documentation_en-US" xlink:label="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockAggregateOfferingPrice" xlink:href="krys-20220331.xsd#krys_SaleOfStockAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SaleOfStockAggregateOfferingPrice" xlink:to="lab_krys_SaleOfStockAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a3b25f8a-fd14-46a0-a739-e0d4eafa1c0a_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8bc297ea-66ec-41b3-97ee-3235d2080ec7_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_StockIncentivePlanMember_9f2299ea-99fb-4366-ba30-734ab0397009_terseLabel_en-US" xlink:label="lab_krys_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan</link:label>
    <link:label id="lab_krys_StockIncentivePlanMember_label_en-US" xlink:label="lab_krys_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_krys_StockIncentivePlanMember_documentation_en-US" xlink:label="lab_krys_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockIncentivePlanMember" xlink:href="krys-20220331.xsd#krys_StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_StockIncentivePlanMember" xlink:to="lab_krys_StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_168f7bbd-5dcc-4a5c-a2c8-05189da21d45_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial recognition of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_397ee9ed-208a-469a-a918-c78c6b6c40b4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_5f8c73f4-fd26-4c78-a70d-e8e976324764_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0c6a9230-c532-47bf-aa95-00979311ab3f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f8aa6574-f2f1-46f8-b8d5-d8cd5415c6ef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_43d46442-3102-454d-b0ac-e4396aad330c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e8802dc0-90d3-4cbe-aaff-192636379252_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f6c1b09f-711f-44a9-9725-d111ce6024a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityTable_3e1d1f6f-6540-4c74-b700-7fabc782d706_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_3313e5be-225b-43ea-9edc-8f62541e61cf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock surrendered for taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_c3f29c58-d93f-45f4-add1-3fcdda369e57_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangement, amount capitalized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bbd371a7-cccf-434c-beb4-fefb9dfe9bef_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_bdefabfa-1128-4519-ab25-20837f421296_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount_f5e6883e-26a9-47f7-bd82-ba7475f54bd4_terseLabel_en-US" xlink:label="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, remaining available issuance amount</link:label>
    <link:label id="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount_label_en-US" xlink:label="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Available Issuance Amount</link:label>
    <link:label id="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount_documentation_en-US" xlink:label="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Available Issuance Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:href="krys-20220331.xsd#krys_SaleOfStockRemainingAvailableIssuanceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:to="lab_krys_SaleOfStockRemainingAvailableIssuanceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_77c594d3-dfc0-42e2-afb7-c7e75b0e4a39_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, term</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_59cea58a-f320-4c7a-9cf8-2620b51fee82_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_88dc2843-ebb0-4b8d-a8bd-c16a564f0294_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_f0976d75-bb4f-4fbe-b681-a4a4fa6f1756_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain related to litigation settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_e3589daf-b883-458b-8d21-0965241c1d48_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_aa1e8004-b3c7-4a2e-8e70-d7648e9a229a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_1e1c763d-8a81-427d-95c8-2d1d31318d82_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_c2d434f8-e3d7-4af7-aa9e-57e2b78245a6_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segment</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a0af51f3-8045-4a4a-b876-6ca632750dc5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_cdc0bfa8-a6d2-4c74-803d-65e162efd102_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share: basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_74f7b1ec-0ae5-4769-bb72-522473d3d62c_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b8ec0c7f-8624-483d-b768-8513f71ce59e_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7d490e6b-aab7-469a-8d2c-0f7a3eeb972a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6d51e6c7-ff9a-4b82-8b00-32335859c6bb_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_da91540e-9e69-430f-b493-a62fba656623_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_62fd1a28-f61e-4b72-ba2e-ec145f0e576d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8fca13a6-ad87-41d5-a436-60f7f709126e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock award outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_99dfcab3-f0da-4771-8fc6-80d9e7fa8e60_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0c9d5320-cdaa-4095-82d1-199e8e488c25_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_7d90c809-4fdf-4486-a027-ec1bf95b8c35_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedFinancingFeesCurrent_f4143a5a-7bcb-4645-8bf7-7b0baa9266f6_terseLabel_en-US" xlink:label="lab_krys_AccruedFinancingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued financing costs</link:label>
    <link:label id="lab_krys_AccruedFinancingFeesCurrent_label_en-US" xlink:label="lab_krys_AccruedFinancingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Financing Fees, Current</link:label>
    <link:label id="lab_krys_AccruedFinancingFeesCurrent_documentation_en-US" xlink:label="lab_krys_AccruedFinancingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Financing Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedFinancingFeesCurrent" xlink:href="krys-20220331.xsd#krys_AccruedFinancingFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedFinancingFeesCurrent" xlink:to="lab_krys_AccruedFinancingFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8213c2f5-e3d3-44db-b151-97df28fd7074_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b3893894-0585-47f7-9969-507dcfbf8e96_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_8201fed5-85dd-4aef-af85-6ffdfc07fd9d_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_d944dec2-9059-497e-9d56-fd1e7fe71aeb_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_32dec5ac-f630-45f5-961d-5a0d2ed3ff07_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3149dbc7-84f4-4386-be80-459c5c9c716b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_8f5311bc-d586-4624-82e5-07e9fa648e8a_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_43a38b33-ef55-4230-bffe-12b9499b2e19_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_9fcaa924-4010-4cf4-a8fb-2bbd4436e6e0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock surrendered for taxes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_c1280c7c-d0d3-4bbd-82a3-0c33cd8fcbfd_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_26a539d3-b1ac-46fa-b375-a32dffe4e8f4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EscrowDeposit_e33b40dc-b546-48f2-9d3b-4bd363e93c33_terseLabel_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow deposit</link:label>
    <link:label id="lab_us-gaap_EscrowDeposit_label_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EscrowDeposit" xlink:to="lab_us-gaap_EscrowDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PeriphaGenMember_14857be8-77e5-4746-83c7-772dc0f50e3f_terseLabel_en-US" xlink:label="lab_krys_PeriphaGenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PeriphaGen</link:label>
    <link:label id="lab_krys_PeriphaGenMember_label_en-US" xlink:label="lab_krys_PeriphaGenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PeriphaGen [Member]</link:label>
    <link:label id="lab_krys_PeriphaGenMember_documentation_en-US" xlink:label="lab_krys_PeriphaGenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PeriphaGen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PeriphaGenMember" xlink:href="krys-20220331.xsd#krys_PeriphaGenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PeriphaGenMember" xlink:to="lab_krys_PeriphaGenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a75b3c54-c2ad-4369-bfda-25a1bb0d5d93_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding: basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_74d7480f-3cec-4da8-a487-77201a3780b4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share: diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_6ef9d359-1254-4a76-b85f-f9087ee408fe_terseLabel_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:label id="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="krys-20220331.xsd#krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_3f9e9367-9140-4fef-9f86-7c369c0dfadd_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LitigationSettlementTotalConsideration_5cc24215-7a66-4305-aaa1-b25cb5649eda_terseLabel_en-US" xlink:label="lab_krys_LitigationSettlementTotalConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, total consideration</link:label>
    <link:label id="lab_krys_LitigationSettlementTotalConsideration_label_en-US" xlink:label="lab_krys_LitigationSettlementTotalConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Total Consideration</link:label>
    <link:label id="lab_krys_LitigationSettlementTotalConsideration_documentation_en-US" xlink:label="lab_krys_LitigationSettlementTotalConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Total Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementTotalConsideration" xlink:href="krys-20220331.xsd#krys_LitigationSettlementTotalConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LitigationSettlementTotalConsideration" xlink:to="lab_krys_LitigationSettlementTotalConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PublicOfferingMember_434d4c13-24b4-4831-b6a8-e655131580df_terseLabel_en-US" xlink:label="lab_krys_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_krys_PublicOfferingMember_label_en-US" xlink:label="lab_krys_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_krys_PublicOfferingMember_documentation_en-US" xlink:label="lab_krys_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PublicOfferingMember" xlink:href="krys-20220331.xsd#krys_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PublicOfferingMember" xlink:to="lab_krys_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CumulativeEscalationClausePercent_ea32be05-b23c-4c65-bf2c-1b51ac1a451a_terseLabel_en-US" xlink:label="lab_krys_CumulativeEscalationClausePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative escalation clause</link:label>
    <link:label id="lab_krys_CumulativeEscalationClausePercent_label_en-US" xlink:label="lab_krys_CumulativeEscalationClausePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Escalation Clause, Percent</link:label>
    <link:label id="lab_krys_CumulativeEscalationClausePercent_documentation_en-US" xlink:label="lab_krys_CumulativeEscalationClausePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Escalation Clause, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClausePercent" xlink:href="krys-20220331.xsd#krys_CumulativeEscalationClausePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CumulativeEscalationClausePercent" xlink:to="lab_krys_CumulativeEscalationClausePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_cfd3c33c-b173-4856-9870-02660b85102d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_e3117207-0092-492b-ae1f-1a5e98950dfc_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_42a2f602-2652-47fe-8599-bc3d4bf4fc92_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_0bd4f0f9-c513-47cd-b995-6bbf1d98d46c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4a292015-e53a-4c5c-a84a-5453cf29dcac_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e4f2b77-0c94-45b4-bf7b-211d41882c66_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_c16d286d-c09f-450d-b18c-814ae7c84cce_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_65eb57f4-5dab-4cb2-8fac-860fdd24817c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_8d86519f-3000-4b3a-830c-1eefc32d3986_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_c06e839e-7b26-4800-b689-d2b2485203b1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_e8cc65ed-f3e4-4691-8bdb-592ea2036e28_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_062661ae-7a31-4444-9194-c12c51f22057_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PurchasePriceOfPotentialBuildingPurchase_bb832cab-3e43-4d78-8883-461e1d891036_terseLabel_en-US" xlink:label="lab_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of potential purchase</link:label>
    <link:label id="lab_krys_PurchasePriceOfPotentialBuildingPurchase_label_en-US" xlink:label="lab_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Price Of Potential Building Purchase</link:label>
    <link:label id="lab_krys_PurchasePriceOfPotentialBuildingPurchase_documentation_en-US" xlink:label="lab_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Price Of Potential Building Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:href="krys-20220331.xsd#krys_PurchasePriceOfPotentialBuildingPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:to="lab_krys_PurchasePriceOfPotentialBuildingPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid_ac71a232-322e-4d6d-a8a2-6896306bf60c_terseLabel_en-US" xlink:label="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, guaranteed maximum price to be paid</link:label>
    <link:label id="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid_label_en-US" xlink:label="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Guaranteed Maximum Price to be Paid</link:label>
    <link:label id="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid_documentation_en-US" xlink:label="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Guaranteed Maximum Price to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:href="krys-20220331.xsd#krys_LossContingencyGuaranteedMaximumPriceToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:to="lab_krys_LossContingencyGuaranteedMaximumPriceToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PaymentsForSuitLiability_e20cc01a-e1bd-4d8e-8dc1-e8b57029ac85_negatedTerseLabel_en-US" xlink:label="lab_krys_PaymentsForSuitLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of ASTRA build to suit liability</link:label>
    <link:label id="lab_krys_PaymentsForSuitLiability_label_en-US" xlink:label="lab_krys_PaymentsForSuitLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Suit Liability</link:label>
    <link:label id="lab_krys_PaymentsForSuitLiability_documentation_en-US" xlink:label="lab_krys_PaymentsForSuitLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Suit Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentsForSuitLiability" xlink:href="krys-20220331.xsd#krys_PaymentsForSuitLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PaymentsForSuitLiability" xlink:to="lab_krys_PaymentsForSuitLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_8341e222-2b38-45a8-91fc-5cad7a9de053_totalLabel_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair value, total</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Debt Securities Available For Sale</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_documentation_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash cash equivalents and debt securities available for sale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:href="krys-20220331.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:to="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_55bedad6-2025-4f0c-bcb3-43395d889ba3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_b91e171a-205c-48e6-8b3d-2cee3c29e640_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_TwoThousandSixteenLeaseAgreementMember_744fa1a3-e4d7-4b82-8565-2a05423a6e64_terseLabel_en-US" xlink:label="lab_krys_TwoThousandSixteenLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Lease Agreement</link:label>
    <link:label id="lab_krys_TwoThousandSixteenLeaseAgreementMember_label_en-US" xlink:label="lab_krys_TwoThousandSixteenLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Sixteen Lease Agreement [Member]</link:label>
    <link:label id="lab_krys_TwoThousandSixteenLeaseAgreementMember_documentation_en-US" xlink:label="lab_krys_TwoThousandSixteenLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand sixteen lease agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_TwoThousandSixteenLeaseAgreementMember" xlink:href="krys-20220331.xsd#krys_TwoThousandSixteenLeaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_TwoThousandSixteenLeaseAgreementMember" xlink:to="lab_krys_TwoThousandSixteenLeaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CumulativeEscalationClauseTerm_6476cb7a-7a67-4d43-81fd-72d56276acca_terseLabel_en-US" xlink:label="lab_krys_CumulativeEscalationClauseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative escalation clause, term</link:label>
    <link:label id="lab_krys_CumulativeEscalationClauseTerm_label_en-US" xlink:label="lab_krys_CumulativeEscalationClauseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Escalation Clause, Term</link:label>
    <link:label id="lab_krys_CumulativeEscalationClauseTerm_documentation_en-US" xlink:label="lab_krys_CumulativeEscalationClauseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Escalation Clause, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClauseTerm" xlink:href="krys-20220331.xsd#krys_CumulativeEscalationClauseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CumulativeEscalationClauseTerm" xlink:to="lab_krys_CumulativeEscalationClauseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_fa08e207-a887-4684-9353-29186f419061_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_cb7a3858-f2a1-4f12-afb7-8c3ebc900de4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_919e56a0-4435-46aa-9c51-4bdf3d0b426d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashExpense_d191faa9-0349-45e2-ad61-c30d2f7697fa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_OtherNoncashExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashExpense" xlink:to="lab_us-gaap_OtherNoncashExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_b788bf9e-9376-4bd0-ac02-e0234c0b26ee_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized impairment losses for long lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_2c9e0d55-01c0-451c-80a7-f21dabc5f3bb_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_NonEmployeeStockOptionMember_fe9ae221-f6b5-470a-b76e-badd987041af_terseLabel_en-US" xlink:label="lab_krys_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Employee Stock Option</link:label>
    <link:label id="lab_krys_NonEmployeeStockOptionMember_label_en-US" xlink:label="lab_krys_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee Stock Option [Member]</link:label>
    <link:label id="lab_krys_NonEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_krys_NonEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non employee stock option.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember" xlink:href="krys-20220331.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_NonEmployeeStockOptionMember" xlink:to="lab_krys_NonEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dac571e5-fa73-4852-9390-30750a8bada1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_44445261-7e27-4ef3-80ae-afdb97b7de86_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued litigation settlement</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_8bf8cae3-d7c8-4b8d-a599-bc4fdae51063_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from initial offering of shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_8e611020-d7de-4e47-875d-ce271426c897_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_95077880-a756-4b60-b9bc-f7bbd4e3f124_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Expense</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_942ab5d3-57fb-48e0-8b93-4f58aa026f72_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e7811110-ba0f-4966-aa0f-a64cf1b53e61_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_9ef7450e-6fa0-4607-a1e9-939796984bea_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_5d48f6cd-e594-45e4-b0a4-2a04acda7056_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_3dfda0aa-b8e7-4d4b-ba68-6f875c4f81ea_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_eb4e2345-b368-4286-92d0-7e9a16a28183_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_993136b8-f168-433b-bb0e-f4ec39eb1986_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_4d1ff514-5f50-4498-8156-88a94547348e_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4260ee40-0cfb-4588-a2d1-331d73bc7324_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4407a759-8cb3-49ca-bc5b-650469a3d050_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_96360188-89f0-4356-a12d-eee103d02d44_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d5caee88-846d-47cd-b120-757c5d5527d8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee39979b-ea40-483c-83f8-9de4d1df20b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_714903f3-0f00-437f-8f3a-abbd85b6f526_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_e0daa5b9-0d50-4064-8b5c-d218bfddc11e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled or forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_78ab5db8-8afc-44f3-94cb-f3a747ed761e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_2b8d8191-f092-4821-a2e4-fdf4055acac6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_6243fadc-5a32-4d13-9b42-9a1a645a1f22_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_fdc783c9-2a5b-4371-9794-32b2d6f1ccfb_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0718a47c-78fc-499b-8b04-a3ec58173d87_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_38ab8c44-2d6a-4aa0-b8f0-c304a5020e64_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_RemainingCommitmentAmount_a7a06c30-f4dc-49b2-aad9-ec59d026d2f9_terseLabel_en-US" xlink:label="lab_krys_RemainingCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated remaining commitment</link:label>
    <link:label id="lab_krys_RemainingCommitmentAmount_label_en-US" xlink:label="lab_krys_RemainingCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Commitment Amount</link:label>
    <link:label id="lab_krys_RemainingCommitmentAmount_documentation_en-US" xlink:label="lab_krys_RemainingCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining commitment amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RemainingCommitmentAmount" xlink:href="krys-20220331.xsd#krys_RemainingCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_RemainingCommitmentAmount" xlink:to="lab_krys_RemainingCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a6db9dd7-b454-4d20-8981-3e78ce0dc44b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_685f16d6-b6b1-401e-a0ab-7d7725427337_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_f802a732-2d6a-4f13-8aca-122ddd99a466_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_SignificantAccountingPoliciesTable_57ef0e48-dcc0-4892-87ce-c1b3fe9a4c30_terseLabel_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_krys_SignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_krys_SignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_krys_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesTable" xlink:href="krys-20220331.xsd#krys_SignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_SignificantAccountingPoliciesTable" xlink:to="lab_krys_SignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_b2a69463-200a-450c-96c5-73c99dc8a9f2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1ce12a4c-89b7-4d73-9e8e-121a5f3a0c1b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_3767308e-a6ca-4aea-8c86-f5d7162f9361_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ad96e60-152d-4848-bec6-d705c99cc324_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f47fd077-880d-41bb-8aa5-e97d53ea5681_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_f79fe33e-b4d4-4694-b48f-d0dc31691bcc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_4bcf9661-48e7-4cd3-9940-cee578aba249_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_ba921f9c-3525-4a59-b2cc-c6aadec37561_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0298176d-01ac-479d-b5ac-27d9adc7fa6b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a316b767-2984-44cf-a1de-e8630e395e20_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_c86e1528-7210-4eb4-9bae-1667f857eca1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_32d4cf42-937c-4cbf-a51e-c8abfa0db315_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_80e154ff-b853-4228-b3bb-57f4d512dc7c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_fed7fecc-d28a-46cd-992f-b9b1e8f2952e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_442167d4-27e5-4404-8305-86eec7c66fec_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_7fcd788f-9375-4036-a5f6-e5c26b5165ae_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0013911b-0ae2-4509-a116-ea3cb57f3fb7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net, (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_666158d4-e591-447d-844e-46b2eedb3641_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedExpensesAndOtherCurrentLiabilities_37d72c7f-1538-4096-a263-71adc97ce948_totalLabel_en-US" xlink:label="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_krys_AccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_krys_AccruedExpensesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current Liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:href="krys-20220331.xsd#krys_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_krys_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_7ca50238-dd5d-4d07-bce8-17d360dede63_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_debb5c9a-d4d0-46bd-b008-bebca7bc9a14_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c3aa7685-44a6-4224-abe1-eb1862ef8a2f_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eedbc8d6-bbc9-4555-ae98-8b9d85f8798c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_48f54d24-e48a-49f4-856e-7d8ae2e41d16_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_9971bc30-c8e4-4c30-b7a5-4a8872d8c9ec_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock; $0.00001 par value; 80,000,000 shares authorized at &#160;&#160; March&#160;31, 2022 (unaudited) and December&#160;31, 2021; 25,199,081 &#160;&#160; shares issued and outstanding at March&#160;31, 2022 &#160;&#160; (unaudited); and 25,207,985 shares issued and outstanding at December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestonesAxis_0acd35bd-9e84-4382-bc0f-11e5fe4a3c00_terseLabel_en-US" xlink:label="lab_krys_MilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Axis]</link:label>
    <link:label id="lab_krys_MilestonesAxis_label_en-US" xlink:label="lab_krys_MilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones [Axis]</link:label>
    <link:label id="lab_krys_MilestonesAxis_documentation_en-US" xlink:label="lab_krys_MilestonesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesAxis" xlink:href="krys-20220331.xsd#krys_MilestonesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestonesAxis" xlink:to="lab_krys_MilestonesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_01fc6012-1c9e-43f6-a8de-347c293ae8a7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated weighted average period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_33d8cac6-61a2-454d-b0de-8416067c0e2b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f4537785-e88f-4da0-b62c-82414fa452b2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_a7502c35-b909-4993-8caa-5432726620ae_verboseLabel_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeiture rate</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_label_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_documentation_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:href="krys-20220331.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:to="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_bc497f1d-878d-4d61-b0e1-77a0d1a52756_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_c9fca226-e9a5-4c6a-bdb3-c3d82dfc7f56_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 6)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_62461d22-bcf4-4655-a9a3-2b65405abfb1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5e91f271-535a-4be8-bd15-e64e1874ea48_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_34151dcf-9146-4eab-ae3e-611f9d44e355_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_96f476aa-bc4d-4cfc-bd46-afa7b8eba175_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive expense</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f9e2dd06-67f3-447f-a80a-12c6aaece82a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_fa961366-8925-4324-a417-3fd133b1a138_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life (Years), exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_0d769d6e-6406-4a24-88f6-2c96b6dd7866_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:to="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LongTermMarketableSecuritiesMember_412d296c-3779-4128-a8ab-a8142362002b_terseLabel_en-US" xlink:label="lab_krys_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Marketable Securities</link:label>
    <link:label id="lab_krys_LongTermMarketableSecuritiesMember_label_en-US" xlink:label="lab_krys_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Marketable Securities [Member]</link:label>
    <link:label id="lab_krys_LongTermMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_krys_LongTermMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LongTermMarketableSecuritiesMember" xlink:href="krys-20220331.xsd#krys_LongTermMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LongTermMarketableSecuritiesMember" xlink:to="lab_krys_LongTermMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5b44caca-b901-4d82-84a6-6509660071d3_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CostOfWorkPercentage_f499d0c5-de5e-4b4c-b74a-cb4047f3fa20_terseLabel_en-US" xlink:label="lab_krys_CostOfWorkPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of work, percentage</link:label>
    <link:label id="lab_krys_CostOfWorkPercentage_label_en-US" xlink:label="lab_krys_CostOfWorkPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Work, Percentage</link:label>
    <link:label id="lab_krys_CostOfWorkPercentage_documentation_en-US" xlink:label="lab_krys_CostOfWorkPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Work, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CostOfWorkPercentage" xlink:href="krys-20220331.xsd#krys_CostOfWorkPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CostOfWorkPercentage" xlink:to="lab_krys_CostOfWorkPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_716b216d-71d5-46a3-b4b4-64200726bda5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8a135ec6-34e8-4ba3-9e2c-b070df52a85f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (remaining nine months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_209a800c-40e4-481a-92a1-aeac40c85e70_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_9c758586-c0bc-4b89-87cd-8d908baef048_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Company, Capital Share Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Company, Capital Share Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:to="lab_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_62d1acb8-730f-4f2e-8d21-3077dcc42a84_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_082237df-40ef-4cb7-b02e-7ede84420b0e_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_b13384f6-e229-429f-9a19-d0397b0a57e0_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_046c2120-515a-4ee6-aeb6-fb63033a0665_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4095b306-b653-41f4-a342-f4290079f839_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f153def2-c11b-40b7-b4f5-644431bf690c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of shares issued in transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d9e67282-b032-46a8-a5b9-9e32f5bffdad_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_29778327-78a3-46a1-9ad0-3840ade8cc45_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold_ea94e21b-0e5e-4625-83de-4f8f7d9fe1f1_terseLabel_en-US" xlink:label="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, milestone payments, sales threshold</link:label>
    <link:label id="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold_label_en-US" xlink:label="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Milestone Payments, Sales Threshold</link:label>
    <link:label id="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold_documentation_en-US" xlink:label="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Milestone Payments, Sales Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:href="krys-20220331.xsd#krys_LitigationSettlementMilestonePaymentsSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:to="lab_krys_LitigationSettlementMilestonePaymentsSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestoneOneMember_da571987-2f2c-4114-829c-00217884d4f8_terseLabel_en-US" xlink:label="lab_krys_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:label id="lab_krys_MilestoneOneMember_label_en-US" xlink:label="lab_krys_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:label id="lab_krys_MilestoneOneMember_documentation_en-US" xlink:label="lab_krys_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneOneMember" xlink:href="krys-20220331.xsd#krys_MilestoneOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestoneOneMember" xlink:to="lab_krys_MilestoneOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d5f18544-a59f-4838-b1c7-d2df9ae05723_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b47a8009-de46-42b5-a650-8e57bdee4e26_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet_5f32aa0b-8f1a-476f-9d93-65b47ef7c919_terseLabel_en-US" xlink:label="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet_label_en-US" xlink:label="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense And Other Nonoperating Net</link:label>
    <link:label id="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet_documentation_en-US" xlink:label="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income (expense) and other nonoperating, net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:href="krys-20220331.xsd#krys_InterestIncomeExpenseAndOtherNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:to="lab_krys_InterestIncomeExpenseAndOtherNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_RisksAndUncertaintiesPolicyTextBlock_ef0468eb-6ad9-412b-b15e-08a941dab5bd_terseLabel_en-US" xlink:label="lab_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties</link:label>
    <link:label id="lab_krys_RisksAndUncertaintiesPolicyTextBlock_label_en-US" xlink:label="lab_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks And Uncertainties [Policy Text Block]</link:label>
    <link:label id="lab_krys_RisksAndUncertaintiesPolicyTextBlock_documentation_en-US" xlink:label="lab_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and uncertainties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:href="krys-20220331.xsd#krys_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:to="lab_krys_RisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ce62a5cb-f705-4f47-a508-4d906443847b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_5a6d3df2-e886-488d-901c-3fed1bea38e4_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2fe84a2d-d8d0-4959-a3b9-25034d2854c2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Fair Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6e4b3c9f-a112-4a8e-b65b-16ef9ab6447e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1fa3bb68-d2da-486c-b80c-5c2ceae79c34_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f37550e8-55e7-44d5-96ae-cd7dfbde490d_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_730c5b69-9502-4868-9fa5-a735b84ca20a_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8040f34c-f51c-48f7-81b5-654a51bd2f5d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding: diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_61e6404f-58dc-4f56-8eb5-03681ebbcd3f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from insurance settlement, operating activities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Insurance Settlement, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:to="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_e40394dd-9b8c-445e-b26c-d44cce87253b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_eb59c55c-d0ab-485c-8d16-db854c415a30_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedPreclinicalAndClinicalExpenses_9de371b3-0d5b-4ddf-a836-d83042613ab0_terseLabel_en-US" xlink:label="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued preclinical and clinical expenses</link:label>
    <link:label id="lab_krys_AccruedPreclinicalAndClinicalExpenses_label_en-US" xlink:label="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Preclinical And Clinical Expenses</link:label>
    <link:label id="lab_krys_AccruedPreclinicalAndClinicalExpenses_documentation_en-US" xlink:label="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued preclinical and clinical expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPreclinicalAndClinicalExpenses" xlink:href="krys-20220331.xsd#krys_AccruedPreclinicalAndClinicalExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedPreclinicalAndClinicalExpenses" xlink:to="lab_krys_AccruedPreclinicalAndClinicalExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_e7fcf15c-93eb-4d01-8c35-3f9f14cf0a12_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1454fc3b-e1e4-41fa-86ed-50b03bd59863_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company's Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5a5d3752-7cf0-45db-81c6-439f1679d533_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_dff4582b-6099-4fcc-8190-2c15f81416d3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_5e13c669-2f58-4186-a27c-0b01c36019d1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_5c659a0e-3dcd-4fba-ad05-418060962e61_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_6fd87363-fb49-4063-851b-4403e2afaa2d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_32f8610a-26ae-4d08-a97f-45113adb8fdf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_250a5d8c-a1d7-4672-b7e1-37ff8f2f528c_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_7513b569-9f71-40eb-a8db-9206d305060b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_dcb2757b-9825-4d3f-b031-5581941e05ba_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_29e8aa96-47c8-486f-9b70-1f2ba6b06573_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_PlacementSharesMember_88a5229c-c843-4df7-b44c-5185d5ce47bc_terseLabel_en-US" xlink:label="lab_krys_PlacementSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Shares</link:label>
    <link:label id="lab_krys_PlacementSharesMember_label_en-US" xlink:label="lab_krys_PlacementSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Shares [Member]</link:label>
    <link:label id="lab_krys_PlacementSharesMember_documentation_en-US" xlink:label="lab_krys_PlacementSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PlacementSharesMember" xlink:href="krys-20220331.xsd#krys_PlacementSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_PlacementSharesMember" xlink:to="lab_krys_PlacementSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_2acf4d31-0761-473e-a19a-62b4478d4150_totalLabel_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_label_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost</link:label>
    <link:label id="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_documentation_en-US" xlink:label="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash cash equivalents and debt securities available for sale amortized cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:href="krys-20220331.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:to="lab_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_35e0db2e-13ce-4e0f-a4d7-a1787a00a870_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2c8057a6-516c-46ad-b3ee-1bdfa64b33d5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxes_5ae1409b-0621-4b57-b83c-cc65439c60d6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxes" xlink:to="lab_us-gaap_AccruedIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_d6498a04-39aa-4add-a368-ed47b8ab9d6a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_26cb41dc-e1c3-4f2a-96b3-fae2f3595f00_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bf04c72f-efb6-4132-b925-c3f27f98f92c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fa863b2a-5d6f-41fd-8846-57284d161e08_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfessionalFees_087cde91-2efd-4ad2-a24c-b777a0ae7e95_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project management service fee</link:label>
    <link:label id="lab_us-gaap_ProfessionalFees_label_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_bc63e1c9-2f49-4025-865d-8cac9bd38e86_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a60a0961-4dc8-4cd8-8db0-3ed2eeb99e6c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e59eb096-2064-4f9a-aa81-f11d390b9e46_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_53386ffc-7d8d-4227-852e-73c57d69fe48_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_2654f9b3-9021-4f3d-8136-9ac33b264899_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AdditionalAreaOfRealEstatePropertyLeased_38d5e29b-5fe1-4068-8231-1aa549d25db3_terseLabel_en-US" xlink:label="lab_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional area of real estate property leased</link:label>
    <link:label id="lab_krys_AdditionalAreaOfRealEstatePropertyLeased_label_en-US" xlink:label="lab_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Area Of Real Estate Property Leased</link:label>
    <link:label id="lab_krys_AdditionalAreaOfRealEstatePropertyLeased_documentation_en-US" xlink:label="lab_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional area of real estate property leased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:href="krys-20220331.xsd#krys_AdditionalAreaOfRealEstatePropertyLeased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:to="lab_krys_AdditionalAreaOfRealEstatePropertyLeased" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_e1dcc086-19c8-4ed0-b28a-ced24c8eaf9d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_63e428c1-b60d-4289-a0e5-b7151bc4185b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_940ace20-639b-4fa7-b124-da93a973d2ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5e644b83-4341-49c2-bd05-6ef1f91b0b79_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term of the award (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_73fd4036-0cc5-4c26-bb21-d9e4af44c56b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_bbe55f6e-1ed8-4d9f-b44c-7c90aebbb3c2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to settlement of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ca41918-f74b-437e-a624-548ae3334ea2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_3b80b124-5494-4043-b188-d55bd376cbdb_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_IncentiveStockOptionsMember_c641f9de-0b15-4286-aeea-3b52e7fb49e9_terseLabel_en-US" xlink:label="lab_krys_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options</link:label>
    <link:label id="lab_krys_IncentiveStockOptionsMember_label_en-US" xlink:label="lab_krys_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options [Member]</link:label>
    <link:label id="lab_krys_IncentiveStockOptionsMember_documentation_en-US" xlink:label="lab_krys_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncentiveStockOptionsMember" xlink:href="krys-20220331.xsd#krys_IncentiveStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_IncentiveStockOptionsMember" xlink:to="lab_krys_IncentiveStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_bb029518-da60-49de-998b-dfb6705c999c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_405d639b-e3fe-43db-a0b3-ad8887969880_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e0f5cf49-d977-494a-b9a7-1309cc9fa3f4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_cbfc0609-aefb-4f41-9ba0-656a53affa05_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentAxis" xlink:to="lab_us-gaap_SupplyCommitmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_3119e197-1ce4-4588-a6e7-7046e8d4f393_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_8db78ca6-670f-4623-ac04-2bcf41c41443_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_28a2d5b2-398e-458f-a0da-47fd187c6fe1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a4fd3b26-ee53-488d-a053-7e9405cea873_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_AccruedConstructionInProgressCurrent_09a8c0f8-8201-4453-873f-09a535d46828_terseLabel_en-US" xlink:label="lab_krys_AccruedConstructionInProgressCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued construction in progress</link:label>
    <link:label id="lab_krys_AccruedConstructionInProgressCurrent_label_en-US" xlink:label="lab_krys_AccruedConstructionInProgressCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Construction In Progress Current</link:label>
    <link:label id="lab_krys_AccruedConstructionInProgressCurrent_documentation_en-US" xlink:label="lab_krys_AccruedConstructionInProgressCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued construction in progress current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedConstructionInProgressCurrent" xlink:href="krys-20220331.xsd#krys_AccruedConstructionInProgressCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_AccruedConstructionInProgressCurrent" xlink:to="lab_krys_AccruedConstructionInProgressCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_e576cbda-bc8e-4956-b06a-4814994162ce_verboseLabel_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="krys-20220331.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_2d38ede2-f489-4efc-beca-e50c83a0ddb1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash, Cash Equivalents and Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_a3affdf6-56e7-4dde-9971-7f5b13ea491e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_4e785709-c0c7-44cc-b9b0-b4bd4f247719_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_OtherContractualObligationsMember_b8db0e71-4c69-45f4-bec4-f1d73e5d1985_terseLabel_en-US" xlink:label="lab_krys_OtherContractualObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Contractual Obligations</link:label>
    <link:label id="lab_krys_OtherContractualObligationsMember_label_en-US" xlink:label="lab_krys_OtherContractualObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Contractual Obligations [Member]</link:label>
    <link:label id="lab_krys_OtherContractualObligationsMember_documentation_en-US" xlink:label="lab_krys_OtherContractualObligationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other contractual obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OtherContractualObligationsMember" xlink:href="krys-20220331.xsd#krys_OtherContractualObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_OtherContractualObligationsMember" xlink:to="lab_krys_OtherContractualObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_59859b26-b217-44dc-9ee6-fb5d880fb5d0_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6b614cc0-fbfe-4b24-a7be-19c2d1209e40_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_3c138d58-44ee-499a-bdb9-3b9c75b9dbe2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_cb96458f-c880-45f8-bb19-a1a8c8d9ef55_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_MilestoneTwoMember_824cd16b-f5a8-4992-91bd-b987c5fb7764_terseLabel_en-US" xlink:label="lab_krys_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two</link:label>
    <link:label id="lab_krys_MilestoneTwoMember_label_en-US" xlink:label="lab_krys_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two [Member]</link:label>
    <link:label id="lab_krys_MilestoneTwoMember_documentation_en-US" xlink:label="lab_krys_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneTwoMember" xlink:href="krys-20220331.xsd#krys_MilestoneTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_MilestoneTwoMember" xlink:to="lab_krys_MilestoneTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_320c14fb-036c-431d-8f56-ec84b22f9d0b_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73ee672a-8dcc-49b4-a0f6-188d7c49f87f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c24709e9-0b6f-4707-b9b5-524152716e1d_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_936b1981-d241-4eee-9a34-c3ccdbbec540_terseLabel_en-US" xlink:label="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Estimated Useful Lives of Assets</link:label>
    <link:label id="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_label_en-US" xlink:label="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives Of Assets [Table Text Block]</link:label>
    <link:label id="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_documentation_en-US" xlink:label="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the estimated useful lives of assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:href="krys-20220331.xsd#krys_EstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:to="lab_krys_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_295a07ee-4db9-4a9f-832a-29ba15bf1d20_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_450fd57f-5476-4e9c-a97e-7515e89be0f4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_d5b9df8d-b325-415c-899b-dcaed9eeeb8a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_99fe2129-3168-49a4-9bd2-f3dce46d841d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3dcf14b8-51eb-4d0e-8d12-e5b40b7c32ec_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8c39c7c9-f3de-4a5c-b9b8-9daf46e7be58_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_b1c1e302-02e2-4800-ae1b-eae336a1f608_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c62bba07-d800-40b3-b516-fed999fcd052_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Operating Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_9a1f7e79-227b-41e7-9ad0-21edb2afaa89_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_41a6617a-87a3-489d-b9bc-6627530f3a89_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_015b3b0a-1637-4265-9651-2d8456f2c5e9_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_f33654de-7377-47f0-96f8-8fbdc72deaf0_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress, gross</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ea43ba90-9383-4861-ad65-219e8af7a82d_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_LabEquipmentMember_21404833-ba51-40f4-9d55-279974e24271_terseLabel_en-US" xlink:label="lab_krys_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and manufacturing equipment</link:label>
    <link:label id="lab_krys_LabEquipmentMember_label_en-US" xlink:label="lab_krys_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab Equipment [Member]</link:label>
    <link:label id="lab_krys_LabEquipmentMember_documentation_en-US" xlink:label="lab_krys_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember" xlink:href="krys-20220331.xsd#krys_LabEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_LabEquipmentMember" xlink:to="lab_krys_LabEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_529abb42-0b99-4ca3-a2c8-3473417f6e72_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_775591d8-628c-4af9-82f5-1846c36d479e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_3ac02f5d-cffc-45d7-94a4-4cf8aaec4a5c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2741be1e-e4f1-495e-9cde-9637f794ce6d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at March 31, 2022</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_krys_BostonLeaseMember_1df24a38-9f46-4368-8a58-5d899aec0016_terseLabel_en-US" xlink:label="lab_krys_BostonLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boston Lease</link:label>
    <link:label id="lab_krys_BostonLeaseMember_label_en-US" xlink:label="lab_krys_BostonLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boston Lease [Member]</link:label>
    <link:label id="lab_krys_BostonLeaseMember_documentation_en-US" xlink:label="lab_krys_BostonLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boston Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_krys_BostonLeaseMember" xlink:href="krys-20220331.xsd#krys_BostonLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_krys_BostonLeaseMember" xlink:to="lab_krys_BostonLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_b36ac433-ea5a-48c6-b7cc-15f9c41c1387_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_f7ed8323-0e7c-4e87-9cee-1203e1ce9c59_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8143ebaa-52cc-45a5-a00f-b1f801b4e2af_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_1eb5f64f-ff5c-48cb-a878-cdfb2ab3beb2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_014579d0-a0cd-450d-8c96-3c2a133fe7f9_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_abd7ea90-b747-4daa-8b04-593f1de0b45a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_75816d03-2dd4-4482-bc6c-c6ffe03b2aac_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives of assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_558948e6-80c5-4c60-8d57-577f5609ddf3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_5e3d5b41-3891-4ae8-af90-ae66542e45c9_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Non-Cash Investing and Financing Activities</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c5528ffc-dc1a-4043-955e-43279529057b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>krys-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:27464c84-a11a-4d8c-aabe-cd82bfdc0a8a,g:c7af04d0-bbfe-49f0-8ddd-58863f20a4c2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.krystalbio.com/role/Cover" xlink:type="simple" xlink:href="krys-20220331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_218357ba-4a2f-4a9d-b81b-e6e951b95f93" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_DocumentType_218357ba-4a2f-4a9d-b81b-e6e951b95f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_82c4db43-3dcf-49e3-9e24-90ef616dddf4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_DocumentQuarterlyReport_82c4db43-3dcf-49e3-9e24-90ef616dddf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f65564c2-34ce-4cc4-b7e7-0f90e6354669" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_DocumentPeriodEndDate_f65564c2-34ce-4cc4-b7e7-0f90e6354669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_52014873-e331-4074-b55e-0e0f030bf058" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_DocumentTransitionReport_52014873-e331-4074-b55e-0e0f030bf058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b5bac272-8d13-4750-9d7e-97053edfd267" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_EntityFileNumber_b5bac272-8d13-4750-9d7e-97053edfd267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_acce033a-25ea-4fca-86f9-d397d41753a2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_EntityRegistrantName_acce033a-25ea-4fca-86f9-d397d41753a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_86d57184-fd5c-4789-9c3e-752f1b6a365e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_EntityIncorporationStateCountryCode_86d57184-fd5c-4789-9c3e-752f1b6a365e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d0d862bf-8aee-4b24-9d5b-0246179f9029" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_EntityTaxIdentificationNumber_d0d862bf-8aee-4b24-9d5b-0246179f9029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0eb73759-e6fe-4283-9964-6ea8a5f34e44" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_EntityAddressAddressLine1_0eb73759-e6fe-4283-9964-6ea8a5f34e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_346a00ce-d683-4200-a595-0b5ff559ac4f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_EntityAddressAddressLine2_346a00ce-d683-4200-a595-0b5ff559ac4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f1b2a1fb-52ac-4747-b538-7357ebf166bd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_EntityAddressCityOrTown_f1b2a1fb-52ac-4747-b538-7357ebf166bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_bc28bdc7-6724-487a-a4d9-44bab29c5a77" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_EntityAddressStateOrProvince_bc28bdc7-6724-487a-a4d9-44bab29c5a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_8d2f7c1c-50e3-4bc7-9682-c21a2d3820f8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_EntityAddressPostalZipCode_8d2f7c1c-50e3-4bc7-9682-c21a2d3820f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2a0f13c0-5160-48e3-80da-9e5e8edd7d4c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_CityAreaCode_2a0f13c0-5160-48e3-80da-9e5e8edd7d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6e56e997-39c1-4cd8-acdd-ed3d0d8ab3a4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_LocalPhoneNumber_6e56e997-39c1-4cd8-acdd-ed3d0d8ab3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3cbec97a-d351-453d-b7ea-01c4bf7fcfaa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_Security12bTitle_3cbec97a-d351-453d-b7ea-01c4bf7fcfaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_33b785ae-abd1-4392-94ba-70a4d5d47c91" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_TradingSymbol_33b785ae-abd1-4392-94ba-70a4d5d47c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_0bca05f1-8ec0-4b50-ad37-8f05bcd1616d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_SecurityExchangeName_0bca05f1-8ec0-4b50-ad37-8f05bcd1616d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_356650ae-f75a-4601-93c9-c231dc148453" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_EntityCurrentReportingStatus_356650ae-f75a-4601-93c9-c231dc148453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_1758d5a5-3e35-4413-a584-f7ed80b5aab7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_EntityInteractiveDataCurrent_1758d5a5-3e35-4413-a584-f7ed80b5aab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d055ecd7-4950-494f-ad14-cfbd9512ca72" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_EntityFilerCategory_d055ecd7-4950-494f-ad14-cfbd9512ca72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_8848b837-e547-41a0-949e-6bba9d22c9e4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_EntitySmallBusiness_8848b837-e547-41a0-949e-6bba9d22c9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_89c10486-99f5-4ece-b627-1fdd6ead391f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_EntityEmergingGrowthCompany_89c10486-99f5-4ece-b627-1fdd6ead391f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_97739b15-7bfd-4610-854c-0408ed928620" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_EntityShellCompany_97739b15-7bfd-4610-854c-0408ed928620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e2e169a3-e0f9-47bd-9dfc-2e6d7b644d2f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e2e169a3-e0f9-47bd-9dfc-2e6d7b644d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_36cd13d2-9c0c-4abd-b584-35777edeb24e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_AmendmentFlag_36cd13d2-9c0c-4abd-b584-35777edeb24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_5cd0d338-503b-45e1-9ac8-36bac8d2bbc4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_DocumentFiscalYearFocus_5cd0d338-503b-45e1-9ac8-36bac8d2bbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_899b53dd-c17f-4c70-820f-91c999446e8d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_DocumentFiscalPeriodFocus_899b53dd-c17f-4c70-820f-91c999446e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d5e55578-735c-4279-a5eb-72f9ae9ae23f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_EntityCentralIndexKey_d5e55578-735c-4279-a5eb-72f9ae9ae23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b2cf7aba-ddeb-45e0-aa23-296396d98601" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f59a6392-176b-4327-aaee-1d221adf8bdd" xlink:to="loc_dei_CurrentFiscalYearEndDate_b2cf7aba-ddeb-45e0-aa23-296396d98601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="krys-20220331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_850a434e-227b-42eb-80df-9b538a4ca281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_16b0c2e7-b01d-475e-a4cd-f875188a1b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_850a434e-227b-42eb-80df-9b538a4ca281" xlink:to="loc_us-gaap_AssetsAbstract_16b0c2e7-b01d-475e-a4cd-f875188a1b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c508114d-8ef5-45ea-8a4d-1c221cfbe0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_16b0c2e7-b01d-475e-a4cd-f875188a1b9d" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c508114d-8ef5-45ea-8a4d-1c221cfbe0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d34203d5-5480-42ae-9d83-958d1edb4b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c508114d-8ef5-45ea-8a4d-1c221cfbe0b0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d34203d5-5480-42ae-9d83-958d1edb4b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_bd4ee753-0746-4757-9286-7d917f305485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c508114d-8ef5-45ea-8a4d-1c221cfbe0b0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_bd4ee753-0746-4757-9286-7d917f305485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4569bc6b-44a7-4796-a62c-955662bab0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c508114d-8ef5-45ea-8a4d-1c221cfbe0b0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4569bc6b-44a7-4796-a62c-955662bab0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0d0ea86f-0730-4c10-ab0c-23462e445acd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c508114d-8ef5-45ea-8a4d-1c221cfbe0b0" xlink:to="loc_us-gaap_AssetsCurrent_0d0ea86f-0730-4c10-ab0c-23462e445acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f0af1ba7-04b8-4b6e-9124-5c4ee99855bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_16b0c2e7-b01d-475e-a4cd-f875188a1b9d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f0af1ba7-04b8-4b6e-9124-5c4ee99855bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_0e3417ab-491b-441a-ace6-8f3a854672eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_16b0c2e7-b01d-475e-a4cd-f875188a1b9d" xlink:to="loc_us-gaap_LongTermInvestments_0e3417ab-491b-441a-ace6-8f3a854672eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9c612774-972a-4ab0-b025-e48b7b2ce70e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_16b0c2e7-b01d-475e-a4cd-f875188a1b9d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9c612774-972a-4ab0-b025-e48b7b2ce70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4573aa2a-6efc-4fe0-a532-97aacc855c91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_16b0c2e7-b01d-475e-a4cd-f875188a1b9d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4573aa2a-6efc-4fe0-a532-97aacc855c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5bfbea94-f717-440f-a205-c1dd56a8cf65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_16b0c2e7-b01d-475e-a4cd-f875188a1b9d" xlink:to="loc_us-gaap_Assets_5bfbea94-f717-440f-a205-c1dd56a8cf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f35ad32-63c0-49ed-b49e-888726831595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_850a434e-227b-42eb-80df-9b538a4ca281" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f35ad32-63c0-49ed-b49e-888726831595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_32391f8c-ef60-4f80-827b-ed6dd5c814ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f35ad32-63c0-49ed-b49e-888726831595" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_32391f8c-ef60-4f80-827b-ed6dd5c814ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_62584de3-c711-4b58-84bb-be7b4169010a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_32391f8c-ef60-4f80-827b-ed6dd5c814ca" xlink:to="loc_us-gaap_AccountsPayableCurrent_62584de3-c711-4b58-84bb-be7b4169010a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ebdfc2b2-9280-462c-b5f2-5b304a34fddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_32391f8c-ef60-4f80-827b-ed6dd5c814ca" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ebdfc2b2-9280-462c-b5f2-5b304a34fddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_0d7e5b43-7edc-4590-8077-cc036115f276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_32391f8c-ef60-4f80-827b-ed6dd5c814ca" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_0d7e5b43-7edc-4590-8077-cc036115f276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_11c2922d-70d5-401e-8b9d-bb22eb9f98f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_32391f8c-ef60-4f80-827b-ed6dd5c814ca" xlink:to="loc_us-gaap_LiabilitiesCurrent_11c2922d-70d5-401e-8b9d-bb22eb9f98f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_516c3877-83e1-4c39-a2d0-5b13a7f0e943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f35ad32-63c0-49ed-b49e-888726831595" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_516c3877-83e1-4c39-a2d0-5b13a7f0e943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f6d63590-bac0-47d5-bd0e-47ddd656251c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f35ad32-63c0-49ed-b49e-888726831595" xlink:to="loc_us-gaap_Liabilities_f6d63590-bac0-47d5-bd0e-47ddd656251c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_935cc0fa-051f-474b-aae6-b6535058d255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f35ad32-63c0-49ed-b49e-888726831595" xlink:to="loc_us-gaap_CommitmentsAndContingencies_935cc0fa-051f-474b-aae6-b6535058d255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_6bb8c506-7b4b-4948-a802-d0a160b4b073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f35ad32-63c0-49ed-b49e-888726831595" xlink:to="loc_us-gaap_StockholdersEquityAbstract_6bb8c506-7b4b-4948-a802-d0a160b4b073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3c928be8-85ff-49cf-93b5-423c907f11a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6bb8c506-7b4b-4948-a802-d0a160b4b073" xlink:to="loc_us-gaap_PreferredStockValue_3c928be8-85ff-49cf-93b5-423c907f11a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8ce0e304-9b59-44ba-bb29-a24e0ba7316b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6bb8c506-7b4b-4948-a802-d0a160b4b073" xlink:to="loc_us-gaap_CommonStockValue_8ce0e304-9b59-44ba-bb29-a24e0ba7316b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_db819253-140d-4ba7-ba2b-3b68e5cf6ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6bb8c506-7b4b-4948-a802-d0a160b4b073" xlink:to="loc_us-gaap_AdditionalPaidInCapital_db819253-140d-4ba7-ba2b-3b68e5cf6ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e84920e5-2753-4729-9943-4f34c6d7b6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6bb8c506-7b4b-4948-a802-d0a160b4b073" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e84920e5-2753-4729-9943-4f34c6d7b6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ce65f935-8187-4d61-9c21-05fea936f6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6bb8c506-7b4b-4948-a802-d0a160b4b073" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ce65f935-8187-4d61-9c21-05fea936f6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8cc2bc02-b397-4710-a0d8-ab463233f086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6bb8c506-7b4b-4948-a802-d0a160b4b073" xlink:to="loc_us-gaap_StockholdersEquity_8cc2bc02-b397-4710-a0d8-ab463233f086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ab3b1eb9-bd2a-4cb6-a8a8-433440043d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f35ad32-63c0-49ed-b49e-888726831595" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ab3b1eb9-bd2a-4cb6-a8a8-433440043d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="krys-20220331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d65a32a3-dfd2-48f1-ade6-13597634b9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d6b74be5-5a58-4107-b37b-3d233efd3024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d65a32a3-dfd2-48f1-ade6-13597634b9ae" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d6b74be5-5a58-4107-b37b-3d233efd3024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2bc4fe5a-3cb7-4b60-8128-d7c829551b57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d65a32a3-dfd2-48f1-ade6-13597634b9ae" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2bc4fe5a-3cb7-4b60-8128-d7c829551b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_9cb37763-7b64-4830-9144-2d988f98b4df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d65a32a3-dfd2-48f1-ade6-13597634b9ae" xlink:to="loc_us-gaap_PreferredStockSharesIssued_9cb37763-7b64-4830-9144-2d988f98b4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_0d5dfac0-0353-44a9-855a-c88b9252ecf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d65a32a3-dfd2-48f1-ade6-13597634b9ae" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_0d5dfac0-0353-44a9-855a-c88b9252ecf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_76c572c2-53cc-4c09-afea-fc15f3fe6ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d65a32a3-dfd2-48f1-ade6-13597634b9ae" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_76c572c2-53cc-4c09-afea-fc15f3fe6ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a02c11c7-acb9-46f7-9a36-7b07441959fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d65a32a3-dfd2-48f1-ade6-13597634b9ae" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a02c11c7-acb9-46f7-9a36-7b07441959fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4d3a17d7-698b-4651-9e24-99906a07cdeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d65a32a3-dfd2-48f1-ade6-13597634b9ae" xlink:to="loc_us-gaap_CommonStockSharesIssued_4d3a17d7-698b-4651-9e24-99906a07cdeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2e44d0b5-f8f7-45fb-9397-19391d7ca11f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d65a32a3-dfd2-48f1-ade6-13597634b9ae" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2e44d0b5-f8f7-45fb-9397-19391d7ca11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="krys-20220331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_0b91917e-8b04-483f-b5d8-a176db79a0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_205907c9-85c8-47c0-972d-5d1d8e4c7cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0b91917e-8b04-483f-b5d8-a176db79a0fd" xlink:to="loc_us-gaap_OperatingExpensesAbstract_205907c9-85c8-47c0-972d-5d1d8e4c7cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b62f2477-cb28-48fa-a7a5-e78834635a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_205907c9-85c8-47c0-972d-5d1d8e4c7cf3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b62f2477-cb28-48fa-a7a5-e78834635a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a9ee7358-995f-494e-8952-d4caa8d3ea26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_205907c9-85c8-47c0-972d-5d1d8e4c7cf3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a9ee7358-995f-494e-8952-d4caa8d3ea26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_00b3a870-1388-42bc-9140-364be4690a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_205907c9-85c8-47c0-972d-5d1d8e4c7cf3" xlink:to="loc_us-gaap_LitigationSettlementExpense_00b3a870-1388-42bc-9140-364be4690a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3602c5df-b881-4e75-b064-448f16a86767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_205907c9-85c8-47c0-972d-5d1d8e4c7cf3" xlink:to="loc_us-gaap_OperatingExpenses_3602c5df-b881-4e75-b064-448f16a86767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b148d6cc-3e66-4a53-9fcd-48f11795be10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0b91917e-8b04-483f-b5d8-a176db79a0fd" xlink:to="loc_us-gaap_OperatingIncomeLoss_b148d6cc-3e66-4a53-9fcd-48f11795be10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4942d414-ac08-4369-824d-57a94962e073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0b91917e-8b04-483f-b5d8-a176db79a0fd" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4942d414-ac08-4369-824d-57a94962e073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_2a823109-f241-4f91-8397-f59b913e0484" xlink:href="krys-20220331.xsd#krys_InterestIncomeExpenseAndOtherNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4942d414-ac08-4369-824d-57a94962e073" xlink:to="loc_krys_InterestIncomeExpenseAndOtherNonoperatingNet_2a823109-f241-4f91-8397-f59b913e0484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_eb78fc7c-31b1-4f75-aa28-5fb3fa6244cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4942d414-ac08-4369-824d-57a94962e073" xlink:to="loc_us-gaap_InterestExpense_eb78fc7c-31b1-4f75-aa28-5fb3fa6244cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d2e027a8-8a2e-4e35-a747-ba22fe34a02e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0b91917e-8b04-483f-b5d8-a176db79a0fd" xlink:to="loc_us-gaap_NetIncomeLoss_d2e027a8-8a2e-4e35-a747-ba22fe34a02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5dab5a66-d640-4b52-af40-159bdbc7ad96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0b91917e-8b04-483f-b5d8-a176db79a0fd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5dab5a66-d640-4b52-af40-159bdbc7ad96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_944cda1c-865a-4204-9ff6-19a7b8d8416d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0b91917e-8b04-483f-b5d8-a176db79a0fd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_944cda1c-865a-4204-9ff6-19a7b8d8416d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_978147b1-3457-45c9-bfbf-53a76f9df3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0b91917e-8b04-483f-b5d8-a176db79a0fd" xlink:to="loc_us-gaap_EarningsPerShareBasic_978147b1-3457-45c9-bfbf-53a76f9df3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e3be92a2-6c56-47e0-9f46-06ad7467f83d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0b91917e-8b04-483f-b5d8-a176db79a0fd" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e3be92a2-6c56-47e0-9f46-06ad7467f83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5d5ded93-e680-487b-9f72-9897e2f73bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0b91917e-8b04-483f-b5d8-a176db79a0fd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5d5ded93-e680-487b-9f72-9897e2f73bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8aa158f2-9d9f-4f46-949d-ab8d69556e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0b91917e-8b04-483f-b5d8-a176db79a0fd" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8aa158f2-9d9f-4f46-949d-ab8d69556e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="krys-20220331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5bbcfda7-e47e-43ef-8ddc-1bcefa7daa03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6a31ab5c-15fc-4b02-914f-1ee7aaf0312a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5bbcfda7-e47e-43ef-8ddc-1bcefa7daa03" xlink:to="loc_us-gaap_StatementTable_6a31ab5c-15fc-4b02-914f-1ee7aaf0312a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1697f7dc-c2e8-4e06-9c80-6000f7441ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6a31ab5c-15fc-4b02-914f-1ee7aaf0312a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1697f7dc-c2e8-4e06-9c80-6000f7441ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e721a25f-0587-4e4c-8ffc-ac5316e880d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1697f7dc-c2e8-4e06-9c80-6000f7441ccf" xlink:to="loc_us-gaap_EquityComponentDomain_e721a25f-0587-4e4c-8ffc-ac5316e880d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_106719c2-a164-41e8-82db-9a40477d5cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e721a25f-0587-4e4c-8ffc-ac5316e880d1" xlink:to="loc_us-gaap_CommonStockMember_106719c2-a164-41e8-82db-9a40477d5cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_18bd1c02-fdac-4b1b-86bf-22eae7eb2e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e721a25f-0587-4e4c-8ffc-ac5316e880d1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_18bd1c02-fdac-4b1b-86bf-22eae7eb2e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f460ec2a-a08a-4836-8867-d501afb8f992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e721a25f-0587-4e4c-8ffc-ac5316e880d1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f460ec2a-a08a-4836-8867-d501afb8f992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e365005c-bbc8-4a02-b60b-b4fdada15279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e721a25f-0587-4e4c-8ffc-ac5316e880d1" xlink:to="loc_us-gaap_RetainedEarningsMember_e365005c-bbc8-4a02-b60b-b4fdada15279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2e8858ad-de2f-4cbc-9c6d-0b0d6ca8c923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6a31ab5c-15fc-4b02-914f-1ee7aaf0312a" xlink:to="loc_us-gaap_StatementLineItems_2e8858ad-de2f-4cbc-9c6d-0b0d6ca8c923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2e8858ad-de2f-4cbc-9c6d-0b0d6ca8c923" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d310cb93-96f5-40a4-84a8-7516363ed91e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:to="loc_us-gaap_SharesOutstanding_d310cb93-96f5-40a4-84a8-7516363ed91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cefab358-e274-4815-a03a-69893bac03a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:to="loc_us-gaap_StockholdersEquity_cefab358-e274-4815-a03a-69893bac03a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b94b1600-5764-439f-ba0b-45bdc6af3c96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b94b1600-5764-439f-ba0b-45bdc6af3c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c4702099-b3a7-48d7-9cbb-1768c2325b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c4702099-b3a7-48d7-9cbb-1768c2325b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_7677d118-5f18-4d05-9150-46aa06fda177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_7677d118-5f18-4d05-9150-46aa06fda177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_922f1ba1-7f95-4912-9412-f8d8acadec9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_922f1ba1-7f95-4912-9412-f8d8acadec9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1a7ba20c-bc63-463a-9fe8-43b916d32cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1a7ba20c-bc63-463a-9fe8-43b916d32cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7352f125-4dfc-46d0-ad60-37ce01ec482f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7352f125-4dfc-46d0-ad60-37ce01ec482f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7a67e620-52bf-41c8-8240-d06edd23e94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:to="loc_us-gaap_NetIncomeLoss_7a67e620-52bf-41c8-8240-d06edd23e94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_807d7222-5124-44ac-8ac7-dfd5fc8e51c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:to="loc_us-gaap_SharesOutstanding_807d7222-5124-44ac-8ac7-dfd5fc8e51c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_88141a3e-3466-4886-9cb7-8eaf5ca13d66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7dce276a-b01c-43ce-becb-38774e1cfd2b" xlink:to="loc_us-gaap_StockholdersEquity_88141a3e-3466-4886-9cb7-8eaf5ca13d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="krys-20220331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_bdfdb91e-247b-4efa-bcda-0f1d38545d44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_136e0821-4bf0-4859-b157-e708284f2575" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_bdfdb91e-247b-4efa-bcda-0f1d38545d44" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_136e0821-4bf0-4859-b157-e708284f2575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ff27c358-86b2-4e56-85fc-cbe8a8794e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_136e0821-4bf0-4859-b157-e708284f2575" xlink:to="loc_us-gaap_NetIncomeLoss_ff27c358-86b2-4e56-85fc-cbe8a8794e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8c957743-81be-4b4b-8e22-74f2c30fc847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_136e0821-4bf0-4859-b157-e708284f2575" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8c957743-81be-4b4b-8e22-74f2c30fc847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_76814d08-4925-4c05-a3dc-737f903d605a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8c957743-81be-4b4b-8e22-74f2c30fc847" xlink:to="loc_us-gaap_DepreciationAndAmortization_76814d08-4925-4c05-a3dc-737f903d605a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c7ffa074-9312-44d2-abfa-26caf9f94654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8c957743-81be-4b4b-8e22-74f2c30fc847" xlink:to="loc_us-gaap_ShareBasedCompensation_c7ffa074-9312-44d2-abfa-26caf9f94654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_e0710cbe-2e4c-4840-b324-d7c9b8dfeeda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8c957743-81be-4b4b-8e22-74f2c30fc847" xlink:to="loc_us-gaap_OtherNoncashExpense_e0710cbe-2e4c-4840-b324-d7c9b8dfeeda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_df67b153-7fe2-4dab-a66f-cb0563d1af86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8c957743-81be-4b4b-8e22-74f2c30fc847" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_df67b153-7fe2-4dab-a66f-cb0563d1af86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fac29653-554b-4208-9ea6-2b34982e362d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_136e0821-4bf0-4859-b157-e708284f2575" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fac29653-554b-4208-9ea6-2b34982e362d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9726b1ce-cb2b-49cd-b3c1-cd1bdd08294e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fac29653-554b-4208-9ea6-2b34982e362d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9726b1ce-cb2b-49cd-b3c1-cd1bdd08294e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_a42eefd2-5691-4a40-8a0e-be92da751b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fac29653-554b-4208-9ea6-2b34982e362d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_a42eefd2-5691-4a40-8a0e-be92da751b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseInLeaseLiability_d1b933e5-e02d-44fe-964c-afe99fd8e806" xlink:href="krys-20220331.xsd#krys_IncreaseDecreaseInLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fac29653-554b-4208-9ea6-2b34982e362d" xlink:to="loc_krys_IncreaseDecreaseInLeaseLiability_d1b933e5-e02d-44fe-964c-afe99fd8e806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3d8d9d18-a806-4c8c-9a32-c8debac8a0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fac29653-554b-4208-9ea6-2b34982e362d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3d8d9d18-a806-4c8c-9a32-c8debac8a0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_e4780b04-e2e6-4861-8321-578b219a4517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fac29653-554b-4208-9ea6-2b34982e362d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_e4780b04-e2e6-4861-8321-578b219a4517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment_1e5f70be-e8b7-4759-83fb-8e7931c4da73" xlink:href="krys-20220331.xsd#krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fac29653-554b-4208-9ea6-2b34982e362d" xlink:to="loc_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment_1e5f70be-e8b7-4759-83fb-8e7931c4da73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28c1680d-eeb5-4820-b649-6666ba9440d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_136e0821-4bf0-4859-b157-e708284f2575" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28c1680d-eeb5-4820-b649-6666ba9440d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_571c8c86-3abe-43d2-a2d5-e4d7fea87cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_bdfdb91e-247b-4efa-bcda-0f1d38545d44" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_571c8c86-3abe-43d2-a2d5-e4d7fea87cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_68a847c4-38ca-4fbc-ba25-855382d79c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_571c8c86-3abe-43d2-a2d5-e4d7fea87cdc" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_68a847c4-38ca-4fbc-ba25-855382d79c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7c282268-3c3a-4309-9b18-dce1e47a1a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_571c8c86-3abe-43d2-a2d5-e4d7fea87cdc" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7c282268-3c3a-4309-9b18-dce1e47a1a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_02761ef8-4b19-4781-82a8-c19849e94722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_571c8c86-3abe-43d2-a2d5-e4d7fea87cdc" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_02761ef8-4b19-4781-82a8-c19849e94722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fcd541ed-8ea6-4826-9678-a0f7b2402605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_571c8c86-3abe-43d2-a2d5-e4d7fea87cdc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fcd541ed-8ea6-4826-9678-a0f7b2402605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_64de0e37-d051-43f7-9c39-4c140b83504c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_bdfdb91e-247b-4efa-bcda-0f1d38545d44" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_64de0e37-d051-43f7-9c39-4c140b83504c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ecb01863-0efb-44be-8075-4138d36764ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_64de0e37-d051-43f7-9c39-4c140b83504c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ecb01863-0efb-44be-8075-4138d36764ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2d05d69c-b309-4940-91f0-aec80b4095cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_64de0e37-d051-43f7-9c39-4c140b83504c" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2d05d69c-b309-4940-91f0-aec80b4095cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentsForSuitLiability_0b102625-98a5-4890-b5a8-39769eba4840" xlink:href="krys-20220331.xsd#krys_PaymentsForSuitLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_64de0e37-d051-43f7-9c39-4c140b83504c" xlink:to="loc_krys_PaymentsForSuitLiability_0b102625-98a5-4890-b5a8-39769eba4840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fb6e183c-12d6-4ae1-a1c2-5c8ea1e002f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_64de0e37-d051-43f7-9c39-4c140b83504c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fb6e183c-12d6-4ae1-a1c2-5c8ea1e002f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_15942c38-656c-4b3b-bbd6-7a3d5167294a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_bdfdb91e-247b-4efa-bcda-0f1d38545d44" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_15942c38-656c-4b3b-bbd6-7a3d5167294a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4110c24d-22e5-420a-bbf1-534712cee806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_bdfdb91e-247b-4efa-bcda-0f1d38545d44" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4110c24d-22e5-420a-bbf1-534712cee806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b2c688a6-6503-469e-ae70-9e09b8091dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_bdfdb91e-247b-4efa-bcda-0f1d38545d44" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b2c688a6-6503-469e-ae70-9e09b8091dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e4e9b100-69b9-4256-889f-f1a3d023f9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract_bdfdb91e-247b-4efa-bcda-0f1d38545d44" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e4e9b100-69b9-4256-889f-f1a3d023f9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c61a336e-4ebe-45b6-b278-c4c7b770bfb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e4e9b100-69b9-4256-889f-f1a3d023f9a4" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c61a336e-4ebe-45b6-b278-c4c7b770bfb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1db7e3f8-81ed-4cde-a49a-53e28894a647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e4e9b100-69b9-4256-889f-f1a3d023f9a4" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1db7e3f8-81ed-4cde-a49a-53e28894a647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OfferingCostsIncurredButNotYetPaid_68531d8a-7d71-4148-84f7-c9a5da8d6dca" xlink:href="krys-20220331.xsd#krys_OfferingCostsIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e4e9b100-69b9-4256-889f-f1a3d023f9a4" xlink:to="loc_krys_OfferingCostsIncurredButNotYetPaid_68531d8a-7d71-4148-84f7-c9a5da8d6dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/Organization" xlink:type="simple" xlink:href="krys-20220331.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e6cd5697-a1f5-47af-ab2e-b9c89978c170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_e2061fd3-153d-41e6-a1e1-aff9191c72c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6cd5697-a1f5-47af-ab2e-b9c89978c170" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_e2061fd3-153d-41e6-a1e1-aff9191c72c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#OrganizationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1562c5cc-73e7-46cb-9df2-220158548cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3e244401-9cbb-47b3-904a-d2afad2ac845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1562c5cc-73e7-46cb-9df2-220158548cf3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3e244401-9cbb-47b3-904a-d2afad2ac845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_e6187dac-34b6-4a5f-b567-33e8f687679e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1562c5cc-73e7-46cb-9df2-220158548cf3" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_e6187dac-34b6-4a5f-b567-33e8f687679e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="krys-20220331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_03b8de34-46a4-4bb2-a3f9-207241dcb178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7069a2d2-4573-463f-80e9-5fdad1184118" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03b8de34-46a4-4bb2-a3f9-207241dcb178" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7069a2d2-4573-463f-80e9-5fdad1184118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="krys-20220331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8ad9986e-9e0b-40b6-a8f3-c173d1d4a15f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_db7a26ee-bdbe-477f-9544-aa62889cc841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ad9986e-9e0b-40b6-a8f3-c173d1d4a15f" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_db7a26ee-bdbe-477f-9544-aa62889cc841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RisksAndUncertaintiesPolicyTextBlock_d7105d38-a5a3-4124-8158-1545ba99bdce" xlink:href="krys-20220331.xsd#krys_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ad9986e-9e0b-40b6-a8f3-c173d1d4a15f" xlink:to="loc_krys_RisksAndUncertaintiesPolicyTextBlock_d7105d38-a5a3-4124-8158-1545ba99bdce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_49150ced-660a-4c38-bfbe-b7eab3e43f95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ad9986e-9e0b-40b6-a8f3-c173d1d4a15f" xlink:to="loc_us-gaap_UseOfEstimates_49150ced-660a-4c38-bfbe-b7eab3e43f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2756f4df-0e7c-4db5-a5c5-973039282927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ad9986e-9e0b-40b6-a8f3-c173d1d4a15f" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2756f4df-0e7c-4db5-a5c5-973039282927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_93eed1d4-3a9b-4132-b119-3c89cbc42729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ad9986e-9e0b-40b6-a8f3-c173d1d4a15f" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_93eed1d4-3a9b-4132-b119-3c89cbc42729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_22f5220c-fdbb-4e8f-8d16-ac086d5f53e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ad9986e-9e0b-40b6-a8f3-c173d1d4a15f" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_22f5220c-fdbb-4e8f-8d16-ac086d5f53e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_210c2185-ce1c-4bbc-b473-cd6895ff3820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ad9986e-9e0b-40b6-a8f3-c173d1d4a15f" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_210c2185-ce1c-4bbc-b473-cd6895ff3820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_90b676f8-f6cb-452b-9c4b-e25029120c63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ad9986e-9e0b-40b6-a8f3-c173d1d4a15f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_90b676f8-f6cb-452b-9c4b-e25029120c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_761f2c1b-c8e0-4822-bde6-3969906745b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ad9986e-9e0b-40b6-a8f3-c173d1d4a15f" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_761f2c1b-c8e0-4822-bde6-3969906745b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_c6f0f885-e28c-4cde-9861-272ee9f27015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ad9986e-9e0b-40b6-a8f3-c173d1d4a15f" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_c6f0f885-e28c-4cde-9861-272ee9f27015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_d86dfe8c-b3c7-4886-8f20-5c2530a2c012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ad9986e-9e0b-40b6-a8f3-c173d1d4a15f" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_d86dfe8c-b3c7-4886-8f20-5c2530a2c012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ac8fdd31-3f10-414d-a5b7-dd13cdb31b23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ad9986e-9e0b-40b6-a8f3-c173d1d4a15f" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ac8fdd31-3f10-414d-a5b7-dd13cdb31b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_7c03e6ab-0651-4359-8f96-431900b26c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ad9986e-9e0b-40b6-a8f3-c173d1d4a15f" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_7c03e6ab-0651-4359-8f96-431900b26c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4c833919-adcf-42d7-bee5-76cc0fc7b097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8ad9986e-9e0b-40b6-a8f3-c173d1d4a15f" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4c833919-adcf-42d7-bee5-76cc0fc7b097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="krys-20220331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4a3ba126-c129-4882-ac16-e54d12cf638c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_365770f8-519e-4d59-a1b5-6d18e4b181dd" xlink:href="krys-20220331.xsd#krys_EstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4a3ba126-c129-4882-ac16-e54d12cf638c" xlink:to="loc_krys_EstimatedUsefulLivesOfAssetsTableTextBlock_365770f8-519e-4d59-a1b5-6d18e4b181dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_84f850e7-4ac6-469b-89da-69a384c399e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesTable_8f563873-6def-4b43-be9e-91ea781d7965" xlink:href="krys-20220331.xsd#krys_SignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_84f850e7-4ac6-469b-89da-69a384c399e3" xlink:to="loc_krys_SignificantAccountingPoliciesTable_8f563873-6def-4b43-be9e-91ea781d7965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_93a376f1-bc6d-44c3-8a90-b6b7ea879e17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_SignificantAccountingPoliciesTable_8f563873-6def-4b43-be9e-91ea781d7965" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_93a376f1-bc6d-44c3-8a90-b6b7ea879e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5fe9e3cd-dfe8-44c2-bc1e-a2e5e619b8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_93a376f1-bc6d-44c3-8a90-b6b7ea879e17" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5fe9e3cd-dfe8-44c2-bc1e-a2e5e619b8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_3c4a99f6-4b24-4597-ba8e-d30a43217a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5fe9e3cd-dfe8-44c2-bc1e-a2e5e619b8a9" xlink:to="loc_us-gaap_EquipmentMember_3c4a99f6-4b24-4597-ba8e-d30a43217a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SignificantAccountingPoliciesLineItems_6356de22-2d74-45bc-9d1f-be5da8b8fb81" xlink:href="krys-20220331.xsd#krys_SignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_SignificantAccountingPoliciesTable_8f563873-6def-4b43-be9e-91ea781d7965" xlink:to="loc_krys_SignificantAccountingPoliciesLineItems_6356de22-2d74-45bc-9d1f-be5da8b8fb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_bb0cf0cf-eca1-46c0-ac5c-527a333c006a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_6356de22-2d74-45bc-9d1f-be5da8b8fb81" xlink:to="loc_us-gaap_NumberOfOperatingSegments_bb0cf0cf-eca1-46c0-ac5c-527a333c006a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_3e215255-a6de-477d-ae61-b614685f4956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_SignificantAccountingPoliciesLineItems_6356de22-2d74-45bc-9d1f-be5da8b8fb81" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_3e215255-a6de-477d-ae61-b614685f4956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7de60acb-43ae-49f7-827d-f58f79aa3f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf3c2491-0c9f-4220-af38-d150cecaa2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7de60acb-43ae-49f7-827d-f58f79aa3f8a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf3c2491-0c9f-4220-af38-d150cecaa2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_609ac055-0535-4a8b-89fa-a3fbd173e8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf3c2491-0c9f-4220-af38-d150cecaa2a0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_609ac055-0535-4a8b-89fa-a3fbd173e8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_edaab1b8-552f-4f1f-aec6-241a53a857e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_609ac055-0535-4a8b-89fa-a3fbd173e8c2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_edaab1b8-552f-4f1f-aec6-241a53a857e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d056e6e0-7cbe-4a99-93e4-49ce5b2406d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_edaab1b8-552f-4f1f-aec6-241a53a857e9" xlink:to="loc_us-gaap_ComputerEquipmentMember_d056e6e0-7cbe-4a99-93e4-49ce5b2406d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember_ee7231ab-fd05-44dd-9cbe-1eafff0072a0" xlink:href="krys-20220331.xsd#krys_LabEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_edaab1b8-552f-4f1f-aec6-241a53a857e9" xlink:to="loc_krys_LabEquipmentMember_ee7231ab-fd05-44dd-9cbe-1eafff0072a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_7ec7fc5d-1d1a-4521-a38c-8b9677c72016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_edaab1b8-552f-4f1f-aec6-241a53a857e9" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_7ec7fc5d-1d1a-4521-a38c-8b9677c72016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1044507a-5043-41ef-8f4a-14d6f989e74b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf3c2491-0c9f-4220-af38-d150cecaa2a0" xlink:to="loc_srt_RangeAxis_1044507a-5043-41ef-8f4a-14d6f989e74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b716c844-a913-4be0-aa63-2ba6a29ef3ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1044507a-5043-41ef-8f4a-14d6f989e74b" xlink:to="loc_srt_RangeMember_b716c844-a913-4be0-aa63-2ba6a29ef3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ec07f6cc-d2bb-4a0e-b2d3-75d35c047224" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b716c844-a913-4be0-aa63-2ba6a29ef3ab" xlink:to="loc_srt_MinimumMember_ec07f6cc-d2bb-4a0e-b2d3-75d35c047224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4acacb39-30f4-4681-aae9-6012bf522bfe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b716c844-a913-4be0-aa63-2ba6a29ef3ab" xlink:to="loc_srt_MaximumMember_4acacb39-30f4-4681-aae9-6012bf522bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f11039d6-8e4a-4b0c-b132-2c18cc4bfbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bf3c2491-0c9f-4220-af38-d150cecaa2a0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f11039d6-8e4a-4b0c-b132-2c18cc4bfbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f6253465-4c3c-45c1-861f-d06c77219650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f11039d6-8e4a-4b0c-b132-2c18cc4bfbd5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f6253465-4c3c-45c1-861f-d06c77219650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders" xlink:type="simple" xlink:href="krys-20220331.xsd#NetLossPerShareAttributabletoCommonStockholders"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f95bda90-5b95-4e66-8aff-947c18a7274c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_243faf81-2154-48e4-8fe1-f89ae1d598b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f95bda90-5b95-4e66-8aff-947c18a7274c" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_243faf81-2154-48e4-8fe1-f89ae1d598b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables" xlink:type="simple" xlink:href="krys-20220331.xsd#NetLossPerShareAttributabletoCommonStockholdersTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0afff3d1-2197-4005-ab89-01b7fa92105b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0dd391cb-b4b8-4295-8533-b90ec67afb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0afff3d1-2197-4005-ab89-01b7fa92105b" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0dd391cb-b4b8-4295-8533-b90ec67afb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a14d8ff7-3b24-4fbe-a315-b51302e8cb18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_68b5b378-38ad-4b1f-92d1-679a447f5726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a14d8ff7-3b24-4fbe-a315-b51302e8cb18" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_68b5b378-38ad-4b1f-92d1-679a447f5726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_53742b5d-7d05-4585-a64e-d5516fb31ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_a56fef95-e2c6-40a4-a65c-747251d4a515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_53742b5d-7d05-4585-a64e-d5516fb31ffd" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_a56fef95-e2c6-40a4-a65c-747251d4a515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bebd1afd-95c1-4887-9113-f697299b3986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_a56fef95-e2c6-40a4-a65c-747251d4a515" xlink:to="loc_us-gaap_NetIncomeLoss_bebd1afd-95c1-4887-9113-f697299b3986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_422e91bc-d966-42c2-9f81-ae76c7e41005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_53742b5d-7d05-4585-a64e-d5516fb31ffd" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_422e91bc-d966-42c2-9f81-ae76c7e41005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_94a23354-cf4c-46b2-8477-fd401eb40970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_53742b5d-7d05-4585-a64e-d5516fb31ffd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_94a23354-cf4c-46b2-8477-fd401eb40970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b78cfc76-835e-498a-9daa-4110d14b37e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_53742b5d-7d05-4585-a64e-d5516fb31ffd" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b78cfc76-835e-498a-9daa-4110d14b37e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_cd91b5bb-f960-48f0-bd73-b84efbcee3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_53742b5d-7d05-4585-a64e-d5516fb31ffd" xlink:to="loc_us-gaap_EarningsPerShareBasic_cd91b5bb-f960-48f0-bd73-b84efbcee3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5c9eadab-51d8-4553-96e0-a74461d77cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_53742b5d-7d05-4585-a64e-d5516fb31ffd" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5c9eadab-51d8-4553-96e0-a74461d77cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstruments" xlink:type="simple" xlink:href="krys-20220331.xsd#FairValueInstruments"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_466ac31c-2459-4f69-bf61-52bf98e3e5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_e53e7e3b-7fd3-47fa-a36c-e29ae1b47787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_466ac31c-2459-4f69-bf61-52bf98e3e5b8" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_e53e7e3b-7fd3-47fa-a36c-e29ae1b47787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsTables" xlink:type="simple" xlink:href="krys-20220331.xsd#FairValueInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_10c940f1-a93f-400c-aa20-b83de5cddee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_7d211dbe-ae19-4acc-8cb0-3e3d32d43098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_10c940f1-a93f-400c-aa20-b83de5cddee4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_7d211dbe-ae19-4acc-8cb0-3e3d32d43098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_435a4e6f-a207-4550-a78d-02c0587d4c89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36aa45e4-a547-4f0f-90db-95c9681d9e85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_435a4e6f-a207-4550-a78d-02c0587d4c89" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36aa45e4-a547-4f0f-90db-95c9681d9e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_30562123-7a38-4539-a0ef-66545916189f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36aa45e4-a547-4f0f-90db-95c9681d9e85" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_30562123-7a38-4539-a0ef-66545916189f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f253f893-ea5b-4c56-896e-53671f881868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_30562123-7a38-4539-a0ef-66545916189f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f253f893-ea5b-4c56-896e-53671f881868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_ba586aac-ae00-4728-9080-73eb105a8b00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f253f893-ea5b-4c56-896e-53671f881868" xlink:to="loc_us-gaap_CashMember_ba586aac-ae00-4728-9080-73eb105a8b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_22e4fa92-d0ea-400d-bc34-e6de6952aa74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f253f893-ea5b-4c56-896e-53671f881868" xlink:to="loc_us-gaap_CommercialPaperMember_22e4fa92-d0ea-400d-bc34-e6de6952aa74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_23cdd73c-a93f-4278-85d6-c2e36f9a838c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f253f893-ea5b-4c56-896e-53671f881868" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_23cdd73c-a93f-4278-85d6-c2e36f9a838c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_2d0a5aa6-43d4-497c-a9ed-cda2e6c96789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f253f893-ea5b-4c56-896e-53671f881868" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_2d0a5aa6-43d4-497c-a9ed-cda2e6c96789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b5d65cbb-6642-4a16-b534-a0418b433dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36aa45e4-a547-4f0f-90db-95c9681d9e85" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b5d65cbb-6642-4a16-b534-a0418b433dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f3025b3-f1bf-42cd-9336-94d837b95f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b5d65cbb-6642-4a16-b534-a0418b433dcf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f3025b3-f1bf-42cd-9336-94d837b95f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_82809ffd-4aa2-4bba-9bb9-b7b99a40d9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f3025b3-f1bf-42cd-9336-94d837b95f9d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_82809ffd-4aa2-4bba-9bb9-b7b99a40d9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_cb32007f-3e8e-434a-807b-140be61091d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5f3025b3-f1bf-42cd-9336-94d837b95f9d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_cb32007f-3e8e-434a-807b-140be61091d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b0b86a9f-f5af-446e-9410-e350a45c75ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36aa45e4-a547-4f0f-90db-95c9681d9e85" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b0b86a9f-f5af-446e-9410-e350a45c75ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2cd778a3-6d7f-4ed7-a533-3a9396e017bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b0b86a9f-f5af-446e-9410-e350a45c75ed" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2cd778a3-6d7f-4ed7-a533-3a9396e017bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_ce77a63c-071b-47f1-9d2b-398667236c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2cd778a3-6d7f-4ed7-a533-3a9396e017bc" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_ce77a63c-071b-47f1-9d2b-398667236c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_4555842b-e148-4f10-ab5a-69c56929073a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2cd778a3-6d7f-4ed7-a533-3a9396e017bc" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_4555842b-e148-4f10-ab5a-69c56929073a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LongTermMarketableSecuritiesMember_1e1ba5c8-6302-4f22-8f87-bd5fbcf852a9" xlink:href="krys-20220331.xsd#krys_LongTermMarketableSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2cd778a3-6d7f-4ed7-a533-3a9396e017bc" xlink:to="loc_krys_LongTermMarketableSecuritiesMember_1e1ba5c8-6302-4f22-8f87-bd5fbcf852a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cf52ad41-6ee1-4536-b139-4bd590a2e599" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36aa45e4-a547-4f0f-90db-95c9681d9e85" xlink:to="loc_srt_RangeAxis_cf52ad41-6ee1-4536-b139-4bd590a2e599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6444d60c-ce85-45fa-b46d-d415f22ae1f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cf52ad41-6ee1-4536-b139-4bd590a2e599" xlink:to="loc_srt_RangeMember_6444d60c-ce85-45fa-b46d-d415f22ae1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3a114078-c0dd-48ba-938c-124a4b43db5c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6444d60c-ce85-45fa-b46d-d415f22ae1f2" xlink:to="loc_srt_MinimumMember_3a114078-c0dd-48ba-938c-124a4b43db5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9ad155e8-eb5e-4b06-85d4-039df7719ea4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6444d60c-ce85-45fa-b46d-d415f22ae1f2" xlink:to="loc_srt_MaximumMember_9ad155e8-eb5e-4b06-85d4-039df7719ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8c31221-df1c-4e2e-b767-beecbcf933df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_36aa45e4-a547-4f0f-90db-95c9681d9e85" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8c31221-df1c-4e2e-b767-beecbcf933df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a113c976-f3fd-4910-a28f-43b97981df2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8c31221-df1c-4e2e-b767-beecbcf933df" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a113c976-f3fd-4910-a28f-43b97981df2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_91f8eb9f-f7f0-4ef0-bd6f-293a1156a38d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8c31221-df1c-4e2e-b767-beecbcf933df" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_91f8eb9f-f7f0-4ef0-bd6f-293a1156a38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4895cd4c-4d3d-4689-aaff-ff9b8e883f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8c31221-df1c-4e2e-b767-beecbcf933df" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4895cd4c-4d3d-4689-aaff-ff9b8e883f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_13baef78-1b7a-4eda-80f6-bbaa5cf19790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8c31221-df1c-4e2e-b767-beecbcf933df" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_13baef78-1b7a-4eda-80f6-bbaa5cf19790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ec500024-cc8c-4adb-9143-6963e6aa022f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8c31221-df1c-4e2e-b767-beecbcf933df" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ec500024-cc8c-4adb-9143-6963e6aa022f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_46462a2c-04ff-48ff-94ce-999d577ee32a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8c31221-df1c-4e2e-b767-beecbcf933df" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_46462a2c-04ff-48ff-94ce-999d577ee32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_70d0e768-f44e-4f3a-afa6-d375309c4895" xlink:href="krys-20220331.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8c31221-df1c-4e2e-b767-beecbcf933df" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost_70d0e768-f44e-4f3a-afa6-d375309c4895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_a01c1ae7-05f0-4f64-9bfc-57c4f48dad2d" xlink:href="krys-20220331.xsd#krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8c31221-df1c-4e2e-b767-beecbcf933df" xlink:to="loc_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale_a01c1ae7-05f0-4f64-9bfc-57c4f48dad2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_76a6b189-96b8-4867-a499-57232117e50a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d8c31221-df1c-4e2e-b767-beecbcf933df" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_76a6b189-96b8-4867-a499-57232117e50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="simple" xlink:href="krys-20220331.xsd#FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="krys-20220331.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e18dc73a-c379-4e90-8c5f-a965f209f60e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_4b4700bd-a2cc-47df-8f34-12f2293d7f37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e18dc73a-c379-4e90-8c5f-a965f209f60e" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_4b4700bd-a2cc-47df-8f34-12f2293d7f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="krys-20220331.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e6360e5f-1b05-4b93-bafa-dba0c51819dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f81704d2-fd3c-492f-ba22-4450236176f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e6360e5f-1b05-4b93-bafa-dba0c51819dc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f81704d2-fd3c-492f-ba22-4450236176f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_10512b8f-32cf-46c2-a81d-ec22130d1a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e6360e5f-1b05-4b93-bafa-dba0c51819dc" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_10512b8f-32cf-46c2-a81d-ec22130d1a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e08f41c7-a1ad-4eaf-9b4d-d6603e755d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d8141fb9-3d8a-4b38-b26a-6dae8c5130ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e08f41c7-a1ad-4eaf-9b4d-d6603e755d62" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d8141fb9-3d8a-4b38-b26a-6dae8c5130ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8e89e9c1-7b25-440e-a1ea-2d15b615a625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d8141fb9-3d8a-4b38-b26a-6dae8c5130ad" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8e89e9c1-7b25-440e-a1ea-2d15b615a625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9e6c46b7-24c3-4cb4-872a-fa77a87d3d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8e89e9c1-7b25-440e-a1ea-2d15b615a625" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9e6c46b7-24c3-4cb4-872a-fa77a87d3d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_480f3e80-b9be-4201-9108-e766c8c389a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9e6c46b7-24c3-4cb4-872a-fa77a87d3d71" xlink:to="loc_us-gaap_ConstructionInProgressMember_480f3e80-b9be-4201-9108-e766c8c389a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_394b526c-0e39-4a29-bcbf-868c4d08ca47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9e6c46b7-24c3-4cb4-872a-fa77a87d3d71" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_394b526c-0e39-4a29-bcbf-868c4d08ca47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_6a22ff6e-e6a2-46ec-9292-eb76f8b48f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9e6c46b7-24c3-4cb4-872a-fa77a87d3d71" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_6a22ff6e-e6a2-46ec-9292-eb76f8b48f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_deec78e4-8cc9-4400-8e80-5639df707104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9e6c46b7-24c3-4cb4-872a-fa77a87d3d71" xlink:to="loc_us-gaap_ComputerEquipmentMember_deec78e4-8cc9-4400-8e80-5639df707104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LabEquipmentMember_dd1aa5a7-79a2-4a20-9eb6-eb4721902e45" xlink:href="krys-20220331.xsd#krys_LabEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9e6c46b7-24c3-4cb4-872a-fa77a87d3d71" xlink:to="loc_krys_LabEquipmentMember_dd1aa5a7-79a2-4a20-9eb6-eb4721902e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_054937f1-8a38-4c29-a993-8f0deebeaec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d8141fb9-3d8a-4b38-b26a-6dae8c5130ad" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_054937f1-8a38-4c29-a993-8f0deebeaec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8e2fef16-1f01-416d-b90e-ff240faffaa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_054937f1-8a38-4c29-a993-8f0deebeaec3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8e2fef16-1f01-416d-b90e-ff240faffaa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_374178c8-dc9b-4ee6-857e-a5de103c45c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_054937f1-8a38-4c29-a993-8f0deebeaec3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_374178c8-dc9b-4ee6-857e-a5de103c45c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fd5e8cc1-c897-4425-8155-bd3de8a49aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_054937f1-8a38-4c29-a993-8f0deebeaec3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fd5e8cc1-c897-4425-8155-bd3de8a49aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#BalanceSheetComponentsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cf067f26-7219-4cbe-948a-8023f94f5faf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_aab8c2ea-27e6-4214-9314-134a54286379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cf067f26-7219-4cbe-948a-8023f94f5faf" xlink:to="loc_us-gaap_Depreciation_aab8c2ea-27e6-4214-9314-134a54286379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d92ca62f-5620-4694-95ab-391a36b71998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPreclinicalAndClinicalExpenses_8bcb226e-a69e-4748-8baf-8305e0d3c44f" xlink:href="krys-20220331.xsd#krys_AccruedPreclinicalAndClinicalExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d92ca62f-5620-4694-95ab-391a36b71998" xlink:to="loc_krys_AccruedPreclinicalAndClinicalExpenses_8bcb226e-a69e-4748-8baf-8305e0d3c44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_6de4caef-58b3-4568-b957-8164e7f9f9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d92ca62f-5620-4694-95ab-391a36b71998" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_6de4caef-58b3-4568-b957-8164e7f9f9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedPayrollAndBenefits_51a1156c-1733-4b1b-99f8-469933e6e232" xlink:href="krys-20220331.xsd#krys_AccruedPayrollAndBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d92ca62f-5620-4694-95ab-391a36b71998" xlink:to="loc_krys_AccruedPayrollAndBenefits_51a1156c-1733-4b1b-99f8-469933e6e232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxes_8f7c870b-271b-43d5-8880-9c0cbbfefb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d92ca62f-5620-4694-95ab-391a36b71998" xlink:to="loc_us-gaap_AccruedIncomeTaxes_8f7c870b-271b-43d5-8880-9c0cbbfefb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedConstructionInProgressCurrent_154236b3-56fd-464c-87ff-c0285e77aeaf" xlink:href="krys-20220331.xsd#krys_AccruedConstructionInProgressCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d92ca62f-5620-4694-95ab-391a36b71998" xlink:to="loc_krys_AccruedConstructionInProgressCurrent_154236b3-56fd-464c-87ff-c0285e77aeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedFinancingFeesCurrent_f172e8d9-648e-4bd9-a498-65ff046b2695" xlink:href="krys-20220331.xsd#krys_AccruedFinancingFeesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d92ca62f-5620-4694-95ab-391a36b71998" xlink:to="loc_krys_AccruedFinancingFeesCurrent_f172e8d9-648e-4bd9-a498-65ff046b2695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_3755e151-054c-4a33-813f-c4f42adc2b97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d92ca62f-5620-4694-95ab-391a36b71998" xlink:to="loc_us-gaap_LitigationReserveCurrent_3755e151-054c-4a33-813f-c4f42adc2b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_304f78a6-ae4d-4985-80ff-e3f54ba16509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d92ca62f-5620-4694-95ab-391a36b71998" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_304f78a6-ae4d-4985-80ff-e3f54ba16509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_7d617ec6-7293-4b67-9e60-a26e69602832" xlink:href="krys-20220331.xsd#krys_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d92ca62f-5620-4694-95ab-391a36b71998" xlink:to="loc_krys_AccruedExpensesAndOtherCurrentLiabilities_7d617ec6-7293-4b67-9e60-a26e69602832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="krys-20220331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_676b147a-9421-45d7-83ef-1233b07213cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bda72339-71b4-4424-8fa8-e372d999a808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_676b147a-9421-45d7-83ef-1233b07213cb" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bda72339-71b4-4424-8fa8-e372d999a808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="krys-20220331.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_438181f6-b4e1-444a-821e-662877d6c025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f221230b-b611-49e3-b28e-c0f18f3a16d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_438181f6-b4e1-444a-821e-662877d6c025" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f221230b-b611-49e3-b28e-c0f18f3a16d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_84d6ae67-593b-4e55-adb4-2ad850a417e9" xlink:href="krys-20220331.xsd#krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_438181f6-b4e1-444a-821e-662877d6c025" xlink:to="loc_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock_84d6ae67-593b-4e55-adb4-2ad850a417e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_be8ca180-e00a-4c3f-b6d4-0805167bbcf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7bf66faa-08ff-476f-a753-eb445b23d30d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_be8ca180-e00a-4c3f-b6d4-0805167bbcf6" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7bf66faa-08ff-476f-a753-eb445b23d30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_01bf0a3e-0759-47ae-a8a1-ce88fe50886a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7bf66faa-08ff-476f-a753-eb445b23d30d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_01bf0a3e-0759-47ae-a8a1-ce88fe50886a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_df502ed2-d150-4d1b-a515-a1ba29c3ac65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_01bf0a3e-0759-47ae-a8a1-ce88fe50886a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_df502ed2-d150-4d1b-a515-a1ba29c3ac65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_TwoThousandSixteenLeaseAgreementMember_4fc144fc-632c-4a0a-a596-608435f82501" xlink:href="krys-20220331.xsd#krys_TwoThousandSixteenLeaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_df502ed2-d150-4d1b-a515-a1ba29c3ac65" xlink:to="loc_krys_TwoThousandSixteenLeaseAgreementMember_4fc144fc-632c-4a0a-a596-608435f82501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_BostonLeaseMember_8487e743-e671-491c-b1c3-a259d79673ef" xlink:href="krys-20220331.xsd#krys_BostonLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_df502ed2-d150-4d1b-a515-a1ba29c3ac65" xlink:to="loc_krys_BostonLeaseMember_8487e743-e671-491c-b1c3-a259d79673ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_9df0770a-b6b6-40e8-b419-d1eb6374bcf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7bf66faa-08ff-476f-a753-eb445b23d30d" xlink:to="loc_us-gaap_SupplyCommitmentAxis_9df0770a-b6b6-40e8-b419-d1eb6374bcf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_4b886e0b-697b-42d4-87ed-2e913befee2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentAxis_9df0770a-b6b6-40e8-b419-d1eb6374bcf9" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_4b886e0b-697b-42d4-87ed-2e913befee2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ClinicalSupplyAgreementMember_e65fd50e-f829-47a9-9b42-aad45ba08f96" xlink:href="krys-20220331.xsd#krys_ClinicalSupplyAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_4b886e0b-697b-42d4-87ed-2e913befee2f" xlink:to="loc_krys_ClinicalSupplyAgreementMember_e65fd50e-f829-47a9-9b42-aad45ba08f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_OtherContractualObligationsMember_1001f86e-3083-4e97-8da7-3bbe42f364a0" xlink:href="krys-20220331.xsd#krys_OtherContractualObligationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_4b886e0b-697b-42d4-87ed-2e913befee2f" xlink:to="loc_krys_OtherContractualObligationsMember_1001f86e-3083-4e97-8da7-3bbe42f364a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ASTRAFacilityMember_732ea2a7-4c80-4d15-a69f-95959d90f81e" xlink:href="krys-20220331.xsd#krys_ASTRAFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_4b886e0b-697b-42d4-87ed-2e913befee2f" xlink:to="loc_krys_ASTRAFacilityMember_732ea2a7-4c80-4d15-a69f-95959d90f81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesAxis_d7803b45-c13a-40d6-b715-fbaa2db6089d" xlink:href="krys-20220331.xsd#krys_MilestonesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7bf66faa-08ff-476f-a753-eb445b23d30d" xlink:to="loc_krys_MilestonesAxis_d7803b45-c13a-40d6-b715-fbaa2db6089d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestonesDomain_6e386f40-1bde-4f19-9ac8-97031e31b301" xlink:href="krys-20220331.xsd#krys_MilestonesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_MilestonesAxis_d7803b45-c13a-40d6-b715-fbaa2db6089d" xlink:to="loc_krys_MilestonesDomain_6e386f40-1bde-4f19-9ac8-97031e31b301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneOneMember_bb58dc00-430a-497d-97e0-fc2079068ec8" xlink:href="krys-20220331.xsd#krys_MilestoneOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_MilestonesDomain_6e386f40-1bde-4f19-9ac8-97031e31b301" xlink:to="loc_krys_MilestoneOneMember_bb58dc00-430a-497d-97e0-fc2079068ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneTwoMember_56a52444-8e26-4f05-bba8-7edfbfd8e839" xlink:href="krys-20220331.xsd#krys_MilestoneTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_MilestonesDomain_6e386f40-1bde-4f19-9ac8-97031e31b301" xlink:to="loc_krys_MilestoneTwoMember_56a52444-8e26-4f05-bba8-7edfbfd8e839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_MilestoneThreeMember_cf2001f6-d287-42cc-a28f-e4d03689bcb9" xlink:href="krys-20220331.xsd#krys_MilestoneThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_MilestonesDomain_6e386f40-1bde-4f19-9ac8-97031e31b301" xlink:to="loc_krys_MilestoneThreeMember_cf2001f6-d287-42cc-a28f-e4d03689bcb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_4044a787-1612-4fa9-9d78-bfa2700b8e98" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7bf66faa-08ff-476f-a753-eb445b23d30d" xlink:to="loc_srt_LitigationCaseAxis_4044a787-1612-4fa9-9d78-bfa2700b8e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_7e703e6f-19ef-49d5-ad9f-dd38b8b668e1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_4044a787-1612-4fa9-9d78-bfa2700b8e98" xlink:to="loc_srt_LitigationCaseTypeDomain_7e703e6f-19ef-49d5-ad9f-dd38b8b668e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PeriphaGenMember_7e8e7e8f-1652-46ea-b89e-aa7f8103cec8" xlink:href="krys-20220331.xsd#krys_PeriphaGenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_7e703e6f-19ef-49d5-ad9f-dd38b8b668e1" xlink:to="loc_krys_PeriphaGenMember_7e8e7e8f-1652-46ea-b89e-aa7f8103cec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_7bf66faa-08ff-476f-a753-eb445b23d30d" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_AdditionalAreaOfRealEstatePropertyLeased_4ced7a8a-aebc-49b6-959c-7dbff7dfd45f" xlink:href="krys-20220331.xsd#krys_AdditionalAreaOfRealEstatePropertyLeased"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_AdditionalAreaOfRealEstatePropertyLeased_4ced7a8a-aebc-49b6-959c-7dbff7dfd45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PaymentToEscrowForReducingLeaseRentals_35f814bc-e121-483b-b830-304a921c8232" xlink:href="krys-20220331.xsd#krys_PaymentToEscrowForReducingLeaseRentals"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_PaymentToEscrowForReducingLeaseRentals_35f814bc-e121-483b-b830-304a921c8232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PurchasePriceOfPotentialBuildingPurchase_ef6a9367-e6de-4f5f-b270-62d3f5c1382c" xlink:href="krys-20220331.xsd#krys_PurchasePriceOfPotentialBuildingPurchase"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_PurchasePriceOfPotentialBuildingPurchase_ef6a9367-e6de-4f5f-b270-62d3f5c1382c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_d5d52df4-8d42-4050-b8e3-44a71dc03518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_FinanceLeaseLiability_d5d52df4-8d42-4050-b8e3-44a71dc03518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_9117fbc2-baa9-4e1a-9c7f-bb4397b86613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_ConstructionInProgressGross_9117fbc2-baa9-4e1a-9c7f-bb4397b86613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_6408cbd3-3517-4b48-a68c-7991de0f4ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_EscrowDeposit_6408cbd3-3517-4b48-a68c-7991de0f4ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_a0073e08-d26d-4d68-9d3a-97582b715a96" xlink:href="krys-20220331.xsd#krys_LessorOperatingLeaseLiabilityAnnualLeasePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments_a0073e08-d26d-4d68-9d3a-97582b715a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClausePercent_b0d29bc9-793d-40c6-9328-5c905a8169d1" xlink:href="krys-20220331.xsd#krys_CumulativeEscalationClausePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_CumulativeEscalationClausePercent_b0d29bc9-793d-40c6-9328-5c905a8169d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CumulativeEscalationClauseTerm_745ddde7-0f92-4e10-a67b-ca2270decef0" xlink:href="krys-20220331.xsd#krys_CumulativeEscalationClauseTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_CumulativeEscalationClauseTerm_745ddde7-0f92-4e10-a67b-ca2270decef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2eb1d6f3-ce4e-4de9-b04c-9519e85ac289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2eb1d6f3-ce4e-4de9-b04c-9519e85ac289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0c4cc1e0-ac9c-4d1c-8e2f-c128360d8e34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0c4cc1e0-ac9c-4d1c-8e2f-c128360d8e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_19e80e00-7852-43ef-9ffd-aea8a9030169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_19e80e00-7852-43ef-9ffd-aea8a9030169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_84fd3445-4ba5-4514-8d67-e93b4740445a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_84fd3445-4ba5-4514-8d67-e93b4740445a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_b70149cb-0fa3-464b-b346-bee3074437aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_OperatingLeaseCost_b70149cb-0fa3-464b-b346-bee3074437aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_8411b3f2-5b3f-4f7f-88ce-adcc5044c705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_VariableLeaseCost_8411b3f2-5b3f-4f7f-88ce-adcc5044c705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_RemainingCommitmentAmount_51e91b3b-56e7-4622-90a8-9c9e1c71fb73" xlink:href="krys-20220331.xsd#krys_RemainingCommitmentAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_RemainingCommitmentAmount_51e91b3b-56e7-4622-90a8-9c9e1c71fb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_0c98ac22-0ccf-4a49-826f-6dea7cd7614e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_ProfessionalFees_0c98ac22-0ccf-4a49-826f-6dea7cd7614e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_d8bfd782-a493-4b77-8c26-ca07bc8619e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_ContractualObligation_d8bfd782-a493-4b77-8c26-ca07bc8619e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_CostOfWorkPercentage_cae8de34-dc7f-4c2b-a54a-79cfaa1bc339" xlink:href="krys-20220331.xsd#krys_CostOfWorkPercentage"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_CostOfWorkPercentage_cae8de34-dc7f-4c2b-a54a-79cfaa1bc339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid_64569787-5edc-436a-9d52-2cb3871cd948" xlink:href="krys-20220331.xsd#krys_LossContingencyGuaranteedMaximumPriceToBePaid"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_LossContingencyGuaranteedMaximumPriceToBePaid_64569787-5edc-436a-9d52-2cb3871cd948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5ea0b478-0933-49a8-8c4c-4f7479d2e4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5ea0b478-0933-49a8-8c4c-4f7479d2e4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_7da66a75-0528-4add-a7c5-26ddd8a7363e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_LitigationSettlementExpense_7da66a75-0528-4add-a7c5-26ddd8a7363e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_9de93873-e3ca-4c28-859e-048d93e038f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_9de93873-e3ca-4c28-859e-048d93e038f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NumberOfMilestones_61a02af4-e1de-462e-9bc5-b1bc71094baa" xlink:href="krys-20220331.xsd#krys_NumberOfMilestones"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_NumberOfMilestones_61a02af4-e1de-462e-9bc5-b1bc71094baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold_64cb34d0-2580-402e-9832-b64507220b58" xlink:href="krys-20220331.xsd#krys_LitigationSettlementMilestonePaymentsSalesThreshold"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_LitigationSettlementMilestonePaymentsSalesThreshold_64cb34d0-2580-402e-9832-b64507220b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LitigationSettlementTotalConsideration_5f034ded-4b9f-474f-a49b-8aa116511b83" xlink:href="krys-20220331.xsd#krys_LitigationSettlementTotalConsideration"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_krys_LitigationSettlementTotalConsideration_5f034ded-4b9f-474f-a49b-8aa116511b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_4e920ea5-243a-4310-9cde-6e0c03a26d51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_4e920ea5-243a-4310-9cde-6e0c03a26d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_3800b107-97cc-439b-99ef-605e76d8fbec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_3800b107-97cc-439b-99ef-605e76d8fbec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_0596278c-a88d-4102-a822-77f3ec0a7123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_97bced9e-3832-4d34-bd30-6cb647148060" xlink:to="loc_us-gaap_LitigationReserveCurrent_0596278c-a88d-4102-a822-77f3ec0a7123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0faf9ae1-19ff-41d8-a4e3-bac95e381819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ff13c97c-89b2-4718-873f-5a8c37cc75d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0faf9ae1-19ff-41d8-a4e3-bac95e381819" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ff13c97c-89b2-4718-873f-5a8c37cc75d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6e40438c-7ac6-4c79-b6b6-ce7c23bb0faa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0faf9ae1-19ff-41d8-a4e3-bac95e381819" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6e40438c-7ac6-4c79-b6b6-ce7c23bb0faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_00ad6d1d-5b2e-4bcc-a153-bd3641007577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0faf9ae1-19ff-41d8-a4e3-bac95e381819" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_00ad6d1d-5b2e-4bcc-a153-bd3641007577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5777d2c7-0b68-4b66-b054-13627cf6f766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0faf9ae1-19ff-41d8-a4e3-bac95e381819" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5777d2c7-0b68-4b66-b054-13627cf6f766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6ccd4c65-66b2-4c4a-bf99-b385f1258fad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0faf9ae1-19ff-41d8-a4e3-bac95e381819" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6ccd4c65-66b2-4c4a-bf99-b385f1258fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_4b0b46af-20e1-438b-aad0-7623db3fa278" xlink:href="krys-20220331.xsd#krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0faf9ae1-19ff-41d8-a4e3-bac95e381819" xlink:to="loc_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_4b0b46af-20e1-438b-aad0-7623db3fa278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_639502dc-ad7c-4a3c-a61b-2ce3e0a02eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0faf9ae1-19ff-41d8-a4e3-bac95e381819" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_639502dc-ad7c-4a3c-a61b-2ce3e0a02eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_98d35578-ff38-4cfd-acd6-b34270fb3f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0faf9ae1-19ff-41d8-a4e3-bac95e381819" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_98d35578-ff38-4cfd-acd6-b34270fb3f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c10867f7-5a23-49b0-a1c9-13a513834403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0faf9ae1-19ff-41d8-a4e3-bac95e381819" xlink:to="loc_us-gaap_OperatingLeaseLiability_c10867f7-5a23-49b0-a1c9-13a513834403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1" xlink:type="simple" xlink:href="krys-20220331.xsd#CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a4423d01-597a-4c86-828f-8c29d66f064f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_83ac4690-079e-41eb-9f0b-8d28d44629e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a4423d01-597a-4c86-828f-8c29d66f064f" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_83ac4690-079e-41eb-9f0b-8d28d44629e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_149e867a-78f4-4478-ad9b-4033e3059acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_83ac4690-079e-41eb-9f0b-8d28d44629e4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_149e867a-78f4-4478-ad9b-4033e3059acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2bc5ad63-99fb-429e-82aa-28b794506fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_83ac4690-079e-41eb-9f0b-8d28d44629e4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2bc5ad63-99fb-429e-82aa-28b794506fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d99fdb36-1d78-4411-9d0d-90d9be50cbb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_83ac4690-079e-41eb-9f0b-8d28d44629e4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d99fdb36-1d78-4411-9d0d-90d9be50cbb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_930b7702-0eac-4b4e-b9f9-4efe04804a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_83ac4690-079e-41eb-9f0b-8d28d44629e4" xlink:to="loc_us-gaap_OperatingLeaseLiability_930b7702-0eac-4b4e-b9f9-4efe04804a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c08a66c6-e41f-451d-a7db-a130eca717e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_83ac4690-079e-41eb-9f0b-8d28d44629e4" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c08a66c6-e41f-451d-a7db-a130eca717e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a072d6ca-14cd-4db9-8c72-b84d2a5cdd25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_83ac4690-079e-41eb-9f0b-8d28d44629e4" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a072d6ca-14cd-4db9-8c72-b84d2a5cdd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/Capitalization" xlink:type="simple" xlink:href="krys-20220331.xsd#Capitalization"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/Capitalization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2d200381-69da-40ff-b125-2446ad333ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_020c8a8c-febc-49e7-86d5-887669aa4a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2d200381-69da-40ff-b125-2446ad333ee8" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_020c8a8c-febc-49e7-86d5-887669aa4a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#CapitalizationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4279b124-3b7c-4f01-92e5-9823763adb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_f0e43315-3882-48d3-8277-cf0a3715b0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4279b124-3b7c-4f01-92e5-9823763adb1a" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityTable_f0e43315-3882-48d3-8277-cf0a3715b0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_aec67af8-ad8b-4d32-aa19-dd540595cadc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_f0e43315-3882-48d3-8277-cf0a3715b0d4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_aec67af8-ad8b-4d32-aa19-dd540595cadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4596c81f-0873-4c5c-8a8c-89cb2b480ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_aec67af8-ad8b-4d32-aa19-dd540595cadc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4596c81f-0873-4c5c-8a8c-89cb2b480ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockSaleAgreementMember_0d5b7353-9110-459b-a9f2-699c28b1c88e" xlink:href="krys-20220331.xsd#krys_StockSaleAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4596c81f-0873-4c5c-8a8c-89cb2b480ed2" xlink:to="loc_krys_StockSaleAgreementMember_0d5b7353-9110-459b-a9f2-699c28b1c88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e18591c0-4cc8-4aab-94c2-53af56f41839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_f0e43315-3882-48d3-8277-cf0a3715b0d4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e18591c0-4cc8-4aab-94c2-53af56f41839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b08204bb-5a10-41de-8ca6-e5db7d461bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e18591c0-4cc8-4aab-94c2-53af56f41839" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b08204bb-5a10-41de-8ca6-e5db7d461bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PublicOfferingMember_be0df882-539d-46ae-a390-7e700c883f47" xlink:href="krys-20220331.xsd#krys_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b08204bb-5a10-41de-8ca6-e5db7d461bbb" xlink:to="loc_krys_PublicOfferingMember_be0df882-539d-46ae-a390-7e700c883f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_2ce536a6-ab92-47f4-96fe-dbf551a3ab97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b08204bb-5a10-41de-8ca6-e5db7d461bbb" xlink:to="loc_us-gaap_OverAllotmentOptionMember_2ce536a6-ab92-47f4-96fe-dbf551a3ab97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PlacementSharesMember_d4488fbd-a926-43ec-abbd-5f9ebc2a39ea" xlink:href="krys-20220331.xsd#krys_PlacementSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b08204bb-5a10-41de-8ca6-e5db7d461bbb" xlink:to="loc_krys_PlacementSharesMember_d4488fbd-a926-43ec-abbd-5f9ebc2a39ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ATMProgramMember_0a57bab5-2257-43fb-969f-c79b0df4d16b" xlink:href="krys-20220331.xsd#krys_ATMProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b08204bb-5a10-41de-8ca6-e5db7d461bbb" xlink:to="loc_krys_ATMProgramMember_0a57bab5-2257-43fb-969f-c79b0df4d16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_9929e984-aa05-4a78-a0ad-b13db6b006a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_f0e43315-3882-48d3-8277-cf0a3715b0d4" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_9929e984-aa05-4a78-a0ad-b13db6b006a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14fa07c8-171b-4343-ab5d-42786b2ab2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_9929e984-aa05-4a78-a0ad-b13db6b006a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14fa07c8-171b-4343-ab5d-42786b2ab2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_c27dca0d-eb7e-4de9-aebd-0a62e080fd5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_9929e984-aa05-4a78-a0ad-b13db6b006a6" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_c27dca0d-eb7e-4de9-aebd-0a62e080fd5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_62861cbe-3c12-492c-936e-2b4571e9e4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_9929e984-aa05-4a78-a0ad-b13db6b006a6" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_62861cbe-3c12-492c-936e-2b4571e9e4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_94e79bd4-0b4b-4f47-9aaa-73915d09d74d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_9929e984-aa05-4a78-a0ad-b13db6b006a6" xlink:to="loc_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_94e79bd4-0b4b-4f47-9aaa-73915d09d74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_4eae2678-dbaa-4e3c-bcb7-1d11952f7992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_9929e984-aa05-4a78-a0ad-b13db6b006a6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_4eae2678-dbaa-4e3c-bcb7-1d11952f7992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockAggregateOfferingPrice_68fa1a22-cb81-4afa-97f0-611f2f750e5b" xlink:href="krys-20220331.xsd#krys_SaleOfStockAggregateOfferingPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_9929e984-aa05-4a78-a0ad-b13db6b006a6" xlink:to="loc_krys_SaleOfStockAggregateOfferingPrice_68fa1a22-cb81-4afa-97f0-611f2f750e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a9d83a4d-3d76-4f15-99c9-88d53df624af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_9929e984-aa05-4a78-a0ad-b13db6b006a6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a9d83a4d-3d76-4f15-99c9-88d53df624af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d22b258f-c7b9-4c40-b80a-ed9f0238fc65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_9929e984-aa05-4a78-a0ad-b13db6b006a6" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d22b258f-c7b9-4c40-b80a-ed9f0238fc65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_77e884aa-6688-43da-938d-276db64ae4d9" xlink:href="krys-20220331.xsd#krys_SaleOfStockRemainingAvailableIssuanceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_9929e984-aa05-4a78-a0ad-b13db6b006a6" xlink:to="loc_krys_SaleOfStockRemainingAvailableIssuanceAmount_77e884aa-6688-43da-938d-276db64ae4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="krys-20220331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ae54704b-47d0-47b8-bb2e-ee061433d6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5b289125-62c9-443b-b1f2-c22da558a384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ae54704b-47d0-47b8-bb2e-ee061433d6e8" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5b289125-62c9-443b-b1f2-c22da558a384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="krys-20220331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8502dc0a-58c1-4bb5-a50d-af83d6a35e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a33e07db-b43d-477a-9d8a-b543159a253c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8502dc0a-58c1-4bb5-a50d-af83d6a35e64" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a33e07db-b43d-477a-9d8a-b543159a253c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_54180efe-2ce1-48f3-b0e0-83d50c0a10bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8502dc0a-58c1-4bb5-a50d-af83d6a35e64" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_54180efe-2ce1-48f3-b0e0-83d50c0a10bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c0ceedb1-3e20-4905-825b-769aa94d0ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8502dc0a-58c1-4bb5-a50d-af83d6a35e64" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c0ceedb1-3e20-4905-825b-769aa94d0ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_3110b118-9925-49eb-b411-ba79cac588ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8502dc0a-58c1-4bb5-a50d-af83d6a35e64" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_3110b118-9925-49eb-b411-ba79cac588ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4ab1c4b5-2185-4f4a-b95c-d2988a9ba9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4155296e-4342-41ff-8e7a-d02e3803bfbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4ab1c4b5-2185-4f4a-b95c-d2988a9ba9a2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4155296e-4342-41ff-8e7a-d02e3803bfbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_034ab009-e079-4f69-90bc-156ddd131bef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4155296e-4342-41ff-8e7a-d02e3803bfbb" xlink:to="loc_us-gaap_AwardTypeAxis_034ab009-e079-4f69-90bc-156ddd131bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b97a840-ba6f-493f-83d9-ff7411c87f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_034ab009-e079-4f69-90bc-156ddd131bef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b97a840-ba6f-493f-83d9-ff7411c87f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_306d0549-1ee1-4406-88ec-22919068f519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b97a840-ba6f-493f-83d9-ff7411c87f8b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_306d0549-1ee1-4406-88ec-22919068f519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_NonEmployeeStockOptionMember_b408fcbe-37e6-4599-a5a3-b6dcb639c9ac" xlink:href="krys-20220331.xsd#krys_NonEmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b97a840-ba6f-493f-83d9-ff7411c87f8b" xlink:to="loc_krys_NonEmployeeStockOptionMember_b408fcbe-37e6-4599-a5a3-b6dcb639c9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_9b5bceb4-df70-4b83-928f-3606328e4bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b97a840-ba6f-493f-83d9-ff7411c87f8b" xlink:to="loc_us-gaap_RestrictedStockMember_9b5bceb4-df70-4b83-928f-3606328e4bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_IncentiveStockOptionsMember_a3057e43-297c-4e46-808b-226cbe5baaba" xlink:href="krys-20220331.xsd#krys_IncentiveStockOptionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b97a840-ba6f-493f-83d9-ff7411c87f8b" xlink:to="loc_krys_IncentiveStockOptionsMember_a3057e43-297c-4e46-808b-226cbe5baaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3c7ac54b-093a-491a-892c-e92f0da5c66a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4155296e-4342-41ff-8e7a-d02e3803bfbb" xlink:to="loc_srt_RangeAxis_3c7ac54b-093a-491a-892c-e92f0da5c66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c42d93ef-6b46-4c96-a3c9-484ca3026c3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3c7ac54b-093a-491a-892c-e92f0da5c66a" xlink:to="loc_srt_RangeMember_c42d93ef-6b46-4c96-a3c9-484ca3026c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5cf8626e-e2b7-4558-94ef-f33f2af36fb7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c42d93ef-6b46-4c96-a3c9-484ca3026c3d" xlink:to="loc_srt_MinimumMember_5cf8626e-e2b7-4558-94ef-f33f2af36fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_960c46ee-4cf4-4cb2-8293-b974fbe2d3a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c42d93ef-6b46-4c96-a3c9-484ca3026c3d" xlink:to="loc_srt_MaximumMember_960c46ee-4cf4-4cb2-8293-b974fbe2d3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_52f19098-7540-4c60-91ab-2ebf2eac9331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4155296e-4342-41ff-8e7a-d02e3803bfbb" xlink:to="loc_us-gaap_PlanNameAxis_52f19098-7540-4c60-91ab-2ebf2eac9331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d74754d0-a6a2-4d34-9622-2a21ba7cf915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_52f19098-7540-4c60-91ab-2ebf2eac9331" xlink:to="loc_us-gaap_PlanNameDomain_d74754d0-a6a2-4d34-9622-2a21ba7cf915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_StockIncentivePlanMember_b3a3a827-c6d2-4421-b7ee-07176c3fe512" xlink:href="krys-20220331.xsd#krys_StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d74754d0-a6a2-4d34-9622-2a21ba7cf915" xlink:to="loc_krys_StockIncentivePlanMember_b3a3a827-c6d2-4421-b7ee-07176c3fe512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_8f39e577-474d-4c9f-86c1-21397002198c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4155296e-4342-41ff-8e7a-d02e3803bfbb" xlink:to="loc_srt_TitleOfIndividualAxis_8f39e577-474d-4c9f-86c1-21397002198c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_22acdbb0-69fa-49b2-9b36-c18266e29efa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_8f39e577-474d-4c9f-86c1-21397002198c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_22acdbb0-69fa-49b2-9b36-c18266e29efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_5c1a6930-f629-4b6f-850b-a933bb88737c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_22acdbb0-69fa-49b2-9b36-c18266e29efa" xlink:to="loc_srt_DirectorMember_5c1a6930-f629-4b6f-850b-a933bb88737c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4155296e-4342-41ff-8e7a-d02e3803bfbb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_db2e001c-32a7-49e6-8462-ab5d65ae00a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_db2e001c-32a7-49e6-8462-ab5d65ae00a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_623fb5fb-918b-4d9a-a439-df57fa18913d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_623fb5fb-918b-4d9a-a439-df57fa18913d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f7d74a88-b21a-4d33-b21c-ae8dba6971b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f7d74a88-b21a-4d33-b21c-ae8dba6971b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e62c75a9-c5e7-43c7-96c4-925d27195fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e62c75a9-c5e7-43c7-96c4-925d27195fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4ccdd5f0-cb4c-4e44-b1e2-1e7b912e2bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4ccdd5f0-cb4c-4e44-b1e2-1e7b912e2bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_30dde037-581b-431c-94f2-a71ced1268bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_30dde037-581b-431c-94f2-a71ced1268bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa56c6f3-2986-4c12-9b85-27be3403db81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fa56c6f3-2986-4c12-9b85-27be3403db81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_128f1aee-19e4-497f-83de-25af074b5a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_128f1aee-19e4-497f-83de-25af074b5a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_04152f9a-eab8-44a6-99fd-beba787fada1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_04152f9a-eab8-44a6-99fd-beba787fada1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_501c8d29-3613-4b97-a966-67437f6d43dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_501c8d29-3613-4b97-a966-67437f6d43dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_fe96c841-ba74-4914-8a72-69337e91bf64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_fe96c841-ba74-4914-8a72-69337e91bf64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_06176094-d218-40cf-88d8-09ec09b52e46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3130db79-1b7b-4041-a0e1-4ad9fce0697a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d206b10-dc53-4cb8-9629-2e15e4d67361" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3130db79-1b7b-4041-a0e1-4ad9fce0697a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dadcb8a7-7f8a-4616-b8de-91ce3a50c067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_74a6d9f2-bb57-48d3-a08d-41d8b9a352fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dadcb8a7-7f8a-4616-b8de-91ce3a50c067" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_74a6d9f2-bb57-48d3-a08d-41d8b9a352fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40c457c1-0284-4b89-b229-caa1c665d740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_74a6d9f2-bb57-48d3-a08d-41d8b9a352fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40c457c1-0284-4b89-b229-caa1c665d740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a7523754-03c5-4218-bfdd-775da4261bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_74a6d9f2-bb57-48d3-a08d-41d8b9a352fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a7523754-03c5-4218-bfdd-775da4261bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7e442711-d84e-45af-aec3-745d0017dd36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_74a6d9f2-bb57-48d3-a08d-41d8b9a352fb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7e442711-d84e-45af-aec3-745d0017dd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_e6d1f5d8-28bd-44cd-a3f0-4d30a5d7076b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_74a6d9f2-bb57-48d3-a08d-41d8b9a352fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_e6d1f5d8-28bd-44cd-a3f0-4d30a5d7076b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7f9df957-fcdf-4e7d-a6e9-0b8338819ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_74a6d9f2-bb57-48d3-a08d-41d8b9a352fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7f9df957-fcdf-4e7d-a6e9-0b8338819ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7705f2df-fd35-4fb4-8275-5775a2fef925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_74a6d9f2-bb57-48d3-a08d-41d8b9a352fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7705f2df-fd35-4fb4-8275-5775a2fef925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_33033226-ab50-4a2c-a0de-7b77330282db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dadcb8a7-7f8a-4616-b8de-91ce3a50c067" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_33033226-ab50-4a2c-a0de-7b77330282db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e9e917ca-9abd-4a01-86fa-6aa6cea56b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dadcb8a7-7f8a-4616-b8de-91ce3a50c067" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e9e917ca-9abd-4a01-86fa-6aa6cea56b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0c63d7fd-4126-4a81-b4ea-cd1f1e970676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e9e917ca-9abd-4a01-86fa-6aa6cea56b7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0c63d7fd-4126-4a81-b4ea-cd1f1e970676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0b030728-45ee-4e34-becc-2e49aa9c6328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e9e917ca-9abd-4a01-86fa-6aa6cea56b7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0b030728-45ee-4e34-becc-2e49aa9c6328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c0da38fe-349d-4b26-a947-2582b582ae8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e9e917ca-9abd-4a01-86fa-6aa6cea56b7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c0da38fe-349d-4b26-a947-2582b582ae8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_58ade476-eb56-42eb-bd36-8123c1712997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e9e917ca-9abd-4a01-86fa-6aa6cea56b7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_58ade476-eb56-42eb-bd36-8123c1712997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_f05f6e0f-cc01-4abb-a36b-ae172800b30e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e9e917ca-9abd-4a01-86fa-6aa6cea56b7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_f05f6e0f-cc01-4abb-a36b-ae172800b30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_05e1dd68-6938-46ae-adf3-b707ebaf43d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e9e917ca-9abd-4a01-86fa-6aa6cea56b7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_05e1dd68-6938-46ae-adf3-b707ebaf43d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cb5145fa-5887-4010-ab7b-e62d4c96f19a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dadcb8a7-7f8a-4616-b8de-91ce3a50c067" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cb5145fa-5887-4010-ab7b-e62d4c96f19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_90613b8a-0cb7-465d-bd4c-80c5549ba856" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dadcb8a7-7f8a-4616-b8de-91ce3a50c067" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_90613b8a-0cb7-465d-bd4c-80c5549ba856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7dae0d37-8807-4f72-96eb-98713cb4593d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_90613b8a-0cb7-465d-bd4c-80c5549ba856" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7dae0d37-8807-4f72-96eb-98713cb4593d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e76f80c1-b8c5-4405-83c2-1ed4f7d2f3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dadcb8a7-7f8a-4616-b8de-91ce3a50c067" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e76f80c1-b8c5-4405-83c2-1ed4f7d2f3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_b4cbfc75-0e5a-412c-90c6-30fc99b7d699" xlink:href="krys-20220331.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dadcb8a7-7f8a-4616-b8de-91ce3a50c067" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_b4cbfc75-0e5a-412c-90c6-30fc99b7d699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a2808093-d846-4620-8953-61e09967a2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_b4cbfc75-0e5a-412c-90c6-30fc99b7d699" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a2808093-d846-4620-8953-61e09967a2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_21e094cf-c4df-414e-8169-d91de1e2cb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dadcb8a7-7f8a-4616-b8de-91ce3a50c067" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_21e094cf-c4df-414e-8169-d91de1e2cb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9b77798c-692e-4294-815a-04b7c3f73430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0935a0ce-a47d-4678-9764-44fa37232331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9b77798c-692e-4294-815a-04b7c3f73430" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0935a0ce-a47d-4678-9764-44fa37232331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_42855abf-c7f2-467f-a3e2-06ea6c724e12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0935a0ce-a47d-4678-9764-44fa37232331" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_42855abf-c7f2-467f-a3e2-06ea6c724e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_44e0473d-c776-476d-b733-7ad59a8f3538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_42855abf-c7f2-467f-a3e2-06ea6c724e12" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_44e0473d-c776-476d-b733-7ad59a8f3538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5da8928f-0507-481e-aa2f-72948e89ac3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_44e0473d-c776-476d-b733-7ad59a8f3538" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5da8928f-0507-481e-aa2f-72948e89ac3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_22a3d6c3-43d1-48bf-a5c5-80722d1e637c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_44e0473d-c776-476d-b733-7ad59a8f3538" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_22a3d6c3-43d1-48bf-a5c5-80722d1e637c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f4c2397b-4f1f-4da5-9e2d-09b3fa68c1be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0935a0ce-a47d-4678-9764-44fa37232331" xlink:to="loc_us-gaap_AwardTypeAxis_f4c2397b-4f1f-4da5-9e2d-09b3fa68c1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60c5e557-63f8-44d0-ae79-8c41f5c3067f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f4c2397b-4f1f-4da5-9e2d-09b3fa68c1be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60c5e557-63f8-44d0-ae79-8c41f5c3067f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_48b240ac-3d6e-4c73-9dc5-add89bccc7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60c5e557-63f8-44d0-ae79-8c41f5c3067f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_48b240ac-3d6e-4c73-9dc5-add89bccc7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_759b2c8a-7526-441e-bbdc-69c56dc2ba7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60c5e557-63f8-44d0-ae79-8c41f5c3067f" xlink:to="loc_us-gaap_RestrictedStockMember_759b2c8a-7526-441e-bbdc-69c56dc2ba7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a594e843-9d49-4a8f-9b07-cf28d86f68c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0935a0ce-a47d-4678-9764-44fa37232331" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a594e843-9d49-4a8f-9b07-cf28d86f68c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bb549d53-2ea0-4c92-9e48-c5fe82e7f25b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a594e843-9d49-4a8f-9b07-cf28d86f68c7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bb549d53-2ea0-4c92-9e48-c5fe82e7f25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="simple" xlink:href="krys-20220331.xsd#StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5bedb253-1b6a-4c2d-a3d9-d491503f40c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_587159a5-c621-4005-a119-0facaf9159a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5bedb253-1b6a-4c2d-a3d9-d491503f40c4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_587159a5-c621-4005-a119-0facaf9159a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_892ba498-142c-4ccd-8a51-3325484279db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_587159a5-c621-4005-a119-0facaf9159a3" xlink:to="loc_us-gaap_AwardTypeAxis_892ba498-142c-4ccd-8a51-3325484279db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10bbf469-256d-452d-88c1-bf580c480b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_892ba498-142c-4ccd-8a51-3325484279db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10bbf469-256d-452d-88c1-bf580c480b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d316ac89-a597-4236-bf41-be251dd4cfe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10bbf469-256d-452d-88c1-bf580c480b43" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d316ac89-a597-4236-bf41-be251dd4cfe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf465975-4a7c-49f3-a3d9-df34746fc58e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_587159a5-c621-4005-a119-0facaf9159a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf465975-4a7c-49f3-a3d9-df34746fc58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3c4e2923-2720-4166-a55c-b08bbf68c0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf465975-4a7c-49f3-a3d9-df34746fc58e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3c4e2923-2720-4166-a55c-b08bbf68c0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_759082c5-1a6f-4c51-bd84-2af4aae2abda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf465975-4a7c-49f3-a3d9-df34746fc58e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_759082c5-1a6f-4c51-bd84-2af4aae2abda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3f74f6fd-5bd0-4ddd-95f0-aea5f0dd9022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf465975-4a7c-49f3-a3d9-df34746fc58e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3f74f6fd-5bd0-4ddd-95f0-aea5f0dd9022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_6212a8a2-5590-409e-a70b-cc8dfe85f2da" xlink:href="krys-20220331.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf465975-4a7c-49f3-a3d9-df34746fc58e" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_6212a8a2-5590-409e-a70b-cc8dfe85f2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_45a86ddd-6e66-4386-80af-cda8e19db706" xlink:href="krys-20220331.xsd#krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf465975-4a7c-49f3-a3d9-df34746fc58e" xlink:to="loc_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate_45a86ddd-6e66-4386-80af-cda8e19db706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" xlink:type="simple" xlink:href="krys-20220331.xsd#StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2bb626cd-7ab1-429a-9f48-123c0b740265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_87c14c9c-6d3d-4200-9121-04395d70528d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2bb626cd-7ab1-429a-9f48-123c0b740265" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_87c14c9c-6d3d-4200-9121-04395d70528d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2b9f02cb-a4df-4e54-9577-a229255e0c66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_87c14c9c-6d3d-4200-9121-04395d70528d" xlink:to="loc_us-gaap_AwardTypeAxis_2b9f02cb-a4df-4e54-9577-a229255e0c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_083ac05f-aa12-427a-9162-fbe36669c721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2b9f02cb-a4df-4e54-9577-a229255e0c66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_083ac05f-aa12-427a-9162-fbe36669c721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b736daad-44c9-4329-808f-80dfbd37a18d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_083ac05f-aa12-427a-9162-fbe36669c721" xlink:to="loc_us-gaap_RestrictedStockMember_b736daad-44c9-4329-808f-80dfbd37a18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd183613-28c7-40cd-8dd5-5349e53e3bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_87c14c9c-6d3d-4200-9121-04395d70528d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd183613-28c7-40cd-8dd5-5349e53e3bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1060f28-faf8-4b17-91ae-2ab8a80ea66d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd183613-28c7-40cd-8dd5-5349e53e3bb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1060f28-faf8-4b17-91ae-2ab8a80ea66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_adcb04c9-1e3b-40ce-adcd-c4cf0ced8383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1060f28-faf8-4b17-91ae-2ab8a80ea66d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_adcb04c9-1e3b-40ce-adcd-c4cf0ced8383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8d75fd2c-fd66-4706-ae3e-b14b5626265c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1060f28-faf8-4b17-91ae-2ab8a80ea66d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8d75fd2c-fd66-4706-ae3e-b14b5626265c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2775884f-ae4a-43d7-8b79-a272a9b27cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1060f28-faf8-4b17-91ae-2ab8a80ea66d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2775884f-ae4a-43d7-8b79-a272a9b27cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3299d78f-8725-4b52-a88f-22aef09ce322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1060f28-faf8-4b17-91ae-2ab8a80ea66d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3299d78f-8725-4b52-a88f-22aef09ce322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9adce309-7fcc-499e-8f0e-2305f7b93093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d1060f28-faf8-4b17-91ae-2ab8a80ea66d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9adce309-7fcc-499e-8f0e-2305f7b93093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_856e8133-4cfc-4177-abc8-2318c8e4d8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd183613-28c7-40cd-8dd5-5349e53e3bb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_856e8133-4cfc-4177-abc8-2318c8e4d8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_55234392-c461-408c-acc7-1a33b77e6a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_856e8133-4cfc-4177-abc8-2318c8e4d8dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_55234392-c461-408c-acc7-1a33b77e6a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_74fa3649-ec34-4dd9-a287-3f78c4b495a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_856e8133-4cfc-4177-abc8-2318c8e4d8dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_74fa3649-ec34-4dd9-a287-3f78c4b495a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_faae18ec-f6ca-4add-bc19-35ac84646bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_856e8133-4cfc-4177-abc8-2318c8e4d8dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_faae18ec-f6ca-4add-bc19-35ac84646bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9620e041-1150-4978-8b6e-48da4522f5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_856e8133-4cfc-4177-abc8-2318c8e4d8dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9620e041-1150-4978-8b6e-48da4522f5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8435dbd7-d5f4-4499-81b7-11d51d252369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_856e8133-4cfc-4177-abc8-2318c8e4d8dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8435dbd7-d5f4-4499-81b7-11d51d252369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="krys-20220331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_b1aa6df3-50b7-47b6-b883-7a467f510b23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_98c390bf-bbe4-4dda-8c0d-43f8992d8ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_b1aa6df3-50b7-47b6-b883-7a467f510b23" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_98c390bf-bbe4-4dda-8c0d-43f8992d8ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.krystalbio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="krys-20220331.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.krystalbio.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_5b8edfeb-eb36-41e7-a036-718973224fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_460dbf57-5070-425f-8bd5-7be978bac099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_5b8edfeb-eb36-41e7-a036-718973224fd3" xlink:to="loc_us-gaap_SubsequentEventTable_460dbf57-5070-425f-8bd5-7be978bac099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_d384efdf-8f12-4b9d-8074-e64d51cb62c0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_460dbf57-5070-425f-8bd5-7be978bac099" xlink:to="loc_srt_LitigationCaseAxis_d384efdf-8f12-4b9d-8074-e64d51cb62c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ea3fa301-a0cd-48d0-b897-51a1fcfa75cb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_d384efdf-8f12-4b9d-8074-e64d51cb62c0" xlink:to="loc_srt_LitigationCaseTypeDomain_ea3fa301-a0cd-48d0-b897-51a1fcfa75cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PeriphaGenMember_563d0868-1047-46f3-ac3b-15e683266200" xlink:href="krys-20220331.xsd#krys_PeriphaGenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ea3fa301-a0cd-48d0-b897-51a1fcfa75cb" xlink:to="loc_krys_PeriphaGenMember_563d0868-1047-46f3-ac3b-15e683266200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_28592ea3-e853-4e90-b6c6-bedbfcf49d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_460dbf57-5070-425f-8bd5-7be978bac099" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_28592ea3-e853-4e90-b6c6-bedbfcf49d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cfcb0a24-d67c-41d6-96ff-2e127f8a6088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_28592ea3-e853-4e90-b6c6-bedbfcf49d09" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cfcb0a24-d67c-41d6-96ff-2e127f8a6088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_krys_PublicOfferingMember_6a0ee409-013f-481a-a705-109c536d136c" xlink:href="krys-20220331.xsd#krys_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cfcb0a24-d67c-41d6-96ff-2e127f8a6088" xlink:to="loc_krys_PublicOfferingMember_6a0ee409-013f-481a-a705-109c536d136c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2e805b59-53ba-456a-ab78-9a19c9aa2e45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_460dbf57-5070-425f-8bd5-7be978bac099" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2e805b59-53ba-456a-ab78-9a19c9aa2e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c0997480-a408-4357-942c-1bfb36092474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2e805b59-53ba-456a-ab78-9a19c9aa2e45" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c0997480-a408-4357-942c-1bfb36092474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_85bf1435-0e8b-4279-b980-25a3fdeda2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c0997480-a408-4357-942c-1bfb36092474" xlink:to="loc_us-gaap_SubsequentEventMember_85bf1435-0e8b-4279-b980-25a3fdeda2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_89124079-5931-4db4-9a31-3d4db6e70dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_460dbf57-5070-425f-8bd5-7be978bac099" xlink:to="loc_us-gaap_SubsequentEventLineItems_89124079-5931-4db4-9a31-3d4db6e70dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_6a3222a4-0a66-4346-9c03-b06526632562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_89124079-5931-4db4-9a31-3d4db6e70dfc" xlink:to="loc_us-gaap_LitigationSettlementExpense_6a3222a4-0a66-4346-9c03-b06526632562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5dfcf155-c801-4b4d-8196-15e0389c715e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_89124079-5931-4db4-9a31-3d4db6e70dfc" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5dfcf155-c801-4b4d-8196-15e0389c715e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2b008f1a-0e0f-4975-923a-6fd8b5e199bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_89124079-5931-4db4-9a31-3d4db6e70dfc" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2b008f1a-0e0f-4975-923a-6fd8b5e199bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ebb62854-801f-48a9-bd16-079e286d5cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_89124079-5931-4db4-9a31-3d4db6e70dfc" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ebb62854-801f-48a9-bd16-079e286d5cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>krys-20220331_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 krys-20220331_g1.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X3)B17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(R.C U.C W(#(R.C W.C,T   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,V-P  DI(  @    ,V-P  H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,CHP-3HP-R Q-SHQ-CHP,@ R,#(R.C U.C W(#$W.C$V.C R      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  (+4         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@!  #% P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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MM?%6DL$P;K<_1?+?./6@#4L;NUU&$RVYE*AMIW!E_G4ER5@B\T[]J99@&.2
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M_P#KT>?/_?3_ +Y_^O0 AN)QU=/^^?\ Z]'VF;_GI'_WS_\ 7H 7SY_[Z?\
M?/\ ]>F23S[H\NGWO[OL?>@!WGS_ -Y/^^/_ *]->:?:/F3[P_A]_K0 _P ^
M?^^G_?/_ ->F23S^6V63I_=_^O0 _P ^?^\G_?/_ ->F23S^6WS)T_N__7H
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M%8IG9<OUB8J>AH0$']BP_P#/Q=_]_C36T:$#_CXN^H_Y;'UJ^=D\H[^Q8?\
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MSR,HBWXW8]C0!!_;NE_\]A_WP:8^N:65&)A]X?P'UJN1BYD/_MW2_P#GL/\
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M %6U^4?-VI?LH_O4 ,2VX;YC]XT_[*/[U !]E']ZC[*/[U !]E']ZC[*/[U
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MM3/MZXSYC_\ ?)H E6=G4,'.#R*BGN?*"/)*$4-U8X'0T)7 9_:MM_S^Q?\
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M/WA_.@!WVI?[IILET/+;"GI0 _[4O]TTR2Z'EM\IZ4 .6Z&T?*>E+]J7^Z:
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MZANGM4RVMK! ;9([AH9G)=6DW=4VG!)R.F?J2>]" @DT/29%*M;W6W<& $[
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M&1P3P,VQ']: +<8=4 D<.WJ%Q4-T9P\?V=8VDP>'8@8XJHVOJ)WMH0^9JO\
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M]G]:B:Y_TB,[?X6_I0@)?M7^S^M1R7)WQ87C=S^1H0$GVK_9_6HI[G*K\O\
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MP:0_9R.8Y3SZ&@!Q6$'_ %<OZT%(,8*2<_6@!,0_\\Y?R-/CCADSA7&/7(H
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M%!04%!04_\  $0@(%@8] P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
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M !L\)0Q>.= 2&UN+2*SO# +M9KJ.W)+^6S1E"Y!1DW*R,C*I! Z3]F/XY/\
MM%?!'PW\1I-'3P__ &R+EO[.^UBY-NL5S+#C>$7=GRB>@QZ<&@#UVEJ#[2HW
M9RBCNV!_G'/7TIJW+'(,;AAVP.>OOWQZ]QG% %BHO./]TXR%[?XTS[4",'=&
M3QD@ ]>OZC\Z^?/VSOVJ&_9&^%^D^,1X8C\6)?ZU%I0L5U'[&4#P3RB3>(Y
M>8",8YW>U 'T,)&P"58>HP#_ "H6;.S(*EN #USC-?$_[1?_  42_P"% _"W
MX/>,O^$!77F^(>BMJRV7]MBU_LY?)M)0F\0-YW_'T%SA?]7D=3C[.C<JX$AR
M['CG)*@\\#@X/&?3&: +]+5=;H%0VUE&<8*\]>#CTZ?GSC!H^TYW8#,5R"%P
M>0>1]>G^<T 6**@CN?-^ZK=2 <<''&14RG(H 6BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EIK-MR3T S0!^5
MO_!<+YI/@F#Q_P AG!XQ_P N'7/;_/TS/A\W_#Q3]O34;GQK>ZAH'A/P!_IN
MF_#_ %RT$MR\5O/%#+'-'Y9A3?,$:X63=)B185WJOFQ:W_!;Y9&;X*NL1=(S
MK*EFX7)%@0"<\9 /7'0UH?\ !0;X2:U^S%\7O#_[4?PIMK"S>.]6/7-/6P9X
MC=3+*CWDH!*".X24P2-^[82.C*QDF+* >H_\%(OVJ/&_[+?BKX-W?A>^']DZ
MC>7TVO:2UO W]J6\$EF5A,DD4ABW(\R;T&1YF<<*!R%GXZ_;'3]G#XQ?$#Q;
M<W/@_6K"WT[Q!X9LXK+2E6&RW32:C%)!,LD@6.W9&"SL)MT 4,6,B-XO_P %
M5/BMH/QX^&'[._CGPJ;B;0M7AUM[9;BV,,JR*UE$\;(2<,LB2(<%@2A*EEPQ
M_6K4-)T_6M+NM/U&RBU+3;V.2":"XB6>*:&56#HZ;2K(1E2I!!!&<Y- 'PA:
M?MV>(]0_X)LWOQ3BU_2D^*=C(OAMY)[81H^H-<1KOCA?"2SBRD6Z^3=&#O.S
M8K(.)\;_ +6_QQ^'?[,?P*BU#Q58:9\1OBK>273>+?$8L([31K$RVXMV"10>
M6L<D$T4KR2B1HPTX*[C'Y7R#X]^'_B'P/\2/%7[*UD9UM=4^(>FOH4FLZD7A
MMT9;BWMYY%A5E#SQ7UF\CHH($"@H2-J?I+^V]XX^%7P)^%_PX\">/_A;J'CG
MX176;$W%C=2>9HK6D*?85A=V5FDD5I$S]H1C'%/S(-ZT )\#--_:[9_&&G^*
M_&OA'QCHNM^#YKSPIXVT<VC6=GJTG_'KPD$;21,K^<S&WE0A8MK<NI^"OV:?
M!O[0&M?MF?%?2/A_XYT'1/BK:?VM_P )#KFH0I)9W>W48DNO*4VD@!><HPQ$
MGRJ?N_=/JG_!/.QU.Z_;4U37_@KHGB_1_P!G_4#<)JG]MQKY,2K:"6.WEDRZ
MM)'<S0^5AVF$3DL2K2DY'A'XO6_[#O\ P4-^-/BGXE>&]?6P\1#57TZ+2X()
MI)X+S48KFWN%WRHC1LD3 E6)5QL*AE8  ^S?VS/&7QXT7Q7I-O\ #[QI\/\
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M]#_X*(?&BS_:%_X)]_#7XA66DR:*-6\4P>983S+))!)%!J4,B[QQ(@>*3:V
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTQD'G\Z=BB@"K';M$2JI&./]9CG/;@ <8]Z=ME+<;.!][_:SSQ^7?\N]BC%
M$"Q,N#\H;Z'CGI36CE97 ,2D-D,R$C'?C(_F:LXQQ1@>E %9HW.5RJKMQN'7
M)ZX]./Y^U-FA>3 !7.#AB>4.>,8]_P"56]HHV@\$9H J?8UW9+97C$>>%/<Y
MZ^_U&>M'DN6!^5/E&YD.#G_)/Y]*MXHH J_93D<J<#&YEW$^OTZ#ZTHMRS[V
M +<8YSM/&>OT%6<"C H K&$C'*_>W9X'<^WI0UN67 ."QSG 'X8^E6:* *LM
MKYORMM=#@ ,.!R,@?E^%#0/(OS;3\N"K<KGKG!]#G]*M8HQ0!5DM?,X.UTX
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBFLVU23VH =17/+\0?#+*Q_P"$ATL8<H0U
MY&,,#R/O=12?\+"\,#KXBTG/_7_#_P#%4 =%17._\+$\+_\ 0Q:3_P"!\/\
M\51_PL3PO_T,6D_^!\/_ ,50!T5%<[_PL3PO_P!#%I/_ ('P_P#Q5'_"Q/"_
M_0Q:3_X'P_\ Q5 '145SO_"Q/"__ $,6D_\ @?#_ /%4?\+$\+_]#%I/_@?#
M_P#%4 =%17._\+$\+_\ 0Q:3_P"!\/\ \51_PL3PO_T,6D_^!\/_ ,50!T5%
M<[_PL3PO_P!#%I/_ ('P_P#Q5'_"Q/"__0Q:3_X'P_\ Q5 '145SO_"Q/"__
M $,6D_\ @?#_ /%4?\+$\+_]#%I/_@?#_P#%4 =%17._\+$\+_\ 0Q:3_P"!
M\/\ \51_PL3PO_T,6D_^!\/_ ,50!T5%<[_PL3PO_P!#%I/_ ('P_P#Q5'_"
MQ/"__0Q:3_X'P_\ Q5 '145SO_"Q/"__ $,6D_\ @?#_ /%4?\+$\+_]#%I/
M_@?#_P#%4 =%17._\+$\+_\ 0Q:3_P"!\/\ \51_PL3PO_T,6D_^!\/_ ,50
M!T5%<[_PL3PO_P!#%I/_ ('P_P#Q5'_"Q/"__0Q:3_X'P_\ Q5 '145SO_"Q
M/"__ $,6D_\ @?#_ /%4?\+$\+_]#%I/_@?#_P#%4 =%17._\+$\+_\ 0Q:3
M_P"!\/\ \51_PL3PO_T,6D_^!\/_ ,50!T5%<[_PL3PO_P!#%I/_ ('P_P#Q
M5'_"Q/"__0Q:3_X'P_\ Q5 '145SO_"Q/"__ $,6D_\ @?#_ /%4?\+$\+_]
M#%I/_@?#_P#%4 =%17._\+$\+_\ 0Q:3_P"!\/\ \51_PL3PO_T,6D_^!\/_
M ,50!T5%<[_PL3PO_P!#%I/_ ('P_P#Q5'_"Q/"__0Q:3_X'P_\ Q5 '145S
MO_"Q/"__ $,6D_\ @?#_ /%4?\+$\+_]#%I/_@?#_P#%4 =%17._\+$\+_\
M0Q:3_P"!\/\ \51_PL3PO_T,6D_^!\/_ ,50!T5%<[_PL3PO_P!#%I/_ ('P
M_P#Q5'_"Q/"__0Q:3_X'P_\ Q5 '145SO_"Q/"__ $,6D_\ @?#_ /%4?\+$
M\+_]#%I/_@?#_P#%4 =%17._\+$\+_\ 0Q:3_P"!\/\ \51_PL3PO_T,6D_^
M!\/_ ,50!T5%<[_PL3PO_P!#%I/_ ('P_P#Q5'_"Q/"__0Q:3_X'P_\ Q5 '
M145SO_"Q/"__ $,6D_\ @?#_ /%4?\+$\+_]#%I/_@?#_P#%4 =%17._\+$\
M+_\ 0Q:3_P"!\/\ \51_PL3PO_T,6D_^!\/_ ,50!T5%<[_PL3PO_P!#%I/_
M ('P_P#Q5'_"Q/"__0Q:3_X'P_\ Q5 '145SO_"Q/"__ $,6D_\ @?#_ /%4
M?\+$\+_]#%I/_@?#_P#%4 =%17._\+$\+_\ 0Q:3_P"!\/\ \51_PL3PO_T,
M6D_^!\/_ ,50!T5%<[_PL3PO_P!#%I/_ ('P_P#Q5'_"Q/"__0Q:3_X'P_\
MQ5 '145SO_"Q/"__ $,6D_\ @?#_ /%4?\+$\+_]#%I/_@?#_P#%4 =%17._
M\+$\+_\ 0Q:3_P"!\/\ \51_PL3PO_T,6D_^!\/_ ,50!T5%<[_PL3PO_P!#
M%I/_ ('P_P#Q5'_"Q/"__0Q:3_X'P_\ Q5 '145SO_"Q/"__ $,6D_\ @?#_
M /%4?\+$\+_]#%I/_@?#_P#%4 =%17._\+$\+_\ 0Q:3_P"!\/\ \51_PL3P
MO_T,6D_^!\/_ ,50!T5%<[_PL3PO_P!#%I/_ ('P_P#Q5'_"Q/"__0Q:3_X'
MP_\ Q5 '145SO_"Q/"__ $,6D_\ @?#_ /%4O_"PO#!Z>(M)/TOX?_BJ .AH
MKG3\0O#*L0WB+2DXS\U]#_\ %?YS2M\0O#"8#>(])5B"=IOHNW_ J .AHKGO
M^%A>&!P?$6DY_P"O^'_XJD_X6)X7_P"ABTG_ ,#X?_BJ .BHKG?^%B>%_P#H
M8M)_\#X?_BJ/^%B>%_\ H8M)_P# ^'_XJ@#HJ*YW_A8GA?\ Z&+2?_ ^'_XJ
MC_A8GA?_ *&+2?\ P/A_^*H Z*BN=_X6)X7_ .ABTG_P/A_^*H_X6)X7_P"A
MBTG_ ,#X?_BJ .BHKG?^%B>%_P#H8M)_\#X?_BJ/^%B>%_\ H8M)_P# ^'_X
MJ@#HJ*YW_A8GA?\ Z&+2?_ ^'_XJC_A8GA?_ *&+2?\ P/A_^*H Z*BN=_X6
M)X7_ .ABTG_P/A_^*H_X6)X7_P"ABTG_ ,#X?_BJ .BHKG?^%A^&.WB'23_V
M_P /_P 52_\ "PO#+*67Q#I3J#@E;V(@?CN_SB@#H:*YW_A8?A?_ *&+2?\
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MQW\1:3G_ *_X?_BJ .BHKG?^%B>%_P#H8M)_\#X?_BJ/^%B>%_\ H8M)_P#
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MD_\ @?#_ /%4?\+$\+_]#%I/_@?#_P#%4 =%17._\+$\+_\ 0Q:3_P"!\/\
M\51_PL3PO_T,6D_^!\/_ ,50!T5%<[_PL3PO_P!#%I/_ ('P_P#Q5'_"Q/"_
M_0Q:3_X'P_\ Q5 '145SO_"Q/"__ $,6D_\ @?#_ /%4?\+$\+_]#%I/_@?#
M_P#%4 =%17._\+$\+_\ 0Q:3_P"!\/\ \51_PL3PO_T,6D_^!\/_ ,50!T5%
M<[_PL3PO_P!#%I/_ ('P_P#Q5'_"Q/"__0Q:3_X'P_\ Q5 '145SO_"Q/"__
M $,6D_\ @?#_ /%4?\+$\+_]#%I/_@?#_P#%4 =%17._\+#\,=O$.DG_ +?X
M?_BJ7_A87AEE++XATIU!P2M[$0/QW?YQ0!T-%<[_ ,+#\+_]#%I/_@?#_P#%
M4?\ "Q/"_P#T,6D_^!\/_P 50!T5%<[_ ,+$\+_]#%I/_@?#_P#%4?\ "Q/"
M_P#T,6D_^!\/_P 50!T5%<[_ ,+$\+_]#%I/_@?#_P#%4?\ "Q/"_P#T,6D_
M^!\/_P 50!T5%<[_ ,+$\+_]#%I/_@?#_P#%4?\ "Q/"_P#T,6D_^!\/_P 5
M0!T5%<[_ ,+$\+_]#%I/_@?#_P#%4?\ "Q/"_P#T,6D_^!\/_P 50!T5%<[_
M ,+$\+_]#%I/_@?#_P#%4?\ "Q/"_P#T,6D_^!\/_P 50!T5%<[_ ,+$\+_]
M#%I/_@?#_P#%4?\ "Q/"_P#T,6D_^!\/_P 50!T5%<[_ ,+$\+_]#%I/_@?#
M_P#%4?\ "Q/"_P#T,6D_^!\/_P 50!T5%<[_ ,+$\+_]#%I/_@?#_P#%4?\
M"Q/"_P#T,6D_^!\/_P 50!T5%<[_ ,+$\+_]#%I/_@?#_P#%4?\ "Q/"_P#T
M,6D_^!\/_P 50!T5%<[_ ,+$\+_]#%I/_@?#_P#%4?\ "Q/"_P#T,6D_^!\/
M_P 50!T5%<[_ ,+$\+_]#%I/_@?#_P#%4?\ "Q/"_P#T,6D_^!\/_P 50!T5
M%<[_ ,+$\+_]#%I/_@?#_P#%4?\ "Q/"_P#T,6D_^!\/_P 50!T5%<[_ ,+$
M\+_]#%I/_@?#_P#%4?\ "Q/"_P#T,6D_^!\/_P 50!T5%<[_ ,+$\+_]#%I/
M_@?#_P#%4?\ "Q/"_P#T,6D_^!\/_P 50!T5%<[_ ,+$\+_]#%I/_@?#_P#%
M4?\ "Q/"_P#T,6D_^!\/_P 50!T5%<[_ ,+$\+_]#%I/_@?#_P#%4?\ "Q/"
M_P#T,6D_^!\/_P 50!T5%<[_ ,+$\+_]#%I/_@?#_P#%4?\ "Q/"_P#T,6D_
M^!\/_P 50!T5%<[_ ,+$\+_]#%I/_@?#_P#%4?\ "Q/"_P#T,6D_^!\/_P 5
M0!T5%<[_ ,+$\+_]#%I/_@?#_P#%4?\ "Q/"_P#T,6D_^!\/_P 50!T5%<[_
M ,+$\+_]#%I/_@?#_P#%4?\ "Q/"_P#T,6D_^!\/_P 50!T5%<[_ ,+$\+_]
M#%I/_@?#_P#%4?\ "Q/"_P#T,6D_^!\/_P 50!T5%<[_ ,+$\+_]#%I/_@?#
M_P#%4?\ "Q/"_P#T,6D_^!\/_P 50!T5%<[_ ,+$\+_]#%I/_@?#_P#%4?\
M"Q/"_P#T,6D_^!\/_P 50!T5%<[_ ,+$\+_]#%I/_@?#_P#%4?\ "Q/"_P#T
M,6D_^!\/_P 50!T5%<]_PL+PP?\ F8M)Q_U_Q?\ Q520>.O#MUN\C7=-G"]3
M%>1MCZX:@#=HHHH *:P# CUIU)0!SW_"!^'V;+>'])(9B[[K-"2Q[]*D'@/P
MV!C_ (1[2A_VY1?_ !-;M+0!A?\ "!^&_P#H7]*_\ HO_B:/^$#\-_\ 0OZ5
M_P" 47_Q-;M% &%_P@?AO_H7]*_\ HO_ (FC_A _#?\ T+^E?^ 47_Q-;M%
M&%_P@?AO_H7]*_\  *+_ .)H_P"$#\-_]"_I7_@%%_\ $UNT4 87_"!^&_\
MH7]*_P# *+_XFC_A _#?_0OZ5_X!1?\ Q-;M% &%_P ('X;_ .A?TK_P"B_^
M)H_X0/PW_P!"_I7_ (!1?_$UNT4 87_"!^&_^A?TK_P"B_\ B:/^$#\-_P#0
MOZ5_X!1?_$UNT4 87_"!^&_^A?TK_P  HO\ XFC_ (0/PW_T+^E?^ 47_P 3
M6[10!A?\('X;_P"A?TK_ , HO_B:/^$#\-_]"_I7_@%%_P#$UNT4 87_  @?
MAO\ Z%_2O_ *+_XFC_A _#?_ $+^E?\ @%%_\36[10!A?\('X;_Z%_2O_ *+
M_P")H_X0/PW_ -"_I7_@%%_\36[10!A?\('X;_Z%_2O_  "B_P#B:/\ A _#
M?_0OZ5_X!1?_ !-;M% &%_P@?AO_ *%_2O\ P"B_^)H_X0/PW_T+^E?^ 47_
M ,36[10!A?\ "!^&_P#H7]*_\ HO_B:/^$#\-_\ 0OZ5_P" 47_Q-;M% &%_
MP@?AO_H7]*_\ HO_ (FC_A _#?\ T+^E?^ 47_Q-;M% &%_P@?AO_H7]*_\
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M]"_I7_@%%_\ $UNT4 87_"!^&_\ H7]*_P# *+_XFC_A _#?_0OZ5_X!1?\
MQ-;M% &%_P ('X;_ .A?TK_P"B_^)H_X0/PW_P!"_I7_ (!1?_$UNT4 87_"
M!^&_^A?TK_P"B_\ B:/^$#\-_P#0OZ5_X!1?_$UNT4 87_"!^&_^A?TK_P
MHO\ XFC_ (0/PW_T+^E?^ 47_P 36[10!A?\('X;_P"A?TK_ , HO_B:/^$#
M\-_]"_I7_@%%_P#$UNT4 87_  @?AO\ Z%_2O_ *+_XFC_A _#?_ $+^E?\
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M7_Q-;B]*6@#"_P"$#\-_]"_I7_@%%_\ $T?\('X;_P"A?TK_ , HO_B:W:*
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M31_P@?AO_H7]*_\  *+_ .)K=HH PO\ A _#?_0OZ5_X!1?_ !-'_"!^&_\
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M !-:JW7!+(R@ 9R/\_GTH6X9C@JRG'<>YP?TSUXR,T 97_"!^&_^A?TK_P
MHO\ XFC_ (0/PW_T+^E?^ 47_P 36J;Q1%Y@#%<^PXSR>>W7GT%8%K\2O"MY
MXPOO"5OXCTJ?Q581">[T.*]B:^@BPA$CP!MZJ1+&=Q&,.O/- %K_ (0/PW_T
M+^E?^ 47_P 31_P@?AO_ *%_2O\ P"B_^)JMXR^)?A3X=:;#J'BWQ)I/A:PF
MF6WCN]:OHK.&24J6"*\C*K,0K' /\)K=2\#K&^&6-U#ABI QUYR..W7U[4 9
M?_"!^&_^A?TK_P  HO\ XFC_ (0/PW_T+^E?^ 47_P 36F;U5W<[BH).,8!&
M,CK[_08Y-/>XV,00>N%&1\W?CG_.* ,G_A _#?\ T+^E?^ 47_Q-'_"!^&_^
MA?TK_P  HO\ XFM9K@KT5F ],>W^/Z&E\XXSM8]<8[XH R/^$#\-_P#0OZ5_
MX!1?_$T?\('X;_Z%_2O_  "B_P#B:UWG$9&X$+C)8D #I_\ 7_(TC7"JI+MY
M6./GP/6@#)_X0/PW_P!"_I7_ (!1?_$T?\('X;_Z%_2O_ *+_P")K6%P.<G9
MS@!CWKP7X2?MJ>"_C/\ '7QG\*-$TCQ#:>(O"@O#>W.HVT$=I)]FNDMI/*99
MF<Y=P1N1?E!)VGB@#V3_ (0/PW_T+^E?^ 47_P 31_P@?AO_ *%_2O\ P"B_
M^)K76X#8X(ZX].N!S[TD=TLG3IQR>G)P/K0!D_\ "!^&_P#H7]*_\ HO_B:/
M^$#\-_\ 0OZ5_P" 47_Q-:PNE*DGY !GY_E/OUI4N%8A3\KGG:2,B@#(_P"$
M#\-_]"_I7_@%%_\ $T?\('X;_P"A?TK_ , HO_B:W*6@#"_X0/PW_P!"_I7_
M (!1?_$T?\('X;_Z%_2O_ *+_P")K=HH PO^$#\-_P#0OZ5_X!1?_$T?\('X
M;_Z%_2O_  "B_P#B:W:* ,+_ (0/PW_T+^E?^ 47_P 31_P@?AO_ *%_2O\
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M]"_I7_@%%_\ $T?\('X;_P"A?TK_ , HO_B:W:* ,+_A _#?_0OZ5_X!1?\
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MA^= %BBOG[]E?]M3P5^UXWB8>#M+\0:?_P (^+4W9UNV@B#>?YVS9Y4TN?\
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MBK*D4\2RH'"LRA@K#< Q /0GC(!TM%0"XW8VAB<9QC\,4&Z4*QSC:,GOC/\
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M>G-;_A?Q?IOC3PUHWB#1IVO=(UBSBU"QN1&R":"1 \;[6 9<JRG# $9Y P<
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MX6T3Q%HMQ]MT?6+2*^LKGRY(_-@DC$D;['&X;E(/S@-SS@\4 =&.E+2+TI:
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MP0QF.:3./(?.<=L9[>]K-N"\'WP.G'^>E $U%0K-N;&".<?Y_P ]ZE4[ES0
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M_##P9^SO\;/#6DS7L-M-JVM^#_*B:>5U1[V]F$N/1G?;A$0*BJJJ%^VE^Z*
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MKS01*V<?*3@KUK]6W;RXV;&=HS@$=OKBO@+XP*S?\%A/@<X1RH\'70+!2/\
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MTD;C$H?$@"_15KX3\!_L_?\ !/W0Y_'/P/\ %VN>#_$/C)+W7O"_B*Z;^U-
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M.>>>HYQ7R1\)/@GXK^/'_!,[Q/:>$=/76=9T3XF2:Y<:7$S?:+N%-+BC=($
M^>4&<,$R"PC8+EMJL ?4FK?MI_M.?!\:?X^^)_P)T[1?A#<7<7VI--;?J]G:
M3;S&T@^TD)(A9-WFPPJSD1GR6D&W[Y\)^,-,\;>&-&\0Z+<->Z/K%G!?V5R(
MV02P31B2-]K ,N58'# 'G'7BOQ7U;XQ_#OXS>!X_"6G:K^U#\1?$VHP0E_!M
MWXJMKNPNI4*S2KN\B5W6-4>17^S#/DJQ5/F9?V7^'?@RS^'O@7PSX3TN6XFT
MK0M.M].M9;L#SFC@C2-3)@*"Y R<*.><#B@#K%R5&>M+2"EH **** "BBB@
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MO'_^%U:]_P!$\U+_ +^-_P#&:/\ A=6O?]$\U+_OXW_QF@#V#>/?\C1O'O\
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M .%U:]_T3S4O^_C?_&:/^%U:]_T3S4O^_C?_ !F@#V#>/?\ (T;Q[_D:\?\
M^%U:]_T3S4O^_C?_ !FC_A=6O?\ 1/-2_P"_C?\ QF@#V#>/?\C1O'O^1KQ_
M_A=6O?\ 1/-2_P"_C?\ QFC_ (75KW_1/-2_[^-_\9H ]@WCW_(T;Q[_ )&O
M'_\ A=6O?]$\U+_OXW_QFC_A=6O?]$\U+_OXW_QF@#V#>/?\C1O'O^1KQ_\
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MO?\ 1/-2_P"_C?\ QFC_ (75KW_1/-2_[^-_\9H ]@WCW_(T;Q[_ )&O'_\
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M /PNK7O^B>:E_P!_&_\ C-'_  NK7O\ HGFI?]_&_P#C- 'L&\>_Y&C>/?\
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MX]_R-(6ZX_E7D'_"ZM>_Z)YJ7_?QO_C-*OQH\0,P5/AYJ1+' _>/C/\ WYH
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M_C?_ !F@#UYB&!'//IP:YB\\;V-CXVL?#;QS->W41E1XV4Q!<.?F);.[]V_
M!ZBN';XUZ\JDGX?:DB]2PD?@?A#]?RKBM9^(NJR?%G1];E\-7-G=V]F8%TYY
M#OG!$OW<H#D^8O;UX/&0#Z5W#T)/?@U5%N4W-U<DDN,AFQT!X^E>5?\ "ZM>
M_P"B>:C_ -]O_P#&:/\ A=>O?]$\U+_OX_\ \9H ]6$3?O%D2-D8DGY>O/ /
M'I@4Y86&-_S?-N)P?P_D/RKR?_A=6N_]$\U+_OXW_P 9H_X75KO_ $3S4?\
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M.  .1_DT>1ZEEYS\G&>N>,<9R:\I/QJUX\'X>:D1_P!='_\ C-'_  NK7O\
MHGFI?]_&_P#C- 'K A_?%S\N1AMHY;T)..O7\Z:L++M+-DA<,=G7@Y[=^./:
MO*?^%U:[_P!$\U+_ +^-_P#&:/\ A=6N_P#1/-2_[^-_\9H ]96,+TR#R,@'
M//7]:2.(JN#NR,>IZ'CD\GCUKR?_ (75KW_1/-2_[^-_\9H_X75KW_1/-2_[
M^-_\9H ]@# <<_D:-X]_R->/_P#"ZM>_Z)YJ7_?QO_C-'_"ZM>_Z)YJ7_?QO
M_C- 'L&\>_Y&C>/?\C7C_P#PNK7O^B>:E_W\;_XS1_PNK7O^B>:E_P!_&_\
MC- 'L&\>_P"1HWCW_(UX_P#\+JU[_HGFI?\ ?QO_ (S1_P +JU[_ *)YJ7_?
MQO\ XS0![!O'O^1HWCW_ "->/_\ "ZM>_P"B>:E_W\;_ .,T?\+JU[_HGFI?
M]_&_^,T >P;Q[_D:-X]_R->/_P#"ZM>_Z)YJ7_?QO_C-'_"ZM>_Z)YJ7_?QO
M_C- 'L&\>_Y&C>/?\C7C_P#PNK7O^B>:E_W\;_XS1_PNK7O^B>:E_P!_&_\
MC- 'L&\>_P"1HWCW_(UX_P#\+JU[_HGFI?\ ?QO_ (S1_P +JU[_ *)YJ7_?
MQO\ XS0![!O'O^1HWCW_ "->/_\ "ZM>_P"B>:E_W\;_ .,T?\+JU[_HGFI?
M]_&_^,T >P;Q[_D:-X]_R->/_P#"ZM>_Z)YJ7_?QO_C-'_"ZM>_Z)YJ7_?QO
M_C- 'L&\>_Y&C>/?\C7C_P#PNK7O^B>:E_W\;_XS1_PNK7O^B>:E_P!_&_\
MC- 'L&\>_P"1HWCW_(UX_P#\+JU[_HGFI?\ ?QO_ (S1_P +JU[_ *)YJ7_?
MQO\ XS0![!O'O^1HWCW_ "->/_\ "ZM>_P"B>:E_W\;_ .,T?\+JU[_HGFI?
M]_&_^,T >P;Q[_D:-X]_R->/_P#"ZM>_Z)YJ7_?QO_C-'_"ZM>_Z)YJ7_?QO
M_C- 'L&\>_Y&C>/?\C7C_P#PNK7O^B>:E_W\;_XS1_PNK7O^B>:E_P!_&_\
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M/Y"CG^\?R%+M%&T4 )S_ 'C^0HY_O'\A2[11M% "<_WC^0HY_O'\A2[11M%
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MEBTI9>,^P_&@#V7G^\WY#_"DY_O'\A2[1]:-HH 3G^\?R%'/]X_D*7:*-HH
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M*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HI=F[  Y/
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M]AF@!^T4;100NYE4J[*0"JYYR<8'KSCIG&>:;\VW.SC&<[AC&.>A/3O_ )-
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M<O\ \=H^JS#ZQ ^E<?[+?]\G_"C'^RW_ 'R?\*^:O^&E/$W_ #Y:7_W[E_\
MCM'_  TIXF_Y\M+_ ._<O_QVCZK,/K$#Z5Q_LM_WR?\ "C'^RW_?)_PKYJ_X
M:4\3?\^6E_\ ?N7_ ..T?\-*>)O^?+2_^_<O_P =H^JS#ZQ ^E&7Y3\C?783
M_3K7.:AX1>^\=:9XH2]:+[+;&U>".VRCY$@Y/8_.*\-;]I/Q,RL/L6E@D?\
M/.7_ ..U!/\ M'^+9K^*5?L%O;*FUK6.WRK\=268L/J#FCZI,7UBF?3O7^%O
MR/\ A1C_ &6_[Y/^%?-?_#2GB;_GQTL?6.;_ ..TG_#2GB;_ )\M+_[]R_\
MQVCZI,?UB!]*X_V6_P"^3_A1C_9;_OD_X5\U?\-*>)O^?+2_^_<O_P =H_X:
M4\3?\^6E_P#?N7_X[1]5F'UB!]*X_P!EO^^3_A1C_9;_ +Y/^%?-7_#2GB;_
M )\M+_[]R_\ QVC_ (:4\3?\^6E_]^Y?_CM'U68?6('TKC_9;_OD_P"%&/\
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MBW6O#%MH/A">XSX?D4%)I+<,P:1\Y#=5!/'L<<CW.'7M%FG@ACU+3'DN$\V
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MJ(UCIWA;QAY,ETTEV8U2*\?;<-.\H;!6XB>X)4[<1[25!8#[Z6(QX9'#2;5
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M"[NB_P [1)=EF"!,JW3)_A8=>BT'X?GPW;V5C9Z_JRZ'9;?L^E2R(\**"65
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MH/JK/A/;_LM^1_PHV_[+?D?\*^[/(7WH\A?>CZ^@^JL^$]O^RWY'_"E6,D\
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MY/RM@XY&W  [#-)M Z#%&.G^-(FVH,H;ALD'@\XXIK(K*H*Y97+H\AW!<C!
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MR\Y &0<\^_2L"/P38Q>-X_%4+2+J:Z?_ &<L?RB-8_-,FX!5!RI( &>F<YH
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M8Z]*7:*1L;3V- 'D'[0DLC+X>4L=LBSN%BD ."L?!'<]:]>CWK @.#"NU?\
M:W8#9^F!61XA?0%DMUUI]/5U0FW^T!?,X$8PN2#GGBM@X5E4%2H!&Y>AQ@<?
M7- "X%&T48%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&
MT4 &T4;11M%&T4 &T4;11M%&T4 )M!XXY[,<"O-]:F<?';P^0[*[6#K^]<%@
MNR?A?;Y?UKTI<*RD@'GH>_YUE.=&35H5FDL3K#*#"T@42A=K9 Y_WOS% &IM
MHVBC _R:-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
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M_>C^Q;?WH P-R^M&Y?6M_P#L6W]Z/[%M_>@# W+ZT;E]:W_[%M_>C^Q;?WH
MP-R^M&Y?6M_^Q;?WH_L6W]Z ,#<OK1N7UK?_ +%M_>C^Q;?WH P-R^M&Y?6M
M_P#L6W]Z/[%M_>@# W+ZT;E]:W_[%M_>C^Q;?WH P-R^M&Y?6M_^Q;?WH_L6
MW]Z ,#<OK1N7UK?_ +%M_>C^Q;?WH P-R^M&Y?6M_P#L6W]Z/[%M_>@# W+Z
MT;E]:W_[%M_>C^Q;?WH P-R^M&Y?6M_^Q;?WH_L6W]Z ,#<OK1N7UK?_ +%M
M_>C^Q;?WH P-R^M&Y?6M_P#L6W]Z/[%M_>@# W+ZT;E]:W_[%M_>C^Q;?WH
MP-R^M&Y?6M_^Q;?WH_L6W]Z ,#<OK1N7UK?_ +%M_>C^Q;?WH P-R^M&Y?6M
M_P#L6W]Z/[%M_>@# W+ZT;E]:W_[%M_>C^Q;?WH P-R^M&Y?6M_^Q;?WH_L6
MW]Z ,#<OK1N7UK?_ +%M_>C^Q;?WH P-R^M&Y?6M_P#L6W]Z/[%M_>@# W+Z
MT;E]:W_[%M_>C^Q;?WH P-R^M&Y?6M_^Q;?WH_L6W]Z ,#<OK1N7UK?_ +%M
M_>C^Q;?WH P-R^M&Y?6M_P#L6W]Z/[%M_>@# W+ZT;E]:W_[%M_>C^Q;?WH
MP-R^M&Y?6M_^Q;?WH_L6W]Z ,#<OK1N7UK?_ +%M_>C^Q;?WH P-R^M&Y?6M
M_P#L6W]Z/[%M_>@# W+ZT;E]:W_[%M_>C^Q;?WH P-R^M&Y?6M_^Q;?WH_L6
MW]Z ,#<OK1\A.&/R]\5O_P!BV_O0=%MP,C(H ^?OV@C*T?AN)4D7$5PSRA@F
M.8\8^4GT]*]A*Q;C$C@QKMV-ZD;2:=XH^'NA^*FB_M2W+F$$1,9B,9*DX'_
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M^] &%&R[URP SS7CG[/<:QV^O>:H1W:V<2,H)+9D8]!QU'Y5[[-H=NT+C:S
MC&T'!/T-8N@?#O1/"<LSZ;#):M<$>8WG$AL= <]>#VH ;N7N:-R^M;XT6W],
M?04?V+;^] &!N7UHW+ZUO_V+;^]']BV_O0!@;E]:-R^M;_\ 8MO[T?V+;^]
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *:QPISTQ3J1E# @]^* /$_VC-<U/0Y-#;3;^>S$RSJZQ
M7+QAV#0[1M!PPQNX/K[U[+N"S1?,I# ]>IZ=*X3XI_#$_$C^S\W_ -D2R,A"
M^2'+EMN!GM]WKVS[5W<*!=B;3@+\I;J/:@"<=*6DI: "BBB@ HHHH **** "
MBBB@ HHHH **** &29VL!UQ7EVO:K>Q_'CP[81WTR6#V1>:V2<K&[!;GDKGD
MY5>OI7J3KN4@G (Z@XKB]2\!M?\ Q*TSQ4MX86L[8VQM3$&$JXD^;=V/[T?E
M0!VJ_=%+2"EH **** "BBB@ HHHH **** "BBB@ HHHH *:W0_2G4C=#0!Y;
MX?U:\D^.VOZ=)?3/90V*R16LERS!25@R0F>.2?SKU(=*XO3? 9T_XC:EXI:\
M,\MY;+;B#R @11Y8SO[GY/UKM%Z4 +1110 4444 %%%% !1110 4444 %%%%
M !1110!'+RCCD<'D9ST]J\6_9W\0:CKC>(/MVIWE^87A6/[5,\JH#OR ">#\
MM>U-WKSWX8_#!OAW+J6[4$U%;UHI"OD"-D92^>=QR/G'Y4 >B"EI%^Z*6@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH 9)G:P'7%>7:]JM['\>/#MA'?
M3)8/9%YK9)RL;L%N>2N>3E5Z^E>I.NY2"< CJ#BN+U+P&U_\2M,\5+>&%K.V
M-L;4Q!A*N)/FW=C^]'Y4 =JOW12T@I: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** $I:** $J-OZU)4;?UH \
MP^./WO 7_8U6/_L]>I#^&O+?CC][P%_V-5C_ .SUZD/X:VE_#A\SCI_QJGR%
M7I2TB]*6L3L"BBB@ HI.<TM !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1133G=UX]* '45R=Q\5/!UI=2V\_BS0[>XA<QR0S:C"CHPS
MP06!'0_E[&M71_%6D^)+8W&CZE9ZI;*QC:>SN(Y45\ [25;&>1Q0!KT5!]I#
M*=OS8;:>1U!QCK2^?R!AL$X! SGC.: )J*A682,RC@KU!QZTOG#KAASCE3DT
M 2T5!]H!SM!;!Q\M9?AOQAI?C#0[76='N&O--NMQAF\IHR^UF5OE<!A@JW4=
MJ -NBHFF"J"3P>_^?P_.FQW(D''W@<$?SZ4 3T5!]H&<#)]\<#!P>?S_ "I/
MM7 /EOCOQD@>N/\ /Z&@"Q15<72MR,G&,@ Y!..#Z=>_]#572_$&GZY8QWNF
MWUOJ-D^=MU:RK)$<$J<,"0>01QT(.: -*BH%N VY>C+G(XR/PS3_ ##N*@$D
M<\4 24576Z#,P'0'&3P.W\\_I3TF#9YY'49Y'M]: ):*C:3:I/7 SBJ5OKEC
M>:A>6%O>V\]]9>7]JM8ID:6#>"5WJ#E<@9&1R!Q0!HT4@Z4M !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2&EI*
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M]12_:!O"'(8\#.,G'?Z?XT 345CZWXKTCPS8)>ZQJEEI%H[^6EQ?W*01LQY
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MV^$2>=Y0;Y.HVY)'S=J;XD^'J^(?'7A'Q&U]Y0T%+L?9?*#"Y,\:QDEL@@@
MD8H X'XA_%C5/A_I=W<3^)/#%[J=D\(GT&UAD2ZN(S(L;%&,Y,;$,9,>6_EC
M"DN%WMTOC[QQKVB>./ ^@Z1;Z>!KWVU)9M0C=O(\F(2!AM89QS\N</TW)D,,
M'Q)\ ]6U;3?$VE:=XNBTO2M=U9M8E633/M-PDK!2R"0S*/+$B*X 0$%1R1D5
MV_B'X?G7/'/A3Q#]L6!-!-T?LWE;C/YT7EX+Y^51][&#SQ0!PQ^+^NVGPO\
M'.O_ -F6^IZOX;U*YTXQP[XXKAHY$ FV%V,:+&^XKO.=I.Y00:WM%^(4S^ -
M;\3QZCI/BNSL;%[R.;287M2[+%YC0R1,\C1MC:V2V<28*#:-][PW\-KOPG9>
M*([36V6YUK6I]:2Z\G_4ERA6%E+'>F5P=K(2I(!4_-7G_P 0/ ][\/?A_P#$
MOQ)%,FI:OJQM[J6/3;9;2V&QPK9C?SMRG<[S*Q(D#,,+EB0#5^'WQ%\3>)/'
M&AZ3=W.DG3=0\.1^(G^QV;+*OF/L2($S.H5>"7 .XYX6N8^!?C:_T+PG\)-
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M_-U7L?KZ_C0!Y%\9M0U;7/%/@GPMH2I-J,E\FN7</V@QQB"U(=%F*QN5CDD
M"OV=$XSTA\/C4_"7QRNY-6M]/M6\961,4-I<2W/[^R5%V[OL\81624G#EO\
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M.F:2=1M-/N6O/M$;7AD"NJQ.K*"J-SF5<9P.O->9+^RCXLDZ:AHI&>OGS?\
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M856\M>/-B=8I S;1G*?.,$'ZU@?%3Q1]IU8Z1X<M%O\ 7;N9DG^S?,(XV8!
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M+_V1>2:_901W$6JRRV_D3P*4A9#$C;HMK-E.#GD/SQZCM%(%"YP,4 >/:O\
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M[V-<Q]HN/^>\GY4?:+C_ )[R?E0!T^[V-&[V-<Q]HN/^>\GY4?:+C_GO)^5
M'3[O8T;O8US'VBX_Y[R?E1]HN/\ GO)^5 '3[O8T;O8US'VBX_Y[R?E1]HN/
M^>\GY4 =/N]C1N]C7,?:+C_GO)^5'VBX_P">\GY4 =/N]C1N]C7,?:+C_GO)
M^5'VBX_Y[R?E0!T^[V-(6/I7,_:+C_GO)^5)]JG)P;F0=B/\F@"GIO@4Z?\
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M>QKF/M%Q_P ]Y/RH^T7'_/>3\J .GW>QHW>QKF/M%Q_SWD_*C[1<?\]Y/RH
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M#SSXH-X+TCQ18W>L^)-2\/:A*@DECTFXFA-TB$*//\E20O!4'*D\@$XP.?\
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M0 ;1Z4;1Z4;11M% !M'I1M'I1M%&T4 &T>E&T>E&T4;10 ;1Z4;1Z4;11M%
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M -H]*-H]*-HHVB@ VCTHVCTHVBC:* #:/2C:/2C:*-HH -H]*-H]*-HHVB@
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M%;MK8PZ?#;V]K%%:6=NHBC@@C"1H I5=H'RIS_"!QD@=3F;:.*-H].V/P]*
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MBC:*+, VBC:*-HHVBBS -HHVBC:*-HHLP#:*-HHVBC:*+, VBC:*-HHVBBS
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M%VYR1V('#^,H?%33^.=6TK7;7P[8Z,HD^SV]C%(]U*EG',[22/P.&6,-_=4
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MT4;11M% !M%"KG@#+'WHVBA<*P)&1F@#R]MP_:,DF8&*'_A$\^<WS ?Z8<<
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MP\M_^$7\._%;6+*6[?4[#5-6\B"ZN))5D\M5D3>A?:200&<_-C(W4[Q%-?\
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MU5TVC[._X6!X7_Z&+2?_  .B_P#BZ/\ A8'A?_H8M)_\#HO_ (JOC#KWD/\
MP+_ZU'XR?]]?_6KI^I1_F,?K3['V?_PL#PO_ -#%I/\ X'1?_%4?\+ \+_\
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M6/7\^:Z;K=CM."#^^Z^U>OLNY2 GF-@_+C)/L*JVN@Z?IBN=/L;>U#?.\EM
M@9OF<!6('^<F@"YBC:*"H!(HVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HH
MVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@!"/;C'<X%
M><:Y))'\>O#H$FR5M/;_ %C@MMV3\+_WS^M>C[>N ">FT\C\:JOI]HVHI=/;
M6\FH1JJ)(R!9E4JV<>W+4 6U3=@*I8]@.M-9MJLQ7A3AB3M _/WXH?:L;%G\
MM0,EMV-H]<]J\A\8ZU8P_&Z/3]?\17&CZ.WAOSXX_P"V9;.)I/M07>"K+N;
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M !/\/Y/A+IOCFR\6>*OA1IWAQ(M5C\/WDJS#5"K%Y)GC^8KC!'(R/K1[2?\
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MW<!!SV^F?3GL=+T^/1=+L["RAALK>TB2"WBMU$:0QJ@7:J* BXP<;5 Q@!0
M !U(L2@T?G+^W?\ '3P1\9#X'N/!^L?VVFGF_6X4VTT!4NML$ \U%#;MC8"[
MLXK[*TKXC^"/VF/ _C7P]X.\31WOF:>^FW=U]CE46QNHI8HWQ*$$@(!8*&Y
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M(-'%$LAE<@,!R7)P"2=S<YQGOM0T&SU:33VO+6&Z73KD7-K%-'O59%5U5\<
M-A@<= 5R "*ORJ95"L"RCID\ >H&W@_C0!YM#X#U2^\3?%$7.-/T[Q%;6MM9
M:F?+D'RV[122*@/)0MNY R%ZUAW'AGQEJF@_#[1U\,F"30-4M)+O-_&87C@8
MQB2,;@70JCM\P1@I10#DE?9?*C^7*(V"#PO+8]>3_+GO2?9HI&(DB5XB=VPJ
M&*GU#=0>!^9H XE?#.H2?'-/$D]MY>BR>'$M&O-ZE3.;EG5&Z$E0P/ ZG/&.
M>3TCPOXJ\+_"^\\#Q:$=0F9+NP@UG[5##:"&9FQ<LH?>I199"41&R% !YX]A
M6",,7,<;L1@\$+SP0!].]*(4W-M5(T).U552%/;J/I0!YI/\/M6TGQ-\+!80
MF_L?#-G=V]W<;5B1";58DR@;.3M.%^88(&<'B&]\!ZR^M?%N>*RE:#7;&"WT
MMFN$(NI$MG3C+#;AV P2HQGD#BO3_L\6!B./;LQM(S\^>6SGK3FAC((PJ_[:
M( QQS],#TH \7@^'6J:3<>$M7EL-0U-(?#=OHM_INFWIM+B!T42+(KB5$D4E
M=C+N4 JC?,>*]#\!^';/P[8Z@EKI+:''>7;7,D4EVUQ<3RNJ!Y7;S) I.P+M
M#,"!G=R5KJ&,C*0KM$^<B1,%B<Y.<KCKZ=LTUL,%W1J7[R<*3]< 4 .QZCF@
M*&8#.,G'\O\ &DP*&7*GZ4 >,?M%2,]OH8V(JW,%PN[[0$)8>7C*YR1]*Y!O
MV:?$JLQ^WZ00 "#YTO.<8_Y9^]>Z>,O =CXV^RB\N+J&*S5S&L?^K.[RCS\I
MXXYKH"BKLC7_ %:[L?@1C^5;TZTJ>QE.G&>Y\V?\,S^)_P#G_P!)/_;:7_XW
M1_PS/XF_Y_M)_P"_TO\ \;KZ6HK;ZU/LB/J\#YI_X9G\3?\ /]I/_?Z7_P"-
MT?\ #,_B;_G^TG_O]+_\;KZ6HH^M3[(/J\#YI_X9G\3?\_VD_P#?Z7_XW1_P
MS/XF_P"?[2?^_P!+_P#&Z^EJ*/K4^R#ZO ^:?^&9_$W_ #_:3_W^E_\ C='_
M  S/XF_Y_M)_[_2__&Z^EJ*/K4^R#ZO ^:?^&9_$W_/]I/\ W^E_^-T?\,S^
M)O\ G^TG_O\ 2_\ QNOI:BCZU/L@^KP/FG_AF?Q-_P _VD_]_I?_ (W1_P ,
MS^)O^?[2?^_TO_QNOI:BCZU/L@^KP/FG_AF?Q-_S_:3_ -_I?_C='_#,_B;_
M )_M)_[_ $O_ ,;KZ6HH^M3[(/J\#YI7]F?Q/N_X_P#21_VVE_\ C=85Q\%]
M<@\56'A]KG3S>WD#3(ZSMY:JH8G<2N?X#T!KZT7)88&3G\?PZU@W'@^ROO%E
MIXE-Q<B\LXA;A8P-G*OD'@'N/UH^M3[(/J\#P;_AF?Q/_P _VD?A-+_\;H_X
M9G\3?\_VD_\ ?Z7_ .-U]+=..:*/K4^R#ZO ^:?^&9_$W_/]I/\ W^E_^-T?
M\,S^)O\ G^TG_O\ 2_\ QNOI:BCZU/L@^KP/FG_AF?Q-_P _VD_]_I?_ (W1
M_P ,S^)O^?[2?^_TO_QNOI:BCZU/L@^KP/FG_AF?Q-_S_:3_ -_I?_C='_#,
M_B;_ )_M)_[_ $O_ ,;KZ6HH^M3[(/J\#YH;]FCQ,HS]OTG/_7:7_P"-UY[X
ML\+W/@[7KO2;QX7N+9E#- Q*'<H88) /1AVK[7<[58X+'!.!R3@9Z5\K_&.P
MGUKXN:Q96,3WMQ++#&D<(+%C]G!]/]D@^AQVR:ZJ&(<G[QA5HJ*]T\X+(&P6
MQZ<&K.G:7=:S>+9V5M)>W3C(MX/F<CU^GJ>W?'6O8?!/[.>HW42W7B"\DL+9
MCQ;P;2^/?.0/K7MWAOP?H_A'3S:Z5IL%I&S;I&3/F3$=&9\%B?QQZ8&!5UL5
M&#]TRIX=R^(\2\$_LXZC=1+<^(;Q["V)&+:  OCT.1Q_*O;?#7A'2/"%C]DT
MFPAL4+ O+&N9)"#D,SG)8_4X]!BMA5\L_*H7V9B<?2EQ7F5*\JCU9Z$:48+0
M9Y?[S&]FCQ][^(G_  I9#MC8@@$#J2 ,_7/2G8[]Z3J2/H.OU_2L-]R]CSC0
M9F7XX>(H=@B@CLT"@S[BS,D62!G_ 'OSKTCAN:Q+/P?:6_B:Z\2B:Z;4+I/)
M>.4#9C"CCC_9_6MO;[8H&&T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4
M;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 'EA\*>A/^>M>-_L
M][98==E$CJH%L=Q96RY:8E>G'.*]C((!*CGMSCFN;\*> M*\#->M8W5TWVQ@
M72:8%-P>0C'R^] '2X%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;1
M1M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M%  %7(!('(
MZD>_:O-M:F,GQN\-HD2MYE@[.OG# "K-SMS_ +M>D\KR-QQS@=_IQUK!NO!]
MGJ'BZT\1M/<_;+6)8@J8V8*OP>/]K^= &\JOD!%)D!^51QS['/'-<,/#&H+\
M;F\2&V=M)D\.K:-<>8H1YC<L_E'!SD@^G>NX,8;(9?E(P>*9]G1=S*H\SG#=
M,9[ =OK0!Q7Q/\.ZAX@_X1-M-A+Q:?X@M-0NBKJ!;PQE@[\G/ ;/3L?;/$2?
M"?Q)<Z#KJFT>.[A\:3:_8P"[6W>\@"CY4E5LP,R;AY@.1G' .X>W>2@92J)A
M1E<ID[N._>FK;1*V BXSDKC/0]>: .(\(^$[>+Q)_:G_  CFJZ;=&S:U>]UK
M5?M4I19%9(443R@J2 3EAM9!@'<2%^*GAG5?%">$QIEHUVVG:_:7]SM=08XD
M+!SR>OS=/05VWV='W>9&LN?N;E"[#V(Q2M;Q,54HK(!W7YL^N: ."T7P/<S>
M.OB#)JFG)+H6NK9K \DH"7.V Q2XVMN"C=WP5'(Y K@OAW\,?%&A^'_B997M
MNMPMYIT>G:7,TD2+,(+>6&/Y/,.PL##U)&X$G%>]K"FY3M4$$'*KM8X]\\?E
MS2; [^8559 =HV@<CT)P#^% 'F=EI_BF^^&]AX5.A/I5ZVFQZ7=WVI3P"$1^
M5Y;M"(I)&9\9*JRC/ XKT/3=-@TC2[?3K-/L]E;6L=O!$A/[A$ &U3@D@X'S
M$9]C5O#KO.]M[-SR<8],$T8!&#TH \.\#_#W7]('PK^VZ<UDNBKJO]H*;F-A
M;F7>8MVQOWH;C[F<=\<UWGPK\-ZOX?F\6_VE9_9%U#Q)>7ELKR)AXW *S  G
M'&?\*[5GD&X[LG&3N52&P>.,?RQ[TQ;6!<@QJ8SPR-DAO\F@#S3Q=INN>(?$
M(L]1\,W^I>$+ )+;V>GW%L$OY P*B<231_(G\*#=N;#MC 6M'Q[X;U#QIX?T
M.>QL6M;[2=3M]432+FX13=&+>?*9XV95+;V^8G!^7.!DUW7D[6;8%C'\**H(
M0^HR#3]H=1OC!DSS*,!S[\+B@#SK3]/U2[\5:]XTGT&ZL+R+2(M)T[3KB]B\
MZZ(E:5O,*;D3,FU00Q&/O;:A\!6FMZ7J0U?6/#.J2>)[]A'<ZG))9_9;.+_G
ME"!<[EA7.YL9:0Y=LM@5Z7ND(.7;=T[#Y?J *9Y.WE68$=#O;_&@#S2:UUS4
MO&3:GK/A/5-2TK2)E_L.QM)[-H2Z\"XE+3J6D.?E0*%CXQNSFO2+5I9HU>6%
M[>1CO\EV4R)D<[MI(Z>A[5-Y8:3+GS(V7:X<%NOIEJ9Y(*8PH93QL&TX]/>@
M"3:*-HHP*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
M -HHVBC:*-HH .,CTI-NV/Y3\^[HPXQ[4NT48HZ:JX:JUG8-TB,61_\ @+\B
MO/\ XO\ P9TCXP>'8[&^1(+^V+&SNM@8Q$CD-GJI]Z] Q1@CD<'L:NG4E2J*
M<-#/D4H\LMCY@^&_@OXE_#WS/#>H6*^(="$K)%<)=@-;(4*;E<\D#.=G3CBO
M1Y_A'/XN\2-K'B2Z62WW>8EE;E@$/&X'(Z' _6O61))D,Q!8'A@ .?3I3%W;
MRY523P4'2NZ6+J.;J125]['+/"1E!1D[I=#S6"ZO/ >M?Z1&S:9)B)/+'RX/
M ..,8KT*RU"WU"V6>"0,K<;0VXK]<=J75-.M]8M_*N8_-7& N<;?H:R]/\)Q
MZ;(6MKZ\MU/\ D##]5KXNEA\9@Z[L^>$G?5ZGT=:KAL133^&2[&S/&LL4D>0
MVY2-N,Y_"O!/V3OV==3^!/AWQCI>MZA#K0US5Y;Y?(0JB1$X7)('S%2>,$?7
MK7N3:?+M.+^<=Q^[BX/K]RAM/N#'M&J7 R.<1P__ !->]S5%O$X%&%M)'RW\
M*_V0]>^$OB+XM66CZY%!X!\665RMAI.UMUI.X C)&W#*BF1>"=P90<;:]3_9
ME^&-U\"?@?HOA77]6M)[G2Q/)=7D*^7 JL\CEMQP0 IR20,8_&O4FL[I@H.J
M7)"G(_=1<GW^2H=1T&/6M/N;'4I6N;&ZB>">W>*/9)&RE64_)T()%/GG_*)Q
MCW/SZ\2>!?#_ ,7O^"B>@_\ "*:I'J6DK;P>(];CMI5DMUN;8,$#%21DC;UY
M.WWKZ6^,WPB^);?%.U\>?#/Q-;6<[:?_ &;?>'==BDETZX02%E?";L/SS\M=
M]\.?@+X(^$ZZ@WA#0;3P_->R;KB>SAC,D@SD98ID >G3BNWCL+I6(;4KET/]
MZ.+_ .(HYY_R@HQ?4^9_A7^R+J^B^#_BLWB?5K(^+OB)'+#<MI-J8K2S5HV1
M1$#R3SR<"O-[']BWXM>(O@3+\,O$7BK13I.@-%/X;-I;.K?:$D9F:=B,L&62
M48PP!(K[@73[CYA_:ETB_P!Q8XN?_'*:VF223!FO;@(!\NT1_>]_DZ4<\_Y0
MY(?S'Q[XZ_9?^.7Q@L_!NJ>*?&OA^#5O#&H6\]GIMC8NEB0N#)(3P0^%"J F
M I/(S7K/@7X!:IX7_:M\>?%.XOK:YTWQ!ID=E';+$RS1E1%R5SM _=]B3TXK
MVDZ7(TFXWUPORY&!'][U^Y3C8W)48U2YSGG]W%_\12YY_P HN2'\Q;.S) 93
M]#2XJHEC(CJ?MLS*IY4QQ 'VX6K>T>GY&M(RD]T0XJ.S"I['[K_6H*GL?NO]
M:8CC]9^&=AXN\3ZS?VWBWQ)IEUO2QN(=,O/(CAQ$KA "AS\KE@>0#(V,,6-=
M/X/\$CPK)=M_;>L:P;@KN&K79F$>W_GG\HQ7)^,/ .CZEXJ:_NO&NL^'M4U5
M8[:.ULM72 287:$CC8')!+,,=&=B!DDGI?!/AF#PS=:G&GB#5]<E9E65-6O?
MM'DL I"J,#!(8$]_F![C/5.3Y+-G#3BN=M(P_CA]WP'_ -C78_\ L]>HKVKR
M[XX<?\(&!T_X2NQ_]GKU$?=%9R_AP^9I3_C3^1S%]_Q_-46*EOO^/YJBQ6-C
MJ#'?O2;1_G^5+M%&T4K &T'KS11M%&T4] #:/3/UH"A<8XHVBC:*-M@$"A>G
M%+M&<]Z-HHVBC?< Q_G/^>:*-HHVB@ Q1M%&T4;10 ;11M%&T4;10 ;11M%&
MT4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;1395'E-N7>,<+_P#K
M[T[:*1LJI*?> .,>N.* ,KQ%X>TWQ%'I[:C:^>EC<1WT&QRJQRKO=2=I&>H'
M2N=^+'@J7X@V.C:>EC;ZA!%J\37+.[Q[8 I:0JRD9)4%!QCYV)&0&KHIO$R1
M>-/["M@TJ+8&^E<QG8@,OEHN3U+$/@8.?+:LG2_B);>([J7[!IFHW>B?:GL(
M]<AB46DC@[<I\WF.N[*%U0KD$YV L #,^+7@^]\96OABUM;!=5M+?7;:[OXY
MG!VVREO,#!F.[&]AC^[QUKIM#\&Z5X;FO)+!)!)>R))=32N\LL[*FU=TC.7V
M =$S@=L5E:QX\M=/\8)X=AT6_P!5OA9?;B;58  GF&/.Z66/+!QCC/4=>E0_
M\+8T1M(T._"79_M75(]'^S+&/.M+M\GRIUS\C+M.0-Q.<@&@"[IOPYT/1I(&
ML+>>WA@+216ZWDYMHWSN^6#S#&!OPZ@+\C#*X/-;VJ:7;:Q:FUN@[I][S Q$
M@;U5\[E([,""."#7+0?%;1KCXE7?@DV]ZFKP!&\QH@UN[-$)@@96)!\LLV'"
M_<;&3@&Q/\1--M;CQ=;O;W?F>&84GO $0F17B,J^7\WS'"D<X&?6@"[H?@K2
MM!U674((;F:[DA\AKB_OI[N18QR(T:5W*)DYP/E.<$=ZW#@*#@G S[GBN4E^
M)&F1Z;X4NXX;JY_X25XULK>'RS*$:/S6E<%P B#AR"=O/4 FHKCXB8\2ZUH5
MEX>U:_OM)6%[F2 VXC7S4+H1OF5B, \XQ[T =A_<^4D,%.Y>@R">?RHP*RM2
M\2+I?B33-*,<R0:BDHC;RF8"50&",0#M)7<1NQG8V/?6P* #:*-HHVBC:* #
M:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #
M:*,"C:*-HH /YTFT>E+M%&T4 )M'7'-&T4NT4;10 4FT>GUI=HHVB@!-HI=H
M]*-HHVB@ HHVBC:* #:*-H],T;11M% ";12X%&T4;10 8HVCL,4;11M% !BC
M&*-HHVB@ Q1BC:*-HH , ]>?K11M%&T4 &T4C< ^G6EVBD9?E/&?:@#RKXXZ
MW?:4?#YL[N>U5ED615GV*Y"QC&._;\Z]363=&BX)8X?<>FW: 1GUR37)?$+P
M$_CQK'=?F 6GFOY*VI<R;MF!N ^4?+RW;(KKEW!1$%Q'N^53]Y0"#R/PH =@
M4;12 <4NT4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &
MT4;11M%&T4 &T4;11M%&T4 "_*P8;A_N\'\#ZUYYJVIWD/QDT*R6[F6SDM"7
MMXI<QE@L^"P]?NUZ$5W*<#GIP,G/KC%<[J/@]KKQ]I_B8WYMS96_V5[=;8[)
M=P<<$]_G% '1;1@=Z7:*-O SSQ1M% !M%&T4;11M% !M%&T4;11M% !M%&T4
M;11M% !C'//X'^O:JZV,$=U)=K#"EU,/WLD: /)QM +\DC'K^&.*L;1Z48II
MM; (J[3E5 ]BQ./IFC:/2EVCTHQ2W=V 8%&*-HHVB@5@VBD8[5)'4<TNT4;,
MCA23VQD^GI0,\]T?4KMOC)K6G/=3RV:VBRQPRS[T4F.$\+VY)_.O0=H]*YNP
M\(R6/C:]U\7WVA+VW*+;BUV>5M2(<OW^Z?SKI<#MTH -HHVBC:*-HH -HHVB
MC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVB
MC:*-HH :P^4D'![&O*_@5KE]K UI;V^FO_*-OL%Q<.R)GS<@ G@\"O5L'J.,
M=PN37(^!_AQ_P@1O4:\;4DN_+/ER0!3&4+@L/QD4CZ&@#K<"EVB@KR>*-HH
M-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
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M?V//Z"C^QY_05T/-'- '.MHT[@KPN[C<>U85_KEG:^,-.\,RP.+V[@:>-HE
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M^./WO 7_ &-5C_[/7J0_AK:7\.'S..G_ !JGR%'2EI%Z4M8G8%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@4 >NBEI!2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.260D[<87K0!W/A'QY9>,FUI;&*XC_LG4IM+G-PBKNFBV[]N"<K\PY-=#YX
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M +#?E6_U2'9_>9?69]CZR_X:S\)?] [6O^_$/_QVC_AK/PE_T#M:_P"_$/\
M\=KY-V_[#?E1M_V&_*CZI3[/[P^LS['UE_PUGX2_Z!VM?]^(?_CM'_#6?A+_
M *!VM?\ ?B'_ ..U\F[?]AORHV_[#?E1]4I]G]X?69]CZR_X:R\)?] [6O\
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MP)"(H; +;B,UU>*-HH \XM/@GI-GX7\+Z E]?&R\/ZI'JUI(SH9&D5W<(QV
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M.GT/^%:1J3BK)V,Y4XR=V>,']D[PH23_ &IKG_@1%_\ &J/^&3?"G_04UO\
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MNR@%F'RXVA<;>=U>[:7HMKH]O!:V5M!:6D"[8X88PBH,DX ';G^M7!&P50O
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MPEN"5.?FN)#_ #-:55%M[B] HHHJQ"5&W]:DJ-OZT >8?''[W@+_ +&JQ_\
M9Z]2'\->6_''[W@+_L:K'_V>O4A_#6TOX</F<=/^-4^0J]*6D7I2UB=@E)@T
MZB@!N#2;:?10 W::,&G44 -VT;:=12L W;2XI:*8!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&989FO+R)IXW"*8P!OZDL"#^[;H#U% '4+]VEI%Z"EH **** "BBB@ HHHH
M**** "BBB@ HHHH *:?:G4A Y[T >;:'X7U6T^-FNZ_/:-'I5Y9)!%,9%.6
MB!! .1RAKTE?NBN7T_QII]YXVU#PK#;SI?64*W,DA15B*G8>#NR3\XZ@=*ZA
M?NB@!:*** "BBB@ HHHH **** "BBB@ HHHH **** &2'Y6XS[>M>2_ WP7J
M_@B;7#K%K]D6Y:)(6,J-YFTR9.%)Z[Q^M>M.,Y'J,<5Q_@/XD:9\0'OO[-MK
MJ![7RS+]I55SO+8QM8Y^X?TH [(=*6FKPH&,?2G4 %%%% !1110 4444 %%%
M% !1110 4444 %%%% #6.T$XS].M><ZUX9U.\^,VAZW#:%M+L[1HI9PZ@!B)
M1C&<G_6+V]:]';\JY>_\:6-GXTT_PS+#,UY>1-/&X13& -_4E@0?W;= >HH
MZA?NTM(O04M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4QE]*?24 -VYYI>:6EJ; ,
M(-+M%.HJA#=O-+@48I:!C=M&T4M+0 WBC IU% AN!1@4ZB@8W:*=28I: "BB
MB@!*C;^M25&W]: /,/CC][P%_P!C58_^SUZD/X:\M^./WO 7_8U6/_L]>I=A
M6TOX</F<=/\ C5/D*O2EIH;CFCS%]:Q.P=13?,7UH\Q?6@!U%-\Q?6CS%]:
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M% &I_;C?\\5_.C^W&_YXK^=9>T4;10!J?VXW_/%?SH_MQO\ GBOYUE[11M%
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M^>*_G1_;C?\ /%?SK+VBC:* -3^W&_YXK^=']N-_SQ7\ZR]HHVB@#4_MQO\
MGBOYT?VXW_/%?SK+VBC:* -3^W&_YXK^=']N-_SQ7\ZR]HHVB@#4_MQO^>*_
MG1_;C?\ /%?SK+VBC:* -3^W&_YXK^=']N-_SQ7\ZR]HHVB@#4_MQO\ GBOY
MT?VXW_/%?SK+VBC:* -3^W&_YXK^=']N-_SQ7\ZR]HHVB@#4_MQO^>*_G1_;
MC?\ /%?SK+VBC:* -3^W&_YXK^=']N-_SQ7\ZR]HHVB@#4_MQO\ GBOYT?VX
MW_/%?SK+VBC:* -3^W&_YXK^=']N-_SQ7\ZR]HHVB@#4_MQO^>*_G1_;C?\
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MR\<@YP&P,8S3[CX<ZI;Z?X(N[&YM9O$'A>!;54G=TM[B-XA#,ID"F2,[0 C
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M;G=O''MUH X;XI^![SQYI,VGQZ9H]ZLMN\<-U?R/%<V<Y8,LB.B'>N50^7A
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M_BJ/^%2>+/\ H%C_ ,"H?_BJ/:8/NA\E8R?^$UUW_H,:C_X&R?XT?\)KKO\
MT&-1_P# V3_&M;_A4GBS_H%C_P "H?\ XJC_ (5)XL_Z!8_\"H?_ (JCVF#[
MH.2L9/\ PFNN_P#08U'_ ,#9/\:/^$UUW_H,:C_X&R?XUK?\*D\6?] L?^!4
M/_Q5'_"I/%G_ $"Q_P"!4/\ \51[3!]T')6,G_A-==_Z#&H_^!LG^-'_  FN
MN_\ 08U'_P #9/\ &M;_ (5)XL_Z!8_\"H?_ (JC_A4GBS_H%C_P*A_^*H]I
M@^Z#DK&3_P )KKO_ $&-1_\  V3_ !H_X377?^@QJ/\ X&R?XUK?\*D\6?\
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MTZUP-48P./FP%WM[^_:L#1_VD]%\%_\ !/OPK9:%_P (_P"*?$VG100W=C?
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M->E # QC\* %VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
MVBC:*-HHVB@ VBD93M;:0IQ@,P! /N#QBEVBF2Q^9&R?-A@5^4D'D8QNQQ[=
M>: ./\,^/M6\:0+J&AZ(MSX8FN)(K:_:[VW4J+(J&982@5(P2QVNZOA&&TG
M,1^(6L:M?:Y'X9T.'6;+2)7LY9+V^>R>>[09>&)?*<[@>"6*CT) )$/@OP=K
M?@RU&@V[:;<Z%#.Y@U*:207*P.YD='@V[2Y9W7<LJC!#%21M,5GX0\1^#Y_$
M\7AR+2;ZSU>ZDU&!M3NI8GM;F3&Y2$C<31@A2 67Y04X!R "-OC&-3N/"O\
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M5?:>5SG/45V,G@WQ/KGC;PCX@U>/1;8:/]K,T=G-+(SO+#L#H[(N Q)!0C*
M'#MO(7-\6_!W4/$K_$9(KBUM+?Q"FG-9!)'5Q);H WFG8=H9EZKN.#TS0!L?
M$*_6UL?!DFNZ):7E\_B*VLH8X;I_+LIG,ACE1_+0OC"_(5 )^E6V^(FL:Q?:
MXGAK0H=8L](E>SEDO;]K-Y[M!EX8E$3Y8'@EBJGJ"0"1'XT\&ZKXWL?"S3I8
MZ?=Z;K5KJ%S''<R2Q+#$7_U9* LY##J%[\U7L_"/B/P?/XGB\.1:3?VFKW4F
MHP-J=U+'):W4F-Z,%C;SHP0I"EE. 4X!R "-OC(NI7'A0^']/GU5O$8N1:_:
M;@0>4T"AG5TVDX#-AF7<VU6*JQPI)OC%;V_@OQ3XAN=-NI)O#U\VFW%E#-O6
M:X#(H",55MI+K\Q3(&3CC%0:+\()O#6J?#S[!>1SZ=X82^69K@D33-<+GS =
MI'#M)P3P,<GD#3\*>"-4\.:1XMMRUA=R:IJ]U?6T,HW1M:RF,^1)E,*6"L"=
MKA=W1J .B\,ZUJ6N6[O=06:95)8KO2[S[9:R1L3@+(50G@=<8.1@DY V/O<_
MS-<#\,?A[<^"]1U^Z>*UTVQU"XCN(-%TZXFFM[1O*"RLA=5&7<]HQM554<8V
M]_MH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:
M*-HH -HHY3E?O=1]0:-HI57<0* .9\8>.-/\%R6:WT=Q*9BXB$$:OMV[<@YD
M7KN'8UT<<TH+*S93I@X^OI7D7QZ5I9M",2/.29R1&I)&=O7_ +YKUR/'SC(R
M'.5^JJ?\:!AY,?:*/'^ZO^%'DI_SR3_OE:?BBG<6G89Y*?\ /)/^^5H\E/\
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M&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% "$
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M*GL?NO\ 6J).FJ-OZU)4;?UH \P^./WO 7_8U6/_ +/7J0_AKRWXX_>\!?\
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M0P':78$.<=>^&_,5;X4YZ >E>::U')_PO3PY*T#2,UA('^90%^6?!QC.?EH
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M*-HI,I_?%&4_OB@!=H/!&1Z?SK-F\.Z==ZY'J\UN'UB%4BC_ 'H!5"C9;'_
MF_*M [2"%8%B, =*\XUR=O\ A>&@(L8=#9,)2)AM'RSX)&>N-O;M0!Z3P>U&
MT4F4X^<493^^* %VBC:*3*?WQ1E/[XH 7:*-HI,I_?%&4_OB@!=HHVBDRG]\
M493^^* %VBC:*3*?WQ1E/[XH 7:*-HI,I_?%&4_OB@!=HHVBDRG]\493^^*
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M493^^* %VBC:*3*?WQ1E/[XH 7:*-HI,I_?%&4_OB@!=HHVBDRG]\493^^*
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M]CA_YY)^5'V.'_GDGY5/10!!]CA_YY)^5'V.'_GDGY5/378JI(]* (OL</\
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M3\J/L</_ #R3\JGHH @^QP_\\D_*C['#_P \D_*IZ* (/L</_/)/RH^QP_\
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M_P H.,@C=CIT_P 10 ?8X?\ GDGY4?8X?^>2?E4PI: (/L</_/)/RH^QP_\
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M?LD5O,VIZW:Z;-YX8[8Y-P8K@_>&.,\5W"D\4W%I)LE24FTN@ZBBBD4%%%%
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MM&/N'OWH ]!7[HI:1?NBEH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\*N]Y,=D*CS6"D[F#'/&U&.#C! .JCN@Q ^8Y&<[<#J./K[=:G7.T9ZUY?\
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M>)_'V@>";&.]\1ZSI_AZQ>3R%NM5NXK6-I-I<1AG8 L55S@=D8].:D\+^-]
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MJ?P%K>H>(?B_FU2W@\1:?:VNF74DH"/(MI)$S<!F0!F'.,X&0#W]8$87:HC
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M /\ R<@_^.4>UH]T'LZIYON_Z8K^8_\ B:-W_3%?S'_Q->D?\,[?$#_H ?\
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M\ :O?Z\^J>$-'N]-\8%[=8/$%C>106TD(=-ZW89MSC&X[1')GRTR6'R  V/
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MFV\XSVC<NH:5B,CN2#1:(:]SQ+X=?M<^)M*_8Q\>>(O$URK?$;PE=W.B%GB
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MP0",8&+^F^ ](TRQO;3R9KZ.\C\FY?4KJ6\>:/&T1N\S.S( 3\I)'SOQ\S9
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M&V76+;[0;7<86,A3;N(Y&#@_=7KZ"M]0(U1#QZ ]>HH#0=Y?MG_@1H\KV_\
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MHSM."P^C&OE#]JC<WQ(TX[L*NE1JQ?& &EE&3W['IGJ.E?64B[E(QGBN>OO
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M?<021]YO?M0!T8YI:1>E+0 4444 %%%% !1110 4444 %%%% !1110 4444
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MOD]3ZT >>_!73=6TSP;/#JR7%O!)?SW&EV%X-MS96#,/(AD^8X<8[L3S@\C
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M+$9#"$9B2K/*Q &"%"+G/M:].*A:$8'RJ ".WITZ5,.!C&!0 M%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -+>U-*_
MSKFO#7Q(\/\ BZ,'1M5M]1;8S^7&X$F%(#'8V&'++U 'S#UKH%N VX@YPVTX
M(X/^>?7FFXM;DJ2EHF>9_'#EO 7_ &-=C_-Z]37M7EGQPZ^ _P#L:K'^;UZF
MO1:VG_#A\SEI_P :I\A:6HFNHE;!<9H^TQ?\]!6!V$M%1?:HO^>BT?:HO^>B
MT 2T5%]JB_YZ+1]JB_YZ+0!+147VJ+_GHM'VJ+_GHM $M%1?:HO^>BT?:HO^
M>BT 2T5%]JB_YZ+1]JB_YZ+0!+147VJ+_GHM'VJ+_GHM $M%1?:HO^>BT?:H
MO^>BT 2T5%]JB_YZ+1]JB_YZ+0!+147VJ+_GHM'VJ+_GHM $M%1?:HO^>BT?
M:HO^>BT 2T5%]JB_YZ+1]JB_YZ+0!+36&?;WIGVJ+_GHM'VB'^^M '-?\():
MCX@'Q=YT[:A_9G]D^2SCRO)\T29QCKD50;X7P66LZEJ.BZUJGAT:D_GWEII_
MV=K>2;J91'-$X1V_C*@;^"V2 :[/[1#_ 'UI&N(L$"10<>M 'B_BO0A8_$RR
MDO[?Q'_PCB>'OLYO-)FU&>:6X2Y^1)C;2,\A57D()'223)/ 5WAGX>WGC[P+
M+:>+Y=8TY6UF35M%62\==1TN N?(#RG)\P9?ABQ4/@$%0%]?^3;D.O.<A>!G
MKNZ9S^-.5HRROYJ@CG&X@<C]?QH X_0_A7:Z/XV?Q:^I:AJ.MRZ?_9LLMW)'
MM=/,#[]J1J$.1RJ!5/)(W%B<RS^!FE:1I7AFST[5=4LI_#KW#V&H!X)+A?/W
M^:K"2)D((?'"@@=Z])^T0GG>IH^T0_WUH \TTWX#Z+8^!]=\,3WFHW]EK5TU
MY=3W5UNG\YO+/F!U5,MN3=ELEB3NW XK7UGX76NO6.CBZU2^.N:3*TMEXC3R
M$OH&8@,%"Q"+:Z@*Z>7L8#E<X([3[1#_ 'Q^='VB+_GH/SH Y70OA]!HVM7^
MM2W]YJ^L7D0@:^U!XVDBB R(X@B*D2[@&(5?F(W-D@&K7@7P/:?#_P *V7A[
M3IIY[*T#B.2ZD#2G?(SDD[><%N*Z#[1#_?6@W$7]]?SH X32]"DT3XO:K?06
M,<-MKVEPR7%S%*Q/VFU/EC<I&/FCN$ P?^6!R.YE_P"%71V.M:C?Z+K>H^'3
MJ,@GN[?31;^1+,,YF*2PR8D;@,5VAN"1N&:[(S)OR679CKGIC'_UZD\Z'^^O
MYT <I??#NSO?$WA?66N;L3^'A.EHK3EPZS1JC>:S@NYPIP=PY.6W<8V_$6AP
M^)_#NJ:1<O+%;:C:2VDKPMM=5D0JQ4D<-@GGV%:'VB'^^/SH^T0_WU_.@# _
MX0NV/@4>%3/.;#^SO[+\_>/-,9B\O=G;C=C/;&<51F^&]C<>$=&\/>?-'!I(
MM/L=TJQ-/ ]L5\J12Z%<X7!RI^\P%=;]HA_OK^='VB+^^I_&@#A=%T*:Z^*G
MB+Q!<6JI]CMK71K21IB6D3'VB>3:%  )FA4$EN8#]W)SWZ\K519@K$EX^#QE
MN<9'^)J9;F+:/G7'UH FHJ+[5%_ST6C[5%_ST6@"6BHOM47_ #T6C[5%_P ]
M%H EHJ+[5%_ST6C[5%_ST6@"6BHOM47_ #T6C[5%_P ]%H EHJ+[5%_ST6C[
M5%_ST6@"6BHOM47_ #T6C[5%_P ]%H EHJ+[5%_ST6C[5%_ST6@"6BHOM47_
M #T6C[5%_P ]%H EHJ+[5%_ST6C[5%_ST6@"6BHOM47_ #T6C[5%_P ]%H E
MHJ+[5%_ST6C[5%_ST6@"6BHOM47_ #T6C[5%_P ]%H EHJ+[5%_ST6C[5%_S
MT6@"6BHOM47_ #T6C[5%_P ]%H EIK9YQUIGVJ+_ )Z+36N(N?G'3UH \F^/
M'C?6_!L6A#2[I8&N?.\Y2BL'VA.,D''WCTKUF-GX!QG/S8Z=#_45YC\8O %]
M\1O['73;RQB-H9O,%S,5^_LQC"G/W3^=>E1WENS$B9#DXQGG_/- %JEJ+[1%
M_P ]%_.C[5%_ST6@"6BHOM47_/1:/M47_/1: ):*B^U1?\]%H^U1?\]%H EH
MJ+[5%_ST6C[5%_ST6@"6BHOM47_/1:/M47_/1: ):*B^U1?\]%H^U1?\]%H
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M:HO^>BT?:HO^>BT 245']JB_YZ+1]JB_YZ+0!)2U%]JB_P">BT?:HO\ GHM
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M92;=TSC?C?\ \R%QC_BJ['_V>O4NJ\UY=\;^?^$!_P"QJL?_ &>O4AT%1/\
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M%&T4;11M% !M%&T4;11M%'D ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10
M;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10
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M6'-'*P3N=3M_.C:*3;BEVBH+#:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:*
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M(ES&-DBFU8,"&!!)^ZP'/Y< 'L$'B[09K&:_36=/?3X)5BENUNXVBC8]F8'
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M9)42XB\I"<\A<,1GN?=B?I:-<1H8E?:K.H"KG"C8N&ST/6@"3;1M%&T4;10
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M"0-\ZX7Y9]IQC.1M_E0!Z5@4;11CZ_B:-HH -HHVBC:*-HH -HHVBC:*-HH
M-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
M-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
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M<Z_CTI?^$\T7_GM.?^W28_\ LE>*?LD_%#XC_%'PYXI\;>.+*WT+PI>71N=
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M&1P"K#:0W0C!Z^U.VB@!<Y9-Z_W?7U'XB@!K1EYWE#>6S,P4K&HP"=Q!YY/
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M%C<G:Q+^A'7KT.[X+U:YOKK7K'4)UFO=/U-X<1\EK>5?/MPWNJ2QIQWM^.M
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M)F@E:VN$?9*IP\;'.%<'&5/()&>M %P1JC%E?CY=GRA2N 1][^+/Z9IJQJ)
MTD4=PK*6*N.$.=Q"KTQG'/K5?3=2L]7LX[S3KNWU"T?[EU9S+-$W)7AE)!Y7
MGGC([U:([8_ \T -6,A<9PX8MYR<,6)RQ/KGI^%.CC2*0.I4C(*+Y8&,#!!/
M5@03_D4;11@>E '/Z/X3CTSQ%K.L27$ES+J0MT2"0@I9QQ(RA(\CE2SR-@\
MRMQG):OHG@?^R?&?BOQ"^HS2MKHM084#1^2((RBC=N.2<Y!X*\?>.6KJ.^>]
M&T#&!TZ4 (V7C=3MCX5 R@?*!WP..G&!@4DJB1<2#?S\H<CCD#<&QU*C;@ C
M%.HVCTH 85\R1GD1&9P=_''/4;?R!.0..E+@G<) ) S[R6X.<YX_2G8HVB@
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M_P#"B_&O_0%7_P #(/\ XNC_ (47XU_Z H_\#(/_ (NOK+R_]O\ G_C1Y?\
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M^,NM:?)=3R6:V:R1PR3[D4F. G"]N2:]"Q0 ;11M%&T4;10 ;11M%&T4;10
M;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10
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M:G!ZD!N3]:?_ ,(S:#'[VY'I_I,O_P 76MC'3CZ48H^K4NPO:OL9/_",V?\
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MWNTEQ#!Y$9!=B@6/<VT*"!RQ/')-=571'FX5\TFT</\ '#IX"YS_ ,578_\
ML]>HKVKR[XX_>\!_]C78_P WKU(=!6<OX</F=%/^+/Y'+WW_ !_-46*EOO\
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MHHVBC:* #:*-HHVBC:* $9>HZ9%<3J_A^_NOBEH^LI /[,M[=HY9FD1<-B;
MVDY.?,7MZUVQ VGCCGO]*Y_4?&TEGXXL]!-L=^H0F4W0E"X WX&W;S]P\@YY
M% '0;<8&*7:*-HYQTHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VB
MC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBDX7D].O<TNT4JL48%3AAR.,_
MIWH X;2_#>H6?Q4U75)K?9I\]DL,4_F(V\JL.>%;(^[W KN-HKF]/\9-=>-+
MOPVMKY,=E;"<3^:&\S<L?&W:,?>]372;1Z4 &T4;11M%&T4 &T4;11M%&T4
M&T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4
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MM_SS:MC^P8_^?B2C^P8_^?B2@#'VM_SS:C:W_/-JV/[!C_Y^)*/[!C_Y^)*
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M?\:I\A5Z4M(O2EK$[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%%% !12<YI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9\9O$6H>$_A#XYUO29?)U73="OKVTD$8D*31V[O&VTJ0V&4<$$>QK [#KOM
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M=:C=-%=1V\_DK:6XN)(_/ <%GPJ;MHY)X%>E+>*8MX#$#.X+ABI'!'!Y.1C
MYR#0!89MN3V'6D\P;L#FH7F!^0_+(R\;N1G'0_X=37#KXROC\9!X1%O"-/\
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M$^TY&#*0-V2/0BOF_P#:[9_^*4C$_DL1=,01D2$>2 /J-V17G9_:"^(!&/\
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M*0!ST_=UWI]37G6M>%]3O/C+X>UR&TW:3;6<D4UQYB *Q$P"[2=QY<<@'O2
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M$XSCT&37EVN:7>W7QV\-7Z6=Q)I\5C(KW0C/EHV)QM)]?G% 'J:]*6D7I2T
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M !1110 4444 ,?;M.[@8Y/2L&[\5Z78>*+/09[L1ZI<IYD%L Q+IALL>,?\
M+-_TK>DQM8MR,<UY'X@PG[1GAD[F+/IY7EL #;<G@?A0!Z\N=HSUI:1?NBEH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6/.'K^E'G#U_2O)_^&9_"_\ S^:M_P!_T_\ C='_  S/X7_Y_-6_[_I_\;H
M]8\X>OZ4></7]*\G_P"&9_"__/YJW_?]/_C='_#,_A?_ )_-6_[_ *?_ !N@
M#UCSAZ_I1YP]?TKR?_AF?PO_ ,_FK?\ ?]/_ (W1_P ,S^%_^?S5O^_Z?_&Z
M /6/.'K^E'G#U_2O)_\ AF?PO_S^:M_W_3_XW1_PS/X7_P"?S5O^_P"G_P ;
MH ]8\X>OZ4></7]*\G_X9G\+_P#/YJW_ '_3_P"-T?\ #,_A?_G\U;_O^G_Q
MN@#UCSAZ_I1YP]?TKR?_ (9G\+_\_FK?]_T_^-T?\,S^%_\ G\U;_O\ I_\
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M^G_QN@#UCSAZ_I1YP]?TKR?_ (9G\+_\_FK?]_T_^-T?\,S^%_\ G\U;_O\
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M?_G\U;_O^G_QN@#UCSAZ_I1YP]?TKR?_ (9G\+_\_FK?]_T_^-T?\,S^%_\
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MZ /6/.'K^E'G#U_2O)_^&9_"_P#S^:M_W_3_ .-T?\,S^%_^?S5O^_Z?_&Z
M/6/.'K^E'G#U_2O)_P#AF?PO_P _FK?]_P!/_C='_#,_A?\ Y_-6_P"_Z?\
MQN@#UCSAZ_I1YP]?TKR?_AF?PO\ \_FK?]_T_P#C='_#,_A?_G\U;_O^G_QN
M@#U@R!ACK^!JA)HMA-J$=]+:V\U]%@1W,L*F1%YX#8R!RWYUYM_PS/X7_P"?
MS5O^_P"G_P ;H_X9G\+?\_FK?]_T_P#C= 'K'FCU_2CSAZ_I7D__  S1X7_Y
M_-6_[_I_\;H_X9G\+_\ /YJW_?\ 3_XW0!ZQYP]?TH\X>OZ5Y/\ \,S^%_\
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MX9G\+_\ /YJW_?\ 3_XW0!ZQYP]?TH\X>OZ5Y/\ \,S^%_\ G\U;_O\ I_\
M&Z/^&9_"_P#S^:M_W_3_ .-T >L></7]*/.'K^E>3_\ #,_A?_G\U;_O^G_Q
MNC_AF?PO_P _FK?]_P!/_C= 'K'G#U_2CSAZ_I7D_P#PS/X7_P"?S5O^_P"G
M_P ;H_X9G\+_ //YJW_?]/\ XW0!ZNSHZD$;AT((.*SM-T'2]&9SIVG6FG^9
M_K&M8%C+?7"C->=?\,T>%_\ G\U;_O\ I_\ &Z3_ (9G\+YS]LU;_O\ I_\
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M6/.'K^E'G#U_2O)_^&9_"_\ S^:M_P!_T_\ C='_  S/X7_Y_-6_[_I_\;H
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MT>E+368KD]: %VCTHVCTJ$72MC!X)QG' /H?2H)-8M(8KN22YCCBLP?M,DC
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M6*L2-FZ,(JH9#^\?R\OZ3<:'!=:]::LQ/VJVM)[./!QA)GB9_P!88\5RUO\
M"6**.*VDU[59=.ANX[RVL0T4<-JR3K,D<>R,/Y*D%5C=F"KM"X*(5 *;^-K^
MU\81V&HZCHNEF2X%O!I6I6TT$UT-P3=!=&0QRN59'V1QL5W+&Q!.Y='QEXAD
M\.V^F16NJ:=8-*'8&:VFO9I\<LL-I RLX&=Q=6^0+R,$D:$W@<WU\)+G6-2F
MT\7$=W_9;2Q^1YJR"8,'V>< )0'"^85X"XV?+4^O>$/[<OK:^BU.\TK4K:*2
M".]L?*9Q'(8V=-LJ2)AC#&<[<Y3K@D$ X30/B)XB\3:ZFDZ>ME%,OVE+B]O]
M-N;9W\E;*19%MI&61?\ C[:,H[#.T2!L?NVDU[XA:]8W&H:=IS1OJ&D6Z17,
MH\.W]U!>WC1K)A/L^_R$ (SDRL-^2F%4R]3H/PSL?#^MRZPE]?WU],TTDK7L
MJR"1Y8[9')^7(_X]4PJX5=[!0%VA;&I^"Y+K4)+NQUN_T*:==MY_9ZP%+I@N
MU)'26*1=X&T;E"DA5#%E5 H!0\2>)#)\)-4UF[TR%II="FO9=*U"+='(1;EV
MBD0XR.BL/3(J&6;7?^$PN=!T!='TO3]/TJTFCGN+62786EG00B))(UV[85P0
M1L(888/\O0ZGX5MM2\*W>@&2X6RN;)[)I#<222A'0H3O<EF(!ZDDD]:GAT".
M/Q!>:N)9%N+FUAM'C5AL"Q/*RD?+U_?-0!P7A;Q[K%QK'ANPU:"RACU!=2T^
M1;1)G7[?:SLNU93\H1XHIV59%##RF^8]#3L_BQJ=YI.DSK&L;ZY/?3V%U'I5
MY<)'8PRXBD>!3YC/(K1,,F)0)3W15?J-6^%.G:MHHTY[W4+,K?S:E#>V-R8;
MFVGEEED8QN!P")YDY!.UST/-:M]X-M;RSLHK4MI$]@OEV=SIX1'MH\ &)05*
M%"J(-C*0"B-C<B, #B=+\=^)[[PK//<:6T%U;:BULU]'I-[M>W\H2)<_8G"S
MC+,(C&"Q#?/N90:KW_B/7-=D\'G2/%^AW3S:Q-;M>:;#)/;7#"QFF59(TG&
MH#?NO,?)$<FX8*5W2^#9H]/,1\0ZL;\S+.-4,D8FW[-A!0)Y.PJ,;/+VY^?&
M_#BG_P *YB6QBQJ=\VJ+=?;FU5C$;@S^1Y!?;Y8B)\G,?S1D8.?O<T <A>^-
M5\/WVIB>XT#1]6N-8M])N]:FA\F(N--6X#RCS 78GS(T5I<("G+%</H:#XVU
M*?0/$>K76O>'GT^VN4M['6O+:&PVD1AYF<SN)0K.4P&3+0E=REFV'BSX?O\
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MK^9H X!OB=?:MH_A^\T^YL-.EU/2K?5!9K8W6L7(\U0W^J@*,(E V^<259F
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 44E&10 M%)D49% "T4F11D4 +129%&10 M%)D49% "T4
ME'/K0 M%)1D4 +129%&10 M%)D49% "T4E'/K0 M%)1D4 +129%&10 M%)D4
M9% "T4F11D4 +129%&10 M%)D49% "T4F11D4 +129%&10 M%)D49% "T4E'
M/K0 M%%% !1110 4444 %%%-9MH)ZX&<4 .HIGF?=XZGIZ<9IU "T5$L^YL!
M6'7^$XI/M'S-\KC )^X<4 344P,20,'&,YI2V!F@!U%1M-M8 @@'OD4"920,
MYS0!)136.T'Z4Q9MTFW:V,9SVZXH EHHHH **:S;03UIK2X8#'4XSQ0!)14?
MF87)!ZXZ4^@!:**0G S0 M%1F95ZD?RH\Y=P&<YH DHIK-M!/IUI/,&[ YH
M?124M !112$]>] "T5'YF& ]>_\ 2GB@!:*** "BBB@ HHHH **** "BBB@
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M$/\ \57P3N/_ #SC_(4;C_SSC_(4?4X_S!]:?8^]O^%G^$/^AIT7_P &$/\
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M"CZG'^8/K3['WK_PL_PA_P!#3HO_ (,(?_BJ&^*'A!5S_P )3HH'4G^T(?\
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MV&*D1@SZ'X=N;CXG6FKS:5<1V$L6J7-D)T*FU,G]GJ"!SY+RLMU)C<&(D?<
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MW9TRV"O/[MCNP1C:HVA0K6?B+J%MJFM?!2_M8UL+>>6&>*")@(XTD:U(4=B
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJD=&_7M^7^(H XZ;P7J_B+2M7TSQ+K5K>6&I64UG)#I6GFS&)5"L[>9+,S,
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M7%XTEU&KHJ216[R%X87 &-ZQL@;&?F!P3U/1LO!QU]ZC\G!#8&XG)_3I^0H
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M/B[X;U*32A%+?1KJDJPV5Q=:9<P03.REE43/&(\D X&[YB,#)(R +IO@^_\
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M'_XFNCWI_>%&]/[PHO(?N'.?\*P\'?\ 0J:'_P""V'_XFC_A6'@[_H5-#_\
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M /$T?\*P\'?]"IH?_@MA_P#B:Z/S$_O"CS$_O"B\@]PYS_A6'@[_ *%30_\
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MAG(/J!6-H/@W^P[Z\O9=7O=7U"ZCCBDNK[RP_EQ[C&H6)$0;6=VSL+'=@D@
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MNT#QMM8,"5((R& .?4 ]A5BXLH[Q56YAAD42+*4=0R[U8,C<CJ" P/8J#VH
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M%Q:V9:VDNEWB)VCF.Y< %>2!D'/%788="^'/A70M0U'0H]8U/6U-P5N#F*)
MH885E.'&Y#@J3DMS6/\ #_Q)I>@^$_%]M?7/V:74+9K.UWQN1*VV0 8 S_&O
M7'?FM73?%GA/QIH.EV'B6[FT2^TD>7!-:.X!4(%P?E8=AQSTKIK1E[>3:?)=
M?=846K)#/%-KX<\<?#NX\5V&G1:%+83?8Y(;;:%;YD48VA.074],\8Q6_K6I
M>'/ _@_PM=W/A*QU34=0LE=E\E$4X2,R,WRG+;F3'R\\\BN0\5>+O#VG^$9O
M"WA1KF:"2;SKBYGY,H&"!EADGA1V_P!6OJ34?Q(\4:5KWAGPG9V-ZL]UIMFT
M%Q"B,"K%(QE21M(^1NX[5$:%6I&$97Y6W]Q*G&+;ZHZ[Q1X.\,7WB[P5=16:
M:;IFN)(TMN-L2X$:O']T?*S%@K8/([U!\5-/M[#3-2B/@2SLXT97L]9L<.&
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M&RC]UES]XR;F_+GK7U;_ ,*1\&_] AO_  *F_P#BZ/\ A2/@W_H$-_X%3?\
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M_P! AO\ P*F_^+H_X4CX-_Z!!_\  F;_ .+I?VQ1?V-Q?4)WW/E%MS;OGD&
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M5>K*HNIZ]&#ITU$6BBBN4W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ I,4M% #<>]&T4N** #:/2C:/2C%&T4 &T>E&T>E&T4;10 ;1Z4;1
MZ4;11M% !M'I1M'I1M%&T4 &T>E&T>E&T4;10 ;1Z4;1Z4;11M% !M'I1M'I
M1M%&T4 &T>E&T>E&T4;10 ;1Z4;1Z4;11M% !M'I1M'I1M%&T4 &T>E&T>E&
MT4;10 ;1Z4;1Z4;11M% !M'I1M'I1M%&T4 &T>E&T>E&T4;10 ;1Z4;1Z4;1
M1M% !M'I1M'I1M%&T4 &T>E&T>E&T4;10 ;1Z4;1Z4;11M% !M'I1M'I1M%&
MT4 &T4FVG44 )SZT4M% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-9MO).!0 Z
MBJ_VG,@7&%()!..>>??CZ=Q3S, <'(YQT]P/ZT 2T4@.0#2T %%%% !1110
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M_=I$9$W1HS?.HQC!P>*T_$GQ^\#^$?@^GQ3U?66LO DEG:7\>JFTG?,-RR+
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M6.L>)81,RVL<,T<=P(F(D,$[HL4^,%AY3-N56<952P[[XD?%CPE\'_#4VO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV&"W[#Z_L[?\)HI Z^)#I>?^8F;XXMO.[?ZO_6=]W^S70>!?V+?#NB?LA1_
M'Q1JDWB71S#.L^J6<7]GS,SWCW<<J*K/M:*1D*@EE)3# J2I^C]H]* H'3B@
M#\^=-_X)9^*=%MW\,6'[27C*P^&#S30MX2M8Y40Z?+(S2VY870A+NCN&?R-I
M9V)C(.ROMWX>^ K'X<^!?#?A+399KG2M!TZVTNUDO&#3M%!$L:&1@ "Q"Y.
M!R0 !Q74[1Z4;10!\N_$C]BE/BO^UYX0^-/B+Q-;W&F^%X+>.Q\-0Z=)&Q>
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M/&%[\//'VA"."'7;"-[G-NCO+$H02QE98YF+I,C*1N;(8A"GU:5!ZBDVCTH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2E
MHH 2C I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BDI@DW X!'./_ *] $E%)
MN'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)
MN'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)
MN'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)
MN'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)
MN'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)
MN'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)
MN'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)
MN'K1N'K0 M%)N'K2%O>@!U%)GWHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW
M#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BF[
MO>C=[T@'44FX>M&X>M,!:*3</6C</6@!:*3</6C</6@!:*3</6C</6@!:*3<
M/6C</6@!:*3</6C</6@!:*3</6C</6@!:*;NYZT;O>@!U%(&'K1N'K0 M%)N
M'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)N
M'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)N
M'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)N'K1N'K0 M%)N
M'K1N'K0 M%-W>]&[WI .HI-P]:-P]:8"T4FX>M&X>M "T4FX>M&X>M "T4FX
M>M&X>M "T4FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M "T4FX
M>M&X>M "T4FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M "T4FX
M>M&X>M "T4FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M "T4FX
M>M&X>M "T4FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M "T4FX
M>M&X>M "T4FX>M&X>M "T4TM1&Q=02"I]#0 ZBBB@!*X'QOH?CJ^UA)O#6MV
MNG67D(KQSA"2X=R3@POP05'WAT-=_24 >2?\(U\7#S_PE&CG_MD/_C%'_",_
M%S_H:-'_ ._0_P#C%>N44 >1_P#",_%S_H:-'_[]#_XQ1_PC/Q<_Z&C1_P#O
MT/\ XQ7KE% 'D?\ PC/Q<_Z&C1_^_0_^,4?\(S\7/^AHT?\ []#_ .,5ZY10
M!Y'_ ,(S\7/^AHT?_OT/_C%'_",_%S_H:-'_ ._0_P#C%>N44 >1_P#",_%S
M_H:-'_[]#_XQ1_PC/Q<_Z&C1_P#OT/\ XQ7KE% 'D?\ PC/Q<_Z&C1_^_0_^
M,4?\(S\7/^AHT?\ []#_ .,5ZY10!Y'_ ,(S\7/^AHT?_OT/_C%'_",_%S_H
M:-'_ ._0_P#C%>N44 >1_P#",_%S_H:-'_[]#_XQ1_PC/Q<_Z&C1_P#OT/\
MXQ7KE% 'D?\ PC/Q<_Z&C1_^_0_^,4?\(S\7/^AHT?\ []#_ .,5ZY10!Y'_
M ,(S\7/^AHT?_OT/_C%'_",_%S_H:-'_ ._0_P#C%>N44 >1_P#",_%S_H:-
M'_[]#_XQ1_PC/Q<_Z&C1_P#OT/\ XQ7KE% 'D?\ PC/Q<_Z&C1_^_0_^,4?\
M(S\7/^AHT?\ []#_ .,5ZY10!Y'_ ,(S\7/^AHT?_OT/_C%'_",_%S_H:-'_
M ._0_P#C%>N44 >1_P#",_%S_H:-'_[]#_XQ1_PC/Q<_Z&C1_P#OT/\ XQ7K
ME% 'D?\ PC/Q<_Z&C1_^_0_^,4?\(S\7/^AHT?\ []#_ .,5ZY10!Y'_ ,(S
M\7/^AHT?_OT/_C%'_",_%S_H:-'_ ._0_P#C%>N44 >1_P#",_%S_H:-'_[]
M#_XQ1_PC/Q<_Z&C1_P#OT/\ XQ7KE% 'D?\ PC/Q<_Z&C1_^_0_^,4?\(S\7
M/^AHT?\ []#_ .,5ZY10!Y'_ ,(S\7/^AHT?_OT/_C%'_",_%S_H:-'_ ._0
M_P#C%>N44 >1_P#",_%S_H:-'_[]#_XQ1_PC/Q<_Z&C1_P#OT/\ XQ7KE% '
MD?\ PC/Q<_Z&C1_^_0_^,4?\(S\7/^AHT?\ []#_ .,5ZY10!Y'_ ,(S\7/^
MAHT?_OT/_C%'_",_%S_H:-'_ ._0_P#C%>N44 >1_P#",_%S_H:-'_[]#_XQ
M1_PC/Q<_Z&C1_P#OT/\ XQ7KE% 'D?\ PC/Q<_Z&C1_^_0_^,4?\(S\7/^AH
MT?\ []#_ .,5ZY10!Y'_ ,(S\7/^AHT?_OT/_C%'_",_%S_H:-'_ ._0_P#C
M%>N44 >1_P#",_%S_H:-'_[]#_XQ1_PC/Q<_Z&C1_P#OT/\ XQ7KE% 'D?\
MPC/Q<_Z&C1_^_0_^,4?\(S\7/^AHT?\ []#_ .,5ZY10!Y'_ ,(S\7/^AHT?
M_OT/_C%'_",_%S_H:-'_ ._0_P#C%>N44 >1_P#",_%S_H:-'_[]#_XQ1_PC
M/Q<_Z&C1_P#OT/\ XQ7KE% 'D?\ PC/Q<_Z&C1_^_0_^,4?\(S\7/^AHT?\
M[]#_ .,5ZY10!Y'_ ,(S\7/^AHT?_OT/_C%'_",_%S_H:-'_ ._0_P#C%>N4
M4 >1_P#",_%S_H:-'_[]#_XQ1_PC/Q<_Z&C1_P#OT/\ XQ7KE% 'D?\ PC/Q
M<_Z&C1_^_0_^,4?\(S\7/^AHT?\ []#_ .,5ZY10!Y'_ ,(S\7/^AHT?_OT/
M_C%'_",_%S_H:-'_ ._0_P#C%>N44 >1_P#",_%S_H:-'_[]#_XQ1_PC/Q<_
MZ&C1_P#OT/\ XQ7KE% 'D?\ PC/Q<_Z&C1_^_0_^,4?\(S\7/^AHT?\ []#_
M .,5ZY10!Y&?#/Q< )_X2?1_^_0_^,5E>)D^*GA3PYJFM7?B339;73K26\EC
M@A4NRQH7(7,(R<+P#CZU[AZU@>.&TE?!^O-K_&@K83G4&^?BW\MO-^Y\WW-W
MW>?3G%.-N97)E=)V/&_AWKOQ*^)OA&P\1:3XCL(K*]\PQQW4")( DC1DD")A
M]Y"1@GC%=1_PC/Q<_P"AHT?_ +]#_P",UO\ P?7PN/ NF?\ "&#_ (IF,RI9
M\2'@2NKX,A+8WA^M=XM:5$E-\NQ--MQNSR3_ (1GXN?]#1H__?H?_&*/^$9^
M+G_0T:/_ -^A_P#&*]<HK(T/(_\ A&?BY_T-&C_]^A_\8H_X1GXN?]#1H_\
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M"=AH?V*#[#]XDP[!L'S?-]W'7FMI<OLE*VM_P,%)NKR]#B1X<^+C?\S/H_\
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M^$9^+G_0T:/_ -^A_P#&*/\ A&?BY_T-&C_]^A_\8KU9;C]X5VM[-MX/3O\
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M/7TJ8=* %HHHH **8S;<GL!FF+/OR!]Y<97C/(_S^1H FHI*6@ HI*B6;<6
M5N"/3\Z )J*2EH **** "BBB@ HHHH **** "BBB@ HIK-M4GT&:B-TH8CDA
M3@G' STH GHJ,R;<YS_^JFI<*VT9PQ&=O&<>M $U%)2,Q .!F@!U%1M(0P&Q
MN>^./\__ %Z>* %HI#4(N,L%QACVH GHI%.12T %%%% !1110 4444 %%%%
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MX%UV'Q%HCR20&X@BDC:.5"-T<D;JKQN 5;:Z@E71AE6!/P%_P2^\"_#OX^>
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M"/0_@7^P?\.O GA>*XAT+2/%5O'$MW-YDLC-:W\LDCMT+/(\CG@*"<*JJ
M?8_@+]M+X,?$[Q-X@T+PWXZLK^\\/VESJ&IS-#-%9V]K!(D<UQ]K=! \2ET.
M]'8%6# [<FN7_P"'CW[.C>)3H(^)UC]N^V?8/.^Q77V,2!]A;[5Y7D>4#@^=
MYGE[?FW;>:^;/^"FWPL\$? 7]E'3K'X<^$-!\*+K.LV.@:A<Z;IT(NKRR2*6
MY6&2X*F5SYUG;.6+%F*#<3N:O5OVDOV=?V>M'_8]\;ZMI7@WP3:V-MX4DNM%
M\16T,"7$DJPAK%X[X?O)FDD$*AC(S3>8JL7\P[@#/_:S_P""B.F_ 7X[^!?
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MKW4-1UCQ!J#R/J=Q.FH3()/M@?ST.(8]RQNH8LY8$NY.5^RSX9T;]I3]KO\
M:>U/XH:5I_CZX\*ZQ%H&AQ:]9QWEM86 N[Y%ABMV7RU %O%E@NXDNV[,DC,
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MB;PK:S3:)X'\+KJ[66E:FT*AU*P3DM;SO''9'SF50K7DQP>52?XV?M%_M3?
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M6DS,DY4YG;?;PMOE+N"K'/SN6]+^+C;O^"P7P..?N^#[I25[GR=8/_U_S]\
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M.D,HFGEVP[(E(7-RXPQ8X5>>IKV;:,YQS2;0.@]J %7I2T44 %%%% !1110
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M;1=4UZ\\.^*OM@OKC4+B&2YB-S:I;2&(K"JC"(I4,C<CG(I/^&+/!W_#+)^
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M7>.&/"-%''MQY".K#YU89!SC'T/M'I2;!Z>U 'Q7XB_X)5_#?Q?X9T[0]?\
M'_Q,\066EF--(;5/$$=P=+@5"C6]LC0&*.-P("1LS_H\8#*-P/HOQA_8FT+X
MP>)-=U9_B#\0O!]OK\(BUG1O"OB$VNG:BXA6WWRPR)(NYH$BA8 !66),KG=N
M^D-HSG'-&T>E 'AGQ _8W^%GQ$^"FG_"J\\.#3O!ND?O-+M=+N)+=[.?RY(U
MN58']Y*!-,V9A('=BT@<YSA_#C]B30/ /Q,T7QWJGQ"^(OQ'UO0XKB+2!XV\
M0F^BT\W"^7-)$H1,,T?R$$E3G.,A&7Z/VCTQ1M''% '&_$[X5^&?C)X+U3PC
MXPTI=7\.:GY7VNS\^:'S/*E6:,;XV5QB10W!'3!R.*^>+G_@G'X0\5W&GCQY
M\1_BC\2M#M93<C0/%7BQ[BQDD,3QAV$<<;[E$CE65U.20<JS*?KG:/2C:#C(
MH KQPN/F9\D$8^@^F/4_G5BC;CBEH **** &GO37.%_#TI[4QNGX4NH'D/[4
MNL7F@_ GQ%?:;J%QI=]"]KY5S:R&*12;N)<!AR,@D9]^M=9\*+JYU#X7^$KF
MXEDGNKC2+62::9F>1G:%"Q+$Y))))J#XQ>(-#\)_#O5=5\3Z8=9T.W\H7-B(
M$G,I:9%7Y7(4X9@<'TK:\#WVGZQX1T34-)M_L6EW=E#<6MKY:Q^5$Z*RKM7@
M84@8' KHDTJ*5NIS1_C'C'[=GQ,\4?!W]E/QIXR\(ZE_8_B/318BVO!%')Y?
MFWUM$XVRJRG*R-U'I^/@W_!.O]K#XD_%+QSXH^'WQ?N/[1\0+HUEXITK5([2
MUMB;&XB@8+(UN50[H[BTD0!"PW3*[ JJ#U3_ (*=9/[#/Q+4?>_XE@'(YQJ=
MH#7QA\7-)OOV=I_V/_VF--58M)3PWH.D^(/[.L[99WQ9#</G<>=)-8O<P*Q
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MO_BJ/^$^\,_]#%I/_@=%_P#%4 ;]%8'_  GWAG_H8M)_\#HO_BJ/^$^\,_\
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M#HO_ (JC_A/O#/\ T,6D_P#@=%_\50!OT5@?\)]X9_Z&+2?_  .B_P#BJ/\
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M&+2?_ Z+_P"*H_X3[PS_ -#%I/\ X'1?_%4 ;]%8'_"?>&?^ABTG_P #HO\
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M=?FX/7BK2^/O#/7_ (2/2?\ P.B_^*K#JS6-K*QT%%8'_"?>&?\ H8M)_P#
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M  .B_P#BJ -^BL#_ (3[PS_T,6D_^!T7_P 51_PGWAG_ *&+2?\ P.B_^*H
MWZ*P/^$^\,_]#%I/_@=%_P#%4?\ "?>&?^ABTG_P.B_^*H WZ*P/^$^\,_\
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M:W$_S;IV22"3$C%LL5P&(W$%F=F^H/\ A/O#/_0Q:3_X'1__ !5'_">>&/\
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MQ:3_ .!T7_Q5 &_16!_PGWAG_H8M)_\  Z+_ .*H_P"$^\,_]#%I/_@=%_\
M%4 ;]%8'_"?>&N@\0Z43[7L1_P#9JW$D#J"O- #Z**0GK0 'UKA?&W@#0/$E
MW!=:G8&XN/+\A&$\B853N'"L,G/K7:-=*,9^4$@;B0!DD@<]^?3U%96O?=M>
MYW-V]J /.Q\'_".!_P 2IO\ P)E_^+H_X4_X1_Z!3?\ @3+_ /%UV.T4NT4
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M_P# F7_XNC_A3_A'_H%-_P"!,O\ \779;11M% '&_P#"G_"/_0*;_P "9?\
MXNC_ (4_X1_Z!3?^!,O_ ,779;11M% '&_\ "G_"/_0*;_P)E_\ BZ/^%/\
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M-_X$R_\ Q==EM%&T4 <;_P *?\(_] IO_ F7_P"+H_X4_P"$?^@4W_@3+_\
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ML,N]SGIW=9W,;_A3OA'/_(*;_P "9?\ XNC_ (4_X1_Z!3?^!,O_ ,778@9
M./>EVBN97:NSITZ'&_\ "G_"/_0*;_P)E_\ BZ/^%/\ A'_H%-_X$R__ !==
MEM%&T4A'&_\ "G_"/_0*;_P)E_\ BZ/^%/\ A'_H%-_X$R__ !==EM%&T4 <
M;_PI_P (_P#0*;_P)E_^+H_X4_X1_P"@4W_@3+_\779;11M% '&_\*?\(_\
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M1/,_>2PCRS-GYG!S@$?B*EVXZCFL9<JO*):NDKG&_P#"G_"/_0*;_P "9?\
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M;_PI_P (_P#0*;_P)E_^+H_X4_X1_P"@4W_@3+_\779;11M% '&_\*?\(_\
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M!QO_  I_PC_T"F_\"9?_ (NC_A3_ (1_Z!3?^!,O_P 779;11M% '&_\*?\
M"/\ T"F_\"9?_BZ/^%/^$?\ H%-_X$R__%UV6T4;10!QO_"G_"/_ $"F_P#
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MQH^JU_Y']P>UAW.@VBC:*Y__ (3_ ,-?]!O3_P#P*3_&C_A/_#7_ $&]/_\
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M!O3_ /P*3_&CZK7_ )']P>UAW.@VBC:*Y_\ X3_PU_T&]/\ _ I/\:/^$_\
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M<9W 9/3=QG@Q\92="HN;6-G&_OV3ZOS]#2C*/+*^E^IYC\)=#LO$7QROM?\
M"$?D>&M+8R@<KGS8752JY.=[;FQM"JK$;5Q@W_&<*^._VG-,T#4OWNEZ;A(K
M7=N5E\GSY"RL2,NX568CE>O(R>>L5T[Q%\>M!G^'MI<>2LJ3W=Q:F2.+F7=.
M\>]OD0H=IC&.I !K>^(UPOP]_:*TGQ1>*\UAJ"I=-,L;%(@T0A?:Z@[]@&_;
MQT&.:]"M#FQ*U]YT_=3^)-=_,C["C:ZON5?VA/#^F_#[Q9X3US0K&&SNH7D=
MK6*)8[820F*57\M>Q\QPV221C!! K?\ CW\++9K'Q/XQN-1FNIVAM8K*PW%5
MLT$BQR 8/(8,QQ@#+.3RVX87Q8UZ#]H3QOX9T+PM)-?6D*2K<7D<$D?E!F&6
M.]5(P!GGKC"Y-=G^T3\1?#LWA/6/"@NUF\01M %M_*D+!!)%)N8JI& K5RTY
M5^;!PE?VGVNZ39L^63J7T3V.C_9QS'\(]$(8LF)DVMG@^=)TR3Z'O7IFVO$/
MV=_B)H*^#="\*?;F.O;IB;+R)-RX>1R&.,#Y7'?L:]NP/7...M?*9M3J0QD_
M:QMJ]^NIWX.SHI7U%VBC:*-HHVBO'.T-HHVBC:*-HH -HHVBC:*-HH -HHVB
MC:*-HH -HHVBC:*-HH -HHVBC:*-HH 1E&WD9^N/YG@?E65KGARVUZ-#=37R
M-$=T?V'4;FRV'L3Y#KO&?85K8I57YE)'<=?Y\D4 ?/\ \*_$%CX5^#^B>-_$
M%[XAOI_/=;FX_M.YE1$DN'A5Y;9IMK(-OW@'8==ISBO9+KQ98V_BW3_#J*US
M?W=K->N87CVVL,95=\H+AU#,ZJN%.3G. K8X?X4_#6]LOV?K3P5XBLY+&XEM
M[R&YMXY%+Q&:27!4C=DE7&WT.":I? 2SN_$NE2^)_$* ZC)!'HT%Q</'<?Z/
M:861_,Q@[[@3NVXG)5#\P4.P4:^D_'31M4T/3=<DT?6M-\/WEP;1]7OH(TM[
M2;S#&JS-ORJEMH\P QYD4%@=RKL:Y\2K32]9N-)L-)U3Q)J=I;-=W=KH\4;M
M;1@9&X/(NYV_AC3<Y'.,5XEX T#Q%\0/V<]"\'6^BM:6-\\BG6?M*"*W@6\9
MV+1DB9Y2R/A5&TX1C)\Q5?0M;^'^H6OQ(\1ZVNGZQXBTW6DM7$6B:PUC):2P
MH(BLD8GA\Q-F3N+97E0G.Z@1Z5H.O:?XLT>VU71;N/4=+NHO,BO(3E#P#@@X
M*L,_=8 YXKR+4M?U-?$'Q]C74+M(M.TJUEL1]I(%LQL9&+)_<.X YSG@5ZCX
M*\/P^&_#D&EV&E_V5;0&5HK$S-<21*\[R'=(7(!.X,1EL$D!B ">"OOA_KTF
MM?&6Z2QW1>(].M[?2F$J#[3(EH\;!<L-N&8<MB@1F:7X@U:3Q!\!5.I7/E:A
MI=X]ZJS,JW3"RC8-)SAB&.<GKGI7IOBKQII_A)M/MY8IK[5-0G^SV6DV>UKJ
MX/&2JLRC:HY+$X'<UY_IO@77#K/P@F-CA/#>GW5KJK^:H^SRR6BQ*OW@22Z\
M%<CH<UN_$3PQJ.H>(O"?BK1M..KRZ+>70N-+MRD4TB3IL9U+$(2F2=C$!R!E
MTH U]1^(^GZ+X7;6-3L=1L)/,^SQ:8T ENKB<L%6*%8RRRLQ8?<9@.=Q!5L/
MTWQ_!>>)(O#]_IFH>'=8NH&N+*'4EA9;M$;;)Y3Q2R(S(<%HV97VD';CFL#X
MD>'=?\>>'=/O;?3S::IHNK6^K6NBW5RA>\\I3NBDD0E(F)=E'WE^5"2 <(7.
MA:UXN^*/AC7[K1+WPOIOA^*[D+:A+!)+=RS1^2% CDD5 $ .\L3P5PH.0 >1
M>&%+_!/X,2AAN?QC"=BIG -W<[COQEL_*,8KW"X^*%OIU]I<6IZ%K&E66I74
M=I;ZA=QPB/S),^6'C65IHBQV\/&"OF*&"'('F^A_#/Q+:_#/X9Z!<::8]5T3
MQ%'?ZC#YT;>3;B>5S(3NP?ED!P"2<D?6C-X"\<:M=^"3JVE:G>ZK9:^E_J6I
M3ZZC63(LYVBWMC* N8W"G;%&!M*A?G) !ZQXN^*FF>$=8ETI[#4=2OX--EU>
MYALXT!M[5#AI&,KIGYL@*N6)4\=,L7XL::WAOPYJ8TW4VO/$.TZ7HHB3[=<@
M\YV[]BJ%(=G9E500"0?EKS[Q5X=OOB!\5?&%I82B4V6DQ:-?R?VFUD6M[@/(
MT)$EG,-_5C(& ,;Q@$%33H-"/Q+\*_#?QCX>T^_.FZ6LML^BQ7QM;M(' MF6
M*Y62,DQF,':2ID!(+@XP >CVOQ,TRXT/Q#J$MI?6<_A])FU/3;B-5NK<QJS@
M%0Q!#H-RN&*$$?,""*I>'?C%H_B+5O#]C'8:E:#7[-KW3;FZA18YU5%9UX<L
MK ,?O* =O!8,F[#B\#B3P?XY;3?#FH:3JNM::UH?[8U5KNZNIA#-'$N7EE55
M!DP'WX^<Y4;0:K:7X'UQ=<^#EP-.\J+PYIMQ;ZPRNH,$SV:0A3\V7RRC&,\*
M,8R  #V':*-HH(&3QCGI1M% !M%&T4;11M% !M%&T4;11M% !P/X=W?;GJ.?
MZUD6OA73['Q)=Z_# JZO=1)%->2$NP"?="!B5C1B,LL87<P!.<5KXSP 6;/"
MCJ?\?I30RLI9"S@ $<$'!Y&<]#CL<8QDB@#)_P"$4TY?$X\0+; ZT+/^SVO)
M&8[H!)Y@#("%#!]W?(WM6;IGPS\/Z5-%);6]P(H96F@M!?3_ &6%BX8%8-_E
MCD;U&W"L!MQU'4X4L$0"3DJ,,%S]-V,CW&?\!?G +HT>>-S@\\XS[C/0]._2
M@#FY/ASH%SK$&HS6<L]S!>+>1QM=RF#SOXI_(W>6LC,SMD*/F9F)R<5<M?".
MFP^*O^$C$+VNK3*BW5Q;W$R17(12J&6(,$D89X=P2O;%;.W>SQ\^9@$QL,/@
MDC=M.#C(/Y5D>+-=7PSX7UG5S!YS6-G-=>0)-C.4B9PH8#C(4@-R/0GI0!D)
M\+_#ESX;U;1I=*4Z3JU[]LO;>.:;=+.S*[N'#[A\Z(1@XX/%7-8\ Z)KVJ6V
MK7=G-!JT,(MC<Z;?364K19#%&DB*LR;@I"GA>2 #S5:U\:+<>&O"VKMHFH7+
M:\;4):VJ&<VBS+O$LTG $:CEB?3H16]8:M8ZIYXL;N*\:VN&M9E@8/Y<RA2T
M;'. P# [?K0!DW'P]T"ZT.WT:;3P-.M;F*]MFCFD2XBN5<L9Q,K!Q*=S9D#!
MVRVYCO:IF\%Z6^I:%J4UN;B^T..9+.XEE<R)YBHL@9LG?N /+@D>YZ6/"^N/
MXDT2RU%M)U'1OM!9?L>K1"&XC(=D4.N[^(KP,Y((]:TX_F"ED:+T9Q[X[9XS
MT(X/7I0!S,?PUT"UUBXU&.UDBEFN?MC0K<RBT-QU69K4N82X8 [BI8M\^0P#
M5K:]X>LO$%FD%Q]H4J_G++;W+PS12 ;0R2J=ZML)4E2N5)!^7(.B/O,@5_-4
M;O*VD2%<XR%ZXR#@X[&DR2P&T@=VR !P3GKZKCC/)!&1S0!RUQ\+O#-UX9U/
M0)M-2XTG4IVNKRWDDDW7$[2F5I7E#^87+[3NW=$ Q@"K6H> ]'U:_P!3NKBS
M5'U2S:PO6CDD4W,+$@!\.!O525#_ 'L$C('%=#MZ_7^M&T>@_*@=S TOP+HN
MBZI9ZI96'E7MGIJ:- 3-(RBS0JR1D%MI.Y2=Q&>1S5GPGX7TWP/H-IHFBP?9
MM-M'D$*LY8JKN[G)[Y9A].:U=H.<C.:7'KS]: $Q[4NT48HVB@0;11M%&T4;
M10 ;11M%&T4;10 ;11M%&T4;10 ;16+XVU>;P_X,U_5+:-);BQT^XNHXY<[&
M9(V90V".,CL<XK:VBLCQ=I]AJGA/6K+4[D6.G7-E/#<W7F+'Y,31L'?<PP"%
M).3Q^M:T[.5GW1,[\KL?,_B3QDWC[3?#>M7*6\,U[I:/-%'@H&$TRY7)) )0
MCKZ5C>6O=?\ Q[_Z]>U6?P.T;4-"T>UT77F;1[6R2&&Y39/YH$DC=4P#RQYH
M_P"&>;7C_B;./^V"_P"-?I.%SC!T:2I2=K7/G/JU6?O7/%=B>G_CW_V5&Q/3
M_P >_P#LJ]J_X9ZM?^@N_P#WX7_&C_AGJU_Z"[_]^%_QKK_MS ?S/[A?4ZO<
M\5V)Z?\ CW_V5&Q/3_Q[_P"RKVK_ (9ZM?\ H+O_ -^%_P :/^&>K7_H+O\
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M_AGJU_Z"[_\ ?A?\:/[<P'\S^X/J=7N>*[$]/_'O_LJ/+7^[Q_O?_7->U?\
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M?W!]3J]SQ78GI_X]_P#94F GS*A<KR%#=?IR>:]K_P"&>K7_ *"[_P#?A?\
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M#) &*Z R0[BIEC#*<%7;;R#R.<9.<#/?-(V-F7C.,E"K9'.,E?4<>G7/&>E
M%?2](M] 2.RME6&W0%E5E:3!));=ELN6))8ODLQ+9W,S'F[7X5Z#97%]<6?]
MJ:?+?73WER;#6;N 7$KC#2,L4JC<1@9Z=,  8I_CKQJG@;_A&P;+[7_;6K6^
MFQJEQY9C,I.U\ -O&T-QD%N@QFNH65)&"CECG&"K%L=< ')P>,C@GI[@#;&S
M2SMTM@9FA! W>:[2GGN[99OH6KG]+^'6BZ7K%OJD=O+]LMQ)';I)>3206:N1
MN^SQNQ2'(0<1JO&5X48.SJVH_P!EV$]P+2YO3%\I@M(_,<L7V!>P&2?XRH4
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ML/F/%#=(J%4$BHRAF7.5D()4@;=I&:O7'@70[S2?#NEW%H9;#09[>XT^)I7
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M,5<9RA?E=KAIU,O6O#6E>))4;5])L=3V$N/ML(GVL<;@N[.WD+C']W-5-0\
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M#,\ >!-0\#_#/2_#^FW\*7D5N2]U<HUU:QSNYE=@@:-MN7.Q<H?NEL%0#A^
MV3P[\6_$NEWX74/$6KV<.L/JT4?D026Z'[.D7V=O]28U.U?G=V )9^0@[9O
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M_)I=HHVB@ P.O>DVCTI=HHVB@ QQCM1M'^%&T4;10 8_SFC Z_YYZT;11M%
M!M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M%
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M6_.C^S+C_GBWYT 5MHHVBK/]F7'_ #Q;\Z/[,N/^>+?G0!6VBC:*L_V9<?\
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MMHHVBK/]F7'_ #Q;\Z/[,N/^>+?G0!6VBC:*L_V9<?\ /%OSH_LRX_YXM^=
M%;:*-HJS_9EQ_P \6_.C^S+C_GBWYT 5MHHVBK/]F7'_ #Q;\Z/[,N/^>+?G
M0!6VBC:*L_V9<?\ /%OSH_LRX_YXM^= %;:*-HJS_9EQ_P \6_.C^S+C_GBW
MYT 5MHHVBK/]F7'_ #Q;\Z/[,N/^>+?G0!6VBC:*L_V9<?\ /%OSH_LRX_YX
MM^= %;:*Y_XA:K<:#X!\2ZG92"&\L]-N;B&3:&VR)$S*2I^\,XX-=3_9EQ_S
MQ;\ZQO&=A81^#]<;Q#%_Q(/L$_\ :.XOC[-Y;>9]SYON[L[>?3G%73LIIR5]
M3.:;BSC/@%XLU;QM\*=&UG6[G[7JT_G)<2( JR*MQ(@RJC /%>A[?7K7,_"B
MUT.Y^'^G/X/2,>&\.EMM\P!B)F5L>:2V-RMUYYKK_P"S;@_\L6_.M<2U*M)Q
M5E<FC_#5RMM%&T59_LRX_P">+?G1_9EQ_P \6_.N<V*VT4;15G^S+C_GBWYT
M?V9<?\\6_.@"MM%&T59_LRX_YXM^=']F7'_/%OSH K;11M%6?[,N/^>+?G1_
M9EQ_SQ;\Z *VT4;15G^S+C_GBWYT?V9<?\\6_.@"MM%&T59_LRX_YXM^=']F
M7'_/%OSH K;12-&'4J ,G@9JU_9EQ_SR;\Z5=-N%8'RCD=.G^-+J,\S^/'BO
M5O"/PKUW6- O'M;Z#R6AN0JR&-GN%1PJR#'0^_>N@^'.HWOB/P/X:U:\E>YO
MKS3+>YNN% WR0([L1T^]CI[U%\5K'PY;> [V+QLVWPT#&UQ(P;:I\U< ^7\W
M+$=/>M/PCIVG3>%-%DT2-AH;6L$EER,&(Q_(,/ENA6NV3C]7C=:WW.:-W6-/
M:*7:*L_V;<?\\F_.C^S+C_GBWYUQZ[-G1TL5MHHVBK/]F7'_ #Q;\Z/[,N/^
M>+?G0!6VBC:*L_V9<?\ /%OSH_LRX_YXM^= %;:*-HJS_9EQ_P \6_.C^S+C
M_GBWYT 5MHHVBK/]F7'_ #Q;\Z/[,N/^>+?G0!6VBC:*L_V9<?\ /%OSH_LR
MX_YXM^= %;:*-HJS_9EQ_P \6_.C^S+C_GBWYT 5E0LP55WLW 7N>?>O'?VF
MO''B'X;^ ].O_#FHR66HSZG%;RRB-'/EM'-(RX;(&60#C'6O:FTVX"_ZDG\1
M_7BO-OC98^![+PG:K\0\0:(UZBP23;CBX\MRO^J]MW4=375A6E63DKHPKW5.
M31W2,9%Q*X$GW0@;(  0L=HX!)/Z5/@5/#8331PLJ.(XP52,X^[C;GDYYQD4
M[^S+G_GBU<\M6VC2'PJY6VBC:*L_V9<?\\6_.C^S+C_GBWYU)96VBC:*L_V9
M<?\ /%OSH_LRX_YXM^= %;:*-HJS_9EQ_P \6_.C^S+C_GBWYT 5MHHVBK/]
MF7'_ #Q;\Z/[,N/^>+?G0!6VBC:*L_V9<?\ /%OSH_LRX_YXM^= %;:*-HJS
M_9EQ_P \6_.C^S+C_GBWYT 5MHH"JQ <@)W)Z 9YJS_9=Q_SR:C^S;C. A7_
M &CC /J::OWT&D>;>,O$VLZ3\5OAQH]E=26VEZL=2;4;940^9Y4"M$ V,JH/
M.%Q[YKO]HP.*Y;Q%I_AG_A//!O\ :L?E^)RMW_8<+$DL?)3[2P(R.$Y^;'M7
M9_V;<$D^2>>>M;SY>2'*NAA3W96VBC:*L_V9<?\ /%OSH_LRX_YXM^=<YL5M
MHHVBK/\ 9EQ_SQ;\Z/[,N/\ GBWYT 5MHHVBK/\ 9EQ_SQ;\Z/[,N/\ GBWY
MT 5MHHVBK/\ 9EQ_SQ;\Z/[,N/\ GBWYT 5MHHVBK/\ 9EQ_SQ;\Z/[,N/\
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M@"MM%&T59_LRX_YXM^=']F7'_/%OSH K;11M%6?[,N/^>+?G1_9EQ_SQ;\Z
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MVM_?-&UO[YIU% #=K?WS1M;^^:=10 W:W]\T;6_OFG44 -VM_?-&UO[YIU%
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M:W]\T;6_OFG44 -VM_?-&UO[YIU% #=K?WS1M;^^:=10 W:W]\T;6_OFG44
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M% "T4F11D4 +2;J,^E-)H>BN'6P[=1NJC<ZG!9W$$$TBI+.&,88@;L8X'O\
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MW:"2"3BLSXFWGB+Q1\5&OM4^'NM:_H&B226NG:?;I.+>XVO_ *UW6)@0YV'
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M,_/@C<@^<;.F_#G5_#.NZU=^%]>M=,MM8N3J-U8:KIKWWD74F#,\4BSQE0^
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M>2PQUJ#3_&^@:MIEUJ5CK>G7>G6F\W%Y!=QO##M4EB[AL*  3R1P,T ::VI
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M\=>']:U0Z=I^N:?>WWDK.;6WNHY)1&RJPDV*Q;:0Z$-C!#J0<$9<GC30I/$
MT0:OIYUEAC[!]IC,Y^4N0(\[LA1NY XYH U5MV5E+,LFW@%DYQ@<9^M(L+J0
M0J*0%7Y<CCTJPH!'04N* *XA?:H+LWJPX)_+CVI8HW5?F*MSV! QVXJ?:/2E
MH 2EHHH **** "BBB@ HHHH 8QZFN=^(&AS^*? _B/1;5D2XU'3KBTC:4ML#
M21,H+8!(&2.@)]JZ-JX[XO7]QIOPM\875G.]K=0:->217$3['B98'(96[$$
M@TZ=W42CN3)VB[GS+XB\%W7P[T?PQX9OI8Y[RRTM!-+;AV0L9Y7)!*@XW;>2
M!WK$SR>@_$?XU](? 6:7Q9\(O"^JZT%U349[0>;=7BEI7^9L99@2:]#_ .$>
MTO\ Z!]K^,"_X5]O1S^6"3H3CS--ZGB_4?:>\I61\6?B/S'^-'XC\Q_C7VG_
M ,(]I?\ T#[7_OPO^%'_  CVE_\ /A:_]^%_PK?_ %H7_/K\0_L_^^?%GXC\
MQ_C1^(_,?XU]I_\ "/:7_P ^%K_WX7_"C_A'M+_Y\+7_ +\+_A1_K0O^?7XA
M_9_]\^+/Q'YC_&C\1^8_QK[3_P"$>TO_ )\+7_OPO^%'_"/:7_SX6O\ WX7_
M  H_UH7_ #Z_$/[/_OGQ9^(_,?XT?B/S'^-?:?\ PCVE_P#/A:_]^%_PH_X1
M[2_^?"U_[\+_ (4?ZT+_ )]?B']G_P!\^+/^^?\ OH?XT CC./\ OH?RK[4_
MX1_2_P#GPM?^_*_X4?\ "/Z:IR+"UX_Z8K_A2_UH7_/K\1K+_P"\?%@&0<#.
M /FVD \ \9^M!(VDX/'.*]I_:&T^VL8=#$42PRS&7=M  .T)UKQ90?,50#NR
M ,*3GMV'-?4X#&+&T%7M9/\ 0\RO1E3GR+4,@*#]W=[X-&,LJ%2=Q"[>2#D^
MPY-=YX/^#.N>*O+FNHOL%DQ!,LV58KGDJN,D]>N!TKW#PA\*-$\'QJ\$/VBY
MX/GSC=SZ@=!^%>=C<^PV%NHOFD;4<'.;NT>!Z=\$?$GCC0;M%CBTZ.6!DBDO
M7;DLI . N1S7TGX,T&;P[X?L=/N+F:^>WA6,S3L&S@8XQV],]JI?%;4KK0_A
MGXHU"QD\F]L]*NKB"3;N*2)"[*P'J"*U/"MQ)>^'=,OIW,UQ/:1,\F"-Q*@G
MCZU\#CLPK8Y<]2UK['NT:*HNR-E>_?FI*CY7%25XL=CJ"BBBJ&%%%% !1110
M 4444 %%%% !1110 R3[IQ7CG[3/PGU;XR>!;#1M%N;&"ZM]1CNW:^D94*+%
M*A VJQW9<=1C&:]CDR%..N*^=_VT_$FK^%_A;87FDZK>Z+<-JL<4EQ83O$WE
MF&<D':>5R%X.1P.*Z<+S>WBX.S.>O;D=SZ!B^547KD[>.V/_ *]6:IQN=L9)
M!_#/I5P5SO<UCLK"T444BPHHHH **** "BBB@ HHHH **** $-,9MO/6G,::
MW*'C/!H \[\8>!K_ ,1?%3P!XDMY[>.RT'[?]ICE9A*_GPA$V *0<$<Y(X/&
M>E>C)]T9XKQ_X@:UJ5G\=_A+I]O>745A>+JQN;>*=ECFV6\;(74'#[6)QD<9
MKU]?N@5K.]H^AE!IMV'T445D:A1110 4444 %%%% !1110 4444 %%%% "&F
M]?Y4YONFF.<*3[?6EUL!YY\=O ]_\3?A5K/AO2Y+>"_OA"8WO&81 )/'(V2J
ML>BGH.N*WOAYH=QX4\"^'-#NWC>\T[3[:TE,))0M'$J,5) .,J<9%<-^U+K-
M[H'P+\17NF:A/I5["]KY5U:2&*12;J)<!AR,@XS[]:ZWX2WMSJ'PR\)75U++
M/<SZ3:RS33.7=W:)"Q9CR223G-=+3CATWM<YTU[6QV*M3Z:N>]/KFZG0%%%%
M, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,<SL)7\^$(FP!2#@KDY(X/&>E>BKG:.U:2M:-C*#O<?11169J%%%% !1110
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M*W.Y8R1\P^5CU]_RS5VL'N:1^%"T4@I:104444 %%%% !1110 4444 %%%%
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M* "BBB@ HHHH **** "BBB@ I*6B@!,4=.*6B@ HHHH **** "BBB@ HHHH
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M_.C^W&_YXK^= &QYB^M'F+ZUC_VXW_/%?SH_MQO^>*_G0!L>8OK1YB^M8_\
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M_/%?SH_MQO\ GBOYT :_F+ZTUI$ RQ^6LK^W&_YY+2?VRS_+Y0^;CN?Z?XT
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M/[<;_GBOYT ;'F+ZT>8OK6/_ &XW_/%?SH_MQO\ GBOYT ;'F+ZT>8OK6/\
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MD(1;&)OD2,S0W!1=QE=@#DQS_P %1E]/^%-]O^PX*^D->^[:_P"\W\J^</\
MG*.I_P"J-_\ N<%?1^O?=M?]YOY4 9FT4NT48HVB@ VBC:*-HHVB@ VBC:*-
MHHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-
MHHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-
MHHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-
MHHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-
MHHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-
MHHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-
MHHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@ VBL?QAK@\+^$=;U@0_
M:#I]C/=^3YGE[_+C9]N[!VYQC)'IZ5L;163XOT'_ (2KPGK6B^>;4ZE93V8G
M$?F&/S(RF[:2-V,GCOT[UI!J,DY;:$R7NNQD_"WQP/B'X'TS7VLH]+>_2;%H
M6$@B"3R*<, ,D[?3O768]JYKX=^$!X \%Z/H,$ANELXBC74D!C\PEF8D*>!D
MYZ'OFNEV_7\:TK\OM7R[$TE^[0;11M%&T4;17.:!M%&T4;11M% !M%&T4;11
MM% !M%&T4;11M% !M%&T4;11M% !M%&T4;11M% !M%-D4&-@<8QSNR1^G2G;
M12% V5P"".C=#2Z@<M\3/&4_@'P3JFOVNDIK)LLR/91MY(=6F569B5;[H.>G
M05J>%=6?Q%X;TK57LS97%]9174MLK O TBHQ4G ! "XZ#K1XJT&+QEX?U32+
MQ_L\&H6DUE,4P $=2"P]",Y_"K.FV\&F6=I8QSX2&,1JS\,P5%10/P'ZUO*2
M]G&+WN9QC^\+N,48HQZ]:-HK+N:[(-HHVBC:*-HI"#:*-HHVBC:* #:*-HHV
MBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #9NR!D$\ KU_#WK@OB]
M\2)_A?X;@U:U\/+KYNK]+,VJ3"(('1Y%9R5;/S%5Z#K7>JJ[AN.Q<\L?YU@>
M*O"]CXQTFTL[BY98K>[@O"T?&YX9%D4'/JR@<=B:VHM*JG/8BHKP9ML3E1,L
M:2[3_K%^;EE.-PQD#/''05)@<T"1D:1R%D=@JL?KUQ^0HZ\GDUEO=HM+0-HH
MVBC:*-HI &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4;11M%&T4 &T4
M;11M%&T4 &T4>7O^4+N9N,'H?U]>IHVBDVI_RT ,?\63CCZT]T5%/4Y/7OB!
M'H/C?PGX<2Q2\7Q UV/MC3JC0-!"C$%-OSEL8ZK@>M=9M%<EXA\"KKWCKP=X
MAGU-8;G04N6^QM K?:S/$J$DEA@H.>,UUW!K:HTX1L<]*]W<-HHVBC:*-HK
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M;H_[_P"A_P *^/OM<_\ SU;\Z/M<_P#SU;\Z/]5Y_P#/Q!_:']P^P=T?]_\
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M@H1EL+Z5U>T=ABO,O'VDW^H?&CX6:C'I\TEC9_VK]KGC@W1VQ>V54+MC"!B
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MW#;Y*]22*WHX&A];E'D3Y8*7O=[$3JRC!--ZNQV3>(/C:R\Z!I3ANF\(5_\
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M[26U9R'6*4V,K"5(\@)(K8*N<E"6VD;VS[W;^%=&M;.QLDTBR^PV$WGVEO\
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M_OM__B*/^%%^(_[UG_WV_P#\17T'M;_GLU&UO^>S4?ZQ8SNON#ZC2[L^?/\
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M=M@>F/:M,1)NM*XJ,OW:$VCTI<4;11M%<AJ&*-HHVBC:*+ &T4;11M%&T46
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M*%[G 'J?YTN!Z4-MZW):NMPVBC:*-HHVBDKK2X[/N'M2;1Z9^M+M%&T41O$
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M*V\8^"-/CM8?"TDNGI::C86L:O%]CG,($<R1Q):E9MH9F:;<H 3 !YR?^4I
M_P"R-_\ N<%?1^O?=M?]YOY5\W_\Y1ER,'_A3??_ +#@KZ0U[[MK_O-_*@#-
MQ1M%&*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -H
MHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -H
MHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -H
MHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -H
MHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -H
MHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -H
MHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -H
MHVBC:*-HH -HK(\7)I)\)ZU_;VT:&;*?[>6$A'V?RV\W[GS?=S]WG]*U]HKG
M?B)I=QK'P_\ $UA9QK->7>EW-O#&S*H>1HF"J2Q &21U(']-J?*VDW;5?F1/
MX65?A;-X>NO!-A)X0VKX;0LEJ%6501YDBXS*23\P/IUKK,"O//@%X;U/P;\*
M=&TC6;1;35(/.-S;B7S!&&GEV\@D=&'>O0]OMCVJL0HQJR47<FG_  T&T4;1
M1M%&T5SFH;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11
MM%&T4;10 ;12HH+#/ SS]*3:*.5Y4;B.@Z_Y[4 <UX_U30=)\'ZG-XKF^S^'
MIK=H+ER&;>DF(R %&<G?CUK1\.WFG7?A?1;O374:5-;QM:[RRYC8 K@$9S@C
M@UQOQZ\*:IXJ^$^NZ)X?T_[7J=U)"UO"[K&Q*2QER#(5  "DYSZ5TGPYTFYT
M'P#X:T^\22&ZM=*MX;A"ZG;(L:JRE^0W/H>]=;A#V"E?6YS1DW5LSHL>M&T4
M;1^';M1M%<NMKM'2&T4;11M%&T4@#:*-HHVBC:* #:*-HHVBC:* #:*-HHVB
MC:* #:*-HHVBC:* #:*-HHVBC:* #S%@S(WW$P3G(''.,_E7&?%#6/"'A_1=
M.N/&%PL6GK=1-:S .ZK=+NECSL4\?N_XL"NRY7YE8*XY#$X _$]/K7CW[4'@
M'7?'G@"QTWPU8RW][%JR7,D331PY18Y06!9E5AN(^M=%",9U$INUS.II%M'L
M$;+.JO&<Q286-\Y# 9Z>W%.Q[<U7@C7]W(8?WBQA!M!*#!P_3Y<C/8U8VUE4
MMS/E*CL@VBC:*-HHVBH*#:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-
MHHVBC:* #:*-HHVBC:* #:*4*3PIP?7CCWYI-HHVJ3@J7'=5[]<#C)SGVI[J
MP7L[G'^($\(R>./!SZFRKXD"73:'$P<DDQJ+DC /1?7TXKL".3GDUY[XP\*:
MOJWQ4^'>LVD376FZ2VH/>W:3(J1^;;JJ *6W,I)Q\H/OBO0=H[<CM6]1+ECJ
M8TV[L7:*-HHVBC:*YS8-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVB
MC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HIT>/-7/'(.>W6F[12<KRHW$<@'D
M9I=06YR'Q2_X1A?A_>Q^,Y,>&\1/*TFX9/F*0!L^8_,1P.>M:GA6/1O^$4T:
M;1W\K0I+>%[%<XS&RC8,2 M]W;QQ]:Y7X]>%M3\4?"77M#T"Q-QJ5R\+01M(
M(F^66,N0TA4* %)SGTKH_AUIL^@^ _#6G7I:&_MM+MHYX6D7(=44,"_(;DCH
M:[FE]7B[ZI['+%_OCH]M&T4;11M%<>MM58ZD] VBC:*-HHVBD ;11M%&T4;1
M0 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;1
M0 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;1
M0 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;10 ;11M%&T4;1
M0 ;11M%&T4;10 ;11BC:*-HI &*,"C:*-HI@&T4;11M%&T4 &T4;11M%&T4
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M_?%=1]CA_P">2?E1]CA_YY)^5 '+Y3^^*,I_?%=1]CA_YY)^5'V.'_GDGY4
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MRG]\5U'V.'_GDGY4?8X?^>2?E0!R^4_OBC*?WQ74?8X?^>2?E1]CA_YY)^5
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MW[UEE"S#CR\L5 ^4D[0, LQ_6I?D_O 5O6T4,L*'RE(/9AC@< _I5H6D./\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM)6A)*,\<2HQ4D XRIQD5NW&-%-[W.>+_>V.E7.:DIB]:?6!T!1113 ****
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MO7I8'!_7I5(J]XQ;5O(Y,165%)OJSZCUKQKHOAMH?[7U.STE9<^6U]<1PA\
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M#YMU=]JGPELM<U[3[[4=5U2]T_3]135;329)8Q!!<IN*R!A'YK@,V1&TA1<
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MRO;Q,\CG)8D#.<]ZU_U@QO)?3[O^"3]1I\VI\Y_\*-\7_P#/A'_X$)_C2_\
M"C/%W_0/C/\ V\)_C7U#M/HOYTUEX.2 ,<X/2H_UEQO9?=_P2G@:5]CY%\4?
M#W6O!]G!<:I;)!'-)Y:XF4\XSV-<WQM!QV]:^@OVC%V^%=*8.VT70&>/[C=<
M]*\7\-^#-6\73*NFV;S(6"M/(-L29(Y)/4#VR>#[5]IEN9>VP?M\2TM3R:]#
MV=3DIHP]PX.T@=#W Z\Y_P ]*W/#7@W6/%LP32[-YDW!6G<8A3.!EB<9 ]LG
M@^U>T^#_ ( :?IJ1W&MS?VC,K!UA4E(5/ICO7J]G8V]C;I!;Q+#$HPJJ, #V
MKQL=Q)!7CAHW\SLHX!RUF>3^$?V?=.L8TGUN7^T9B01 A*1+SG'O7J]KIZ:?
M"D5LB0PH,+$BA5 ^@JRJ_-[5)7PV(Q5;%N]65SUJ=*--6B(HIU%%<FQL%%%%
M, HHHH 9)]TX]*\<_:9^$^K?&3P+8:-HMS8P7-OJ"7;M?.RH46*5"!M5CNS(
M.V,9^A]C?.#7SS^VAXBUCPY\,-.N=%U*^TFZDU:.![C3IGC;RS#,2#M/S*2%
M&T]\<5T8;F]M%P>ISUU[CN>_PG"HO7)V_E_]>K(JE#(6CB)W#TW+D]N?Z5<6
ML'N:QM96'4444BPHHHH **** "BBB@ HHHH **** $IF<<T^F;0V<C-'4#SS
MQAX&O_$/Q4\ >)+>:W2QT#[?]I25F$K^?"$38 I'!'.2.#QGI7HJ\* :\@\?
MZUJ%E\=OA'80WMU;V-\NK?:;9)W6.<I;(R;U!PV#G&>F>*]?5?E'&*UJ7M&_
M;]3*&['4445D:A1110 4444 %%%% !1110 4444 %%%% "-TIO6G>M,;./\
MZV:74#SSX[>"-0^)GPKUGPWIDEO#?WX@,;WC,(P$GCD;)56/13T'7%;_ ,/=
M#G\)^!/#FB7CQR7FGZ?;6DK0DE&>.)48J2 <94XR*X;]J'5[[0O@9XAO--O;
MK2[Z$VK175FS1R)FZB! (Y'RD@GL#UKK/A+>7-_\,?"5U=R2S7=QI-I+-)<.
M7D:1HD+%F))+9)R:Z7=4%?:YS)I53LEZT^H\]*DKF\SI"BBBF 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% #)&*YQR<5R7@3XJ^&/B=HUUJ?AS5([^SM[J2QF<H\9BF1MA1E< @YZ<8
M-=<PZ^O:O#O&G[+>GZIXNN_%O@_Q-K/PZ\3WO_']=:'*/(O!_P!-H6^1CG'(
MP>* )OVPM?M-%_9I\>M=R;&N].DL[= 1F667Y45?4DG_ #TKN/A)IMSH?PF\
M'Z=>0M#>6FD6EO+"3AE=8E##VZ9]:\ST?]DG3[KQ+9Z_X]\6:Y\2[_3Y/.L+
M779E^PVC@8#);H -_?<22#7O+0^8K \'LPZYQC/3&>: /CO]D/X%_#SX@?##
M5-1\2^!]#US4'U_4E%YJ5BDTA4R] S*>WO7U'X-^'?AKX<:>^G^%]%T[P]92
M3M,UKIELMO$SD8)*J.3@?G7BNF_L5VV@F[CT/XK?$;P]9S74MU]BTO5H8H0T
MA)<!?(..3ZU>_P"&2KS;@_&WXJ@="%U^/I['R>M '0?M::;=:Q^S=\1K6U@>
M6<Z7),L:CE@@#L!ZD*A.!_\ 6KH/@CXGTWQ5\'O!>IZ5<K>6<VD6RK)'R"RQ
M*'4@<@@J0<]"/PKJ/"OAN3PKX7T[2&U.^UJ2SB$7]H:I+YES/_M2, ,M[XKQ
MR']DVP\*^)&U7P'XP\0^ [2:Z2YN=!TRX633)"&!?$#J=I<9!VL ,\#'%-;I
M"EL>G:'K=OIOAR2\O;]YX(6N#+>7B"%MJ32!@5[!<8SW&#BO'/V1XS>ZEXVU
M:(%K*>YCCBDP?F93(Q_(,*Z3Q%\%+'XM:A!JUYXDOKK2\-%]F5%1)MLTN<\9
M'!5/<1@]37J/A/PI8>$-)BT[3(([6VC!PL>!O_VCQUKVO;T*.%G2A*\YVOY6
M.%0G.JI/9'@?C,Q_\-9^&(V*EQ;1DJQ X,<WJ?\ .:L_'7X7:AX;UB/Q_P"$
M(574K1A-=0H=N<<L_ P00"#DX&21R3N]3U3X1:7J_P 0K/QA+<7<>IVJ")%C
MD&PJ"W4$9Z-ZUV=W;BYADCD52D@VLK#(8'@@Y]JZ'FWLI494]HQY6NC(6%OS
M\W5W1\H?L_\ BYO''QWU?6C"B375BTIC3MS$I ]^_6KOQ"\.:5XG_:>LM*UF
M'SM/N+9?-$A*[=L#E1GMEN.#7L7A/X&Z%X+\97'B33YKU;B:*2$P/-F(*Y4\
M#''W:S/'W[.NA_$3Q+_;E[?:A:7;Q")OLS1#( QU:,GH>QKT99MA?KTJM)N$
M7#E7=?\ #'+'"U(X=1<;NYL>&OA'X(\)ZQ;ZKI5I';WL&_RY%NI&^\N#P6(Z
M>U=U#J$-PQ$<BR%2 P5@2N1D9KPX_L?^%N6_MC6!SD?O(O\ XW7>_"_X1Z;\
M*X;Z/3+FZN4O&1I&NG!(VJ1Q@"OG\8Z%1>T]O*4O-?K=GI4>>.G+8[]<X&1S
M3Z8O"BGUY2[G4%%%%, I*6DH ^56_P"4HP_[(W_[G!7U77RHW_*48?\ 9&__
M '."OJN@!K"EQQ2T4 ,VGUH"D'UIU+2L@&[ :39S3J6BPQA7L*-IQCM3L4M%
MD(9M].12[:=12Y4MAC=OI3J*2J$+1110 4444 %%%% !1110 4444 %%%% "
M8ZURGQ$\!VOQ)\'ZAX<U"6:VM+LQ[I+4@2?NW613D@C.Y1U!Z5UE)0!SFA^%
MK_1[QIKGQ1JNL0[=J6][':JL?3H8H48GC^(FN*TG]GG1O#^B>$[#3-6U2RN?
M#$UU-IVI[X9;A?M&_P Y6$D3(01(PSM##^]G);UC:/2C% 'FGA/X,P>"_"][
MI>G^(-;%Y=WSZE)JLES&]R9WC5)"V8O+<, 20\9!8[@ 54K+)\%=!NO!NN>&
M+U[R\M-:NI;V_NI+@)<37$CAS+^[554JR1X"J%PO(.6SZ-M%&T>E '#ZO\,D
M\1V/AV'5];U+4YM%U2+5X;N;R8Y9IH]^Q9/*B1"HWX^50< <\G+;KX3:7>7?
MCFXENK[=XPM([.^42 +"B0-"##\OR':YZYYQ7=;1Z4;1Z4 9/AG0T\,^'].T
M>"5YK>PMX[:-YFW.51 HR0!Z5K"C%+0 4444 %%%% !1110 4444 %%%% !1
M110 4444 -90RD>HQUKD/$OPZMO$.O6&NQZA>Z+KMBCPQ:EIDB)(\+9S!*KH
M\<L>3N =3M8!EP>:[&DQ0!P^M?"VPUZPTA;C4-275=)N/M=IK:3K]MBE;/F'
M+*T>V0,ZM%L\O:P 0!$VU1\'=.N(_$3:CJ6I:QJ&NV<FG3ZE>O&9X;9T*^7!
MLC5(5)PQ"IAF4,V3BO0MH]*-H- ' VOPATJTU#P/=QW5T#X0M9;6QBRGERK)
M"(2TB[<EL*.A'?UJCK7P.TG5IM>$&H:II-CKRM_:6G:=<+'!<S,&#7!RA*2$
M$;O+*K)M D#C(/IFT?\ ZZ3:../I0!P=]\(](O\ P_X0T>2XNQ:>&+JSN[%E
M= [/;(5C$AV$8VYSM"GT(JWX6^&]GX-US7+_ $S4+Z.UUB\DU"ZTN0Q-;?:9
M-@>5<IYBDA!\OF;1G[M=EM'3'%&* /-M,^!^C:/X/T'0K2^U*"70YGFL-6CE
M3[9 SRF20 [-C*^=K*R$,O!R>:G7X.Z=<0^(6U'4]1UC4==LI-.GU*\>,SPV
MSH5,<&R-4A7.&.U/F=0S9.*]"VCZ4;0: .!M?@_I5GJ'@F\BNKE7\(VDEK8Q
MY3RY \(B+2@+DMM5>A'(HU;X3V>M^(-/OM2U74[W3]/U--7M-(DEC^SPW*!]
MD@81B5P"^1&TA5<* -JJH[[:/\FC:* $7[H%.HHH **** "BBB@ HHHH ***
M* "BBB@!K5A>-?$'_")>$=<ULVYN_P"S;&>]^S*VTS>7&S[,X.,[<9P>O2MW
MUK \=>'CXN\&Z]H(N?L;:I83V(N?+\SRO-C9-^W(W8W9QD9Z=Z%:_O;$RV9F
M?#'QDGQ!\#Z-XA@LI+$:A%YC6\A(,;!MK#/<9!P>XP>*[+FN-^%_@\?#WP/I
M7A[[5]M^Q*R?:/*\H/ERWW,G;][ID]*[-:TK)<[Y=B:?PB<T<THI:R-!O-'-
M.HH ;S1S3J* &\T<TZB@!O-'-.HH ;S1S3J* &\T<TZDH PO&'B"V\*^%]7U
MJ]CDEL["TENI8XE#.R(A9@ 2 3A3P2/K5K3+X:MIMG>QK(D5Q&DP5@ P!P0"
M,G'X&J7C3P]_PEGA'6M#:9K8:A:2VIF49*!T*Y'N,U<TG3QI=A96PS-]GA2
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M "BBB@ HHHH **** "BBB@!IKBOC/@?"+QQDD#^P[[."1Q]G?TYS]*[:N?\
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M?VJ+_GHM'VJ+_GHM<IM/]\T;3_?- '5_:HO^>BT?:HO^>BURFT_WS1M/]\T
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M*U62O<FE_#1U?VJ+_GHM'VJ+_GHM<IM/]\T;3_?-<YJ=7]JB_P">BT?:HO\
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MR_\ :,TJ_P!8^#.O:=I=M=:I=EX1';VL3/)G[4F3A,\;-QY[ UT?PLL9=/\
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MPR)()<L&X:-54Y+FNHP*WQ'+[63CL327[M!M%&T4;11M%<QH&T4;11M%&T4
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M_J:3 [?SS7+:9XVTC2M%L6UO7= M;K^S;>]NI+>[CBMQ&3L$ZEG)\EI"%5R
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M_6C:*SV-$VXAM%&T4;11M% PVBC:*-HHVB@ VBC:*-HHVB@ VBC:*-HHVB@
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MHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBD;A20,G'
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M?4/^^O\ .NGB^[4@/I*6DH ^53_RE('_ &1O_P!S@KZ/U[[MK_O-_*OG _\
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MJR19'2PN',NUD5P=@C;LP!]_7K7)_M8QFSOO"-Y:6ZP7V;E$ECP7)66+RP7
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M=Z18 )Z@DG[QSTW=* /E36K>TA^#/QJOQ!9O/<>+IXI;K*;YHTN[<I&6 !(
MW$<=CP#DGLM8:\T;XS>+Y->U/1-$M]1TVWCTJ[\16 G2>U1%6[AB?SXE3]XR
MEX]Q#??V8R:]V;=N9I4$<[/\XSM!QN7ALD[N5YZ9&?8R1Q[93]U@S EU4KC
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M_:%,^E-P_P X_P :-P_SC_&OFO\ X7!XQ_Z#'_DK%_\ $T?\+@\8_P#08_\
M)6+_ .)H_P!6<;W0?VA3/I3</\X_QH#(>&)"]R#7S7_PN#QC_P!!C_R5B_\
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M*KZGCC_/K2[11@A6QD<9^4'(I=06YR/Q8\/Z)XK\!W^E^)+_ /L;2;I(1<W
ME6+R@AC=&#-PIW#J>*U_"]K::=X5T&TL;HW>GV]E#%:W33+,98PBA>5 [9YK
MDOVA/"^H^-?A/KNAZ3:/?:A=^2J0R,L)*Q7$;,<R$# "G//3M71?#O3KG1/A
M_P"%]/U%4AU&TTFU@E@RNU76-5<!EPI.2.A-=KY?81O*VIA3_C,Z+ HVBC Y
M[T;17%%*QN&T4;11M%&T4P#:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:
M*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:
M*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:
M*-HHVB@@"@ VBD9/E] >Y&<4TN.<+N/91WI<J< 8;.,;64YR<9&#Z\<\>] '
MA?[:7B#4_"OP!U/4-(U"XTR]CO+11/9OY;8:Y4$^U>I>.YYK?X>>(9H9Y(KF
M'1K@I,F?,WB(D/O'.[()_*O'OV\M[?LWZPA1D=M1L$56(&6:X0[1ZX [5[!X
MZ4/\/O$#,@"2:/<[3(."!$3@_7<* /G#X)_ F3XG_"7PYXJUWXJ_$BRO-2A9
MIH8==>.+.\A-JE#M'')S7>0_LFVMM+YP^)_Q+:6$B7R)O$32*<'(W*!R#7G'
M[-'PF\::U\$?!=_I7QDUO1;6XM/.73+2RMC'$/,88!9<Y]J^F? ?AG5/"?A>
M+3]8\07OBS4T+F34[X(LDN<X!"\<4 >9?MC>(M1\*_"6UO-)U"YL;I]5T^WD
MGMY-LC)YP7!/?=M(/UKVN^1GT^YB,23G8R9<_.YR,#/8\'FO _VZ&7_A2L3>
M:#'!K>G"27G:H\_.?<#(Z>]>_7?[ZUE78&,BMB-VV$[AD*3ZD-^M7#XK,F6J
ML8T+MIW@>-%C>P>*QPL"R[C%MC7Y1)W*<?-WS[5YS^S/JVH^(/!FK'4KJ6\E
M6\,2M-(9"!Y4?<_\"_.O0+B'[#X#:#[*;18]-.ZV#>8(@D0_=E^^WIGOGO7F
MW[*8D7PKK2%2'&H.2S'@$11@9/ON%?14H4O[.KSDKM-'G-VQ$(7Z'#^/OBMK
M_@OXUZM=P7%W=:=#.I>U\PNL<.U2Y"'@$ YZ]J^D/#?BFT\6:)9ZE8RK.DZ<
M[6&=P'*\=&')_"O"=/T:V\1?M)>*[&\A6XM;B!U,;="?*0&L^QO;W]F_X@3V
ME[+--X1U%P8YFY!;(^8=,$=..U>[C<'A\71IT::M5C&+7][R.)5*E%RJ-WC>
MQU7P)\1:CJWCGQK#?WEQ<6\-SNCC:4E53S)0 #ZXQ^5<O+#XC\;?&7Q!H6G>
M+[[2HK?.U8)Y<#;QT4K6I^S?<0W7C[QS-"ZR(TBL"N0&!>0Y&17-R>&]2\2_
M'KQ+;:3K[:'>*TK&6%"00-IY(^O\Z[53A2QE>]HV@MU=7LA<W/3C.+T;.[_X
M47XU 4R_$G4@K ,P'G X)Q_SU]:]0\%Z!J/A_P +V>G:IJLNKW<+L7N9 Q+]
MQDL3ZUS'PZ^'OB#PCKMU>ZOXKFUNWE@=%BF\T%6,@92,MC &17HFY<XV\GD"
MOB<9BI57[/G37DK'JX>C9<ZT%Z\]:7:*,?C1M%>-Y'7K?4DM?^/J'_?7^==/
M%]VN8M?^/J'_ 'U_G73Q?=H&/I*6DH ^53_RE('_ &1O_P!S@KZ/U[[MK_O-
M_*OG _\ *4@?]D;_ /<X*^C]>^[:_P"\W\J ,W_@6PYSNQG'^?Z5\]R>']87
M]JHZT^DWD6G ",Z@+>1(B/L#*26( (W#'!ZXKZ$5MOS8# '."< GT)I@4KYN
M J;O[N,C//7!SSQVXS7=A,8\&YV5^9-?><]:BJUD^CN?.^I>&M:^!?Q8DU'P
M[8:EJ?AG429)[338%_=J2?W85!M^0[=A^4D#:3U8YWC8>)/"_P"T+>^*+'PQ
MJ>L6MN4"^3#*HF+6P1\;4.\#GW]!7TYPNU $,8.2%4JV??!Y_$4T0J% W&/D
M<J!\H!R,9%>M2SJ4)<]2FI-Q<7YK_,YGA+JRE;6Y\P^)_#OC'X_^(M)AF\)7
M7A'3M.#K)+=JP9!+CS&&0FX?(F%QQCJORX])\:_$+QIX1UR:WA\"OK>D3 )9
MW6GS,S[2N9 ZCS,[G+=0N!C.:]36)/+0;-FUONHV %_B'&,Y''-*J%8WX$SM
MCS%D^ZR^X&..V#P:QGFBK>SA4I+V<+VC=]2EAO9IN,[-GSE:^&/%OQ6^*6E^
M+=4T5_"FDZ;)#C[>I623RY#+MPP5F9FVC)& ">O .I\7/!/B+0/BAIOCKPYI
M4E_L6+[;#"29)& 97 &"2&C( *@D9Z=!7OBIMD$@4;L;3(X+';Z#)QC\Z8D:
MHX;R]P7. SDLN>N#CD'T/%6L[K0J*:BN51<>7R?0EX.+@TG=WN?.=YI/B3]H
M'QEIEQXAT&Z\,Z!I>&:"_,B,?G+2E6**<R)M0GC:,D9(KK=:^*WCSPEJFH6M
MUX$O-5MEE>2UOM.+!7ML?*6"B0;@!ZY.!Q7L<?[EMRL2>RL!@?E@TSRE^;Y%
M3+;B%W8W==P!)PU9O,X5E&,J2Y(JRC=Z&D</.FG*,G=GBOP'^'WB.S\1:OXO
M\369T^\U)9#%:K(& 66022$@$[ I V@DGKD]*]LQ_G-,,:R-M;Y5!W[5? 8_
MWF[YX[T_%>?C,94QU9U:BMLK+HEL;4:2HPLMPVBC:*-HHVBN(W#:*-HHVBC:
M* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*-HHVBC:* #:*1D60%&S
MM;@C)Y'0]QZ^M+M%&* .-^'/PWMO _P[LO"E[=)JT$*RI-,]NJ)*CRN^6C)(
M;A\$'&17*_LVZ!=:?\.AJ=VS27=\XS-)9QVDJ6L"):V\9"[MNU8_, !/+'DG
M+'UP97[AVMG(J-8E52OE)&I4(-GR@ '.0,=<T ?/OP9^'M]XO^"_AW3;W6I+
M/P[<223W6C_9-D\@CN9&\L3;@4C+LLK +YC$%1( 1M]/NOA_>6/BJ\USP]J=
MMISW\"1:A9WEH]U;SO&0(I5 E1HW5/E/S%6!^X#\U=J(53&&W?,S%0@0,<?+
MP.F#3BOS9Z^E %'3;&ZLK6-;J_\ MEV!NDNC$(RY.X#:H.%50> =QP!ELC<<
M30?!<FB>-_%WB 7^?[?%H!;1VX0VOD1E#ALG=G/>NIVC!';O1Z_XT <+X+^%
MZ>#_ !QKOB'^T[F^6^FEDL[*XFD=-.6:0R7"H-VPAI-A&U%.U "QRV=;QQX'
M@\<:';V<UU):7MC=IJ%A>1(I\BZ0DQ2&,_*VUB3M/!QBNDVCTXSFC_\ 50!Q
M^K> [CQKX3U/0/%E_;W]I?($>'2[7[+'"RG<LJ!FD;?OQ]YMOR+Q]\/GR?#C
M5==U'07\4ZW::S9:)<+>VUK;Z:+8RW2HRQSRDR-G:2Q\I B98YZ"N_V@C!Y%
M+C_]7:@#RWQ9\#SXH'CY1KK6B>*FTYQ"+;S%M&MRF3DN#)NVDC.,9I/%7P<O
MM1OO&4^FZ_;:?:>*K.WM]22]L#-(JP(T8$;F9553&Q5@RL>2=PP#7J>T'/\
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M] +4/_ 5_P#"C_A#=>_Z 6H?^ K_ .%?5^P>O_H/^%&P>O\ Z#_A1_K3B/\
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MYU+5VU66*:&9$2&9<@$!W// QP0/K63JWPS^(&G_ !$UGQ%X9FM5AO&=OWC
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MPQ3,T:_NV8C.%';G%=-I2IVOU,[>_N:.T<4;12;12[17-Y&@;11M%&T4;13
M-HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH -HHVBC:*-HH
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M<9'''WJWJ_#'4PIWN[CMHHVBDW)ZC\Z-R>H_.L#47:*-HI-R>H_.C<GJ/SH
M7:*-HI-R>H_.C<GJ/SH 7:*-HI-R>H_.C<GJ/SH 7:*-HI-R>H_.C<GJ/SH
M7:*-HI-R>H_.C<GJ/SH 7:*-HI-R>H_.C<GJ/SH 7:*='CS5SQR#GMUIFY/4
M?G2-(JJ67:S+DA21@D<X_P ^]%M0ZW.1^*7_  C"_#^]C\9R8\-XB>4ON&2)
M%( V?,?F(X'/7VK4\*1Z-_PBFC3:._EZ%);PM8KG&491L&) 6^[MXX^M87QD
M\"WWCKX:ZOX:T9K:WOKXPO!)=2OM5ED1FSL5F7A#@@&MOP'H\OA_P7H6F2S>
M=<6.G6]O</"V1O6, G)&XKD=>*['R^PCKK<YXW=5HWMM&T4FY/5?S'^-&Y/4
M?G7'T9T=!=HHVBDW)ZC\Z-R>H_.@!=HHVBDW)ZC\Z-R>H_.@!=HHVBDW)ZC\
MZ-R>H_.@!=HHVBDW)ZC\Z-R>H_.@!=HHVBDW)ZC\Z-R>H_.@!=HHVBDW)ZC\
MZ-R>H_.@!=HHVBDW)ZC\Z-R>H_.@!=HHVBDW)ZC\Z-R>H_.@!=HHVBDW)ZC\
MZ-R>H_.@!=HHVBDW)ZC\Z-R>H_.@!=HHVBDW)ZC\Z-R>H_.@!=HHVBDW)ZC\
MZ-R>H_.@!=HHVBDW)ZC\Z-R>H_.@!=HHVBDW)ZC\Z-R>H_.@!=HHVBDW)ZC\
MZ-R>H_.@!=HHVBDW)ZC\Z-R>H_.@!=HHVBDW)ZC\Z-R>H_.@!=HHVBDW)ZC\
MZ-R>H_.@!=HHQ2;D]1^=&Y/4?G0 NT>E&!2;D]1^=&Y/4?G0 NT4;12;D]1^
M=&Y/4?G0 NT4;12;D]1^=&Y/4?G0 NT4;12;D]1^=&Y/4?G0 NT4;12;D]1^
M=&Y/4?G0!+:_\?4/^^O\ZZ>+[M<Q:LOVB+!R=ZX (SUKHQ,45<(S9&>* )Z*
M** &D=37'^,K'Q;>7T(T$:";4("W]JK*9-^3G;L' QM_&NRI* /-/['^(_9_
M#..V7N?\*/['^(_]_P ,?]_+G_"O2Z6@#S/^Q_B/_?\ #'_?RY_PH_L?XC_W
M_#'_ '\N?\*],HH \S_L?XC_ -_PQ_W\N?\ "C^Q_B/_ '_#'_?RY_PKTRB@
M#S/^Q_B/_?\ #'_?RY_PH_L?XC_W_#'_ '\N?\*],HH \S_L?XC_ -_PQ_W\
MN?\ "C^Q_B/_ '_#'_?RY_PKTRB@#S/^Q_B/_?\ #'_?RY_PH_L?XC_W_#'_
M '\N?\*],HH \S_L?XC_ -_PQ_W\N?\ "C^Q_B/_ '_#'_?RY_PKTRB@#S/^
MQ_B/_?\ #'_?RY_PH_L?XC_W_#'_ '\N?\*],HH \S_L?XC_ -_PQ_W\N?\
M"C^Q_B/_ '_#'_?RY_PKTRB@#S/^Q_B/_?\ #'_?RY_PH_L?XC_W_#'_ '\N
M?\*],HH \S_L?XC_ -_PQ_W\N?\ "C^Q_B/_ '_#'_?RY_PKTRB@#S/^Q_B/
M_?\ #'_?RY_PH_L?XC_W_#'_ '\N?\*],HH \S_L?XC_ -_PQ_W\N?\ "C^Q
M_B/_ '_#'_?RY_PKTRB@#S/^Q_B/_?\ #'_?RY_PH_L?XC_W_#'_ '\N?\*]
M,HH \S_L?XC_ -_PQ_W\N?\ "C^Q_B/_ '_#'_?RY_PKTRB@#S/^Q_B/_?\
M#'_?RY_PH_L?XC_W_#'_ '\N?\*],HH \S_L?XC_ -_PQ_W\N?\ "C^Q_B/_
M '_#'_?RY_PKTRB@#S/^Q_B/_?\ #'_?RY_PH_L?XC_W_#'_ '\N?\*],HH
M\S_L?XC_ -_PQ_W\N?\ "C^Q_B/_ '_#'_?RY_PKTRB@#S/^Q_B/_?\ #'_?
MRY_PH_L?XC_W_#'_ '\N?\*],HH \S_L?XC_ -_PQ_W\N?\ "C^Q_B/_ '_#
M'_?RY_PKTRB@#S/^Q_B/_?\ #'_?RY_PH_L?XC_W_#'_ '\N?\*],HH \S_L
M?XC_ -_PQ_W\N?\ "C^Q_B/_ '_#'_?RY_PKTRB@#S/^Q_B/_?\ #'_?RY_P
MH_L?XC_W_#'_ '\N?\*],HH \S_L?XC_ -_PQ_W\N?\ "C^Q_B/_ '_#'_?R
MY_PKTRB@#S/^Q_B/_?\ #'_?RY_PH_L?XC_W_#'_ '\N?\*],HH \S_L?XC_
M -_PQ_W\N?\ "C^Q_B/_ '_#'_?RY_PKTRB@#S/^Q_B/_?\ #'_?RY_PH_L?
MXC_W_#'_ '\N?\*],HH \S_L?XC_ -_PQ_W\N?\ "C^Q_B/_ '_#'_?RY_PK
MTRB@#S/^Q_B/_?\ #'_?RY_PH_L?XC_W_#'_ '\N?\*],HH \S_L?XC_ -_P
MQ_W\N?\ "C^Q_B/_ '_#'_?RY_PKTRB@#S/^Q_B/_?\ #'_?RY_PH_L?XC_W
M_#'_ '\N?\*],HH \S_L?XC_ -_PQ_W\N?\ "C^Q_B/_ '_#'_?RY_PKTRB@
M#S/^Q_B/_?\ #'_?RY_PH_L?XC_W_#'_ '\N?\*],HH \S_L?XC_ -_PQ_W\
MN?\ "C^Q_B/_ '_#'_?RY_PKTRB@#S/^Q_B/_?\ #'_?RY_PH_L?XC_W_#'_
M '\N?\*],HH \S_L?XC_ -_PQ_W\N?\ "J6M>&?B1JFDWMD+O0+,W$$D(N;6
M>YCFAW*1O1]IVL.H.."!7K%&T4:K8-U8\=\,^!_B+X8T2STU=4TG55M0RK<Z
ME<W$DT@;KO8*,X[<5K?V/\1_[WA?\'N?\*],VBC%5)\SNQ)65D>:?V/\1_[_
M (8_[^7/^%']C_$?^_X8_P"_ES_A7IE%2,\S_L?XC_W_  Q_W\N?\*/['^(_
M]_PQ_P!_+G_"O3** /,_['^(_P#?\,?]_+G_  H_L?XC_P!_PQ_W\N?\*],H
MH \S_L?XC_W_  Q_W\N?\*/['^(_]_PQ_P!_+G_"O3** /,_['^(_P#?\,?]
M_+G_  H_L?XC_P!_PQ_W\N?\*],HH \S_L?XC_W_  Q_W\N?\*/['^(_]_PQ
M_P!_+G_"O3** /,_['^(_P#?\,?]_+G_  I/['^)'9O"_P"+7)_I7IM)1U \
M:\6> ?B-XKT&XTMM6TC2#<!%?4-)GN8;N$(P93')CN1@@]JN:3X9^)&FZ;8V
MC3^&[LVL"0?:+J6YEFD*J<LS[1SD^E>L[1Z4;1QQTIW;278E12=SS,:/\1\#
MY_#'_?RY_P *7^Q_B/\ W_#'_?RY_P *]+I:11YG_8_Q'_O^&/\ OY<_X4?V
M/\1_[_AC_OY<_P"%>F44 >9_V/\ $?\ O^&/^_ES_A1_8_Q'_O\ AC_OY<_X
M5Z910!YG_8_Q'_O^&/\ OY<_X4?V/\1_[_AC_OY<_P"%>F44 >9_V/\ $?\
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M_P"&/^_ES_A1_8_Q'_O^&/\ OY<_X5Z910!YG_8_Q'_O^&/^_ES_ (4?V/\
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M?V/\1_[_ (8_[^7/^%>F44 >9_V/\1_[_AC_ +^7/^%']C_$?^_X8_[^7/\
MA7IE% 'F?]C_ !'_ +_AC_OY<_X4?V/\1_[_ (8_[^7/^%>F44 >9_V/\1_[
M_AC_ +^7/^%']C_$?^_X8_[^7/\ A7IE% 'F?]C_ !'_ +_AC_OY<_X4?V/\
M1_[_ (8_[^7/^%>F44 >9_V/\1_[_AC_ +^7/^%']C_$?^_X8_[^7/\ A7IE
M% 'F?]C_ !'_ +_AC_OY<_X4?V/\1_[_ (8_[^7/^%>F44 >9_V/\1_[_AC_
M +^7/^%']C_$?^_X8_[^7/\ A7IE% 'F?]C_ !'_ +_AC_OY<_X4?V/\1_[_
M (8_[^7/^%>F44 >9_V/\1_[_AC_ +^7/^%']C_$?^_X8_[^7/\ A7IE% 'F
M?]C_ !'_ +_AC_OY<_X4?V/\1_[_ (8_[^7/^%>F44 >9_V/\1_[_AC_ +^7
M/^%']C_$?^_X8_[^7/\ A7IE% 'F?]C_ !'_ +_AC_OY<_X4?V/\1_[_ (8_
M[^7/^%>F44 >9_V/\1_[_AC_ +^7/^%']C_$?^_X8_[^7/\ A7IE% 'F?]C_
M !'_ +_AC_OY<_X4?V/\1_[_ (8_[^7/^%>F44 >9_V/\1_[_AC_ +^7/^%'
M]C_$?^_X8_[^7/\ A7IE% 'F7]C_ !(5@0_AE<<[DDN-P^F5Q7H\*LN\L<EC
MGKTX _QJ7 /448H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***:S;03V
M% #J*9NW8X/3.:;YIW[=I P?F.,#I[^] $M%,CDW\%2IYZ_6G4 +14?F4\4
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M2WUI<&.,_N9XH@9(VB+NP.Z+/F 9E"LJ=+J*ZKIWPPT\1:-96VJQI9RS:?\
M8_.M;+;)$97C@1P6$05W5%<$E0%RQ H Z72_B!X;UR&6;3O$.EZC#$\4<DEI
M>12*C2MMC#%6.-[<+G[W;-):_$+P[>:)/K4.MZ=)H]NP26_6[C\B-N!M:3=M
M5LLHVD@@D>HKQSQ#IM]XFUJQC:+Q!XFTY?)BGGUS2U@5 =3TUY(O*6")W4Q!
MW)=2NU" 3B0+WOQ"L;LZ_HFIKJ6I65A8QSB5],MH[J9'D:)8F$1B<LI"RQ[H
MP9!Y@Z*ST =IIOB#3?$6F17FF:A;WUG<@B"ZM7$D<O.,J5.& .>GI6#HWB1[
M>VU&\U[4M%CM5OKA+*:TF)0VT>6"NS8!F41R;U7(&T^AJA\-=+L]*T_4;BW?
M6)AJ>H//+=:Q9I:37,GEHAD\I(8B@_=8^9%))8C(92<2T\/7%U'X3%[8R7/V
M7QAJ=ZRS6[$(F[4FAD.>G,D95N@)4CL: .\M?'GAV^MXIK77--N8);A+..6&
M[C*/.PRL2L&P78=%'6KYUZQ75CI9NX/[2$/VG[$)5,WD[MOF;,YV[OESCKQU
MKS;QEX/OM6UCQPVD0?9M4ET?2[JTF@\M3-?V]Q=2PAW=<-ADA4[L_*W:J$NB
MZCX_\-^(]9BAU+3)]9>R6+2;Y(HKI+&WD$DD3Q.I3S)'>[P'9XF$D>X["5 !
MZ=H?C/1?$S2#2-5LM4$9"R-9W,<GED@D!@K$J3@X!'8^E9>H?%+PU#X=UO5K
M;5[35+;28/.NETZZAFD7()1,;\!WQA <9)%<98>'=-\2:QJFH3_\)1XBF?2+
MC2IAJFEQ:?YMO(ROY",T-N[L=K;&WE4+/N*,PS4O;76O&&D>(=,M1=:Q;OH=
M_96UQJNB2:==I-*L?E1^:ZQ*Z/AL^6B!1&@<EOF8 [6/Q8/$6O:0WAG5_#VI
MZ&IG&I,DXFFRH0*(2A*Y5I(]^[H'4\Y%:.E?$OPKKEY!::;XCTK4+F<N(8;6
M]BD>7:NYMBJV6PN#QGBN!^(%TWBZUU"ZTZVU&%!X7UNU\^_M); 12/\ 9"JD
MSQQ[<A20Q(7]V_WMIVV_"WB#4]0\2:3J7B2VN[22Y@EL--#645M$[2*D[I(B
MW5Q)YH6V++G8 $=3\Q7(!W4/CGP_J.L2:-:Z]IMQJREE:PAO(VN%*YW QAMP
MQM;.0,$&N3USXK:?JD.K:3X9\0:''XGMKQ;"T75;Q$CGF^1G";=S/PSIA5SO
MC=>,9KD)/[8O-)\/63KK8GMM1TM[O1++0UM]*LUCNH/ECD:++1Q[ ?W4KY(#
M !,[=CQ,MS;ZAKNF"PU"6XU3Q-I-];-9V-Q(C0Q_85D=[A%*1D?99@=[*0%!
M_B7(!Z5K'B+3/#MK%<ZKJ-II5K),L$,EU<I"LCMRJ L0"QP2 .2 :;=>--#L
M=-M]1N-9L+?39H!<QWDMU&D+0G;B0.6VLA,D8W D9=?[PKF-6F;0_&3Z_?07
ME[I]UIL-G;365I-=/;2J\[R@11!G02!H<E1@^0H8_*E8V@^'+F?XG6NKS:7/
M!I\D>J7-E]HB/^AM(-/7=M(_=O*RW4F,AB)'W ,750#T"3QEH2Z(VKOK%@NC
MCAM0^U1BW'S;/]9NV_?^7_>XZUBMX\L-0O/#C:#J=CK%KJ&IM8W,UE.DZKBT
MGG RI(!RJ=>Q'KSR5Y::CH-]KLEA9G3K*3Q']HDG@THW,UO%)IT8DN;:-0=\
MAG81[E1P#)(75OFQFZ+:ZM??%#2M0(\0:GIRW-LJ:EK-@+=V"VNK+)B-(HMD
M8=XP&D16+2#&Y6B) /<=QVY R?2N)'Q,T;1M6U^'7=:TW2([._6VMFOKJ.W$
MD?V2WG<_.1NP9CG&<97.*V]$\6Z?XFEU:#3Y&G;3;QM/N&7&WSEC5W0,">5W
MA3Z,".HKAK:ZM=,\5>-DU#PWJ&H+J]W''$UOI+3QZC&+&W7RS+RBJ&WKNE*1
M?O&&[*R;0#N]=\7:-X9L/M&LZM::1:,RPBZO;A(4,AR-@9B/F&"<'_'&?=ZM
M>7WB+P\-&NM&N-(N(9;FZCE8M=2P@+Y<MN <,NYE!8\892"<@5PD^B:WH-SH
MVH:SKNNP2Q:):Z4]UHED-2D-VF]IW*/;RNOFCRR'55#>4!)AA&M:'A'PJFA:
M_P"$X=.L+ZWTJUTW5U$EY9I&R^;=VDJC;&JI&' =E3"L B@KN1@ #M;/XA>&
MK^_@L+7Q!I=QJ$Z"2*SAO8FF=3&)0RH&R1Y;*^1QM(/0YJ/_ (65X8_M5M+'
MB#2O[5$OD?V>;Z(3^9NV[-A;.[./EZ\CIFN&L?"HB^$?@*R;3&6ZTZ71[AH#
M;[989A/;M+(>P8*9BYSSN>N?^&.H:N-%\#GQ!;W$.B:6+>&QO(;2!8WG:-K.
M-GD%Y*TT3F; =(55RR2!@AY />FF/ICC)Z8'UY]JYZW^)GA.]L;Z]M_%&C36
M=CM-U<)?Q-';[F*CS&W87+ KR1D@CJ*A^(>AWNO^$KFSLI)%G,L4C);F/=+"
MLRM)&!(#&6:,,H#_ "$D!B%R:XG2O"EGXQU/57N-1\47UQ=Z/+HTNHZGI$>G
MO'#*02JDVT)=N"ZD!D4[LA20& /3;_Q1I&EW$-O>ZK9V,\R2R117,Z1M(L2A
MI64$_,$!!8C[HZXKG==^)FF2^"/$>L>'M4T_5IM-TV:\W6UU'-'&PA9X]Y4G
M ;;P>A ->?Z?)XJ\2:2GB#4]/N!JFBV=GI<EGJ=@LD4ER)X9KV^2&(@S "*)
MHO+DY9&"KN(%5/%%E?:\==\BX\2:Y9_\(GK%FMSJVFQVP6>06Q6")%MXI"Q7
MG!4@[=JDL)  #W7[5&UT]L)!YT:JYC0\A6)VD^F2C@?2LW4/'6A:38_;KW5[
M&SL?M#6HN;BZBCC\Y2ZM'N9@-P:-UQURI[#-<UJ&K2>%_B5J-_=Z;JTEE?Z3
M:P1W=E8R7D8>"6Y)5EAW.&/VE2,KC"-E@<9Y;3)-<T_3]-EFT^\T&&>\UI[J
MYATS[9J$!DOVFCB0()E19 2Q8HZGRE .61@ =[JWQ<\)Z/#HES-KVG-8:Q-)
M#;7R7D1@^1'9W+EP"@9/+R,X=T4]>+VH_$+PYI%O93WVNZ=8PWT33VCW5W'$
MMQ&JAF>-F8!U"LIR#P#7F&@V^J07RZS<0Z[?6UOXH-\]Q?68%Q-;MH_D1RB*
M).07>,?NTROS;U78X%C5-/6XUK6KV_U/Q#:Z1X@B@FM8['1%NDDM1!$CPSQ2
MVDLD1#EV,;JJ@3$C+&4* >I:YXGTOPY )]8U"TTJU:584FOITAC=V!*J&8X)
M.#P.3Z5G>%?$#:]I-S-<-&K#4+VQW+T'E74L*;O0[43ZDUQFDQV_@.^THW.E
MZLVF?\(_:Z99+]AFOIM/>++3I,858*75X"74[7:W8$Y1,[?PEM'T_P '&S?2
MY-%"ZCJ#+ITEOY#6T37L[(H"DJ1AA@H=K Y4XYH O:+XC>&"_NM>U'18+=;Z
MXCLYK><A/L\99MLCOA?-01R;PN0NP]@:W-&\5:1XBMS-I.JV.J0JVPO97"2K
MN[C*D\\C\Z\YM?#MQ?+X4%]9/<BU\8ZI>LLMN66-"VI-#)@^A>,JQX!*$#BN
METS1_L7Q*\3WB6\,$=UIFG;Y8U$:R2I)>;B2!DL$\H')Z*O2@#=U+Q9H^F3V
M5K>ZM9V-QJ#F.SCN;A(WN6XXB#$;SROW<]:YFW\5:QJ-OIDMM/I-M/)K]UI\
MT-^9$,UM!<3HWDX)W2[(0V#QUS@#FI+>1Z%XP\6Q:GH^HZO)JGD26S6NF27"
M26YA6(6AEV[$_>QSOM=EC47.XL"SXI:1I=Y9OX4@>T9'A\4ZK.T0C;;%"PU+
MRI&Q]T,)(<%L@EEQ0!VMUX^\,P7MO8R>(M)BO+IWA@MY+V(/*ZNR,JJ6RQ#H
MZD#G*,.H-1QWFI2>,);59],_L>"S66:-2_VQ+AI1@E/NB(HK<YSG/&!7$ZAX
M2^T?!KQU91Z6);J\EUJY6+R0'GE,\Y@< ?Q#;#L;J J'.16UKNCZMJFO>-H]
M,EFL9[WP];6EC>'=&B7.Z]^8.!D%3)&Q//;'/4 Z>'QAHEY_:D<&L6$LFF _
M;5CNXR;4#=DR8;Y -C_>Q]QO2L'5OB5ID^DQW7A_5-/UDK?Z=;2-;7,<NQ;B
M[BBYP3C<KOM/0[>V*P-0\21:OX5A?0O"<UK-8I"Z1ZSH3QI86ZSPLZ"([&D9
M%1I%2#/S6R\D^7OYG6+34M:\5:5<02>)M<M(G@1[C6--CM!$W]JZ;*55%@BD
M/[M2[,P*83 /$@4 ]Y>;:-Q;:HY8GHOU/^?QK*T/QKH/B99&T?6]/U18]N_[
M'=1R[,Y(W!2<9"MU_NGTJEXZT>\UGPU)!:J)Y%GAFDM5VXN8$G1Y(2&(4EXU
M9,,0I+8) Y&''J)\7>)-$NM*L]0M!83R->7.H6$]F# ]O(/)C\V-#(&E,,A
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\%W(W$_>/?)Q^OZ444 (L)9E8GYASU.,XZX_$_I35M%9BP51N;+^K$8 ;ZX
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488007360440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Krystal Biotech, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-1080209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2100 Wharton Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pittsburgh<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">15203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">586-5830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KRYS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,635,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001711279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488007393416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 269,303<span></span>
</td>
<td class="nump">$ 341,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">165,329<span></span>
</td>
<td class="nump">96,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,366<span></span>
</td>
<td class="nump">4,171<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">437,998<span></span>
</td>
<td class="nump">442,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">136,927<span></span>
</td>
<td class="nump">112,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">33,339<span></span>
</td>
<td class="nump">64,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">8,453<span></span>
</td>
<td class="nump">7,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">616,874<span></span>
</td>
<td class="nump">626,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,209<span></span>
</td>
<td class="nump">8,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,411<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">50,817<span></span>
</td>
<td class="nump">16,297<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">60,437<span></span>
</td>
<td class="nump">25,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td>
<td class="nump">7,883<span></span>
</td>
<td class="nump">6,983<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">68,320<span></span>
</td>
<td class="nump">32,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $0.00001 par value; 20,000,000 shares authorized at &#160;&#160; March&#160;31, 2022 (unaudited) and December&#160;31, 2021; 2,061,773 &#160;&#160; shares issued, and no shares outstanding at March&#160;31, 2022 &#160;&#160; (unaudited) and December&#160;31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $0.00001 par value; 80,000,000 shares authorized at &#160;&#160; March&#160;31, 2022 (unaudited) and December&#160;31, 2021; 25,199,081 &#160;&#160; shares issued and outstanding at March&#160;31, 2022 &#160;&#160; (unaudited); and 25,207,985 shares issued and outstanding at December&#160;31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">740,500<span></span>
</td>
<td class="nump">734,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive expense</a></td>
<td class="num">(1,197)<span></span>
</td>
<td class="num">(163)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(190,749)<span></span>
</td>
<td class="num">(140,784)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">548,554<span></span>
</td>
<td class="nump">593,576<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 616,874<span></span>
</td>
<td class="nump">$ 626,295<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488007458104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">2,061,773<span></span>
</td>
<td class="nump">2,061,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">80,000,000<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">25,199,081<span></span>
</td>
<td class="nump">25,207,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,207,985<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488013246408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 9,314<span></span>
</td>
<td class="nump">$ 6,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">15,908<span></span>
</td>
<td class="nump">8,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">50,222<span></span>
</td>
<td class="nump">14,353<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(50,222)<span></span>
</td>
<td class="num">(14,353)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_InterestIncomeExpenseAndOtherNonoperatingNet', window );">Interest and other income, net</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,492)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(49,965)<span></span>
</td>
<td class="num">(15,812)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale securities and other</a></td>
<td class="num">(1,034)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (50,999)<span></span>
</td>
<td class="num">$ (15,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share: basic (in dollars per share)</a></td>
<td class="num">$ (1.99)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share: diluted (in dollars per share)</a></td>
<td class="num">$ (1.99)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding: basic</a></td>
<td class="nump">25,114,453<span></span>
</td>
<td class="nump">21,253,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding: diluted</a></td>
<td class="nump">25,114,453<span></span>
</td>
<td class="nump">21,253,508<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_InterestIncomeExpenseAndOtherNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest income (expense) and other nonoperating, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_InterestIncomeExpenseAndOtherNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488008564200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Expense</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,714,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 292,084<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 363,292<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">$ (71,214)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,489,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">152,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">2,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on investments and other</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,812)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,204,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">430,652<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">517,675<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(87,026)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,207,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">593,576<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">734,523<span></span>
</td>
<td class="num">(163)<span></span>
</td>
<td class="num">(140,784)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Restricted stock surrendered for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,379)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Restricted stock surrendered for taxes</a></td>
<td class="num">(649)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(649)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">6,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on investments and other</a></td>
<td class="num">(1,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(49,965)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,965)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,199,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 548,554<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 740,500<span></span>
</td>
<td class="num">$ (1,197)<span></span>
</td>
<td class="num">$ (190,749)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488008605032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (49,965)<span></span>
</td>
<td class="num">$ (15,812)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">6,430<span></span>
</td>
<td class="nump">2,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other, net</a></td>
<td class="num">(135)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">820<span></span>
</td>
<td class="nump">1,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_IncreaseDecreaseInLeaseLiability', window );">Lease liability</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(554)<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,013<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment', window );">Accrued legal settlement</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(15,493)<span></span>
</td>
<td class="num">(9,654)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(17,191)<span></span>
</td>
<td class="num">(2,473)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(62,754)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from maturities of investments</a></td>
<td class="nump">24,037<span></span>
</td>
<td class="nump">1,726<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(55,908)<span></span>
</td>
<td class="num">(747)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock, net</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">152,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to settlement of restricted stock awards</a></td>
<td class="num">(649)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_PaymentsForSuitLiability', window );">Repayment of ASTRA build to suit liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,960)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(542)<span></span>
</td>
<td class="nump">144,304<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(71,943)<span></span>
</td>
<td class="nump">133,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">341,246<span></span>
</td>
<td class="nump">268,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">269,303<span></span>
</td>
<td class="nump">402,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosures of Non-Cash Investing and Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid purchases of property and equipment</a></td>
<td class="nump">14,507<span></span>
</td>
<td class="nump">2,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Initial recognition of right-of-use assets</a></td>
<td class="nump">1,394<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_OfferingCostsIncurredButNotYetPaid', window );">Unpaid offering costs</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 214<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Accrued Legal Settlement And In-Process Research And Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_IncreaseDecreaseInLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_IncreaseDecreaseInLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_OfferingCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering Costs Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_OfferingCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_PaymentsForSuitLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Suit Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_PaymentsForSuitLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488009631336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization</a></td>
<td class="text">Organization<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Krystal Biotech, Inc. (the&#160;&#8220;Company,&#8221;&#160;or&#160;&#8220;we&#8221;&#160;or other similar pronouns) commenced operations on April 15, 2016. On March 31, 2017, the Company converted from a California limited liability company to a Delaware C-corporation, and changed its name from Krystal Biotech LLC to Krystal Biotech, Inc. On June 19, 2018, the Company incorporated Krystal Australia Pty Ltd., an Australian proprietary limited company, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies in Australia. On April 24, 2019, the Company incorporated Jeune Aesthetics, Inc., formerly known as Jeune, Inc. ("Jeune"), in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions. On January 7, 2022, the Company incorporated Krystal Biotech Switzerland GmbH, for the purpose of establishing initial operations in Europe for the development and commercialization of Krystal's pipeline.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biotechnology company leading the field of redosable gene delivery. Using our patented platform that is based on engineered herpes simplex virus type 1 ("HSV-1"), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#8217;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a doctor&#8217;s office or potentially in the patient&#8217;s home by a healthcare professional. Our goal is to develop easy to use medicines to dramatically improve the lives of patients living with debilitating diseases.  Our innovative technology platform is supported by in-house, commercial scale current good manufacturing practices ("cGMP") manufacturing capabilities.  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the Company had an accumulated deficit of $190.7 million. With the net proceeds raised from its public and private securities offerings the Company believes that its cash, cash equivalents and short-term investments of approximately $434.6 million as of March&#160;31, 2022 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q. As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company&#8217;s cost structure. The Company may never achieve profitability and unless and until it does, the Company will continue to need to raise additional capital or obtain financing from other sources. Management intends to fund future operations through the sale of equity and debt financings and may also seek additional capital through arrangements with strategic partners or other sources. There can be no assurance that additional funding will be available on terms acceptable to the Company, if at all.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to the failure of product candidates in clinical and preclinical studies, the development of competing product candidates or other technological innovations by competitors, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to c</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ommercialize product candidates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488009514632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;), as found in the Accounting Standards Codification (&#8220;ASC&#8221;), the Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;), and the rules and regulations of the US Securities and Exchange Commission (&#8220;SEC&#8221;).  In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods ended March&#160;31, 2022 and 2021, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation.  Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company&#8217;s previously reported financial position or results of operation.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, as filed with the SEC on February 28, 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The novel coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect our business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. However, the full extent, consequences, and duration of the&#160;COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that these events could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and Geographical Information</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#8217;s chief operating decision maker view the Company&#8217;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceuticals. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#8217;s policy is to invest its cash, cash equivalents and investments in money market funds, certificates of deposit, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Investments</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments with maturities of greater than 90 days but less than one year are classified as short-term investments on the consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity in the consolidated balance sheets. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#8217;s financial statements, are reasonable estimates of fair value, primarily due to their short maturities. Marketable securities are classified as long-term investments if the Company has the ability and intent to hold them and such holding period is longer than one year. The Company classifies all of its investments as available-for-sale.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale, short-term and long-term investments, which consist of, commercial paper, corporate bonds, and government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of remaining useful life or remaining lease term</span></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress ("CIP") is not depreciated until the asset is placed in service.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has not recognized any impairment losses for the three months ended March&#160;31, 2022 and 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, Leases ("ASC 842"). Right-of-use lease assets represent our right to use an underlying asset during the lease term and the lease obligations represent our commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#8217;s lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, we have used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain "sale-leaseback" criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on our assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, related clinical manufacturing costs, contract management services, regulatory and other related costs.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#8217;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third party service providers and the Company&#8217;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value recognition provisions of Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 718"), to account for stock-based compensation. Compensation costs related to stock options granted is based on the estimated fair value of the awards on the date of grant. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Once the Company's own sufficient historical volatility data was obtained, the Company eliminated the use of a representative peer group and uses only its own historical volatility data in its estimate of expected volatility.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the expected term of its stock options using the &#8220;simplified&#8221; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses and is presented net of taxes. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU 2020-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2020-08") to provide further clarification and update the previously issued guidance in ASU 2017-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20: Premium Amortization on Purchased Callable Debt Securities) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2017-08").  ASU 2017-08 shortened the amortization period for certain callable debt securities purchased at a premium by requiring that the premium be amortized to the earliest call date. ASU 2020-08 requires that at each reporting period, to the extent that the amortized cost of an individual callable debt security exceeds the amount repayable by the issuer at the next call date, the excess premium shall be amortized to the next call date. The new standard was effective beginning January 1, 2021 and should be applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. The adoption of ASU 2020-08 did not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488009649752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text">Net Loss Per Share Attributable to Common Stockholders<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of shares of common stock and common share equivalents outstanding for the period. Common share equivalents consist of common stock issuable upon exercise of stock options and vesting of restricted stock awards. There were 3,226,962 and 1,423,540 common share equivalents outstanding as of March&#160;31, 2022 and 2021, respectively, in the form of stock options and unvested restricted stock awards, that have been excluded from the calculation of diluted net loss per common share as their effect would be anti-dilutive for all periods presented.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.596%"><tr><td style="width:1.0%"/><td style="width:64.187%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.683%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except shares and per share data)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,965)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,812)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; diluted common shares</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,114,453&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,253,508&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per<br/>&#160;&#160; common share</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.99)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.74)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488009626808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Instruments</a></td>
<td class="text">Fair Value Instruments<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category as of March&#160;31, 2022 and December&#160;31, 2021, respectively (in thousands):</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,741&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(724)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,961&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,058&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(440)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,281&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199,867&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,201)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198,668&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165,329&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,339&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469,170&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,201)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467,971&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,303&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165,329&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:22.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(114)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,196&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,768&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,428&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,390&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,221&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,850&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,371&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502,636&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,371&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company&#8217;s short-term marketable securities mature in one year or less.</span></div><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company's long-term marketable securities mature between one year and two years.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 to these unaudited condensed consolidated financial statements for additional discussion regarding the Company&#8217;s fair value measurements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488009693208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,933&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,340&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,736&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,723&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,938&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,530&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,603&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,569&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,676)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,214)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,927&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,355&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $462 thousand and $438 thousand for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-indent:29.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical and clinical expenses</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,647&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,168&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,011&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,560&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction in progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,097&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,606&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued financing costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation settlement</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,817&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,297&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488009525304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Contracts and Agreements</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Agreements</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2016, the Company signed an operating lease for laboratory and office space that commenced in June 2016 and expired on October 31, 2017 (the &#8220;2016 Lease&#8221;). The 2016 Lease has been amended several times to increase the area leased, which currently consists of approximately 47,000 square feet and includes the commercial scale cGMP-compliant manufacturing facility, ANCORIS.  As a result of the lease amendments, the lease expiration date was extended to October 31, 2031. </span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 26, 2019, we entered into a lease agreement for our second commercial gene therapy facility ("ASTRA") in the Pittsburgh, Pennsylvania area ("ASTRA lease") with Northfield I, LLC (the "Landlord", "Northfield", or "Lessor") with </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an initial lease term that expired on October 31, 2035.  The ASTRA lease contained an option ("Purchase Option") to purchase the building, related improvements and take corresponding assignment of the Landlord's rights under its existing Ground Lease (the "Ground Lease"). A cash contribution in the amount of $2.4&#160;million was paid to escrow on January 21, 2020. The contribution was intended to reduce the amount of the building construction costs and had the effect of reducing the base rental rate of the lease and as such, was recorded as prepaid rent in the consolidated balance sheet at the time of payment.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2020, the Company was provided with notice that the initial delivery conditions of the building had been met, including completion of the building shell, interior slab, and exterior doors, and on October 15, 2020, the Company gave the Landlord notice of its intent to purchase ASTRA for approximately $9.4&#160;million, subject to the parties entering into a commercially reasonable purchase and sale agreement. As a result of the Company's ability to exercise its option to purchase ASTRA, the Company obtained control over the construction in progress of ASTRA as of October 5, 2020.  The Company recorded a $10.0&#160;million CIP asset and a corresponding build to suit lease liability related to the costs incurred by the Landlord, offset by the previous cash contribution of $2.4&#160;million.  </span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2021, the Company entered into a Purchase and Sale Agreement ("PSA") for ASTRA with Northfield related to the purchase option exercised by the Company on October 15, 2020, for a purchase price of $9.4&#160;million. The Company held approximately $1.5&#160;million on deposit with Northfield under the existing lease agreement and applied this deposit as a credit against the purchase price at closing. On February 1, 2021, Northfield delivered the space as substantially complete and made the space available for access by the Company, thus triggering lease commencement.  As a result, the Company concluded that this transaction did not qualify for sale-leaseback accounting because it did not meet the definition of a sale.  As control did not transfer to the Lessor at lease commencement, the transaction continued to be accounted for as construction in progress and a financing obligation. On March 5, 2021, the purchase closed and the Company determined that reclassification of the construction in progress to buildings and leasehold improvements was not appropriate as the interior of the building was not yet ready for its intended use. The building continues to be held under construction in progress as of March&#160;31, 2022. The interior of the building is currently under construction and is expected to be completed and validated in 2022.  From construction completion to the closing of the purchase, the Company recognized interest expense to accrete the financial obligation to a balance that equaled the cash consideration that was paid upon the close of purchase. For more information about the expected construction costs associated with ASTRA, see "ASTRA Contractual Obligations" below.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the transaction, the Company also became the accounting owner of the Ground Lease, due to obtaining control over ASTRA, and recorded the applicable operating right-of-use asset and corresponding lease liability as of October 5, 2020. When the PSA was finalized, the Company took assignment of the Lessor's Ground Lease, in accordance with the Purchase Option, of which lease payments are based on annual payments of $82&#160;thousand, and are subject to a cumulative 10% escalation clause every 5 years through 2071. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 15, 2021, the Company entered into a 3 year lease agreement for our Boston, Massachusetts office (the "Boston Lease") location that commenced in January 2022 and expires in January 2025.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, future minimum commitments under the Company&#8217;s operating leases were as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"/><td style="width:83.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.756%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining nine months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,487&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental condensed consolidated balance sheet information related to leases is as follows:</span></div><div style="margin-top:2pt;text-indent:29.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,453&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,228&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,883&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,983&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,294&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,024&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term, in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:2pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded operating lease costs of $409 thousand and $218 thousand for the three months ended March&#160;31, 2022 and 2021, respectively, and variable lease costs of $49 thousand and $37 thousand for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Agreements with Contract Manufacturing Organizations and Contract Research Organizations</span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various agreements in the normal course of business with Contract Research Organizations ("CROs"), Contract Manufacturing Organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. The agreements with CMOs relate to the manufacturing of sterile gel that is mixed with in-house produced vectors as part of the final drug product applied in certain of our clinical trials. These agreements may also include research and development activities, storage, packaging, labeling, and/or testing of our preclinical and clinical-stage products. The Company is obligated to make milestone payments under certain of these agreements. The estimated remaining commitment as of March&#160;31, 2022 under these agreements is approximately $3.1 million. The Company may also be responsible for the payment of a monthly service fee for project management services for the duration of any agreements. The Company has incurred expenses under these agreements of $1.8 million for each of the three months ended March&#160;31, 2022 and 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Preparedness Activities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to facilitate, coordinate and perform agreed upon commercial preparedness and market research activities relating to our lead product candidate. These contracts typically call for the payment of fees for services upon the achievement of certain milestones. The estimated remaining commitment as of March&#160;31, 2022 is $4.3 million. The Company has incurred expenses under these activities of $3.1 million and $1.3 million for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASTRA Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracted with various third parties to construct our second cGMP facility, ASTRA. Additionally, we have entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. The estimated remaining commitment as of March&#160;31, 2022 is $20.2 million. The Company has included costs incurred to-date associated with ASTRA within construction in progress as of March&#160;31, 2022.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On June 30, 2021, the Company entered into a Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction (collectively, the &#8220;Agreement&#8221;) with The Whiting-Turner Contracting Company (&#8220;Whiting-Turner&#8221;), pursuant to which Whiting-Turner is constructing and managing the construction of ASTRA. Subject to certain conditions in the Agreement, the Company will pay Whiting-Turner a contract price consisting of the cost of work plus a fee equal to 1.75% of the cost of work. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective September 13, 2021, the Company entered into a guaranteed maximum price amendment (the "Amendment") to the Agreement to set forth the guaranteed maximum price, as well as the date by which Whiting-Turner is to achieve Substantial Completion (as defined in the Agreement). Under the Amendment, the guaranteed maximum price to be paid by the Company is $82.3&#160;million, subject to certain additions and deductions by change orders as provided by the Agreement. Whiting-Turner&#8217;s work under the Agreement represents a portion of the work necessary to complete construction </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the ASTRA facility and, therefore the date of Substantial Completion of Whiting-Turner&#8217;s work under the Agreement does not equate to the date of completion of ASTRA. The guaranteed maximum price under the Agreement constitutes only a portion of the total estimated cost of building and equipping ASTRA. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2020, a complaint was filed against us in the United States District Court for the Western District of Pennsylvania by PeriphaGen, Inc. ("PeriphaGen"), which also named our Chief Executive Officer and President, R&amp;D, Krish Krishnan and Suma Krishnan, respectively. The complaint alleged breach of contract and misappropriation of trade secrets, which secrets the plaintiff asserted were used to develop our product candidates, including the vector backbones, and our STAR-D platform. We answered the complaint on June 26, 2020 by denying the allegations and brought a counterclaim asking the court to declare that we did not misappropriate PeriphaGen&#8217;s trade secrets or confidential information, and to further declare that we are the rightful and sole owner of our product candidates and STAR-D platform. In addition, we filed a third-party complaint against two principals of PeriphaGen, James Wechuck and David Krisky, alleging breach of contract and seeking contribution and indemnification from them in the event PeriphaGen is awarded damages. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2022, the court officially ordered the parties to attend mediation on March 11, 2022.  During the course of the mediation process, the parties were able to exchange information, allowing the parties to value their positions.  On March 12, 2022, we entered into a binding term sheet.  In consideration of settling the dispute, the acquisition of certain PeriphaGen assets, and the grant of a license by PeriphaGen for dermatological applications, Krystal made a payment of $25.0&#160;million on April 28, 2022.  Upon approval of Krystal&#8217;s first product by the U.S. Food and Drug Administration ("FDA"), Krystal will pay an additional $12.5&#160;million, followed by three additional $12.5&#160;million contingent milestone payments upon reaching $100.0&#160;million in total cumulative sales, $200.0&#160;million in total cumulative sales and $300.0&#160;million in total cumulative sales. As defined in the settlement agreement, cumulative sales shall include all revenue from sales of Krystal products by Krystal and its affiliates and licensees, as reported by Krystal in its annual Form 10-K filings. If all milestones are achieved, the total consideration for settling the dispute, acquiring certain assets, and granting of a license from PeriphaGen will be $75.0&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final settlement agreement was signed on April 28, 2022, and, because we deemed settlement to be probable as of the balance sheet date, we have recorded an accrued liability equal to the settlement of $25.0&#160;million under accrued expenses and other current liabilities on the condensed consolidated balance sheet and under litigation settlement expense on the condensed consolidated statements of operations.  The additional contingent milestone payments were not deemed probable due to uncertainty in the achievement of these milestones as of March 31, 2022, and therefore no additional accrual has been recorded.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has received $768&#160;thousand of insurance proceeds during the three months ended March&#160;31, 2022  and we have recorded an additional $301&#160;thousand as a receivable within prepaid expenses and other current assets on the condensed consolidated balance sheet as management determined that the amount was probable of collection relating to legal defense costs and expenses associated with the PeriphaGen litigation. The reimbursements have been recorded as an offset to our legal fees included in general and administrative expenses on the condensed consolidated statements of operations and within operating activities on the condensed consolidated statements of cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488009735240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capitalization</a></td>
<td class="text">Capitalization<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2021, the Company completed a public offering of 2,866,667 shares of its common stock, including 200,000 shares purchased by the underwriters, at $75.00 per share.  Net proceeds to the Company from the offering were $201.9&#160;million after deducting underwriting discounts and commissions of approximately $12.9&#160;million, and other offering expenses payable by the Company of $227&#160;thousand.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2021, the Company completed a public offering of 2,211,538 shares of its common stock, including 288,461 shares purchased by the underwriters, at $65.00 per share.  Net proceeds to the Company from the offering were $134.9&#160;million after deducting underwriting discounts and commissions of approximately $8.6&#160;million, and other offering expenses payable by the Company of $198&#160;thousand.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company entered into a sales agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen") with respect to an at-the-market equity offering program ("ATM Program"), under which Cowen will act as the Company's agent and/or principal and may issue and sell from time to time, during the term of the Sales Agreement, shares of our common stock, having an aggregate offering price up to $150.0&#160;million ("Placement Shares").  Related offering expenses payable by the Company were $172 thousand.  The issuance and sale of the Placement Shares by the Company under the Sales Agreement will be made pursuant to the Company's effective "shelf" registration statement on Form </span></div>S-3. During the three months ended March&#160;31, 2021, 262,500 shares of common stock were issued pursuant to the ATM Program at a weighted average price of $66.50 per share for net proceeds of $16.9&#160;million after deducting underwriting discounts and commissions of approximately $524&#160;thousand, resulting in a remaining $132.5&#160;million available for issuance under the ATM Program.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488009508168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted to employees vest ratably over four-year periods and stock options granted to directors of the company vest ratably over one year to four-year periods. Stock options have a life of ten years. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 1,179,500 and 502,450 stock options to employees and directors of the Company during the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:38.740%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.460%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In&#160;thousands)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,043,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,179,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,475)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,342)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,152,862&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.99&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,364&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439,954&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.52&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,929&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Aggregate intrinsic value represents the difference between the closing stock price of our common stock on March&#160;31, 2022 and the exercise price of outstanding in-the-money options.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value (the amount by which the fair market value exceeds the exercise price) of stock options exercised during the three months ended March&#160;31, 2022 and 2021 was $36&#160;thousand and $808&#160;thousand, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value per share of options granted to employees and directors during the three months ended March&#160;31, 2022 and 2021 was $43.09 and $50.04, respectively.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $101.1 million of unrecognized stock-based compensation expense related to employees' and directors&#8217; option awards that is expected to be recognized over a weighted-average period of 3.4 years as of March&#160;31, 2022.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three months ended March&#160;31, 2022 and 2021 as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.842%"><tr><td style="width:1.0%"/><td style="width:53.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.982%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.887%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,950&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,131&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the portion of stock-based compensation that relates to work performed on the construction of new buildings. There was $141&#160;thousand and $37&#160;thousand of stock-based compensation that was capitalized in the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense of $6.0 million and $2.1 million for the three months ended March&#160;31, 2022 and 2021, respectively. The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three months ended March&#160;31, 2022 and 2021:</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.672%"><tr><td style="width:1.0%"/><td style="width:54.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.004%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.348%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of the award (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.22</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.53</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.46</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards ("RSAs") granted to employees vest ratably over a four-year period. The Company granted zero and 98,800 RSAs to employees of the Company during the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"><tr><td style="width:1.0%"/><td style="width:50.452%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.630%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,379)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $5.7 million of unrecognized stock-based compensation expense related to employees&#8217;&#160;awards that is expected to be recognized over a weighted-average period of&#160;2.9 years as of March&#160;31, 2022.</span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to RSAs of $480 thousand and $182 thousand for the three months ended March&#160;31, 2022 and 2021, respectively, within general and administrative expenses in the accompanying condensed consolidated statements of operations (in thousands):</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.134%"><tr><td style="width:1.0%"/><td style="width:53.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.783%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares remaining available for grant under the Company&#8217;s stock incentive plan were 1,028,815, with a sublimit for incentive stock options of 26,546, at March&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488009692376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 28, 2022, the Company entered into a final settlement agreement and paid PeriphaGen an upfront payment of $25.0&#160;million for: (i) the resolution of all claims in the trade secret litigation with PeriphaGen, Inc.; (ii) the acquisition of certain PeriphaGen assets, and (iii) the grant of a license by PeriphaGen for dermatological applications.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2022, pursuant to an inbound request, the Company issued and sold 434,782 shares of common stock at a weighted average price of $69.00 per share, under it's ATM Program, for net proceeds of $29.1&#160;million after deducting underwriting discounts and commissions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488008628040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;), as found in the Accounting Standards Codification (&#8220;ASC&#8221;), the Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;), and the rules and regulations of the US Securities and Exchange Commission (&#8220;SEC&#8221;).  In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods ended March&#160;31, 2022 and 2021, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation.  Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company&#8217;s previously reported financial position or results of operation.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, as filed with the SEC on February 28, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The novel coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect our business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. However, the full extent, consequences, and duration of the&#160;COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that these events could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographical Information</a></td>
<td class="text">Segment and Geographical InformationOperating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#8217;s chief operating decision maker view the Company&#8217;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceuticals.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Off-Balance Sheet Risk</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#8217;s policy is to invest its cash, cash equivalents and investments in money market funds, certificates of deposit, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Investments</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Investments</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments with maturities of greater than 90 days but less than one year are classified as short-term investments on the consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.</span></div>As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity in the consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Valuations based on inputs that are both significant to the fair value measurement and unobservable.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#8217;s financial statements, are reasonable estimates of fair value, primarily due to their short maturities. Marketable securities are classified as long-term investments if the Company has the ability and intent to hold them and such holding period is longer than one year. The Company classifies all of its investments as available-for-sale.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our available-for-sale, short-term and long-term investments, which consist of, commercial paper, corporate bonds, and government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of remaining useful life or remaining lease term</span></td></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress ("CIP") is not depreciated until the asset is placed in service.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has not recognized any impairment losses for the three months ended March&#160;31, 2022 and 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, Leases ("ASC 842"). Right-of-use lease assets represent our right to use an underlying asset during the lease term and the lease obligations represent our commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#8217;s lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, we have used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain "sale-leaseback" criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on our assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, related clinical manufacturing costs, contract management services, regulatory and other related costs.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#8217;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third party service providers and the Company&#8217;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the fair value recognition provisions of Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 718"), to account for stock-based compensation. Compensation costs related to stock options granted is based on the estimated fair value of the awards on the date of grant. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Once the Company's own sufficient historical volatility data was obtained, the Company eliminated the use of a representative peer group and uses only its own historical volatility data in its estimate of expected volatility.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the expected term of its stock options using the &#8220;simplified&#8221; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The </span></div>Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses and is presented net of taxes. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASU No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU 2020-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2020-08") to provide further clarification and update the previously issued guidance in ASU 2017-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20: Premium Amortization on Purchased Callable Debt Securities) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2017-08").  ASU 2017-08 shortened the amortization period for certain callable debt securities purchased at a premium by requiring that the premium be amortized to the earliest call date. ASU 2020-08 requires that at each reporting period, to the extent that the amortized cost of an individual callable debt security exceeds the amount repayable by the issuer at the next call date, the excess premium shall be amortized to the next call date. The new standard was effective beginning January 1, 2021 and should be applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. The adoption of ASU 2020-08 did not have a material impact on the Company's financial position or results of operations upon adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19347-109286<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488009508728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_EstimatedUsefulLivesOfAssetsTableTextBlock', window );">Summary of Estimated Useful Lives of Assets</a></td>
<td class="text">Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lesser of remaining useful life or remaining lease term</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_EstimatedUsefulLivesOfAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the estimated useful lives of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_EstimatedUsefulLivesOfAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488009698072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.596%"><tr><td style="width:1.0%"/><td style="width:64.187%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.683%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands, except shares and per share data)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,965)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,812)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average basic and</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160; diluted common shares</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,114,453&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,253,508&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per<br/>&#160;&#160; common share</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.99)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.74)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488009728616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Cash, Cash Equivalents and Available-for-Sale Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category as of March&#160;31, 2022 and December&#160;31, 2021, respectively (in thousands):</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,741&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(724)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,961&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,058&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(440)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,281&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199,867&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,201)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198,668&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165,329&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,339&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469,170&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,201)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467,971&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">269,303&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165,329&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,339&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:22.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(114)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,196&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,768&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,428&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,390&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,221&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,850&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,371&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502,636&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,371&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company&#8217;s short-term marketable securities mature in one year or less.</span></div><div style="padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company's long-term marketable securities mature between one year and two years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488009703816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,933&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,340&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,736&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,723&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,938&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,530&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,603&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,569&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,676)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,214)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,927&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,355&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses And Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-indent:29.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical and clinical expenses</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,647&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,168&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,011&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,560&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction in progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,097&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,606&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued financing costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation settlement</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,817&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,297&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488009723976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Operating Lease Payments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, future minimum commitments under the Company&#8217;s operating leases were as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"/><td style="width:83.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.756%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating<br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remaining nine months)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,487&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock', window );">Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases</a></td>
<td class="text">Supplemental condensed consolidated balance sheet information related to leases is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:67.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,453&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,228&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,411&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,883&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,983&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liability</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,294&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,024&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term, in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental condensed consolidated balance sheet information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488011867864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Company's Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"><tr><td style="width:1.0%"/><td style="width:38.740%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.460%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In&#160;thousands)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,043,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,179,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,475)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled or forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,342)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,152,862&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.99&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,364&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439,954&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.52&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,929&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Aggregate intrinsic value represents the difference between the closing stock price of our common stock on March&#160;31, 2022 and the exercise price of outstanding in-the-money options.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three months ended March&#160;31, 2022 and 2021 as follows (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.842%"><tr><td style="width:1.0%"/><td style="width:53.746%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.982%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.887%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,950&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,131&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to RSAs of $480 thousand and $182 thousand for the three months ended March&#160;31, 2022 and 2021, respectively, within general and administrative expenses in the accompanying condensed consolidated statements of operations (in thousands):</span></div><div style="margin-top:6pt;text-align:center;text-indent:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.134%"><tr><td style="width:1.0%"/><td style="width:53.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.783%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Fair Value of Stock Options, Valuation Assumptions</a></td>
<td class="text">The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three months ended March&#160;31, 2022 and 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.672%"><tr><td style="width:1.0%"/><td style="width:54.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.004%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.348%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of the award (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.22</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.53</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.46</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeiture rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"><tr><td style="width:1.0%"/><td style="width:50.452%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.630%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,379)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSAs as of March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.89&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488010203624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 190,749<span></span>
</td>
<td class="nump">$ 140,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">$ 434,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488007351848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Recognized impairment losses for long lived assets | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488009951032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember', window );">Laboratory and manufacturing equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember', window );">Laboratory and manufacturing equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488007360552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common share equivalents outstanding, excluded from the calculation of diluted net loss per common share</a></td>
<td class="nump">3,226,962<span></span>
</td>
<td class="nump">1,423,540<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488007232360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss per common share</a></td>
<td class="num">$ (49,965)<span></span>
</td>
<td class="num">$ (15,812)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding: basic</a></td>
<td class="nump">25,114,453<span></span>
</td>
<td class="nump">21,253,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding: diluted</a></td>
<td class="nump">25,114,453<span></span>
</td>
<td class="nump">21,253,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share: basic (in dollars per share)</a></td>
<td class="num">$ (1.99)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share: diluted (in dollars per share)</a></td>
<td class="num">$ (1.99)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488004103176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 269,303<span></span>
</td>
<td class="nump">$ 341,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,201)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">469,170<span></span>
</td>
<td class="nump">502,636<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">467,971<span></span>
</td>
<td class="nump">502,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">269,303<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">165,329<span></span>
</td>
<td class="nump">96,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember', window );">Long-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale', window );">Aggregate fair value, total</a></td>
<td class="nump">33,339<span></span>
</td>
<td class="nump">64,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">269,303<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Aggregate Fair Value</a></td>
<td class="nump">269,303<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">269,303<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">199,867<span></span>
</td>
<td class="nump">161,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,201)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">198,668<span></span>
</td>
<td class="nump">161,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Short-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">$ 165,329<span></span>
</td>
<td class="nump">96,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Debt securities, available-for-sale, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Long-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">$ 33,339<span></span>
</td>
<td class="nump">64,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Long-term Marketable Securities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Debt securities, available-for-sale, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Long-term Marketable Securities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Debt securities, available-for-sale, term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash and cash equivalents | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 269,303<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Aggregate Fair Value</a></td>
<td class="nump">269,303<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash and cash equivalents | Level 1 | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">269,303<span></span>
</td>
<td class="nump">341,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">39,476<span></span>
</td>
<td class="nump">40,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">39,439<span></span>
</td>
<td class="nump">40,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Short-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">39,439<span></span>
</td>
<td class="nump">40,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Long-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">106,741<span></span>
</td>
<td class="nump">83,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(724)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">106,019<span></span>
</td>
<td class="nump">83,196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Short-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">81,961<span></span>
</td>
<td class="nump">35,768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Long-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">24,058<span></span>
</td>
<td class="nump">47,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">53,650<span></span>
</td>
<td class="nump">37,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(440)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">53,210<span></span>
</td>
<td class="nump">37,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. government agency securities | Short-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">43,929<span></span>
</td>
<td class="nump">20,616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. government agency securities | Long-term Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate Fair Value</a></td>
<td class="nump">$ 9,281<span></span>
</td>
<td class="nump">$ 16,943<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash cash equivalents and debt securities available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash cash equivalents and debt securities available for sale amortized cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=krys_LongTermMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488009917016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 141,603<span></span>
</td>
<td class="nump">$ 116,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(4,676)<span></span>
</td>
<td class="num">(4,214)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">136,927<span></span>
</td>
<td class="nump">112,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">128,933<span></span>
</td>
<td class="nump">104,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">5,736<span></span>
</td>
<td class="nump">5,723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember', window );">Laboratory and manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 5,938<span></span>
</td>
<td class="nump">$ 5,530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488011837688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 462<span></span>
</td>
<td class="nump">$ 438<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488013168632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_AccruedPreclinicalAndClinicalExpenses', window );">Accrued preclinical and clinical expenses</a></td>
<td class="nump">$ 2,647<span></span>
</td>
<td class="nump">$ 1,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">4,168<span></span>
</td>
<td class="nump">2,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_AccruedPayrollAndBenefits', window );">Accrued payroll and benefits</a></td>
<td class="nump">1,560<span></span>
</td>
<td class="nump">2,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxes', window );">Accrued taxes</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_AccruedConstructionInProgressCurrent', window );">Accrued construction in progress</a></td>
<td class="nump">17,097<span></span>
</td>
<td class="nump">9,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_AccruedFinancingFeesCurrent', window );">Accrued financing costs</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Accrued litigation settlement</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_AccruedExpensesAndOtherCurrentLiabilities', window );">Total</a></td>
<td class="nump">$ 50,817<span></span>
</td>
<td class="nump">$ 16,297<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedConstructionInProgressCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued construction in progress current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedConstructionInProgressCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current Liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedFinancingFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Financing Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedFinancingFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedPayrollAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued payroll and benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedPayrollAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AccruedPreclinicalAndClinicalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued preclinical and clinical expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AccruedPreclinicalAndClinicalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due.  This amount is the total of current and noncurrent accrued income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=116646759&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488003074728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> ft&#178; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 12, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 15, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>milestone</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 15, 2021</div></th>
<th class="th">
<div>Sep. 13, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 05, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 21, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_PaymentToEscrowForReducingLeaseRentals', window );">Cash contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_PurchasePriceOfPotentialBuildingPurchase', window );">Purchase price of potential purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments', window );">Lessor, operating lease, liability, annual lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CumulativeEscalationClausePercent', window );">Cumulative escalation clause</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CumulativeEscalationClauseTerm', window );">Cumulative escalation clause, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409<span></span>
</td>
<td class="nump">$ 218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_LossContingencyGuaranteedMaximumPriceToBePaid', window );">Loss contingency, guaranteed maximum price to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities', window );">Proceeds from insurance settlement, operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Accrued litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=krys_PeriphaGenMember', window );">PeriphaGen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_NumberOfMilestones', window );">Number of milestones | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_LitigationSettlementTotalConsideration', window );">Litigation settlement, total consideration</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_MilestonesAxis=krys_MilestoneOneMember', window );">Milestone One | PeriphaGen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_LitigationSettlementMilestonePaymentsSalesThreshold', window );">Litigation settlement, milestone payments, sales threshold</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_MilestonesAxis=krys_MilestoneTwoMember', window );">Milestone Two | PeriphaGen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_LitigationSettlementMilestonePaymentsSalesThreshold', window );">Litigation settlement, milestone payments, sales threshold</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_MilestonesAxis=krys_MilestoneThreeMember', window );">Milestone Three | PeriphaGen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_LitigationSettlementMilestonePaymentsSalesThreshold', window );">Litigation settlement, milestone payments, sales threshold</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=krys_ClinicalSupplyAgreementMember', window );">Clinical Supply Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_RemainingCommitmentAmount', window );">Estimated remaining commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Project management service fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=krys_OtherContractualObligationsMember', window );">Other Contractual Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_RemainingCommitmentAmount', window );">Estimated remaining commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Project management service fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=krys_ASTRAFacilityMember', window );">ASTRA Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_CostOfWorkPercentage', window );">Cost of work, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_TwoThousandSixteenLeaseAgreementMember', window );">2016 Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_AdditionalAreaOfRealEstatePropertyLeased', window );">Additional area of real estate property leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_BostonLeaseMember', window );">Boston Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_AdditionalAreaOfRealEstatePropertyLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional area of real estate property leased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_AdditionalAreaOfRealEstatePropertyLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CostOfWorkPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost Of Work, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CostOfWorkPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CumulativeEscalationClausePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative Escalation Clause, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CumulativeEscalationClausePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_CumulativeEscalationClauseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative Escalation Clause, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_CumulativeEscalationClauseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LessorOperatingLeaseLiabilityAnnualLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessor, Operating Lease, Liability, Annual Lease Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LessorOperatingLeaseLiabilityAnnualLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LitigationSettlementMilestonePaymentsSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Milestone Payments, Sales Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LitigationSettlementMilestonePaymentsSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LitigationSettlementTotalConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Total Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LitigationSettlementTotalConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LossContingencyGuaranteedMaximumPriceToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Guaranteed Maximum Price to be Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LossContingencyGuaranteedMaximumPriceToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_NumberOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_NumberOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_PaymentToEscrowForReducingLeaseRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment to escrow for reducing lease rentals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_PaymentToEscrowForReducingLeaseRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_PurchasePriceOfPotentialBuildingPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Price Of Potential Building Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_PurchasePriceOfPotentialBuildingPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_RemainingCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining commitment amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_RemainingCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=116646759&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3337-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21B<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080549-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInsuranceSettlementOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=krys_PeriphaGenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=krys_PeriphaGenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_MilestonesAxis=krys_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_MilestonesAxis=krys_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_MilestonesAxis=krys_MilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_MilestonesAxis=krys_MilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_MilestonesAxis=krys_MilestoneThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_MilestonesAxis=krys_MilestoneThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=krys_ClinicalSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=krys_ClinicalSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=krys_OtherContractualObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=krys_OtherContractualObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=krys_ASTRAFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=krys_ASTRAFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_TwoThousandSixteenLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_TwoThousandSixteenLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_BostonLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=krys_BostonLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488013241144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (remaining nine months)</a></td>
<td class="nump">$ 1,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">1,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">1,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">1,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">12,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future minimum operating lease payments</a></td>
<td class="nump">18,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="nump">9,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liability</a></td>
<td class="nump">$ 9,294<span></span>
</td>
<td class="nump">$ 8,024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, after Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488011741992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 8,453<span></span>
</td>
<td class="nump">$ 7,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,411<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td>
<td class="nump">7,883<span></span>
</td>
<td class="nump">6,983<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 9,294<span></span>
</td>
<td class="nump">$ 8,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term, in years</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">14 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">9.30%<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488003920088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalization - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 03, 2021</div></th>
<th class="th"><div>Feb. 01, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering expenses</a></td>
<td class="nump">$ 227<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="nump">2,866,667<span></span>
</td>
<td class="nump">2,211,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share (in dollars per share)</a></td>
<td class="nump">$ 75.00<span></span>
</td>
<td class="nump">$ 65.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial offering of shares</a></td>
<td class="nump">$ 201,900<span></span>
</td>
<td class="nump">$ 134,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees', window );">Underwriting discounts and commissions</a></td>
<td class="nump">$ 12,900<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">288,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=krys_ATMProgramMember', window );">ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial offering of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees', window );">Underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_SaleOfStockRemainingAvailableIssuanceAmount', window );">Sale of stock, remaining available issuance amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=krys_StockSaleAgreementMember', window );">Stock Sale Agreement | Placement Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_SaleOfStockAggregateOfferingPrice', window );">Sale of stock, aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_SaleOfStockAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Aggregate Offering Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_SaleOfStockAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_SaleOfStockRemainingAvailableIssuanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Remaining Available Issuance Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_SaleOfStockRemainingAvailableIssuanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense related to distribution, servicing and underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCapitalizationEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCapitalizationEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=krys_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=krys_ATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=krys_ATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=krys_StockSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=krys_StockSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PlacementSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=krys_PlacementSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488003837608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">1,179,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Share-based payment arrangement, amount capitalized</a></td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">1,179,500<span></span>
</td>
<td class="nump">502,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=krys_StockIncentivePlanMember', window );">Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for grant</a></td>
<td class="nump">1,028,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share of options granted (in dollars per share)</a></td>
<td class="nump">$ 43.09<span></span>
</td>
<td class="nump">$ 50.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,950<span></span>
</td>
<td class="nump">$ 2,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="nump">$ 101,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted average period</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember', window );">Non-Employee Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember', window );">Non-Employee Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock award granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">98,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock award outstanding (in shares)</a></td>
<td class="nump">74,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense</a></td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted average period</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 480<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=krys_IncentiveStockOptionsMember', window );">Incentive Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for grant</a></td>
<td class="nump">26,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=krys_StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=krys_StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krys_NonEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=krys_IncentiveStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=krys_IncentiveStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488003810984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">2,043,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,179,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(1,475)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled or forfeited (in shares)</a></td>
<td class="num">(68,342)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">3,152,862<span></span>
</td>
<td class="nump">2,043,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable end of period (in shares)</a></td>
<td class="nump">439,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 57.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">62.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">37.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled or forfeited (in dollars per share)</a></td>
<td class="nump">61.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">58.99<span></span>
</td>
<td class="nump">$ 57.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable end of period (in dollars per share)</a></td>
<td class="nump">$ 44.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- average Remaining Contractual Life (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (Years)</a></td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life (Years), exercisable</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="nump">$ 30,364<span></span>
</td>
<td class="nump">$ 31,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at March 31, 2022</a></td>
<td class="nump">$ 10,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488008513560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 5,950<span></span>
</td>
<td class="nump">$ 2,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">480<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">1,368<span></span>
</td>
<td class="nump">516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative | Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">4,582<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 480<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488008452632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of the award (years)</a></td>
<td class="text">6 years 2 months 26 days<span></span>
</td>
<td class="text">6 years 2 months 19 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.79%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 62.53<span></span>
</td>
<td class="nump">$ 77.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>krys_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488007232968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details) - Restricted Stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">98,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">98,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(14,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(10,379)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">74,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 78.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140488003794408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 29, 2022</div></th>
<th class="th"><div>Apr. 05, 2022</div></th>
<th class="th"><div>Mar. 12, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PublicOfferingMember', window );">Public Offering | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=krys_PeriphaGenMember', window );">PeriphaGen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=krys_PeriphaGenMember', window );">PeriphaGen | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=krys_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=krys_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=krys_PeriphaGenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=krys_PeriphaGenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>krys-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:krys="http://www.krystalbio.com/20220331"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="krys-20220331.xsd" xlink:type="simple"/>
    <context id="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i92219a3d65e04e42ae2386983e67244f_I20220429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="i905c5a481a8b4f42a9009703d3ecf075_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i99c92e6ca8634fd79257a600a35f3f21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i38aea91663634289b7f60b7120c11d27_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i86b8575463f64b2a97e77aaf2dd5e8b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5cccc0f95b584f8db0533775037f4666_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie8b763ffc1fc42a380e6da94773832ed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a174e96b10748d3b41c69212ebe2cc6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03e20359e3ba42acaec22a55b3fabb99_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7d3866220aae469d99c8d6687e42ce45_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie46a796ec4c446038a3653b810fcbd77_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i57267989876b466d9ebc59f49913b75f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6e52f1591d1347c4bb2558fb1f9ee147_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i65beb9114acd4ee1adef1dde5c44ba5c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i87c8b8e1430a4c708d973ff2e25ae17b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6ddceeccd7914fa1bc3f31fd69e6830a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia6ffefd397c440af90b9447cc5a238f5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ica68c43f75604a03a077b382685b1a41_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib67facf3d8f849e2b66fd1c7f68989ad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i67063c7c5279465183dd7e83d8f84145_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i381f9df67cae40a4b3c35dfa60c3546f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic12c80c1247f4acaa167064b8bb02705_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i77370fc21ec5473987c50059d5cab0bc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1f9b5535cbbc4e22af9f06fe59eaa400_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1c06fb3b4ad5401d80b059fc7e9e1d3d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i861f0c6362bd4446bef9d197ad8a4835_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i17fb83d3cf56449095121eab4cdd43b7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8440da614aa3444894a316404ee33125_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i395b8e2070414f429d49289ac92db97b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idf458d33964c41e09d92634f029b4c61_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie8265b62d98547d1b612aa5059737994_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iff7c8222f2ec4030bb73e073b01cc801_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8526152bbd814c19af8798ebbf6df780_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5b7a2cb4937f4539b4d97203dc50610f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie1ef4419eb8c470d85aacefec56909e5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i41aa2659a9d349aca4310c4ac210e321_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iee85b21ece4849119c1efceb43453fde_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ice1e26d5975d48f7995f61e80667d911_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i63849f9dca98492397cffbdb5ad8bc0a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i71df1d506a1d42f59d5769c25d50de0d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6b56a800b1dc4d59b0579103fb3856e3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if5e3ccafd6e7408e8d72c7ed3d59aa1d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie0718e9e6a304faa99a8d0ba4d170a50_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i63e06177b3b947ed827f1ae04d3f6c24_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i91af162b5ce24bcca39b1802458f9c63_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i12453054567d425ebb3db8321c10080c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0605bcc794c8466488458ac6a40a567a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6fc83aec7ccf4e56b6000b187c116bc9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iac939cd950c94172a39585927ae3707b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i52a9c36697194609ac56e04b9aa3d9a8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8c95f3dd9aa1471889572b02d7094b9d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2740425fee244d2f922f4b25973e349b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifdbc6dddacb448d9ad60106137194932_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iebe00a10a2724634b1c0118d2d67a4a8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibeaaf7239b4345778bad76871b818c5a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3140340b83cb4218b934f3877760f87c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icba6d511515a4acf97d285fa1677f2cb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9a3729b490084ba89c9abadcac13b833_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i23a4767bf6e240bda02a5dbd7afc4ff7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d1b20d4b556453996c9073c1c2716ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f0e12c30bc84334939e2e4bf442dfac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i49e8debc5cb94ea6a469f4196d724fa5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i46c951025fce41ab952849ce6a3ab2e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf8f54899b4a4148a67b60622acaf77b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ba725ffee7e42e6a8128c65b3a212bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf6969542ce14c959f3e2e0e56bcb784_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1502ff476f7844a8b66df5fd7220258e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3bad5e70d1fb436897da83e0b8eeee55_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa7daa0072cb419cb2dbaaf3afff522e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c36492a3b734099aac3b58956194853_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc7984fa6b0c43debd86bc7ec5c8ddef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idbf78e0869994741ae4e6b2efdb39bc9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f5b030412564955be828db44eb6b956_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b8b8c8c466f413999e0992ec12716e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i63e50181337f4deda50f8a1ec567dd37_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if60f2e99fb10489cb879593621b5e8bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a8a378d87ac477fa9eb1f74361e0f3a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icd44f57ba38a4bbfb2f25ef586c2f644_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">krys:LongTermMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idbf226c7773f451cb39f05cc616016f9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie70bd060e96749a89eccb6ac7c4aa94e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8144f7ab623b4afca039c1cbdf57e750_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1c8d6050468f4d63a79e15bdcd8ec20b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a8d28f658e64c9cb72dab709adfb297_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6ce87c71085b42e9b14d17fca3b617ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i16934897395943d38eb471fd6a4ab451_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0c5891e652c44560a9dfb628c66faca5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4980d8ad41eb414591647b2b42093a20_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i95c8dea3eb594cc3900cf46e3694ed5b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idbf36e2c49fc42d9a41ee8670488e982_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:TwoThousandSixteenLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i259ce76551454123911c8f7e6cf9cd6d_I20200121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2020-01-21</instant>
        </period>
    </context>
    <context id="ia5b58230696440249bca1a1906cb63f3_D20201015-20201015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2020-10-15</startDate>
            <endDate>2020-10-15</endDate>
        </period>
    </context>
    <context id="i2384fef03d174e7293ac35a6c188c7cf_I20201005">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2020-10-05</instant>
        </period>
    </context>
    <context id="ib1f1bacd274b4e44b1a1f8151a2b5097_I20201015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2020-10-15</instant>
        </period>
    </context>
    <context id="i6642a4976dcc4bbb8b89924a05835ed9_I20211215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">krys:BostonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-15</instant>
        </period>
    </context>
    <context id="ib888a32279a646d6bc98bb4650978ad1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic9ac354f7bd046949c8c5c9a884f44b6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iab4cf6bacbe94549a3840f7cc0180c4d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ClinicalSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iea664a78d9854e7982861ce146a3ba39_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib712ea82a3604445a0cc14028e0d6896_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3b26ab4e640a459f8745fdfc687a4c41_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:OtherContractualObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if89acc13e6c64c308c9dfc70390e2d45_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">krys:ASTRAFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia7f4b2c43112444b9e122e360545adab_I20210913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <instant>2021-09-13</instant>
        </period>
    </context>
    <context id="ic40bbdf109724a63a017b7987802289f_D20220312-20220312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-12</startDate>
            <endDate>2022-03-12</endDate>
        </period>
    </context>
    <context id="i2e9524e5aa5c470a884b1e3b3fd4d2fc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic24584a607d040f58ee27bb2c65542e0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifbc91ac07e524baca470f06f672c1d2c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i36d06bb51d1041f08406992557a842ec_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic65f36fa2aab4beabcc772980cf0f956_D20220312-20220312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-12</startDate>
            <endDate>2022-03-12</endDate>
        </period>
    </context>
    <context id="i5edf1309bf4c4394b9c48237c6eb3b9e_D20220312-20220312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-12</startDate>
            <endDate>2022-03-12</endDate>
        </period>
    </context>
    <context id="i4203d07f57134f55a0643e1e7a9ea003_D20220312-20220312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="krys:MilestonesAxis">krys:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-12</startDate>
            <endDate>2022-03-12</endDate>
        </period>
    </context>
    <context id="i5afc353e283647ec9083f64e9ed8c939_D20211203-20211203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-03</endDate>
        </period>
    </context>
    <context id="i60ec291ee12943d1a98627ef006017cc_D20211203-20211203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-03</endDate>
        </period>
    </context>
    <context id="i08fed205929d4c55ae8e914a0a90a14b_I20211203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-03</instant>
        </period>
    </context>
    <context id="i0c1f8e7fe2fa45fd8b4dff23e6288333_D20211203-20211203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-12-03</startDate>
            <endDate>2021-12-03</endDate>
        </period>
    </context>
    <context id="if01cbed47b8d4cc3bfbc1d974a9fed3d_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="i8ff87f18f6694c9ea3a6fef4996ab07c_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="ica2c921cbe27424bb2a3e6cab5b07128_I20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="i289cb50e19984c88a48c5a07e1b8a29a_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="ida8733e7f8b54da6ada1a0ab22fe829f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PlacementSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krys:StockSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9fbd96b4612a4a66b26fde342c7e05ba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PlacementSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">krys:StockSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5c9fb5f61e014e0d8958ffdb2f7baa47_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia295d7f2365647ae8d0fe3f1f16d1308_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i286d68b1d6d2436481fb4a0d8428bca6_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:ATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="i80af56866df1412e92048fc6c85f5bc4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic542a3c28cfa40a79269e8998b92ebd4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iecc1050fb75f4c92929ea53bb5db6e2e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:NonEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iea276893239144509596b8ab8da16fc9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7bd1d3ebc2374d15b477f6f17769c8b5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id1df3a737f254e1890366151309871c2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ice42d3e965264766b589d5585c17eea5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8c01f855c0c84b0e9b660ee225b9ec6f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4351d78dc27b42ba8f8b3dc0f50aab47_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i728d1afbbec24034b661de93f72a65fb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4a13b8bd5de345f7816207b985555ac2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if5ef3f34ff534130b14863a9e62343c7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i159a69784f534b459befa6407a0a7b31_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i95cf472c8b2540888dd2f36a876d9c9c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic9e66ec8312f4f8c9a9dff635bd641f1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idcde6861ff0841f797527708e897648a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id2f80cb0be8e44f88a74d836902c06d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i34ffbc56d9c943f2b61272f256499cfb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie2d9d3e6725f41cbba150ba4c1a85196_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i383ec6469caa4edeaa4b2d6d77e7fba4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i29cc8ebc55e7487dac7291d42222cb41_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">krys:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i28da46ff21b84b0aa5a790183dfad270_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">krys:IncentiveStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7448456091a9407bba292044857bb844_D20220429-20220429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">krys:PeriphaGenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-29</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="id610a4a750eb45a88b570c32459f3956_D20220405-20220405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-05</startDate>
            <endDate>2022-04-05</endDate>
        </period>
    </context>
    <context id="iec19ce2f98484127826acb386e5ebf55_I20220405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001711279</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">krys:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-05</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>krys:segment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="milestone">
        <measure>krys:milestone</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180L2ZyYWc6NGQ3MTE0NmFhOWMzNGIyMDgwMzBjODRkNTY1ZjY3ZGYvdGFibGU6ZDgwODY0N2Q3ZWEyNGM5MTg3MzE4YTliZDZjMTI1YTYvdGFibGVyYW5nZTpkODA4NjQ3ZDdlYTI0YzkxODczMThhOWJkNmMxMjVhNl8zLTEtMS0xLTIwOTc3_b569c529-9686-499f-b144-9516b391f4b3">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180L2ZyYWc6NGQ3MTE0NmFhOWMzNGIyMDgwMzBjODRkNTY1ZjY3ZGYvdGFibGU6ZDgwODY0N2Q3ZWEyNGM5MTg3MzE4YTliZDZjMTI1YTYvdGFibGVyYW5nZTpkODA4NjQ3ZDdlYTI0YzkxODczMThhOWJkNmMxMjVhNl81LTEtMS0xLTIwOTc3_753ee795-433d-4c66-b68b-b6a7fff3907c">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180L2ZyYWc6NGQ3MTE0NmFhOWMzNGIyMDgwMzBjODRkNTY1ZjY3ZGYvdGFibGU6ZDgwODY0N2Q3ZWEyNGM5MTg3MzE4YTliZDZjMTI1YTYvdGFibGVyYW5nZTpkODA4NjQ3ZDdlYTI0YzkxODczMThhOWJkNmMxMjVhNl82LTEtMS0xLTIwOTc3_46449e69-e462-4b36-bb6e-3a3d35f74182">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180L2ZyYWc6NGQ3MTE0NmFhOWMzNGIyMDgwMzBjODRkNTY1ZjY3ZGYvdGFibGU6ZDgwODY0N2Q3ZWEyNGM5MTg3MzE4YTliZDZjMTI1YTYvdGFibGVyYW5nZTpkODA4NjQ3ZDdlYTI0YzkxODczMThhOWJkNmMxMjVhNl85LTEtMS0xLTIwOTc3_8c434271-55ab-41ea-8dcd-48efcfd7ebc5">0001711279</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180L2ZyYWc6NGQ3MTE0NmFhOWMzNGIyMDgwMzBjODRkNTY1ZjY3ZGYvdGFibGU6ZDgwODY0N2Q3ZWEyNGM5MTg3MzE4YTliZDZjMTI1YTYvdGFibGVyYW5nZTpkODA4NjQ3ZDdlYTI0YzkxODczMThhOWJkNmMxMjVhNl8xMC0xLTEtMS0yMDk3Nw_ab4dff3f-d256-4ad0-bbb5-682fc56a1d34">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDU4_1d710e49-0351-49af-bfe6-fa0d8c88c277">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGFibGU6N2M2MWJiNGIzOWRhNDgyZTg4ZTVmNjEyMmU0Y2I0NmEvdGFibGVyYW5nZTo3YzYxYmI0YjM5ZGE0ODJlODhlNWY2MTIyZTRjYjQ2YV8wLTAtMS0xLTIwOTc3_77c653fa-35dd-4840-b915-cae8e6b19bd7">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDI_70cc69f3-997a-45e0-b746-a1f9eb8ee2e2">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGFibGU6YTgxODFhYmUxYzQ4NGNkMWJlNmRiNzg3YTNlNjJlMDEvdGFibGVyYW5nZTphODE4MWFiZTFjNDg0Y2QxYmU2ZGI3ODdhM2U2MmUwMV8wLTAtMS0xLTIwOTc3_65f2bde9-8489-49b9-892b-dcea3f062935">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDU5_ed53a6cd-a307-47c7-9242-ca65ace93864">001-38210</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDcw_384278c1-fde5-46a6-b338-afa3df3e55fd">Krystal Biotech, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGFibGU6ZGVhZTgxNThhYjJmNGYxNmI4MTlmZmNmODc4ZjdkZWYvdGFibGVyYW5nZTpkZWFlODE1OGFiMmY0ZjE2YjgxOWZmY2Y4NzhmN2RlZl8wLTAtMS0xLTIwOTc3_6e7a5021-c4c6-443b-8e68-da08c1a357fa">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGFibGU6ZGVhZTgxNThhYjJmNGYxNmI4MTlmZmNmODc4ZjdkZWYvdGFibGVyYW5nZTpkZWFlODE1OGFiMmY0ZjE2YjgxOWZmY2Y4NzhmN2RlZl8wLTItMS0xLTIwOTc3_9299777a-7526-4c73-b2a3-dd73b77ec47b">82-1080209</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDcx_0cf5fc8f-b60e-471d-9618-cec25cea929b">2100 Wharton Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDYz_706263bf-7f1b-4660-b6eb-54d95df5221c">Suite 701</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDY2_c856342a-d3e8-42a8-8ef0-eff7cd1bd3b0">Pittsburgh</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDYx_6a522abd-92d7-4f81-8d0f-dc38cefba765">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM181OTk_736cbe42-2983-4efe-9207-7b057a0d01f5">15203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDcy_001351e7-e136-4476-9377-a13db0f7e93c">412</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDYy_fcbceee5-d05d-43d4-8745-9e6c121f81a6">586-5830</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGFibGU6ODgwY2VmMzE5ZmNhNDEyM2EwNjJhMDMzZDE5YWU1MTIvdGFibGVyYW5nZTo4ODBjZWYzMTlmY2E0MTIzYTA2MmEwMzNkMTlhZTUxMl8xLTAtMS0xLTIwOTc3_0a2f5e49-5fc1-4f16-bd05-ebdbe9f4328a">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGFibGU6ODgwY2VmMzE5ZmNhNDEyM2EwNjJhMDMzZDE5YWU1MTIvdGFibGVyYW5nZTo4ODBjZWYzMTlmY2E0MTIzYTA2MmEwMzNkMTlhZTUxMl8xLTEtMS0xLTIwOTc3_ac552ddc-574b-4c6e-91ed-70bfa6481617">KRYS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGFibGU6ODgwY2VmMzE5ZmNhNDEyM2EwNjJhMDMzZDE5YWU1MTIvdGFibGVyYW5nZTo4ODBjZWYzMTlmY2E0MTIzYTA2MmEwMzNkMTlhZTUxMl8xLTItMS0xLTIwOTc3L3RleHRyZWdpb246MDEyZDM4NjllOGExNDVjMTljODc4YzJlODMyODNjYTlfMTY0OTI2NzQ0MTY5Ng_88ba4eae-0ac4-47ef-9e5f-8cdebe307acc">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDcz_ab45d3b5-ef7b-4e53-aa1e-8cd3c1928c41">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDY1_7e0f3dce-3a17-4b7c-a98e-0a8e14d6a836">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGFibGU6NmNlNzRiMWQ0NDQxNGY5ZGE1ZDQ0NzY5ZGI3NmU0YzMvdGFibGVyYW5nZTo2Y2U3NGIxZDQ0NDE0ZjlkYTVkNDQ3NjlkYjc2ZTRjM18wLTAtMS0xLTIxNTY3_c7410ef4-cc2f-4ed2-b057-6773b2c8234b">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGFibGU6NmNlNzRiMWQ0NDQxNGY5ZGE1ZDQ0NzY5ZGI3NmU0YzMvdGFibGVyYW5nZTo2Y2U3NGIxZDQ0NDE0ZjlkYTVkNDQ3NjlkYjc2ZTRjM18xLTYtMS0xLTIwOTc3_0af5a414-1031-4b1b-a2fb-c63a76d5dbe8">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM18yNDY3_6549b1b2-c22a-4931-a341-60ad0a17984d">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM180OTQ3ODAyMzI3NDcw_e7a221a8-d1fd-4822-9df0-4a88785f17ae">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i92219a3d65e04e42ae2386983e67244f_I20220429"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xL2ZyYWc6NzdkMDkxZGVjNTU1NDc4M2IzYWUxYjNhZjAyNWI5YjMvdGV4dHJlZ2lvbjo3N2QwOTFkZWM1NTU0NzgzYjNhZTFiM2FmMDI1YjliM183MTQ2ODI1NTgzMDcy_ced74b7c-5428-4ef3-a57e-8c31e929f6d9"
      unitRef="shares">25635138</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfNC0xLTEtMS0yMDk3Nw_b2777597-182c-4342-9623-2f5198cd1a43"
      unitRef="usd">269303000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfNC0zLTEtMS0yMDk3Nw_74409a17-79ac-49de-959c-52cf652946e0"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfNS0xLTEtMS0yMDk3Nw_be6e653d-ce0c-48b1-abba-33e4b2c116cd"
      unitRef="usd">165329000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfNS0zLTEtMS0yMDk3Nw_c8e21cb4-fbc1-4540-bebf-f40e6df492b6"
      unitRef="usd">96850000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfNi0xLTEtMS0yMDk3Nw_94fb84fd-628f-4b19-808b-0968f9629115"
      unitRef="usd">3366000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfNi0zLTEtMS0yMDk3Nw_cd6365a6-5efd-443d-9b58-817d01e34460"
      unitRef="usd">4171000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfNy0xLTEtMS0yMDk3Nw_ca29c2a5-9f2b-41eb-a99b-d5817ebb5dc2"
      unitRef="usd">437998000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfNy0zLTEtMS0yMDk3Nw_5e374c27-6124-4f0c-af47-6c1ceed23ada"
      unitRef="usd">442267000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfOC0xLTEtMS0yMDk3Nw_3125ba51-4ce1-4a2f-b526-baf7c3045759"
      unitRef="usd">136927000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfOC0zLTEtMS0yMDk3Nw_d2b20c5b-56e5-4847-9759-e7a9c3500849"
      unitRef="usd">112355000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LongTermInvestments
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfOS0xLTEtMS0yMDk3Nw_55fae7f5-737e-4a0b-b0cd-a97ee493d7b3"
      unitRef="usd">33339000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfOS0zLTEtMS0yMDk3Nw_c3d40d36-8fdc-4390-a489-869cb55c80b6"
      unitRef="usd">64371000</us-gaap:LongTermInvestments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTAtMS0xLTEtMjA5Nzc_9be160d2-77cd-4bea-8f7b-28f26b3211e7"
      unitRef="usd">8453000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTAtMy0xLTEtMjA5Nzc_42ecb77f-1e80-4b65-b574-b7ac5e987703"
      unitRef="usd">7228000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTEtMS0xLTEtMjA5Nzc_f1d33a11-6446-47d9-b2ae-b784699450b9"
      unitRef="usd">157000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTEtMy0xLTEtMjA5Nzc_81ca7916-bc14-448d-8859-635cd1f9f130"
      unitRef="usd">74000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTItMS0xLTEtMjA5Nzc_5d96ec78-1db0-43b6-8c29-8fda22adde3a"
      unitRef="usd">616874000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTItMy0xLTEtMjA5Nzc_bfc41976-4202-4a4c-a0f4-701b48507ca3"
      unitRef="usd">626295000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTUtMS0xLTEtMjA5Nzc_ecb9b2bb-6ccb-4fdb-80eb-48dded202b11"
      unitRef="usd">8209000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTUtMy0xLTEtMjA5Nzc_774e1b5b-d8da-44ea-8beb-0424bb1b33ad"
      unitRef="usd">8398000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTYtMS0xLTEtMjA5Nzc_bf4688ec-1de6-4595-a3ef-36c9e2aaf708"
      unitRef="usd">1411000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTYtMy0xLTEtMjA5Nzc_2bb5083a-dbec-404e-98e3-5c317eb6a0ac"
      unitRef="usd">1041000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTctMS0xLTEtMjA5Nzc_e2bb2d08-d437-4c04-b472-2c3ca2880db3"
      unitRef="usd">50817000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTctMy0xLTEtMjA5Nzc_ef3efcff-9258-4135-b3c3-6f7504f35427"
      unitRef="usd">16297000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTktMS0xLTEtMjA5Nzc_2236fa40-c481-4c09-a35f-3a9a8b137b76"
      unitRef="usd">60437000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMTktMy0xLTEtMjA5Nzc_2704f0cc-318b-4da7-af00-e27b2f3dd547"
      unitRef="usd">25736000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjAtMS0xLTEtMjA5Nzc_d1a71b0f-298a-46ad-844a-03bee9e10485"
      unitRef="usd">7883000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjAtMy0xLTEtMjA5Nzc_30e56a55-5037-4c1f-9971-03343f957c9c"
      unitRef="usd">6983000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjEtMS0xLTEtMjA5Nzc_ef290029-3d44-4c85-abf3-301cd00ed679"
      unitRef="usd">68320000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjEtMy0xLTEtMjA5Nzc_a8a5fdbf-2d3a-47e0-8949-7af78f9ed2e5"
      unitRef="usd">32719000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjItMS0xLTEtMjA5Nzc_a47b453f-596d-45b3-bbf6-c6bd44792c18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjItMy0xLTEtMjA5Nzc_83c69032-bfd3-4ee8-895b-762ddb5677f5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjQtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjpiZTliM2E0ZTYxNjY0NTU1YWEwYWU4NzlmZjBhN2Q3Nl8yMQ_6914fa46-6ec1-4a26-8f9e-3fdd976fd3c8"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjQtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjpiZTliM2E0ZTYxNjY0NTU1YWEwYWU4NzlmZjBhN2Q3Nl8yMQ_dcbc01ee-e93c-4fb3-b90b-aa4aa958662c"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjQtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjpiZTliM2E0ZTYxNjY0NTU1YWEwYWU4NzlmZjBhN2Q3Nl8zNQ_521dafba-a542-4852-bd6b-7c027826f4a4"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjQtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjpiZTliM2E0ZTYxNjY0NTU1YWEwYWU4NzlmZjBhN2Q3Nl8zNQ_ea5ef308-78a2-470b-96ce-16195ae6cca3"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjQtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjpiZTliM2E0ZTYxNjY0NTU1YWEwYWU4NzlmZjBhN2Q3Nl84NQ_1cb2cb07-d1a5-4849-b96c-4ac2f8d576af"
      unitRef="shares">2061773</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjQtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjpiZTliM2E0ZTYxNjY0NTU1YWEwYWU4NzlmZjBhN2Q3Nl84NQ_5dfe611f-99ef-438e-9e5b-3bdf0522f868"
      unitRef="shares">2061773</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjQtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjpiZTliM2E0ZTYxNjY0NTU1YWEwYWU4NzlmZjBhN2Q3Nl8xMTA_53d970a3-7516-4234-b1ae-8ee9c9fb8908"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjQtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjpiZTliM2E0ZTYxNjY0NTU1YWEwYWU4NzlmZjBhN2Q3Nl8xMTA_99ea9136-99fb-4ed7-a40d-337c07046d36"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjQtMS0xLTEtMjA5Nzc_88a47e4a-7655-4b31-ae28-6b7ca4b4fde6"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjQtMy0xLTEtMjA5Nzc_a7ff7e66-063c-46f4-9e25-a6ef5371f0dd"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjUtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjo2ZTZiYzFlODVhMGI0YjA0YWU0ODcyMTVkNzk4OTVlMl8xOA_44ed94c2-2065-4b64-99ef-db3f724635b4"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjUtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjo2ZTZiYzFlODVhMGI0YjA0YWU0ODcyMTVkNzk4OTVlMl8xOA_b8401fbf-7989-4ef9-b0a4-6e9b1bd76b62"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjUtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjo2ZTZiYzFlODVhMGI0YjA0YWU0ODcyMTVkNzk4OTVlMl8zMg_a6f7d203-d08c-4616-a419-1ed93920751e"
      unitRef="shares">80000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjUtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjo2ZTZiYzFlODVhMGI0YjA0YWU0ODcyMTVkNzk4OTVlMl8zMg_c954c2ad-eeca-4018-a669-5ac65c57a9d0"
      unitRef="shares">80000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjUtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjo2ZTZiYzFlODVhMGI0YjA0YWU0ODcyMTVkNzk4OTVlMl84Mg_51f52c6d-6518-40b6-ac53-5b35df873fb7"
      unitRef="shares">25199081</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjUtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjo2ZTZiYzFlODVhMGI0YjA0YWU0ODcyMTVkNzk4OTVlMl83MTQ2ODI1NTgwODA2_3e2e51fa-9eb7-489f-8e3e-5592788dae2c"
      unitRef="shares">25207985</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjUtMC0xLTEtMjA5NzcvdGV4dHJlZ2lvbjo2ZTZiYzFlODVhMGI0YjA0YWU0ODcyMTVkNzk4OTVlMl83MTQ2ODI1NTgwODA2_641fbf0a-74a4-450b-810e-a148af1689a8"
      unitRef="shares">25207985</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjUtMS0xLTEtMjA5Nzc_749292f7-5616-4ea4-a65c-a97a985d66df"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjUtMy0xLTEtMjA5Nzc_c8e662a4-0dd1-4e9b-b382-0dbf63ba8826"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjYtMS0xLTEtMjA5Nzc_3b384da6-1b68-426d-8f65-6051eadc7012"
      unitRef="usd">740500000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjYtMy0xLTEtMjA5Nzc_e27b5a2a-732f-4219-8be1-3e3b499fadfb"
      unitRef="usd">734523000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjctMS0xLTEtMjA5Nzc_9fc95ad5-e517-4581-83ec-8eadc722449c"
      unitRef="usd">-1197000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjctMy0xLTEtMjA5Nzc_16e18088-920b-46ce-8122-4c1c1d59ae90"
      unitRef="usd">-163000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjgtMS0xLTEtMjA5Nzc_5506f84d-afb8-41a3-ab0e-b428891e9eb6"
      unitRef="usd">-190749000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjgtMy0xLTEtMjA5Nzc_3da070fa-26d9-42c3-91a9-e01e91dfd31f"
      unitRef="usd">-140784000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjktMS0xLTEtMjA5Nzc_ca5075a5-27e3-4723-b267-bf7be63f98ce"
      unitRef="usd">548554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMjktMy0xLTEtMjA5Nzc_74a4ad7a-100e-4283-a272-60c0e3b8caf0"
      unitRef="usd">593576000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMzAtMS0xLTEtMjA5Nzc_d114a3ee-36e2-4aed-a63e-2ee42c778f15"
      unitRef="usd">616874000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xNi9mcmFnOjkxOThkNzc0YTBhZDRjYzM4NGRmZjU0YWFhNWRkY2Y5L3RhYmxlOmU1YTIyYTYyZTc0NzRmNjg4MTU4YTIxMzc1OTU5MWYyL3RhYmxlcmFuZ2U6ZTVhMjJhNjJlNzQ3NGY2ODgxNThhMjEzNzU5NTkxZjJfMzAtMy0xLTEtMjA5Nzc_ae9006b4-d156-494f-96b8-9bb452fbe83b"
      unitRef="usd">626295000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMy0xLTEtMS0yMDk3Nw_0df25442-2b89-473d-af7b-7c408e757e1d"
      unitRef="usd">9314000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMy0zLTEtMS0yMDk3Nw_64d88426-c062-4eed-99dd-8c26f5f0f526"
      unitRef="usd">6201000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfNC0xLTEtMS0yMDk3Nw_de334658-942d-422f-bc12-e732737f0c86"
      unitRef="usd">15908000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfNC0zLTEtMS0yMDk3Nw_4b9ffe80-1e25-400b-81ba-d051284b3b26"
      unitRef="usd">8152000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfNS0xLTEtMS0yMjE1Mw_5c4f7e1f-2bf1-41ce-8370-144b289add0c"
      unitRef="usd">25000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfNS0zLTEtMS0yMjE1NQ_6e80ec8a-2e48-4496-b7b7-c2244b0e9fbd"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:OperatingExpenses
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfNS0xLTEtMS0yMDk3Nw_a1c0e289-871b-4b65-aa26-5c771641116c"
      unitRef="usd">50222000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfNS0zLTEtMS0yMDk3Nw_55ef8264-2d60-4f84-8bd3-3400b8e662f3"
      unitRef="usd">14353000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfNi0xLTEtMS0yMDk3Nw_df28a5f6-4f60-4968-a9f7-5e1615872495"
      unitRef="usd">-50222000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfNi0zLTEtMS0yMDk3Nw_e4189390-1416-4676-a9b9-8d91e85115dd"
      unitRef="usd">-14353000</us-gaap:OperatingIncomeLoss>
    <krys:InterestIncomeExpenseAndOtherNonoperatingNet
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfOC0xLTEtMS0yMDk3Nw_813bf024-83bc-46c4-8de4-327266f06236"
      unitRef="usd">257000</krys:InterestIncomeExpenseAndOtherNonoperatingNet>
    <krys:InterestIncomeExpenseAndOtherNonoperatingNet
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfOC0zLTEtMS0yMDk3Nw_8c3d5ee2-19fe-4671-be29-f5ca8606ab73"
      unitRef="usd">33000</krys:InterestIncomeExpenseAndOtherNonoperatingNet>
    <us-gaap:InterestExpense
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTAtMS0xLTEtMjI4NDg_74bc790f-209b-4299-8a5d-8a858b1f7738"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTAtMy0xLTEtMjI4NDg_b9cd0a43-4f07-4170-8d7b-25eef6b68cc0"
      unitRef="usd">1492000</us-gaap:InterestExpense>
    <us-gaap:NetIncomeLoss
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTAtMS0xLTEtMjA5Nzc_74ae9e1e-a076-4ee1-b856-11c60919134d"
      unitRef="usd">-49965000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTAtMy0xLTEtMjA5Nzc_7a05d9a5-c7f2-4017-a5b0-154ae7292421"
      unitRef="usd">-15812000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTEtMS0xLTEtMjA5Nzc_8f0d13bb-e856-46be-a4c5-72c235e5f01b"
      unitRef="usd">-1034000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTEtMy0xLTEtMjA5Nzc_d9e3e145-cc9c-4093-a526-f3e7297e310e"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTItMS0xLTEtMjA5Nzc_bfb21e2a-eee6-4f2d-8025-761a2ad3b1c4"
      unitRef="usd">-50999000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTItMy0xLTEtMjA5Nzc_3a2cc527-f034-4b01-8828-fa9448e51526"
      unitRef="usd">-15815000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTQtMS0xLTEtMjA5Nzc_31b8a3b8-a84f-459a-9425-9ded64e21cd7"
      unitRef="usdPerShare">-1.99</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTQtMS0xLTEtMjA5Nzc_6ffb17c6-07c9-4f17-a605-5de9f282777a"
      unitRef="usdPerShare">-1.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTQtMy0xLTEtMjA5Nzc_1f64faac-6641-47cd-9a11-9bae3a720f69"
      unitRef="usdPerShare">-0.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTQtMy0xLTEtMjA5Nzc_95d2af5b-742d-4c3f-b820-19d65e6bbd06"
      unitRef="usdPerShare">-0.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTYtMS0xLTEtMjA5Nzc_71f784e6-efaa-44fd-b340-d116bae46d07"
      unitRef="shares">25114453</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTYtMS0xLTEtMjA5Nzc_7ea6455c-e31e-4a49-b1b3-e61a9705cbd1"
      unitRef="shares">25114453</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTYtMy0xLTEtMjA5Nzc_308e3098-fbb6-4ef5-a3e3-c4df6681c01a"
      unitRef="shares">21253508</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18xOS9mcmFnOmU3YzhiZTQ3ZGM1OTRhNTI4ZjA4MTI1MmRkNDljMTM1L3RhYmxlOjQyZjg1NzZmYTJhZjQzN2RiOGNkODFkZWFhNzVmMDM3L3RhYmxlcmFuZ2U6NDJmODU3NmZhMmFmNDM3ZGI4Y2Q4MWRlYWE3NWYwMzdfMTYtMy0xLTEtMjA5Nzc_b79e100b-0d2a-48e5-9380-1ccaf1929300"
      unitRef="shares">21253508</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i86b8575463f64b2a97e77aaf2dd5e8b8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfMy0xLTEtMS0yMDk3Nw_dd24c72a-99ce-4f74-bdec-116678439d59"
      unitRef="shares">25207985</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i86b8575463f64b2a97e77aaf2dd5e8b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfMy0zLTEtMS0yMDk3Nw_6525a887-5f69-4212-9457-0bd428856401"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5cccc0f95b584f8db0533775037f4666_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfMy01LTEtMS0yMDk3Nw_e2137c54-8a47-4a50-b098-eb87bcf4866a"
      unitRef="usd">734523000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie8b763ffc1fc42a380e6da94773832ed_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfMy03LTEtMS0yMDk3Nw_83183d1a-4aca-44d3-8c08-61190a3ac32a"
      unitRef="usd">-163000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7a174e96b10748d3b41c69212ebe2cc6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfMy05LTEtMS0yMDk3Nw_4b862be7-c07f-48d6-8961-0a90bbdcb1d8"
      unitRef="usd">-140784000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfMy0xMS0xLTEtMjA5Nzc_fb01ca27-f119-4e25-a4c2-c8ae901b126d"
      unitRef="usd">593576000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i03e20359e3ba42acaec22a55b3fabb99_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNC0xLTEtMS0yNDIxMg_36695cbd-06eb-4615-826e-0b1a2fa9d186"
      unitRef="shares">1475</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7d3866220aae469d99c8d6687e42ce45_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNC01LTEtMS0yNDIxMg_fdcc7078-40bc-4310-9f69-00f135111ad1"
      unitRef="usd">55000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNC0xMS0xLTEtMjQyMTI_21a1a6ff-70da-4816-a732-2e62d29e9e25"
      unitRef="usd">55000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i03e20359e3ba42acaec22a55b3fabb99_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNC0xLTEtMS0yMDk3Nw_bb36a795-da1e-4636-97b4-0997ca9a579b"
      unitRef="shares">10379</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7d3866220aae469d99c8d6687e42ce45_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNC01LTEtMS0yMDk3Nw_6ae8b7de-cd85-4d5d-b506-9ddece65ce2d"
      unitRef="usd">649000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNC0xMS0xLTEtMjA5Nzc_520ea695-86e2-46c4-a416-5dbae557cb4f"
      unitRef="usd">649000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7d3866220aae469d99c8d6687e42ce45_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNS01LTEtMS0yMDk3Nw_d09a5226-75c7-4c7b-af4d-a1e736c685bc"
      unitRef="usd">6571000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNS0xMS0xLTEtMjA5Nzc_e60bf288-2651-481f-b98d-557c075ded6a"
      unitRef="usd">6571000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie46a796ec4c446038a3653b810fcbd77_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNi03LTEtMS0yMDk3Nw_3a1b74e3-c51d-461d-9346-47e16aca28a4"
      unitRef="usd">-1034000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNi0xMS0xLTEtMjA5Nzc_0001ecff-3392-4cb9-97ae-3d6b9e3d740a"
      unitRef="usd">-1034000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i57267989876b466d9ebc59f49913b75f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNy05LTEtMS0yMDk3Nw_c4966300-e718-473e-b8b5-22a60a613ecd"
      unitRef="usd">-49965000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfNy0xMS0xLTEtMjA5Nzc_115f06c9-8788-43bc-88c7-aa6ba1ec3e7e"
      unitRef="usd">-49965000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i6e52f1591d1347c4bb2558fb1f9ee147_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfOC0xLTEtMS0yMDk3Nw_acd31267-83f4-43b8-bfc4-066634d5ce1d"
      unitRef="shares">25199081</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6e52f1591d1347c4bb2558fb1f9ee147_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfOC0zLTEtMS0yMDk3Nw_dd68c464-af8c-4093-b12b-afe640e35f67"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i65beb9114acd4ee1adef1dde5c44ba5c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfOC01LTEtMS0yMDk3Nw_fbf4b4c7-efee-4eb1-a196-4dca1cdea47a"
      unitRef="usd">740500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i87c8b8e1430a4c708d973ff2e25ae17b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfOC03LTEtMS0yMDk3Nw_89c6a142-3f38-447e-acaf-7d9869760732"
      unitRef="usd">-1197000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6ddceeccd7914fa1bc3f31fd69e6830a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfOC05LTEtMS0yMDk3Nw_bf465440-f338-4ab4-9f52-1d7156bf06f3"
      unitRef="usd">-190749000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjVlYzdhM2U2OTVlNDRhMjY5NzkwMmQyMDU0MDUxZTE4L3RhYmxlcmFuZ2U6NWVjN2EzZTY5NWU0NGEyNjk3OTAyZDIwNTQwNTFlMThfOC0xMS0xLTEtMjA5Nzc_e89ee3eb-aa7f-43eb-a969-bc4eef6ac839"
      unitRef="usd">548554000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ia6ffefd397c440af90b9447cc5a238f5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfMy0xLTEtMS0yMDk3Nw_b5e5ab06-9336-4692-9cf7-9d5c1153b61c"
      unitRef="shares">19714220</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ia6ffefd397c440af90b9447cc5a238f5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfMy0zLTEtMS0yMDk3Nw_c0dc5dda-51fc-4909-ba2b-e9641e14059f"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ica68c43f75604a03a077b382685b1a41_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfMy01LTEtMS0yMDk3Nw_3e4d0f03-ad85-4dd2-9a40-1e5851efad67"
      unitRef="usd">363292000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib67facf3d8f849e2b66fd1c7f68989ad_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfMy03LTEtMS0yMDk3Nw_e955fb62-f955-465e-9564-2a687505daa3"
      unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i67063c7c5279465183dd7e83d8f84145_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfMy05LTEtMS0yMDk3Nw_1860fcd9-8c7d-4004-bad8-bb572286255a"
      unitRef="usd">-71214000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i381f9df67cae40a4b3c35dfa60c3546f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfMy0xMS0xLTEtMjA5Nzc_addf437d-d951-488b-935f-29385a23203f"
      unitRef="usd">292084000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic12c80c1247f4acaa167064b8bb02705_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfNC0xLTEtMS0yMDk3Nw_ed81c41f-ffec-4bac-acc6-0b3438683952"
      unitRef="shares">2489837</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i77370fc21ec5473987c50059d5cab0bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfNC01LTEtMS0yMDk3Nw_be53a5b0-0475-4ecc-9ace-b0a9dd2f38d9"
      unitRef="usd">152033000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfNC0xMS0xLTEtMjA5Nzc_d165c443-8da4-43eb-9a9f-120dd4055dcf"
      unitRef="usd">152033000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i77370fc21ec5473987c50059d5cab0bc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfNS01LTEtMS0yMDk3Nw_458c6173-3190-4d41-82a1-5bc6e06e4f63"
      unitRef="usd">2350000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfNS0xMS0xLTEtMjA5Nzc_12e20228-6ce6-4c45-b7c4-c2193280168a"
      unitRef="usd">2350000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1f9b5535cbbc4e22af9f06fe59eaa400_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfNi03LTEtMS0yMDk3Nw_53494e29-75a0-472e-af4d-a63c87c8d2f4"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfNi0xMS0xLTEtMjA5Nzc_682d212c-151f-48b3-8e1c-9d4d11d804ea"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i1c06fb3b4ad5401d80b059fc7e9e1d3d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfNy05LTEtMS0yMDk3Nw_cfe6d0c3-ff5f-4ccb-bd05-ef92d4c7b236"
      unitRef="usd">-15812000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfNy0xMS0xLTEtMjA5Nzc_8d0fee8b-ee70-4a8d-8d4f-b51866b823d1"
      unitRef="usd">-15812000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i861f0c6362bd4446bef9d197ad8a4835_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfOC0xLTEtMS0yMDk3Nw_9591c853-69fa-47a6-a902-298435f13883"
      unitRef="shares">22204057</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i861f0c6362bd4446bef9d197ad8a4835_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfOC0zLTEtMS0yMDk3Nw_45e8136a-282e-4ede-b9c7-8e0d3b46951f"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i17fb83d3cf56449095121eab4cdd43b7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfOC01LTEtMS0yMDk3Nw_bd72ea4a-f14a-44ac-90bc-ca7eae5eab9d"
      unitRef="usd">517675000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8440da614aa3444894a316404ee33125_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfOC03LTEtMS0yMDk3Nw_1bd35400-d86d-496d-b8c1-ef8c874214cf"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i395b8e2070414f429d49289ac92db97b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfOC05LTEtMS0yMDk3Nw_eafb007b-85f3-4e8c-8904-c76999ffbd49"
      unitRef="usd">-87026000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idf458d33964c41e09d92634f029b4c61_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yMi9mcmFnOjc2MDg2M2QyZWU2NjQwZWFhZjJkODc5YjE1OWM3NmFiL3RhYmxlOjgwZTlkZGYwOTJiYTRjYjdhMzZmZjNhMGRjYmFjYTc2L3RhYmxlcmFuZ2U6ODBlOWRkZjA5MmJhNGNiN2EzNmZmM2EwZGNiYWNhNzZfOC0xMS0xLTEtMjA5Nzc_cc3fcc86-7f05-4d6a-9186-bce2b0a2a26c"
      unitRef="usd">430652000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMy0xLTEtMS0yMDk3Nw_86362dc3-627f-41e2-bec7-b1db97bfa301"
      unitRef="usd">-49965000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMy0zLTEtMS0yMDk3Nw_efc9c9a2-8781-4449-b9a1-a55d007c1181"
      unitRef="usd">-15812000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfNS0xLTEtMS0yMDk3Nw_72b0de6d-b459-4bc2-83bc-d38b35425655"
      unitRef="usd">1015000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfNS0zLTEtMS0yMDk3Nw_47b2e5dd-3ad5-4b4f-9b20-f102c2915e0c"
      unitRef="usd">536000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfNi0xLTEtMS0yMDk3Nw_1f6db0c2-8660-4f38-8f6f-b03774f655e0"
      unitRef="usd">6430000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfNi0zLTEtMS0yMDk3Nw_4268f7f8-7441-42b8-92ac-0061c0aa87e3"
      unitRef="usd">2313000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashExpense
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfOC0xLTEtMS0yMDk3Nw_ebeed404-1502-40b7-ac39-acc90f216df8"
      unitRef="usd">0</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfOC0zLTEtMS0yMDk3Nw_712c55c1-3481-4434-b460-d682352fc61a"
      unitRef="usd">1492000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTAtMS0xLTEtMjQ2OTc_10ed003d-407b-459a-976e-e8b82876a41f"
      unitRef="usd">-135000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTAtMy0xLTEtMjQ4NTI_85873ae4-aff0-40fd-9426-7498fae7e502"
      unitRef="usd">12000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTEtMS0xLTEtMjA5Nzc_6d568b0e-f615-448a-a030-b3929c8e99af"
      unitRef="usd">-820000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTEtMy0xLTEtMjA5Nzc_7cb0663c-5572-4e80-9cec-cf47a57b10c9"
      unitRef="usd">-1312000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTQtMS0xLTEtMjQ3NDY_8cfcdd43-3ff8-4840-9642-c6cb80d5ab39"
      unitRef="usd">-9000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTQtMy0xLTEtMjU3MDM_6eaa176c-6228-46e0-91b2-204340c401d8"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <krys:IncreaseDecreaseInLeaseLiability
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTMtMS0xLTEtMjA5Nzc_78c077ae-c28a-41f0-9f1f-be288d361af6"
      unitRef="usd">-126000</krys:IncreaseDecreaseInLeaseLiability>
    <krys:IncreaseDecreaseInLeaseLiability
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTMtMy0xLTEtMjA5Nzc_4de9ea09-cc41-4ca3-ab46-b7ed4421e073"
      unitRef="usd">-77000</krys:IncreaseDecreaseInLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTQtMS0xLTEtMjA5Nzc_3d878ccb-66a9-40e9-b23f-4218f9e4212f"
      unitRef="usd">-554000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTQtMy0xLTEtMjA5Nzc_32b1ca68-43b7-4da1-a5ee-e40b7ede816b"
      unitRef="usd">294000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTUtMS0xLTEtMjA5Nzc_8dcaee6b-96e7-4772-bfcd-66e500055b4a"
      unitRef="usd">2013000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTUtMy0xLTEtMjA5Nzc_8bff05fe-31f9-45a5-b810-41103f60f2b4"
      unitRef="usd">276000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <krys:IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTgtMS0xLTEtMjQ3NTQ_49ac598c-9947-4eb0-bc28-baa08eba5cd9"
      unitRef="usd">25000000</krys:IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment>
    <krys:IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTgtMy0xLTEtMjU3MDk_c0ea259a-d6d8-49c7-ad4e-a017904bf2de"
      unitRef="usd">0</krys:IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTYtMS0xLTEtMjA5Nzc_8679e61b-16f7-4e8f-9231-33fbe66f02e1"
      unitRef="usd">-15493000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTYtMy0xLTEtMjA5Nzc_084b889d-77fc-4d68-b7ad-e2390f7d1729"
      unitRef="usd">-9654000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTYtMy0xLTEtMjA5Nzc_a2b09f27-3e20-4a2b-afb0-7a87d264c6ee"
      unitRef="usd">-9654000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTktMS0xLTEtMjA5Nzc_007b2f4c-8ee1-42b2-beee-9b4991963c79"
      unitRef="usd">17191000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMTktMy0xLTEtMjA5Nzc_2e931167-7881-41e9-8fcf-8ad88a92167a"
      unitRef="usd">2473000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjEtMS0xLTEtMjA5Nzc_3bfebe76-c480-42f1-87b0-1b0b43655d58"
      unitRef="usd">62754000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjEtMy0xLTEtMjA5Nzc_d01c8c27-b754-4c7a-a988-2dd9fdc72487"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjItMS0xLTEtMjA5Nzc_406a0ce2-f1e3-474b-a4cc-22bee967a5a6"
      unitRef="usd">24037000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjItMy0xLTEtMjA5Nzc_f1f4ca40-4e43-4765-9478-8e44303fe40b"
      unitRef="usd">1726000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjQtMS0xLTEtMjA5Nzc_1fb166db-7360-42b3-a612-b8de8b6ac299"
      unitRef="usd">-55908000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjQtMy0xLTEtMjA5Nzc_ca1fe9b1-c014-4464-9556-638f0037627c"
      unitRef="usd">-747000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjctMS0xLTEtMjA5Nzc_aaa268ee-bdfc-4562-ad00-e0e8535bbf51"
      unitRef="usd">107000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjctMy0xLTEtMjA5Nzc_7942a2d6-60f2-40ac-b085-30f027a54b21"
      unitRef="usd">152264000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzAtMS0xLTEtMjQ3OTE_83495cdc-e06f-4c09-9718-ee2b83ba6c15"
      unitRef="usd">649000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzAtMy0xLTEtMjU3MTU_0bb2cabf-d900-429f-9a12-4a45aca4d2c1"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <krys:PaymentsForSuitLiability
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjgtMS0xLTEtMjA5Nzc_89d23893-c522-4770-baa4-20f75fc35899"
      unitRef="usd">0</krys:PaymentsForSuitLiability>
    <krys:PaymentsForSuitLiability
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjgtMy0xLTEtMjA5Nzc_7e092476-ec5c-46af-986a-d7023aa65876"
      unitRef="usd">7960000</krys:PaymentsForSuitLiability>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjktMS0xLTEtMjA5Nzc_28c4aa92-4ff3-41a0-bf57-b2bb05ff3c97"
      unitRef="usd">-542000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMjktMy0xLTEtMjA5Nzc_5d72bb34-ad69-461f-b754-29063af9edd8"
      unitRef="usd">144304000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzEtMS0xLTEtMjA5Nzc_15a14535-b3bb-46d7-90a8-c4e5587cdca8"
      unitRef="usd">-71943000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzEtMy0xLTEtMjA5Nzc_e603e63b-6993-41f0-b680-b1f3d559ecea"
      unitRef="usd">133903000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzMtMS0xLTEtMjA5Nzc_35bd3314-6d13-480b-ab11-d8f099550164"
      unitRef="usd">341246000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i381f9df67cae40a4b3c35dfa60c3546f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzMtMy0xLTEtMjA5Nzc_0082ecaa-8981-4f58-9656-0905708ba652"
      unitRef="usd">268269000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzQtMS0xLTEtMjA5Nzc_8ad413bf-d554-4cdc-b613-c1ab166d4077"
      unitRef="usd">269303000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idf458d33964c41e09d92634f029b4c61_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzQtMy0xLTEtMjA5Nzc_fa491bf2-d6b3-4306-933d-17e96e9172c0"
      unitRef="usd">402172000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzctMS0xLTEtMjA5Nzc_7bc29c4f-09a2-4400-8145-c765be751343"
      unitRef="usd">14507000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzctMy0xLTEtMjA5Nzc_453bca85-e8c3-49ea-82c2-a6946efd6bbe"
      unitRef="usd">2615000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzgtMS0xLTEtMjA5Nzc_ded70b03-2966-40fc-82c5-f3fb043a7269"
      unitRef="usd">1394000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzgtMy0xLTEtMjA5Nzc_163cf058-c430-45a2-90fa-9ae9062eafb7"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <krys:OfferingCostsIncurredButNotYetPaid
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzktMS0xLTEtMjA5Nzc_f8337501-a686-4cc0-9f52-ef5f08a8a492"
      unitRef="usd">24000</krys:OfferingCostsIncurredButNotYetPaid>
    <krys:OfferingCostsIncurredButNotYetPaid
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18yNS9mcmFnOjVlODhhYTA5MzFlMDQ5MTg5ZGI5MDYwMmQ0MmI4Y2ZjL3RhYmxlOjI3YWMzZjkyNzFhNjQ3YmU4Mzg5YmIxZThiZjc5MzZiL3RhYmxlcmFuZ2U6MjdhYzNmOTI3MWE2NDdiZTgzODliYjFlOGJmNzkzNmJfMzktMy0xLTEtMjA5Nzc_fb5d53da-e87a-4ce2-aa87-9c3deccc426c"
      unitRef="usd">214000</krys:OfferingCostsIncurredButNotYetPaid>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zMS9mcmFnOmU2OGMyOTAxMzFkYTQ5Mjk4NjYxOGI3Mjg3ZjE0OGMyL3RleHRyZWdpb246ZTY4YzI5MDEzMWRhNDkyOTg2NjE4YjcyODdmMTQ4YzJfMzM2NQ_a314f5ee-7361-48de-9b27-99087de35fb1">Organization&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Krystal Biotech, Inc. (the&#160;&#x201c;Company,&#x201d;&#160;or&#160;&#x201c;we&#x201d;&#160;or other similar pronouns) commenced operations on April 15, 2016. On March 31, 2017, the Company converted from a California limited liability company to a Delaware C-corporation, and changed its name from Krystal Biotech LLC to Krystal Biotech, Inc. On June 19, 2018, the Company incorporated Krystal Australia Pty Ltd., an Australian proprietary limited company, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies in Australia. On April 24, 2019, the Company incorporated Jeune Aesthetics, Inc., formerly known as Jeune, Inc. ("Jeune"), in Delaware, a wholly-owned subsidiary, for the purpose of undertaking preclinical and clinical studies for aesthetic skin conditions. On January 7, 2022, the Company incorporated Krystal Biotech Switzerland GmbH, for the purpose of establishing initial operations in Europe for the development and commercialization of Krystal's pipeline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a clinical stage biotechnology company leading the field of redosable gene delivery. Using our patented platform that is based on engineered herpes simplex virus type 1 ("HSV-1"), we create vectors that efficiently deliver therapeutic transgenes to cells of interest in multiple organ systems. The cell&#x2019;s own machinery then transcribes and translates the encoded effector to treat or prevent disease. We formulate our vectors for non-invasive or minimally invasive routes of administration at a doctor&#x2019;s office or potentially in the patient&#x2019;s home by a healthcare professional. Our goal is to develop easy to use medicines to dramatically improve the lives of patients living with debilitating diseases.  Our innovative technology platform is supported by in-house, commercial scale current good manufacturing practices ("cGMP") manufacturing capabilities.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the Company had an accumulated deficit of $190.7 million. With the net proceeds raised from its public and private securities offerings the Company believes that its cash, cash equivalents and short-term investments of approximately $434.6 million as of March&#160;31, 2022 will be sufficient to allow the Company to fund its planned operations for at least the next 12 months from the date of this Quarterly Report on Form 10-Q. As the Company continues to incur losses, a transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and the achievement of a level of revenues adequate to support the Company&#x2019;s cost structure. The Company may never achieve profitability and unless and until it does, the Company will continue to need to raise additional capital or obtain financing from other sources. Management intends to fund future operations through the sale of equity and debt financings and may also seek additional capital through arrangements with strategic partners or other sources. There can be no assurance that additional funding will be available on terms acceptable to the Company, if at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks common to companies in the biotechnology industry, including but not limited to the failure of product candidates in clinical and preclinical studies, the development of competing product candidates or other technological innovations by competitors, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to c&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ommercialize product candidates.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zMS9mcmFnOmU2OGMyOTAxMzFkYTQ5Mjk4NjYxOGI3Mjg3ZjE0OGMyL3RleHRyZWdpb246ZTY4YzI5MDEzMWRhNDkyOTg2NjE4YjcyODdmMTQ4YzJfMTc0Ng_6da58673-2158-44a7-bdcc-e36f0b73c8a3"
      unitRef="usd">-190700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zMS9mcmFnOmU2OGMyOTAxMzFkYTQ5Mjk4NjYxOGI3Mjg3ZjE0OGMyL3RleHRyZWdpb246ZTY4YzI5MDEzMWRhNDkyOTg2NjE4YjcyODdmMTQ4YzJfMjAwNw_9cbeaa0c-dd06-42d9-9938-7692865babcb"
      unitRef="usd">434600000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNjg_4c9f2907-7b35-40c8-b50b-93d60d82bd2f">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim condensed financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;), as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;), the Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;), and the rules and regulations of the US Securities and Exchange Commission (&#x201c;SEC&#x201d;).  In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods ended March&#160;31, 2022 and 2021, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation.  Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company&#x2019;s previously reported financial position or results of operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and the notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, as filed with the SEC on February 28, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The novel coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect our business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. However, the full extent, consequences, and duration of the&#160;COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that these events could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment and Geographical Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#x2019;s chief operating decision maker view the Company&#x2019;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceuticals. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#x2019;s policy is to invest its cash, cash equivalents and investments in money market funds, certificates of deposit, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#x2019;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments with maturities of greater than 90 days but less than one year are classified as short-term investments on the consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#x2019; equity in the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#x2019;s financial statements, are reasonable estimates of fair value, primarily due to their short maturities. Marketable securities are classified as long-term investments if the Company has the ability and intent to hold them and such holding period is longer than one year. The Company classifies all of its investments as available-for-sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our available-for-sale, short-term and long-term investments, which consist of, commercial paper, corporate bonds, and government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;lesser of remaining useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress ("CIP") is not depreciated until the asset is placed in service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has not recognized any impairment losses for the three months ended March&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, Leases ("ASC 842"). Right-of-use lease assets represent our right to use an underlying asset during the lease term and the lease obligations represent our commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, we have used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain "sale-leaseback" criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on our assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, related clinical manufacturing costs, contract management services, regulatory and other related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#x2019;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third party service providers and the Company&#x2019;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the fair value recognition provisions of Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASC 718"), to account for stock-based compensation. Compensation costs related to stock options granted is based on the estimated fair value of the awards on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Once the Company's own sufficient historical volatility data was obtained, the Company eliminated the use of a representative peer group and uses only its own historical volatility data in its estimate of expected volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the expected term of its stock options using the &#x201c;simplified&#x201d; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses and is presented net of taxes. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the FASB issued ASU 2020-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2020-08") to provide further clarification and update the previously issued guidance in ASU 2017-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20: Premium Amortization on Purchased Callable Debt Securities) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2017-08").  ASU 2017-08 shortened the amortization period for certain callable debt securities purchased at a premium by requiring that the premium be amortized to the earliest call date. ASU 2020-08 requires that at each reporting period, to the extent that the amortized cost of an individual callable debt security exceeds the amount repayable by the issuer at the next call date, the excess premium shall be amortized to the next call date. The new standard was effective beginning January 1, 2021 and should be applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. The adoption of ASU 2020-08 did not have a material impact on the Company's financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNjI_1ccb6aae-d803-4bd5-b454-c4120bdd6302">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim condensed financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;), as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;), the Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;), and the rules and regulations of the US Securities and Exchange Commission (&#x201c;SEC&#x201d;).  In the opinion of management, all adjustments, which consist of all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the interim periods ended March&#160;31, 2022 and 2021, are reflected in the interim condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation.  Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts have no impact on the Company&#x2019;s previously reported financial position or results of operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These unaudited interim condensed financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and the notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, as filed with the SEC on February 28, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <krys:RisksAndUncertaintiesPolicyTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNzQ_d025514e-24bb-4cb3-9162-b24b23544724">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The novel coronavirus ("COVID-19") pandemic has resulted, and is likely to continue to result, in significant national and global economic uncertainty and may adversely affect our business. The Company is continuing to actively monitor the impact of the COVID-19 pandemic and the related effects on its financial condition, liquidity, operations, suppliers, industry, and workforce. However, the full extent, consequences, and duration of the&#160;COVID-19 pandemic and the resulting impact on the Company cannot currently be predicted. The Company will continue to evaluate the impact that these events could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2022.&lt;/span&gt;&lt;/div&gt;</krys:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNjM_cc268b34-c9bd-45e6-b3b9-9e8c42fc40a2">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNjk_016b908d-dc0c-4c03-a1fb-617771b5e101">Segment and Geographical InformationOperating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company and the Company&#x2019;s chief operating decision maker view the Company&#x2019;s operations and manage its business in one operating segment, which is the business of developing and commercializing pharmaceuticals.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMzk2Ng_6199d66d-3327-4fad-a529-7725202d18dd"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNzU_8bcc9031-7589-480c-9a59-3177dfadbe01">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#x2019;s policy is to invest its cash, cash equivalents and investments in money market funds, certificates of deposit, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company&#x2019;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the balance sheets are in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNzY_6d798cb8-08c8-470c-8b11-2cdcb26a13d1">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of money market funds and bank deposits. Cash equivalents are defined as short-term, highly liquid investments with original maturities of 90&#160;days or less at the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments with maturities of greater than 90 days but less than one year are classified as short-term investments on the consolidated balance sheets and consist of commercial paper, corporate bonds, and government agency securities. Investments with maturities of greater than one year are classified as long-term investments on the consolidated balance sheets and consist of corporate bonds and government agency securities. Accrued interest on corporate bonds and government agency securities are also classified as short-term investments.&lt;/span&gt;&lt;/div&gt;As&#160;our entire investment portfolio is considered available for use in current operations, we classify all investments as available-for-sale securities. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive loss, which is a separate component of stockholders&#x2019; equity in the consolidated balance sheets.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNzA_4a1a7db5-bb9e-4bf6-a349-14f61d57564f">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There is a three-level hierarchy that prioritizes the inputs used in determining fair value by their reliability and preferred use, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Valuations based on inputs that are both significant to the fair value measurement and unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that a valuation is based on models or inputs that are less observable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized within Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no significant changes to the valuation methods utilized by the Company during the periods presented. There have been no transfers between Level 1, Level 2, and Level 3 in any periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of financial instruments consisting of cash and cash equivalents, investments, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities included in the Company&#x2019;s financial statements, are reasonable estimates of fair value, primarily due to their short maturities. Marketable securities are classified as long-term investments if the Company has the ability and intent to hold them and such holding period is longer than one year. The Company classifies all of its investments as available-for-sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our available-for-sale, short-term and long-term investments, which consist of, commercial paper, corporate bonds, and government agency securities are considered to be Level 2 valuations. The fair value of Level 2 financial assets is determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNjQ_241a2bb4-b7c8-435d-b6e8-055f283e34f2">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net, is stated at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred, while costs of major additions and betterments are capitalized. Upon disposal, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;lesser of remaining useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress ("CIP") is not depreciated until the asset is placed in service.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <krys:EstimatedUsefulLivesOfAssetsTableTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNzc_98c52112-459c-49d8-ac18-c6620c6e6c2c">Depreciation is recorded using the straight-line method over the estimated useful lives of the respective assets, which are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;lesser of remaining useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</krys:EstimatedUsefulLivesOfAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie8265b62d98547d1b612aa5059737994_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RhYmxlOjJkZGY0YmJhZjc3NzQzYzdiZGM5ODMyY2M1YTNjNDdmL3RhYmxlcmFuZ2U6MmRkZjRiYmFmNzc3NDNjN2JkYzk4MzJjYzVhM2M0N2ZfMC0xLTEtMS0yMDk3Ny90ZXh0cmVnaW9uOmM3NTU3NjY3ZjZiZTRlZDFhMmIyOTg0ZDg5YTRmOWYwXzE2NDkyNjc0NDE2ODY_8d6fed03-0e76-4a97-b173-b373528f899f">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iff7c8222f2ec4030bb73e073b01cc801_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RhYmxlOjJkZGY0YmJhZjc3NzQzYzdiZGM5ODMyY2M1YTNjNDdmL3RhYmxlcmFuZ2U6MmRkZjRiYmFmNzc3NDNjN2JkYzk4MzJjYzVhM2M0N2ZfMC0xLTEtMS0yMDk3Ny90ZXh0cmVnaW9uOmM3NTU3NjY3ZjZiZTRlZDFhMmIyOTg0ZDg5YTRmOWYwXzE2NDkyNjc0NDE2OTE_338c6e2a-a889-4f8a-a02b-8883a3d26137">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i8526152bbd814c19af8798ebbf6df780_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RhYmxlOjJkZGY0YmJhZjc3NzQzYzdiZGM5ODMyY2M1YTNjNDdmL3RhYmxlcmFuZ2U6MmRkZjRiYmFmNzc3NDNjN2JkYzk4MzJjYzVhM2M0N2ZfMS0xLTEtMS0yMDk3Ny90ZXh0cmVnaW9uOmI2ZjE0YzBiZDI3ODQwNmRhYzczOGY0NmY1ZWI2ODU0XzQ_ac05c603-a920-450b-b918-fff748ec9920">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i5b7a2cb4937f4539b4d97203dc50610f_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RhYmxlOjJkZGY0YmJhZjc3NzQzYzdiZGM5ODMyY2M1YTNjNDdmL3RhYmxlcmFuZ2U6MmRkZjRiYmFmNzc3NDNjN2JkYzk4MzJjYzVhM2M0N2ZfMS0xLTEtMS0yMDk3Ny90ZXh0cmVnaW9uOmI2ZjE0YzBiZDI3ODQwNmRhYzczOGY0NmY1ZWI2ODU0Xzg_eb661bb0-520e-4867-a319-a987b6f7705f">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie1ef4419eb8c470d85aacefec56909e5_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RhYmxlOjJkZGY0YmJhZjc3NzQzYzdiZGM5ODMyY2M1YTNjNDdmL3RhYmxlcmFuZ2U6MmRkZjRiYmFmNzc3NDNjN2JkYzk4MzJjYzVhM2M0N2ZfMi0xLTEtMS0yMDk3Ny90ZXh0cmVnaW9uOjFjZjQ1OWVlN2JkMDQ5MjNhM2I2YjhmNThlMmZkZWE4XzE2NDkyNjc0NDE2ODY_212aad5d-26d8-4db6-8f21-a99f2944830d">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i41aa2659a9d349aca4310c4ac210e321_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RhYmxlOjJkZGY0YmJhZjc3NzQzYzdiZGM5ODMyY2M1YTNjNDdmL3RhYmxlcmFuZ2U6MmRkZjRiYmFmNzc3NDNjN2JkYzk4MzJjYzVhM2M0N2ZfMi0xLTEtMS0yMDk3Ny90ZXh0cmVnaW9uOjFjZjQ1OWVlN2JkMDQ5MjNhM2I2YjhmNThlMmZkZWE4XzE2NDkyNjc0NDE2OTc_218a9644-894f-4f2c-b04b-57d999dfaafb">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNjU_14ff46ca-56ec-47bb-b239-ae719f8730f6">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates long-lived assets for potential impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount of the asset. The Company has not recognized any impairment losses for the three months ended March&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="iee85b21ece4849119c1efceb43453fde_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTAxMjE_5c3bf040-8c32-4598-9d43-bf282b4f6250"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="ice1e26d5975d48f7995f61e80667d911_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTAxMjE_b6fdee0d-70d4-42d1-adf2-eb0fb410b7fa"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNzI_933d4a5d-b0fc-4a6a-8865-665a7ce7ce91">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its lease agreements in accordance with FASB ASC Topic 842, Leases ("ASC 842"). Right-of-use lease assets represent our right to use an underlying asset during the lease term and the lease obligations represent our commitment to make lease payments arising from the lease.&#160;Right-of-use&#160;lease assets and obligations are recognized based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s lease agreements do not provide an implicit rate and as the Company does not have any external borrowings, we have used an estimated incremental borrowing rate based on the information available at lease commencement in determining the present value of lease payments.&#160;&#160;Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease expense is recognized in the period in which the obligation for the payment is incurred. In addition, the Company also has made an accounting policy election to exclude leases with an initial term of twelve months or less from its balance sheet and to account for lease and non-lease components of its operating leases as a single component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For lease arrangements where it has been determined that the Company has control over an asset that is under construction and is thus considered the accounting owner of the asset during the construction period, the Company records a construction in progress asset and corresponding financial obligation on the condensed consolidated balance sheet. Once the construction is complete, an assessment is performed to determine whether the lease meets certain "sale-leaseback" criteria.  If the sale-leaseback criteria are determined to be met, the Company will remove the asset and related financial obligation from the condensed consolidated balance sheet and treat the lease as either an operating or finance lease based on our assessment of the guidance. If, upon completion of construction, the project does not meet the "sale-leaseback" criteria, the lease will be treated as a financing obligation and the Company will depreciate the asset over its estimated useful life for financial reporting purposes once the asset has been placed into service.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNjY_8b7f5cf0-18a4-4a4c-917c-2b6029900a32">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred in performing research and development activities. These costs include employee compensation costs, facilities and overhead, preclinical and clinical activities, related clinical manufacturing costs, contract management services, regulatory and other related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates contract research and clinical trials materials manufacturing expenses based on the services performed pursuant to contracts with research organizations and manufacturing organizations that manufacture materials used in the Company&#x2019;s ongoing preclinical and clinical studies. Non-refundable advanced payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third party service providers and the Company&#x2019;s estimates of accrued expenses using information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNzM_4eda2160-269d-4f01-9b47-2b79b491ae3b">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the fair value recognition provisions of Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASC 718"), to account for stock-based compensation. Compensation costs related to stock options granted is based on the estimated fair value of the awards on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 718 requires all stock-based payments, including grants of stock options and restricted stock, to be recognized in the statements of operations based on their grant-date fair values. Compensation expense is recognized on a straight-line basis based on the grant-date fair value over the associated service period of the award, which is generally the vesting term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of its stock options using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including: (i)&#160;the expected stock price volatility; (ii)&#160;the expected term of the award; (iii)&#160;the risk-free interest rate; and (iv)&#160;expected dividends. Once the Company's own sufficient historical volatility data was obtained, the Company eliminated the use of a representative peer group and uses only its own historical volatility data in its estimate of expected volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the expected term of its stock options using the &#x201c;simplified&#x201d; method, whereby the expected term equals the arithmetic mean of the vesting term and the original contractual term of the option. The risk-free interest rates are based on US Treasury securities with a maturity date commensurate with the expected term of the associated award. The &lt;/span&gt;&lt;/div&gt;Company has never paid and does not expect to pay dividends in the foreseeable future. The Company accounts for forfeitures as they occur. Stock-based compensation expense recognized in the financial statements is based on awards for which service conditions are expected to be satisfied.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNzE_70514d37-fbc2-43cf-ad64-ac601e58cd88">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as the change in equity during a period from transactions from&#160;non-owner&#160;sources. Unrealized gains or losses on available-for-sale securities is a component of other comprehensive gains or losses and is presented net of taxes. We have not recorded any reclassifications from other comprehensive gains or losses to net loss during any period presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNC9mcmFnOjU2M2MxMjExMjhmMzQwZjM4N2I2MjUwYjkxNDUzNjRkL3RleHRyZWdpb246NTYzYzEyMTEyOGYzNDBmMzg3YjYyNTBiOTE0NTM2NGRfMTgxNjc_d41ee735-e5d8-4702-ab03-93e7393b3308">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASU No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the FASB issued ASU 2020-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements to Subtopic 310-20, Receivables - Nonrefundable Fees and Other Costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2020-08") to provide further clarification and update the previously issued guidance in ASU 2017-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20: Premium Amortization on Purchased Callable Debt Securities) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2017-08").  ASU 2017-08 shortened the amortization period for certain callable debt securities purchased at a premium by requiring that the premium be amortized to the earliest call date. ASU 2020-08 requires that at each reporting period, to the extent that the amortized cost of an individual callable debt security exceeds the amount repayable by the issuer at the next call date, the excess premium shall be amortized to the next call date. The new standard was effective beginning January 1, 2021 and should be applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. The adoption of ASU 2020-08 did not have a material impact on the Company's financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RleHRyZWdpb246OTYyOTcwYTU0NzhiNDAzMGFhZDczM2QwYTIwYmI3MjJfOTU4_458293c7-0ab5-4ea1-974c-9e7cd09c3280">Net Loss Per Share Attributable to Common Stockholders&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of shares of common stock and common share equivalents outstanding for the period. Common share equivalents consist of common stock issuable upon exercise of stock options and vesting of restricted stock awards. There were 3,226,962 and 1,423,540 common share equivalents outstanding as of March&#160;31, 2022 and 2021, respectively, in the form of stock options and unvested restricted stock awards, that have been excluded from the calculation of diluted net loss per common share as their effect would be anti-dilutive for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.596%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands, except shares and per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,812)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average basic and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160; diluted common shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,114,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,253,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per&lt;br/&gt;&#160;&#160; common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RleHRyZWdpb246OTYyOTcwYTU0NzhiNDAzMGFhZDczM2QwYTIwYmI3MjJfNjYz_3c06cb58-6719-4327-833b-c02f69fff47d"
      unitRef="shares">3226962</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RleHRyZWdpb246OTYyOTcwYTU0NzhiNDAzMGFhZDczM2QwYTIwYmI3MjJfNjcw_251e7c2a-d1e8-4bb7-9dae-5030ebce206a"
      unitRef="shares">1423540</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RleHRyZWdpb246OTYyOTcwYTU0NzhiNDAzMGFhZDczM2QwYTIwYmI3MjJfOTU5_023e22f5-a411-44fa-8ac6-547287e65ddd">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.596%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.681%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands, except shares and per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,812)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average basic and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160; diluted common shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,114,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,253,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per&lt;br/&gt;&#160;&#160; common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RhYmxlOjE1ZjMzY2I1MmU2MTQ3MGU4MzgzMDE1YTEwY2JmN2Y5L3RhYmxlcmFuZ2U6MTVmMzNjYjUyZTYxNDcwZTgzODMwMTVhMTBjYmY3ZjlfNC0xLTEtMS0yMDk3Nw_3fb312de-38c0-496b-9afe-e2c379714d3d"
      unitRef="usd">-49965000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RhYmxlOjE1ZjMzY2I1MmU2MTQ3MGU4MzgzMDE1YTEwY2JmN2Y5L3RhYmxlcmFuZ2U6MTVmMzNjYjUyZTYxNDcwZTgzODMwMTVhMTBjYmY3ZjlfNC0zLTEtMS0yMDk3Nw_2a48040f-5a78-4b64-a3c1-2ef683c38837"
      unitRef="usd">-15812000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RhYmxlOjE1ZjMzY2I1MmU2MTQ3MGU4MzgzMDE1YTEwY2JmN2Y5L3RhYmxlcmFuZ2U6MTVmMzNjYjUyZTYxNDcwZTgzODMwMTVhMTBjYmY3ZjlfNi0xLTEtMS0yMDk3Nw_0f282d69-6a72-45cd-b0c8-1df2ed903a9a"
      unitRef="shares">25114453</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RhYmxlOjE1ZjMzY2I1MmU2MTQ3MGU4MzgzMDE1YTEwY2JmN2Y5L3RhYmxlcmFuZ2U6MTVmMzNjYjUyZTYxNDcwZTgzODMwMTVhMTBjYmY3ZjlfNi0xLTEtMS0yMDk3Nw_70e843de-3670-4874-8a38-682b88d630e7"
      unitRef="shares">25114453</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RhYmxlOjE1ZjMzY2I1MmU2MTQ3MGU4MzgzMDE1YTEwY2JmN2Y5L3RhYmxlcmFuZ2U6MTVmMzNjYjUyZTYxNDcwZTgzODMwMTVhMTBjYmY3ZjlfNi0zLTEtMS0yMDk3Nw_697d879b-4bae-4a84-89f8-b31a847ddc24"
      unitRef="shares">21253508</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RhYmxlOjE1ZjMzY2I1MmU2MTQ3MGU4MzgzMDE1YTEwY2JmN2Y5L3RhYmxlcmFuZ2U6MTVmMzNjYjUyZTYxNDcwZTgzODMwMTVhMTBjYmY3ZjlfNi0zLTEtMS0yMDk3Nw_fb3a1b13-0a4f-4827-8690-4c95539805bd"
      unitRef="shares">21253508</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RhYmxlOjE1ZjMzY2I1MmU2MTQ3MGU4MzgzMDE1YTEwY2JmN2Y5L3RhYmxlcmFuZ2U6MTVmMzNjYjUyZTYxNDcwZTgzODMwMTVhMTBjYmY3ZjlfNy0xLTEtMS0yMDk3Nw_37c1b87e-e918-4cab-9353-bdcbace39cdf"
      unitRef="usdPerShare">-1.99</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RhYmxlOjE1ZjMzY2I1MmU2MTQ3MGU4MzgzMDE1YTEwY2JmN2Y5L3RhYmxlcmFuZ2U6MTVmMzNjYjUyZTYxNDcwZTgzODMwMTVhMTBjYmY3ZjlfNy0xLTEtMS0yMDk3Nw_5371e751-8240-48ed-bca8-b26c81886b59"
      unitRef="usdPerShare">-1.99</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RhYmxlOjE1ZjMzY2I1MmU2MTQ3MGU4MzgzMDE1YTEwY2JmN2Y5L3RhYmxlcmFuZ2U6MTVmMzNjYjUyZTYxNDcwZTgzODMwMTVhMTBjYmY3ZjlfNy0zLTEtMS0yMDk3Nw_425d00d4-8181-477b-a396-50c6e33d9bb2"
      unitRef="usdPerShare">-0.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y18zNy9mcmFnOjk2Mjk3MGE1NDc4YjQwMzBhYWQ3MzNkMGEyMGJiNzIyL3RhYmxlOjE1ZjMzY2I1MmU2MTQ3MGU4MzgzMDE1YTEwY2JmN2Y5L3RhYmxlcmFuZ2U6MTVmMzNjYjUyZTYxNDcwZTgzODMwMTVhMTBjYmY3ZjlfNy0zLTEtMS0yMDk3Nw_5db1c0e4-ab68-4a6e-b758-fedee9ab4690"
      unitRef="usdPerShare">-0.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RleHRyZWdpb246MDNiYjNjZWZiMzlmNGM4Y2JhZTljZWNkYmY0MWQ2NzBfNTAz_b809b21f-c752-4ff8-88c9-494f7b3966a5">Fair Value Instruments&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables show the Company&#x2019;s cash, cash equivalents and available-for-sale securities by significant investment category as of March&#160;31, 2022 and December&#160;31, 2021, respectively (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(724)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;199,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,201)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;198,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;165,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;469,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;467,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;165,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;502,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;502,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The Company&#x2019;s short-term marketable securities mature in one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The Company's long-term marketable securities mature between one year and two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 2 to these unaudited condensed consolidated financial statements for additional discussion regarding the Company&#x2019;s fair value measurements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RleHRyZWdpb246MDNiYjNjZWZiMzlmNGM4Y2JhZTljZWNkYmY0MWQ2NzBfNTA0_c20e8ea6-6c48-4382-b7da-495605e7d9bb">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables show the Company&#x2019;s cash, cash equivalents and available-for-sale securities by significant investment category as of March&#160;31, 2022 and December&#160;31, 2021, respectively (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(724)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;199,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,201)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;198,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;165,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;469,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;467,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;269,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;165,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash and Cash&lt;br/&gt;Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;502,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;502,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;341,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The Company&#x2019;s short-term marketable securities mature in one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The Company's long-term marketable securities mature between one year and two years.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i63849f9dca98492397cffbdb5ad8bc0a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfNC0xLTEtMS0yMDk3Nw_7e299ae6-f413-4297-8447-d8285edf93d5"
      unitRef="usd">269303000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i63849f9dca98492397cffbdb5ad8bc0a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfNC03LTEtMS0yMDk3Nw_53cd8d61-ac4e-4a0e-ba7f-327836e6e945"
      unitRef="usd">269303000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i71df1d506a1d42f59d5769c25d50de0d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfNC05LTEtMS0yMDk3Nw_1f75855d-e928-4485-b611-b1b3506b445e"
      unitRef="usd">269303000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6b56a800b1dc4d59b0579103fb3856e3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfNS0xLTEtMS0yMDk3Nw_899d5e6a-6697-438d-92cf-635961172310"
      unitRef="usd">269303000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6b56a800b1dc4d59b0579103fb3856e3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfNS03LTEtMS0yMDk3Nw_584bbe1b-b0f7-4c2b-aedf-54954e08c27e"
      unitRef="usd">269303000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if5e3ccafd6e7408e8d72c7ed3d59aa1d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfNS05LTEtMS0yMDk3Nw_dc28570d-32d3-458a-aa35-46ed3a1b0f89"
      unitRef="usd">269303000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie0718e9e6a304faa99a8d0ba4d170a50_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOC0xLTEtMS0yMDk3Nw_7d4683f3-b1a9-4c77-abec-1d6d480b675d"
      unitRef="usd">39476000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie0718e9e6a304faa99a8d0ba4d170a50_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOC0zLTEtMS0yMDk3Nw_9cc49d31-dac8-4098-bfbe-4af6b5cdbc7c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie0718e9e6a304faa99a8d0ba4d170a50_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOC01LTEtMS0yMDk3Nw_fa49547c-9b2d-4be4-b73d-ce4f80e97943"
      unitRef="usd">37000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie0718e9e6a304faa99a8d0ba4d170a50_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOC03LTEtMS0yMDk3Nw_cc82f3a4-adb5-4036-bf71-41ffaf07aafa"
      unitRef="usd">39439000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i63e06177b3b947ed827f1ae04d3f6c24_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOC0xMS0xLTEtMjA5Nzc_d1448050-f763-4f6e-82b7-3378c5b655fe"
      unitRef="usd">39439000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i91af162b5ce24bcca39b1802458f9c63_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOC0xMy0xLTEtMjA5Nzc_64ca78ef-45d1-459f-a219-ccc327174dcf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i12453054567d425ebb3db8321c10080c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOS0xLTEtMS0yMDk3Nw_72b21390-43dc-411b-a338-8358e1353f12"
      unitRef="usd">106741000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i12453054567d425ebb3db8321c10080c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOS0zLTEtMS0yMDk3Nw_7719a689-014f-471b-84e1-204f93998274"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i12453054567d425ebb3db8321c10080c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOS01LTEtMS0yMDk3Nw_0e2d8dd6-39d7-43f5-a97c-ef436e6bdd5e"
      unitRef="usd">724000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i12453054567d425ebb3db8321c10080c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOS03LTEtMS0yMDk3Nw_89842cc4-ac15-4bf3-ab6f-5c8abcf6e6e0"
      unitRef="usd">106019000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0605bcc794c8466488458ac6a40a567a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOS0xMS0xLTEtMjA5Nzc_5cefef93-b4cc-4cd8-a142-dae3554f3c0e"
      unitRef="usd">81961000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6fc83aec7ccf4e56b6000b187c116bc9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfOS0xMy0xLTEtMjA5Nzc_0a03ac45-548e-446e-9753-73a549036ba5"
      unitRef="usd">24058000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iac939cd950c94172a39585927ae3707b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTAtMS0xLTEtMjA5Nzc_29c1793a-51b0-4897-ae03-1acc3e575660"
      unitRef="usd">53650000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iac939cd950c94172a39585927ae3707b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTAtMy0xLTEtMjA5Nzc_a6f223f9-3f82-496e-a466-a5cefb8081ef"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iac939cd950c94172a39585927ae3707b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTAtNS0xLTEtMjA5Nzc_31839ecf-108e-4867-87b1-43e8ff4cdc19"
      unitRef="usd">440000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iac939cd950c94172a39585927ae3707b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTAtNy0xLTEtMjA5Nzc_33f451dd-382c-4334-b199-1ea23e86d7d1"
      unitRef="usd">53210000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i52a9c36697194609ac56e04b9aa3d9a8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTAtMTEtMS0xLTIwOTc3_a3ed5018-fb86-4a7c-b698-c81824d94a91"
      unitRef="usd">43929000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8c95f3dd9aa1471889572b02d7094b9d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTAtMTMtMS0xLTIwOTc3_b2e0e303-4caf-4178-8efb-a16b59114495"
      unitRef="usd">9281000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2740425fee244d2f922f4b25973e349b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTEtMS0xLTEtMjA5Nzc_70cc1430-283f-4025-b2a2-6b461a784989"
      unitRef="usd">199867000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2740425fee244d2f922f4b25973e349b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTEtMy0xLTEtMjA5Nzc_a727258a-dc56-4da5-9f82-27b5717d1758"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2740425fee244d2f922f4b25973e349b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTEtNS0xLTEtMjA5Nzc_4fe4b0a4-b38c-4928-bf02-199fc244a686"
      unitRef="usd">1201000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2740425fee244d2f922f4b25973e349b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTEtNy0xLTEtMjA5Nzc_7fc839f1-fa35-46da-8c6a-6ae47fad0ff5"
      unitRef="usd">198668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifdbc6dddacb448d9ad60106137194932_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTEtMTEtMS0xLTIwOTc3_888b22d0-a259-4cb1-a317-7375810a6bf4"
      unitRef="usd">165329000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iebe00a10a2724634b1c0118d2d67a4a8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTEtMTMtMS0xLTIwOTc3_c1db0bac-ffa7-45e4-9ca2-c8de07e544c5"
      unitRef="usd">33339000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTItMS0xLTEtMjA5Nzc_e680e2d2-871b-4dfb-a8b2-e51dcbcace49"
      unitRef="usd">469170000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTItMy0xLTEtMjA5Nzc_2452b61d-e2b2-4fc3-b5e7-a2fa9e7a038f"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTItNS0xLTEtMjA5Nzc_9466cf14-af55-4cd8-a657-4fc03ab40d52"
      unitRef="usd">1201000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTItNy0xLTEtMjA5Nzc_74f6a9a9-2e87-4746-aa61-cfb800751d5c"
      unitRef="usd">467971000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="ibeaaf7239b4345778bad76871b818c5a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTItOS0xLTEtMjA5Nzc_d9b9f35f-02a0-44a8-a4cf-0bed5f0b3300"
      unitRef="usd">269303000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i3140340b83cb4218b934f3877760f87c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTItMTEtMS0xLTIwOTc3_4eeb11e2-53da-4824-857c-b48ceb95dfce"
      unitRef="usd">165329000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="icba6d511515a4acf97d285fa1677f2cb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOmFmMzA4YjE0ZTQyMjQwNDY4N2I4YTlkZDM0NGRmZTEwL3RhYmxlcmFuZ2U6YWYzMDhiMTRlNDIyNDA0Njg3YjhhOWRkMzQ0ZGZlMTBfMTItMTMtMS0xLTIwOTc3_37de22da-3abd-45cd-93ed-1837983315a2"
      unitRef="usd">33339000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9a3729b490084ba89c9abadcac13b833_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMy0xLTEtMS0yMDk3Nw_1e58ff7e-c2b3-44e8-9bdf-f0f9c84c2417"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9a3729b490084ba89c9abadcac13b833_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMy03LTEtMS0yMDk3Nw_1675de11-be89-4880-9429-e4abaf03172f"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i23a4767bf6e240bda02a5dbd7afc4ff7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMy05LTEtMS0yMDk3Nw_7bb6059a-5650-4e8f-bad6-787f0b6e6e35"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4d1b20d4b556453996c9073c1c2716ee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNS0xLTEtMS0yMDk3Nw_5b26db29-a21c-4333-b39b-bc153f0c0379"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4d1b20d4b556453996c9073c1c2716ee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNS03LTEtMS0yMDk3Nw_135d18be-957d-413f-8dba-c7aaa739eef7"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9f0e12c30bc84334939e2e4bf442dfac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNS05LTEtMS0yMDk3Nw_03512803-5c21-4dd3-83b1-e092dff4cdb6"
      unitRef="usd">341246000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i49e8debc5cb94ea6a469f4196d724fa5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy0xLTEtMS0yMjE2Ng_140df78c-af4f-4731-8ef9-861dfccc013d"
      unitRef="usd">40469000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i49e8debc5cb94ea6a469f4196d724fa5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy0zLTEtMS0yMjE2Ng_9ad908a1-598f-4f16-86d5-55009e723641"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i49e8debc5cb94ea6a469f4196d724fa5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy01LTEtMS0yMjE2Ng_c5573c72-ced9-4038-9210-172b0505c4db"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i49e8debc5cb94ea6a469f4196d724fa5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy03LTEtMS0yMjE2Ng_5854c516-e4d1-400d-b5e5-55a3f3b0592e"
      unitRef="usd">40466000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i46c951025fce41ab952849ce6a3ab2e4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy0xMS0xLTEtMjIxNjY_682321d5-8675-4d84-9611-68502fa25ddc"
      unitRef="usd">40466000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaf8f54899b4a4148a67b60622acaf77b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy0xMy0xLTEtMjIxNjY_d1056f54-91d2-4531-bd0d-c9a2cf7515b1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5ba725ffee7e42e6a8128c65b3a212bd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy0xLTEtMS0yMDk3Nw_44ac8f70-3109-4403-88ce-d637ae7e6491"
      unitRef="usd">83300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5ba725ffee7e42e6a8128c65b3a212bd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy0zLTEtMS0yMDk3Nw_051878d4-4c5d-4c42-9b05-84046a2c28e2"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5ba725ffee7e42e6a8128c65b3a212bd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy01LTEtMS0yMDk3Nw_3fe88090-2599-49a0-a493-010ba3ebcffd"
      unitRef="usd">114000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5ba725ffee7e42e6a8128c65b3a212bd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy03LTEtMS0yMDk3Nw_ce3fc119-7771-458c-81d3-47a0978092af"
      unitRef="usd">83196000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icf6969542ce14c959f3e2e0e56bcb784_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy0xMS0xLTEtMjA5Nzc_03056371-b1aa-4811-8040-ce3071dcc571"
      unitRef="usd">35768000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1502ff476f7844a8b66df5fd7220258e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfNy0xMy0xLTEtMjA5Nzc_688c53d2-236b-4f29-b002-ac2d16019a92"
      unitRef="usd">47428000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3bad5e70d1fb436897da83e0b8eeee55_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfOS0xLTEtMS0yMjE2Ng_c3c08ed2-b2bf-4fcd-8a25-42b98b072a30"
      unitRef="usd">37621000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3bad5e70d1fb436897da83e0b8eeee55_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfOS0zLTEtMS0yMjE2Ng_427d84cb-1e76-4b83-888d-559945af9aed"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3bad5e70d1fb436897da83e0b8eeee55_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfOS01LTEtMS0yMjE2Ng_2436ee8b-3441-4dcf-acba-e10048b1e500"
      unitRef="usd">62000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3bad5e70d1fb436897da83e0b8eeee55_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfOS03LTEtMS0yMjE2Ng_cb7c1eba-8d23-48b6-b3b5-83c59454f3dc"
      unitRef="usd">37559000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaa7daa0072cb419cb2dbaaf3afff522e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfOS0xMS0xLTEtMjIxNjY_4690be64-881b-4579-94fb-f1b5335daf06"
      unitRef="usd">20616000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6c36492a3b734099aac3b58956194853_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfOS0xMy0xLTEtMjIxNjY_4b0a90c4-bd8a-4f06-8dd5-e83378c1b707"
      unitRef="usd">16943000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idc7984fa6b0c43debd86bc7ec5c8ddef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTEtMS0xLTEtMjA5Nzc_71b9a3da-3e75-4986-a10a-6687ec326547"
      unitRef="usd">161390000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idc7984fa6b0c43debd86bc7ec5c8ddef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTEtMy0xLTEtMjA5Nzc_f55353d9-adb1-48f9-899f-11325d7fe277"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idc7984fa6b0c43debd86bc7ec5c8ddef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTEtNS0xLTEtMjA5Nzc_c1ee533e-4bfe-4fcb-ad79-bb7799fb4445"
      unitRef="usd">180000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idc7984fa6b0c43debd86bc7ec5c8ddef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTEtNy0xLTEtMjA5Nzc_5c3adbc5-d5c6-4888-bbd4-a76af96eb1f6"
      unitRef="usd">161221000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idbf78e0869994741ae4e6b2efdb39bc9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTEtMTEtMS0xLTIwOTc3_42b4c6c0-6a97-46a9-af29-c43189ac622c"
      unitRef="usd">96850000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3f5b030412564955be828db44eb6b956_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTEtMTMtMS0xLTIwOTc3_bc256a4d-c27b-423e-9fb2-607d65491334"
      unitRef="usd">64371000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTItMS0xLTEtMjA5Nzc_96f61483-6175-4218-87d2-cc5ffe6486f5"
      unitRef="usd">502636000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTItMy0xLTEtMjA5Nzc_e77abdb3-f82e-410c-bdc2-d5237380a628"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTItNS0xLTEtMjA5Nzc_6a202c0b-d35a-4176-944a-21b9409443f6"
      unitRef="usd">180000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTItNy0xLTEtMjA5Nzc_8f9f52d1-030a-463d-90ca-7b5389fdfa76"
      unitRef="usd">502467000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i2b8b8c8c466f413999e0992ec12716e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTItOS0xLTEtMjA5Nzc_4cfc6c6f-b811-4fc5-8b57-12e7a2a9e60d"
      unitRef="usd">341246000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="i63e50181337f4deda50f8a1ec567dd37_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTItMTEtMS0xLTIwOTc3_cb556deb-ccd8-469a-a74f-d0b9af846ece"
      unitRef="usd">96850000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale
      contextRef="if60f2e99fb10489cb879593621b5e8bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RhYmxlOjljNzVkNWEzNTFkZTQwNjc4Mzg2NTA0YzVhNzIzMWJjL3RhYmxlcmFuZ2U6OWM3NWQ1YTM1MWRlNDA2NzgzODY1MDRjNWE3MjMxYmNfMTItMTMtMS0xLTIwOTc3_b65fcc62-602f-48f4-b1c7-9716907b7460"
      unitRef="usd">64371000</krys:CashCashEquivalentsAndDebtSecuritiesAvailableForSale>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="ifdbc6dddacb448d9ad60106137194932_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RleHRyZWdpb246MDNiYjNjZWZiMzlmNGM4Y2JhZTljZWNkYmY0MWQ2NzBfMjcy_ef074a95-b03c-4418-9ad2-4e93d45f9bcb">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="i8a8a378d87ac477fa9eb1f74361e0f3a_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RleHRyZWdpb246MDNiYjNjZWZiMzlmNGM4Y2JhZTljZWNkYmY0MWQ2NzBfMzQ1_9f7d578f-36e8-4975-8c7b-729edf62ef7b">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="icd44f57ba38a4bbfb2f25ef586c2f644_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180MC9mcmFnOjAzYmIzY2VmYjM5ZjRjOGNiYWU5Y2VjZGJmNDFkNjcwL3RleHRyZWdpb246MDNiYjNjZWZiMzlmNGM4Y2JhZTljZWNkYmY0MWQ2NzBfMzUy_ab7751fa-6189-4b15-9b6d-4ba048df1863">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RleHRyZWdpb246MDI3MzNhNDY0YTg4NDY0NWEwOGZkZGU3ZGNlMGE0MzdfMzgw_01b569b1-103c-44b0-aa55-cc7c13a3a48a">Balance Sheet Components&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $462 thousand and $438 thousand for the three months ended March&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued preclinical and clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued litigation settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RleHRyZWdpb246MDI3MzNhNDY0YTg4NDY0NWEwOGZkZGU3ZGNlMGE0MzdfMzgx_c9b4b441-b165-4e9d-acd1-cdc7b1f4f064">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="idbf226c7773f451cb39f05cc616016f9_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfMi0xLTEtMS0yMDk3Nw_62319e15-18ef-4c15-b46c-0e2e3ea060a5"
      unitRef="usd">128933000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie70bd060e96749a89eccb6ac7c4aa94e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfMi0zLTEtMS0yMDk3Nw_d1414ec5-fdb3-486d-92d6-21f529559c6b"
      unitRef="usd">104340000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8144f7ab623b4afca039c1cbdf57e750_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfMy0xLTEtMS0yMDk3Nw_be9eb413-3dac-4e70-96c0-37bd05aed9a8"
      unitRef="usd">5736000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1c8d6050468f4d63a79e15bdcd8ec20b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfMy0zLTEtMS0yMDk3Nw_e6895ef0-0207-4b4c-97f5-bf165f3e88e4"
      unitRef="usd">5723000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5a8d28f658e64c9cb72dab709adfb297_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfNC0xLTEtMS0yMDk3Nw_4887811e-f0d0-4952-808a-56be7cea29b3"
      unitRef="usd">900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6ce87c71085b42e9b14d17fca3b617ca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfNC0zLTEtMS0yMDk3Nw_f43faff6-84a7-4c20-b3a9-3c27a0bd0d47"
      unitRef="usd">891000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i16934897395943d38eb471fd6a4ab451_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfNS0xLTEtMS0yMDk3Nw_e54bffb0-3026-4604-afb7-6db2afca403d"
      unitRef="usd">96000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0c5891e652c44560a9dfb628c66faca5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfNS0zLTEtMS0yMDk3Nw_99100dc4-b9ec-4b27-a3b9-f9caa9524100"
      unitRef="usd">85000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4980d8ad41eb414591647b2b42093a20_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfNi0xLTEtMS0yMDk3Nw_e6eec1f2-0cb5-4608-a073-83336b311c3d"
      unitRef="usd">5938000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i95c8dea3eb594cc3900cf46e3694ed5b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfNi0zLTEtMS0yMDk3Nw_eaf2b023-9e28-42ba-9859-4cde9dfa1aad"
      unitRef="usd">5530000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfNy0xLTEtMS0yMDk3Nw_4dfdebc6-f7ad-44a2-86dc-b114dd95cdb4"
      unitRef="usd">141603000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfNy0zLTEtMS0yMDk3Nw_3fd8fb25-75f0-48e3-91a5-6c8a6562e85a"
      unitRef="usd">116569000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfOC0xLTEtMS0yMDk3Nw_8e354b87-34d9-4751-8543-ed12c9655fb9"
      unitRef="usd">4676000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfOC0zLTEtMS0yMDk3Nw_6089690c-62cd-45ce-8354-218b1c5b9656"
      unitRef="usd">4214000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfOS0xLTEtMS0yMDk3Nw_bd016f2b-778f-45cf-8fc5-60581c7e3e33"
      unitRef="usd">136927000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOjhlYzE1YjdkNTM0ZTQ3MTFiMTViY2M1YmVjZjZkZTVkL3RhYmxlcmFuZ2U6OGVjMTViN2Q1MzRlNDcxMWIxNWJjYzViZWNmNmRlNWRfOS0zLTEtMS0yMDk3Nw_002cff31-d60b-45a6-83e4-e02b6790fe4a"
      unitRef="usd">112355000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RleHRyZWdpb246MDI3MzNhNDY0YTg4NDY0NWEwOGZkZGU3ZGNlMGE0MzdfMTU3_76d997ad-f549-49b6-b38e-1aa8c737424f"
      unitRef="usd">462000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RleHRyZWdpb246MDI3MzNhNDY0YTg4NDY0NWEwOGZkZGU3ZGNlMGE0MzdfMTk4_c7829ca9-ff2d-4b4f-bc7f-8ce25c75ac60"
      unitRef="usd">438000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RleHRyZWdpb246MDI3MzNhNDY0YTg4NDY0NWEwOGZkZGU3ZGNlMGE0MzdfMzgy_3030f2b7-ded3-4649-86ae-f3c601baf9ac">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued preclinical and clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued litigation settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <krys:AccruedPreclinicalAndClinicalExpenses
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfMi0xLTEtMS0yMDk3Nw_2f48f532-5aef-4e82-a849-01b312d923b8"
      unitRef="usd">2647000</krys:AccruedPreclinicalAndClinicalExpenses>
    <krys:AccruedPreclinicalAndClinicalExpenses
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfMi0zLTEtMS0yMDk3Nw_3102efc3-5c0b-4730-8d64-a0138d690fe4"
      unitRef="usd">1602000</krys:AccruedPreclinicalAndClinicalExpenses>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfMy0xLTEtMS0yMDk3Nw_b9a2d61d-b49a-44e1-86b4-04dd9e51063f"
      unitRef="usd">4168000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfMy0zLTEtMS0yMDk3Nw_baa3ccf8-b3e5-403a-a353-4c771c93ec0f"
      unitRef="usd">2011000</us-gaap:AccruedProfessionalFeesCurrent>
    <krys:AccruedPayrollAndBenefits
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfNC0xLTEtMS0yMDk3Nw_5ecf65a1-723e-44d3-9ad8-2129a355bf89"
      unitRef="usd">1560000</krys:AccruedPayrollAndBenefits>
    <krys:AccruedPayrollAndBenefits
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfNC0zLTEtMS0yMDk3Nw_2ed6d525-07df-4344-9385-3531f675ca63"
      unitRef="usd">2882000</krys:AccruedPayrollAndBenefits>
    <us-gaap:AccruedIncomeTaxes
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfNS0xLTEtMS0yMDk3Nw_f1261bea-6558-4da1-b0cd-f5a66dff356a"
      unitRef="usd">149000</us-gaap:AccruedIncomeTaxes>
    <us-gaap:AccruedIncomeTaxes
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfNS0zLTEtMS0yMDk3Nw_c1acc423-7f56-46d1-b279-1f50ecfe048a"
      unitRef="usd">83000</us-gaap:AccruedIncomeTaxes>
    <krys:AccruedConstructionInProgressCurrent
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfNi0xLTEtMS0yMDk3Nw_905b2e15-17b9-4732-a8d6-f93d48e7d6eb"
      unitRef="usd">17097000</krys:AccruedConstructionInProgressCurrent>
    <krys:AccruedConstructionInProgressCurrent
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfNi0zLTEtMS0yMDk3Nw_1f2f35cc-d36b-4a45-8654-0a82d57646df"
      unitRef="usd">9606000</krys:AccruedConstructionInProgressCurrent>
    <krys:AccruedFinancingFeesCurrent
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfNy0xLTEtMS0yMDk3Nw_296ce04d-aaed-4cd2-868f-054f852c419c"
      unitRef="usd">54000</krys:AccruedFinancingFeesCurrent>
    <krys:AccruedFinancingFeesCurrent
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfNy0zLTEtMS0yMDk3Nw_50b0c3a2-ccc4-40b1-8ccd-c17e6d1cb115"
      unitRef="usd">26000</krys:AccruedFinancingFeesCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfOC0xLTEtMS0yMzYzNg_55c0cc5a-0f4c-42ae-9b24-74e19c9d0464"
      unitRef="usd">25000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfOC0zLTEtMS0yNTczMA_a53a3dbd-59f8-4de5-a800-86f07fa45c6a"
      unitRef="usd">0</us-gaap:LitigationReserveCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfOC0xLTEtMS0yMDk3Nw_7a1ff240-980c-4bcb-b1c1-3dd0be2019bd"
      unitRef="usd">142000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfOC0zLTEtMS0yMDk3Nw_402e26fd-ddfe-43ac-9755-c6846b306292"
      unitRef="usd">87000</us-gaap:OtherLiabilitiesCurrent>
    <krys:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfOS0xLTEtMS0yMDk3Nw_9c26283b-7df1-462f-a2c1-b555137a7ce7"
      unitRef="usd">50817000</krys:AccruedExpensesAndOtherCurrentLiabilities>
    <krys:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180My9mcmFnOjAyNzMzYTQ2NGE4ODQ2NDVhMDhmZGRlN2RjZTBhNDM3L3RhYmxlOmExMmIyOWM3ZmEwOTRkN2FiYWZlNzA1MThhYjJiYTk3L3RhYmxlcmFuZ2U6YTEyYjI5YzdmYTA5NGQ3YWJhZmU3MDUxOGFiMmJhOTdfOS0zLTEtMS0yMDk3Nw_33ff902d-6654-4635-bbcc-2f17576f56cf"
      unitRef="usd">16297000</krys:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTE3NjY_71b565c5-bd54-4348-810e-0963a18dde43">Commitments and Contingencies&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Contracts and Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 26, 2016, the Company signed an operating lease for laboratory and office space that commenced in June 2016 and expired on October 31, 2017 (the &#x201c;2016 Lease&#x201d;). The 2016 Lease has been amended several times to increase the area leased, which currently consists of approximately 47,000 square feet and includes the commercial scale cGMP-compliant manufacturing facility, ANCORIS.  As a result of the lease amendments, the lease expiration date was extended to October 31, 2031. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 26, 2019, we entered into a lease agreement for our second commercial gene therapy facility ("ASTRA") in the Pittsburgh, Pennsylvania area ("ASTRA lease") with Northfield I, LLC (the "Landlord", "Northfield", or "Lessor") with &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;an initial lease term that expired on October 31, 2035.  The ASTRA lease contained an option ("Purchase Option") to purchase the building, related improvements and take corresponding assignment of the Landlord's rights under its existing Ground Lease (the "Ground Lease"). A cash contribution in the amount of $2.4&#160;million was paid to escrow on January 21, 2020. The contribution was intended to reduce the amount of the building construction costs and had the effect of reducing the base rental rate of the lease and as such, was recorded as prepaid rent in the consolidated balance sheet at the time of payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 5, 2020, the Company was provided with notice that the initial delivery conditions of the building had been met, including completion of the building shell, interior slab, and exterior doors, and on October 15, 2020, the Company gave the Landlord notice of its intent to purchase ASTRA for approximately $9.4&#160;million, subject to the parties entering into a commercially reasonable purchase and sale agreement. As a result of the Company's ability to exercise its option to purchase ASTRA, the Company obtained control over the construction in progress of ASTRA as of October 5, 2020.  The Company recorded a $10.0&#160;million CIP asset and a corresponding build to suit lease liability related to the costs incurred by the Landlord, offset by the previous cash contribution of $2.4&#160;million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 29, 2021, the Company entered into a Purchase and Sale Agreement ("PSA") for ASTRA with Northfield related to the purchase option exercised by the Company on October 15, 2020, for a purchase price of $9.4&#160;million. The Company held approximately $1.5&#160;million on deposit with Northfield under the existing lease agreement and applied this deposit as a credit against the purchase price at closing. On February 1, 2021, Northfield delivered the space as substantially complete and made the space available for access by the Company, thus triggering lease commencement.  As a result, the Company concluded that this transaction did not qualify for sale-leaseback accounting because it did not meet the definition of a sale.  As control did not transfer to the Lessor at lease commencement, the transaction continued to be accounted for as construction in progress and a financing obligation. On March 5, 2021, the purchase closed and the Company determined that reclassification of the construction in progress to buildings and leasehold improvements was not appropriate as the interior of the building was not yet ready for its intended use. The building continues to be held under construction in progress as of March&#160;31, 2022. The interior of the building is currently under construction and is expected to be completed and validated in 2022.  From construction completion to the closing of the purchase, the Company recognized interest expense to accrete the financial obligation to a balance that equaled the cash consideration that was paid upon the close of purchase. For more information about the expected construction costs associated with ASTRA, see "ASTRA Contractual Obligations" below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the transaction, the Company also became the accounting owner of the Ground Lease, due to obtaining control over ASTRA, and recorded the applicable operating right-of-use asset and corresponding lease liability as of October 5, 2020. When the PSA was finalized, the Company took assignment of the Lessor's Ground Lease, in accordance with the Purchase Option, of which lease payments are based on annual payments of $82&#160;thousand, and are subject to a cumulative 10% escalation clause every 5 years through 2071. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 15, 2021, the Company entered into a 3 year lease agreement for our Boston, Massachusetts office (the "Boston Lease") location that commenced in January 2022 and expires in January 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, future minimum commitments under the Company&#x2019;s operating leases were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future minimum operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental condensed consolidated balance sheet information related to leases is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-indent:29.25pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term, in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;text-indent:29.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded operating lease costs of $409 thousand and $218 thousand for the three months ended March&#160;31, 2022 and 2021, respectively, and variable lease costs of $49 thousand and $37 thousand for the three months ended March&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Agreements with Contract Manufacturing Organizations and Contract Research Organizations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various agreements in the normal course of business with Contract Research Organizations ("CROs"), Contract Manufacturing Organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. The agreements with CMOs relate to the manufacturing of sterile gel that is mixed with in-house produced vectors as part of the final drug product applied in certain of our clinical trials. These agreements may also include research and development activities, storage, packaging, labeling, and/or testing of our preclinical and clinical-stage products. The Company is obligated to make milestone payments under certain of these agreements. The estimated remaining commitment as of March&#160;31, 2022 under these agreements is approximately $3.1 million. The Company may also be responsible for the payment of a monthly service fee for project management services for the duration of any agreements. The Company has incurred expenses under these agreements of $1.8 million for each of the three months ended March&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commercial Preparedness Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has contracted with various third parties to facilitate, coordinate and perform agreed upon commercial preparedness and market research activities relating to our lead product candidate. These contracts typically call for the payment of fees for services upon the achievement of certain milestones. The estimated remaining commitment as of March&#160;31, 2022 is $4.3 million. The Company has incurred expenses under these activities of $3.1 million and $1.3 million for the three months ended March&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASTRA Contractual Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has contracted with various third parties to construct our second cGMP facility, ASTRA. Additionally, we have entered into various non-cancellable purchase agreements for long-lead materials to help avoid potential schedule disruptions or material shortages. These contracts typically call for the payment of fees for services or materials upon the achievement of certain milestones. The estimated remaining commitment as of March&#160;31, 2022 is $20.2 million. The Company has included costs incurred to-date associated with ASTRA within construction in progress as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On June 30, 2021, the Company entered into a Standard Form of Contract for Construction and the corresponding General Conditions of the Contract for Construction (collectively, the &#x201c;Agreement&#x201d;) with The Whiting-Turner Contracting Company (&#x201c;Whiting-Turner&#x201d;), pursuant to which Whiting-Turner is constructing and managing the construction of ASTRA. Subject to certain conditions in the Agreement, the Company will pay Whiting-Turner a contract price consisting of the cost of work plus a fee equal to 1.75% of the cost of work. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective September 13, 2021, the Company entered into a guaranteed maximum price amendment (the "Amendment") to the Agreement to set forth the guaranteed maximum price, as well as the date by which Whiting-Turner is to achieve Substantial Completion (as defined in the Agreement). Under the Amendment, the guaranteed maximum price to be paid by the Company is $82.3&#160;million, subject to certain additions and deductions by change orders as provided by the Agreement. Whiting-Turner&#x2019;s work under the Agreement represents a portion of the work necessary to complete construction &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the ASTRA facility and, therefore the date of Substantial Completion of Whiting-Turner&#x2019;s work under the Agreement does not equate to the date of completion of ASTRA. The guaranteed maximum price under the Agreement constitutes only a portion of the total estimated cost of building and equipping ASTRA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 1, 2020, a complaint was filed against us in the United States District Court for the Western District of Pennsylvania by PeriphaGen, Inc. ("PeriphaGen"), which also named our Chief Executive Officer and President, R&amp;amp;D, Krish Krishnan and Suma Krishnan, respectively. The complaint alleged breach of contract and misappropriation of trade secrets, which secrets the plaintiff asserted were used to develop our product candidates, including the vector backbones, and our STAR-D platform. We answered the complaint on June 26, 2020 by denying the allegations and brought a counterclaim asking the court to declare that we did not misappropriate PeriphaGen&#x2019;s trade secrets or confidential information, and to further declare that we are the rightful and sole owner of our product candidates and STAR-D platform. In addition, we filed a third-party complaint against two principals of PeriphaGen, James Wechuck and David Krisky, alleging breach of contract and seeking contribution and indemnification from them in the event PeriphaGen is awarded damages. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 9, 2022, the court officially ordered the parties to attend mediation on March 11, 2022.  During the course of the mediation process, the parties were able to exchange information, allowing the parties to value their positions.  On March 12, 2022, we entered into a binding term sheet.  In consideration of settling the dispute, the acquisition of certain PeriphaGen assets, and the grant of a license by PeriphaGen for dermatological applications, Krystal made a payment of $25.0&#160;million on April 28, 2022.  Upon approval of Krystal&#x2019;s first product by the U.S. Food and Drug Administration ("FDA"), Krystal will pay an additional $12.5&#160;million, followed by three additional $12.5&#160;million contingent milestone payments upon reaching $100.0&#160;million in total cumulative sales, $200.0&#160;million in total cumulative sales and $300.0&#160;million in total cumulative sales. As defined in the settlement agreement, cumulative sales shall include all revenue from sales of Krystal products by Krystal and its affiliates and licensees, as reported by Krystal in its annual Form 10-K filings. If all milestones are achieved, the total consideration for settling the dispute, acquiring certain assets, and granting of a license from PeriphaGen will be $75.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final settlement agreement was signed on April 28, 2022, and, because we deemed settlement to be probable as of the balance sheet date, we have recorded an accrued liability equal to the settlement of $25.0&#160;million under accrued expenses and other current liabilities on the condensed consolidated balance sheet and under litigation settlement expense on the condensed consolidated statements of operations.  The additional contingent milestone payments were not deemed probable due to uncertainty in the achievement of these milestones as of March 31, 2022, and therefore no additional accrual has been recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has received $768&#160;thousand of insurance proceeds during the three months ended March&#160;31, 2022  and we have recorded an additional $301&#160;thousand as a receivable within prepaid expenses and other current assets on the condensed consolidated balance sheet as management determined that the amount was probable of collection relating to legal defense costs and expenses associated with the PeriphaGen litigation. The reimbursements have been recorded as an offset to our legal fees included in general and administrative expenses on the condensed consolidated statements of operations and within operating activities on the condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <krys:AdditionalAreaOfRealEstatePropertyLeased
      contextRef="idbf36e2c49fc42d9a41ee8670488e982_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMzYy_c1889a3a-8d4e-4474-8ddd-7ed4fdb0d591"
      unitRef="sqft">47000</krys:AdditionalAreaOfRealEstatePropertyLeased>
    <krys:PaymentToEscrowForReducingLeaseRentals
      contextRef="i259ce76551454123911c8f7e6cf9cd6d_I20200121"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTAxNg_a9741fba-c839-4eb4-9974-696ba4e3d644"
      unitRef="usd">2400000</krys:PaymentToEscrowForReducingLeaseRentals>
    <krys:PurchasePriceOfPotentialBuildingPurchase
      contextRef="ia5b58230696440249bca1a1906cb63f3_D20201015-20201015"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTYyNQ_d206f724-22b4-4d27-a0f6-5667ca2ea6f7"
      unitRef="usd">9400000</krys:PurchasePriceOfPotentialBuildingPurchase>
    <us-gaap:FinanceLeaseLiability
      contextRef="i2384fef03d174e7293ac35a6c188c7cf_I20201005"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTkxOQ_8bd612a7-1897-4ac4-8797-b42a12e6dcf0"
      unitRef="usd">10000000</us-gaap:FinanceLeaseLiability>
    <us-gaap:ConstructionInProgressGross
      contextRef="i2384fef03d174e7293ac35a6c188c7cf_I20201005"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTkxOQ_af480ce4-72ea-4e08-906c-3288842b654d"
      unitRef="usd">10000000</us-gaap:ConstructionInProgressGross>
    <krys:PaymentToEscrowForReducingLeaseRentals
      contextRef="i2384fef03d174e7293ac35a6c188c7cf_I20201005"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjA3Mw_43b4ce40-e129-4965-9b20-b65157a34983"
      unitRef="usd">2400000</krys:PaymentToEscrowForReducingLeaseRentals>
    <krys:PurchasePriceOfPotentialBuildingPurchase
      contextRef="ia5b58230696440249bca1a1906cb63f3_D20201015-20201015"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjI5MA_8f85497f-cd31-4976-aa5c-b436abf38c7a"
      unitRef="usd">9400000</krys:PurchasePriceOfPotentialBuildingPurchase>
    <us-gaap:EscrowDeposit
      contextRef="ib1f1bacd274b4e44b1a1f8151a2b5097_I20201015"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjMyNQ_1f7b7d74-4012-4b51-9901-e70622dc89b0"
      unitRef="usd">1500000</us-gaap:EscrowDeposit>
    <krys:LessorOperatingLeaseLiabilityAnnualLeasePayments
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNDE4MQ_223ef89f-0090-4301-9897-4c5e05c3f05d"
      unitRef="usd">82000</krys:LessorOperatingLeaseLiabilityAnnualLeasePayments>
    <krys:CumulativeEscalationClausePercent
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNDIxNw_5bd5871a-2580-4fbe-b3bd-2dbb89e42d87"
      unitRef="number">0.10</krys:CumulativeEscalationClausePercent>
    <krys:CumulativeEscalationClauseTerm
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNDI0NA_638a1abf-6083-4c34-88c3-176e1b8d8a9b">P5Y</krys:CumulativeEscalationClauseTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i6642a4976dcc4bbb8b89924a05835ed9_I20211215"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTA5OTUxMTY0OTUzNw_843bba20-5221-4230-af7e-6bb5003863d8">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTE3Njc_7640c77c-32e7-4a1e-b313-5a1f3daa6468">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, future minimum commitments under the Company&#x2019;s operating leases were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.756%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (remaining nine months)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future minimum operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOjc5ZTE3YWUxY2VlZDRjNzdiNDc4ZGZjNjA2ZTgwMWNjL3RhYmxlcmFuZ2U6NzllMTdhZTFjZWVkNGM3N2I0NzhkZmM2MDZlODAxY2NfMS0xLTEtMS0yMDk3Nw_52956351-2638-46b2-be20-cba1a681b26a"
      unitRef="usd">1115000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOjc5ZTE3YWUxY2VlZDRjNzdiNDc4ZGZjNjA2ZTgwMWNjL3RhYmxlcmFuZ2U6NzllMTdhZTFjZWVkNGM3N2I0NzhkZmM2MDZlODAxY2NfMi0xLTEtMS0yMDk3Nw_4536fb58-7075-4951-995e-a5905cc61c77"
      unitRef="usd">1510000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOjc5ZTE3YWUxY2VlZDRjNzdiNDc4ZGZjNjA2ZTgwMWNjL3RhYmxlcmFuZ2U6NzllMTdhZTFjZWVkNGM3N2I0NzhkZmM2MDZlODAxY2NfMy0xLTEtMS0yMDk3Nw_2df4682c-25d1-4ff1-bf0f-d2b63c2b785a"
      unitRef="usd">1539000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOjc5ZTE3YWUxY2VlZDRjNzdiNDc4ZGZjNjA2ZTgwMWNjL3RhYmxlcmFuZ2U6NzllMTdhZTFjZWVkNGM3N2I0NzhkZmM2MDZlODAxY2NfNC0xLTEtMS0yMDk3Nw_00de5a91-e11a-4422-b6ad-194d7271d379"
      unitRef="usd">1277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOjc5ZTE3YWUxY2VlZDRjNzdiNDc4ZGZjNjA2ZTgwMWNjL3RhYmxlcmFuZ2U6NzllMTdhZTFjZWVkNGM3N2I0NzhkZmM2MDZlODAxY2NfNS0xLTEtMS0yMDk3Nw_5dea588d-9078-457a-84b4-250c0bdca8d6"
      unitRef="usd">1277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <krys:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOjc5ZTE3YWUxY2VlZDRjNzdiNDc4ZGZjNjA2ZTgwMWNjL3RhYmxlcmFuZ2U6NzllMTdhZTFjZWVkNGM3N2I0NzhkZmM2MDZlODAxY2NfNi0xLTEtMS0yMDk3Nw_6ab8b030-c8dd-43a7-8822-4dde3c8a2347"
      unitRef="usd">12063000</krys:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOjc5ZTE3YWUxY2VlZDRjNzdiNDc4ZGZjNjA2ZTgwMWNjL3RhYmxlcmFuZ2U6NzllMTdhZTFjZWVkNGM3N2I0NzhkZmM2MDZlODAxY2NfNy0xLTEtMS0yMDk3Nw_61df90aa-1b96-4c9f-ac59-0e1daeae7c8f"
      unitRef="usd">18781000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOjc5ZTE3YWUxY2VlZDRjNzdiNDc4ZGZjNjA2ZTgwMWNjL3RhYmxlcmFuZ2U6NzllMTdhZTFjZWVkNGM3N2I0NzhkZmM2MDZlODAxY2NfOC0xLTEtMS0yMDk3Nw_e6b308cf-d1b7-4431-b589-3a88342da506"
      unitRef="usd">9487000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOjc5ZTE3YWUxY2VlZDRjNzdiNDc4ZGZjNjA2ZTgwMWNjL3RhYmxlcmFuZ2U6NzllMTdhZTFjZWVkNGM3N2I0NzhkZmM2MDZlODAxY2NfOS0xLTEtMS0yMDk3Nw_d7731bb5-d893-46ff-bd86-3a67a904bb5b"
      unitRef="usd">9294000</us-gaap:OperatingLeaseLiability>
    <krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTE3Njg_94aa7965-c00f-4fdb-adca-b44230c41afa">Supplemental condensed consolidated balance sheet information related to leases is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term, in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</krys:ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfMy0xLTEtMS0yMDk3Nw_57300471-89d3-4aaa-a1e8-968e1e81f482"
      unitRef="usd">8453000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfMy0zLTEtMS0yMDk3Nw_aff7ef56-fc73-4eba-82e8-7d690287fcf4"
      unitRef="usd">7228000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfNC0xLTEtMS0yMDk3Nw_6dbbab2b-7472-446b-9b80-f83e50278e8f"
      unitRef="usd">1411000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfNC0zLTEtMS0yMDk3Nw_83fe68cc-4052-4bd6-8642-4445ae237447"
      unitRef="usd">1041000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfNS0xLTEtMS0yMDk3Nw_5277a61a-aa82-4814-bd97-d1de30750f50"
      unitRef="usd">7883000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfNS0zLTEtMS0yMDk3Nw_e0e165aa-2d33-4949-b732-57c38a7ebcbb"
      unitRef="usd">6983000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfNi0xLTEtMS0yMDk3Nw_cf1b10d1-1b9e-4763-b060-4c0decd6f929"
      unitRef="usd">9294000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfNi0zLTEtMS0yMDk3Nw_5612bf92-ed97-4a8c-bd8c-634d19b53a2a"
      unitRef="usd">8024000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfNy0xLTEtMS0yMDk3Nw_9a070c8d-b44a-409e-a775-e7938b3e409f">P13Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfNy0zLTEtMS0yMDk3Nw_ffe10a50-2b8c-4624-a7fd-18e43f3fc803">P14Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfOC0xLTEtMS0yMDk3Nw_45b599ad-1e57-4dc2-8f75-9a7d60ff86e3"
      unitRef="number">0.093</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RhYmxlOmU5ZjU4MjgxNmUyNzRmMTliNThhODU2MDcxMTYwMDFlL3RhYmxlcmFuZ2U6ZTlmNTgyODE2ZTI3NGYxOWI1OGE4NTYwNzExNjAwMWVfOC0zLTEtMS0yMDk3Nw_c9f89a16-3b9a-4869-b626-c97f26fa8e52"
      unitRef="number">0.095</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNDUxNQ_d71b1a86-32c8-44ec-9a80-a59ae169f207"
      unitRef="usd">409000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTA5OTUxMTY0ODI3NQ_6d7f2885-e929-490b-a8c2-af64d9d78798"
      unitRef="usd">218000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNDYzNg_083cdb59-ad82-4b93-9d45-eb17cee56e57"
      unitRef="usd">49000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTA5OTUxMTY0ODMxNg_91d8e9c6-d3a5-4e14-8bfd-a0034a3b6832"
      unitRef="usd">37000</us-gaap:VariableLeaseCost>
    <krys:RemainingCommitmentAmount
      contextRef="ib888a32279a646d6bc98bb4650978ad1_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNTczMQ_90ee0831-82d6-452b-81a0-70fca86fa8d1"
      unitRef="usd">3100000</krys:RemainingCommitmentAmount>
    <us-gaap:ProfessionalFees
      contextRef="ic9ac354f7bd046949c8c5c9a884f44b6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNTk0MA_ad645641-1b52-4b91-8070-afa2368a1046"
      unitRef="usd">1800000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="iab4cf6bacbe94549a3840f7cc0180c4d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNTk0MA_bb1bd259-496d-4a90-8a19-aece20501e97"
      unitRef="usd">1800000</us-gaap:ProfessionalFees>
    <krys:RemainingCommitmentAmount
      contextRef="iea664a78d9854e7982861ce146a3ba39_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNjQzNA_94839dc4-26b9-49ca-886d-63991dc50a2a"
      unitRef="usd">4300000</krys:RemainingCommitmentAmount>
    <us-gaap:ProfessionalFees
      contextRef="ib712ea82a3604445a0cc14028e0d6896_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNjQ5OA_a9d727c4-cdb0-433c-bb9e-b07527a27208"
      unitRef="usd">3100000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i3b26ab4e640a459f8745fdfc687a4c41_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTA5OTUxMTY0ODc0OA_510c0dd1-64e6-4bda-a472-7042aa2386bf"
      unitRef="usd">1300000</us-gaap:ProfessionalFees>
    <us-gaap:ContractualObligation
      contextRef="if89acc13e6c64c308c9dfc70390e2d45_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMTA5OTUxMTY0OTQxMQ_8f0e2369-83f0-466e-acd4-ea8db6b36fa3"
      unitRef="usd">20200000</us-gaap:ContractualObligation>
    <krys:CostOfWorkPercentage
      contextRef="if89acc13e6c64c308c9dfc70390e2d45_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNzY4MA_1810d878-d050-48ec-948d-66a3a16b8d22"
      unitRef="number">0.0175</krys:CostOfWorkPercentage>
    <krys:LossContingencyGuaranteedMaximumPriceToBePaid
      contextRef="ia7f4b2c43112444b9e122e360545adab_I20210913"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI3NzIyOA_d3d731f7-682b-45a5-8133-dc39b94051c8"
      unitRef="usd">82300000</krys:LossContingencyGuaranteedMaximumPriceToBePaid>
    <us-gaap:LitigationSettlementExpense
      contextRef="ic40bbdf109724a63a017b7987802289f_D20220312-20220312"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDI4Nw_e7a10e19-93a3-4148-97eb-ae7da7163459"
      unitRef="usd">25000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i2e9524e5aa5c470a884b1e3b3fd4d2fc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDMxNQ_23a4fd1d-04b1-4ddb-99f9-0ac7a86a83db"
      unitRef="usd">12500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <krys:NumberOfMilestones
      contextRef="i2e9524e5aa5c470a884b1e3b3fd4d2fc_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDQyMQ_150964fa-79f3-472e-9bc6-b17f94790984"
      unitRef="milestone">3</krys:NumberOfMilestones>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="ic24584a607d040f58ee27bb2c65542e0_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDMwMA_3247e999-f09f-4f50-bf18-cfc0d5e0f124"
      unitRef="usd">12500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="ifbc91ac07e524baca470f06f672c1d2c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDMwMA_cca55d7d-9c1e-45a6-bbaf-277f5c0775c3"
      unitRef="usd">12500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i36d06bb51d1041f08406992557a842ec_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDMwMA_f8d30c29-055e-45f2-a875-2f1ac6ef11d0"
      unitRef="usd">12500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <krys:LitigationSettlementMilestonePaymentsSalesThreshold
      contextRef="ic65f36fa2aab4beabcc772980cf0f956_D20220312-20220312"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDQwMQ_0f6a3b45-ffb4-4985-bd87-b63768b44114"
      unitRef="usd">100000000</krys:LitigationSettlementMilestonePaymentsSalesThreshold>
    <krys:LitigationSettlementMilestonePaymentsSalesThreshold
      contextRef="i5edf1309bf4c4394b9c48237c6eb3b9e_D20220312-20220312"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDMzMA_9a1a29a2-2868-403e-b6e0-f017b0b4436f"
      unitRef="usd">200000000</krys:LitigationSettlementMilestonePaymentsSalesThreshold>
    <krys:LitigationSettlementMilestonePaymentsSalesThreshold
      contextRef="i4203d07f57134f55a0643e1e7a9ea003_D20220312-20220312"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDM0NA_3ae2a2d6-fcb0-4adf-a83e-fb64588700b4"
      unitRef="usd">300000000</krys:LitigationSettlementMilestonePaymentsSalesThreshold>
    <krys:LitigationSettlementTotalConsideration
      contextRef="ic40bbdf109724a63a017b7987802289f_D20220312-20220312"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDM1OA_4ad88b2c-4c1a-4035-89eb-efe5d080db05"
      unitRef="usd">75000000</krys:LitigationSettlementTotalConsideration>
    <us-gaap:LitigationReserveCurrent
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfNDk0NzgwMjM2NjE4Ng_19b8c763-6cb7-4a24-b74d-e9518dd25eb1"
      unitRef="usd">25000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDM3MQ_a58a8045-a321-48cd-8df7-f87a1ee07e1b"
      unitRef="usd">768000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180Ni9mcmFnOmI3ODk1Yzk2MTM3NTQyZmU5NzFlNzMyYjZmZjQ0MTY3L3RleHRyZWdpb246Yjc4OTVjOTYxMzc1NDJmZTk3MWU3MzJiNmZmNDQxNjdfMjE5OTAyMzI5MDM4Ng_640772bc-0303-4c27-b7ff-56216c3f4aff"
      unitRef="usd">301000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTc0Mg_d67b1f71-2a9d-43f8-853c-aab9818a411f">Capitalization&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sale of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 3, 2021, the Company completed a public offering of 2,866,667 shares of its common stock, including 200,000 shares purchased by the underwriters, at $75.00 per share.  Net proceeds to the Company from the offering were $201.9&#160;million after deducting underwriting discounts and commissions of approximately $12.9&#160;million, and other offering expenses payable by the Company of $227&#160;thousand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 1, 2021, the Company completed a public offering of 2,211,538 shares of its common stock, including 288,461 shares purchased by the underwriters, at $65.00 per share.  Net proceeds to the Company from the offering were $134.9&#160;million after deducting underwriting discounts and commissions of approximately $8.6&#160;million, and other offering expenses payable by the Company of $198&#160;thousand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2020, the Company entered into a sales agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen") with respect to an at-the-market equity offering program ("ATM Program"), under which Cowen will act as the Company's agent and/or principal and may issue and sell from time to time, during the term of the Sales Agreement, shares of our common stock, having an aggregate offering price up to $150.0&#160;million ("Placement Shares").  Related offering expenses payable by the Company were $172 thousand.  The issuance and sale of the Placement Shares by the Company under the Sales Agreement will be made pursuant to the Company's effective "shelf" registration statement on Form &lt;/span&gt;&lt;/div&gt;S-3. During the three months ended March&#160;31, 2021, 262,500 shares of common stock were issued pursuant to the ATM Program at a weighted average price of $66.50 per share for net proceeds of $16.9&#160;million after deducting underwriting discounts and commissions of approximately $524&#160;thousand, resulting in a remaining $132.5&#160;million available for issuance under the ATM Program.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i5afc353e283647ec9083f64e9ed8c939_D20211203-20211203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTY0OTI2NzQ0MzQ3NQ_40cb4ba3-825f-45bc-94f6-b93e070b6ac8"
      unitRef="shares">2866667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i60ec291ee12943d1a98627ef006017cc_D20211203-20211203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTY0OTI2NzQ0MzUxNw_8affafee-cb06-4f6a-9f68-d4dbb767ba6e"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i08fed205929d4c55ae8e914a0a90a14b_I20211203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTY0OTI2NzQ0MzU2Mg_4b522fad-c3ce-4dd9-a7db-f71d690e82a6"
      unitRef="usdPerShare">75.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i5afc353e283647ec9083f64e9ed8c939_D20211203-20211203"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTY0OTI2NzQ0MzYyOQ_8b56af83-71f0-496b-9557-76c8943cfe70"
      unitRef="usd">201900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="i5afc353e283647ec9083f64e9ed8c939_D20211203-20211203"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTY0OTI2NzQ0MzcwNQ_e4205800-850c-4a5b-8986-ec0a56fac9a0"
      unitRef="usd">12900000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i0c1f8e7fe2fa45fd8b4dff23e6288333_D20211203-20211203"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTY0OTI2NzQ0Mzc2NA_4a13d079-833c-4e1b-a6f2-66395042769b"
      unitRef="usd">227000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if01cbed47b8d4cc3bfbc1d974a9fed3d_D20210201-20210201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTA4_dfb3bd23-39bc-42de-aa40-3c5b75ca8c83"
      unitRef="shares">2211538</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8ff87f18f6694c9ea3a6fef4996ab07c_D20210201-20210201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTQ5_0a62d70b-5d0f-4b41-a695-e4d58b06cfbb"
      unitRef="shares">288461</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="ica2c921cbe27424bb2a3e6cab5b07128_I20210201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTkz_f677ef14-86cd-4bae-a33a-72be231bbc75"
      unitRef="usdPerShare">65.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="if01cbed47b8d4cc3bfbc1d974a9fed3d_D20210201-20210201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMjU5_9e665bb0-513b-4781-9a0f-18edac6adb82"
      unitRef="usd">134900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="if01cbed47b8d4cc3bfbc1d974a9fed3d_D20210201-20210201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMzM0_62def278-f226-4fce-a095-6e5a5b294f45"
      unitRef="usd">8600000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i289cb50e19984c88a48c5a07e1b8a29a_D20210201-20210201"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMzky_f3290a41-2268-483a-ab85-356601994978"
      unitRef="usd">198000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <krys:SaleOfStockAggregateOfferingPrice
      contextRef="ida8733e7f8b54da6ada1a0ab22fe829f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfODM5_7f264825-d281-4ea6-8a1d-334a80ba0428"
      unitRef="usd">150000000</krys:SaleOfStockAggregateOfferingPrice>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i9fbd96b4612a4a66b26fde342c7e05ba_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfOTE5_d1570228-2a35-4fc0-91af-da605ff9561b"
      unitRef="usd">172000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i5c9fb5f61e014e0d8958ffdb2f7baa47_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTEzNw_dcf91001-098f-4e60-9147-f575bb4606de"
      unitRef="shares">262500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ia295d7f2365647ae8d0fe3f1f16d1308_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTIzNA_4ce9dcec-ade0-41cc-a398-57fac7d107e5"
      unitRef="usdPerShare">66.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i286d68b1d6d2436481fb4a0d8428bca6_D20210201-20210201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTI2Nw_8c2e12f6-b766-44fd-a54d-d4ac510f72e9"
      unitRef="usd">16900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="i286d68b1d6d2436481fb4a0d8428bca6_D20210201-20210201"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTM0Mg_1fab4118-b1b9-423a-99c7-3fbe8a8c6c59"
      unitRef="usd">524000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <krys:SaleOfStockRemainingAvailableIssuanceAmount
      contextRef="i5c9fb5f61e014e0d8958ffdb2f7baa47_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y180OS9mcmFnOjAxYjY4MjliMDU5MTRkODhhZjJiNTBhYTJhODI0ZDFkL3RleHRyZWdpb246MDFiNjgyOWIwNTkxNGQ4OGFmMmI1MGFhMmE4MjRkMWRfMTM3MQ_6b6313e9-b245-430f-8851-b9e2076eb4f8"
      unitRef="usd">132500000</krys:SaleOfStockRemainingAvailableIssuanceAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMzc3NA_3f4e7267-0d1d-48df-81a9-b50252f2830b">Stock-Based Compensation&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted to employees vest ratably over four-year periods and stock options granted to directors of the company vest ratably over one year to four-year periods. Stock options have a life of ten years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted 1,179,500 and 502,450 stock options to employees and directors of the Company during the three months ended March&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.460%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In&#160;thousands)&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,043,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,179,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68,342)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,152,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Aggregate intrinsic value represents the difference between the closing stock price of our common stock on March&#160;31, 2022 and the exercise price of outstanding in-the-money options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value (the amount by which the fair market value exceeds the exercise price) of stock options exercised during the three months ended March&#160;31, 2022 and 2021 was $36&#160;thousand and $808&#160;thousand, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value per share of options granted to employees and directors during the three months ended March&#160;31, 2022 and 2021 was $43.09 and $50.04, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was $101.1 million of unrecognized stock-based compensation expense related to employees' and directors&#x2019; option awards that is expected to be recognized over a weighted-average period of 3.4 years as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three months ended March&#160;31, 2022 and 2021 as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.842%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.746%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.982%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize the portion of stock-based compensation that relates to work performed on the construction of new buildings. There was $141&#160;thousand and $37&#160;thousand of stock-based compensation that was capitalized in the three months ended March&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense of $6.0 million and $2.1 million for the three months ended March&#160;31, 2022 and 2021, respectively. The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three months ended March&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:29.25pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.672%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.348%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of the award (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards ("RSAs") granted to employees vest ratably over a four-year period. The Company granted zero and 98,800 RSAs to employees of the Company during the three months ended March&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,379)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was $5.7 million of unrecognized stock-based compensation expense related to employees&#x2019;&#160;awards that is expected to be recognized over a weighted-average period of&#160;2.9 years as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense related to RSAs of $480 thousand and $182 thousand for the three months ended March&#160;31, 2022 and 2021, respectively, within general and administrative expenses in the accompanying condensed consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.134%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares remaining available for grant under the Company&#x2019;s stock incentive plan were 1,028,815, with a sublimit for incentive stock options of 26,546, at March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i80af56866df1412e92048fc6c85f5bc4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMzc3NQ_3f54c038-ad5a-486a-989e-47bf2a6e9798">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic542a3c28cfa40a79269e8998b92ebd4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMjA2_851ad44d-9eb7-4797-9a57-3511f6965179">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iecc1050fb75f4c92929ea53bb5db6e2e_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMzc2OQ_f20b6002-973d-4ac2-bb6d-ef27c4dc36b5">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMjU4_f4721150-b95f-4748-a16a-040ed85d0887">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iea276893239144509596b8ab8da16fc9_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMjgz_c23bbd6c-41a6-4aab-99f1-26e2bb7cf2ec"
      unitRef="shares">1179500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i7bd1d3ebc2374d15b477f6f17769c8b5_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjA2OA_06427162-4705-43c5-a8a0-fbfb57373829"
      unitRef="shares">502450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMzc3MA_04b1319c-1230-443b-950a-0865a89145be">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.374%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.460%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In&#160;thousands)&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,043,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,179,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68,342)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,152,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:29.25pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Aggregate intrinsic value represents the difference between the closing stock price of our common stock on March&#160;31, 2022 and the exercise price of outstanding in-the-money options.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfMS0xLTEtMS0yMDk3Nw_0015d5ec-bfd0-404b-80ca-0f3bcfc16b9d"
      unitRef="shares">2043179</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfMS0zLTEtMS0yMDk3Nw_6d668754-44bc-4274-aa3e-a62e75085d59"
      unitRef="usdPerShare">57.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="id1df3a737f254e1890366151309871c2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfMS01LTEtMS0yMDk3Nw_047234d3-d441-44af-b953-33048e7ecb78">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i99c92e6ca8634fd79257a600a35f3f21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfMS03LTEtMS0yMDk3Nw_a31508b9-b6b9-4e10-9c12-3cc55fd9b046"
      unitRef="usd">31331000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfMi0xLTEtMS0yMDk3Nw_a50aa2a7-55db-4a6b-8d7e-8dab19cf5c46"
      unitRef="shares">1179500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfMi0zLTEtMS0yMDk3Nw_b0657829-412c-4557-8447-6668a71e00a1"
      unitRef="usdPerShare">62.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfMy0xLTEtMS0yMDk3Nw_93f66360-9f40-47fa-bbc1-ab2781d53760"
      unitRef="shares">1475</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfMy0zLTEtMS0yMDk3Nw_0be3ae40-2c88-485b-9bae-b9d77911b4fe"
      unitRef="usdPerShare">37.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNC0xLTEtMS0yMDk3Nw_448a03bf-3ae1-4a64-83be-2f95250d1f0d"
      unitRef="shares">68342</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNC0zLTEtMS0yMDk3Nw_8e9b2ad7-7450-409b-b75a-0eef63332cb3"
      unitRef="usdPerShare">61.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNS0xLTEtMS0yMDk3Nw_13c083d6-999f-4cbe-9980-1b56caa465bf"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNS0zLTEtMS0yMDk3Nw_7bc91e54-f08d-4969-8aec-04aad2be3c2e"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNi0xLTEtMS0yMDk3Nw_203b3209-717f-4dca-909f-8d255ae1649c"
      unitRef="shares">3152862</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNi0zLTEtMS0yMDk3Nw_aee5c889-0828-4394-8bc3-98af7dff81f7"
      unitRef="usdPerShare">58.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNi01LTEtMS0yMDk3Nw_136e558b-788b-4e3a-af5d-593d5f6dc322">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNi03LTEtMS0yMDk3Nw_d0524399-d747-49a3-a983-f0a724164a18"
      unitRef="usd">30364000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNy0xLTEtMS0yMDk3Nw_0bbcb1ad-8592-46de-b836-082416db6d06"
      unitRef="shares">439954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNy0zLTEtMS0yMDk3Nw_98cae8cf-b15f-4fcd-8bf6-11489a6064b6"
      unitRef="usdPerShare">44.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNy01LTEtMS0yMDk3Nw_ac993130-8005-4a12-aebf-52204320d2d8">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i905c5a481a8b4f42a9009703d3ecf075_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjIxZTcwNDBlMmQ0ZTQ1MzNhYTI3ODc1ZGRiNmVlNjFhL3RhYmxlcmFuZ2U6MjFlNzA0MGUyZDRlNDUzM2FhMjc4NzVkZGI2ZWU2MWFfNy03LTEtMS0yMDk3Nw_603f43ec-927b-4471-98dd-c16b88a205c2"
      unitRef="usd">10929000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMTAyMQ_b00a1694-43ca-4087-b782-823514ea8647"
      unitRef="usd">36000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjE1MQ_40d00eca-02e3-4952-bc7b-e16a1ff6f83d"
      unitRef="usd">808000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i80af56866df1412e92048fc6c85f5bc4_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMTI0Mg_4afc1e05-c092-4eb3-beec-95399f249e96"
      unitRef="usdPerShare">43.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ice42d3e965264766b589d5585c17eea5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjE2OQ_04be9843-aca0-4d97-a50b-45c69f5bb577"
      unitRef="usdPerShare">50.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i8c01f855c0c84b0e9b660ee225b9ec6f_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMTU0NA_97dad5df-6a01-4f4f-a91d-31131d8503d8"
      unitRef="usd">101100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i4351d78dc27b42ba8f8b3dc0f50aab47_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMTcxNA_3c8615e6-976d-44ad-a669-69294d8e7b39">P3Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMzc3MQ_0f33028f-c5fb-4c7f-b7c3-0ac38780706a">&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the condensed consolidated statements of operations for the three months ended March&#160;31, 2022 and 2021 as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.842%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.746%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.982%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:29.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense related to RSAs of $480 thousand and $182 thousand for the three months ended March&#160;31, 2022 and 2021, respectively, within general and administrative expenses in the accompanying condensed consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:31.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.134%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.488%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i728d1afbbec24034b661de93f72a65fb_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjFhMDY2Njc4OTgzMDRjNzk5NDU3MjdhNzYzNDQ3NTk5L3RhYmxlcmFuZ2U6MWEwNjY2Nzg5ODMwNGM3OTk0NTcyN2E3NjM0NDc1OTlfMy0xLTEtMS0yMDk3Nw_abe134ca-a5d5-4d17-93f3-9ae782130b3d"
      unitRef="usd">1368000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4a13b8bd5de345f7816207b985555ac2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjFhMDY2Njc4OTgzMDRjNzk5NDU3MjdhNzYzNDQ3NTk5L3RhYmxlcmFuZ2U6MWEwNjY2Nzg5ODMwNGM3OTk0NTcyN2E3NjM0NDc1OTlfMy0zLTEtMS0yMDk3Nw_680dca92-8d43-401d-95a6-5b0b2bf9c0c1"
      unitRef="usd">516000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if5ef3f34ff534130b14863a9e62343c7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjFhMDY2Njc4OTgzMDRjNzk5NDU3MjdhNzYzNDQ3NTk5L3RhYmxlcmFuZ2U6MWEwNjY2Nzg5ODMwNGM3OTk0NTcyN2E3NjM0NDc1OTlfNC0xLTEtMS0yMDk3Nw_28d31a1e-169d-4786-9fda-977cc7016498"
      unitRef="usd">4582000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i159a69784f534b459befa6407a0a7b31_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjFhMDY2Njc4OTgzMDRjNzk5NDU3MjdhNzYzNDQ3NTk5L3RhYmxlcmFuZ2U6MWEwNjY2Nzg5ODMwNGM3OTk0NTcyN2E3NjM0NDc1OTlfNC0zLTEtMS0yMDk3Nw_c97d89e6-558e-42f3-aa29-855dba019be7"
      unitRef="usd">1615000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i80af56866df1412e92048fc6c85f5bc4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjFhMDY2Njc4OTgzMDRjNzk5NDU3MjdhNzYzNDQ3NTk5L3RhYmxlcmFuZ2U6MWEwNjY2Nzg5ODMwNGM3OTk0NTcyN2E3NjM0NDc1OTlfNS0xLTEtMS0yMDk3Nw_0344f065-bc5a-4b19-bd1f-65d5b7eba493"
      unitRef="usd">5950000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ice42d3e965264766b589d5585c17eea5_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjFhMDY2Njc4OTgzMDRjNzk5NDU3MjdhNzYzNDQ3NTk5L3RhYmxlcmFuZ2U6MWEwNjY2Nzg5ODMwNGM3OTk0NTcyN2E3NjM0NDc1OTlfNS0zLTEtMS0yMDk3Nw_1f0fc897-ff23-41c0-8fad-7f5fa4b9fa35"
      unitRef="usd">2131000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjE4OQ_ee56ed8c-8586-4b31-a20d-0e36dbfe3b5a"
      unitRef="usd">141000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjE5Nw_9812b281-319f-473e-9ab5-2c6286575bb5"
      unitRef="usd">37000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i80af56866df1412e92048fc6c85f5bc4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjQ1MA_edc95c24-ec32-49a3-98ec-2aabf7c36b8d"
      unitRef="usd">6000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ice42d3e965264766b589d5585c17eea5_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjIxNQ_fd1b5b31-0632-43cd-b565-9dfadbd0077b"
      unitRef="usd">2100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMzc3Nw_37ec10c3-abe5-44c7-b63d-a5ebefed2e81">The fair value of options was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions for the three months ended March&#160;31, 2022 and 2021:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.672%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.348%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of the award (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i80af56866df1412e92048fc6c85f5bc4_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmI1OTNlNTYwN2M3YjQxNDI5ZTVlMDE5MjU1YTdkMjU3L3RhYmxlcmFuZ2U6YjU5M2U1NjA3YzdiNDE0MjllNWUwMTkyNTVhN2QyNTdfMi0xLTEtMS0yMDk3Nw_3adf980f-1fab-4ae0-ad2a-238e7d262841"
      unitRef="number">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ice42d3e965264766b589d5585c17eea5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmI1OTNlNTYwN2M3YjQxNDI5ZTVlMDE5MjU1YTdkMjU3L3RhYmxlcmFuZ2U6YjU5M2U1NjA3YzdiNDE0MjllNWUwMTkyNTVhN2QyNTdfMi0zLTEtMS0yMDk3Nw_fc394031-5ef9-4d06-afd9-44d4f68f82a8"
      unitRef="number">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmI1OTNlNTYwN2M3YjQxNDI5ZTVlMDE5MjU1YTdkMjU3L3RhYmxlcmFuZ2U6YjU5M2U1NjA3YzdiNDE0MjllNWUwMTkyNTVhN2QyNTdfMy0xLTEtMS0yMDk3Nw_0de1c2ef-7437-4322-ba6b-eb1f867b7b93">P6Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i38aea91663634289b7f60b7120c11d27_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmI1OTNlNTYwN2M3YjQxNDI5ZTVlMDE5MjU1YTdkMjU3L3RhYmxlcmFuZ2U6YjU5M2U1NjA3YzdiNDE0MjllNWUwMTkyNTVhN2QyNTdfMy0zLTEtMS0yMDk3Nw_7cb8f479-7601-4d41-a7fa-858047d72485">P6Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i80af56866df1412e92048fc6c85f5bc4_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmI1OTNlNTYwN2M3YjQxNDI5ZTVlMDE5MjU1YTdkMjU3L3RhYmxlcmFuZ2U6YjU5M2U1NjA3YzdiNDE0MjllNWUwMTkyNTVhN2QyNTdfNC0xLTEtMS0yMDk3Nw_5529744a-14b2-40db-a8b7-9c1bc266a089"
      unitRef="number">0.0179</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ice42d3e965264766b589d5585c17eea5_D20210101-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmI1OTNlNTYwN2M3YjQxNDI5ZTVlMDE5MjU1YTdkMjU3L3RhYmxlcmFuZ2U6YjU5M2U1NjA3YzdiNDE0MjllNWUwMTkyNTVhN2QyNTdfNC0zLTEtMS0yMDk3Nw_a7ebc815-9a45-4b0b-9933-c0fc861379fd"
      unitRef="number">0.0100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice
      contextRef="i80af56866df1412e92048fc6c85f5bc4_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmI1OTNlNTYwN2M3YjQxNDI5ZTVlMDE5MjU1YTdkMjU3L3RhYmxlcmFuZ2U6YjU5M2U1NjA3YzdiNDE0MjllNWUwMTkyNTVhN2QyNTdfNS0xLTEtMS0yMDk3Nw_59a3a845-ffac-4d21-a679-486321271f42"
      unitRef="usdPerShare">62.53</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice
      contextRef="ice42d3e965264766b589d5585c17eea5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmI1OTNlNTYwN2M3YjQxNDI5ZTVlMDE5MjU1YTdkMjU3L3RhYmxlcmFuZ2U6YjU5M2U1NjA3YzdiNDE0MjllNWUwMTkyNTVhN2QyNTdfNS0zLTEtMS0yMDk3Nw_3ac494b8-d93f-4897-933f-a7d8afee4738"
      unitRef="usdPerShare">77.46</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="i80af56866df1412e92048fc6c85f5bc4_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmI1OTNlNTYwN2M3YjQxNDI5ZTVlMDE5MjU1YTdkMjU3L3RhYmxlcmFuZ2U6YjU5M2U1NjA3YzdiNDE0MjllNWUwMTkyNTVhN2QyNTdfNi0xLTEtMS0yMDk3Nw_4c44a8a6-2e4f-42d1-838c-8a0a165daa37"
      unitRef="number">0</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
      contextRef="ice42d3e965264766b589d5585c17eea5_D20210101-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmI1OTNlNTYwN2M3YjQxNDI5ZTVlMDE5MjU1YTdkMjU3L3RhYmxlcmFuZ2U6YjU5M2U1NjA3YzdiNDE0MjllNWUwMTkyNTVhN2QyNTdfNi0zLTEtMS0yMDk3Nw_48064962-7dd0-4339-9ce8-3bb8b707b4e0"
      unitRef="number">0</krys:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i95cf472c8b2540888dd2f36a876d9c9c_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMzc3Mg_4f37b107-d63d-434b-b824-ec348a2d0f89">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic9e66ec8312f4f8c9a9dff635bd641f1_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjIzNw_53b1b7b6-48ce-4631-a8e5-adc8ed95a345"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="idcde6861ff0841f797527708e897648a_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjI0MQ_1dd4e579-2071-4b42-ac5a-8b712ff9eb77"
      unitRef="shares">98800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMzc3Ng_64f48419-ea0e-45ac-b6a7-2113e8dda6fe">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,379)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSAs as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id2f80cb0be8e44f88a74d836902c06d0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmEwYmU5NWNmYTVkYjQ1NmQ4MzA1NzlkOWQ0YTZkNzdiL3RhYmxlcmFuZ2U6YTBiZTk1Y2ZhNWRiNDU2ZDgzMDU3OWQ5ZDRhNmQ3N2JfMS0xLTEtMS0yMDk3Nw_9186eda8-034d-414a-bff6-1148cab84d76"
      unitRef="shares">98800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id2f80cb0be8e44f88a74d836902c06d0_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmEwYmU5NWNmYTVkYjQ1NmQ4MzA1NzlkOWQ0YTZkNzdiL3RhYmxlcmFuZ2U6YTBiZTk1Y2ZhNWRiNDU2ZDgzMDU3OWQ5ZDRhNmQ3N2JfMS0zLTEtMS0yMDk3Nw_a0a0f391-51cf-4f93-b0df-974f12034ceb"
      unitRef="usdPerShare">78.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic9e66ec8312f4f8c9a9dff635bd641f1_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmEwYmU5NWNmYTVkYjQ1NmQ4MzA1NzlkOWQ0YTZkNzdiL3RhYmxlcmFuZ2U6YTBiZTk1Y2ZhNWRiNDU2ZDgzMDU3OWQ5ZDRhNmQ3N2JfMi0xLTEtMS0yMDk3Nw_2d2fa97f-76f6-4bdb-b271-0f4e048fba99"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic9e66ec8312f4f8c9a9dff635bd641f1_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmEwYmU5NWNmYTVkYjQ1NmQ4MzA1NzlkOWQ0YTZkNzdiL3RhYmxlcmFuZ2U6YTBiZTk1Y2ZhNWRiNDU2ZDgzMDU3OWQ5ZDRhNmQ3N2JfMi0zLTEtMS0yMDk3Nw_0501491f-4b34-4abb-b280-06c2456990ab"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ic9e66ec8312f4f8c9a9dff635bd641f1_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmEwYmU5NWNmYTVkYjQ1NmQ4MzA1NzlkOWQ0YTZkNzdiL3RhYmxlcmFuZ2U6YTBiZTk1Y2ZhNWRiNDU2ZDgzMDU3OWQ5ZDRhNmQ3N2JfMy0xLTEtMS0yMDk3Nw_3a7d28ed-c26b-4d7f-910d-f52421c19587"
      unitRef="shares">14321</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic9e66ec8312f4f8c9a9dff635bd641f1_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmEwYmU5NWNmYTVkYjQ1NmQ4MzA1NzlkOWQ0YTZkNzdiL3RhYmxlcmFuZ2U6YTBiZTk1Y2ZhNWRiNDU2ZDgzMDU3OWQ5ZDRhNmQ3N2JfMy0zLTEtMS0yMDk3Nw_0a76298c-0d9b-42df-8e5f-f863a1a353ae"
      unitRef="usdPerShare">78.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ic9e66ec8312f4f8c9a9dff635bd641f1_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmEwYmU5NWNmYTVkYjQ1NmQ4MzA1NzlkOWQ0YTZkNzdiL3RhYmxlcmFuZ2U6YTBiZTk1Y2ZhNWRiNDU2ZDgzMDU3OWQ5ZDRhNmQ3N2JfNC0xLTEtMS0yMDk3Nw_8a3683d1-d5ec-4138-b21c-4736591a536f"
      unitRef="shares">10379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ic9e66ec8312f4f8c9a9dff635bd641f1_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmEwYmU5NWNmYTVkYjQ1NmQ4MzA1NzlkOWQ0YTZkNzdiL3RhYmxlcmFuZ2U6YTBiZTk1Y2ZhNWRiNDU2ZDgzMDU3OWQ5ZDRhNmQ3N2JfNC0zLTEtMS0yMDk3Nw_bbb68cfc-3b62-4bbf-b4b6-4327828765e8"
      unitRef="usdPerShare">78.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i34ffbc56d9c943f2b61272f256499cfb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmEwYmU5NWNmYTVkYjQ1NmQ4MzA1NzlkOWQ0YTZkNzdiL3RhYmxlcmFuZ2U6YTBiZTk1Y2ZhNWRiNDU2ZDgzMDU3OWQ5ZDRhNmQ3N2JfNS0xLTEtMS0yMDk3Nw_c800cdd7-f50e-4207-8efe-5b52b87d5c45"
      unitRef="shares">74100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i34ffbc56d9c943f2b61272f256499cfb_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOmEwYmU5NWNmYTVkYjQ1NmQ4MzA1NzlkOWQ0YTZkNzdiL3RhYmxlcmFuZ2U6YTBiZTk1Y2ZhNWRiNDU2ZDgzMDU3OWQ5ZDRhNmQ3N2JfNS0zLTEtMS0yMDk3Nw_2dd8c6be-371f-494e-8674-53220257002b"
      unitRef="usdPerShare">78.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i34ffbc56d9c943f2b61272f256499cfb_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjI1Ng_5031a674-6c3e-4189-95ef-ac3e3a594448"
      unitRef="usd">5700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic9e66ec8312f4f8c9a9dff635bd641f1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjI2MQ_7f9d1d03-2009-466b-a19e-e7543ea08d86">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic9e66ec8312f4f8c9a9dff635bd641f1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjI2OQ_33963d86-919c-406b-9dd5-3a598aac2378"
      unitRef="usd">480000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idcde6861ff0841f797527708e897648a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfNzE0NjgyNTU5MjI3Mw_b2dd3173-daaa-446c-84ed-8c03ec6c2df7"
      unitRef="usd">182000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie2d9d3e6725f41cbba150ba4c1a85196_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjZmZWMwNzNjM2YwMTQ2ZDQ5MWFlMDdlZWE5ZDUwNzhiL3RhYmxlcmFuZ2U6NmZlYzA3M2MzZjAxNDZkNDkxYWUwN2VlYTlkNTA3OGJfMy0xLTEtMS0yMDk3Nw_ab368b01-f047-493f-8410-4518a6568faa"
      unitRef="usd">480000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i383ec6469caa4edeaa4b2d6d77e7fba4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjZmZWMwNzNjM2YwMTQ2ZDQ5MWFlMDdlZWE5ZDUwNzhiL3RhYmxlcmFuZ2U6NmZlYzA3M2MzZjAxNDZkNDkxYWUwN2VlYTlkNTA3OGJfMy0zLTEtMS0yMDk3Nw_3ffee157-1ad3-4571-86b9-2ddd1ab5a8fd"
      unitRef="usd">182000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic9e66ec8312f4f8c9a9dff635bd641f1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjZmZWMwNzNjM2YwMTQ2ZDQ5MWFlMDdlZWE5ZDUwNzhiL3RhYmxlcmFuZ2U6NmZlYzA3M2MzZjAxNDZkNDkxYWUwN2VlYTlkNTA3OGJfNC0xLTEtMS0yMDk3Nw_a3cdb6ae-70cd-44cf-a5a2-08afc33ae192"
      unitRef="usd">480000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idcde6861ff0841f797527708e897648a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RhYmxlOjZmZWMwNzNjM2YwMTQ2ZDQ5MWFlMDdlZWE5ZDUwNzhiL3RhYmxlcmFuZ2U6NmZlYzA3M2MzZjAxNDZkNDkxYWUwN2VlYTlkNTA3OGJfNC0zLTEtMS0yMDk3Nw_987c2ef7-3c38-488b-9233-99656f18f78a"
      unitRef="usd">182000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i29cc8ebc55e7487dac7291d42222cb41_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMzcwOQ_f376e5b8-22e4-46a9-9408-94f85e5cd4c0"
      unitRef="shares">1028815</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i28da46ff21b84b0aa5a790183dfad270_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181Mi9mcmFnOjEyNTY5MzQ0ZTc4MTQxZmQ5NWViM2Y0ZWIyMDRhYTQ3L3RleHRyZWdpb246MTI1NjkzNDRlNzgxNDFmZDk1ZWIzZjRlYjIwNGFhNDdfMzc2MA_644d538a-a3ef-4ca0-8a92-51e1222aee20"
      unitRef="shares">26546</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181OC9mcmFnOmRlNGZjMWMxYWJmNDQ4M2ViZjI2YTkzMWU2ZjE3NzQ4L3RleHRyZWdpb246ZGU0ZmMxYzFhYmY0NDgzZWJmMjZhOTMxZTZmMTc3NDhfMzcw_49aef8cb-75eb-40e1-b886-3954992df5c4">Subsequent Events&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 28, 2022, the Company entered into a final settlement agreement and paid PeriphaGen an upfront payment of $25.0&#160;million for: (i) the resolution of all claims in the trade secret litigation with PeriphaGen, Inc.; (ii) the acquisition of certain PeriphaGen assets, and (iii) the grant of a license by PeriphaGen for dermatological applications.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 5, 2022, pursuant to an inbound request, the Company issued and sold 434,782 shares of common stock at a weighted average price of $69.00 per share, under it's ATM Program, for net proceeds of $29.1&#160;million after deducting underwriting discounts and commissions.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LitigationSettlementExpense
      contextRef="i7448456091a9407bba292044857bb844_D20220429-20220429"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181OC9mcmFnOmRlNGZjMWMxYWJmNDQ4M2ViZjI2YTkzMWU2ZjE3NzQ4L3RleHRyZWdpb246ZGU0ZmMxYzFhYmY0NDgzZWJmMjZhOTMxZTZmMTc3NDhfMjE5OTAyMzI1OTY3NA_be7afcf0-af1b-4bb3-8852-687642f1f11f"
      unitRef="usd">25000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="id610a4a750eb45a88b570c32459f3956_D20220405-20220405"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181OC9mcmFnOmRlNGZjMWMxYWJmNDQ4M2ViZjI2YTkzMWU2ZjE3NzQ4L3RleHRyZWdpb246ZGU0ZmMxYzFhYmY0NDgzZWJmMjZhOTMxZTZmMTc3NDhfMjE5OTAyMzI1OTY4Nw_0a54fd3f-570e-4e95-acba-7cb7c42c3d03"
      unitRef="shares">434782</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="iec19ce2f98484127826acb386e5ebf55_I20220405"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181OC9mcmFnOmRlNGZjMWMxYWJmNDQ4M2ViZjI2YTkzMWU2ZjE3NzQ4L3RleHRyZWdpb246ZGU0ZmMxYzFhYmY0NDgzZWJmMjZhOTMxZTZmMTc3NDhfMjE5OTAyMzI1OTY5Ng_df10760a-92f2-437e-8ded-8c628a75a7dc"
      unitRef="usdPerShare">69.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="id610a4a750eb45a88b570c32459f3956_D20220405-20220405"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFkMThmMmNhODI5YTQyNDBiYTM2MzlhOWFiMDRmYTljL3NlYzoxZDE4ZjJjYTgyOWE0MjQwYmEzNjM5YTlhYjA0ZmE5Y181OC9mcmFnOmRlNGZjMWMxYWJmNDQ4M2ViZjI2YTkzMWU2ZjE3NzQ4L3RleHRyZWdpb246ZGU0ZmMxYzFhYmY0NDgzZWJmMjZhOTMxZTZmMTc3NDhfMjE5OTAyMzI1OTcwNA_fa68aa19-f000-4f0b-be8d-49252b494c2f"
      unitRef="usd">29100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>53
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M_2J$5VPM8,<B];M)#+0IA@WHMJ!IM[\9B8Z(2J(K4DZR3[^CI$BV1-'N!BQ
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MN)M?:+4V=GJ6#SG8 I O878"FUGI\9"-;6'7:05S7N*&^JW!E4,\UW-:Q6+
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M$[ UM$5FS;HDBIR="'X/A)'6VLS ^L;.UM:PVFSCK1+Z*]/SU-F:UX7>%%H
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M=LJW4UUD(N=#[)ZO(%Z-NR&/5* DXH%#<9Q#.Y_S[5;'J-[2G,L 1/<N#CD
M/3)P7.]F1U? %14[>S,N@3T*ME>H_=O^]OW<WCF/WE_ C^OV#GU0TU[I?R%"
M%P^ICSY;K3+Y8.[ 17M+WCXH?K 7S1NN%*_L<$])0841T-^WG*NG![- _[^*
ML_\ 4$L#!!0    ( ,^ J52BWU\V" @   H2   8    >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&ULM5C;;B/'$?V5!F,D7H B14I[\TH")-GQVMF%Y=W8?@CR
MT.RIX734TSWN"RGZZW.J>V8TTFH71H"\2'/IJCI5=>HR/-L[?QL:HBCN6F/#
M^:R)L?MFN0RJH5:&A>O(XDWM?"LC;OUV&3I/LLI"K5FNCX]?+%NI[>SB+#^[
M\1=G+D6C+=UX$5+;2G^X(N/VY[/5;'CP06^;R ^6%V>=W-)'BK]T-QYWRU%+
MI5NR03LK/-7GL\O5-U>G?#X?^%73/DRN!7NR<>Z6;WZHSF?'#(@,J<@:)/[M
MZ)J,846 \7NO<S::9,'I]:#][]EW^+*1@:Z=^4U7L3F?O9J)BFJ93/S@]F^I
M]^<YZU/.A/Q7[,O9$UA4*437]L*X;[4M_^5='X>)P*OCSPBL>X%UQET,993?
MRB@OSKS;"\^GH8TOLJM9&N"TY:1\C!YO->3BQ4]^*ZW^0W*(SI81&OGY4O72
M5T5Z_1GI$_'>V=@$\9VMJ'HHOP22$<YZ@'.U_J+"]](OQ,EJ+M;'Z_47])V,
M[IUD?2>?T7>IE$LV:KL5-\YHI2F(?UUN0O2@P[^_8.!T-'":#9S^C_'[\]+B
M'_X0HC3B2KM(JIF+'ZQ:B*]C0^*O?WFU7A^_N79M)^UAGF]7;X3SPYL]39XY
MB*#N=*N-]*+SSB(&X9E0KD4Y*:H$:MIGHT' \&7GM1&KYQSUU8N%^,D*Y$$U
M?2)6+^>"0?36H<;NR$>HJ;UKA137TFBT!ZNE,##*;XR6&VUTY--%*CJ<_):,
MW$L/74?*^<X5$',A;254(^T6HCH&865+1?NCH(AW[ZY9U=.Q O ?DR6Q>IUQ
MOWJ(6]O!)JP,"BX3<P%PQ0W OHO5@M'</[8</\2'(EK6Z%[O%(Z*?>.,.1RY
MO<7SD#9!5QI'YP(1R>:[!*.!A*M%0I7X*&^9CFBA"G30"B"R^\--B*EBFNH)
MBNQ:2=/Z-/OV^@N^_4@<A$L*.!&U"B4Z&5%+WAS$K05<(4,Y.1!MEN]FS^9L
M>LC4_]5%EI<#3!$@Q.2J=&9F2:>TB0/_LG2$/Y'0@2@?]SK^ 6_9\/?MYNV3
M:&%;;HP.#<,%N*BA85(< /1=0OYI%*YHAT'6H8YB\8EKRBO(#64,M3V6OP71
MZ8ZXZ!?B-Q),?#F- J:>V!2\UAFWO:\6@_G*F-ADK<E4K-93Y0+PDMB292@&
M \T?%N*7P&==0K$C%I;#T1D9.=_0(*/0(8^NBJN=[!: ",H$VD2'-*!3=(;N
MQ$[[%$0\P-T5Z/#VXZ]'*Z;#GH3"P(\D=IBESH>BE.J:&ZJ-8%2/A?%ZV5'B
M?(*Z-C#2P!6K,'@#>Z&!SR/P'-P6LU/#-KH6&J$("!NUR/P_X38+<%-;O7P#
M.?"UE0IY@L-LQ1;URNL-]',F\CV\9G,01Z-SF$F,,H-F#)&]X X)9NXX@Y4.
MA+CD['"T$LOG0 Z><MZMLT?:[F2 BRR-,:Q;B9(0XU./?8>R>[+BUURW9>L
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M=UQO#<4IHI4L6'EKE3GO^417#%8(R+\O>X]7?;&EV%A.]#OR+J@,$4'_7\0
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M16K@NFOQW<2J-K357%EJTF%8TU<1:G^ ]BNE[&[B#?3?68O_ %!+ P04
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M..#YY1HG:JZ= >I7"LNVW[@#^AG]ZB]02P,$%     @ SX"I5(IRD?0 !
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MX\4"/^?'"]]0Z+X[G9Z='27/I^?X^<4TL;?R4%1T,.GS&_?(*;I18VY#]7K
M0]>68<<A]K@X0IFS.)[M6)GECAVNU/KGLZ/D)_P\P<^=-=,8#!(NR(D<S\\C
M9-F0]I:+L^X)&2\'@BW,V0,VD=QBI!5Z6UP$.6#-TX;B?NHC.3(:\M\/3A\?
M?G3ZYYT]Z_=WV?^&Z(?U_0[D)[M1R 4D%,:.,K_X&=; 9PW?^3+V@DZ<(#%*
M%:'J#O8-E8J@3X;26@GXJQ99"F570\H>.7!_<OGYDYL\F_X8#WC]([TNG0QJ
M2U)A8+/83"#9UI3- GXIM8S"L:Z!U6DW3>)7*$P0[24UUE*22:'3/]YI>PL_
M[B0M5&.Y@QAO\B%+&RZ'/!QEDH#(1A?B[^$0ROQ[2&7RZH!P046<H0X:0 4]
M&\M>HY^R<.Q.,MMN_*M-K!:ABE1;RCWH98I)(R:9>C>@OU0^V?$=[DY2)(0,
M ;0PM=2E!+N\8>$AC)&93D%9>J,VW/I$&8AJDCYAY2%AVTO3T])7!Z<R_I<#
ME)J;P'?CAJ4VA.2S4G&F);5146=K"J0]I^]3\([[9L2H;$L4E;Q7YYJZV+BS
M$.CBY5!PY,^'+8"CV6)WOR#*>,7BK2EQ#B6S=,#N0[ZEQ ]@.X\X&D%X-!M.
M?  LB(O?#Z",&V6MC64;9[$C]F,#0_6Z0+XL<(\Q2GYL,3N+W0TZ3"/!B3GT
M#[NO&1$0!@I7U)7%^>PC+B*V'M"9>G\0#"6XH*&] QI^* %EP+@-X@(,Q3<M
M$!TH- M7OCKIS3;J/BEB^_:&B\Y@"AUY;.7<E#:,:GC\+!IBBL6<&@1#2^-\
MKKFO">S43L'/7:J'HD634:VQBH*T<RVE-+T98![MX-] -V"\=XSPNKO1]:]Q
MTDF&<-(S 8EWBV[K/R/>/57C_7'DQ$IS,/OZ]>-5?W9'1X."3!KVI$D>J&VI
M2SXH%,(QE:D.4DH/BV+4M^YLB\>KIMH<,(Q(=Q*,L,U6%S72(8-JNC;4:9=Q
MXU9G;<'YD6UK/SJP<24R421[\ _NST%@;^O_/SBB9%T^B4=I!XZ:V8TYR*2K
MM*-'P!_SZO>V@#[Y<?;1_ ?*P^L&L%5 %ETGH=UB)D,BO1QWAZ2MUJ_F?]45
MS[,O'TR%'M]I/T5!T26CO8EZS W#0%W$0>+\MLW)A1U\:2VU,L+N1$/@;=_O
M,GPU;#4E,+M6R?A'JOO1IGF_C]FE5)PK/&PIAD')#&57K.\#KGI3,I]L1MY&
M$SA@AO \ID5%*_ M<C_^[W71"$S<J3#V)JD+2G$Y\G+7BXA9S$Y/?MKU]BSY
MA2>6U(2XUG7C&PI'/X"8#<IXR)!"4JF^<U7K6_CA&H#O&UR$WV7V/! !SWXT
M0\-W8![;=DHHOX,["IU7MI?5_:,*Y$8AFSJI)4P$F!O?DMQ73MKFDGT."'LV
M2[[&5D/D8/HDB;Y/RCW$T>R&/,/9L@LG@SEB@(K* E(D>\T$7SR2@/.MD&=2
MP>BSZC"L]2===&/$A[#G!@FCH^N?=#I  B%]!<)-K]ZFMWA1I6DR0ET;CC=^
MH#*V@2;>1X@W++CY106.7E//-*H-;S^B$WSS>\G/C)96.\&]JV'"0<.9LS?4
M+T^I<=<AS&S>M W%E0IAZ(&D&NXR=&$CF%GLNG,C[!]M7M?TFR?D@]YP.FE2
MT,%S"'_7:1$F?$HX $ :W_ZD1G88H;71K7RMJ!]#CKR1RV*HFE*Z9-7:)L;+
M;YHJN:K[&@0.;KH 35>(F/56P:%/D_=5.J.19GQ$1:Y8'-<$%8P]X\3C$J:V
M3G[YKM.6O<DG;AU:YIK:5L JV<_GOZBR_OGM-/FKS=U6?E9*@LIU6ZKX9)P]
M?=GJGB"0 ^@-@=^&9#XZ2?;5N>MF-4%'EH9_R(^LI@M*PH3_57()WCI?K[DE
M93D&4PNQ=5*]^7+2EX.CG-GUKSG0;E( )S3"6U%6X>\M8.WUEXO/!V_IN(;R
M>M@KY?GN+DXR.S9-N)'V7-! ZH$<[\,A+(9>9V3%+>*&,4-3.9MB'U0.[J8+
M7 0'Y@;?63\>N=/=0+$O.MT#0S3$@2 IR8+HUZQ>LN5>'U%8IN(&9U*78WRF
M\CZ!QP7K5BIK9VB4$,84NX4M<!G+\7WG0CF[]98B*?,!I<SW?0B%(?2=(;NO
MTKRF/)$-HC. WQ1=S_NFTVU+LU@<^U;![S),;ZB!1AK@V>QN)#JM;^(L)5Q
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M1>6MV@U58V.;)!!>5<; O=Q-%@K'N1^V]D./U#/3L:2>=$LVDU^_Y]6O&5E
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MH@L.;"^M];M-"##,Z_E?4$L#!!0    ( ,^ J53D?42(H@(  +@%   9
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M5])0I[ME3J,5E76@\[64YF#8 .VPGOX!4$L#!!0    ( ,^ J51YL%D6=00
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MV?=]'0X<IL$1AW#O$/JXFXM\E/?,LNN95EO0SAK1W,:GZKTQ."%=4^96XZE
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MO-%@RCP7^ND",[4^Z_B=S<:MG"^LV^B?GR[%'._0?E[>:/KJ-UQ2F6-AI"I
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M@911 RFC5DBY$E+7K>D9.AB/]RNI4ZJVO-K>!PGM,KCC.CFKC9P:$V%-M4/
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M J/!Z#H@NKV#K8%JX\=XJ=!>"K^L[;,%V@58_THI?#?<S>@?PN(/4$L#!!0
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MJWQ+]!,C&]=5UM)@CW+#"O\BH.P"_%Y(:;83*]#_E])?4$L#!!0    ( ,^
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MLL)'#91UP/.-E.9HV #],YG_!5!+ P04    " #/@*E4%D%!A3P#  #E"0
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MY8KG"H(OP55P/(4\R_K7'_4;+8KJG/]1:"VRZN6:4=@]FPO@^Z40^N6-^>E
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M]#BZ#?J6N/T?7]2535=5E]GH$ Q]%(0]U0\;\P8> /LZCW5H],0'MRG)7?%
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MOE TZ+1&/VCT*\"&-M152;S.M^RY7NB_^^3[AD'/@_U?%FK6%31J73%?/99
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M<R]S:&5E=#0P+GAM;)U6;6_:,!#^*U8T::VT-F]00@5(0-=M'SI516L_F^0
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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ME<W1GW7_2>:?4$L! A0#%     @ SX"I5 =!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #/@*E4\;M!
MI>X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " #/@*E4F5R<(Q &  "<)P  $P              @ ', 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,^ J53]%AT3-@4  .<5
M   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    " #/@*E4>S07NZ(%   X%@  &               @(%Y#0
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ SX"I5$K&EJO:
M @  7PD  !@              ("!41,  'AL+W=O<FMS:&5E=',O<VAE970S
M+GAM;%!+ 0(4 Q0    ( ,^ J52-U8^?.P0  ),.   8              "
M@6$6  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #/@*E4
M%,US2_@$  #(%   &               @('2&@  >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&UL4$L! A0#%     @ SX"I5!R*'G!,!@  MQ@  !@
M     ("! "   'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (
M ,^ J52BWU\V" @   H2   8              " @8(F  !X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q02P$"% ,4    " #/@*E4_R$[RO,8   72P  &
M            @(' +@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#
M%     @ SX"I5/FQ1T?) P  <PD  !@              ("!Z4<  'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( ,^ J51=G*;CIP0  *\+
M   9              " @>A+  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL
M4$L! A0#%     @ SX"I5(IRD?0 !   Y0@  !D              ("!QE
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #/@*E4QTQ7
M1JX3  #8-P  &0              @(']5   >&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;%!+ 0(4 Q0    ( ,^ J525BL!'+P0  $0*   9
M  " @>)H  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @
MSX"I5#7F['M+!P  %A4  !D              ("!2&T  'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6Q02P$"% ,4    " #/@*E4\;EBS"D#  # !@  &0
M            @('*=   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4
M Q0    ( ,^ J51#\F2\,AD  ,Y/   9              " @2IX  !X;"]W
M;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ SX"I5'^JP'VA @
MNP4  !D              ("!DY$  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6Q02P$"% ,4    " #/@*E4Y'U$B*("  "X!0  &0              @(%K
ME   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( ,^ J51Y
ML%D6=00  #,+   9              " @427  !X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL4$L! A0#%     @ SX"I5'5]S6?O P  X@@  !D
M     ("!\)L  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,^ J51=2->0"@,  '\,   9              "
M@6*O  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ SX"I
M5$QE/7U\ @  C04  !D              ("!H[(  'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6Q02P$"% ,4    " #/@*E4;F]&[PH#  #@"   &0
M        @(%6M0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0
M   ( ,^ J51L?W-BG0<  !8U   9              " @9>X  !X;"]W;W)K
M<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ SX"I5-30*&N3 P  <@T
M !D              ("!:\   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q0
M2P$"% ,4    " #/@*E4P K#_4D"   R!0  &0              @($UQ
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( ,^ J50604&%
M/ ,  .4)   9              " @;7&  !X;"]W;W)K<VAE971S+W-H965T
M,S$N>&UL4$L! A0#%     @ SX"I5"($F')<!P  CR,  !D
M ("!*,H  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #/
M@*E4BU9??.H"  !Z"   &0              @(&[T0  >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( ,^ J50-WU53)@,  )L(   9
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M970S."YX;6Q02P$"% ,4    " #/@*E4MI<=[#,#  #I"0  &0
M    @('(Z@  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (
M ,^ J52:"2T0'0,  &0*   9              " @3+N  !X;"]W;W)K<VAE
M971S+W-H965T-# N>&UL4$L! A0#%     @ SX"I5.(PA\$, P  P0H  !D
M             ("!AO$  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"
M% ,4    " #/@*E4\<+.32$#   8$@  #0              @ ')]   >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ,^ J527BKL<P    !,"   +
M      "  17X  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ,^ J52[95.8AP,
M -L;   /              "  ?[X  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " #/@*E4*5V(H),!  #B&   &@              @ &R_   >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #/@*E4B(RI-Z4!   O
M&0  $P              @ %]_@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    ,0 Q $X-  !3  $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>149</ContextCount>
  <ElementCount>245</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>44</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Fair Value Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/FairValueInstruments</Role>
      <ShortName>Fair Value Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2125107 - Disclosure - Capitalization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/Capitalization</Role>
      <ShortName>Capitalization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2127108 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2134109 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Fair Value Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/FairValueInstrumentsTables</Role>
      <ShortName>Fair Value Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/FairValueInstruments</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2316304 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/BalanceSheetComponents</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2321305 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/CommitmentsandContingencies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2328306 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/StockBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail</Role>
      <ShortName>Organization - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail</Role>
      <ShortName>Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Balance Sheet Components - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail</Role>
      <ShortName>Balance Sheet Components - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail</Role>
      <ShortName>Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Capitalization - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail</Role>
      <ShortName>Capitalization - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail</Role>
      <ShortName>Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="krys-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.krystalbio.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.krystalbio.com/role/SubsequentEvents</ParentRole>
      <Position>41</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="krys-20220331.htm">krys-20220331.htm</File>
    <File>krys-20220331.xsd</File>
    <File>krys-20220331_cal.xml</File>
    <File>krys-20220331_def.xml</File>
    <File>krys-20220331_lab.xml</File>
    <File>krys-20220331_pre.xml</File>
    <File>krys-20220331ex311.htm</File>
    <File>krys-20220331ex312.htm</File>
    <File>krys-20220331ex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>krys-20220331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="457">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>58
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "krys-20220331.htm": {
   "axisCustom": 1,
   "axisStandard": 15,
   "contextCount": 149,
   "dts": {
    "calculationLink": {
     "local": [
      "krys-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "krys-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "krys-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "krys-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "krys-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "krys-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 375,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 5
   },
   "keyCustom": 32,
   "keyStandard": 213,
   "memberCustom": 18,
   "memberStandard": 26,
   "nsprefix": "krys",
   "nsuri": "http://www.krystalbio.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.krystalbio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Fair Value Instruments",
     "role": "http://www.krystalbio.com/role/FairValueInstruments",
     "shortName": "Fair Value Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Balance Sheet Components",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Commitments and Contingencies",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125107 - Disclosure - Capitalization",
     "role": "http://www.krystalbio.com/role/Capitalization",
     "shortName": "Capitalization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127108 - Disclosure - Stock-Based Compensation",
     "role": "http://www.krystalbio.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134109 - Disclosure - Subsequent Events",
     "role": "http://www.krystalbio.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "krys:EstimatedUsefulLivesOfAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "krys:EstimatedUsefulLivesOfAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Fair Value Instruments (Tables)",
     "role": "http://www.krystalbio.com/role/FairValueInstrumentsTables",
     "shortName": "Fair Value Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "i905c5a481a8b4f42a9009703d3ecf075_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "i905c5a481a8b4f42a9009703d3ecf075_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316304 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321305 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328306 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "i905c5a481a8b4f42a9009703d3ecf075_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail",
     "shortName": "Organization - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "i905c5a481a8b4f42a9009703d3ecf075_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ie8265b62d98547d1b612aa5059737994_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail",
     "shortName": "Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ie8265b62d98547d1b612aa5059737994_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share and Per Unit (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "i905c5a481a8b4f42a9009703d3ecf075_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)",
     "role": "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
     "shortName": "Fair Value Instruments - Summary of Cash, Cash Equivalents and Available-for-Sale Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "i905c5a481a8b4f42a9009703d3ecf075_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "i905c5a481a8b4f42a9009703d3ecf075_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "i905c5a481a8b4f42a9009703d3ecf075_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "i905c5a481a8b4f42a9009703d3ecf075_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "i905c5a481a8b4f42a9009703d3ecf075_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Balance Sheet Components - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail",
     "shortName": "Balance Sheet Components - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "i905c5a481a8b4f42a9009703d3ecf075_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "krys:AccruedPreclinicalAndClinicalExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)",
     "role": "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail",
     "shortName": "Balance Sheet Components - Schedule of Accrued Expenses And Other Current Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "i905c5a481a8b4f42a9009703d3ecf075_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "krys:AccruedPreclinicalAndClinicalExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "i2384fef03d174e7293ac35a6c188c7cf_I20201005",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "krys:PaymentToEscrowForReducingLeaseRentals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "i2384fef03d174e7293ac35a6c188c7cf_I20201005",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "krys:PaymentToEscrowForReducingLeaseRentals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "i905c5a481a8b4f42a9009703d3ecf075_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail",
     "shortName": "Commitments and Contingencies - Schedule of Future Minimum Operating Lease Payments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "i905c5a481a8b4f42a9009703d3ecf075_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "i905c5a481a8b4f42a9009703d3ecf075_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail)",
     "role": "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail",
     "shortName": "Commitments and Contingencies - Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "i905c5a481a8b4f42a9009703d3ecf075_I20220331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "i0c1f8e7fe2fa45fd8b4dff23e6288333_D20211203-20211203",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Capitalization - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail",
     "shortName": "Capitalization - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "i0c1f8e7fe2fa45fd8b4dff23e6288333_D20211203-20211203",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "i99c92e6ca8634fd79257a600a35f3f21_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail",
     "shortName": "Stock-Based Compensation - Schedule of Company's Stock Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "i80af56866df1412e92048fc6c85f5bc4_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail",
     "shortName": "Stock-Based Compensation - Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "i728d1afbbec24034b661de93f72a65fb_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
     "shortName": "Stock-Based Compensation - Fair Value of Stock Options, Valuation Assumptions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "id2f80cb0be8e44f88a74d836902c06d0_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)",
     "role": "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails",
     "shortName": "Stock-Based Compensation - Schedule of Company's Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ic9e66ec8312f4f8c9a9dff635bd641f1_D20220101-20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationSettlementExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.krystalbio.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "id610a4a750eb45a88b570c32459f3956_D20220405-20220405",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia6ffefd397c440af90b9447cc5a238f5_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia6ffefd397c440af90b9447cc5a238f5_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization",
     "role": "http://www.krystalbio.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Net Loss Per Share Attributable to Common Stockholders",
     "role": "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "krys-20220331.htm",
      "contextRef": "ia7b6049f1eb649989dcc9eedefd21746_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 44,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.krystalbio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "krys_ASTRAFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASTRA facility.",
        "label": "A S T R A Facility [Member]",
        "terseLabel": "ASTRA Facility"
       }
      }
     },
     "localname": "ASTRAFacilityMember",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_ATMProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Program",
        "label": "ATM Program [Member]",
        "terseLabel": "ATM Program"
       }
      }
     },
     "localname": "ATMProgramMember",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_AccruedConstructionInProgressCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued construction in progress current.",
        "label": "Accrued Construction In Progress Current",
        "terseLabel": "Accrued construction in progress"
       }
      }
     },
     "localname": "AccruedConstructionInProgressCurrent",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current Liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AccruedFinancingFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Financing Fees, Current",
        "label": "Accrued Financing Fees, Current",
        "terseLabel": "Accrued financing costs"
       }
      }
     },
     "localname": "AccruedFinancingFeesCurrent",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AccruedPayrollAndBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued payroll and benefits.",
        "label": "Accrued Payroll And Benefits",
        "terseLabel": "Accrued payroll and benefits"
       }
      }
     },
     "localname": "AccruedPayrollAndBenefits",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AccruedPreclinicalAndClinicalExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued preclinical and clinical expenses.",
        "label": "Accrued Preclinical And Clinical Expenses",
        "terseLabel": "Accrued preclinical and clinical expenses"
       }
      }
     },
     "localname": "AccruedPreclinicalAndClinicalExpenses",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_AdditionalAreaOfRealEstatePropertyLeased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional area of real estate property leased.",
        "label": "Additional Area Of Real Estate Property Leased",
        "terseLabel": "Additional area of real estate property leased"
       }
      }
     },
     "localname": "AdditionalAreaOfRealEstatePropertyLeased",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "krys_BostonLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boston Lease",
        "label": "Boston Lease [Member]",
        "terseLabel": "Boston Lease"
       }
      }
     },
     "localname": "BostonLeaseMember",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": 2.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash cash equivalents and debt securities available for sale.",
        "label": "Cash Cash Equivalents And Debt Securities Available For Sale",
        "totalLabel": "Aggregate fair value, total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndDebtSecuritiesAvailableForSale",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash cash equivalents and debt securities available for sale amortized cost.",
        "label": "Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_ClinicalSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical supply agreement.",
        "label": "Clinical Supply Agreement [Member]",
        "terseLabel": "Clinical Supply Agreements"
       }
      }
     },
     "localname": "ClinicalSupplyAgreementMember",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_CostOfWorkPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Work, Percentage",
        "label": "Cost Of Work, Percentage",
        "terseLabel": "Cost of work, percentage"
       }
      }
     },
     "localname": "CostOfWorkPercentage",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "krys_CumulativeEscalationClausePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative Escalation Clause, Percent",
        "label": "Cumulative Escalation Clause, Percent",
        "terseLabel": "Cumulative escalation clause"
       }
      }
     },
     "localname": "CumulativeEscalationClausePercent",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "krys_CumulativeEscalationClauseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative Escalation Clause, Term",
        "label": "Cumulative Escalation Clause, Term",
        "terseLabel": "Cumulative escalation clause, term"
       }
      }
     },
     "localname": "CumulativeEscalationClauseTerm",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "krys_EstimatedUsefulLivesOfAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the estimated useful lives of assets.",
        "label": "Estimated Useful Lives Of Assets [Table Text Block]",
        "terseLabel": "Summary of Estimated Useful Lives of Assets"
       }
      }
     },
     "localname": "EstimatedUsefulLivesOfAssetsTableTextBlock",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "krys_IncentiveStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive stock options.",
        "label": "Incentive Stock Options [Member]",
        "terseLabel": "Incentive Stock Options"
       }
      }
     },
     "localname": "IncentiveStockOptionsMember",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) Accrued Legal Settlement And In-Process Research And Development",
        "label": "Increase (Decrease) Accrued Legal Settlement And In-Process Research And Development",
        "terseLabel": "Accrued legal settlement"
       }
      }
     },
     "localname": "IncreaseDecreaseAccruedLegalSettlementAndInProcessResearchAndDevelopment",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_IncreaseDecreaseInLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in lease liability.",
        "label": "Increase Decrease In Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiability",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_InterestIncomeExpenseAndOtherNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest income (expense) and other nonoperating, net.",
        "label": "Interest Income Expense And Other Nonoperating Net",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseAndOtherNonoperatingNet",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab equipment.",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Laboratory and manufacturing equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LessorOperatingLeaseLiabilityAnnualLeasePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessor, Operating Lease, Liability, Annual Lease Payments",
        "label": "Lessor, Operating Lease, Liability, Annual Lease Payments",
        "terseLabel": "Lessor, operating lease, liability, annual lease payments"
       }
      }
     },
     "localname": "LessorOperatingLeaseLiabilityAnnualLeasePayments",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LitigationSettlementMilestonePaymentsSalesThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Milestone Payments, Sales Threshold",
        "label": "Litigation Settlement, Milestone Payments, Sales Threshold",
        "terseLabel": "Litigation settlement, milestone payments, sales threshold"
       }
      }
     },
     "localname": "LitigationSettlementMilestonePaymentsSalesThreshold",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LitigationSettlementTotalConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Total Consideration",
        "label": "Litigation Settlement, Total Consideration",
        "terseLabel": "Litigation settlement, total consideration"
       }
      }
     },
     "localname": "LitigationSettlementTotalConsideration",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_LongTermMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term marketable securities.",
        "label": "Long Term Marketable Securities [Member]",
        "terseLabel": "Long-term Marketable Securities"
       }
      }
     },
     "localname": "LongTermMarketableSecuritiesMember",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_LossContingencyGuaranteedMaximumPriceToBePaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Guaranteed Maximum Price to be Paid",
        "label": "Loss Contingency, Guaranteed Maximum Price to be Paid",
        "terseLabel": "Loss contingency, guaranteed maximum price to be paid"
       }
      }
     },
     "localname": "LossContingencyGuaranteedMaximumPriceToBePaid",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_MilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone One",
        "label": "Milestone One [Member]",
        "terseLabel": "Milestone One"
       }
      }
     },
     "localname": "MilestoneOneMember",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_MilestoneThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Three",
        "label": "Milestone Three [Member]",
        "terseLabel": "Milestone Three"
       }
      }
     },
     "localname": "MilestoneThreeMember",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_MilestoneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Two",
        "label": "Milestone Two [Member]",
        "terseLabel": "Milestone Two"
       }
      }
     },
     "localname": "MilestoneTwoMember",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_MilestonesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestones",
        "label": "Milestones [Axis]",
        "terseLabel": "Milestones [Axis]"
       }
      }
     },
     "localname": "MilestonesAxis",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "krys_MilestonesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestones [Domain]",
        "label": "Milestones [Domain]",
        "terseLabel": "Milestones [Domain]"
       }
      }
     },
     "localname": "MilestonesDomain",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_NonEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non employee stock option.",
        "label": "Non Employee Stock Option [Member]",
        "terseLabel": "Non-Employee Stock Option"
       }
      }
     },
     "localname": "NonEmployeeStockOptionMember",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_NumberOfMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Milestones",
        "label": "Number of Milestones",
        "terseLabel": "Number of milestones"
       }
      }
     },
     "localname": "NumberOfMilestones",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "krys_OfferingCostsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering Costs Incurred But Not Yet Paid",
        "label": "Offering Costs Incurred But Not Yet Paid",
        "terseLabel": "Unpaid offering costs"
       }
      }
     },
     "localname": "OfferingCostsIncurredButNotYetPaid",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_OtherContractualObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other contractual obligations.",
        "label": "Other Contractual Obligations [Member]",
        "terseLabel": "Other Contractual Obligations"
       }
      }
     },
     "localname": "OtherContractualObligationsMember",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_PaymentToEscrowForReducingLeaseRentals": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment to escrow for reducing lease rentals.",
        "label": "Payment To Escrow For Reducing Lease Rentals",
        "terseLabel": "Cash contribution"
       }
      }
     },
     "localname": "PaymentToEscrowForReducingLeaseRentals",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_PaymentsForSuitLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Suit Liability",
        "label": "Payments For Suit Liability",
        "negatedTerseLabel": "Repayment of ASTRA build to suit liability"
       }
      }
     },
     "localname": "PaymentsForSuitLiability",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_PeriphaGenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PeriphaGen",
        "label": "PeriphaGen [Member]",
        "terseLabel": "PeriphaGen"
       }
      }
     },
     "localname": "PeriphaGenMember",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_PlacementSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement Shares",
        "label": "Placement Shares [Member]",
        "terseLabel": "Placement Shares"
       }
      }
     },
     "localname": "PlacementSharesMember",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_PurchasePriceOfPotentialBuildingPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Price Of Potential Building Purchase",
        "label": "Purchase Price Of Potential Building Purchase",
        "terseLabel": "Purchase price of potential purchase"
       }
      }
     },
     "localname": "PurchasePriceOfPotentialBuildingPurchase",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_RemainingCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining commitment amount.",
        "label": "Remaining Commitment Amount",
        "terseLabel": "Estimated remaining commitment"
       }
      }
     },
     "localname": "RemainingCommitmentAmount",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_RisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks and uncertainties.",
        "label": "Risks And Uncertainties [Policy Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "krys_SaleOfStockAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Aggregate Offering Price",
        "label": "Sale Of Stock, Aggregate Offering Price",
        "terseLabel": "Sale of stock, aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockAggregateOfferingPrice",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_SaleOfStockRemainingAvailableIssuanceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Remaining Available Issuance Amount",
        "label": "Sale Of Stock, Remaining Available Issuance Amount",
        "terseLabel": "Sale of stock, remaining available issuance amount"
       }
      }
     },
     "localname": "SaleOfStockRemainingAvailableIssuanceAmount",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "krys_ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental condensed consolidated balance sheet information related to leases.",
        "label": "Schedule Of Supplemental Condensed Consolidated Balance Sheet Information Related To Leases [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Condensed Consolidated Balance Sheet Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCondensedConsolidatedBalanceSheetInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate",
        "verboseLabel": "Forfeiture rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "krys_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "verboseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "krys_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "krys_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "krys_StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock incentive plan.",
        "label": "Stock Incentive Plan [Member]",
        "terseLabel": "Stock Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlanMember",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_StockSaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement",
        "label": "Stock Sale Agreement [Member]",
        "terseLabel": "Stock Sale Agreement"
       }
      }
     },
     "localname": "StockSaleAgreementMember",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "krys_TwoThousandSixteenLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand sixteen lease agreement.",
        "label": "Two Thousand Sixteen Lease Agreement [Member]",
        "terseLabel": "2016 Lease Agreement"
       }
      }
     },
     "localname": "TwoThousandSixteenLeaseAgreementMember",
     "nsuri": "http://www.krystalbio.com/20220331",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r178",
      "r184",
      "r208",
      "r209",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r346",
      "r347",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r178",
      "r184",
      "r208",
      "r209",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r346",
      "r347",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r178",
      "r184",
      "r199",
      "r208",
      "r209",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r346",
      "r347",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r178",
      "r184",
      "r199",
      "r208",
      "r209",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r346",
      "r347",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r136",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32",
      "r303"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxes": {
     "auth_ref": [
      "r12",
      "r13",
      "r255",
      "r321",
      "r336"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due.  This amount is the total of current and noncurrent accrued income taxes.",
        "label": "Accrued Income Taxes",
        "terseLabel": "Accrued taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r34"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r29",
      "r154"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r42",
      "r43",
      "r44",
      "r338",
      "r352",
      "r353"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive expense"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r41",
      "r44",
      "r50",
      "r51",
      "r52",
      "r83",
      "r84",
      "r85",
      "r261",
      "r348",
      "r349",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Expense"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17",
      "r248",
      "r303"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r245",
      "r246",
      "r247",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Restricted stock surrendered for taxes"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r210",
      "r212",
      "r251",
      "r252"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r196",
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Offering expenses"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r212",
      "r241",
      "r250"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Common share equivalents outstanding, excluded from the calculation of diluted net loss per common share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r80",
      "r121",
      "r129",
      "r133",
      "r145",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r259",
      "r262",
      "r278",
      "r301",
      "r303",
      "r320",
      "r335"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r38",
      "r80",
      "r145",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r259",
      "r262",
      "r278",
      "r301",
      "r303"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": 3.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail_1": {
       "order": 1.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r141",
      "r147"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r138",
      "r142",
      "r147",
      "r324"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Aggregate Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r140",
      "r147"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r213",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r264",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r2",
      "r82",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Unpaid purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r25",
      "r72"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "krys_CashCashEquivalentsAndDebtSecuritiesAvailableForSale",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Aggregate Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r9",
      "r73",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r67",
      "r72",
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r67",
      "r279"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r36",
      "r163",
      "r326",
      "r342"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r165",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r83",
      "r84",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16",
      "r303"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock; $0.00001 par value; 80,000,000 shares authorized at \u00a0\u00a0 March\u00a031, 2022 (unaudited) and December\u00a031, 2021; 25,199,081 \u00a0\u00a0 shares issued and outstanding at March\u00a031, 2022 \u00a0\u00a0 (unaudited); and 25,207,985 shares issued and outstanding at December\u00a031, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r46",
      "r48",
      "r49",
      "r55",
      "r328",
      "r344"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r112",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Off-Balance Sheet Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress, gross"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-sale, Term",
        "terseLabel": "Debt securities, available-for-sale, term"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r70",
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r70",
      "r152"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r56",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r96",
      "r98",
      "r100",
      "r101",
      "r102",
      "r106",
      "r107",
      "r267",
      "r268",
      "r329",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share: basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r56",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r98",
      "r100",
      "r101",
      "r102",
      "r106",
      "r107",
      "r267",
      "r268",
      "r329",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share: diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "terseLabel": "Share-based payment arrangement, amount capitalized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Estimated weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r50",
      "r51",
      "r52",
      "r83",
      "r84",
      "r85",
      "r87",
      "r93",
      "r95",
      "r109",
      "r146",
      "r196",
      "r197",
      "r245",
      "r246",
      "r247",
      "r256",
      "r257",
      "r266",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r348",
      "r349",
      "r350",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EscrowDeposit": {
     "auth_ref": [
      "r325",
      "r361"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.",
        "label": "Escrow Deposit",
        "terseLabel": "Escrow deposit"
       }
      }
     },
     "localname": "EscrowDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense related to distribution, servicing and underwriting fees.",
        "label": "Expense Related to Distribution or Servicing and Underwriting Fees",
        "terseLabel": "Underwriting discounts and commissions"
       }
      }
     },
     "localname": "ExpenseRelatedToDistributionOrServicingAndUnderwritingFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Cash, Cash Equivalents and Available-for-Sale Securities"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r270",
      "r307",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r179",
      "r200",
      "r201",
      "r206",
      "r207",
      "r270",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r200",
      "r201",
      "r206",
      "r207",
      "r270",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r307",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r290",
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance lease, liability"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "terseLabel": "Gain related to litigation settlement"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r70",
      "r151",
      "r156"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Recognized impairment losses for long lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r150",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r157",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r53",
      "r120",
      "r287",
      "r288",
      "r331"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentCompanyCapitalShareTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company, Capital Share Transactions [Abstract]",
        "terseLabel": "Investment Company, Capital Share Transactions [Abstract]"
       }
      }
     },
     "localname": "InvestmentCompanyCapitalShareTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Operating Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Future minimum operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022 (remaining nine months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r80",
      "r130",
      "r145",
      "r167",
      "r168",
      "r169",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r260",
      "r262",
      "r263",
      "r278",
      "r301",
      "r302"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r80",
      "r145",
      "r278",
      "r303",
      "r323",
      "r340"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35",
      "r80",
      "r145",
      "r167",
      "r168",
      "r169",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r260",
      "r262",
      "r263",
      "r278",
      "r301",
      "r302",
      "r303"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r36",
      "r163",
      "r164"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 8.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Accrued litigation settlement"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail",
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Litigation settlement, amount awarded to other party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation settlement"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.krystalbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r67",
      "r68",
      "r71"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r45",
      "r47",
      "r52",
      "r54",
      "r71",
      "r80",
      "r86",
      "r88",
      "r89",
      "r90",
      "r91",
      "r94",
      "r95",
      "r99",
      "r121",
      "r128",
      "r131",
      "r132",
      "r134",
      "r145",
      "r167",
      "r168",
      "r169",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r268",
      "r278",
      "r327",
      "r343"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss per common share"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental Disclosures of Non-Cash Investing and Financing Activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other Income (Expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r121",
      "r128",
      "r131",
      "r132",
      "r134"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r293",
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liability",
        "totalLabel": "Total lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofFutureMinimumOperatingLeasePaymentsDetail",
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r297",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r296",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term, in years"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesScheduleofSupplementalCondensedConsolidatedBalanceSheetInformationRelatedtoLeasesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r40",
      "r42"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on available-for-sale securities and other",
        "verboseLabel": "Unrealized loss on investments and other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r34",
      "r303"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail": {
       "order": 7.0,
       "parentTag": "krys_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.",
        "label": "Other Noncash Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "OtherNoncashExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to settlement of restricted stock awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r59",
      "r61",
      "r139"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r213",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r15",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15",
      "r303"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock; $0.00001 par value; 20,000,000 shares authorized at \u00a0\u00a0 March\u00a031, 2022 (unaudited) and December\u00a031, 2021; 2,061,773 \u00a0\u00a0 shares issued, and no shares outstanding at March\u00a031, 2022 \u00a0\u00a0 (unaudited) and December\u00a031, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r23",
      "r24"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities": {
     "auth_ref": [
      "r65",
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.",
        "label": "Proceeds from Insurance Settlement, Operating Activities",
        "terseLabel": "Proceeds from insurance settlement, operating activities"
       }
      }
     },
     "localname": "ProceedsFromInsuranceSettlementOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial offering of shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Issuance of common stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale, Maturity and Collection of Short-term Investments",
        "terseLabel": "Proceeds from maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Project management service fee"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r29",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r28",
      "r153"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r155",
      "r303",
      "r333",
      "r341"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r27",
      "r155",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r10",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives of assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r254",
      "r317",
      "r366"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "auth_ref": [
      "r30",
      "r148",
      "r149",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.",
        "label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r197",
      "r248",
      "r303",
      "r339",
      "r351",
      "r353"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.krystalbio.com/role/OrganizationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r83",
      "r84",
      "r85",
      "r87",
      "r93",
      "r95",
      "r146",
      "r245",
      "r246",
      "r247",
      "r256",
      "r257",
      "r266",
      "r348",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r295",
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Initial recognition of right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Sale of stock, consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of shares issued in transaction"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses And Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCapitalizationEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Capitalization, Equity [Line Items]",
        "terseLabel": "Schedule of Capitalization, Equity [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfCapitalizationEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCapitalizationEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the equity component of the capitalization of the entity. The table may be detailed by subsidiary (legal entity) (if applicable) and include information by component of equity as may be included in the Statement of Changes in Shareholders' Equity.",
        "label": "Schedule of Capitalization, Equity [Table]",
        "terseLabel": "Schedule of Capitalization, Equity [Table]"
       }
      }
     },
     "localname": "ScheduleOfCapitalizationEquityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r212",
      "r240",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r212",
      "r240",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock Based Compensation Expense Related to Issuance of Stock Option Awards and Restricted Stock Awards"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r29",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesofAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r213",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r218",
      "r230",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Company's Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Fair Value of Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment and Geographical Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Stock option vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock award granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Restricted stock award outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares remaining available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted- average Remaining Contractual Life (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Cancelled or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled or forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value per share of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r220",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r211",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail",
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysRestrictedStockActivityDetails",
      "http://www.krystalbio.com/role/StockBasedCompensationSummaryofStockBasedCompensationExpenseRelatedtoIssuanceofStockOptionAwardsandRestrictedStockAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r213",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Stock option expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r236",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term of the award (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationFairValueofStockOptionsValuationAssumptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable at March 31, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life (Years), exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedTerseLabel": "Restricted stock surrendered for taxes (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term Marketable Securities"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r78",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r37",
      "r50",
      "r51",
      "r52",
      "r83",
      "r84",
      "r85",
      "r87",
      "r93",
      "r95",
      "r109",
      "r146",
      "r196",
      "r197",
      "r245",
      "r246",
      "r247",
      "r256",
      "r257",
      "r266",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r348",
      "r349",
      "r350",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r109",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net, (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r196",
      "r197",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/StockBasedCompensationScheduleofCompanysStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r196",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r20",
      "r21",
      "r80",
      "r137",
      "r145",
      "r278",
      "r303"
     ],
     "calculation": {
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r79",
      "r183",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Capitalization"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/Capitalization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r286",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r286",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r286",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r286",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r304",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail",
      "http://www.krystalbio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplyCommitmentArrangementMember": {
     "auth_ref": [
      "r14",
      "r322",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Supply Commitment Arrangement [Domain]",
        "terseLabel": "Supply Commitment Arrangement"
       }
      }
     },
     "localname": "SupplyCommitmentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplyCommitmentAxis": {
     "auth_ref": [
      "r14",
      "r322",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer.",
        "label": "Supply Commitment [Axis]",
        "terseLabel": "Supply Commitment"
       }
      }
     },
     "localname": "SupplyCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CapitalizationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r81",
      "r200",
      "r207",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. government agency securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/FairValueInstrumentsSummaryofCashCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r110",
      "r111",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r294",
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r97",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding: diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r96",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding: basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.krystalbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.krystalbio.com/role/NetLossPerShareAttributabletoCommonStockholdersScheduleofBasicandDilutedNetLossPerShareandPerUnitDetail"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e15243-108350"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(d)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r367": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r368": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r369": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r371": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r372": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3337-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080549-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>59
<FILENAME>0001711279-22-000016-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001711279-22-000016-xbrl.zip
M4$L#!!0    ( ,^ J53_*RFXH6D! $6B#@ 1    :W)Y<RTR,#(R,#,S,2YH
M=&WLO6M7&\F2+OS]_ J]S+PSW6M1..\7W,U9M,'>]%BB#;(]XHM77I&P+FQ)
MV,"O/Y$EB3NVL"6DDLLSFY9455F9&1%/7#(R\H__>]YI5[Z$_J#5Z_ZYAC?0
M6N7_;OWQ_V79__YU\+:RTW-GG= =5E[U@QD&7_G:&C8K'WT8?*[$?J]3^=CK
M?VY],5F6/_.J=WK1;QTWAQ6""+ESL;]))!/,*989C$W&O'*9,39DSBMBHW?(
M*+-^O.FDB8AYE%D;0\9T1)GRWF=<*4$C088YLNXWL<<J$F<4T881AJRA@FJC
MC44L&NW2:YM#&!V,L#O8/+?]=NO/M>9P>+KYXL77KU\WTB\;O?[Q"X(0?='J
M#H:FZ\+:Y/[![;N_TLF]^,7_5M\>NF;HF.SN4V?#_J/OT"_@ZOC&AYK&6NL7
MYZG+D]9:@QXC6'ZKUZ,[)@]\[E_<;CK],#1MV^IMN%[G12(+HA1?O>!\^'#C
MK6Z[U0V)!UX,^Z8[B+U^QPR!1U(3*$,DPV3MQLSZZ\FZV4'Q8G3QZE9H]?/C
M8T]7KV9RD!T;<WIU<S0#F]\ZOI Z@C.$L^O1^'"G%X/@-HY[7U[ A?SV?[/)
MK8/^\'[+\.,#K=[K\FT*I,O6#,+UE#YV,Z8WIO4&!3+HYJUG)MW^%A$PSY":
M]'*S;;K'?ZZ%;O;^< VX/AB_]4<G#$TEM9J%?Y^UOORY]JK7'8(L9_6+4^BM
M&WW[<VT8SH<O<JY[L?5__L__^6/8&K;#5F*<;,(N?[P8_?C'BU'3MN<OMO[P
MK2^5P?"B'?Y<\ZW!:=M<;'9[W0 =:)UOIAM#?_2QY7WHYA_A>@T I=]RH_>?
M#P]"_'.M9:05""0=!RN8UDI[YW0(/D0/W,W$IYV\*Q@(<\W"7=-)KPZMS6W
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M>X1XG,Z31Z#7O?[FY)T1^#:+IM-J7VS^=QT$<E"IA:^5@U['=/][?6"Z@VP
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MYA%E(4;I/+:>6K2V]4]K.!S8L_YQ<W$(D!L2^_U_P!,#@V%%';6?HN;Y)V$
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M<%C8 D#)5,5D*J<Y:$CCLQ"<R0#J%-B[0F?<. &L(8WV:&U+E:NZ\UK5G9L
MELMO2RU\#(2/X\B)$SX3'.2.(0N([CC-N*7<1R5IM*/Z(%CK=:0>,B\*)5:W
MEMM&E4U7."[]\D?6$^=FY#VZ[E-BPM)@ JW6W\&[]G"M?OQU?V>;?**!!$ )
MD^E@9<:4CID*-&2<:R*5\B:DS-)EX;%2Y12,O01+KBTRF63@TJ;3ZC.%4<@,
M9LI$+)0V*E= X%VL:W7_L,1'K;_',?XG5^I^U2K[,UK"NR&SY6K"3.7TSOJ=
M9)IH$F7&DZ/. LB7 8\J,QI\*L6]$#[^X&I">3Y&H21W1DN!I>3.2W+OK ,Z
M%80@(*_(>PR2JVUFJ2+PU49!K5&*_.C*>WD<QE./PX ^IVDU[<JI:7GP]RK.
MG+:&IEW6;)S5T1=74_P/S/!>]]5H?LN"+;/#F/MG9U% %.:-R+ 5*F-$^$Q%
MP3.!. [&.XDP6=N2#*WS!V*N97;/:JCT4O2>0_3NGF1!I.6&@,]+2031PSH=
MH(DS&JAE6D?CHP71HVR=DX+7:%Q^]>[<6>>LG9(>)H=<]3JG_= ,W4'K2YB<
M@O6+G:/YV[-8 0,8)WQZX-B="4GR\W9>W23(7A?H$][V!H-:&.['NCDOL6IV
M6'7_("P=G>;&\RQP+#/&%<X4$#93N8U "&,Z/Y<//W#HSKV28F7TH) "_L.V
MQJP$O)3AI\GP'7L#BX 54BK3!-F,I2WS"A.2:D,[[+DV0:-T<M9]6V,A$KR2
M480;9H8/L>5:P]4,'RS4<C@(0P,]\KNFWX5Y&]R8]9W1I)?&PNR YOB>L< Y
M$E$QGYEHTQ%]AF;&HI!91I32..A@!0"-1NN2W:\"^QC8E.&$ NKX4A2?613O
MG@+A#9(HFHP(KS-&',TT-CH+",00^^@ICB"*#$11L6<5Q5_P"(C!4RI^EH7A
MGV/-X681UMV<("4>S0Z/[A\^Z0P'ZAB>$1EHQB2AF25"9C9*&P2-6KFPML69
M6N?\/AXM:8'X\DR((JYYE*(_9]&_N)N'9)CQTF1 \0"FB *O@$B2">10H%8Y
M$Q&(OJ;K7,[]$,K%G U1)&/EQGE5>?+D-,;+A!RC61_-U":%<?O>F6V'JYG_
M.?3ZYF;Q14S8?\Y_'E8'O6=_B-=VUY=8/D<LOWSH?$_,# TAHR*0C)G@,R-H
MR$@(X&-*J2+F:UL"BW4EGVK&S4QHGB=(5&)>B7G/?XI9B7GSQ[R[57D"J"IA
M6>8Q%QG3+&9:6)5I:QDGT09%+6 >$>M$W]^?LN28E]NQ+X8&7OK #L>.Z1^W
MNOGKR6U<<@'XO/_RYA9(BN>[!3)O<3.EI[7<M^64Y-9L,U2,2]D\IGN1=OYT
M>\-DTO;AYVZE!=T_[N=)O?UAI1<KPV88A,K5WLDDR#YE_N2?\GG/%^]BJVNZ
MKI4']>"'_-2HC4=WB(X[Q,C(\C_M#?)LN\U^:)MAZTMX^;7EA\T)L-QX<,P1
MZ/H18Z$39\/''[E!*[QX8GV3-/3.7JL;?]. <I3"'JM( #J)-HPP9 T55!MM
M+&+1:/<)Z[7)0\W^M;(^#IGM!_,Y,Q'&O&G:7\W%8.W%[:F">;I#FB?-ZD-S
MN/6'[;_8>FA@=W<,WZ3)W D@'R3 __0O!LG7^ZL%,N&:ZY6]KGN<BY>EUZ^N
M1/+539$\O!+$),?CT\?AAMQ[O95;4DEI)4L_S!L;N!_MZT^QY?UVQG"3-W6C
M:?X0C$##N;JXH\-@=MKF=! V)Q]>^M;@M&TN-EO=?(SY0R]OOS"]X&[X([UO
M='DLE$)N*"J27([C+>,7CT5V(Q?9.XIU=(WC#2(?OXPV\*/7OM4L(1M8\A]J
M]MO7E)3SZ:R:MMD'_)\)&<&H"<MQYX^?*3=6A,OD3CQL'UX-2R_]L.Z!V"B6
MV.R'4*G"?<U!91> R>= E)?7J%"\/L6!AXMBD@6ZW _/Y6][73!/>V?0AA^L
M5\*Y"\D7:(Y,65\!C3?^!@K13'.0[U/<BB5GM%L56GYRQ-.<?KE2,X?G+H8+
M$.V9UZ%=!'%V1_M.!M.P]D\M@BWZU-A9=7(%V#3F_WYF']5"+9F#, BY>D\Z
MR8<OH=T[36[9U&NW#XR_X#'QJ8:X,N%N(ZU 3$<<K&!:*^V=TR'X$#W!DHE/
M._D2'T8XFVZM;\)1VUV_<\U/8V@L1M![_W <].Z\IXW+9NNH_HX>O:GB_?I!
MLU;?@W:V6;6^AZN=@\^UG?9)M5[%5T'ODW<71R?'N'9Y!.__NWET\NZR1@Y:
M^V]JG_=W7G\^2H'RRP^=ZDZ5W@UZUW;^[NSOO*>USE&SVGG=J<$]1V_V6(.\
M8]6/!^W&QUU:^]CX6KWT\2K@?8@NJCN?:>WK)^0CX8R1C-A4<UC2E-,MTQ&>
M#*D@N0S8KVWI=8I_.EGK&Z@WKWRL.Z]\;&6O!*@5 RBJ3#K62 @J*"-*6QD%
MLA(3Y##V1.8 A2< A4N 6AZ NKP#4()YI1@1F4."9 RT3*:U]YER1$0>4>2I
M1(Y8)P^41%\V@%H!T_7G2P L%$/>A&Y(BX')<C6^T^JV!L-^OD+WBVW\7Z2U
M-R8"8.GV+1*4<#IC.*V]NF?O^4 I$UQEFA&?,4)B9ATF69"42"HC<BKMW./K
M&JDE*CA6;O9?=@NI%.KG$^J[-A*S.L:@4(;3(6+ &ZFVKC691QP3Q2RUR492
MZYB3I9?I%;"1"A[>>]L:MH[SS(K*( R'[?!0;&\J))W6C2XTDL[</+J>_\.K
MZ2]1=-8H>GC#-#K9Q=6OG[AC408<,V(CSAA.U5.H!%!ES(*&!"9&+J]0CIY:
M)[$(L;!2H.=F&DTMT$M86;D@LGQY4Y9K[SX)L(:"4R8C@:F,,2TR*ZW,7"ID
M9E'0T?[H :MEW&@QM1T6"A^C'9.]4<II]WA2+?+Q5?MRA_>SVDS[$\I,TBE*
M2VDNEM+(WS38H0":,5,2VW3:+<^,(2+C3DHL&,98@*7$T3HALW(XRQ(/*P4
M,[>Q2@!X'O-J! "<AZB(8!GQ F4L*I8IZVE&4^PI/],BTE1T:IWR)]:U7C8
M6 '3ZQOF:1%,K[25IQ+[O<[$_.IU?\SL*J[S^I0"?S,PK1ZI]'<%L=>5>TN0
MG1G(MNXOU46B#(\"\#6!K!8J,SJ=\A6PP%Q)PC1_U,J:OJ!O&8I:8FF>@9U4
M2O-"I/FNR1085IKJ%$Y.A_0)*4":+;A07N.@.,;<^T=-IB62YA4PB JX2R0O
MGU\9B6KEM[&/,]4&L'ENZ7CF-E: ]0J^-+R7]K:%P7!TV&[.DZV<)]<KW5"N
M$<\_WOFY?S'8G%!A! =C,-CNCL[8J/6Z5V'J6AB6:OL):GO_?KZ<PM1&1%BF
MJ'7I2 WXY /+*)%$B(@$H2(M"M\_%&?9%I%*,WSQT<I2?.<LOG>M;N6HYR&0
M#.L8DM6-,QN(SB)/M=J0,%;2M2WZTT'*TNQ>^:T#5[;/KWE2X")7=R=37R;-
MS'"K5?UFT=<]5MLY_B29=5*C"&31-F-$ZTP9[N&/XLKB*"55RW@<>;D[8 GC
MCD\0X3+4^)-R?'%;CJUV'AE&,Q:1S!B6")P6:3,"IE 45BCGTCF ZTS_S,)!
MN17@1^,]2VWG@-=1:=\LGSBE[?OH OVOL(U^RL&OCH*8WS(S\%^Y)#5O>^_J
MP):@ PZ905*DO?7@'2LN_A][7][41I+T_544Q!OQS$2HV*KJZJ,\&XY@C#W+
M/ /,V'CFL?]QU F-A<3JL V?_LVLZI9:!QAL,!+TQ@X&J8\Z,K-^>1/&3$8E
MDRP1=NNYD%V9+=>[OK5/ZF8\LD%&K^^0>)O-_/?GE6Z9_P> Q(KY%4VM5"DQ
MN>=$4)83E6I*6 I2(>>2"\Y")GC![B"\Y"&8_Q'@QPU/FWC;'SH8QJ6S 5)V
M0*RH3ZKL885H LQ-1@KK2SLS&<[Z4 6_XA.SKJT'] H>B+E"ZE$8S[;Q/X,>
M+NUOJNRCA#[LOYGNW<ZP',%7N_!G__A/6(:!!6E^Z(_4EU:0WYT@?[F$X@I/
M+4NT)@ZQF\@TX#EA4I)SPY/4I9XRC=H^36[>_[<UUVV42+C',,%[$PDMU]^.
MZQ?@FY4N<4P ?#/2 'R3"< WGA&?('C+7<*H"PU8UI?C'P$^V_#<BOFF*7=J
M]7OJAK_6]O<- '3%0=-BR+L_3?:6,*3VFC/'%7'.8<()MZ2@'#!DQA17-M',
MB)!K(J6\1V/ FAD#6^'7"K\?![5;X?>CA-\"E$X4-R;E.?&@(A.A8>N*@A=
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M[846H!$Z[QP13C.BF,R(L$8Q8YT2.;;Y$;2;4MI*ME:R/1+)=AM+6)&;0A>
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M6\]%0KM9>MN>-@\KVK[BT;3EZ+RG+G Z[GIIV%ZYF5>V!/#$KVP)X(E?V1+
M$[^R)8 G?F5+ $_\RI8 GOB5+0$\\2M; GCB5[8$\,2O# 3PK['2/0?_VO+3
M\W_#C_J.,S4\+OO1$,GGG1'&]<=N&#\I^Q;^>I:P[33X1.[4',]H;8\/3WR&
M%01+<[V%GJ.%_NC$=93!TN6J?U'VCSO]P1BS'X;P,996&[OCH>IUSM5PC+W(
MQB=NY#J3OIK8<AQJGN.L8O7S?C#!*OS8EWW5-R7<.!K#!Z$VV_;4RKNX@-6
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MWG-?.I_*X00@X 5L#P/R_<^;OPE#\OWL.EB&9^PZGYP9#X:C^%!0D4M3PNN
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MW'@ASBD"T,A/ZI,J>T$%0G(#>3=",.'.@X,M0/S9!H#>[0/^[O4V3UULDF1
MS_H4-)) />7HXZCN=(^*5;BJLG#@].<U2I@,6CUP->HBJAT]&:/S;FI^J=;-
MP]H&XO&K^!"-"4WK0],:41D@NDLJ/3P*Q^?&$;\O/71*&],1A^?5Z@32K[ZH
M'X$*67<J<TR@@8_N @LAC08@.GM=? 4\J98H35/3;$F"TG&.MBAX1"#:8U"
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MYV@8BL?.52*,SL6ZEN5%/.JB0Q<NQ3^F"N%J)IH)SL!/<4AM?-A=DS*CCRI
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MMS&,[9?F6@6NZC*X^-@J:F9:>1TK>P8,HK[@@/ZI8MQ0ED[K#%:!,%6AZ]K
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M_.[H+3VX/"D/=G<N]W][=?)^UUSN<WCWT1Z\?R_9/_W='QZ]%1]$"L23&!#
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M&UL<UV&Q5T3QUX445+K]Z+K]*[6-?#R=OIS2:6.#P=H2)(P&G4Y$@CH'@83
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M)NI*Z@KDUDL32=Z125S)!&K'K792AB124!0T4.B%SQ)7FOBT@?I2$Z767K!
M$672(9ZH00YCBJRG =2,&&O Z^:JSNEZ:^(O<!;B\^:GS=I1!T;4/HWM?LT>
MQ;:_J/7&JE(=CK@!LYBS042% TF.,ZF-"E:SB)V.\)^H#D>L/7;M?9HY'.&9
MQSH"=#GJ<B*U#TA;*A"GSFB'%;4, XE0=4FK;.I*MQ]I$Z!**%B%KD\?FN!4
M!<V]0R0JB;C3>9=.!R2$,5S89&P,+S6?X,4K^S*;#4^M[=5FPSVT>OKH!(45
MC%$[Q#C/)4Q\ K_#611!+KAV) H,%ES2ZNS$L]'E-5#E*I#P"*H\?7;".^5)
M!-W5@3($RBN18TX@S;P "\T3RPF\0,;!8E?V^7GI='5VXCFLTC)IUA:@UF)P
MD;WCQ'A'@[,V,9M2$I16(=QU1MZ9LQ-<&NRBY. 1$8>X4 89GAQ*Q G&1+ )
MRXTMBNN25&<G7JY22\\D-]0RIQC'QECKP0!K(R0Q7(N%VZ552OTD2CUU@(([
M; WV'+F@+>*@PL"L@D!1,Z:T)TYAM;%%9-UP]L*4NNJ!4GWS";]9B5_US4K\
MJF_^FM]\.8<7EVGT]()J!2_A,02OC.;)2@=$DX4(5%,ZKZ(7'KAF3%56Q+I[
M#KME$/9:1I<BSE@6+&(QEU(P6B)+L$52:EA:1J7@A>= ZLPL>9CJ*4I)+^/W
M5VK\@&I<G8)\&/6=2LA,0C#!@D$V.(*XSM5>C4F($$9%4"E2E=5WV8RF2G/7
M,9OAJ56WRF:XC^HVIBRO)S$*QB+B+L6<D.A B95!SBD%*NPXYP)45\]:W1OS
M&2JU_84,;A5I?Q2MG3*XPC,PM5Z@(+P$@ZLU*&S@R"IIDY'1D21+ODR7SB.N
MU'>M<A2JY5A'-'5)Z8BU-,9PQ8F-/$I'8PJY);$W%9JN,YI>12#>G^_M>W;(
MJ>->>HRD-0IQ^!?9?*H,+"71QGI)J=_8,K*N115]> 'JRY)PF&%.J)#<".&B
MICH UXU..B-DI;[KK;Z[U]77>5A'RP/R5#G$*7@SX+E0)+$*4G!#&.,;6Y+7
MF7JN9.@7."FZ/V_CXV?/-UR@<MRO&"Q$Z Q (6NCX?X4Q]9M&O[K8:?@I4"X
M,=[0*+W5DO$4E*%"68FQ92*Q1,G/(/Q;]Z)7- 2>[@;<#E.!J"F,O[8U5 '[
MZH#]_<RND)%)$JX9DB3O"E&BD5:!(N]SX2C)M4QB8TM@6I=LQ=V"%].F)TXC
MK<"Q L<' <=J=^U)87 JV!>5LBXXAI*F$7&"/7+!4Q0$98II;"75=]A=JQ"P
M0L#GA8#+[%(^-016NY3W@<#I74II8;4\=B@P80$"E42&<XLH<89C>,F*_8YE
M=BDK^*O@[WG!WW/PCBN'>*4P.,4$=3))T$ 09AA@4+* #/86*2>8-BDDJV3I
M$'.I*CI8X6&%AR4>4J>=]MIS*1,GS!@3L0&$](0J(N-/RW94>+@6>+@W10NY
M3UYZF9#+U7AY\@)I)Q0B-"I+K8D2AXTMQDF=\BI 6.%AA8>C<_<L"DPT84PE
M'F*P B=M2?1"JA"8JO#P6>#A3"*+=T+($!WR/F@@B,8BJWA" 3MCD^8R^GC'
M1)8*#RL\?+%XF"1.-.9\=X*Y-MYI981ADA(GHG:^PL-G@H?3F4%2).]E3@6B
M*1],XL@1KY !UF^P<HI+?,?,H&>/AT5*T7_Z61CA_Z'Y?>N_X9_1M4YM]ZC9
M+C.?**C;\!(H ]PK:C:I& %?LQU U%\AHHMKKU31"?Z9IM-B8X",P[R/?_OK
M4R,W&<_SL'\<:Z\[IS":BR+-6_W1J_6..]T^ZL?N:0VF]ULLYGZB%#Z\VQ]T
M8ZW9K@VQJS$XA2'Y*; *SLL0@O6.<QV,#1(3+ G(L.&&T0*L*&89K*YO9MR.
M1?LPL&MX!//A7X5!]QQ$NA?;SQ.$6O'_?;PX^!+.'/B NSOPO9/&R<&7@R:,
MZ;3Q;I=_I7\='\"8#KXTOGT]_8IWO_P#(/-GVCWQ%X<Q8<6M$<AAYA'G1".8
M;XIX-"QPD8SS;F.KTXZUBVB[(P@9+MM6K=.MM6*OMSD&D6DU6V^UHNNL5O^W
M5VMUX/.?ZY.+_?,8;U<J;;5E2@>MK.=*)6OR(1K%F201)V8KI5J-4EW^0PY-
M4D$HG1"3$;P4HP327CFDJ(DA21J3NDVI;#O<NI0^<)Z$<I9IRYU+CB8J8A):
M>IHDY]52KF@I/U\<6J>4(,DB2;1!W!&!C),!7ED@TB$1+=G&5O^\4RQE;WHM
MIX!QZM/;^,@D1C*R*9X,)#_%6&MT^K%&:_U.K7\<>Q$\#3L(S7[,+"T/L5>^
M*M+'<ZY +37;MNV;M@6CA3=R9YQ>EJQ:QKQ,/N&3T.SY0:^7/9=N/++=#(;Y
M^C.T(MEFMP8.QR#63J/M >(5UYLSMUE-FNV!+>CMY.P.GXC3394-T%FG5XSB
M53>VX,O?XQ_GS= _'OE5$S\<TEQ\]1/KX#$'_9M_,G<E2Y+K8=RQNSYK2^C4
M'$[\FY^HT'<2B$[46TV-Y93GEK.2&6NLPQS,B#_D;&/TH^/NE>$_BLAUH_V&
M;(*'?F5;Y_:BM_&?ZW,%$S6U-DM-Z[Q)W/IOUX6[S'FP&Z[V& 1$S9U_L5GZ
M8+/_WH;_5CF)N4DD.LF-T29X;V(,,050&"X/=PK\)YB@FPS!I\'96:M0(]OZ
MT[9 5^.GXQC[.Z"3K4Y6L=X^W._/5L=_>VK8OQC#_D7C<O<2KD\;[][PO1WX
M_\Z_Q[L[QZ<'[\!WIA]/#O;_/&[L[+)9V'_/=B\;\-E7#/?D^?_@6Y_OO3OX
M=O#N,SMXUVCMOH-Q7 : _:/S0TR<D,811$I:[#"R5@CDO?*$66:YMF6(!> F
MANUL+P4.VF#0"N,3#UZ8E)1,C AB+2B.W*C%GK=GL K][B!N; WGO59,? %Z
MP @ UV:LQ#5)GD*Y<FU^>NNGD?WBBJ^:(&--OX V?.AVSF*W?U$0H!QD.LL"
M6H<;]F?FX %U8S2,#[ \_>UV&(_D%]:('X?>..YR1Q!'I,CN84#6!X)\ &9+
M4BZ&RZ<E_ :AD^M$;ZX)7;P2NC;H9*8TS5Z_UDD%+TF=5JMSGEG*;\TVO-,9
MP(U#[_=7-WJ_PX<>DHC";$W,@YA'#F :AF[>M1-Z,!TM>]:+KT8O_A@5"FRV
MBX<J?O3']1OF&TR%V8K[E1\/+:TAFTSQ;&R'Q^^&-Q[:X<W"#D\%!\O/I-H4
M_.:/\2:Y\;/;+DO8IM)WN^SMGTG\ @=[]]J00S+Z*!L:/U?&8<&(>1'I9_18
M,X:M>*Q=V_7'-4;J!3/-=F>)1[SQE/MSG8V=Z..IB]W)"2%WG9!G*O[S9V9A
M\;_QV/:<_9<U?^;?/H]B"3.9[/=3BA<T1TO#XCV/UJ>$DU_V:#U,]!-9C==
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MBED%FU2!*64KU^CG][\^7A=2TDY@S3SA2AL3 Q4N)DLX(0R[&PM\KU4)^D^
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M.!R$(1M;7,W-@*CU_F< LI(+D?4+D04I:@U"EBB0HD*TN[X)8E;,<,V_V_T
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M%X,:\DO_]W/[4]M[U^NYZJD=3-#?5N 'H17C-LBKK7<[VVB<5()9AWCY2"O
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MK)?#\Z$[-_,*7)364J(3:7"M0S\3ADD69DQDDJ4T3$#R12@RO1&=%1"=_9^
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MR-(@Y2P(S%9IU8*)OHU*0DA!$Q$%H6T?%8/N5<J/M"\-*F*3;GD:=,8%+,(
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MP/A&IEE"C*$A88'T26JX(HF)#&<B,SR,MM[05A!.Y_*_+(Q=4;]AG"9B,58
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M?3A6A\4A="*7R=HD:)+4QVT; %T.0*>R\7WNFS +2!1(0YC)0B)\94B6,!.
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M=S&$5P[.5M0:KE-K[3GZ=!NV-6A<YMC^O;X^YWD74POX)<\[]D ?4QUL\RE
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M86EXX1+_2LM2F&J8M[*$KP':_JJMP1IXE[33.^*=;6(Q#GE+PLX-C7,*V]4
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M$70A3Z2\QPSN:$F0T7.[])2)X46"@M*6R=ZEA6!C^Z<@"\*DFKS&9,?V<.)
M+VS>Q9<9W,"180HZ!C2,@'KU36NG+P;4)$C^$/;:]L+*<EK?-%H4AE\=C>"5
M,\Z.3P3:'C3-*6*NP^$"=WDR1^I[<[!EC.U2]P4]VUP;]\NKO:)9)1L&^30F
M*AYILQ6(XHHW"Q]^\ 5S>,;+V^-E4T$LGCQPYEA&*8$U976>+L&+MBUH_E#=
M,V  9V1\1S(:)9%:#4BKCH/-,2UCE(P*J@@:V(_PMV6%G9_QLQGYWM47?A+<
M"6;WN(C-0U%]HNYH8JJ'-)+H#5W8S@.6HJ>SNHV[<2+%TZNK^&A&CZJ 5)[7
MLCK'I<7=RV,->:OC629MI!Y+;.-1]=RJ.%*YE9Z<U$/6'(U(Q%MF-BDJ;2SK
MOL,_<6>1]^0*'_R[B9Z)H$,DXMFA["&_8>B-^AA1D*:'JFC%H3@.)@SZ.L?,
M%BD7X061Q7!MMISE 1("^Y%E4#7L<0$K Y1&3VEW_H[=A\T%V-9JLZ[ %[$I
ML7*Y>:Q?5><9+W5G.:3J#'/6$[V*,ZM(]7 BR\!YQ@X=-DF,T02!%(-S[+GT
M1H\1%4?+5YO%D_4=:FNE, TL07V$BO'BM>=3,.=PA%4/FS$H7D#F.[GV=B";
M=<F'"YD%=X<VVT^SD)"J?.$C,Y^YH2]Z(YN^J>9>$"<DGW1L8:KYPJR*AU,>
M+%8])M?H([6!+%-JC<$3D6H!VVEH$5R;W>-;:K2D(+>)D8U=/93(Q F?M"G,
M?JO2;N ,,WP?:?9XL7=2-HZ$"LW#*!K:)K(+"O-&&&*CXE/BV2?<YI-:=U\$
M#NLZWB7?!CI@/![J\C/T(3YEC'QL/,MLC] C,QP7;DN _4-*M8*M[J'TD /Z
M7#CZ!46+FY371%K!*Y+X\=VH)B-YFO&3).$&G/((\FS]F:)[U1/1E@7%>,;W
MLH?@W Z&ZUHD>Y/JQ'[3@8>]VQ3.(Q8(9F,<6_8/;FNF>W2X#EKW2P!''5&2
M@R?G!,=K%03'L!(X\0M;ER]6R64:^4M7:1*(3^H?G^&V3N 2?W)<V@A]28UA
MDAEI?$%LXB^]C_\L4Z_U8KY\6L'LJX2!D"^6B=D\)69CXXOY;[73?+62_.="
MOICXMU6/+9;SIV>O>^SJO]4*![C8%P \5N ;RD*#?9J:_0+"87WOM[4<QK-#
MTSNN/)KOT RG=UCE8FX-.,?7 +=L@HVY 8;OGA\T]ENO@X^YSH[7/SDI;1<?
M=5@G6]P5J]8/D56/P,2?];%_:!T\WUTB((^=?G\D=HC71/;5+."YE<;$$YW^
M_17PK4.#V%BVQ3V'RBA6<Y7Z!E 9>P:AEC%<VABNGJM5*ZGEM]=;_/LOW7GH
MVFKIWEL$E4PA=N11M9JK%\Z2N'![S+8!5F<:C_6T<KHG9_I;F6>8O7'0L3V2
M5_D8*R[#H34;7>=#PH@]JE8R"-_])4^Q4LF5"YO"M^\9F0[,(M (*D<*\>.8
M2J_,E$*,0JM0\S:*Q*3<.G^[<]CO:WMT6LS5*\D^XYN=P_O87AD;_YYL7"R7
MP0DHK]8^:>+E0X'_#,?\-18-U[2DL]>*G6XZ8IYP8XK5?#4R%#X&#A-B?='
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MO;#EC*G[6ZDT%T[,PRGD6(EK]V0MIL(%4ZV]$] ^/-G;&+R$U=82Q>./6LF
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M/78F:[5\U> A]H1--B+)4=L:BU1+E1B-(W!N]BCP0K!,\#M*(1 UVG,)O&0
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MS(TAH.+IY\! >\BQ6)-0,H(-&QY]"RMR)9;VLF?(F%,_)$W/),U$DT8%GH[
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MN(DFA$!ES )D;[OK(:Z"ZQG1E(T8C:\ ZH-^6) AM=^*LCO27G##EGF\.78
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M@#\U>JFS.\R:"55\?O<W4$L#!!0    ( ,^ J52$E746/Q<  !;?   5
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M%R;< >I S6%[9K123#.FK!A?< ZYUYEX:@,HH0NXH@5DYV-*@GN?^WC-;UG
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M^&_,_S,9U:X7?P_#<87YZ_AR<>+)=#BCCY[3R_'[WW ZG.0+N6! Y$(H\"0
M4)E&X\EK0XB).T/C<:53,M!I1(?D?7L1\B#8T'Z2]B)1\B&KF#3%DKPNS*+G
MY)D"I_O,!:%TY$GVJ5?\1H:Z39W,#$E$=3'Z.7[$T62Q2W[I-8L7VI#;I-%E
M2B]E*21N9H&B):<M9SGE/MN3[X1U2"9]-VY\71S32AO-R/]W'-,(1X3H23X9
MCH>S>1WOQV6,/8@Q:L4%Y58Z1P(E)056R$'DC(4C\\[VB6._ >R0S&Q;DK34
M2,,UV_GP_4(6;W$^'^%5WAIA=<I<$@*50=41AT3NQ!DFH^/%L=QKB_.MH YI
MY:$M/5IIXK[7&&IMU(O1Y%.?Y83+7]_3RL$MPVFT2$ !4KW ;]/)QR']VM,O
MOQ.4E^,+9CU)9"'.-D-2%N"L,@62DY15BQ# (:>(2N>@68A&\3X&>WV,;?-0
MY[W365$61!$B*&\3>(P1O)$R6F$]I47_67EH)[;<G99NHH9F;NDY4@J2AF>"
M)H=Y,IG.A_]>O!QH%UUBQD%.#FO!!^4V6L;:*"R)X+A-ID]P>P>H0XI:]L22
M5BIJM__R.$SQ:5C8\I/J-\^P"!FX"RQ#J 7IRF)=G]<!C+/<JFP2BWW*I%?C
M.:0 9D],::"8MO-=M:U&K>"^F&..)3AKZGHIC<T6 \%'#<9&5D1F6$P?S[H"
MS"'M/]H3/7952<.EGC2MU6//\>S_E^/S4MOGY_MO5Y;<#ERA\%PI#\P*PLI8
MA(#TC&#&Z'P**O0Q,-OAW7"/4O>%HWU0; ^:;;4(?1/H]7K&@8O2J\(2\$B<
MH$PP @$1H&-0PB5-X[E1073KPO/=5UJ')N;/88C:2[ZC2;I1GSA0A3N!Y$43
M<X%"+9'!<5\;@B,/6+3$FX3H9GUN0%N'0?;/P: ^ZNK+HAOEK$O3=UE(?:41
M$U>8N+<$,U=WG)6#*+6!%"1+*6:A+>Z/9!L@7X>#[C^ @[V4W38N7R&*Y?3;
MQ93<(&,(TL7:*K&VO_"<X"6&8 ,7GJ,6.?3AXMH0UR&=_W.1KH_Z.AK BZ3C
MK(K_/. SS#+$JOTZ9:%R%. EH_@OH51"<69"GQ6/-0&N-1G)_O3!^^[*ZQ.M
M+PTMO@^CRT4<,K8UWY@DG,U6+Q0/I'8\>LU )@H(E";4CF=&-X500KK,DERW
MG+0-HK6(]B>9]KX_5;:LQ5\EH1?#<1BGZQ)**C..B0)0*4254 +*8C1@ME:A
MB%)%M<]EI!48&YSBD1#S[ 4QZ>5L=EH/N/FU7.FC-<#L%7/% M.U=WR=8R*&
MB#K'9#Q/QF#J4YSV36@/8+EI5U:M./.CH;K:6'9*UQ;KO[4[P^EP?CD+H ++
M*10#4@IR,JD>2V.#@X*%&U%<-C=OGULL]6U7V' EZ5X\?"L&M!-UNY87YVC>
MX**UT;O)N_#Y'\/Y\?%9W6,%N7HUP_"8#*]'K]G(ZYY3#]&P"$63&*0S%CNU
M4]D6\:%M(-B+J=F'=GM[];.C<:X+I=@@K=024-8%5RL)7XP:.*)%37>-P&XU
M^VMB;'5GOIL\2?\Z'4[QUK.B!N0JA C(0 =7*^DIT8R25*:X3\AY[13=1QKK
M8SRH':J=B';;W==8@\UM_P6^NYLT#93#"C.1*0@4Z@?N(6B>P)K@D67-..^S
M\+<AT(<04G3G6D-=MCQN\"+RK9A^"?.*Z<NBO?UHA*G*\]?R]G@RG<]O'(J6
M6'1>4$QLG:EW" G'"[I#L"3FN;,!2Y\JJ!U /X#:E^8\W).*V^U])*'<:&_X
MAA!-AXD"IO/VA]??N/+-LUT_7T_8I=%I7M1)I^,P?H]O*/CZN6Y3F@^RLM$J
MBN$DKZU:1%$0DL\T4"L4BU;R3ML0]CO.3J'@JBDPP91/E&J"Y[Z>DEGJ>2FU
M PY/LI!,,84^<QO;U@G?\][.P^7[BKK<'B2XCWR%R2Q=U@&*J<>;2[)O47$+
M+ FNDC'>QS[>:]M\Y9[W>SYXDNY*@ON8*L\I(F>R@,N6Q)!2(;\? B3AN>'6
M\]QIJ_^V4^7W&U$]?)+N2H+.6Z]>A.%TT6#ZY9BD>+H($M]6Y4R_G.U3NB'3
M,,X764_Y.NN9TT?7D:^W1ZL'C#:;N;H+:,==7XOY[A4X%DN(5[L^WTQ6SS=7
MU$G)V7Q U),!'24@S I07D=P+CDH-E&"DE-AJ+^EQ#90]M/HWIF8M56:HI>8
MZUF_&9RB07NI56':QY)2MQSA032ZOP=B;=<9?Q-5=NN,?T,D5T7P-,R&%)@4
M$H+*#K)DM9+$";+YHK:L2"*9Q)SOU+MD4Z2'$*,> />Z*KC-@O(V J+8HQXE
M'$1MVV[K(6\4($>7(:(V/E'XG/-ZB\W;7+V/;;]PT<^'LS2:S$ZG.%!!6"4=
M ZWK 5:9*XB%"[#>.%&$,Q1E[=&^KX#XH&W\1C1:SZSOJL6]'WHR")%RS+J
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M+R;<J;^X9S4>&Q6+-*KXH!B"B4PG8YD/%IE1UHGBO?"VS8G,\5'P@9LUQ\C
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MI!"E!68S$'XC%(<VQ_*/L&'@+F1IHI!CN5"]3LLICSY@H GAHJQ=8V@W!X'
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M6=!),J.@&%NTN),&W=NUW1603M5>Z4<'+>H!W(@#P1E]>V-&7*0^K8.P;4&
M!S$>JB) +TJ])S+7HT9:U 5X&&GD7G(=(S-0E[Y:PMPGL Q-CBYK*V*,)\69
M!RL#'(@RFRBB]V31+P[H+V\$(<^E+J1&A<RTK76T5."L)EIRVA%5T6Z]A-$E
M3S] \*UG%4SZE%\#H^+51YP^'XTF\T6IZ#K,"V RH5&6Q@4QT#;IBF;!%MJ%
M8S%&@**/79,IOQ+2R;"A7^'W/LU'D#JS=W&0=($H:^U]B9E,WGJ'3&$B;/2C
M*0%CDL197*_OQ]+'GXQJ>Y)@W[4"GK_]]??IY-T4SBY]&3 N0C1,2N,(3*%M
MJA8N2"Z0_5MT%G:]T_O;3SXM3>XDMY5Y03UG_7=#_[Y>1_MA<E8SGEID_V_^
MDEYN >PXMENW 3*W.@0'*8:@B\C!536B H?69>,'F[^NAUSFN^^[#FQ\__GZ
M3R[:Q71=HJZ/=%26W$:B=4ZFQCFB)T;*P"0*@SI;IVR;MAN[8^\E$WP;!-V7
M?^)L?I7C+@8Y2N1<)*:Z>BX!+?/:RBZUW1J@WT&;'@)]CN( J^]^&;PT%?T0
M%&AUL2$^/)9X>RP_??HP7/0-6HQD8"5M3*;N3:*+?P=@H%5@N1A70/@@5*.>
M!WT-X6D2>>_*;Q%-VE:."P=H]DOMT3M[<3&:7Z:3V6Q07'8:O&=1"JCG.:I^
M1_8S^AS!!B=B&U^TP6">)K,/2(@6T?8=A_33)YRFX0RO1M5U@'LQGD^'X]DP
M_1-&YSA *Y,S$%@R6%V-Y$CF2;,@399.!%.@T:G.'D;W=18<FC(-;JUL/<;%
M\=R+\6P^/>\.>+LRFF_?PWCI&C#0*>5L"F<IUI;;J#6+ B43Z&(0$F4L:Y6A
MV=_4V'"$7Z?',5"GQTLU[<?YVV3\D=P9S(M[  /%<T:N'#.^NZ5-NV/0A9P9
M)Q)F(:V/;1(8]S;$KY/D*,C3XO91KR;COW#X[CV-[?E'G,([['[Y(\SQ9QA.
M%_MF 6.3+8K)X"TI14@6HC=,NHA*<Y6C/[(8VG8#_3ICCHA(#6Y8_73V833Y
MC+BXVHS+1W\UU[N!SBZ:3U__OEX^_6TR_V^<O\8T>3<>_B_F+BY^(9.!D+X(
M0*PUE'0M EJ85QF9-%"XT]& ;W2_?1_#>W)SY/A(T^,=L^:#7*P,/T^F%Q_5
MOQ,#KH61)0!#(%5H#9:%4#*+&&OMN (9VFPH^QWGU[ER/#1J</MNK='6!);4
M??>JW!Y/5\?@*A.7!+*X5&BX2#Z3R$G2I($8'(-@+;-.*U=LUBH?< /9?$!?
MI\$!B'&7[V'GFSD+Q)B7#^BBG,R@8+U9H 6C25BW,J&9!U?O 2CE,(A8;)L+
MI^OA>W)L;*"V)>=B_1SO[L5[YU8XRX-F60K:-G@JM<2#9SQ@XB$:B;I1\<3#
MA'[VJ(LOBVQ<W9JGC;OS!@=**)ZC"TS$VEV(-G &'&L!EQQ*0FZ#:UB"L,&(
MGMQJ<A346++^['YH>74WZL$ASE:-<7&#BJQ2(X/%6OM3,BT*K2_H@&4N4=4&
M,:75;9"^AK"WN@P'YO)!5'XLA1T6\#]?-GQ7&B+G@2&G.:B+#2SPF)@P-N<L
ME(BW6U_W9;7=A''XBY%[9<)M2VUKC1PB46FE(*Z',<ZU^WA-.[_(-%]G3&TO
M6388U6&N9>Y EDVW]'UI^K&P6)#G#;Z6 0-;NR2H+E@;6"E."W+17?&--OA'
MP]X'+H@>.7DW47 #TE[%CZY/""[NURAN,S>:C&2LIK'FEEQ73$S*(&I_N6)$
MFZ2WE9".T %JKO%5X;Z=U-5W/\#?)N/5P*+FOG35PQW:6JLC,#"@6+0Y1:M"
M"G K^V7%_;;[WO*$J=&O!AHL,:^QUOI.\XMCR M0(9J8,&J6B^-,1Z]8J-WT
ME.5628\ZEC:UE);"><+\Z4]-?5^5?3%.-.;AQYN4OJH@IKAQJ&MZA^N2!VFY
MXS[2<F>)Z28"Q/4N0=_SDB=,BE[EWV-^<^TH]KH*HS/F5'*0C(Z,A]H#.0A@
MOG:GP" +SV"2M6N%>-?JA'?UVJ<9.-A>\CWW0NU 7!H]:\#HO1/F#0#[;WZY
MI0IN*W$'^?7<YO(FG*1E#@H+LU'7G+U@&:A$;IK7B18<6EK6NRQY'&J\IYEE
MOUK<1&P]:^]7DM39^65)!I.*MY+6%931D:%I/ N:<!6EBH2B;%GO<N!:^OOB
MU?OM:;FU\"=]2*Y'[ZT# I]N  F6)VV1MH94=#WCD,S+0+Y"<+I$E%E!CRJ\
M^>I'J,*M)=>BX=J%T=>M*D86<OJ#9\[H6O_,<D8K"UEG2.8Z0@ID C=QKFZB
M>)IVTL[Z:' ;\)9#L Z:IB<CQW"FL;U^5BAZ!^$V7 XN4&6G"4_F#"S(>DN[
M5C&3DDF0(H)+)8@V?5V.X "@E:8WD6F3<M-7_GD%=AGK4Z# 2\>2S01*DU*B
MHTV).^%H'RMHQ*VPVGWEII>\8?]!D5W$?J>:]*XRZ]GX>CN<UXWJQ3@//P[S
M.8PZDOJB AI'AJ#3N1HDM._8))@4*CA.$RWXM2Z,KF6$+87P-/?N?C32XUWE
MI8#^-9R_[QIIUG#<^^&'MY.?B-'SSQ?S8QVHO<=$-@2Y_[A)#VJ]CR0-=-*S
MI[XI9"DAY1@YLZ'4P$2L]R>594EX:2W*0&A/BS[WQ&L.RYY-5-$S:WX<3C'1
MKZ_"% )L4)R5FO>HHZ41&UZ;+R@5H_=.N?XVIB_?O=_P0%,537J1[TI+9"\U
M3=^<GYW!]/.D+/_UE_V>YY/+7G87?[\X2UI<RH-QOG7TN/B\[P*I>T/<L-KJ
M8:1^JW2K%-FGVK=4::T!!7 M9)8BZ:RC0+&B=.O>L!_#3<N75TGC8()&KQ4+
M6=.4!E]H9>"UQXGTV=MB?6I3,*_G@>SI1E^,1H=L%#GD4/WS0 LI:L^2*>@E
MNB)O][(^\1M]A^3CEM?[-M%AB^*M5SYD/[);^),\* ,\(0/M:G<(YUEP5C.M
M"R@GE6P54F\RG'W=NCDF]AZ>%\=R'>?%F.P,?#.GJ5P?]_)BG)U3HZ4W!F*M
MHU]D'4]AH% R;A%L<E+C[0!B3SR_!]3AHU$'8\RDC>8:G#BL@';A(*T#KNF9
MT[WP#G,$U9LRUR/)#IK8/UTT<NU4)I#.,NUL9M$IQ1QD$VC55T:U*2MZ )H\
M<'QU()9LH( V.>-(#WS_?)Q_Q(\XFGRH&"\,S,M@20;?Y2)S0Q: ]H)65)"%
M.1FT1Q\@J39E-=< MW\_H4=UWDT,[U47#4S^7W",4Q@1PN?YC$0]F]<Z_!_Q
M2Y!2@LHV*:95%@22Y@V89)CG3LHLT*X9O=R8,&O!.R7*]*^/%MV_O[@86'22
M*M1R$$44IC,8<EIE9CQ$58#\"A&Q"3F.[%+ZL5BZVVOG$%T&MKF7L<Z8OEY0
MW^*"^D9DV<<=WVTT_5@NJ%N>#!KCF%6E%D:LB3GH O-)BV*2XF24/G'V;G1!
M_>C(NXF"]WI!G0P&J3DD1D9$S;IV-2I(Y@/D[$-,*;G4N';EB=Y"WDCC:U]0
MWT1=#5R$Y==;G0E1)@_,F=H)5I/?$F-.S(9D;$XR@FMC]9WR+>1=^+.[FE:N
M07O)B[@J0/_%N?6L?K00[6QV?K;XK.\$A\U?W3!384<YW$HY2.1L!B-5M!8U
MCQ@"1$O_1I64!LY7I!QL#N+@/613T=8$9YB&>J\Z%,6@7M;.16FG;4G&MUF0
M=L=^L$J@5VJ^H<\:::BKR#\G-6=K-)Q_?@US'*BD40:IF'2RMI^VEH$QB47N
M8ZRGA[Q1U8D]#.X(=X]^^=Y;?=!&A#FF1K3W#?$M3L]$W5.YEV2 B:XL1#*"
MQ>PUDU T $J(N6%]W"9C>IHSX/#T.*;>M<M&]GHX^^/G*>*+\1RG9& N9G9Q
MNMB2F8EDH.J<,PNU&QT@T+]R#F1Q'?]6L&QH3W,:' U9^BZ#U.OH;C7.NNQE
M^COY7#BP4DCP()FAR<\T#\C \<A2\KF@-T7>WA)671[<%^0G0_4C9D*/%];[
M'^7EIO;S9%IP.#^?8C>?M0%?"WXRBV31:>5K^2HH+&7P*$*.CMO],WTYV*\<
M/Z3V6W2>[>V2J_%.F "&)9JP-$VY82!$8+Q @GH1.H!JG)3\=,K_[V2A'$3E
MQY)O_.4)EP\R@@Z>"2U)CBEEYH'<"Z6DT5Y+1Q/P*61:[)4)]V97;**1QW(N
MO<Z8OF97;)%=L1%9]G% O8VF'PN+!8^1MIW I+&9:2-I;#X)%HOQ/&G/HVZT
MP3\:]FZ477%TY-U$P7O-KLA*6$B^E@H/CFFI+&&J+?M0&I&S3@7;,._4LRLV
MTOC:V16;J.O E0,N#*!)J9_"^//L]F7N-!]^K*45NB/968\5 #9]<\N;_#M)
MX=;Q.+=<:6Y-\D)K[23QB3P2HS&"#<CEJAOYFV(X^.EXSL)W#6FE3ZZVTZ2Y
MD[-A1NF 1J&*\4#;X?&>CJ_?T//U9#3Z>3*M_]$@"R)5D9X5J#D\4;A:)P^9
MA.C!<P1KVR37[7><1[BG]#L+>CLJ:4^C5L?G;4=[T>@7<HI<I]I^1]66HO72
M0R;%)-IYZ8?LE3^RE6FW1K]'/57VP-7]3ZLMB'9,Y_(/#K1KS3M[,5[<(AKX
M[$S)Y*257&/TCEL&J)!%H:.QDOYGVES6V]<(O\ZG@\RG'6AVB(ME6X_SGYT^
MKL8IG3/>ZT*CTU O7#KF:P=LD$Y"B-*E8TM\W'"$7Z?30:;3#C1K4.B^W3@O
M3I!O#%7)$++SA7DG#>G#2 :>?I02L/"04!U;_MCF@_PZJ0XRJ78C6XN,A;V9
MMX&,650\,%=2/60/R'SAI!#%37$QT*].RH\Z2EW<2@WK3*8?88Y7*38WIY W
M%KU0JO:](8T)YQC$Y$ECPB>/.OO\:"-%FPCB$:V5CR:4U(R(C\HS7E\< V.D
MTBI(EK2M.2$^,4BD60%*1>?0@CC=R?B(9N Q3($CG,X;\?=1S>$OPPX/"\+5
M$CE6!X9)Z7KAH/I0WC%5G$\ZZF"@4;G98Q'!U]E\G+.Y)9,?<83M84$4 !0>
M$RLV =.0,XM)!*8,)*^MMC&WJ6EY-"+X.J6/<TJW9/)CC/*=3_'V]:@E4@A6
M<N1:,"$,9SHXSWRLI6U\!FVD+ ;T(YO/FXS_ZV0^SLG<C,./,Z[XL R\5B;'
M[%@VM7&S#H%Y$<GG$-F(+,DCL>&1S>-M?>9#WF7S+@F=0F(VJ\RTY+4S:Y4;
M^8,F.VZD;Q2Z>()WV7:*^QU$Y<=YETW&4+A,D8'.A6DTFH7:$1"D#-(8Y,G:
M)J0]L;ML&S'AWKMLFVCDL=P"6F=,7^^R;7&7;2.R[.,ZT#::?BPLYEY!XJ8P
M "%ICCN@.6XE*Q&5M38D)P\4TCP:]FYTE^WHR+N)@MOT#%E2.C0Z93, ;2HU
M:58K2=8]KXD4/)>8E0/1R*P\Y0JO&VEZK0JOFZAI;_?7SN,,_^><Y/'3QRJH
M72ZDK7A4/S?,UL%YZ\J8,T%G<%" %XU*A$)>KI.Q*&>E1#=8]= =-Y8OGWKM
MD'@R]S1W@9F@!-,YTF(&])W*]+U%1S1HE.Z] M&NJ]%+4N6[Q34[G,\73LAE
M@TP+2DH)FG'HZL]HRT+BBD5NC;1626/;I [> ^H *U,?7+B]NO0E]A:7D:#S
ME.JBM\@$NW";9K75<0V_OZ4U>0:I@A\8&F,1QK#D28TZ:G+01;!,T+ZN/"VP
M]$V;^; !RA/A3#/%M+#,K[%VE=I^QVF'E:Q!3ONE ,:1EQK)-2Q(!<R6[*-!
M$4)LU(=C!:+3(\?V F]QKGV-ZX<)N0_TU&[9>XT)AQ\QO_J"M1BCE9X\!"(M
M@?406,S",A(*2F^S2:W.GC>!>7J4Z5DU+0Y3OY3 (ARG+<^Q&,<,=YSL>[+T
M?<R&N8C!^4BV?VAT)+($S=["ZDVXL*MX#QWWGDWG-XRJ'\A)[((/67F-)1/P
M4CW &')MVZ<96IV-2$3IQ-=A"#W^!COHI]O,6/[^@T6\=U;GI#>Q]FA=W$53
M_?X+9W\=3)M$G[=0^36:_4:-^]#22H7O*.)]J1]!%5"D':BGA-IGSJ(/1'8!
M@DQA<":M5:[Q"-6^(MRZ+ZUO(MD>M=V5V:VI7A_>PR]X64#*6)6YMYX)KAW3
MME8W32I6O\9Z1>ZQY+<6]!45D6\_>7]&77_"GO0EJ19A!-J"AGD(T\\W[,S%
M@8 W0=(X&7JCF,9 0[3)LHBT/:6B0^;MK+:ED![]-MVOT-NZ@34^_ZK<<"TN
MSQ370-CV]/A!C(<Y"^Y)J?=$DWK42-M8TBJDJ:3(06J6;:UY+;)EP9;") KI
MB@?+??.XP5XY\\ )[,$HLXDB>K<5SN-HF%Z50COA^-W%+FB!(VH>2'>JABT$
MU X1AC;%D(RR62B;UK,7ECS] (&@GE4PZ5-^C:R(FSOD55(!>FZB"<RH"$P;
M2[!B[=L.(J0 (%&;O41^#IW:UL*"V%7@>PC_71O,ZP!K:S:L@G8X:V%G!3Y,
MBAVDW\)$6 FP<MUISQEH[IE6-"M"K:DM8HG*\B"U:W3[9;^T6,,@V!\K-A%Z
M>S9<[&3>Q"(("^/H8TT&"BP&PB@-N=P9,\C4Z*AZ&9R#GR%MJZ[[2;"%K#=-
MD[KXN'Z),,.__^7_ U!+ P04    " #/@*E4"+W<V!%!!0#8\08 %    &MR
M>7,M,C R,C S,S%?9S$N:G!G[+T'6%/?MB^Z0@L=Z2 E*"A=>B]!I8I(+U)$
M>I..4@2"H"!=NB "TD$00:H@ 6G2BQ2E2I,F)=1 2'*#_]W/OF^?>][W[CO?
M/HQDKLPUUYCC-\988XXY)U^RP'[#_@ NW%+54 5 (! PC7L!V'E1:Q4_)WL
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M;^^QP&#''!HC/C[\!A^C>.TD_OA!D//Q=_D\>*45%LB.AJ-.G2KR;ES(KK;
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M,!EZ>\6C-#[7<>N[(^TV0PN75T"&$=XIWNPD83BK@*,PN("NI3+DL=[] %)
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M-OB@G&Z3Q22UIN&-;C^+>HY S%-?^G1E;5=.'KR?.FJ><<[JUGZC$>GYW(T
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MYI "V2V;:@9U50W#32X%-\6[Z=*.3!^^;74K4Q*%)OEL&5X7N,$O0GJC1)H
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M Q@;O;@I'Q5-2F!DFY">0K("NS]"BR&-1*E4Q]; %O*6LK(1<G68FB_! UB
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M''AB7(P$D:)O2("/Q14?8#^*$J5.A0?;/?#=H=^?!B!*3$465\7,C4]IW7_
M0A[&?X?BAO>!$("TW^A(^/1KH\)BM79W+K]R78I=.53O61N'X>1W@@?FCW*H
M*)#,4O%P.SCR"C2FR;_P'NRSS(*%L7&$^?"2(T&5BHM$Q[/LEPAM9M4]&F8N
M_0A]ULJ/"8VQ\9&6M5(=V[A]0ZM4,&V@<27"L0ZQU;!PMQI]TUC6XE5Z^;B6
M.L%NAI"@JN";91U(VCL-[E4XDO<KK)/\5%V)1$#\%]%2IK-1S.-#(&GB3?>&
M)=&I790VTGNB9<G'\0LBI57QOCS^M<KN4^(<*GMD%^I&\,2)]N?7M(=/J]-:
M,6Q(.^$/C>Q4=2;OM@B3]WY.FG5SQ0O8TICEL?@GA"2P]$8^?14TM<"XN5;H
M"*TD>HWHTAZFJ"VI*%T[40U[>VN;>E0Y4>5R=4)\ACC#7A^)2#K-%:!SESS0
M&^%^V.7.$MRN2(PDR":7M[1:G/%6'Q9'J3;73KD&N9*_1V>M]RWV-3!"[",-
ME9W%Q(#M]^Z'<S%SE=DQ-KCPL$>*S6]EI9EFQ\ISB@=?25.I?G+1/S]ERS9K
M^%'/=3^C0]>R5S'E#^@917ERJ&@0C)OEJ-M^L)8 WPY&Y.!.SV'/^KI<@R+[
MVE&&^61L>5/BLG7BM%"&#>D%T;)^6:X&UP);VWTHDB>B,QHZR8@A.=J96*!/
M3;H:)>%.U_K31%NTFXM&A:B /+K)\S(X2JL\Q.3^BWSZ"A+<FH?J^YVNUA/M
M\"9=E QRR@C9X4YU:#B>YEI\3XWML.QEM$/OHRK5D=[J*L$&QTF]J/@:[ZWL
M'1T8V#$8=Y-#O7%COIJ*=/"'B] FBG]X_E7)S_I7MQ-_CIPLF#E=>4E"HL'M
MX0MXR9+K$%C62)U-=(?NZ%28'172./BJ.VXUY.HG*50;_WYRQK]9*_7U\IZX
M=AV[3[8O\\S@]7@['$!R\%B6##JE26O';>_SQ)2/@NKNB:N[AHC2W*2'V:?T
M7?*1FYPJ#7;IOAQ?YK(\" /C<6MGIAMS57._'@#<[F$O:11^^53L0%,"LD\9
MJ2=\6VU2["%36C7Q!/9MD)7)$-%F\> Q6,W$KP@$;6O&7(?<)IGASMSS2<V#
MG<+7A*5F7/>+LHO24SG%O6Y\X*!D-YQYOYT)IM@7.J7C//PV 7?X9/.Y&4 &
M,;R0#UH0]\\Z,KDL[=/H1-9*T+K\G?A14I^[J-KNX@6IE\\L)>;A.V;YRKC=
MJ@@D/42U*A@#/JT'U+L*MV1MB@+&<::^#20=?R@494F%$5:;C]YF\Q/3JC:C
MHG%\Q(=X62[HD+J6<=?&ALNSEW6">.0I&55*ZH./4<"B*]Q=* ;V0:@#3EG7
M7A$93(J<__$8R>SVM<57UF?S@7P+4W@X#V[G[WH_,9Y/J>])F+TZW(QAL<^J
MFNVIK48GE8+LQ!(XQ UN*Q0SJ[ S\;29#=,_*XT@*BEQ-MJQU'Q</-O%GF['
MU4LWL2MN[)UJ\GTTQ<Y@N4[V"!U@IM?XB$;RA<@4/M-&UBC(Z8[2(EUU])&*
M($"GJW)>_JME0J?G.O,BW3H/7D7B*='DBLP5."M5G]"2D]%,LT4?:07('Y_U
MX>9DF76,#N'=\M-93T@?Z0LL(-S:Y;YW,G),[NM%Y[!LC@=6@.EOGHR]SHW-
M&PE1Y-T1^F6\*(EN#KR)0'5^?!?JDVD.L[[K:"R&SE.\\?WZ8?%RA)MB=U-W
ME?9!XZW3!E.4V*]^N-]]*INDP=OQ79 5>A='\?ND0&FM<X,TZ3<,;0PK]6F)
M;5A?HD)/%0_4/XYEI^M8PH'.I@ PWF5Q&Y>K"@@U7D/+?;W',"E2)[/:DA '
MZT*<.@_IR)+K*M&/,\0F$WT.RYH1"0'3BW$\Y$_ZR@S.'G@=Q8-7]FB3FJ^$
M:1%M+S/H!K#:S+ZNU9M^\"-H^_##("0-UOLI2D3I@L#M>BB/^YO%K.3Q."-C
MH#U?\J8HC<A<3/Q/YP&1#B;V9-#=/.^4GM+-SOD)[G<*TIC@T>]O_(5!YC_F
M(Y<I_3H5L$"*V23/)!6!?0A?4*RO;:UQC%H6W9',QO8!\X9:XO*38_UEEG1*
M2E@W-/M6'4ZMBN]WU/@\1!K2/!7A=\(V;@GV*AX"=4PK<MK,&_OT#G@QI$"9
M%2=KQ>Q,%MA[<^VF6:HY?FB73 LD7#'%/@IX*UCQ:K=VXF8(/B68DR/8\AD%
M_A>XY-?='V^]&C8R(3>S1\I_WT_!P '*B3L Q3?/EM,G_8&]*%AP+X8?7:I(
MM3I+NQ.+B2YR9@C8-\T?+-?@NS%<QDC]@MQ3O;7NCAREV*#S29+CABHAX $C
M/"6#[6S_& P)Y"SI=Q7$A,VC*/BVS/0&:7L)JSU%8E_R\J<\8-!1EW\R\G'/
MI<'<WRE4)+8K,R#3^P4C%.W<&"49-AG"?ZQ7*VJHQAG_<G$].#11TZNOR)N<
MO:%[+6XQ_HX<K9'C))4S4#R^*_XF[#)%P:U-P:Q&OT5\9BQP.<7JX1<C,+1]
M.MNJ2[<K6+NBO#SOZV044)JZXMC*S'$Z;>O M/EE$7Y/[';<6%[*>Z7;]VV7
M*IA:]G]0-@PX;\GIXORUW$#*K)LF%Z<=N *=6(=2._HPLP[7G?Z, DQY<D-(
MS\MY^;<JA1]<];2=@8?T@T+M$/*JRK-G7FLR>3V56+(AI^+<?DB7O?.^25@6
M&:TQB(:U88$.';"*BC=\IU)>" O<9$C" D]VL #" /:Y?0>.)C?5QH#/N<ZY
MSKG.N<ZY_A^YX&>)-< O6@.JB80A2X%5QW<^IS=V>BHI%@1YI0?[@W ;77J,
M]ZVY"TW"+RD6%*Z8A#YZM=H(:RG&?Y/;L(TTN<?$"J%VDL$"%6?]M9$F68Q8
MX$VT!A9H^4-@\3M?# /W,RRP:CT"VU&$8/CB_]V8(.%R?A$:T$,L<.8M32Q
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MCTT#DZYD*2!<EF?C#""$]#:-1S;F[P")7/T)?4E5QX/]IS%;NQ,<8<ZF?Q7
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M6@S. (OK5('BAYC.+[5_;XNV>^"6C^:?-C=[6=ZR-QBTYVWQ657;ALJ* UO
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M.O_V9ZR?/)NWZ.7_6A-2N#H;FPQQTWY::F'P08LQR^T'$19P3H%ZE3'IYL#
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M0A(FW5W>JS%>6$;=[?T7I!_\?N(*4/";OE9ZH[]O7PO[5Y<L\L,PE"QBO(U
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MM@\6ZI9IKA@!_/W!:S-8O[/SC5&&7NAR[+T+R965?/NEY ]1@L=+7S5-:\)
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M/ZA)-'@?9\)CKJACUFT?<J4KXK09P46:'7"BX7$T6'"*<AF]"Q:?U8N%_G&
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MFQRW;<PATS@G1K@D 9U*5:.N3,.A+:0PO%.LX_G9YRS*5:5$QDIK)UCZSD,
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M\2V(^6#RL.J^!?:^!+GFSPEPLAD13IU1@+TX4CBM+3LME:% U%*TZ/!IJNS
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M+M@[ ?GX6BU@))&/>D&!;$%Z]."W\Q>5U;C9'=5&QU_6]V87O9Z]#WGX++I
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MG"N=X/DU/QK);.VD45<@S5I"W-'1&D'&DP'[K4.T$<KO/V0&>:88!$S?D;[
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M1$<03\DD=,?NG)>.4?AJ>. JO[.PK(KPM<=VQ]7&M#+]-JA%3$U+();AJO7
MGP_>G47W/4EV:Q_K1,7=ZJ5?!5\L]#$#G0<*J.9FZSD>PMFND\*]9I]^G.#*
ML; ?NF[#OK@H9PL]7%G7 O2Y26.GNWD@>.HZB(0.T:Q(\=<KPF_,XE]E=FA7
MI>XIZ#W28ZJT@>HMR&,DU$7+OQG&LL^Y? 8_#6.,M)T:<,.K5*31^;#XJB9C
M^/L3LC89TH\P=D&>^5;N,QF&O%G)'_5E#"ME=2[B4OF_3T6UR^^6%LP]MRVD
M+I9_%K1J%-19(MM3,L-J[L%,OQP9-P=# 1*MA';_WOY)SK"(8HBTZ?EC6=_%
M]+'?6" $R<]6>(9BP5EJ^!Q'16RH:BUL_639<5?26-U$:<<\85_V(\6GR^;#
MR.BE(*\0""'=3@MZS3"U<GVH^ !S&DTH;F\=1N"@U[Q43[E8S$DB0K:;=&8K
MOV*H]\EM3>OMZ:5J1'%AB67EQRY*F-BZGW!-:GZ5A ):U)$Z R;PT<S'*""+
MENOZ2A4%0&Q00/ GA-#EF2WX=,_D6DS?3]OLO),PW_FZ'[S$?,D"N>!  ;Y9
M\/+4UI5\\9L5DOHF5Q?)*"!Z! 7@/UEU.CL810'[\ZV7[C'??DE6H&\9@BN7
M3GM1 "[/GUNP;90C;=5)P$-)-ZO\UU$ M!K<H>29=NU;W7IQRH4":'.WJPA+
MI,]U0+MU5P?@]LB_;G!6?$WULG/I<#T?!2PU@)$PT%_ <]R [[\%?U[2L7-?
M,O&O('/_LD.+W=]))7_)7Q#6NMFOC ):75  8E:RF/N_24J-Y'4I!C]WDBO1
M*9%"S^?[S6Y?/7.X]+DJYZAU/HB]R5U3$)&(&63K,#A)0/"Q$5;8FL;=='^W
M&]9@W#@,.,*J-?S5!>:/RJ^3-=%+K)=N3"G?SP-3)8MX_,P^'^V;K#CUH( @
M"A1@>6MYLD.3/T6'*(-T-VY19?V##O,@QZ$@)>A?**(1<V)P?2:U8B+P]_C_
MWABO4OS,L$;K_W+2O\&Q?SGB[ZTQ8072?7]4)C7C=+'V-V!U_MY.4G]OCF.]
MD$EZ/[:_@)3[ZQ:^$_]@I[\WAY_VZ_]F.1FX:-AN-L4W$4 !?WMFOLFL3N?[
MX!U:-D>OJ_GI<W#IGVPYI95J)Y[VG-) H!M[A;EAASE<]W\OZ*7:]/ WE\IX
MY^NN#7'Z="M^&R&,$DJQEQ?_U%RBX>*[0,6+S.7<NU(15#5_Z,7D7_62//&8
MJ^3E?\1GP%HIU__T[_\\*1?JLCYS$PY\3UWSQ80CQ GJLA#<1MIBG<'J'#GH
M_9:\+H()5X@SG8@Z&-.JE0GR<(STQ#+<,&90EK4T"T:VVN,1465=]%:\<,^T
M'1*8'O41].LOWB(S505"XOS38O]I4N;K=I8P3!MX8-P'&[-M9/WCL8K(Y)R*
MT= ASWRI"^VT=K59G%7Z(Y*3>',4@#.9X1K\06O,S%1GW>FXC&=/LN9IFQ2=
MN/**VX.ZIQ<N$#3M1:?C4"S5THD?B96B>*6N=$*(+A00(R!<<^]WZ7*F, 8N
M!P-/V?"@3\*.X7+W+@R/[U37 E1(]KL]_,16V74H47Y@+^NUY]/5Z"#H[Q=Z
M2R5"]9U)\?=Q)!"#DY++6=XU19Z2RN5T6RU,0JU6\8-WJ^,GZ*E-6*'TFUDM
MHE8M_%$1*GLZ(FLY(MIM@]@H@+#[!V%;*[6O_$I:,6-C4YK66,XBU:A,0QBK
M;"PL?AJ*J[C51M;[$O<T;$RM:59^0L87V=Q&HA)46UD$R_0:4O>=2MO1_UI5
MXFOFA/>T1/6+;8>LPU.'DK<B\4[5N_1G%8)R$Y(S A4KH/!%$.+X6P1UET&7
MR>*T>HWN^WIB(=\22>.W:F+1$R'%GG)2]WW]R+T+0A*T;TBQ0F6CZ;.CP?'E
M%V>=E\P"I9"#"(3FCH].&N/J[N!TKZ(1]2)CBR1-'7P]+Y,UM6_#SWAQ?E'=
M*AGT!F]PR6HV@/WU.-D\P" ",USJ ),__IR'W'\Q>:S'6%&%8#I@ZAJ/>@2A
M>O.02)IQF6?YCF?1]6.DBP)_*Z;>[U3K1$NL<';'KR'J-4P.JV@1(G.)+]#6
MWD]/$3DOESI"928=.79KL*\[H%O' ;'=Q!OVGM.N=^IGV(A)OUCC1V<4D?J8
MA/B^SO?\XB#'(;KZTJV@Y_N"P0!&[, ](0;?-^AH,4,5 H.^>HB[Q=EM*PK5
M35OL>>.73VU?L_>%[J_W1%([I92@+2\O1Z<3=6G!H^,LBSP7Q&6G4J]S"SF3
MSKV-[*GL9MHKJHL?_Z2B4/2@-)VF#Q*AC\4'QU!II7;'K&A<)4A66&.%EC*W
MU(0/E'V:^^BW/O*JCG.LI\/;](B>E,/W=>FL+0H@2X8MS<;]?NLX5I,4S??D
MLZE[!N47HVCS6!9ZO#ONM81DO^DP)SAKG-"1'IH-*6E-&9R3MGJD+%8\\9X8
M!-"Z%6,CYUQ51C 1,WPRP2T?:88"I'W>5?CH<<R>7S( )W#>NR#FOC;99$>E
MBFZA=R94RC>=55 ME5]98HGBJACM0_KP03\"^)-Z!?<@,PVM)Z:BWY?3XZ0)
M(KH;(9?L/;1[XD-W!\"20;@]+8:V+G%/2)S>\'>M&Z3HX&KQ @2JWG9UJ;RA
MAAYMW1(QXOYN*[R^;(@'R7"P4F7T]LP^_SNJA:@\T7?=>V(]E[UW[I+ '+HB
M32M)@LVC(&X^1HDKD_SV!DG525*USSCI%@_X:.+(T=HKO0,*Z$FF?@#.B[3(
MH%Q;?\QA@0SS+F[[!W53=T<)[PL4Z\OSEQSX-O%<U,A0WU'O7Y)P'K'QYQH5
MUTH>T3443]!/5(ZP_>)I'?&V+REJ7+08K8.LPYU98/4<%'SL PYJQ>4P4&@Q
M4IKJXIXW[& G=@HF$NCWBLI*)*$YWI3PA@XW4WXUT;_41<:X26:Q"]:I?KUG
M'Q$PTD%_0-'$E@@DFHI:I[OQHXTB(V0FW!0IW]3L_,#NPL:8,WCZY!!;[%FP
M]-,#EV>6U&6$;-%8JLB&;]LFV+Y")<KY,ZVAOJJ>[R(\I7EF.W@R1GDW$RJT
MF5WKF!F<*,E*$6*&#>-YM?#J%]O:^FJY#BB !-]N2JV^F<T1XI2 "R&)$3G0
MJKC(7G/L9LV*J'ZYJHZ.]+KD^FJLY"M5K#??D;=HH/QFK(1"*[1ZQ4A:\ZV_
MHW0/)9,T+=1G__ZE\##L\JE4J-44C*.3:(=H<;:#PB95^JL"AG..GLQ2D >K
M>#>SF)P/(9%-8V910S4*(.K/3OR(G7K/QNK0LFW64*%T@T5"]J,P<Z;<$C>R
M%WK/B1B)*\$I06U<7?$C\6ZNC]?7P>*\/$W&>/5'G_J_4UZDQ<*D!)R0%UTD
MGB%](_Q'35D=YU%5$4-$MK6$7N2QC)Z9DW?#&%_L9:^GX>94I4>^P!P*:>PN
M0A"N#,85_UC][;(4]JM*KQM/\IF+0J#-IYZ<%%*Q+#!:,GJ@IB>6X429^*O5
M)0)[(1Z3*#H#<[S1N=""A$$]ICNR6?2F^9ZXO#)WHY2[ CO\L>M,<&UF,W-8
M>PG2[$DG=6P>M1/']T5_T XC3R_;S01HG[90=.3^3B(7=6L]23 Q,I3,+URR
MT_<;")\W5. ]\#]@?+;VEB2;UGL82V=EB4C7L_5YW41UV*+]O2!SLJ&DE[D.
M4NSAV/0G#)FBX0?[H<:2"%"P/[O!<UM7 +Y0F^8$+M25:(BMQG<?Z65TZ-]_
MY29^O_7)<ES@[Q9<A%](=#-?P4ZCKP[(LDD/PWF!10^'X$7%\[ZDGF,:%UXY
M+*8B3T=5'6C0K,G6F.+*13F.8H$Z?VB[$/Y;]*_2S.XWA0<5 .X>HK27I(-G
M-$O2-!FH*G1)',6G,,9I+F+W]W5^?#U#ZD@Q_YO0^'%"%U7=)1OH7J^U_\XJ
MK3NU\.MF@Y=\$/YB:M6'4=SU"I,>9]^EW%TAQN3MUQ2(5Y" 2SL!F$3\IOSP
M&OPD@;;ZY< F=EQSKP;%2JK<P8?O:*$R 6AS.N],\)$)A@CFCFD'AACY*GAY
MR)=#SF-\0<47QLKW(V7!7G1*7_:MJ#\(O@J=MT$?;J%&AE]T+F+5U(]_D2F>
MV?O>^H$ZZ%.7N*:X92"GT@-ZNG0L#.LZH64PK;UH5I2LG8[BXY!R&8'!F$:>
M-W>>\CTJE!.;60_+27-&OXJ5-S;O]-8)\V6PAH((]?6,MD>1\0_]\%+]$QC=
M)Z=(>DP;Y9F6",Q9+B+?HV%^!]K&$>2!;B@ ZW<+\7AK]9@&W?V#G&!:(45G
M9U>'E-5Z6?]A<TJ9^&F:;IYJ8A;T&4KG],!TC]5Z$,&E[$AUZYW?5(-5JRD"
M/@8[@;9W6R9+K1*4AIC[JT!-KXB^,U[^.!"!N&]7LL>]P2 #/2:@9DL'V#9A
M)!VIS:![_J1S@G'>C1GEX:_K&X.5O80ZL%/7F[NQT&ZCC50L5HTGN)M*/9P*
MQG\VJPBC)5Z=M<FD7)WG+4$TAKQBB.T$%JI2YV8E6X/9AL3)OR[]$9<\)#/X
MW>OPOUZEVL8E4<K'+IHSD*&%9ZDA=XQ#WDO?O7U2^\=;;&;?\C*R"7;;Y)WT
MEX_WHQ?1X5W06;O4<_U?,16M(U_=MN4\6,FNB;VG?.+H#*/Z) _.H^M/R] A
M5+3!55[.YH4&^MM$):QXO')Y/-PJTUB4E- "I=&T@H&+@8]0$9_O\[^KP31(
ML/'PVL2N@(%!!/:9;> RVK9,&RT*X!2;\!-:%0IQ>\U3.9[;?*#&>"',N]M+
M3U(GC%%$N;4_VR(Q64W+U=YX4KPR=&_[)=BJNMC9QX>G;UU.UUJ*Y?D1#91L
M'XP='<0<]"YMB6 W2_V-O$#W"&V' B=#^T#=!T_SO8+WQA;%VIU::>V,6Z6<
M%UG/==#DN=I>%D6"?R3/[#9E-GRU/_<O(]]-*"EQ/4B:[4"O%S\NOLZUA49.
MQ=AI$\^5>$_$:F4*0ZW5\BK<A0W!C6 >X_?+*."!_"HMG^/^43V2;=N^I]VJ
M1J*IPVPB?^Q7!U%RX?!Y%XZ1FZB IJYOI+PO06)<H6>QTJC5@1/7HV#_%@-!
M:KKZHW))9!M"SD'R6%PBNRZKL ?#]0WE*WQ(F>N HR\'TH\PZ*A*XO*KD>,N
MCK%!8$.P%PO:(*9?1_LW_A^E#ER5V[XNW4HU)I;R!HX.0IT@_&])#L;C:$-+
M0W35!:M8P:=OKJ=K.*49"$3ISK:B+P\-7D+6.ACR<!B^Q=_GTA0EW#+A\Q_*
MJAE%CJUDQ30;0..^VE)Y!+FEI5FF$B:FTC=$R<8=*GA;3\&''GUBK)4@7'3X
MY8=^4RYOAM3N4Y561!*FJG,[O RBMY906QGC7T+JTM%"KQ]/MI["=2*N>UNI
MQ/404^H(Y@BW<CP#&\G[F5!)4)R,8EX=7EN>[YK0*PS$KG//J; ;[('M<K"$
MLHH7)\E  $>G24M,UN*3A4/T2.??KNJG9E>;+@67[(0$X&']J>MK7*R89E'G
MFXQG;W*Q+Y!K6V@[=>YM8F"D-V#VVX@S]V$N/9W+3/=='2F- 1FO57QJ]4J#
MN>(KR<&1H5Z)SEYB811@.0V3\*'B4I'RU%8'>3JGEY]T?8>X,Y,&0A9I][_-
ME6$Q5G3[B;J5.(6#B-[M8UZR([ BCK9*W+3&JOLC=OR2'^;4>T*ML&G>JFFA
M!RZ%]UUE7G/((Y*7ET+$S=V<+&V]BO0_.Z[497D_6YEQD8='<F&LQBQ$G(88
MB_NM+$JMVCM-79Q=BFK615^*1Y)NGY3P9/2=;=6#=[_FCUZJ9^^0;PQ"M$;W
M'*?$OM351\THP XJ+J]VNB^Q$!W:"'F8+?2FBZO2G^W*_9TJ\&.]6"XEV95?
MIB[SLB'WU/QJ95?P6GC8L>S1!PZU144+T_!OT(18J<+2&M-I*,U+WT0H#H5C
MP]QH>@6LI*#_1-7\5\O#!58?4",*T/]04'%1?ES(OO5-\+J&26YI,D"\ QJS
M"">_BM*6NI#PCKVF.EB*EO+Y:7(BH(L"=H^WGR+M;<$$(+[H+,0WWVBSBVNI
MU.8+Z ;6S];07_(@>-2VD4RW9#^3-_[M8WOG5G)^ZB52WR>(KU%?#2(RU#5'
MN!PX7L\7;_R"BSY:B[VKS-+[<[,<B[+KH"E#LP'.O%M>[NLYZD]FGP3"O4E^
MVU0JL^D7QV*?32^>D3]>)%ML>=/'3<9 3\K :$%D-+7+!BW'N12#QW0Z2)XJ
M3/+OT]C45MGI+S01-?H8R/[LHLKX(A35_R3J0$U]4&<MG/"#),G55Q1@C0*P
M%WX;@Y >>0LS0]ZGL*L<L./!9RKA!-P=EWJ*($_T']Y+N\470LBTE:P(@2$:
M)-0P>*>;ZL@%JZ+&S0:J9W&XSNN YI$L+5C0)Y@P*+=8Q[_J>M"4FG4/!3B"
M@$L#1,OG%3\NY:DW^P+H+(HU!C8,M:IQE,X,.&$=:.\#7-2%:6*P$6YKX"IR
MV/J#PBCS D^#;CJ59%6FF2A--LC<V['FG._:J\SU3&KS\M6)F $76V8\*W$=
MBC72#V7)&"2P17XKP(YA)J+^<R TMY@H$\)W)_#)1-K]T"/[X\]FO&=RRK:D
M)7U!?;GW=]")Y]% 6(Q)?>FY%=4)%6N9]%4@6JGE',')MQ",6:'W724)0P6\
M]1&[OZOH$YP?IABK##>680,?2(L%S*[G/*BZRF%>\$55 F&GX^EJF/ 6PA#S
MH*">*JA#KORP$-?$1HH7[AV=NR!E'O/1F M.FQ5UO!3ZMC8-ZD2\O;[W/FEA
M!/K"8O$#S4=\QBG,BO>_3#$[2-K])T%WKQ][0DX^P,$QOI@KA6Y(?@G)00O[
MB'IB!G$AESZBB7PY!N+'T@Q1TZ4D&XE[3R/6)0R6P>&20CN9[#_JD)^7KT#M
M+2![K#BNHRV-?/M67MZ*-?4GP$-W2@IH*MP)^;C-Z;X]B-AM03%U4R]A%]<-
M9UB@E]@O)^]7B:)8AFC%O-)#L=KPDY@@?_ZK+\?JH526=3'BF"M76.U3ZD*S
M7"5[YEZO'PGRT$1\QF8ZH3?*(QMB '0^>^Z?>"'+X>50P0:$V/+Z573=58/S
MII&MQY>%Q[^JKK[8T"A6J%"/2+/N/"H'/C3].O:.G@59?>LTY)Y.9RUA[;"+
M))I;GPG\B8Z4P;"(2W!:V8SI%FUIF2(:G(V*RDAMXW]>Z\7U]J+.PG%HEIL4
M+>KC81-Z5\N#+10 $C="W%.:NF8PWO+'AU\G'99?,H@ZSM"=N^*%TV88S5D]
MMMHP:_H2<ZIWMO-;?2AN9]R]S(>_3V//,R94$MW.NS8*BL\YNRE7.RS^M!3?
M!?H\7BR,,6,BQRH$]N6%J>) )?D<.L4EY-4\&9LZ5&BW:X4K6G0@.J?4T$Z;
M/&GX*L70=HKMP=JB+@-;]S:P"&6+:58< KP7'H_4.9EQV_W(94NDLU[%%SQL
M/\]ZGR /GRPJ0_H\K6KBT=-5=>1DWWNFB$<L-&MEU&;J4WCP:UZE 4_Z44S@
M)4.9\FH,%;44[*:VYRSUL"WJ6H_B;J[+UQ=+H'NP\LP%H\:JA]DSKNJ0YGPY
M7N9G7,S36( QL-O?>-QQ$>). 6K^6/76DZ&PV]:5>UT^VM.\+=Y3>=DAL3Q*
M_&F)7YKZ* =7OD^*0[]-Y4PWTUTT4DJ'8 PQBT/%AVB'0L+F*V'CE_((W$WM
M\69S6Z@NOP,5ONB0UJ@#M+8ZWG9CP86VHX_*U\! !.?1EY(^P2>FL)WM> <+
M6Y6^#OP-%K]-+';Y5M*(.VR4XM51O8QG]M5D(A!0NYR/&T1"E>:7R O$!ZS1
M9)OL:#7OD6HMTG_KA2D*V ?U[!YFQ.U+!["VXVX;]%\MP@K]Y $3&].PU07Q
MIEQ.P3@&FNC2ZSUL$4BI[0[5U7ZP_Z.G]M_L@)M6?VS-1]AQ[EJBS.$396@L
M 8-->@7G(/I#H S3$5G5+FC,'J.@/./X)4*Q-40K7$Q;Z] RM +W9Q$CS?LI
M"?O$F^QOT$IC2T673*I3I2Q8>D?5S9P^J'39QD*OEUV4PL*M;=DYH6X]F\#G
M%2(K_#7<(U @356C1("+&!E,(6MDT"5JH-]G95-Z4BC=^_TN\WXZ45.LO=).
M-WD+.H(\])W]F=H/:\L<Y54V@[!G&@,8SO'E=MW\TU"PHFPQWDJ$6W$K9;7(
M<3\(6\;:VHO=!)Z@5P.9]F!H<ZJNDDH)>-,&^=5<.(C_+M4D8+=Z#J;\HJF^
M<<KM7D_+ .-L2F0"L 4\EZ&2STKY]E49K\+Q.>"U&7+IMNJ3! _:<M Q]K.S
M5'VIZG!7V=Y'81UM5,%1/%;O-;7,_ &6-J-#ES<X4EP(*_R2K?#WJ)>SC)L#
M^]-!$YY7<V(4D6N[PJ^WI=?<2@;NK9S!)W[D!R6'"CCGS#C<MW5@/</]UI4H
MY, ;.IY)VN/_"G?N4V)9E2N;HT;PH)P,Q<GRYG$V(:BNV2G,'X3TR]_FV6;?
M=V-:S*OCR6]4FA0)ULV/\6!U]"U/<"3\%JMJM:TGN@D)TI;[S!_AII?YND>0
M]S R5LS%!WW+.&HE*SB5*TA<HW2GENA[T\0:KPKC#'TH#SZ++/E;G;=E_>G$
MV=: @T%,<*/;!"3"(G4/24BBGU^Z&J+Y_<NSX6)9P:C2BB%F\?=;TB2^ DDW
M]_F3/-F0O*(:43%[;KT!N(B@,V2B@&2!@4N>B9I]6EO!:ZX$0P=QXU^ZME+F
M0:6/ZO24L&=E(_@2OE?VQI*%G@EN".X=J3[B('PZ5EV_%J_ _CH:>RT-GX$U
M6R/^SB'$)-_4)HO P5?,*X-/HW6,OSJC($:AVB9ID?FAVHLS?[.BM[_,";]?
MC>;K%@&K_. 'GLE=)O?V)>F[2OLM8DZBY.;D%!X)AN$W2;Z.^ZPOCV=.7V^!
MK7L_=V^\,;/Y^B'BM"WMZ)[C>6)9CALCM0<F\4PN 10K,X2RK6W+B'T)QX'J
MWMP](^N78]746[\2;-P'R&<2%8Q&'EKPLCL<!C]SP^ !"E=KRGS1O\[O7%-/
M?+$>RX=O_TJZK[MBKI6(88E-O_(6K1V:V9!-R(G4657V40]LP5-LEG?-ZQ5/
MQL'P=B@V7*S;7Q?1XE$2Q'./&-LT%-2Y?E#;9 L/Z3[OU.&5S,G>/MB:%!(2
M[*59U,D@M;/4H'@5IVWFSFO-,F/,5CO60K"5*IF\$F$@UH1DAL_-TTH>&S_^
MK&UZ;<?M^1E;#)'1<+K:X.>ZT@"7^GB4YD!E9&\<;D+45FA'[C@J<<F32#3$
M:#77[[+!+4^=$I( 5%  "1W^ N.Y::L$V><_(&'-;"L[S^+[WM86T_;JXHUR
M?2:UH_A0C\D7&-6> S^-;G[)F$DR3G:L:N=GIF6DKBZ*43LYJ<@U1%.AOIYC
M&;*N:2R'5UI/!JM:86,KWJ>RJ^JXRKTICS3&S*L-G.Y+]-]K^H("Q)XE6Z;0
MJQ2_Z[U^0.O-@77C' L_$J,R6XLY0RSK=L^U*AG:PW$LI>>>-6FE8QX2O)+E
M854 :"1_K)H0*ZX2AA/-V=]47;7P@4CR!SRA'($\]MJQ12YY'\6\J#U,@;+T
MO:,EK!T=.D:X4\BQ\D<]3LZ2[/J$#>#Z@&,&&BU\7-(?$SQ[2W7+I.TKK+#2
M^$G8TZ+[><[\K&;4<M3VF0T;=>]4'TG<TK,GSR.X':,N7.^GAZ7NQ%TU\N%A
M3%ANG9)@.#:E%/2FY?V7WO?NB'QR$[T<R(/:(,"O:DZRVH'4 ;^;YWIR8?J2
M9P#@WY";UM@T:H[JC/VX6=2S ]'0FSUY3Q@J+E5HJ\/2SE;/6/=ICF4^KC*1
M6?SP@Q^8:OD23;()RK9/-C^TFJ'41\METO3]P^SLXL3]I]3%+$Q?..HDWOX\
MG&PL?0F9I0LIELDQ65+GK#MQ=J-1QHB?5VJQ&B8RP_*)YZN^(_MAS0$C #_C
M<??8\['7%=_#2F$<Y@:>&HKSX;DV:Y>=L%>4XID>) %V_0II*F)X[[]O1NN>
M#$Y()>NO^NJL[E"7!Q\B0U00+VU2W\6U.QQ/.^#W2XMWZ;R*H YEER66TTJ(
MZ[8#A2[=KRX%=;1P5:CJ&SBH=7<[;(PP:E5]SG9(VWC.1AK/0ZWUG3$N,A78
MUWC*G4+OSFR**82)52^-1;GWUEENB?LU7+9.S46'?GDY<K- 9'F*9*7UP:Q-
M*YXO<Z&]SN"!L>X,O;]50_WGU1#<XN!X364PP)PZ4X<8#'1=N7IJH SGAXD;
M4I<B%&F^4X G&3IU?A'<-7"<CQ5]@7EE+QMH.+S_KCB,29>+@ZI/[Y%IY+>^
MIYCTYB(2A_\/>V\=%E>S[0DW@4#PA! <&@+!W5U"\*#!W36-NS6$  D!&@D0
MG. $=W<G0./NC01W:*"!(>][WCOGSC/G/G//=^_,G>^9/ZIW=?5>JU:M7:MJ
MK:Y=OX)(*F3\*H-[2(U5%6I%[Y_=>&9\SIW;VR7)5W',, ]?#Q",'5Y#I8(G
MKI9G0(MO&R2S)<GL'32G3"-+5K5,,#Q. ]RW[/=$Q[LE[@&8+AU6ZB0>%]_U
M>FMOWG(T5XW>YE)W")-&H0?QH6\<+,DQ/D$903/#T:BW- 5ZODJ)IPM:%O,0
M.1[[X@?[T)45K'F[>N7H73",-DY\6>+D3P5WJR+=M[J1>*=<X1&YFBT=)KLN
MS6C&P8\#I Y0?][#-98[VF23M=M0W9-LQ]VI6AMLR9O@[C(OW^=AG/DV;+C)
M#1F9FD8%=7AQ0W@F')="./OD(H!=YF=@.W)DW@<?,O5D&>3S74/EHZP>5;E2
MS];7$VZDA<5233+YF-SU..K=SS.L5P?V+57:]C29\8/"S2.WWAT?A&8N&+U:
M7/\TY>$XJ[ AP<0%9>/H?:I!JT45.!/X"8OS,0!4]&.W7H*2C$),WXJ[Q31D
MKBTH_/J.3.L93(Q(MS:P&J0TWI5@2,J[AB\8M%TAYV)^,^UJN3@A&(^3(EB
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M.YWAZ[[ >NRIVZ'TZ';8[_N5F7_$+= 8UC'*^,)"SN\LDW8T5()58#>]PI&
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MC4XB!+)FYG=T)P=5^69S&VHU9250C%>8!:"7N,5^',>A%YY3PJK'0LKP+RM
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MT!PGTT=S7N@@(<G-?M1*L:LAC*2/&K(\VN4_YM1EAG&$]3&3=NYD3V$ZA'@
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M.*3OA"#>*3*R*8@[O0&P 5OX,,'D3>LI4M<T'KF<;3<?D>2Z?;BA+52[.I
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M]Q<8"5O8N13</.@OA]+A"5)LQ \2M)+/KT5[-PW3B7T'(P(FVH3HD&+&A G
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M?"P@_+;9--A [O;]63Z8L9RTJL*J)RCG34Q:=")@K0 6E[*-[HPM[;18AB!
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M/^=-GKE/*KH-\8DRUOVT?Q8PHO;JI'^;.)_8]<(X$TNV>.#P3&0.]4US_KC
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M/HWVP'8DQA-*79HZ@[GJLTTK/TRMHAB8$Y\O[E4AN>J70]D)IN#'1#!U<0!
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MD0/EZ7.%=@*;%9ZLETT5+1&R$7+3-0<1\RT'7^BL=4<8&Y]RV:E(XL:TUN5
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M+5\D>HO9'NW4:F@32FE?,,=61IJV.XRU*IHMD[*AF88NO;<#(Y"<#_(.>DM
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M5YB!T0*9TT!GGZ]33$[9S8BU7CO9P"L3(3-3CQT#%ZA7EU![6)9BBF*-]69
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M.Z?X<Z9.9:QXN:M^,AGY7;\'!,2'LPV&V,7W@.Y7H)P>O"L995GX5*BQ,+7
M^-6>01UW]*?_<>FSH[10*T&9[BPS[+CCJX1]G,M:T*C2'33&EV-HBG+TX#YI
MUCH]H1K1_#+0J1[QI'BY>G&VA>K"S#Q:&<_!7,/4EE"T@W-;0I;RD[$X91U/
MV+CQU?;O4TOS/R)&?]5<",QSA YI;ECRTB"X:[2TV<02[N;JV+@X0LGD"Q./
M"'@V3+X#;!9%V&=NVTD]T?<Q4 9C=..Q.'LJF#[_[)Z1O;%EE&4@LR-.,7?Q
M^G ,]0\]]VA,E-'S?Z56^/])<[^;%XY".'-P)AM%-JWO59H)NEKG^'9(V=F(
MN0X':F_M;JV01L0$;H__Z@T&Z]^6?Z_[E<Y.8.\>0%HPH#J5'/=;M?>_5[?S
M7_&]H;TI2/>Z?K-7DI,8HRI.7A_>8OT%]DJWNV2%5GH'%&;VL0Z.&]</6$]!
MGE,@(U1Q+/%*$O$E6/>K?<K-'JJ"]HFA(?%*!A#P Y/*L/7*HK57A5GBHZSZ
MFXZ+CFP,_)K _Z/^*J-@_E^5@45I!.?=6#3>'!-8:X@QU$Q\;=(ZU\T[-0H:
MHOOLZZST'N%$U&$PJK3!S#3.0&8#D_Z09#TAF>7:TT +@+*8,-VPX2\*4IMB
M7\:O^;NC4WLZFYS:O[@G3GX;$UZ3=HQKL#NAGP>NK0JSJ,=--#=,015]?)5R
M6A;\'OT$B!W#?1$.I:E,82QX'M#,>&DD@M-_5JZ'#ZCY]TIPI]DKNE 20,>B
M-K8;(J0;;]XFMVFE/\[D\#\"F$4^/:EUG3)C% 2\SPQL(;LP5;XBJ>=T.[4;
M4%%&O0S]JH3ZW%_TIZ]K3<2E]/NI"00I?)6_]R'I':KY5.O=7H;7%%/AZUB]
MT6=Y7SKE6?'R!]Y(NR"]*."*LGZK;W:)BW.@G :*\O0B$C(X3.@C4LX"0+(;
MW%MR$J=L8;0F.@K_^T5J_W-?K(4_X6\,5'+Y^W7KT10>)C^)S$\G_F&QB%,:
M0_N/01A_%"B6]</R=.BG:EUCOR']/>DCG+>F/13G<[\R[+N81+F\CM2>H@4X
M[]K+HE(8=5+EJH=OJC2K8 X.U/'X/&.T,Q6+IZHZR)Y<TN.(HD@/QJ_0[^ <
M0YWZA#>IZMG#C(=-)+9U"]0QY,9\*4"3[O5^ CGQ+="*3!*S@AHW0.E4L%_M
M\3@^ AT!XA)*E)YYDC\-Y2WCG:7#QOA7!D1Y1D8KP)=PAO_Q[ZOLXL,^A\)X
M-JL_)%,*,-V_IHPIX5(HU%Y8]O3D;('FQ@6B==+0)!G(9)^5*O$SCDUP<8A]
M::&YR(S;3.M&I^4(9(L^YD9R/ G?">HW'&N=%;$#B^W'HK8K6?VJ@ORK;G:B
M"N*DG!2 K(BP2:J#WH928I,>J8U)0Z^P/*O=^OC).P.2&1%ZCZ_O^'5L5_?H
M\FICV=QKD.V1GW23K$'>K5-ZF)C3$;A['6?R(V0N[%W/-#?L&7+#,"YR3T;X
MVECJN@K5A:+"#REHR/(BG$0]XE5..!!=#.X!Z_< 0NM,ANG>HP0/BMO*S?^/
MO;>.BK/9TD>; "$$"PD:+ &"2W"W$#RX0X#@%MP:;0C!'0($=W=W">XNP:$[
MN'6C36C@PIGOG#OWW)EO9L[,^MV9N^:/6OUV==73N^HMV;MJUU->@H>\*"78
MQ9UOKZ2Q#M7Y50)W@M7"+[B=Y)1"_'']YV/Z@.>_'53\]W^41DC<UPQ2V<0E
M),]T-&^WQBIZ>1BUM#G9ES)9:V(D;%P\'():HMS\XGYL("8&641A9%/AQW:]
MZ_UX2*0;;N(!I4.>EV!^E?<GMU!WOXI,*E!5)*;Q93\\*^,F4S[*KJL+4_F$
M4IUKN54-%3;BVPV=-6AF'!!DW[D#U$J%^F$^U>I3<F_I^+)&:V[7;CW?^Z<7
MDN..CMAR'T..TA'.I:,\XE-GCKKRTV5,&@;M%]$,A =(#'S[.N7(C(\XEI*A
M!@NQ[_I[1.L?[YMAM;C*G**3\5[7(AT;\VXE1#O\ZQWM(6#9!G60,;+8L,JG
MJ 5N:3&;SLP@X4WU!9KH>Y":$S'K1$PDGX@\&QB^?@_4PR4J37A.P+!MT;5L
M3#7O)TK>_&]>[/QGX0W-T<P@]<]RCW7SJ=:UGK5:*=]6"@>FE^V-GU=IZ(YL
M:$Q48_E,WPF\S".D-0G^ED.VL.M9N/(Q/0S&T2U,/6DZ6[MB.W:L\-5,)CN:
MK&DW9L:'LMCBOLFTLE6(.PBG%#,C['%6ZYJ3\'%(GZ/I2QBJ9.>QR+1P9*>]
MK#,>5\#J[Q"O/^5(199KKJR-(MSE'PE/<)L<&))4VU04[JMW0_S</BG,TTES
M\5!I>AZ>E1L?@F%<Q6E;J&-?5;-1R;^N@9T'.423;(V<.U9OB-P2:S)B3NR?
M<-)C"TL8&%(-%Z8USEV1:VZB@:=MU.GUJRK? 3ZGW@$.:H_AVOKDE@GX,TCQ
MO@SMNB?HD+0V[^*F-S_UI\C&*EQ(2F+N[=JLC6H>+)DG$&HJTD?L. K?[C/=
MOKP#9";? =8*[@!@2\?ARK9<@32S/1Y-^CL AD"WP=D+Q>N+.P!"GA;!=(P%
MFE 6.5ZZ \ X[U-Z2KOQC\[8EBO>$@0%-AR^3(XE=/6J[Q-AT'@0#E"?6TQ2
M,+"6N%(PR-)]$7WD\E#+&0BF.\ ]C/P?,#E@M\#0P-MI^=QULJ@[0,_D(,N/
MP]?+>[W,3@0=N%XB[DYXS_:D3T; G'H1PZ2?G"_Q)W,2B/N$ZUB8;4/#O]53
M9\<FQ+R[UWRL9",ZR@#N07\WB&]VD/I<^G8<6%7= 1;V9X*@<U.WI,+F9"(0
MM:NG;8PI\ CPQCH% )C1,PIH?LF2Z%)$XD07+OTZ('>IU;]!P*'1/WS[<;/8
MI?58AX4I#A0'_(D6 #=7)=Z^]:8^*TW8UN7#6>B_B/&'-'0+&?1I_OY CE4U
MS85^L!T(ABH$Q_P@+:,:4'X$&>&#(%L[K3:.!W34N]P!>FW0P#C!!\)D^@MP
MJ2X/E\T#C[JY[*2V9+SG4I^-M<8&R=FUZXE13 !.34Y7QP5>4G.EMX^T@-PF
M35.M%*7 8O#O.X!&E;#-YG W:G8K)0!VC&LKP_YS%<Q<FJ[[XK<>F/41W/Q^
MF#MP ]MAP87MZH!6:UTZWQ(T91PNXEQ(YZ:EWV@CO;XD9&T"]B\#/F%MHA)K
M#<K4]-6"X'3SH:TR&RG'SRQ%D+DBI"0KL5E<,#RO@QI\LX/LCYA"RV<_]=/Z
M&8C[C*W5:OA=2P&%]U6G;(XX6VZ$U>MF./>3GHVBY.%7/ZIZ@\Y2//+X@R.F
M5WX[T4W,K0CP=".HBQDD P5U>>OVW0&L9FF;Y8WF,#)J?MA/O LCC9%"6JNE
M_BSU/?>+C^GA'@CZ 6F#\5[\<@PL,RE8Q/0[.V?/PBYJ@LHC7$&,MK"(J?H+
M%3P^9(N-Y6_/&R7ETQ3[[.#TM%^]T,LE\H!R'\@%Z0[Q5P[;((M+_0RQW#VW
MJL2= #;3+GP7ANU4;S]24S5Z 31HI:,TT3E5N@RBXRGBOD%^"?3B@EYV96!Y
M,4QXO<GIS[?86^P=UNTT^9X(JHH=.=(>( 7(7*GC2N*KX4R)LP]D^3\K;>6'
M9/7AW $,\LSI2F@B7K14G58<3%\;2,%.>].IH/D5&Y:"Q&!F@A46$H7&1O=?
MT>B"39?^S]TE^9ZRS/$-4QREBER ;BJ8[P 6BB'";Z"K,1M-F1.<P*T$BN=,
M1[!E)'9J)(C%BT%WY7 _[0:L<.Y44J^6.P#J$P(*;&%!+7B8:'.H'JB''W6V
MO2!O$"5 3<:&.?1CB)R-)I!X4NT3??VRN&VWM_PU)MS@W<2#_QG&R@[A:*%$
MZ55SQ.9VPG!*@4TL#5D*S>N77=H^FB=NX;9\!2@YCGAI!V+7G+?SDPAOF'DP
M@K$$J&/P&!@FX6=+(O]WQ:#IXQO&[>L.$3%?6_R-LX@!5@P1%,B!FVFUBN3D
M3G6#WZ2M"D33O/\J:(9RHJ]F%DW%O8[;N [9'(?32?T4)D4 JV $?FYXS9?!
MM1@EWHH?8M&?%B8LZN(U/T]8)%LWEU "4)@MB[$&_LZYP(>.A63=CI'CMT!O
M(%;*^X_U9"^.AUVPG,>KI:$'"VQ?GR48Q"/2NDF:2%4B?LBL]D]:K;%8SHR+
M*9;*O_N7)MRX9!T3_TU;>[8Y7[:@\-H,N!QH@Y@'.._3?Y-U01G1<G!KGKAE
MV[=L"R$>KZ.$#\L(,PL3\:2X;)C>Y%QP2XXO(,991U8B&E?Z.#*L3M=:KN6Q
M?D#\6E^VL@T=$:[PD8D9GN</_+PI(&;WJEF??<USA-J^O/*83]"%/'4"K=R]
MWYY$-UK!H9>MW)>VP6 :D3&<59':2@7#Z3U<[PC2IVF9VVS-Z"%_%2775!,[
M]03,??RFQ_![\?:(,A&5,0.T*3RV]WJ8S%,3YM9S!WBQP^]:W(R?&&1S,.3.
M735F9Y+TH7#*CH*) 2_S_>)H J783V20&'QPX]"IZY9B7N_(>4G/\?1:>(BQ
MT$UZGMQ8DLJ.J;E<&X<:0C2XKU>0_BBVLQP@>#T_8H EJ%D,-%_7['*;.NH"
M60!CF&P[0TQ8,1-Y!')0 AD>3T]O$?5)J2[NZO//VOA0ZUNLTL]5"'*Y.!35
MZI!GL&3@7+AF664>2F\]_3C:@-D]2F3V :>-"'#A8$\<K\;QG.<1&HHWZ&F7
M >D"3Q3.USF2P([;L=OITUF\'YM7^<PM-=$;@?:2;&MU]NF$<W4=P3IK8;9E
MK6(L8=:Y5B<[<W/<]="Q:IDGJ)MI27+"B(J!0/;0MT1Q,?U>6K#1\>Z.L,6Y
M%O-'>BL_X6]T2-R1%H]^AQ::V3:B_J![:V__9'T";?+=.L<GET[>_?FLBYS#
M5_1,3Y'F77DOQF5/6)_OW;Z"&Q3"977'<67 O%QZ"F3D%T/@L2?O!GG?L!BR
M459OQ)Q$;-EB2ZYK<LG)P.:*K&$TQU(PC1KWC9:2".7LB;,%9SBHIN(0SZN(
M=$DN*72]X5@4<^ 1='("K<X[2SL)V70>#D0C[Y!%Z4U\Y;KNH(]<Y/4!QE+G
M"9'A/!17J6R>.,Z=/CM\V?W>&FZGCRF0M"E]\O+C(9))V*?7D?+._GW-_6&"
MYIE 1W3;5KHIN+>7N.NJ[*!CRMKP-1]'/EX1WYOHN 8B_5JD9;A4?X(^NXWE
M9Z/&J&M:E12YU&7*\MWLI0Y;]"%$=YP>3CI@9\5A* -:07R3BCBN0HC+Y 7J
M%B(,"B4X*_LW<WB?^9\D&+55$J=&J? 2<MV8&\RV\TMM"##;VC#*&F"79[$N
M'!C'JL4=ZB)3-5<'0BC>N@"VS>S7D><0!U4DNLA%_=,(RS"7)C'D6%Y2KW[B
M5T[SH5!F)W!#<)G/4_B2LMQ,_3R"IZ0]ZB:?2K2FUHVM(I7*Q.7=#IP^\$B,
M].7.]HR@F N,9?Z''!C]4,[2T;HAN:PME=S83.SI4F=D>$P?^C)Q3[D:*NNR
MKP?X TD'$:WK6_ZIJV[;C8$^X%D%60ULJR+W#M U.7WT*TRY&?J5PJ9^EO:K
MQ(7OQ2BG)0.=<M.C '::B2$/>N)2Q:_MG'->!I!1%A&X;/X<9QUT67,Q1NM0
M[_7,FS@*4W>C@*=X1)2")1G@48#G=D;M>N#X=7Y,>;R!&;935 7Q[<?Y("\V
M6$)3,8*B 988*FC$I ]>?9^V./5D:D5E8WILJ<9I[-VA\FW%&[2$7VQQ4IVW
M_#,LPHSR&]U%>SKY,3>!+FPT'?D8)(5FVCWF3UX'L<4S#^K+II(BBY)WL2#S
M  +&>-[V*6;BA3F6(ZEHD0>H1;OW;^JCDK=!A*R[[H<"E^^"AL*I7D+%>\]^
M=M43C+T4L"?+CFY.+2)^JFE-3UWE4$=PZP\!/1<)%2:0\?9HL >V]X&W3GJ9
M58B8DIB-DJFP.>C[9-/&AMQX,$X" )>H*4Y(QPW"ZZ",H;R*9W!Y2)J<&@R%
MWSSDW'J4JO?]V!3<]5(QDE'[M6:<2;TC97CX,[X$Y:]QQPYO/!U3"S-1_T.6
M9XVA KUN'N=VPT<EM&\(H-ZC?KEI+@/<"!U=BW*O[SE3"WSF>CV\GTU!SA[D
M=X $3E"=VU=E)2P!'0')R6 CD6O-Q>H[@'7)?G!M!Y8VR[2=X*D<PW;L@"^+
MR'%]1=+7F"K%548"^>WT]/[5-B9A<J[7KO9S970"5/NL<&L1=-"$@,X=H./9
MO7ZZ*+)1BGAS!Q ]M+Y%B-\!^JU_K72<C78P<-\!*M?B[<ZE74'NB7/F/W\/
MW[X<[S(XPY[K..X10;A&_3W0%8_=-=:5<L--(*+P=Y[P^#%.Z7C5>2*"*^-K
MQPY9&6@M& 0_I(#.^3R_U\==Z^X /J_O )"Z$]NU"Y*3G+_D/9?USEBET,XP
M?A"3]?^!?F(0N89?FQ%RF,V=:.=I=\$J,G)MQ+ -2GC,70.ROS5JS><="7]A
MN])/+%3SKL]$P^3=DN)HK3E^[MN)KW&4ZIM<9GXR$?$S7D..'+\=SLN8,7H\
M$@/M<MJFN4A*,.(7,:,'P^D6 GX,,,;3&EX!=[53I/(8BLRZ?KWHW.ZX$BES
M&:1GY""Z+M_Y3=AI4$>8^&L16/_S4*78A?&99C765&]C>M8@G?L $N.:,RNA
MI3[-O>F=Z(E_6.%N;/O"5]KNJ')@J)[(0W,;/$#5,Z06\ FXC<9@;X_-)]3/
MRS7G)33MI>=2&K=A,H.*T%61H?K\/H?J5TPP'>&ER95-M\FGYP[ZWI^9!9PD
M?AX4Z.A2N(8DOG8:SR*BR2VW_@'=G[2H#P,+A/'5*3V^J [.-B;U3[\#'(&;
M]9<UH\?.N$6UI<?8W_*5&YW^J'=KYZR&D<8MYYVG@LRE)_N_=6['LLUO6^WQ
M5?#.MJJ6:"-,)FKQTR237*Q.I5,<Y9#Y* )Q00SB0J\]GNJ(_8E!S-4F4L8?
M-^?+9R/RH]YUE:L51NW&HZ+_\<>%><A/=UF OK^=0;0;UTS%"O[6;];0<]WQ
M"/U7T+.IW&3ULN2/$N1KW]FT/&^T._C/0@$Z?UVZ_!<",8UK*NE+, (-.M>]
ML9Q8EB_O8M\0R!7#8H)FH?(+M__:95'8M1Y[>E]?"DK;E[P63J'SLNYTA40<
M[5L+E1+>,1JO\IB&KY [4(G>DC#OSTUP]G]7S<F[MY>!TW3&(30!F:5[G,,E
MFLGOEV*UB <0;\.NE-!R6<7DI/_Q]:U'](F_?' 49K=NV>MJYE@+IH_+7C?[
M#W76)XE%BOT:&0&2 7L]/OB7*Z"ZF_?:T/9>*@VDX]?4L2]+; KU3-F<^$"7
M<V*!MO%ILE,YA+Q6OTF4<S E)&1MJ'^W!PT*TTPX*V+L+U8$"KYVX^1_';UJ
M\%%ZO?2SOR==OP3 [3;^S.#'?@2R"K0\S&'#(O[LH-3M.<>C0YZ,EP'1F(:5
M)!0!BM#^"Y<I0?H-&X5I/8GVMMF8G"9W="/<IDY>M KA]KI3E];FC@,GF)$U
MXRG7_-?C7]KV[*N.K\>_Y^2?GQW[*2>8[I.]K(.Q7E;/K>I%&0B.TF_<I*.A
M'+[C-V@Y\B8NMW3JJK+Z_3FIJ2& W'3A<IB BD(^L(UV8SO"$,:=5K5\4RY,
MK,#N[? Q+^\\XT)%W_*TW\F<N=6QF[VYFO_J!0=69[3L;TU"B-"[Z0WY\[DR
M&\?7C4VNH7VS(</LE=BC/VD4T:9%Q$^5AF"\'_K8NUA=#9X?;DEXN9(#B9GD
M+G-*#4!4F? %F.VV8EM8MS")$TT=!Y-=Y:-G]8_YM^W'K(O@$M!109*<?B>@
MSVS9"@ZW9TG B&^ZZZ]?E^?E&!<><*M#%P?PBA5/AFJCHR&AX%!QO[ QMN_O
M3^F,.^^#MI=UW0P-0,$E"JE" 80%FEM>DL_#]]6 Q2NN'P)=@!!+X8^%M$?I
MLR=2![!K8U"7.C0*+!4I3*UHG&OI0SAWQ*QB;?!M$$ LW17+(^W421KK7;)?
MLNN5(A#REN3SYR5%<3^#$&%D.!I,!*+9_< ]E6G )$P([2MQ**%)Z&8M-MC>
M#+''=NTK:Q#I4W.([1[9\AZW2Q"*FF+]>0S1C+H5M!2FA@6%M(J8;ARCRO.2
MDZ@-#<SM/*UI.BHH5R1SZ/7,%1: ;O;VUM4*OYK*;VP,'T6Q="&V5#)GZN 9
MX3TT$/!Z ]_-]7*^B> :U963\WYY*3=QS+E_P]_[WMI2T)[=\$5V#DX2J"7F
M6)_O&N6VWP<)UM^Y]AA^;=#0W HC:DJ7D\MM!<ZA:@+GWOJN8Z-3T0K=T*]<
M8FM="%_7SS.QG,44=8,L65)J!R\&?FD$68Q!6MF(B/B$'F-[J M)]7G0Q!6(
M@T"EEG,:+R"#S8W-(91QM,C6A(!;_*N"?(3$C _6[7 &L?#3TBT#_%UA2F&*
MJ:PQ:D_=74(4>KY-E +D+R;$G=21TQ"T@V,PSKVE M?F:O O$V8",G:E$P4I
M=$#-%\=34" ."6?O?S(11Z'\=BYJ.2*M.O#.@:F"TPJ^"&,#<_J:7<8RO)+U
M4QS<;4<9:E\TOS\*)M/%BLWTRDWWT% \6(/%^'!YX4,OPUGO #6'7!@MXD+G
M;;5#NY]_?/=:WI0D%.%FA+ ^LA1Y*NA^3>OE-E6+(>^QRLQ"$J&,( 83/SY\
M?&CDJE@#FZ@D.IS0".I^8'\2@H(0+X(49\]M7"]_. "3B43J7;P)")+W;@)Z
MLEZ_7^F#LOF%;Y4DW=?D'8#^,CT*AM&U2ME^C1T/UB-1;?T,7AS[36_*>]UO
MX04;L^Z[)?=RGD=H7AMZ2<!-7?!+?<@GG#T]A[DCGL3GFD6Y0M*!T3[J,)%(
MYQN>+I%G[6A _Q\9:'5V7^MMRI86^HNM>,3'9PT=RS9;7T<B$=OT-J=J3AD\
MGF.[M^_9X8NQ["'W>@;3PHN9S[74VWO=459\&?:;4<8'FT%;I*PWIQKX[\H!
MG9G.V0DY,LS1*I,2R,__T8U _=D?"-?IHW.[+QG/2FNO+>WLRKT$"L7MK#'E
MJ6,'YJ90)=2OOL>*=ITXLHVZ^>=1T;V"XMAZS@F;&T*##GY<\ZP"KR\482 _
M+_/<O57\]C887F*])G] R)>CQP07JQ_W(D,!U(*?7]BJYZHSIE/!2=QALA0+
M=P!P8E<%*9"G9^MW?[='+K]PUIL0"_/P=S ,HH&/-6CV1D^GT"1?VU,17]<U
M; 82+FV)*/_>/LF7LL)/V11+=6RUYXB:QB\0\(P9BAIC70@"!_4J+O1W-@<%
MW@$VQ. =/8KNQ8-%)!W5>MJH:WC*APL7FJ1/@OB./.8+??HZD%M=<A$?8.9]
M.!2[$W"0*HR:@XA3*V>DD,4T%"Q3_T7G5:Z[(85S$/R+S=7MI(4<(^OPZ2,<
MO AD6R:<BN']\\.?JDZ-=#\1+3?%"$68XD6*W5-"^&OP'0"+.]C6?O+G\IK[
MEAUU$,7.?B4R&AG05JI@(0/M5@18<=]?O R+X"4;(L%>9#<!9@T$%V],TO<U
MWM"XR0%7Z08=?OF6Q,51G@Y4N&FE*8OR]2F(]>$8^KX5S3WAKD FHK+R#U#B
M[=]5V78QS#-WVHA:6%KO"!;F1IC"PV \X(Y +C)*#/C6=*ESFPIAS;<?#KA?
M?36'HJ]<1UYC&R,ANARK)7\J+MC=OCA>B.I+%X(2!K>^ '?@P@W&6F8.N/0H
MI"TI$[36+>48'YNN.+VD9-*W&V9R*)^8BA7>TI48)@MUN]FD95Q+A2S#CBQU
MEJM9B06JU5/LA5HB!<B%Z+:G>D[VG38R%M;6&X)]N!$F?Y.)!@.^.?W9N4V!
MMN9;MP-Z@*_)R4IKB]'KYY_O91+3IOILX=.W*!75CH30@DEU'>,"C?7:H6T7
M65QS&6!>9S"3BC*NDV!LH(MZ.I?$PA8%\X;$(F;N_&+VJ./A9M%:VI""&.GI
M](-,MV)7CARGM@RZ]A>"9^>0QJS1MJ>;FDW\$ L(48$**X:?G)+2O[@QZS$U
M*4H*"FDG6X2'Z53-&;:W39P/<UFHJDZM/-<(N#UC1\>=4AMD0BY:[,3_L94[
M>4OQT_)E7E_E,7<>&"-88]5;!_8C+4?#3$TIM*J/O3,Z.*L2PY:*:Q8<D>TK
M")Y>3X\SWP!A[*![>WUN%2F6*M&1'@N4C-%;IB+SQ1\)JG=8K75A#=0@3*=N
MG"L[*C\K"1O06+WBO/IJ"0SU4:51V^B***&TB5&++N6EJE_$T;=8I$,>K3W^
M\E(H,:"5+=.[^*H4(5"47V:AHV9N&?_+GMJ.-7ZD;.)Q'[O,5L4>"..S2YFQ
M?/,,E[SDQ;!BAY[L](<$Z=ZVUCT*:^3-J]Q'O[Y:/JT  /">'M5'R;*)DHH@
M&."?9NM(1@5T9LZ Y_0H#7/\7E5YK>.I+0S5'._'Q[9#8D($0I:1'\/]-\@#
MP!FXJU:_JV6*F%>CG;69:#Y]LL#,UEOH@U[[=C^^\@@GMV[NY$P!'(J2@TRA
M":@=4[8N$4Z:,)5=AI=#6&86^G1;2W7FAJ2R^J(<08Z];FQ$@K,1JAOJZ76E
MEO,\OQ.R/ T+]C"*="P=:T'F7TQQ:HMPKP+$G +,&7@!J #L;0MP1$X^'7)@
MW(:7QN_Z E"V=7-#D$@=]>DQL_/QZTSWFCCVW$G^G 88.\1]L[J;BR4/NCIW
MK71OX,A+7DO/GET[625'I(:\Z:G"[Y9B_!#Y1L6U8PQ].<L/I?YHVN(LLU!(
M N!PBP9W,X7>#JO63Q\=FP<IM2<JQU2\.<V5(<4,,$+_Q#8[S#?.Y/#1K&9#
M3US[)C-[!G,Q/<DLG? D>^; 5TUF=)[QM(21K.Q23QL4#.A\>4'SL8AB.#1<
MM]#VE^W*%YGMBM-,[,?'ZV-!GM#;RRZ&>8($PK$&0M6^H<L7BFTF[FF_))>/
MAG@(T"(?KR[>S[B>-A76!(LS/)HZ"@W6+\2P"PJ">[H>H;^M;F;G?Q&XV+G1
M1&)=E5_]& 5W!E>4G ]&L7&63-$-PN/V0]UJ \L-&C<UMD7'>7(6L0_$/@XS
M-GLFXD(*5!?I<A13Q%Y:,_"2G3Q"<*Y2UDPRV^3K&5][R,V&KO-'U?3C:9J[
MGG^2<5%?!\CLZG=."M /(U;[D2L\K):JJ\,166'D3JFGB"L$'?+7!CAKECBT
M#8%*F^:4Q3^4%)T9SS,R_9A$C9YAT_[I.B3:0[55!)I AM8WG\[2..\28:?;
M5$V ^?LK+'CJC4LT0ZE#IKZ:,^#YF+1 R02>/6]_'<ODKBBI4%17FX#BA)=N
M;K^;JTVKO(N;B^OFO+.=?8N!^; OVP0IY%$8**#9NV[>GT:NI/(6K]93[LUR
MBHEF@!&-6 -?%_(/9/]>-Q(I'>XH12O 1JDPP:(./$5NKMQ%2%$E149F6C[P
MPF)9%_T=6O=7;1-J&@[&)KXW(9]QET.?^L\E_*OVU[\8%, )L;Z"!1!0UXHX
MV,H2]^>*[E)9T7?9:>D!N+<O7M?;@:75*JJ;;X@W-$[N99(F2 .G8"+AC+U]
M$(2VAUEJ8]\2RQ U-QLZ1%80GD@B^HM['6V53*SB0Y1 ,&TYOS<.7".FB+>$
MUIA/-3QM 8)VH0#-HKX#6%EGP'$)[Z?VG%MBGJZ,,[RY.P"4DO662W^I5KE6
MW=,JK?< \A/&"C=9>PJ:4-6] W0&=\!G*:"#[7AW@,S\ACN 'RX(5GRQDAV1
M'66CVNC)>R$H]W=84@AVNP"1'?JR.\#Z>P.$55O#@X_YDMH1^9A0%*[= D]7
M@/3MS#R_:U/8'2!",\[+$2Z3B^#PQN)L"1L.ZN!P#X3E>'U#CPSM6*/PK:A*
MV429_WH[U8XY)VCCO:%K0SEZ%,PC1^5WTAL?_F4Y4ECR"%OZDJN,86K[X[@X
MPS=-EJ"AZ[AA;*+/XV3C$KRO'(4O^$C7(?D*:X%>^&7 H:O2LS)AZQ!-#,9B
M1(PYU?9GWX(O[Q)0FUD4%7V@K <-AN:OVF""=P"[9M-%IL,\MKXV>[T9EHOK
MQL47J(JK%2Y39]8VE(LDN@) &YO71)%$JD:%@^M(2W%Z\0[>E$[=V*O;7^$4
M%[J5==\-@.D.WJ[#?N;65._#4M=;Z%"_>S4N$I*XK^@?YNW4-PNU$M1K3.CH
MB+88!Q)U,6#&^:+9@LH^XE:J8W2.R<O5:B;QQQ:5F'^V["/!=3>/:&_B.U:9
ME--.#K;VGVTE] 3!="5@U(ZB]1K<HQA]O:USU#)#OHU]IOJYSEPKTCR,2//D
M2>4X:K"(\ZA>&YQN1OR:GZLZ@N.,KT^1D>B1W/M$W$3)3L[R<O_,*4EE6K<-
M8*^C^.6XU(?5VH<V5HM$L:U&#@A1636JQ/VBH&DK+#X1-U!^[K-3CBP!B]]<
MZVUSZ\8B:UY86'HS)1V3\3:V$BKS&82[(\0X@2;[I\L41#WAL!A]<ZCGQE@1
M]$+>^/J=M9R_ZVO<,&WBJMK!M*5OQD%D0E@>'_T95OC=?FDF>9'!0XH1[VVD
MK91TEH2B8C4/=B!O6CL7AD&5('[ .>JNG'3;O^$P\+H<1P.J=_BP]4K8$S/X
M:$%KB9.5A.!4*X:6X1&$.-XC9F+>Y=5R*=I'#[-&(=4^GCD1_%H1S%*-<6-W
MBU/!TJ 13)1<U&VBFQ6 V_!40K3*GSI&_:G3%+&;B3,^VH+4=Q+D*.51[46^
M')M'5GLC7R670CK[K2"W-%[,4\)T<%MO1DT_K9MK]QF?$V*VD^JX'??RI4?1
MA?UY'ZEW!Q7XV6398AVLQ;=P@NX 2#Z4B#<S% J3+FF,2M#4&@X,QEG[5YBD
MIGCT_5CC5(+SN5)0X;%+@Y?SP7:_YLH'A(VD'[WG=U:></BM67Q U6Y)+%XT
ML#_7;!Y>0L]WL%A3-0#]=F5C_1.6)G>MN;$6++Q:+>.0-P(9?<+^#OO[[Z?G
M.#CPP*6/M3)E&?;]"D$G)6[)SIJ5M4Z2U268-@Y]C#3CG<E"$<.*6 5Q'*0)
M$0N@F(J8K*^]A@P=9L>/C\V\43]*,)S-SN;6\I@I.Z#$-&]JRZ9SS$?&W^O.
M-2('$)R#[5Q@<A>9=IU_F?6+O6P9-=:XMFHJY ED_<;%#[J^IRP@*(WB+4/B
M-0%+NLV8R/[6_9>V7K[SD.V3_J;3!C^0T:' QGA4.X/5;Y8V!\LLX%Z?KC:G
MFL&*CMQKVE'E/72[0J<=QB8X#K1Z^,(43E@ U-E7MU[A$6UH;$H^>0\X7#VI
M@0UVTC98G>,<:+4,.]T/ANP@F)I,YI)T!&F$8' W9JSB:PVTPE<-E)'NKAA4
MIQ7R4UXDU\J@'Y*U%7APRBT;N6[^-U]?)M04ZO:HK.KN(%-CG+I\>N\M5>;-
M!TNY,)CU,H<)*,+CUJ->K@!)^@DNQ#\T-D:R<96M%)J9/G\/"GOCOAL.TQ_.
M0@A [P"!1LE"5!^"Y&12G,/,OS>D;M-:$I=Q9/> -LO&IP\?)',:KO1L&W\$
M-[\FVUU] 8WJ$6!]#@S<[TU_!3M@U]WG'X&5VFVV?DZA4IY@.1)Y>LK,>(N^
M5#0*352&>X,50U\F5&5W58D$;>BZA%NJ4N<K<GS!3!H;<?C!^VI^0?Q]&-^I
M+1K?'2 J201>+%*YL;NU;'S;?C_+@(M.ARN;C)>OJ'H,*C-"VE^#NH2*X$L0
MFH8*>-R[ML"],=!KJMK@URH_OU*T]DJ-IH9KEL,Y+EP,T&ZGR-_"*YM_);*"
MA;A7N_2X,M6UDMF(3I'-.Q)X+RMT;GNC;CWU0.L?,A#J%#^K0..Z&8@G<0\W
M':7K^2<(C:+Z_!3)$SEVQ#*7RI4@#>W2_:*VO=48?0?@T%%7MCEB%<T.9>AY
M([DVEUNX]'L"[;N7P_7JHSM 5?$_7?-,T:VO^W<.@#8/M!H.T[=<BM$E?_6*
M_?:=<X\.J9$SQ?),"=DU^:WES/W'9'V:!"-@I;8Q+_O[G_E _5L!/91-[A]S
M<?I+^ I)UA%?]14,@S1\<:D@!AF1T4R,,>L8,MJI,U"8/4'Y!;%$[,]1V0R5
MJ^5OI)7->%O'POU@M')P'^>+F;)R<QXS^<!5+N\L[J.QK8_>&]-<<Z>^CXG]
MB,?SW3/1+?^Y!Q;7#]-7I"\F9FR>\.[NZ:X5G!45L8GB$BU9!4#0YKEH<&SI
M'>1$T:,\=/[PH:U:1._S2;,><ZG W'/+(*X5LB5YMZB7EB/!M#$#Z)%E"_]U
M!RC57ZW;.;S29 5!Y$A$7EK>$B<0)Y^<T*3S/,E_^_@VM_+5[6$S\HP2FE*'
MZ_W+>/JONXC2%RRF28MNMP'<ZX,VO#6F(68M%>,6D[N:"3(HJL1XF[[!ST3Y
M2+,J9 R:&1.G$98%J\ E)6@I]VG>^3=&)^H ?",&5W+L@[C3R$SG\BR?G3_=
MJT**I8AO'&\H<V?M7$/=NWV2\I&_MV*!8#-;6FLH8LN&W61#9K_5IVY?@2-F
MCZW7X189'I/O)>IY?+!D74@^/\Q^DZ?NU%K/5A?ILW%#AUQ-1F]9TN47[DT_
M\Z<.T7,"8KSCTV7N8W4/!Q<AW$%EW1:Z<C6U%GFI_+Y$(9)LJ1GG84MS;60=
M#)O'"$MC<XB\2#=[-X>^_OOIO@V\/L#:3 (*Q4J#J$<H8(_P:&J*]<]V*_Z]
M@2UQ*D-&%&LIW=(]+Z^H$O/5U"'>'L-7'CO.1CRC!+^()<E).3E1+'#X4Q>\
M)[:H1'A[=$0KV6DR?[C[/CALR2@WG&?BO/W[A:G6!DC4*I3P)D+CX?1YHJ&N
M'-S^*M7Y+Z?-&<[R\@,AR8*]YZ4*/V94O7K/<T8,=  N>&MLWA:GA'.^9!(\
M]Q'WOV>B*<O?1T3=QR/];\+_3$(5M]S[F"3JL-J-IG[C40!0\9"KW1GZ(Y(V
M?K!16">\7CH*^6J^F='$O_9+/^G%>O(60ADB3])%N2ID!7W/PN-NF&G)8T/%
M>!*.'/A14XJT)2[5%@T-.5*([I&'COGW]MIVH]\3R(7Y5V'[4O?? 'OT]Q&3
M6ZQE /Y0N_L(][!]4>SLE/L(\G\M(7T%]?S7N(?34=^D:&,3V)%9NE1%=JE0
M?I\A]F=_):EK'>UP3%66>ZGG+@+SI\73=REGCZ*7Q6R-AVN-W6EY.RFH)M#$
MY3X\9RW,^R^HSF_I1K^GW/VK1@'NM(&0N-N7'+WL5^SNM(H1[_.>R"\QCW'<
M>FB6AVY_]M+.,P!&7DM\V36=M?DFQRFLK*$N8.\(I,*LFT GO.[RI?@O>J\R
M1)0)QG52&N/(JZTD%Z8QQG$]GDGJWY<8\C?B1H*HEC 95U9-E+0J 2Y<8T#-
M?AW:<$%8MGZ_UQQ81& 8U:MRR1=-J&\N$SO5.2\?G7!&Y>K??B7_0]_=_^"$
M^OV<+86 >X5GYN&< ^ 4)U+$L]/@@DOK#G!POJ<7\'=G'!;_^0; <..<5U)K
M91)5F=1-X]II+X@_R_L.0%&A;(,?\M,*9,N#@!F,11WVW0'2&:_F]!^(7%YF
M+$7< 00U3W.N'3JV0V]=$A^.<C\NN(" QO$1.[?+=E?@CC33!W(EI*(_0$4:
M2&Z!%=O:G@\L'O\+^[^P_T-@)><IT"ZM>/=P9$<6Z:OMPSU]%7=%R=6O9?3D
M"EF#)OHYK;+=,4I0U]U]OCKU>HI<S!\K/<&X,K:]09#ZC3J2TT'+H\"NDG.9
MRA?V']@Y?4%X[KRC=B5O$^@Z1_0_?N69#*1#5GV0)O;6^0^9J^$Y%IE8BG](
M/OF'',,/A$/_E#3T_TYZ\<#9,?.'X!1_E*ZT[8$<@^N/"I'ZI]+MLUK\!V&G
M;1SJXS99W(\/]8TK].7N !C7W0ULO52T/TF<W5'",=(5[1E;%G%03#Q _",I
MW<DV6PWD%5R-<5H!*G1W (_'SW),(+<H:_& >_WMGR2;+ON;B.U"_Z>+\V_!
M[NI_D.L7))^];Q/]XM-Y /MD_%_[L(>+6W!(.T%FF11OZ12&'>T%7&ZP/$ /
M0KQ!['\/ZFXV3:^C*4%M[B]:II?)/45^WL;ONJ%1"_OOU(;_'C9FCLO <5DS
MU&>,_YL&(QCWNO*-M272J681AU<'/9^@\V6%ANF5%@,QC@D*8G79!S\Q$RXN
M \U(=_84J<GK8I2G'#H><.O\=9T,V /=0[NS_NVM,%H0X;7\-^[5^2[UVY>R
M.+;6(R[[@YH7OM#-+@DJV@M/VZA7,2?+)YY^>JN3T\07I249.);SR;]T>N;V
M?K<RQ/1A9AJQ1R3T@V>09NX ]T*<&"C4_K5U006<_WMTV/^%_>\$*RL<+]1>
MM4U_Q:]!,ZGZ\PQ4!G">_4=.H4JQ/>ACH\I&>>UW@*BMPBJMM-+_%W$3RO\1
M[K7_?SP@B7-/=PJ"%/<E)Z6'6\*5T")O)W@4B:$'+>]*8Y:?@^T+'+]#96,%
MP&TAW_MZ'<N>L@X-K[F*%)5;]^D_GO;Z7/]E[P1X._!4"@_836"R?Y(NK)IN
MG7L"87Q)WV586=9M_*H<Q !P4(Z3G)1$RR.1>/M7PJJPO['X:/V5EBF[\Z^"
M$?R-@KSRKVR<$K[R[1O>@\B(LPJ>.9:7BA&K9.H2=NQ]XI0AC4@:/@[IP"7]
MN$M)*8J"LU*!<73+RU76>AA>0YR4I_6S$%QI.@0OU='E,ETEB:>WQ]3]^'?^
M[_IGZ9]*BH8R;6_?_AB$8(S1 P[_!0*N%*K/$<&OGJ'_\N4(=9V4ELKZ(>AH
M3X<\QDDLB["'X0F@*$E9I#CQ&OWE@HESM-,**2+!.?R,@,^O84+C(<]/+%T8
M<T_TB9\\S7G*,7V3OEK7YO>?O=(!?;,T@WX'6$%ZDWXQC-U"%S/[;C$U06.8
MX'M\'^\V_L$'UQ+\ZTY2IT@'^!V 8;N5%GJI"!5KM>&6?V<,%!\D#7<M)X[<
M.,$6MIORY1=\>M^I(*O_.#/97Q]0E1L="6/&-FX]-5.L58F%>8 V!&]73?UK
MP[8Q 24\U.8WBV=I2YI";,>AG2W0]#1O"(8!KIP[)T_]Y!-E,522()1[[>FS
MCZ0OS\6%D,4BW=)T^#_,M?4_X$'UY\W\[QE\H:B5_[+ADOI3Z @08"YR8]5O
M!SQL4%ZZ;_$4]*GOA:^H4;=3,;=Y=U>3,$JOD#<9)->U3"4Y8H6_^GPZ>S5M
MM2C]<=)2X$CDOJ_DESQ66M+"YL\Z<HAUB*37M%QH+/7LV,X"^->FXNZ?--R<
M6#HN+.R@]];'$3XDKZ$LUWWM\PD;6P8Y&DTUW#R?36%#K_OV4&TCJ1FY$=/E
M.)TACR!%+C-.14-1Z8$]E'#[8W8-^>X7$KX?>HV#_>7TKH%4EJN-F_&*:$(X
M&Z.RBG+Q!'G%AO=UI.*]$:]!R[OPA4*@4G**W6&>LQ'K4@0HTIJY3GHF#-^N
MS+*K="Q9W7BH4%]WXO[/YSD669^__D?'2JFFWRX($7[NT,]?2S\/H;\R!YBD
M.DUG(2R0[$=;<*LZ4=9),3-\&@4]I] BZLGVJX;IHOGC!\@BO8'WTZ.]1O0=
MH(L/%J=<1^-@#B;C9RQQB=T?B<CW?6(J'9?*%G;PZYRZ?S;QZ-0#)P0"1?@P
MPFHG^\M7@ 6Z41^FF)C*&_)V&\R_+#-6+J8,)?$\[R9ZM>V+M+]E,<=MYD*T
M_P4'S%?D5;_RI44WKBZ2P]\__/Q7*+C,ATI0\_=<"IB74*IU^J O;UM[X-+U
M5/MH<2QJL\3DF28JSW-V9!9T>9S>="H83:)I\2+<BK5ZI:0N=?YE-W$L$T'
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MX%<B$ZX3^\,KY^S:&IBH?8(34?#H88?S5)(^"7\7=S2$61^7Z5WV!68+%?P
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MX1\.$$<;4U2O^LB'#)G?_531D"&HA&)E:V5+&_Q6R.4T*C?@.WJ?\UKK; .
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MWBQBW0@B/_3,G7TI\O=@L0GH5(WR$X:&YL /_H=E>2UM&3!/$S.VK:NRGAF
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M_2'10"8'KP[8#\.T_:%)GT.(P6\1H) CE!!GIFW![;?>G7X2&6#HP(^+T:7
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M-B.^A/N5NVL8J$>VSN76M!0I?U;E2<N2+>OJ+O&8$T-U4&'2[WD-2@S N;P
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M+>]@)HP /"Z[8]"7K%*,NWR>=S7RQ^TV&H>[7&E-CB[_EB:V9S]PR\!R&E8
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M\'C"XH\[J@X;=ZWT#4""%/3'(X#Y_XX$7^L\^W3,P3DW@(Q()>OPQHL^%1W
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M],9_N3=,QT3(3A6O[^.GVH.YQ(??%_S@PJ9=<2Y?GTQ&/APA0WHK^^]/FMP
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MG(9/<#:7N?!C8<II6GO6@&DKE-3DR7VJ!(9+D.CE9.YC ;4$;<(/?)7<Z!@
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MBE"F#5!=_%IU%Y5#<Y&^;6"QK0A[EL%9]&0[)_[G7%A.#.67 :+[4EP+>XF
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MW3[2,*N75FWQ4VDQHPU?F+L8FAS^5D9XD =BP F[:;0CM+<A_L*17)D8<N^
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M@K\:P<ZWGS6JA7V5Y/SJ8X31>^;8 ?CL@T/\)/OEQO<(9CCQDAVAN[(5(4?
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MGU<-Q>,?! *^&E/>Q\/7]U3&#(3]Z&H;\C(?/>H='T4*ORG1V<PFNZ<W;:2
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M)Y)BR:"G0NL*CRX2#PNL6R]2-CJ-\*T_PFQ'0/FK(=:17 !-.N.'EL*1'(*
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M=Y+R?#/*P378#?2D3D(4,/-1T7K\[56J%Y9#'E/NC2MV5?_0WXBWL:_SF>N
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M?T\;(9?*8_CP4H7$ BE,/?U975_FA?=3D:B [=.F)Y/5WWR'TJ.))18]30L
MVEF91.6 &]'ZB]0U4[Z[:!HS4FR+U,J: J</2J3N2'_3S_F,48PCGTWQ!-R%
M+(.,5&5V3K!_[^)=]:%M]1E.)1-.*-M:<[<!\,VF8BZ)4]?7P'@FXJ)\-G^G
M0T;5C8QJ7RIC E\O%SS>:X]/Y"U8[LW5^QKG:2-@=IN#@MG_:>](+?%EX_BJ
M#]7Y-<"BB*".S+'6D>6\%.J*WOPSS/TD!H#]=^?H;U-N(*X!VUJ\2Q#*S7GN
M1.<16UTXG.]91F_4+9)9KCA2H#-*8^3GXFWJC2PP<*>7&K+$--\Q.5 E<'N5
M9I[ZLP!E"."T8DM>YN?ZB=_OZ5PG<.%JTM6C?(HFXBU7:I:R(?.Z!S_B6=<E
M;- )M@)[J;FN 4\6C@JVN"I"';GZW6F"GT++S0,5UY]<N!OJ_5S [7>FC%G$
MX1IVG)5I5/O["U7_2RF[#)2CKF:684S$14^AO4AC^PF %6^[$]U8G74H7;1E
MJ Q\VX1SOKM\J:EN]IB.D&DX6NE45#;S&A!HCFA"HJP63J^ 9R& XT@!#]0G
M][;)HR+F?YTW1X/H0SV\!D#[]5#7@)QK $4:OO9A4-&6=+(H1.X <O86@GT-
M&%PON 9 1J\!X</7 )S!)<@Y<KQI[P*R7_L']!_0?T#_ ?T']#\P= *IRQ5;
M]S5@Z3.2\QH 3*RZN@8HH?BED3S FV'\QJ'F-:!IZQK0N8D^S&N$;ZF[&@Q[
M_[Y@11I5D.UG$/]E\:/,FK22Q):NB*WF7!65;]'C7P57W13<]*M@3B2/]"\@
MC?\--(X<WKY0V< W&JF'HLB@K=> P_,\R,+1-6#%&=+&<V:$@O#:7:*@2%M?
M4=,!ZJ8L:OOC_T,>)T26_L&AC;^3FA8M6KU+9'\'>^<V IOI]R:Y[<;=FOW"
M$(P;YM?KX[*^\.=MG?$3=.%?,-&VJ2V.KUA^MK^ATDTG&OZ33@3\,W;%J4M^
M,O:S9\6N7@/^(O2?\GN#;?^GV(/_N-@?JXW%1:!VJ KW?]NF?R8% (]70F)0
MNZ^\2$W-_?GJ&<;6Y^G2E"XV;XYH8HT.M?ZMP(;\@]75WP?VCYW-'Q(40<_O
M"N3#^25&CMXZY5A.)$(^HTH*C+5[O>TS>#>,$/W4_PKE-X>[T>GD7ZE.Z;^F
ME8/_<6KK[P:[^ T.UR2"][D"22OHN? 6"+3>&'I+^/-K-3I.D3N=XFM-0H=V
M?]DXVOVI<7SVI\;1XA_7I/\!_0?T']#_\]!:AT$B5^",08W.PS)Z>C?B5?@E
M#UAG++=^/%@$4A1Y4\#0ST\\G4H7KOG<LL"M>]RR#%=CU.5HV[\FQ#_]G-[P
M4/';DO^Y]^:6U/ ?B?_K"86W;#$3O@\MCC(LCKZ^'*E\"F8FZP)<T,CY*YB,
MD!:N1J\++)=APKEEFI]H*V\XP ^*[;( !C!1%ICH8T:H(R8@:A(=\V*$M^<.
M/9AR990*TCQT>T8ZBT(ZZZUE*EWQY).ENE&.+V,%C"9Y3N9TO2029G8ILI@X
M68I8+9BB6'FM#@<;_A(VWD+7 "YQ CCU)Q!UK.JVJG^_FP)=9^:W0-=[V#P8
M&MT"W6\!Z&.I/"JZVW%"@5]<S*S=,3K&$XPJ)(E"!N\L?<)+6Y/'DY(6MT"7
M_*<W:9XB17!%8Y&1;D.SF&$^)M4V?JD!J3*HSVE8)Y%R?)%R 7#K&G&,JEN.
M&?3HN8/+CY6>D="+1$*L #Z_*D:Y8*3R.;*=DO*^ZV%8JJ77-:!>YK'T2Q%S
MY,IQ&I;K/T%(.AV?RYQ+88F=T42NR=G>^\I X/T4TZX H%#NH5+NH2ZU1.R_
M.SO=.4ZY0=9RM!Q9CMOB%##Y=6O[G]\54$NM]#G@U(U8X+9'P)[*O%4<S.,#
MQRY=17"M%,/G5HY3XV\UHKW$ #<&-'&2WQC_8'MG2,;680;:6^2AQC=?LQV1
M>L5R2R%C)#QC)$VO?"9Z!CS8WT*S00?=X"03&;J=]*LUM!K':$?AYM4UL>R+
M[W&BY=DP-%2Z&5(!5-T"5/NO*L;9C[%)[6S6Y7ME5W2^)&)J16A/F>EH4Q+3
M!J0F/$.S^ZU6Q<:(T9AO)P/ #,=;1QM$O$,:S#&^CG>$PO8GB\Z4;U_^*DGR
MQ-<I#"$HVJ1K42]9;KMZX2_XG520DEIZ\AF:Z2^<_.]>+W/FK!ZZWC><&?2V
M4-;7[>(F>SV/I;"=7+A(0=9I;[5QTV)\3V'<B@(;HY,YV^*$O]76O3EZD+ O
MCHRJS$;1&4W/MUGK"1*WN+B8>0F,\2F[LC8&/T/O#"<;S#A8?;(Y>HPX.<4O
MCB1.PDSW' 4HW$4QE;IFB+#3(-,"#&_L[1TF]_^Y-[RWC8UG7MNHH1*UXH0+
M0RI[K3CHK1.&J1:U*,;UBS7IBX5I,*\"MP-\L3U_0:)_Q&7_^Q#@_Z<2C$3E
M_^W[P_R7DTIW2B9>3D3UE95<@:<=XW@^HL.!,3.:GF[V.5']FS!,@Y[>:FJI
M1>FO=+YBH+%&!K#C3*<6S?V9=CY?G1\E6U$S?'GDLDP?\]9ZZ5X^8*=+^D"]
M:(=;*T"4:] FNO=!XV'+C2W5.?CN=;54@XYB)$G;W_(5NDC<SD=16B9"VD87
MMU\S"+T>A2I8TC^.^5X85O3(3%RD\XE^,8#$Q$%EQHN_O K1V) ^Z.(.H2YY
M$/)C_<=KA@-(>I=U=27@B>D'V94]0G$2$>_\>3"D;=LI9P8V")Z,<XV2!'>8
MV@G]8)%AE&!K0X@+=$F.Y&Y>%%:9+N<,N_3"Q8YM"QCJRJJ+RSU-_%DUF'1(
M9(T$"%H"%;&X;370G(#MHG1V#\#>SML6JRD+*J-]_3@%V)FR;CC10K7%9H^(
M@\UH [[GZ?*_@Y2N6M?U7A98*\-4A?.:&*D>/JJD#1$8EWB<N1^WR/6(T (3
M=ZGHOI6:I=C=$23/ZW2+[=Q-)ZMP MVJ:="<PA<FTMA/Q$!+!]\5C+)HB3M7
M>^WR5[<&]/0VHU=T%'2.,J-;>]R-N_T*XXQ8L;\OZA4SWL&*(I/ /@PR\!).
ML)HG+!O=*SJ:\6:3JBM3>#X^U!-9.TSHNGJPVB.U@D]&>4<Y/RWB<SVVZ=6G
M$W_9Y3I+L0D7XQ4XQ*J9VMWXBQO@&U=X$F9\6>\Y"_I@(5(C?QL&N@K, T0+
M4UE+>H(4G.M2Q%A/%V9VE3A6@-Q"!*YUMZCL)=_@%N@9),G:D1AN78@E)I9:
MZ]K&KPO=[1_I/GDYQ^:KJ&[P5%421+I42^WG=8>C8)KSN$!-_=,L;+:@H_<Y
MF=C@XU<A! (C7/&:LS-N]U=MF\4KS1 *];U?[Z0N7M6I58PS"'=JRHB$APA<
MYNQT1^U:H"?7[[O6+#;HGGO),D&_;N5E*.5)7=BH2@IY)W1MY(;/C;=A*>?B
M5--;8@KG =L:Q?9QKP$ASX2EJG3*ZU:>.7T=KJ!P+8XR<2=*^O")81,']*"G
M73;J;B<?5'Q,A-?RF[6RT6Q[3+FF%@F=(, ,G -.U##V"%A-0QZJET?>G=V*
MWW8 !O."GL_3G)V6UG[&43$F)C-[&6T4&WRUW1T3"'QZ&Z ^61$N>:DF/U*>
M^[JBKKXJ;EVX-Y-' D>Y7B(AO72/?8,6W=$7FV_Y>9X6:FJ?:CVM%K<<9A"8
M:PHB'E]#3HP,@NBZ&88[2Z08PP/XH_MFDL_=-:AME[?SBL OK-V$O,=TWP^$
M0MX>",U;YCU,V-S42'_-8(MCOFI2?3DLY?'UFZ,7\,X\7^6DBY[H"WIIL0R*
MCB=5,GW:^7D,=A2X?7*^ ;VW\SWOEW[$@ZCM!Y8>6L)>EGN )[(GDJ1K$I=9
MR1=0(HQU.BL*,XV;'\)>23]:6?@>ES^]<-:SW>%1^>X0[,-?(>\Y=<Q8GA"#
MDVJ2_W:AC^:IQ9O>\ZG.A?B8\#HC@'9KK7QY/+Z3F0<L8+;\2V9=2AI8)^N1
ME(0.WBT0]EKGMULL<N-!$E4!^DWCD3SSNI*63(J8\81]6X-751Z Q7(@&3BT
M<](U1Q[$(U<1+S'JXIIX(&C;IZKOG7%*BQG,?S?(1SG,D51@VDEA/RXO'[8Y
M05(R-;5=]6"!?:ZOI [V?,*IH'[M/G=YB)G+@T"S<^X^QUN)'DIMGBG,[:D&
MJ5G?+$E<=9F2LO46Q(?*%-9$OS_>+P>1^%@D/4+#=+V7^ZAV.Q(=YNW?@TU6
M^*PNE'T9>\8<5VCO4=;L&RT".Y&J!!JGUX,#Q+Z8(B)FW[3/,F01N^EQ6EH'
M!IUOZZNJHEG>5,7!=E^8?<@TI0BJ>-Q;TT(JB''2N?<0W*8ZXJ*@V3H"ZW0+
M%*7OD?=7<ZAKB)L+N$\*(.%]5#R[L2;Z>.ZT-13[S#11X?FYR_?=E08#5_YP
MSMO!#!J4M&%=I3HQO:S%'S(9Y86Y:,_T,&$<NW85!I*:#76)K9:%'*F\YGSQ
M=\#VW_P>1J/=_7:7K-EDH!DKQVJ>?M3K3:U8C4/F'&Q^:\10K_]M](R($G9G
MS!TI-YR< 2D<,H<PXPW[=:^7>=M"DX'."A 2V?0?Y(4Q3L2?_%7<[ CG9Q)F
M>[3S"/ALP^B^D>'OT?3V7BAT!F%,-%CF<0&M*LM3!T0H7S.!/U\#M$T['">N
M 5@F(0(%F9,5.LZ;MBOUE26X1/:P4L4R!H>=,&!T)K'V7,)C.+9_L/JMI#,8
M:K+SP9254$1HUF<.C'IRS2S0,T(#W!9^"><W7#UK.C1O'$H,>BGN*ZX-[\<'
MOT' &S\3%^;F:#_[,D56D-V0Z.78BYN)D[]H[N!B]Y&3_G;4%WZ__F-$](;V
M6/9H1[L;9!KTQ$<ZL10K '-Z \"(UGK^'HP=#F57*@)+7CI>P"[8%0_EQ@K2
MH^_NV7AE.U &\CG//)9),,4Q%W;ZM.TO 5AZAA^<2K?/5YNHF%JI\JK)4CYT
MYHIO?7JA6X^5Y&5E5-S+:T!D95A&\< PK8T//'.R\9'U!#]Y8$K.,[NOEB1;
MQ'T9;56GRH;SSZR9"'<ND>\ 8:L];3YRK]5[QS:!.#M>P(+>?,;CJ^.C_F?1
M%3MYM%%K$=.4T'AZE*C:O6J-^19Q@R\V5C[8T=O*T;M=>DU#V2FN\Q#S? R.
M!(ZQJ!'M3(-%$,4GUD?J7&;J]] DVU,9N+T8QGF3&KA)$@WN64\[%SQG'_[^
MLL8UY(7 ]\U\4>['9&\G(4M/:X:<,8:/&H!*(P5,$9ZA.HQ3NCI#S^EDZ0WJ
M7NO?EVHE?1V ;,#+6=(#R;=6>:!%+]D4VJ1V9_(3R+)(/W^WYZ@3C)G+$#.1
M$R0> ;QO:+6L0[*\/D$A':YM@TW8TR/=.WG:+T[Y\'V]9[Z^-35%\7A:::"H
MA N[V,MRV12?!6MACO%/R"_4+#EF.D1/#Y+617&%@:'D*>LQF0,E^7:%2MZB
M[\<\--9:I4UQJD.D_902!NG*7W&;*#.*#FM<A.LM*:;D660H>LX][RM PC[Q
M5_(S4219KL7ID'8NVM]-?;-*6#$HV6^U .:;.!CH85.%O3C!7IN>W5IZ ,]H
MOL.((4?T.)B/^^,]>E-'>@ >L_S^PH>]>C:14W(]"1?0UXHR(^G,>;@GA$4F
M'FAB7Q96=C?,N 3W<-?L3M["6:3^Y!N$^XB(T9<Y$5C[!-P]NXWA9!+GR=O/
MFC(C#KYI_+OU7=T/NJN-L]SD%Z<S1ONDV_\7>V\!%'?S+(HN@4""A^!NP=U=
M0O#@[NXL[B[!+;A;<+?%/;@$UP466=R"N[Q\WW=NO7O_Y]Y[WCNOGE7=FNK:
MW^SV3$_W]'1/;\VOAZ^NFYT!JLHF0;7>8/3VC2<_8K3MQ<W>WN 33\DK ''W
M4]T?WB^MHUQO=N<U^^V07R2_&]BGD%./C/MSF!KN_786(0SY':/1=PM.RX&*
M3%_;Q!BO2[<O%(>-A+?,JF\(%(R_7<IEXU!/?8?H-.#P@(\6TTA[A?;A<%'[
M-BQ7H:E5UIO(9LS2EBL>US-]_/03XH0*3"+C>[U1K29BACN_5X!)J"9J1:6>
MOZU8J;ZTE0=CC2QC:=,:4L7GB@Y*HT'5MPEZ[?)K):%/%*4V8OJ@>89K.8+/
M[DV)7^.4YU[6?+'F[&8$I]RLOG@8P0_W@?S;J"U7>P*H0Y^L*@[U28%4.HTI
M-E&TIR>GIP*"GL5#MB8)E.#IB5?  4R&Z6-EB!MA;I8)^V8AN'%G+U"BG2NU
MZA=3(.-SU78*@7U5&I+FB%6&A3E;94QG4+44WA"B=Q5S+YO5"VF85ML")XKQ
M"X'G"8;L"+G:19%'5DS\ETA<W+!Q *7#0&T[V=DKH,]#@+]2$R)>88W#U>8:
M?)""[_*3A'P!VS("4?F36T\0)\%R"W$)!TS$'ZL5"H+@&>"SSBJ$OO2T%5C9
M ZE7WI:%-T&9,U2E&QB;QP8E4SN"=R-,YSK,JJTA] U3=AS\9$5K49JFW0T9
M%MF_LC#B6 K+&N"5+@.6D>$'+BX>UL^JC0F BUISH1&YF>+CY/.+)(<C'^Z#
M!**/T9I)2&&$9,"S/OSPZ9Z5NA):*ZIM.B-]31+GR"P;R+YKM36[EK !]A&+
MX*:XS<=?0KM]\JDJ,U77HN9-W-H#PY>JW ^EB"P1(BM[&&KI 62HL-V;.1T0
MFO/0AE*YCV+LFMKBI&8)Y!"]TR*,UEBQ-L$7Y>84)PVW&?9$'8<G5EDD02%&
M=OUYES*@+=GL=ENS)67*)MDK0-WTTMAUE9W*+;!]W'8/*72_^_TQ!Q&W6D/M
MO*N-_0F]1I/WM]9?_9^*6])&" MQ+F'UA,>/][;%1I U89M#C<AKSG943VQ-
M+1IEM1Z$TL#ZN5;6BQAKSSF?PE=U:ST+P:RM:3 )O@[TG__/97KZ7_#?0N*;
ME$B 7,%,?"II-)3CD.8-UK<F[F;2*Y5 ^62%E$W41=( 2!B1M8P,(&R,+' 2
M$)=*O)>[<Z^Z(EF$6Y0'!^:YR:/YZ\@U$#-3G._OGF(*8FDM\^"/B=/S4X47
MLJ5%T"61:AB6W0;]%5ZZ]U1.B+/KQ/_Y'^"O<]@%L,5_?0S@_MT)?$S!4X8V
M#0Q7).O?(;#$]#^1L-18RX=9"LP_PX/_-ASF[;Q? GBV5+6U \ ?]-[^L7N9
MF'_=2?3766Y6446OF6D1%+ @K5OT=O2?Q_>R_X/3E?\+_G\(TA+B $;,=$Q3
MQ3?3TO'_OI+D?"2")/X)#Q, 4C95BO_S3"7^=T5ILNJOG_]'[?[#BJ30O[Z2
M)F<.?G\4F*4(6UKLF>L>6U)2@E?R!U.)X3$31M/UY6.D LCGUT5+#_4IH2+<
MG HLADCO('N&\A)>'H*2$FA%\\T[A"[Q-V:4R'L<,)\P%_A%'U2P@3- \-*@
M\THUS9N_3ZO35JZ("EI5,>$BN_),8L)\PB))#QE!J.93V8>Q_/$]"WGJ#[WT
M9*_XI]++5 >\"<LW,G^U$,JV$NAMA\T ^&(F_76ZF$S0^R_$^S1#0>]7@(Q'
MWMO_\"AJ0L%'>%*@4:[2*<)UWGO+PK6+W;19NMN\]S2E&<!*>%0%>3::RS8,
M7/B;OY(/OK<LS7!H?6%ZO^'EEE\$[C&\'CSEFX(#J<HR26AB/4 ?%*GU6H<-
M;F/_L$4GS,O#'TK#3K[!7BJL)(*AI!0AYH*R./LP&V4DW2MX+H+Z(WW7%\*7
MDY-EGM0$(Y1M"3.G\C<[KG]F0QD?H$U'(AQR+\4XK6#@I9;JH=Q*FMLAE/YG
M#/^3A+7_7P':HCKYTI7??I@PF15W%=)3>/ E9<L'$/,OYJ<N46ZL678"4,[,
M5P"2\$_A*X[][CN6L%= 9,W'YQIR"?]WVZ9E[61N99,?O.*\[E<<7P$YCB^?
MVP^,DJ6<=:'9%C@FO^WOM"#HKX#\DC^Q1.\WX2<UDK.&IS_.6$P^ZA40_,[_
MKOR.^M_:Q0R]> [=(ZX<*KV8,%<)#4'6_Q55>-/B3NPE-!OG%0#_I]-SM3-Y
MZ"M  /H40A#W=!EW@>DK+SQ.HNT;U]G]+YBJ_C\GS\*>4?B87Y#_=+E5L9']
M#S5NDOL]DFV:ARS_-"'0(XGWO^"5O@)"<C?1'O!=#)YPQ?ZZ"Z^7_Q]2=L*7
M$\+#2M<\KP 67ZL;H9M_Q53Z6V@D_Y70@MS_(;;JOY?E_[W@T/'%\&'VV/?H
M7Q$+7K##O@GO6TW[GQFAO0*P#.!^'W))"+44I7>D/?VL.]['-;R4,U0!BU[7
M4/PEX)?_0, 4CJOPPQ,23BWV.[(MKX#)/T,FDYQ3AHA>ERP]KKQ@^__7Q"2?
M&%X![_RG9G^\ C9^DKS0=;W_M_'^VS25_!FWT?-_AN.2:YH_PNKZ(V:O5\"_
MEW/^O\KYEH(DA#J#+Q )IL^$A':OIL1^(J.G!!1\)+G^[YC\]ZHA2Q2-<\O@
MF%5#4>SUXH)-%GX!/3J0/:2U)_M/#;[H[YGN^G]61TK^;OKRGR;:!?(]^>]H
ME_]_JUVG_[3XWU4#^M3[GU*-N+*A^^ CA;K;YG_%C/M7+?7Y^%_(2?S;$B91
MB;M$6,@U^3^BT?]B,H1*2';1_K(8W?^*2; 5]@W+^4\ )!^)H.P/^F?I5_W3
M2N+-UPIRH%%P3]'UI^FPA8ZX*5^2 6W)<&WQ64Y9P2^#F*V-+=)O]G@F9KPV
M%AI]EA])2ST%=,C/6ROO\'"'LH2+?*D:>]51LU;YB:92.>P8,96TL/_RPY_,
MCOQ(@S\'\5I$WIC%WZ#5+?UR$3U(()<@]8[7!F81.OBEE_K\H&3\SL:R!)L[
M$\ S">,C!CJG#@9R1MUD*B0P<B&=?/8^T@("9UU$EQ>TL)22@)3)E#!!'A2"
MKCGY*,^5*CHR#:(<1M ,*N3H=QNA>'#>C[&-8_MMA%U8=R86)8<W8Y79PE]B
M%TX')TAX=-,V$,^'\!!)W AA0B8VWAUS^; [OKT)+I&SM^#*A$NI$W!C^T+.
M0JN/GK<IM2^Y*8*KCW0N&2&@8E)H[:[-E%EBU99<OUJF)R/-1*$1YU23 DQV
M]_>PAR+@#5A8^0F=?_H="A009P[92)5I:90=#/[:[1TU)REWB(T="$LLX;!]
MO=*.F8OH\P%8X$']TYU-NH+QRDNO0?KM1)6+L<3%!YDTY!Q-V,?\ST%\ZNY!
M/K8/]GW":%9-#URM_EO\>DP$JK/;LW8,_8F%-'CXG@6:4X[9_1L!,F$\<+ F
M0^M8FV=VJ<7Z8*L&CU#^TISG@MGUI(88K-T6]:&47J6Y %U[X_)6ZMBS50M2
MT^L="2]OM,NGHSX!B@V2#UQEGKC=]4#F+S,;9P/Y\U=1Z<9M(88QU44Z_GP<
M*_0ARLN^/TGSHK'])C>.O5+2-TJO](RJGTY0#Z&RLA51!M0G+ -DFN8*:4^A
MC,'46<&33C ".:SGQ'56SIZ;KP 4'<@2=1I9HN*<W\2MCM!Q;8BD>LPK(*"A
M>#/(K0S9U>45$,['.1AB4;YVB W^JH']XJR]/OI]Q$ZQ?*(FL>_+:2GTSB X
M6'<QZ$F..<1%AQEY_4![.R,G(5@^:F1V.T%0E%RQ;KP^>H@D[4WB+M\W)M4Z
M6,^P/GV"]H9SR6^[7;7J'=C:$_DT9AJRM*=V)[L7WP(]7=<IO0,( IPD.6 6
M5WUDSJHZ.YREM_2(:4I> 2J4J>=T8X^@Q)U/K?>4,5VQ)?EX99[0,2*< 7!R
M<56IUD&;+1>7!OJ:WG@=Q0A'JLPH7NS[?AJ16\X1S4,N]1?:\^?.EQ#_TN*B
M4C%@)I!G%0GT,MFL9$/!],70WMCG.3Z.Y[ODA(I8SPM>^\R3XLS1AZJ%(H10
ME_;WG%3(N](+L@4.V))XAA,F)I._+K;=\U G+@?!V)E%*];N&0,Q.>E.GWM]
M!7\R8.S(TFJQ@X+RXB<Y*J!Z[T%+C3"52_X6H[J2;G;H7QZQLINZ')8TMZD1
M?G#?R@OT*=1UGD$RBRO5<?"QLU(SQA6\2ZS@#T_?K2M9-$>^O5@9BQ0GB,+-
M$(RO6:/B0K_S%^V8<SVBKSB2T[^ /_?LC)4S'\1,T4R4I"7<,1'7G)-NU/!0
M5U=31Z(2!W@MQ&U54?2[[0*IU>KGMM8:QNNSJ?26$/"4O6 S?LYWB%<W1S)=
M^9)(S?Y. 8\BM9IUSA4V4O_R3/Y\$OHU?EO(.;;B]]<9ET"3<_;^VQ\07)/6
M61<H9=V/P4_QIAV0<9$1PV)2)P7$1@6E<S@AO+OXRE6(EG6-#5>\881@2K*S
M6TB"S:^QQR3[M/?HT*DI^-CL<]1?W2#2A2]>;R&Y5,LF':V*"25),Q%;B<(=
MX85.W_MA'].=X <';S*WY-BU49XS2[4/$<L).RL/:!"U4@6(TZ41Y@EFL7;=
M\5$F(SI\?QS=9G".8\>4B\2+.:.ZB[_-/H[PV'_/NJLUK68&,UWPV>%7Y'+G
M@O\FUEU$J1[$2CMQ2=]*/8+H.OM;*DT-UD"OBR-B ST)B!XVI@79B7480;;T
M2?1L-\X>[B&TLWA)G-<UYK0:&LTJ@7BWVL>O&<(S\;YWP&#6=87(6R'R]]?.
MH)L9X]%4KIG"^%/DT3ZGA/?(15)P&T$H'MRAIQU&^1Y!3U;:C/W.!I*.CLY6
M5+F$,U_\035+=BC>[^(<LF5J+;185E"71FKT[OQ10KJ_N53H"8^G+/S$FE7]
M^O&7BJWV1X+C>W?ZP9Z3T<1V.PF:-YEWF?W@T,8:K0-MJD3&IFRGE&+O$V7-
M0G>6 58A[966'JW4NS"R,$+\J=DG5T,(2=L"IZ0!FJ@%;7-'\SQ5*(45>==Z
M]BT63!\%[>1X]3??P][9)S6+38./'@/,59S*=IR:N[&R@L2GAUQ*1I:M:YA?
MA2Y8CI:>Z9/Y4&O;&FLB[84;?82M%]V=?Y58.?1Z.IH/TGM;$OWX,$["NB+,
M$C3]7/0=.YK_.YIBV_GOT!.0VOS>HLN*+YV%I5%W2UL,XXX#JIINK;HPO8MP
M#R2TX16P29[XZ'BJHCQM\#/>*LKK]L/7KR\FO([4MP*)^%P$@J*',$-()?M-
M0GA_5'RZ0^[M\Z^3\2'55$EIB#2EIGMET_>?]9YV4U0Z8Q+C\E_"B;2_QF@S
M.@GBZ,^=<BQMMM$6Z>E4\GF+,&EQ1J7WHDN3L\L,&W_OVT5@9E5I3!<'>%/%
M0"=1[X(NCS/4.XL/W8F5?VTOKPW0P_'TH5=Z\*?FA#E!J[@FMQ#".!DEUN5!
MBU?M,3*;L -F6,<*[&714N]$EBG&#.\)@:17O-4*/;<:W6>)^ES=1LXE-MHA
MM4@P39&XA4'OB=*GR5M:[OM6=Z+X3E$S5;_W[UJ]8+X"HJ0W^+%G-->L+O9O
M&>T8ZRC9D:+<TB?-R+X637BN_HDV 5=X'=Z;*WJ&!Q^/P+;XM<E&7!B0?B9N
M%N2"L;5VAB)-9--00F?=^;W!R?<0;1NN!_](EW>N]"YFC4!)Q0C@G@FB5$)0
MM:Q8.I8LZF; /OM/CV.;U!R<<[^$BNH5B"SJ#T87.;3/!O6Z0V3)TY#-#<.9
MT>CQ%YT*G^- @56<*R"\_;$_OD?&S-;,F72Y]7MW*THW-@YF_&51//,LVACY
M?5-=?MJ#Y^OAMVO, ^I>]J$N,9+:\Z TH65D^INT$LT3JO3OS:=Z*ZB5,/2Q
M4GC[SMHX.1Q3QRXMKO39YC]7Y#)@G%(;]"1J092E&&&,H&+3:#NXZ+:'Z/ON
MH,W<W@>%,%=&'?DY9+G-*GYY4:N27XZ<R3_)K.;S8Y##3>'194I)]I>,"R60
M'TC"[.R$J+6M+ZTT/BS)8I<YFU)_+IX;><[)"YQ,N*A?DX[I#8^_!0S,BP@2
M"V-:.5O65#"56#VGX_-W[N7D?+7^%F;N T4*3LQAL;Z.S8<OL,<: %4(=@P3
M\_XPW#_TA&/9B'/4][6PL=AL-XC0< ?KC!2,>#(^:E;5A[2&/0JM3"#A\9M"
MCFCXVQI8!'^YNW'5+8G9VR/3PWT8+(W_G$\1C8Q27I"W5]((T"=ZRTAZ\#_.
MC_VA'5V>]TEX\D#?=^//#KCNKF!(>STLYEN3O6D<8\$(TZ4WH<H(D'_3J:S)
M,G*C2<J,!["H!461N)4Z:VKT+=;.7), CUI557T#4F?2#8Y'-/J9CP%8>'FW
M.G[<5P)7>G*7L!\V.L^>^[D^-$+"2NG&3"@D47X.NU&:(-:-M?:J>3M\OLU#
MTZ]?.':U!U7%/'<N!VDT)ZV,UNS(Y-G%U'HXQB<+1.X4_MEUV7/&^*W(3KND
M5X'&DINX<=HJ:]OK@FBEEYHF>[1437B'A?K7SZH&DA=O1L&6*OLVSR4"SO<I
M4>\ZD]A.6PF<.W4=.\,9@^,'C+3NB%?4SZFC:YA256+-YRDLQ8LK7*T3:&I!
MNL>QXLK<],CH7OB 3NI( 6G?*AMU;8FX8MW>8KVB"CG?LC&X!.SF2-L368N?
M@6S1IWM6$_S3BUTT8S:;6-VS((***CN@Y",=(_SFM!U*CTFK;IFI(KED&CN+
M"BY*%DNQID?"^L\7FG,?[J8V4)">,JT15X;@VE;:RX!EZSJA0FXZ2;>BI/4V
MJ!OUKKE?&(N9DR=>0-#>_)<W5E>9!>?/JOYIQOJ@J8GX4?'.\M:^6C$WQ>T
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MBM^3L\5(,9##V#S/D7FB+6<P[*T1]C7A$(]QG!X1S)&V%"!+U)?LICFG>\K
MW07@O%(@UA3=$$:]"^[W"LF)Y23@]S3+N' -8A;<4E]IK8N^C"O9U%Y\X3J[
MR2Q<L>;.V,TT*UDC;^R<GY^A=*HH,Z7K#Q!5,W]XXXU_D8NV#TZ)^W'W^>7A
M2'=Z(Z[/35W&)8;5CKHIC=1S1DJNHPK7?VW/.(0*@S H'K;$)@]\)]G'A[E
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M;^5ZJZMI!M2-^?2E=NXJ+D((9_88M)7CVSE?>?C5B9;4)7D)G7>XA\+IN^B
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M<"+0;19AVCB70YNN^@KP2-:((ZMW1#S514=0*Z2.;CQ:YA#&ON.6;3@+Z5=
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MKRF_.>>2O==84U,\H<>7:,K9L.X^[XA7:8EG0KSP3=QW$HQ!O2W^;<P=[FP
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M*/ ($)O+W.5P1:S3;/CLU2BP#M.@QGT$Y*I*/ *ZK,7N%.#K1#PTOXF2W$?
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M3(CM65]#,DR8R0[\!!>*54#Z7U0SC,6BWK6SZ-\DED_H,'^+[?Y=G[C!8Z#
M/IM,F*,4U@BJ:"WX51:DT12*WS_E8<D9BCWY]-<@F0>-:3,-@55;X6 SVCQI
M#EZ&F/EZ\-HSF,N&'=DRK 5TQV/L04SL[H*L;9U(WV%]2#/$.#'4%;9ER03
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MJ)O*3/UIV$UR)FB[L15\ 69K/QSXKEA4EI:!TC;8,8DIE(JL\D:+^2?QK7P
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MHN( %6&=9<L&!ZZ>2>FKH]AQ!RF^:N^<FPQ'7I:E:Y6X+CDDL038$[SLR.E
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M,L_>(\;82>RQ&^.-=8JV.GOEB_C[C4^H>,P72Y"(,&QA+7T=)B-JY$HO.+#
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M2=D#K]J=H]R/"<$1DCNI5Y];('LB(\AZO]SZV4?\-3#JXL>,L@P#=_$0;TQ
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MJF9CA_)R T4*"X.;E>D_/?&6'J(QAL$F)JYMW?_$/:SA8\W'.FF2FZBL7"=
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M)<<04LL<*ZV1_2Q1]YD.3('JK1&=,XWD1NGM1;H=J.RJ%\/0'Z.NC^@Q1\0
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M7G+]0\KP8]K(5:CR2_>.N)+XR<"WN-A+.+BH2/<MV>_Q01 KI*ROBZEKIE,
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M%#^^XX;$X]&SOCC7K73)P1WQQ=M4^__9#^#R,W'5/Y+$?:@GZIT':!<'5FJ
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MW\LIU+<QQAG3^)S7D3] ]7:()W%!O2(HHN_6ME4WU><VV:.>LEU@ !VS4!?
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M+%Y6RTX##<CV&19_QA_DJ6L<&/@3ZOGL]]_3:=^HGFB.-#HADI&:A5[F,/[
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M"=3V@+;>#)%4).B7-+] HCO)2$#H=IOT?@_N7D%OQK<ML123FRECIJEOC;+
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MN4A*\A/ -ZA.-0X!4W%#<DQK_F1#]&==%E^D/1?P[.6 Y[8E'HB*3;^WNK]
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MVT2C-^/%[A)%X %1Y;%<,E3BS(?J]1^1COH9N^NG@;-7O/C&.5!)B4:M-()
M$>%XZ51<#ET"59^'U34F H_H(H)I^)US9YL?9[N%*-?-E'W/0%?EUES4T= ;
ML]PB#+0V"Q-GRO+3QQ"FI'#-8\E$VX%2M:).YD#%2Q3<$CMN%(7W;AD3#"K3
M6(PI0,LY9W4%&X*,1GU7'V_Y)_N3))+H./;6KXTJJM'*% 3E%D).-YYE"@%N
MOSD(<$E- L^UG.IJ/N(6;<62X/,8RM@,X;PT[*YF81C6J&X)5^.PA92+5J?
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M\G.%+"P08PINMP*,TR+(S.?I.,.*YT"-84/ GNL4T:.*-1?,^#1O"WP>PG<
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M,G_Z?"_$R+7(F>]@(-0I.B J]AL*HJ%RHFYZ;6M /#C_16FVFI<!4[Z46)R
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MSCWFI\LPTPR$Y$O,.C=EUNY/70_8OP(4ORKM_LQ:]!83=]?3VP/,!OD.%FN
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MDFVZ').=?0M0!"1$*.(L)M[5?#UU7V,D27V5LO!$_/LI3.J1NOK1^1E-A#^
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M9['L#37<5^172SJE;Q;-W1*^WS]$%UIO]3U+16J6H4SA[&&Q^4L+/6Y.)7+
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M]583B!/LB0/T%D D&,Z/3[<M/=<H1';,E?;J\9#L,)=6)Y:PFA"#<*>H"5D
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M1SA8.FN^OR9O 3:@",_&1&EKC[+GB<]SG(2/-UKE8;J*$WA;4L4?U-[=Q0H
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M.ZEX<3E:7G_(NW#S_:DDQQYVR$2M_Z8E&GJ#-%%P?!1'%,%=AR;73T^PKY*
M'+?U2H^>;7H:>-E7:]"1(F8#=JT0UGWS:B,*\A8UC79 Y=2+3ZPP4<DXAU*"
M7/EN3K$?5>F+SD/#S1O&Q+V^2FC*OV3-O ?<[_-H2"]LSW,B[:M#+!D,YT'2
MF0@26+KP"CQH8N0J_;;A52O4U5$K:+QR!/N@,$_7Q;ZG?N--&?9\#C$M"AH
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MB HMDM&L'] ,LQ222*I9LX=)ZL!CPDML!5;-)@\/\K)GYX9T4259I/&>U>B
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M]K\[/&?U.$G*>Q2<:H!.>T$ZH<J2?UIM*5I_<%$YT]ZK1*SYLXEI%OR;".D
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M,(^8@6?793/#5Z(KD\B<2N;[W!UFI3S32*D=#_"7N0.QZLU0*G!&DX=^Z"5
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MD?V>N6L(8\K7):X5W #^DKK6.3ZH :8\HZC6GS2@FLG='1B2.\QO^>XR,OP
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M7R5+>.B8/<,WTX.BX50BS"0!\W@S#=[@@_CYYEF)UR&>'^",$CH:G.=&8]<
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M5Q?@JX<MP=,+A]_S?[U= W3+TZ=F)?/'?@Q#)9=DD)"+2?#IS#4 00S^$H4
MGA9= _9NG&DXVX;X+S QO]XAQU$4<WYMQY2&WP_7_^'F$*2Z/_W5,?3RY!J
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M#_P&>J<*A@,RPD3DI*0737&P)WG?KF@_-&C$D\(@?^5U6JK[]J1Q?ZNP%O7
M2%QW DM4C/_Q^F&I&]ZJ)K-\L%E=M%/:29?H"_>&N&U>!Z,WD+QF@-=P)Q!+
M'^6-9"K:E#_8M(;3B'/:Y;2$=TT>H(KQCE]W3:H\Z6DE^>++>YE5TB1T+AAT
MQ>CY0G=_/6HBJ_QE=EF2G<1Q! &6R8<GW\CM5@(A7UH"#P84?7,)WB:R!V/8
M+TKU#LFP?B&UZ])QI2MDH7!H3;J2TF+ZK$U<#*)E@9=&38=&F.*%Y5B?>I^4
M\E?8?77GLUH-1 L*G!&ZX=>3?6"KH#_:?G'WS#*6']AYBK/P;:P0=:!AZ1L+
MLFGQ]&5#7+6^>I]LTC8Z0$";? ]]KB3E!&20*KAG2#?6)0B#?T>KN_35ONOF
M=\4AU>98K3#?+6<?6D:!"']8U>A7W&AX^^N[RZ]G('1YQ@57;K,H+23(#L'6
M;F?I1.ZG.,NK-^?J:NN^#%.U77'I=!]\2T@WZP29YZ7YWK.<EVLMD$:3![H&
M8'4YO=0< +F,%2J_;--?"3NVZE60*#KK/_'8;RG-]-S6B]*K2*?A>&,$PI_K
MK:YP["Z1.B(!1G'QEV*@_"?$GF*$EKKYN$4\I-54#7RGU4,'5#Q7J.@A_BB\
M,81:W]^5UQF X#0R6O1:]>,$>.X9O:FLU^Q4(M!.L5$<SEMQ:<?HQVQ3G"U9
MCRC=O0,7=H3M!]J8)0$ !X2RWI;F'F!<E)/?,D@XKWG_<BV<7M1][D>O1,<G
M=VGV5V?%T2<:D@;C)"\UNZO(#^/KRAV&^=?A3JZL<DDQ>#K;X('Y=)%R_Z.2
ML&4$RN57>@=;C^&'"9^$?\AK,>C\CZ07^$7U4PDO9.(%U[RO/#+.P1(!_>9/
M9>-1DU(:X4OT*.+.V'9R33%%I(*]Y>SH,^W)/L$0,E .IQ /KTZ^E3]&[#A<
M, *ES[@U.[N5Y$ZIZ=B1I3$_]G68[W4]8XZU@[W'X^E&',7[Q)9OX<#IY8XK
MS'W5[E $?A?%\04'2!'!%+K7 C0TP)I1@BA%KG4IJ\U$R9B#0IP\+<@ O94[
M00^"$H\L=[811++(0009'!\B!KRSLH!7NEO5*$JC]V.BF&Z"7XAR;S?Y?OLC
M!E%3/XEO QN?8CYFLI=Q F[,TK,^J3\/NND[ES2ZJ('M"1Z4IDG^LSR9?'1!
M8O4;8YQO*T  TCW53"5W= W8_A4ER5.;/-4/'8UVWY0=<1;]V?5"SR9XC4J.
MSW3_I]C_Q-9?$EA<[-B]-!,KB2T0//U3A819H!IQ!1K"#H\'R7]IA]QP8/YO
MA?CW<O:X94<W_Q"/S-."EK!2[U^]CYFGQ;E_=6-5>?MHP/_8\9 ]]E^3Z8EV
M0#/S-+!7>\.ON3)R$26WF&X$!.IZ#C])&OMQR;<VQEGDAI4R3_9&,*52[J'L
MJAEAR&(ABWKK"\,UC.7M^6B<%4<_.6*T5L_"-I'Y\GQ/_8ZD@\WVCA3BP]IO
M9I;ZPDOISYQEUED_:(W>LDO408LC?$_':?1I'Z:+8#R-<DN7J;H0-U8;L1BI
MNA!]N9(P3^);GJ##G). I*;#KB?W33D6PV\?KWXTVDV1B?^X&FE8*%?HR]28
M=/(=MD0TOE;58EM)0;$S!GBHD>W\ T\%GG?;*4'F2;XO-X(3FH=<D!VU'%L=
M]]4X%4R8M;DS!J<JB)_41+O/'E_;6X6*?L\0(37MIW\S9.O1EJ7-Z/5K>J7M
M'!H7;5!<U_<_=C76VW7.#2=6LK[1%U?),!P,C2DPK#Y%B_\:^17IL;AKW";2
M';&8(BZR+3=1K91N:$_GH="1L'/K4=AKZ<=AZ_AM5Y0_\J>YHYVD:-F6H$$-
M"Z$HID6=R).QO8XK\KI&)W1#1?820B\&3K&14!G'6('[=492&L+%?DI+L:5P
MT +IMEZP]8EW37;F8-;FI'ME+V.5_)D#CPYSD8()!N:M$EG@HV:5F.QQ/LS#
M>\8AYU4BM5]\>AV*9ZX(Q"5 2G":=L5!BSCFJ-45^U]LH;;X )<,F<X+]Z>S
MIEQ1VZ34K!');WG[LLPR]@?\_B?ERF<%T3SL3LG6NDL*,]5-65NZMZ)=3S:E
M[F*8QF]O_[_2Q_Z]!AL4&98]ZQF\= V(J.H72@+US_&L39-_3_1H[.@K3%J^
MG>;L-#S9@/NQ?B\\)7$^8O_&?YJ.A7)]W]OEZR^,\JH)KI )B:P5HR:8-:G)
MA'G].*/XZK]='[$OV7Z>'')%BO10GE@D/75\UL^ \P)S!FI/H8(_3X,EJ??C
M!/)<AV3?I9/,7P!IOG1IK%%G?7ROWX''8QJ#=06/N\JY.<3]&^W[DV)N0ONJ
M$E:>RVDBJZ-/OZPC9\K0/PDH^VVBR 3\7I_LOX.IZJ]P/T;_$@^ :1;\N8?)
M5CDGF7B6</M4GV)?<00I-$]V;,' NO9Q&V4:K_SH8RV,&H5MO2M@;=VXJ[@(
MA=;'^MJJ2"85ZJ-VL\CLY1AGAWM();V)W47]U%0JBA_9$;'H54Z5(:;?"&%#
M57SZ]6ZXM[HV,P_,4Y@_/>ZZD-[K\J_K116Z>:C,6_BHK.YF.LF.*K2M)5L5
M<=CU_Y6M^G\FQ)#_$DQY$X]9C:W+MC!['2/8?1(G#.PIR!<ABN74ZC/=J]V$
MK)9OAGLDHJ:A5>K1KLN(O($S+X?,HE+'3B!T_9=<TJCZ]KK*^P\.O" IHN".
MZQ-\+*R^!8I"%F=MZ?T(MK3+><HP-K-U0L95%?@FUMP:JW?%#N.@9."'P3O#
MH;O2H5VJKZ_\0.^1(?!^*,;FB8>[N[4G8TMUU6OZE:Z$'H+WA%[T'@?%5J5^
MNA]L73=K^V.?!U&0**ZG!4XF6^7Z%A6DG15E#>>)%US(/#MZ^S3V]\YE3>*_
MZ7;0LTP[P<3]G[Q%^HSM$K,6WJ<.J%\Y]X;V9;3YJ4H@2D/<#!W@"^TQ[M-C
M+$?%=#:2]G4Q\)E[2O81%&H+O+=F?0.6IYLQ;C7=>+<2CR9=H9$+>'P^H@4<
M1\7&%PK55.;/'JFRSE'2D4=_#@X.:3LNE9J6O-0:U9*0G_V27O+;X2@Q=?S/
M9JZT87_K699D%KY1,!#@^T^.6&(X8UOW7(8EK53O;4GP(U5+K+R5LQ=L!/T5
M<WAXOKPTR1 P_8!)CJ;BM6E(UIXNL2Z#!"_YB:IK1KVH'.-XE0+H#W&+T=KO
M;Q,-WS2XL1^@I#8MN$BM4I >[O?:EN!>S[P'QM8^;^0 0EV83%-9)<%+\Y^\
MX%SH2!?-%C8W/Y]<_;G9P0-(^I*LOXBI^WSP9.,";WOG4?T@%6O11CB%^,8T
M\\SNN4G,QSKM*1'ZZK]<KM?_R02H_Z)&Y&/Q7QQ%$X \UUB&_:%M,8>-K*;_
MZ =TB:@?'.@N>1/.W?RWJDNRU"UMO2#%C6+S;@@-LQ1NOAI/S!Z>QO%_(<GH
M4ID'[+&H(<=^9EA./L*NOKZJ^X[9:!W@#5U7"MQ\:K?MK-?P5TZYXK92['"=
MCX8=[8?SL9\I.+((P)\PIUGFSM$-T7\>UOWS+T<BB:'Z&@#)!R\8KQN*&;O7
M1QDCS\,NCZ_<QCM/K=!78LA.DI#=%S*>8*4IB=N^XJ-'8*RYKBD"9"'<?"OG
M!9]+KP/'QY>Z_>Q],U\)>!,-Y.C8^GC=P>7S,<L^PZ$-QK$H/P25&F*M&KX+
M? Z+)1U?+*L:6[+"^4*^&+QJK:1*YS5T[TV(=&D2SQZQ?_LU (=?:?.8"WOS
M%(HM)L.864:YWNYSQB<:OGBHK:W*22TU$YEO@N"F=Z#[2##B/PS#0MGM.ZBV
M[.=6+[,YD"/I56,G@?<4.#.24F)"BFP0?K$NF 0#\1U)GRRF*3[DSF;>;L5(
M@YXI2OUU:N'O8SVT#L&H50KGQ^ EY=-K0-EB:0[_7B/HZA#,"AB\D=SD_WU[
M>/[_T2B"D#U*\&4J!CO845)40'=7W[SQ@_8["/[P7?"0](".59]$KOL_M/:@
M[+Z9!$2Z+[LJC0PW/03VNP8^T\I&!!6P2U$PN-&!E0L.:MZZ3_B;J2Z9&X=4
M>GIOMPD0>CZU0=K=8\S72GQ":Q85W:<@^5@B'5346BJ&O+/4K-H&PW:UHW]9
MI:^L@2\T.Q/AVT9NO3K3P^#Z>KX9WZ%&_',Y-G<A(YFS]34 ]S_.^_A;#S_1
MJC0^!K6+X1P>Y=PL9"_UNMC@TK-=*>HIR+$RAL*^?YY@Y-J%9%ANK16G0:C=
MYB-ZNCL4O0L0O=']W;5TCR4_TCUE-TK-241UR4'_^V^WZFY;"M$'&SATEV+;
M9+#>B-N-#.#XU53!G,(]_2\_RLM9V,U[>$@ @)QUB<0Q7^$Q>U<@  E2;5)X
MT% ]5KQ4)[WEWE/^N2)Y15 BK-FM[NDW%F/]M-&W;K9#4;15-VX#,,S^JQU)
M?W')Z-AOK47WMXQZ?.Y7 S&G1+?7Z9R&>,]T*!!/=??#PHX,19:[R.Z19M2J
M\Q>UBGZ>X]PT'>H4\]]#EK%5K/J;ORH1QE$!H%15BSU/=Y\LTGAT9P#*QWWY
M33DN=_0J#'J)E*F%96+5=$G-M:G"SZ=D,+O<"%.K![:L24=W""J&/B/2.A^1
M"@X]1<O(F'U1OCNH$\1_.1L*G&=_?7=$$8=:4C697CQ&=^:E9BWO*JOH[W--
M6+'_IN/RCD6,I>UX&>)O?2-+"X18#3RT]J;0H]/6IS.VVGQ$T\#A1%]X/)?;
MA@LJ2B-N&0J$$6$PO*6,2GB,+W-\!&^\)2R\,I6!;/^2TE*,>+$T7VE-9&C=
MH&2#[^/^]F&.OUW#9\"G6IX$IX/@O<@CFNQ:^FH'=4[=+5/EQO+?3SO7!?XF
MRG\UTFG%)H:I@S/FK!MEF-CZ8CJ<T58LDM7TT\(ZN9"R9$N7._Z\;VFI.E39
M%.K,SB*EJ"1,#PE:UXMM/+7%J:X(E"GM:%#%V$J>1ITNT5U] CCR]_SFFIR.
M2W26IT*J)8E]&:>JQ&]US-KH<-U[0B7_T"%)MS]NC 0;H.$"5=RXHK&NW)!
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MGP%3A!\NTG2.'^"K5/#R>?G\]\U:P?L2<]_B32Q>!+>U >#-P)VX:\ P\S6
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M>YWSMV$(C$[)L"OZFH8@#DDIT$ECJ,YKAE#/V]9E=^B#L.@2;^CY6#JW'GF
M'TXYF6V-6%@2@-Y9'?#V@V]U;4T+?S!--:^R#1FAEIADHJ"V: Z@G/2AIW1O
M+*NJ4G])]:_F*:9U3 ]]*?')K]+'_AD?/DVV>G5W<P'F4<^1.L5(D**/)U?U
M@[N3]?$)CS4\YR*8B^3Z\N)$EO<WFM"RAI<@MST]9.H3<2?37]^I@EK:]0S$
MAS"0 A)[M@- H9<%U85S&(O&X:6N<])^G >DU02&>O(F\5B-$8Y%PA08U*;!
MDPT+;Z9J1<+:N; ,#94X.G]6/ZX8Y$UV_UW]V)#KP^MQ'X/UAI,:T3OVK'HF
M%__7Q8__G1=ATJ]B0SF9^(GZ5QK1O_/")MP.LL%]ZF&7\;#+(>SSD@!L%A9!
M]TP,=>5!#@ '\>S%&*3XYG-:^*9+0=8*S2KG4>SESP_BJG]:G4Y='D348<19
MN=_W[#3.1J,H#'V'TGQP";CGQ5VS4  /$&0N8?L"(T5)+EMG*I,JRYZSG-HV
M7O4TQGZO">T]G'Y R_/)_U0]MDE'GV8D#@<]=&/6%'6$VKC527)KCDU@Q/GR
M*^V3(SZ(*Q$&;I"CT/HU8.+*VR* 75V-*L3@;1W.<AZU2\JZ!3)Q:=NGE&BF
M/S\DN?WQIZZBEA?02EG$!^(TKL%W&H[U8FH8+V2<XWV?[Z-JYRDJR8K7D0D4
MG'R)!\:7K'SAB@.8Y ;TZ*%M)R6071H\\@+ .K7+I5_^#1+XTX AE^V,#N_U
MO'5Y>PPUE[>!>U=>J/Q;WFR#[%?B2/^+M@Q"!(_>%DL>,EE3^>&H620W@T95
MPJ--610K.I%94/=MIV_>7.FA;=K;T<NQ'S*Q\O,9ZC"_ 6HD3F9I8'K&HN@9
M5)DOHM<INE>EB&ZH"HS_6C+7$3B^OSWLD)7;[9GPK *,CA.ZB_2^]%:[D\)&
MU9'!,=;T(&L>)-*YXRYB]W$OQ8LWA*(5 % B[& &$"H ;BF;;1@3$&DAB#:2
M&VB+LXPOTPR_\&/"K7X\G/W<R1BJ0.2<+*56YI"N(I V@F$L(UU[2[IN27X(
M3)D40/JKA!GHL4&"(W=*'X(IDF\!<^,TI:;4O4;$+<??MK('Z\P%\@XGB2'N
M5H " P"+#ZU4QF*C8;<TG*\15['K*7_B$9:+ ^<8>M=643'$L3VR;MQ.0_5U
M H\X[PUYZEBA\BNF)8[,A[!6VHZ1VU4Z;(M[X2D.,=WAN$$&SQH>%4I 7*>P
M,[U&=N=U0,#D->HTX&O#^PWDMX,RKP$^T9>2QOXB:G<B61MF29=-+24*MR%Z
MO5^;0#G6$G2CKDK];7?SBM@'3>^Q/'1@?-HCB!98K4LK/^0Y"'!05_/+Y"%3
MTP57+J#6$BW8NU=M\01?O3I?SOB*QD_2AY)"1N3Y"N_[G4;P8Y:4LA=UR,#'
MEPD'YLVB*'<-VR5Y\2[1BOU,.TB]\=[Z%!CUC7S_WGK*.U!>^2:&N%* F- 1
M38CZ0NUN.DEZ-BBIA6YTQTT4B])'=,;S1_$*LUJ32E9\9-D=9WQI-.IU$CM[
M=,O\=0=6+XGY&]C$[_YQ774525(:;Y[+O7%KW-6;VIW6*GYW:#A#/OF$G8W"
M4KDXQ#:?_G: RZ #05L)"$X:+!GIBP$7)YU8CMU6'R]AAWM5$.C)?WAB@B;4
MN\,<4Y\X5Z+T/=&?8IN2$[:8#E3;WXW<G&;L$-TMUB:.ZJ,0-@Q7#,(4P]Z>
M^N0(O"M&XK:_O10;N-2_F5776!Y=5*%?R<-+9B&J %CFF-7QQJ=-+#8RMF8D
M<W.V1C'[$<];K57PT<@(IOR4%<IKL59H7U]X9:< W'Y>"?CS@L;_P]Y;1\6Y
M+7G#32"X!M<F>/#@;CEX@ #!+0D.P1T:AQ \0(#@[A;<W8,[-.[!N]$&&OC(
M.??>F3MS[EISYWO7S+O>=?^H_3Q[/S2KGMVU:U=5[ZJ?FI,L#T+T1LD1MPKD
MN,"MC%4II]>.=@4MYPRWBR")GQU;R];QI9JEEF;L7IWC@H?#PB 9"1][#Y/L
M4*WRRUXS^&^0I7MV",=G9R:ZJ!>UY!CAOWG(H^?++2 ([ )Y+=S=5+SY9:?*
MZ,1Y:UOL8QN8%0I)@?$:B?3'YI<C&D?):M-?0PB1 TJ3!#H)FDN^0ONCV4!H
MUJ9.7A15>DNO:1AX,=4#%/%B?GIZ:CP <&!#\E#>[RDJK5&;$=^F(S?WA6;+
M(PVE-627:=/YJ\W6[:Q<9*IL3U1&3+1_(>N]^_?;(9?RIY;ZS=V(%MHU(]2%
M?2KN\>C/-0L<FJAEO;G\3^E?#G1>#KQE)R3?0:$52ZI0^^A607J7WT:PWT[2
M@F6<\[.>B--@<?^%ZX@W+3.A=IY4.W/EV G!^4^<S39*R9FPPL,(%@-U&ZIV
M,BBING]& :&)AO8WK&(4E.B!F:S)[V>\T5V/)A 3TY]!RKUVR>=G45,750+8
MMS% D?WS'^?4,+YP+\-JCA=8YVNZBN&^>MBFKS"%=>C&L-UQ+3G*:=UD^-9S
M+LV]NY-_A096]NLD3\*97EYBR/T*NW'2-X5[T'/\=^B2G?JI,9V;HBP3<<<1
MLW&U.<9,PG5"84RE(W\&X_@[E*/H7EE: =77_+AQM7T4+*AO#QDPZ)YJOZD^
M]+R[]*?KO1;XXV]H@HG.$\7P6-P"S!_V*E9@B').P0$5W@0O)</BH9#&3"HW
M&'RM"(S'SZYBGUFW1R6AP-3BAFYV\C_:BV($UH844_3UG^[A4L9>?>^?!:4+
MDL06]V>G!Y:S^*[/!HL'@]#61YX=;7JU"BO7U<1GT>6(.#"_5),0^)%JHGG4
MQZ/NM;0;?G<4%>^4'/NMU?+"___<3FW\4H.Q'-GA0+EP<1OI,A/%[KIR1*CQ
M!+E&S>++M_RF>"(=!.L>EN=BQD]01:NP12L-GJ1_!5=_Q\Z.NU8S^_)X<2$H
M?S(A+[//_M@J_H$]&9L0ZR>F\?>X@',_(O_.TV@"1,G,DS:M.5-:$[A/_?8
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MS*CP( ,'1)W..6UK#,V/N87Q#C&H>GSLCVQ>D+.9")8GG(F'GMF^H_)[>?X
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M2&OE(ZDX*2YNX((N/38GPZF36DJM1V5R?B?-JZ?$(&^,*^F8$C9 (KO3@+F
M5Q-,#$"HU9!NYOA4IVL7Q0LDU%E9T5FU"D6WTIRHL;'SG) Q_MRVQ9XGN4=.
M+4#NGXF3;E,[AN>.T_$ (&HQR+'NF[L5[IM38TBO4_V:E&RAJ=' GA?VI0.'
M8^B=XK,MW*(56-R&6&4)7 ;*[F]9:DU%63->QC;+$HG_F[?&<3D[+3X:/8L=
M3:X#XP]\P&"S<"=)>=W9&GN@]]H#@-#=5K'D ?#=/?%MG'9;O"Z'@+Y(3!LM
M@VB69(2+FO>!D0[L/=95*+N(9/Z!4/2G6J_"!):%F@I:FXU\D79!LS!IL]>X
MI02XN8$QO0#W^A[K!P >;*SS 8!ZD6:R3T4PPP%2-[462]SJQ:WY*B\4VC6$
MS^F(IZ,1SDC+O&P]"=+8L-'K;B?R(8+Y8$EG*$]/J86KRD]R72D];6JQE7M#
M6 ]:I0:<B J4K>*#6*JAFO[YEFY-";FQ>_65^WS@["761!;'B$.Z[JSPV-TM
MI@F_10T"9IMZ7\CIJB94-JCEE8>7BUC!^GRY&O*2OYGEIO:6)4 R'5EF.8<Q
M#^#0CN;B^PPN#[F+CK3CW6.E;F_T4'^EY^7!^LZ?P6+8QW:")T(JX1F*QM+;
MPXZ7:>*19/VA(L+KY%X5F+I&KP^*]+"D:^:1KF)TB8>K7I%'",?5.**2TD4@
MAM\0=PF+8U@A6=STE158*#K/E:S#&")9)V6HOP3)[O23@AI#Z?"V8NK?FXH2
MM:[O792\I!"JO8QQK"JM7+$\#*=Q"$ 7XK&+B0DE_*0G\*,(0(4&#>DA$N.Y
M2VS1<C/>D(5*ARU)A;K;)+#X:>X -*51PQML!WLL\BBY4)?&IG3@4G-PI345
MH/LL><-Y0^E'CK+S(\R.=._<V2$&TQ;VH.N\N,_] \4R;G$Q$R,0XM^:(%2M
MZY8<M4B!^FTVZF_:PWXC5M>OF?@QBCT2AA9*C""(R+A#EZ9X$B0D?9FUL=B;
M?#RI0K!74F 5TS%8]5IFHK3D*[T^[?>U8,%!*8],'!Y(>UB+^B8'J;N61%R/
MVI[F51MR[1R'V:?1Y0++Y1E*/V=3M072)4J'+P04 B=MB+"IM[!02$7W"O4L
MDCA8ZP533(YJ8)59M ^*([X@":EM8)X.Y*3SCJ6KC6:R-EPXO*]I"B1._"DS
M2EYKB*^RJJD9D'3&CW"&&$$57PTYZ:AKQP+1OE\?$?(*+V'A?BY?0<)3 (I\
M/@@P3Z MD&!"S#<D,,X3BDWX.^.;S#H2UN[MD ]G@<8?Y4[I&>C]K(_M%<&I
MDEMXYTBJ!]/&1;5=TOJP?(#1!X[\%+UVYWBK44><;%H;<;:LQV--G4 8D:A4
M*E4G08OD9]F]J:N?!&+=;#>/_'!B .-?]UJ6NK1>W+,92W)P>.Y!_^X0C=4I
M=;,BS],\V;?!]Z41U0$0-ZK2-3&=I+%U B[,@R=:EHJSQ8INK*9E8E-#V1.
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MKP$935 ,,FU!C M0[AZ_YUTGL]GNBW9F_VAJK9>VP"4%JALK$MU7/#)6F][
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MBY:!\*!GKZ;:* [X$YLHEWLX/.O.,#[_N*[8D?V"&O.,#_ARZ8U)PA(:^;U
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M%ER.69_X^;E-$8^_OV&G0\05B<"CCHC9Y&]*C*RU\+=^<6P<]8+3QTR=%CC
M61[78_24U8?-"M=J+IVNK6D2,N&=I*K*L,C3.$9*0:CB0"*JY!D=!'_Q?AV+
M@4WX=8"PGD5G5[]_^UU.O^YE:RNZ@,YD4(4@^%Y3X"VC4+&*B3LP8M@7,NM#
M$AF62#016RJQUL]?]  0+!&G]"&VHB*?I84^ (*>:TR7D2BYH%,V]K/",7$E
MJ+?63&(&A5M5WL*D\_8? +BE\/=LO4N>:<6H,<9?/C)CN""9YWC.F;O9LK^/
M%214D..K^C[PSIUZ%]Q$97.8)_/V,L)#]^> MM[9F8N;[ ]@]0,@/*4?2'GA
M;=$5RCL3KF"LO-23B^-S9W72PX%M:<AX5U!:4V8&%%9IJ#/BD5,X6D2,)SU*
MV PT[%T7]V\B#H";.FPHB5G/-"2_>,XILO"9)5X$T^'*FKM_M;H\!(K?T[Z8
M6 \.SEOLH;&KYGE%C>EB,?C3B^S<-.6]3RMS34J0OJ"6RP, T[$?0TW A9B\
M.86*#":[%HUV0'13'F])V7I(#F\DVI>Y'0KL_"#DI>6"G875C4<1_EP-\>D[
MA2T3LQ:!^_Y[HNWV.E[_4=D3FE_EW5?@'##9?#C+IQM1KIW];0Y2,IDF>SEP
MKH,?RRXT*ECZ2+0ECX/W9CD]GLI];\BX77_-Q$DEGP/]Q<4V^^X;56F"CA<O
M+)D0MQ_UVM<<G%M:W]M4P@L#4.'JZ=?W?RMV6I*)_#VOGZ#F#2)?ANZ3+]Z6
MTS6E?K8=EGQ.RGG9W21:WW,L^X35*Q6EOWRR.=]2.RI058QG^\1OER<4II"%
M\0\"XD^,RQPS\$10K*&,G3<A(;QH9G4US2^/8Z?]&8^73=1C44>W*27W#$SI
M 4[)P."*<Z^^Y-U>LO)*[.4B.R_*XE)O(9(L&<;H#8:&,L9+CXD6\6QWY>[7
M,[6*+!F82BY\:44GG_2";V4>I4Q;'O\YDERW\"N<$W/Z5F.+\QP"A)UT?!@W
M2@"<PRMO[YYZMG=[^6Q?S:I*O^^*P2U236HA?,B^X]FK/DGC!H"&PA!CIP'R
M06?3[B<.P]/3*=VFA,O[?46_1'Q]N?7A]F8-#>9!JB>%^AS4V]4_%Z7)9?,
M]C?MW710RNB0]S,7K8KJ*=(S-#/KS2F#43KYT3Z]<3]"<0M7H^,E.RA.'1<K
M@L &VZM1MO1-;<N;&'*')U_EGG2%(DIABG,,N#8>I#L8S/XJF+@G02I&.C[5
M+0:<JG&G]R@[9-NLB]RQ&=7 91H$>&I^S_E'25)_H=DW/V0+^W6W1!0A^XL]
M0A>?FJFRO+(/ZI@@O466L31RD#HGI.*?T"$JY35*Y5F$1)3D0\N7$A1BM9"Z
M;L/ODT2;;Z83-29MQ>8LRW(/+N?S/EZ'L)91+2 *U>B)M)8")/#X9H HS@>?
MX;^!H_**K,D^-9LSI(GE>4*3UNN<6;8[JWCEWJ:^1/]F]F8D+NR<+6<R,G,<
M!='Z]Q.$(CANE#/C8KBU";-]K 6)S(.H037A]?3?<[(H[ZRB:B'"\C/Y<T%D
MGXIRYP]^K()U7=/L*SN=N)&Q[!V#<H/PFH>8JVR>2&Q2WY@]&L\'N6"!S3T)
M"LJK+M''-=)]CSNQU=!,E$[25-U<:>J,/?8QV/@999"QK5/-BW.:,IC>>FM&
MH,N(XP/@]31'3NTL!]TT>TTCII+-91(?2KQC^H=87%";V41&LT'"Q!2%:AC@
MS(9[S2<R!R8N.5[&4<M$/[[C4<IKL:U2)S'V(E8">R2B(JVT-(@+XNA1-+=V
MG.: \UE/=?J"TEAU[F/N5,%T!16W"-]H\&O[CY%JA*,D1RI)T]PF&ZT8%C>J
M-62 -1L?G#U-SY  .YJF1BU(9&Y"W<MMD4;$+AHV)HS810U/O($<39B*>1DL
M4*5MNM9 ^4IEZH)GYH@GE#[Z$+*4Z1V+C!>J_^0:KR98"QT +LYI XL/YEAD
M(ADU/17ZDQ35WYU&;4->* J<QA!OCK?:UO8!4/W1O/66JVZ*/Y%<;'AM4]@A
ME:J5Q6WVNXC+^N;&"?(!&+7QEMPJ 7\^/(-C^+1E?H'_:& Y<J%/QM,M2_?^
MLF?(S ST$AH+DH2(16Z0L.96D@49&NL-R+W\;E/*O61"0;6)$G;86,Z_[AO8
MW[V*N&=(=:NUZ--3FF%QVI)Y[;CJQ&BWLA<WV<Q;QD(_>NW*D-'%R..D\,*:
M5K)E8D0H#&#'XZ2<[4<^0C%5F(E\)LNSSX3P;P]R,S$Y2-P#%KO:B&<N2N:W
M$D:[)O6*C$-?"=,\-P,\0Q!0[Z0]T*P96B^QK'.K+ TE[+'DU 1PHB ]X7*
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M_U+7%ECAO6ATE7+]!MF6"?PB-_AIBA]WK#M!P&]K+]%[13K0#E7J89/G9%K
MQ_E5-WV/'C"/OH3,BK(Y&^] ^]30Q.2,$&%4QMO3Q]G@(Q'QXRME<=Y>J]:
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M[&6(\_G6F 0 F)L]K(ZNXG7+TP1D9B?XPD85EIZC;"I8+D]0!P+)*GJ([$1
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MY[V'DIXO)&+B/$W.F?36RMDCT^O+-2VUF'4E&A@6&2*.%U;^YKA_2/+M(4B
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M!Z7IUW5D=IK5C<W?9T\7]JPT$?V;=4TQ*NAK:1PU&2TL5%Y,ISPE[,4/N'1
M#,4$B3_>AU.&Z(OE1V![KFE";A+U52 _MN%)7Q=U?I*97NGFY^]SM^6^YPE+
M$"@M$+<-,5%8VS(WH3_$86%7"V":3NE9@7ZQRD2S\L'0J=/QFFEIOO;]PM90
MNV3L0C5CIDQ:+[I8L$E"_6+Y8X?@ D<8%?E4+<G+:P6_-XU39N(,ZLK+/2<R
M!9PT]\- 7 HK/KXF<&PZ[8C(_$IO*;CLO,34U*T(F&2&-=PE=:$ PF5YHGO<
MPNX9<6(%Q/#P>RR,9@ZV8EO.O)(<?#5SS1"@(M(L3POL>E73#+O9YBET<;#+
MA>?V0JT$V<ZK;\IIS(4S. ]S4J>ZOD?RQL6RH:8F-FJ81DN.''<[Q2'E?T7(
M3; A\-=\K'H\V[)R1TMV8'I9=;H,Z,<DN6YS) %BH[8O/':YY_0ME2W.)T:%
M2PB>Y,HR)#SY2.A[@C?7@5+\$U6$Y<=+\W)ACFRX(HQ^^E3!H@5H^G H/%?>
MQ\+>..IVR_WK(QDPW6''8:2H(>DG%F;GIHC=)K=N+&')7"T=R\K\]&J+^W77
M_U6L5;Y%X83;14I:D"Z)11&DNTM:4H$E)*1C27=I)0199$GIDNYF%UA Z160
M3MFE.Z5;O/SN'W'OA_EZGG/.O.\[9YZ9DRHW9#]E\FHH,RTEON\;$[QD'.\>
M8L#V^Q_W[LVPIX!E>J0M"TCUJ+TUG?VIH^&\X!@A8\D%+/^'"[=QLUOEP_T-
MF#R"O*E$LP!3J^DQ?:# (;X$=I8 &P]RSVFP)>SPHF55BA?],LWJX/E'A+#&
M]>-W.<$^VB :G,G3F42!Y]:P^5=*V%3#5OT072#)PJUR7:OT':RLNJC,% 1"
M2R:?#CH=%*LGY(/27K[S'E >9-WJC/</SV\8)70NO@S7.:)-I]E(+S5?-,6&
ML:$07D#ODYBRUY& S9(BZZT%8& @6.W$<K(1M&]\O?RBN#'MJ_C8>EBK.$[Z
M2V\/HY],>GGE3\C>M\KQZDVZ\RV"TEP"PD?XINL<4I(L^M?S&60+(SG"+T!7
M"9I<43_MGU%-=,_0&5R^LISM]SFWHG?QK6PPKWN8B7@:J9*3U<]@O$5D*,,(
M^,,7Y+^,V?4K1LR(8M*XFK4EUR,/A.-D2"NU.FO??E9E<;F:J30QEC9M#;_1
M4#G/K2-Z,[1V@-EP&X8>7/G$MD%JQ(]2P_\@P+9HLD*E<[#AVR?:J,8,"KY7
M,^<7=(9=+/.>LW81NGNW57.EVOD[\@J'BU%G:7F3C?UGJ?6@QLRU:-["NJ9X
M3:#>XS(]8?7 -D)'V*>$ QDB?9SMN2<QIU:/1<,UIMP02@PDG*98]+,4#2 !
M<4^9I"0>5#XYM33(\'!2GF7ZS!5L.?$&.6Y]4IVJBXITIF/[^LJCP[?O$;-=
M@H7]Y\_O%ZE<&8OS%&ZY6#G23[_ >6S*G;V<[\!M,35KG*+B!WM09-^"$8G\
M2DRWF  84D/OS,H^P:<Z7>=^S?(W&=%7D:]9\K9PO/+#FP^NE5I;EVY73J$O
MG9A3KM)P$7&]X3UFY_$+#%.W<F5;+HZ,2< 5Y_J\!U%:5"W&B7(W*,+7PZI.
MVU94M[S5EDKW=1"G-<GOR,\>.7W^G/5M10N2!VE.$M[G5TVX@C_AAYK11TU4
M(>CU_:S,$2=_]KEJ*37^ >QX"D>8 [VIXWLB_F+^[I> ?Y#XA;^>E-4LW+$$
M(EL;$S>(W$1'IPW,7^YS%!XD<LQ;:&Y$(%^TS +47Y_0_"2$4,0&*93N4CE-
MH\XSO2J>V[L^].!TC>#-[NAC\NR;'E;L)&B1\UE!YI:K5#C+,QP1?'X"VZ^A
M[1J#F/=H;&:N.1(U^2B0;D=8_('/Q#BT$"D@!41S*4RE=]\%@M6U ]NI!E7,
M@WF&;%'AZ[%J7_B8 W'^3M8DX@(>RT!E7S6)7T>V%I.0*9O#7_?,Z9PUF,YB
M->"D'VU,60XHM=34?SL0!C['4;KC^DE8Y,K*,2$KXTHS7%$ZYVQ<_ZI6A6MJ
M0+E>QKN4Y!$),Q5@+<2YR5)T=.\])EAMU;2V:<(AQ +MSS?I3*(,75%<1]8_
M!MIZ NUG;KI:X&8.H[=VUW]/Z5)1P=.99-F-T\9);^4:RT_:OJD^<E1B<_)^
M8WU%3'];!IJC^,SO>)GM6C%4-$*0"PPH&DJ=XU#8 K--S$#'%:#']?.:,9$<
MZEA<.B/ *9&L?1Y_U%SK+BU)02R3_LV;=]@@C,*T.^;BSNJB>1=4M3I(IGS2
M#?^V Y7NK<XK0\!_3;\NW&ENS/$4+@SQ+INI8VT[-DG)B T/KNZW<7B_^UQ6
M_1SV+%Q+0L2\]VDV?>+&G!AA4"24\N"-)VDBG?%576;^W,[,(K5HE6+<(Y<
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M6H9=G8D@YSR7N:_7D!2$C7\IYN"D"GQ@J&D[.U#3HC2PG*[TDQYHDG7IJ-2
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ME=_V=''^__T'&(5_O_\'4$L#!!0    ( ,^ J53-<Y6:3*P   !E!P 5
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MK@&"*@%<0052E&$,S?]119U=/I?'&QN[_#Y[,E*9G4XM>"2LY!YN#0>$'?Q
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MQ%.+&%4R1FLAW1CF'(+M7!( EYY9PP\29WJXH/@)(BB5^.5^_O57<V?% ?]
M]D=0_UA]^.>>.<@G?D&A]<=\Z;*.Y1^*F2WEOU]O>X(SDN70;!TR*JCY>%-F
M\U,42#*; BPU3!._,@^G1AG;)]P(N79%=RRR?QI0-[O@:IAZ_J+7"!V6T@]8
MC:$-@;!5%TZ.-&QUA39ECZHHM%[<<6.A[JU5\$D]S1?6#5V?@!V>%V?VW#[#
M"4"QW5CDBML,V!CD+&89C85,$N2UL7 9=6SDT A=G1__1=G2LT\/50CBVYF>
M+QX[Q&2[@>^XH0@-:=\;B@;-C<##G,![P11V1^$T\K ["A\PCG847C?[[RB:
M#+;OK[^)!^M:?6]>IDF,\ESR/ :Q@A@@1A- 829!JF.D*4Q9FN2N6XI3 XR/
M<VH9H[60D972?5-Q$L3+NXIKH>F=.[Q0\=I7M*G>>6-Q\J&#[2S:5-K=6K1>
MU]4E8#,_%H8BJN6Q\D*\G*]FR\7WEW-IOF>.A2 : Z@R6T(Y839$4 &%,8KS
MG"LFG;]GA_'&]GDW^^,]F6_JW"4#<]1('EG1?1T)[;B[.A:"H3F,H^$J(#NX
M'YS@N=(=T3[&P.X))X6/W15NMPU<[GU3?^ZV+%>/=25>V]KTS4*I=47Z3T;4
M"5=)@N,$ T4Y!(AS#6B<(9 E9O<#&99*.K4$&TSBL=&<E1%H(V14K'LIF%?!
MLUY8__/LN-$:T^SU;6A='S^S4\MS1^^;NH.V53W:]-?XU/9.#%?!W7>>QE&Z
MW5GJ'Z-FN^\D!"O6[CUPAQYH-O1SOCC3Z?)V-ENQ:?6[1JYR(E*8)(IC@'EJ
M:TP*!@C#&B0991R).$W<RA]T&GULJTDM_TTT/XP<GV[[NK)*C?H/T5.CB$>/
M,>\9:E\[>L>]YW5@#7E;*]U:@_H/ZT6@5\@]VK[U"?U ;>'"3X%?$[FN$+8V
MF?-^Z'!-Z+KJN]>DKO-#QM;YZLU\H56Q7)DW^F_*UDU4\O:KT>I>_<4\?/G*
M+(B;A7.2*"TAY01@$B. I$* ZRP'G$J..*%"Y5[%>L:AUMB6P4;VIE66G$^G
M;%'79*YJCXVF:Y;7J]/S%NS97HCQ[],<.V[M '03K2&*&HRB"J3(HK2S[QO!
MEJZ7>1_'OB^L:C_&YK"7Z1RNW5<GZ3IL,U^:/]@ A<^KIZ?I]]M[LX.U\C3%
MG\SBG*<2"L 8P@!IB0 C<0JXBB%33!$&G6(Z+@\UMI5S+6Q42QMMQ/79KK2#
MZ[ =# 99SVO+6;2Z].YN1\UC1Q<,O8&V;QL4RQI%MI;XET#[,R= 6C=C[4\8
M;N?EI,G>-LOMCFY[JM\_WRVJ$G/?MR65F]>5RTPRE"6 *!X#I!((J*8<4)EI
MED@%2>X5%7=^J+$QZ.^_?/XENI^;16M6A\3=JYGX'I4;L?TV'RT8NVT(PB#7
M,Y'^_CE:2[E3E;V'KHJ7T0AJNK8,-Z@Y>5GM0Q//X8X@I8PWN6%<2((3@D""
M,P%0QIDQMR "&9%(("81AU[-M<Z,,S:Z.*K)VS4#[QRN;BP1 *V>*:(+4-?6
M+>XUC>[<6,]9K_A2JMRERSOLQ(*>1A[L&5]_4PM1E.KCHA!JDFF"".0")#F%
M #'" 4,R 3@E)*8Q0M(M!7A8L<=&6!O'%FL<6ZJ1-GJRXE[E<1WXA7#8B8YR
MFH?PF$8OVCVF+QJ/:7/=GL?T3&#+L4]TC4!403#*=\1CWSW*=V6@/7S]+M3>
M<['[SK!]+WNY<UT3>Q"QZIW1]IWY6KTS;.>=^:.=;D*Y" :?NU9WPW#2#.>Z
M&!SA/3?(\*-W,86*^UFA"\',V$+8*.!U[I#9?+TK9NJM,;O*B>0P2UBN08IB
M8\?$*08\PP+ A&LJ-%4I<8JY]1AS;$;(CM315NQH+7?TQ4H>5:+[N& =)\#%
M;@@.:]^+_K,BZK/*!D=VJ"5R!V&V1?BI$3W82N:%3_LRY/:H =<0+]WV%P"_
M6[NF='U2]X7=$\^653HAES+/&8% \009JI88$,09T+%,L4AR%2.G2A'G!A@;
M+S>Y1ELA/7,R3X+83K<AH.F96SU1Z9!L=5KU*[.K#AXZ<#K5:96.\Z?.7!>B
MV?F!G?=)V6IUN_6(DPD1@BN($3 FF0*(DAP0F&D@(80XD7F*4MF]__EE <9&
M $?>H<5:YB;@W)8POXF*6?1=L<55[=(=9L?-]]TGYCTSRU'$\Y&+92-_$_IL
M->BKS[H[=#VV7G<0XAF[L;M#U-Z@W>,Y'9G0!F95S=_+]T;1IBVXP&F6(=NV
MQMQD6QE#P+79?R8T43&&@@CL5?GJY"ACX[0ZUG,VGX%&0.N@4KX=V$\#ZLA0
MU\+4-PU5"-4"WD1;$0,231L"8=GDY$C#4D:;LD>\T'IQQV0)\:#D:JH^Z(M^
ML_*<X^S.]E^?: HSPHQ!)/(\!BC-&2!I2@ 3<2P(QXQ*Y97O$$JRL9',6K&J
MAJQ#R'K9&K,>?:F4]"WB&VS:W6CM62:S;S_:L//HGR<0&O.PH?[!I!LV6C\T
MJ$<!]\$'Z'(\L17"!I-6H['IR_E,VN9\1IY9.9\6TK96?,&FMASCYP>EECLE
M #^IJO'BW;PR4\M*HFTQ/ZP$)I AH+2B34WD&-GO L<JYR+#N=->>@AA1[U\
M["@<;32.=E6.&IVC2NG=*HU1HW:TG-<[1I_ _[[?$)>#E_',^U KS8=04WZW
MGO)FV7$J,SG\6^!S6#2>MV&H4Z8=(BAWWPJQ>2O$[EO!F[>BK-Z*8N>M6&R)
MH'+=A3NA&F92VH^V>I9AP#.Q8=#</TP;:,R!4_W?KVQ\>V-CE;=?63&U<KV9
M+ZKDPPE+29YSR4&&,@)0%N> 8,8 S80B*=(YUE[._KX$'9UQ4HFY<Q3 UA)'
MYH6([JW, Z7D7YIBQXWK"":N;^OB^K3Y6MG-1KB,;O>F_2^MTSY< KSCG(PC
MI?V2L#]&DKHCY,'2SEW'Z[;>O&3E@_T_F]S^E4WM'OR3*I>+0I@5SO[A=B;W
M?[%S9=WO\.U,V&PK]4K5_S7_GJZDH<IUO6%;5NVUUDHL)WD2,YI""DBJS"K$
M6 P(QPG($HA%CED<0S59SLV"[+8*#2N^U]JT4:(_GGM?6;VUV-%/LE'@9WM"
M+8RJ54>#Z@>U5=IOK1KX]7!;P<8[Z3VO:U:5&]OL\2':T>@FVBI;_]'.^^'O
M]FZH08C>;MZ=-0X_WT0;*+95V"T848U&N#7O>68QZ$HXL J#KH_/,SV'J^8S
M27%-G[QZO9Y@2%C&\APHKE. ""* 8H7,SBL1POR+X=PI)?C4P\>V1WJ];0?7
M&,Y=VN,UP+6O =?"T3-#>R#1L2O>OLH!6N(U#WR&?GC[JIQNAG=PS0A*R;_^
M]J0LV?QU/C6/L04?JR+C0D AF8Q!G$/K7Z$"$)(+(#*29G&.LSC#SU9,_K3,
MHZ.11LJHM)U,FY3<KQN1G[&L_)DY[]GATL],CM_W<JZT_.;]V"H_YMKR[5,U
M#I>,A]P_AG?&?R)ZK3!_8>ANR]FM_*]5N:SB)>[FMU(6=B@V_<@*8^R^9$_%
MDDTK$?FA%I^L(Z LENJS6GPU[%I;R)^4F-_/JJ?4U5HE141EJ0182@T0UC$@
M,$^ D&E"8H42F:0^:UG? H]M(:LZ<8,3">7JF_W9LT%*[]/MMHR-:1)[7L-N
M/[Y]>7-ZA=K2P,W6?:*K5E2VT\E6IW"+TE# !UV1>A=ZT.5HJ"DX7(L&&]??
MX7%KI))6LC=3=C^1,DM5C&W#SAP#1#@&+,LU2#3F.<P@E,2I9.+1D\=&[1OA
M(BN=NYMC'Z[+/H[.(/1-C6[Z>SDW3NK:V;.Q_[3!W!HGE=CU:9R^8&"'QH>U
M65I7_2C?SFIBN+.G56]GRT4Q*PM1FP4ZY3J3&00Q8Q @&9O%$*H,2")DDB<J
M,[\>Q*/A(?38Z&(C75,=:*ZC>5,<:%T+2 [DU_"9^IX=&SU-Z/@]&Q^VKHQ&
M=7M66RMO[<GURS*6_@H=)FH<?@T?P7\,QT:'J0CFV>@R=H<<C=^*J2J7\YDJ
M7\UMM-U$Y)1HJ!,;J2@ ,A8E(!F*@5!8);E*)$J<$O!./GUL2\56ONA++:%/
MW/H1=NT4?C4B/7-M8# \HNZO 66@,'D?</RBV\\IWQJ.?G33</'CY^3="_@^
M>U%'VWM=0+CN!V.IU#S;[-!OOQ7EA&B5IC3F .<T,T:SV0/3%$, ::RQ%#HG
MR"]GN&VTL5%8TVMJ*Z2G:=N*K*--&@JOO@,%#J&*OE@)0R;+NB 1UEIK'7%8
M,\M%^2/[R.FFKK%!=^S;6VF>5A5RLPM$$^\B52JQAC'@"<\!RI &G L(4DT4
MR>(X3]RZT%\<:71L4<?*&&FC?7$[QA"= _BRLRT8;'V31E?$.L0:74#CRL"C
M<T\?. KI@I+'(4F7;G@>=]Y.X[G;F7S][:E85$_8;-0F.DN25/(4\(Q3@&+!
M "-0 JR37!.499*DDYFZMWEMPWCS+LKL]-W1^KO;E;R_S^^E30:<3I4TDVO/
M_';:M%:EP<NA>K,Z3_LP?KPP4_GC.?%V]*Y"[G<TW[KUQN/%<YZF4;GP+DO]
M0_GOG"<AM//.?> .GKM;(1:K:EB#Y=0\_X6:*5TLRPF$*2>2)2 C5  DA-D/
M,P@!DYIJQ+!,N+L+[^PP8S-M&T%MEP@K:<4.O)'5PX]U'E8'[UX0L/H^36YP
M:H2,C)31BY X>3C^@N UD >P[?T*5>GB(AZM3L'S=P_G';RHP9Z;\/+5W8S[
M35CHJZ(4TWE9,?"ZP1U&%&:YX"#.TQ@@J7) M<9 I7E*4<RXCKTB+=L&&QM)
M[H1Y[TC;N8=@*\YNAG H]'IFS>[ >=N<+H@$-1=;!QS4TG-1_=!(<[K'WX'X
MJEE5WIBGLFEMKKTQORLG2,8\Q3 %*A<$("AMVW<A04)PC/-4I,PMZZAUE+$1
MQUK0J)9TG<U<R>KN-#P/ZF6'81"H>F:)3BAY.0HOHM#927C^R8,Y""\JM^L<
MO'QQQTR/JC3RRZ;>=L8@03H3@ N, .+0GA2H%*0X0S1%-),P]RF>L?=TKX]\
M@-H656Q)=$W1\GWPW"R SI#TO5%JRI._#%V;_*3"83,!]D88-FS_E')',?8G
M+^KHR&=573F;_F,;NGS0=PLV*\WB;W:#32A*S!)-4DU!K&P=-IXB0!-,@)0H
MYR17&O'$*T#@XI!C6[ZMQ%5A+2NSI\?\,KZ.+N^@J/7ML]X%+&#(CS\883W#
MEX<=UK7K#,.1;];]SFZ\\DX9DE+[753>%8Q7&:6-L[=\93,W$ZY3S9DM\&C^
MAW(,.,$<T QG!,8DSA,O$\%UX+%9#V]6UM,=/1:SXG'U&,TWK8;J1DY-]UY/
M@\)Y%MPXJ ]L>V:B6F1[!';0NFDC]XTMN<M59%/4PC&4+U1!><IY\$'9RA>2
M0\[ROG_@T(8Z!NOMK%PNJJU56?6*N7M@L_T#+24WI]T\Y0PJLS5*")( Y1("
MDIG]$2=90@7,-8_9.LCA;H"\)7\5.L0\W WAJ7W&6(<.[X&C"3BR:?UAXA^:
MT-4= **ZA];20' 4'6'N'U,L1/?)&T=41 ?Y?XSXB.X3$RQ2X@H1.BZ.*UZJ
M?ZQLQ/%7\S]WYBG-+C;32"!,.4AEB@'"2  .H00Q0QIE$*8Z<\JGOSC2Z)P#
M&T&C2M+(BNJ9 W097L<5(@1H??-Y-[S\"?<2%F'I\>QHPY+9):6/J.?B#1WW
M_\6RN*]H[+-:+NN>%:_K6D(3'<<LC84]^+/Y THK0!+)08RDLEVI<D6]'(HM
M8XV-++:B1N5&5L\]?0NRCMOX,'CUO7/?0K45LRZIUU:0RG^G?AF-L)OSEO&&
MW8]?5OQH"^YP2\A==VW%W,YL262;P_!5?33O2/EQ/BW$]PE'FE&<:I!GMH,=
M22B@YA< "\22),>YEDX%BZ^086S\4M=Q>W&\6;KTV02;E&NVLL&@'G!+>J+.
M6O2EEMBIH5N@C:03= -L"-OE&,'&S@DHMPV:VZ,Z!*<?%X#?=W9.(,>I@MJ^
M@]*6F= 4<$6U^6>:Q81FC*5.051.HXV-XRKIHNE:/(^HZXNXMI-7<+1ZIJE-
MM<>UK-';67W\L3W]"(F>1^AZ2!0'BF!_>[IMS73_;0P5R^X*4&M(^\6'#!?9
M[JK/7H"[\TU7QKG7 36&R-=/+E3YFQEIM5#RP^R3LC%=Q>S>7/!^/ENL_VG6
M@Z)\5\S4VZ5Z+"<XAA(ADAKS4]JL^#P'/*,QB#D4&FG,!<L[!<:'D&YL'+X-
M"+^):OVJC) =#:.UBE'5,K?1JKIJ5\VHTC/Z8C6-*E6[!N$'>0G<K-]GF]J>
M%YQGF=7N&0(AT>\GI2"(A,^3@Q 2W+-)"T$'N;*XT@?]IIBQF2C8]..\K"H6
M;Y)Y-%(J$3 %*<QB@'C& <F8 DA2I3"5B5"L4XVEED''1OD;F6U@X$;J:"UV
MYRPJIPEP]$H$AK5O-\3UB':OT>0 43^EFMH&?IZ*30Y0G"W<Y')O3W%,Y<7B
MF4<9]W]3Q?W#4LG;KVK![M6ZO.9'V_=H0K($YA(J0#5+ *+8NB<4!7$N4"YD
MII),!*V^'%B!L1'F6K@ZADG.IU.V**,GM:CCF4*',X5^':YQ!(]CD@?T(I\+
M;"K=RS.?J.1R$ZVAB!HL-F6<HPJ- <.;>IK'86.<0BLQ G]X_U/D'>W4EQS=
MUM&_LD5AVY=7KB?;,V<BA%(RQ@(D-*< 08( 44D*L(12I!IGJ?!:Z(Y&&-M*
MM!:P<78*(Z)G(L(QB&[+PU70],S?&U2:C (K7CA"/:MY4,8['F502CJKY"%G
MG+^PVT>]GT5PP!ZV%,)\-5O:QG>&7NS9WH03P?)8* "Y,-]\FN2 Y%( J @Q
MVW?*<NX5WN@KP-@H86-8L,:PD(W,T:*MOV68R7#CCCXA[IE:CK*5CNRXM?Q5
M.]&;J%$A'/UT!2\H.WD+,2AY=87HD-LZ/Z=CA8;9LI#%=&7C%3Y;EVCE-7W]
MS?:85_*-4=.:9:OZ./6#?LT6,R.;;4U?&66WCU:<B4!F0Z\) 013:?@P9X!R
MH@%5A.F84Y(+IQK00:4:&TD:D1_G3?I19-O;?673:E,W7RW+)9M)H\)-I!HE
M(_N*1<L'8V"QJ5A-Z\W@7$<5+N;O,[6,IO.R]@&(G6=[5ID(\@*X<?#@T]HS
M,>_J$VT5BE[OS>&.3G;^UEI9EJXW\S=1K5G JA@A@0Y;32.(9,-6X0@)YE'U
MCJ /[[8&?%*E,C<]W,[D*_553>=/.Y&\OZFZRC_.,JU$ E@:QP )G0(NH 9"
M242SE&2)]BKTYS#FV/A[+7)U/BVW0OOQK0O8;FP:&,*>N7(/O1UYU['(T9=:
MY("G4QX !>4XEW$'93 /( [YR>?6;NSS^O%I.O^NUHU^3_L#W\]G7U5I#6'K
M^2NKXEJ[?[=.@/?SY7^J9=,B^+^5K*+?&R?A1%&>)@1RD'*< 83-MIURK@""
MC"(<I]S\X,-?@T@]-@;\W49--')&9= F\<.\!6[$.KJY'?#HZ62C^(VN^P=-
MM9/3_'49?5>;YO%&S_ &[:!3$G0Q&$;R09>302?C<$$:=O".2UK-@)_4M*IP
M,G]5E,M%P5>5#;^H):\#T7Z?F:?^88W^V?T;I<H)(VDJ1<(!BS6VN1RVWX!"
M0.>2*L0I8ZE7_[WNHHQO\=G*M_$OUR&EUOM1E*6=.<]5I_M$.2XE@\#?\_JP
MMM ;+6R%K%T];#>AC2;5?.Q-E54FX$)P-:!AV;V[.,-2]M6P'?'P]4_L1JX?
M%[8:WO*[S:Y;VE8P_U@5U:9DISZ&R).8B02"/,<4((YR0%(( 6084JVE('[!
M9PYCCHTNUR+?1)70=8.GM=@W59D-/ZYTP=V-% .CV3/[O9O/[L&[XJLAOCOS
M^\*>\5>1YCU4*?% )BB-N8P[*%]Y '%(3#ZW=B][5,B"+;[O%$ZM>OQF1"8J
MU3%0G'* <EL<&=$<I(K%$*4)1S#S+7MT<J2QL<TU-9'/HNG&)D$PZGN'O5\!
M.72GY$L(!*]M='JTP6L;M2I]JK91^PU!BJ#Y]NPY=_N8WMZ#&EW]M.JY!$2?
M!;J>J47/)94OE.>ZMC7/=L546BT6C0OD(UL8^]UFI,@JJVY]U#C!5$+*8@H(
M5Q(@*21@&&& $L(I9EF2^_7Z<AMV;"O=1NK: 7X3/;%%]+5J9A4B,<-Q+EP-
M[= (]\PT6W _U^ :F2OW0B5UTS-L$S<1TN[V 2JPZ>TT],#6MP\<QP:XU]W=
M..LE*^V9I/W/ZVTHU2=EG1#"C'7Z[TU5*DJ2/$=Y!O(\80"16  BLABDD$L&
M4YS"1/LPV37"C(W?K) WD?W?:$?6RGWPMG*J=V@\<-5DN5'=4%/0,P%6N%NL
M#R?@)MKJ$K5<U=0:Z[7F6 BL@W+H50(-RJPAH#ODVR#/'%MWA+^81RS/)715
M?WQEEI1-Z8=)1A*.B8P!Q[9W0L(4H$F< 4BQ$!EEN4I@T'3CH30;V_I023A4
M%O)@KX_C7GTL\HYHQ1JN(4.-46L^<W5)9*&*MM6'?H2N#1WG_P?IZ>"KW;@2
MH8>>U.'Z0705<&!CH2.G8ZQ9+" $*K&)V7&& 54L R+/E<W-MAE*@Y@$_S,6
M_K7 8)WC>6]%!M*2K;9D6SO!-K: />^8UYK7ESZWT3!.T^#_-P!N_D<L\?\3
M%O+_T<OU2!;E9UEZ:TO 2CJ?&4&::!T-(=-*4""%)F:!3+E9(%4,(&>2:1%3
M1;TZ)IP<96S+6+/9V$CI&3!Z$DBW)>)J>'HF\D-D>HAO:H4@;&#FR9&&C;EL
M4_8HG++U8K^OOEPL)W?%T@8YO)W)XFLA5VSZMV+Y4 5K6O9Y*)[NYJ]G2S/D
MIJU['!LV("!-$VZX@!- H.2 9S&/)94IB9TR^#N,/3:&J,2WUNM6 3>2Z()[
M.W7TC&;/A'("R("<<@4V;4QC'KO#,N9?APS39=Q!>.<*0-9L=,TC.I9>LBX)
M2WL+]6"LJ.*K>CL3\T=E4PW9U.;E_,=\:BMC_,6,]6Y>EA]FVS3YVT51FC^]
M6MDZSK4E]5XM/^@[]FTB-62"([/[ATD.D,XI(!A1P'/.J)2YX+G7[K\O0<?&
M?EM]ZNHB9B/'OK)B:NMM 3U?@-+&,I;;8A?V'')NP?$L\]37Q"><IY(I#I(\
M-BN93AC@V+HMTI1 FM$$Q^G$V-E\_B--_:[ @TY^L3WT']U4N]G=8YB^GE?:
M#R_?WD2O%%_N5*&YB6[WOEL;]7H3[<QPHW5DU8Y^LHK_?!-Q9:Y5T:W\KU4]
MZS<1TX9W(J-PP'IB/4])V+IC?0D[;'VRGB$_JF/6]W@=#R'$@Y(K:^#L%UJ3
M=?.(._NY3#"E,1:I DAA#!"4&2 \RP&DL5()4SI/_5I).@PZ-CM@+;.UWP\*
M$,IU.Y<OE>2^'1I<9L#1Z1X8U[X]Y0$@]7=H>V 4U@OM,O"PKF,/*([\O3[W
M=FR2K<RCU/[C-\W-&A=R^6JEWJMOR[L_U/2K^FT^6SZ4$YXP3JC, 6<< 21D
M"D@&,Y D0N=)KE*9QGX6;U=1QF?1VC9XGAVUNTY#%J><$T8 Q8(!Q&,-N,:I
MV8+$FF<RPW'L5;IAB$D88B4Q4Y .- 5NR\80P/:\E-0JW!PN(S?;5IXWMDP#
M5]%'5LB;Z#\56T0?9B$;I5\)8M@NZEV%&;;%^I60'?5?O_9Y0[<2JO['IF'?
MSJ1-SWYOWO#&#ZXHT2SA%*2V; /*(3'DF2: L!ARE$*%9-A@G0Y"CHU8*TD[
M5'+H90(#A<GT/"T]T_)V1GHX/.T3NY$TSFD1=%Q!)E= ':X!CL-8?@PO53%Y
M9][#Z<>'^4R]7U7%:&$F<JAX!G)*$X"P%( FJ028<"&4V6' W.ED^-3#Q\:H
ME7Q1)6!42^C&K">!:V?$:^'HV\!T1\*9R-I4/D% I1*_W,^__FINJ[CG'\C^
M".H?*\(Y^<!!B*)-E?4'WGI-QVX-=8?;=84);*#(8P4!S#()$(V-T13+&.1*
MII1)317U*C>S__BQ?9RU=)[=#?8!<S-2NL/0MWG1^ A[J+YQ6N>PI?_WAQBV
MAO])]8Z*\9^^RN];_?OB>SGYK9BJ<FD^^SL#X;JL>R(SIA)L,Q-MMV>1QH!P
M1H',*8&0J!SIW.5S/3O"V+[8C8Q1):3;IWL>O_:O-P@J/7_ !X!<KGGOB(R<
MBRK#IS(=^T5H;ZCG?W6<B>ZB\C77V<LL@<$X;>CK_(V#,-A%N=<D=OG"YTG;
MNI6R:F3-IK9[U71>KLQ[LC5A%*):9 P08CM'D30%C&80,$5BC%*:9$(.F:35
M*NW8^'63DK7IN_=)V>V?]0>_G,\JF6W0Y;M"J^@GZP,N!TZV:I_\0#ZCH::T
M[^/A@(E46YVC':7[J=LVQ/2,*C^J7>)Q.:I"@!\Z]\EMT Y6]]N96-A#D%>J
M_N^M$(N5DN_4/9M^5LOEM)+N=B;?SCXNYD*5Y>GV-A/"E9"V1TR>0V8L=<H!
MS14!)$NI3A6D'#L%  65:FRK3Z-'-+6*1.5&$P]C-MB$.6P-GF,:>EXQUBI%
M/ZV5^CE:STJE5[15++JM*GB!1K=HTX_K=K\?UW/,GL?VY3EF<: MSZ"SZ;=O
M"HUZZUXKV&##[<]"X[.WIPO^\&[[P$,QWL[6@C0A!S9N=R:KN-]M3,+V;Y,L
MP[%*-0>JBH^2.00\P1H@"A/S:ZECZ.3^"B706-?3IG_:3KI%)%:+A?WJIUOI
M_?9Q5T^>VU9MR"EYAK6UF&T)>2MT-4]UP:J=<"R'F?+>:H6"-^ANZFJA!MTP
MA8+P<$\4[+G/XZ1[_4TM1%':*.;F]%K&<9ZS%(-,2P10+!/ ,IR"6&"8P)A+
MAM&0CKDC"<=&WSL"1LHRM[8ECHIY7?6HJG0TM/?M>%:'\;A=-5<_D)=M1\^;
M8%$2O4_"J'QIQU+^4/ZSLR"']IF='ZCC@F$KLMM!WA4S]=;\6$YB"06D& &!
M4@J02LSKGZ0Y2+6 >8811\3+/C\>8FR4O9$P^F)EC"HA?=/9CH%T)-FKX.F;
M)?V0\2>WL\J'9:?C88:EE[-J'O'#^2O]B_^\,R;E?=WHUOH+;"\M)3"&.I8@
M3GD*$%("\!3%0&BLI2)Q3+%31\33CQ_;A[V5T);(5Y<Z;KD V/Y17P]+SQ^T
M)R)>57C.*WYUH9T3CQZLELYYM7;+Y;1<U>$$JU[;/^A-'$<YR3G522(UT"AE
M $%N-V)" RR0YEC'D&3N46/'SQ_;IUM+:'=/CQL9/<XD3@#H<#9T'2P]?[I;
M1'X+A(C'><MUR QT<N*%D-_)QWG]6\\P3MPVW&G$>9GWSA5:+NN8P+ZAPIUC
MB4?;IKW:R=@NT97_ZR-;++]/&,0Q@I"#E.0)0!G/ 5$D 43C/-9)K 5URBOI
M-/K86&]G>=X>I-]$K)(_8K4"-J.W/@]XLCIXYE1[38[;%J8WR(<SAC[OH%V+
M'MUNT:Z]^A];T?;/G.Z"6MAT:2\)ALV1[@+.46)TIX>,NP72)$>*0RC-?"J2
M 2119JB2,4 843&4FN2:C;'#T=BH=J>/6M7!LV;7O18%PSKK?5\$\TT3RK4&
M,B48H)Q(0)5.@.9,"*:)9 CYE7L9XZLP3'F8O_PPL][SR4V/,SG^ YV.#:A&
M<-;3<=K&<03D*_R/<3+4<4J>J^O3,P<>?%@MRR6;V4*0!TTPFA,O]=$LUNK3
M?#K5\X6]<0)CF<,<49"0Q)8[BR4P.T@()$<YSZBBF'AE/0^OPMA,HN,\HK7D
M427ZL%$+'5Z)8<(:^IWH\2^3FX5P!X@3'9KVWYU1YAQUG\EQK)S=U?@QUM"K
MIRET^,45DG1;5S^:]TPM%DI^MGO4NA,=S.,T)U "D<4,()8D@.<Y KF"4&'$
ML$;89^$[,<;85J:-B/5>_5^B_SO^)3;_+[$NT+KCX+]$,+XQO[+_U^SA(K9:
M/LP7595SMHS^GW]*\OA?ZO^-?K.!\?7/:7(36==]]--JQE:R,)/Z<Q7,^TJ)
M*G-Z[[+$#'03Y\D-QNG^(YM!B[)<*4.3]@FS^?JW\^V;8V4Y-?S>P]QD\5N1
M3[U,;DOFE:](SVO:]NVHQ+NIFP'>1&^KF0BWW+2@$'0].#7.H(3=HN@AH[9=
MVI7RYD]JL?QN2YG9=!:[D:D25^I6]7?JV_*%$?;ODXS+E.=Q!O),48 R# &5
M.0:$(,%Q"IGTZ_7N.O#XR+&6N^*)C= WT4QY=K5S1MZ5-,+CV3N3U"+?1)70
MAXC6@D=?FO]:#:)*A8 VK2]J@9G'<?"!Z<@/DF..\KS_V7T@39@^BS.*!5<@
M%D0 Q$4*B-+8_J23-&,:QGA29Q=\7K+%<G!'AW]8_Z&T_7W++]1],:MJH'!F
M_F"VH,^6@'$\LTE&9*)Q#*B".4 XYH#3Q*Q=<4SC7,0B):B9V=<S^</,ZUK6
M_F;U=6U"CW!*!W<^_8_.J=GS+8TMI^;L)(S5+?0CYM2<!;E'ITZ8G)J*C^K-
M9^4.^J@6U>\FJ5 (DD0#+C,&D)84<*(%R!(J*35O 6->L6YG1QK;%N7SOFOD
MJ?((FR6CYNZ*Q>5\.F6+<OO;+H1^$G4/8KX6RR$(MFS\&C>-8]W(63-J8'YL
MPR(\SYT<;7B^:E/Z).^TWM"QNO.Z7^.;^<)V:]SVP[.M';?_FB0T5YQ@!@2G
M%*#8.H)CS4&F,<N50DJSV*ONL^/ 8V.7V_O[A;IG2Q6]8<6B]OYYUH=VA=R-
M2_H LF=JN= UU';[#5AEVA.?L/6G70<?MC*U)R1'-:M][^_&39_4DA4S)5^S
MA=U:E^O"PP(I9HP80'DB &(0 0(9! E%*,$ZU7'BE%;8/LSH>$>(U>-JRNRI
M]RNE"U%X.ES/H.E&,M=CU#.EK 6,UA)>KG/MS23M( 3EC3-##<H2[>H><L*%
MJ[ON;N:+Y9U:/+[==@1?%[8G&&I."<!YE5R<<\ 1Q" 6.F<PSVV3&+_MS;FA
MQL8$E:3 C/1H3W;_;G"WY5^VK.N[E3D+L>M>)@1PO6]F-ICMB-D#1UQ&(_!V
MYNQP ^]G+JE]O*&Y>$>HFH$?%^J)%?)5<WC\NJYUMZZ,53?@F.!<(<DU!9H2
MVS]58, SJ@'/A<@)ECG'<C*K+']'%WDW09P^&EI_-+OB]!KQ8*5NJQ'(.K3)
MZ3A/;J34(_;/6@IP/1>-^#ME "]T*@I0]\\'P9ZK_3F)\LPU_GS@NES9S^MI
M_?8"MST=WI@7?2*0C'%BIBS'E .$&0-,66-,X4S1#$+S0S\]P-<B^'RP@_7^
MSOII/+V!'3(N:9K'($=:F?TO,BL54C' <4JDYC)5<=)'S^\NH _4ZSOO&7*W
M1:=/('M>;CKU]K8Z#-_<^Q"]9VGJO1%BE,V\#R'JVL3[Z#D=J@LUC[N;ORZ-
MKG^\F2\^*;D2ZV$_V4HMTW)BEI&4)R@'"IM-/$J2!%!&%* IQPSE<0*U4YRY
MQYACX[&7K'R(A&VA5/"5/2SV*+CCB'([C_6$7<_4M0[JN)M'M<B&EQ;16NB:
MQZ)&[/"(>I0U"H_L0*6.U@B;!4#5"&N#\&*-\+1">%&+_TN@&DA^8+7617)\
MU'"UDOQTVZN?Y'EK![Z^_7SWZ?8-$]5:T#@",ZVE0)K8LDG"F/<4 @HE!RI.
M-<U8BM/<Z<3EW !C8^)*Q&@MHP=IG +/@7.OA*1G@KV-/D=WT:=HBTB7'J*G
MH/$@SRLA&H@IZQ='-V*&XL(6W5N)[]1]P[%<B]1[E-9V73='QLOYXV-1>Y1O
M9](VI33\J&;"GD]OFK_MI/;@',,LYB")D00(\PS0!!(@.$08TXRKU"M0SF_X
ML7'?CO25=W%/?K]MMN<\N&VR^T.W9QIM!7:G8V;TI9=4GVZX!=U<>XHPZ-:Z
M&SR'&^N.3^E&<S;^K H_>SM[6BW+=[;K%FQ65JRI5E(C0V=Y#) 4*6 IBVT1
M;HEXHE//0I<M8XV-P"K9(NA'56U8NO%2((1Z)J%MS.)-5 MZ$S6 ]7 8[H!)
M4()I&V]0-G%0_) Z7&X)G./\XON=>6)5:3Y%Q@JBW%;XM@6_&9. "TF )#))
M,T142KQBZAS&'!MO7$C'M6('RG#>P=V-6P*CV?=9PGQV#]X57Y6,[LSO"QN=
M5!U0!FL T &783*7=\8=1]+R,1#.^<HG;NW@3K+AP1]T5:]A$SG_06NU,(91
ME<<P(89H8)PQ((1A'93B!! )-4 )4AJS!%+B[OF_.-S86,<*;(O(EW4Q$;;)
M+I@W4M?Y2QZ.ELN(.WBD@N+8,]]4$'[0ZWHLVP2-M< ^!>4<(?3P7 6%<B _
MUK60^OFWG!%J]79=?LIPOB]GC?8\8>YWA<GUVD_6N'V<+Y:V?-7+>;E\P4IC
MG;"4PTP3!K2T52]SLX%D.*5 Q1(IIEDB8C99SI=LZF85^@K@1=8;,7IT[ZXE
MC*R(UV5]703?S33L$]*>>=LA"ZSJC^ "^=598:ZX]9H==E&(9\T2<X7H4K:8
M\W,Z>O_94V&HH(J0E,5R9=-F9U6@LGRQ6KZ?+_]3+6T0DS4\(<6*@3Q7PIB;
M/ 7FGPJD,,V,14IB);Q*&[H./#83]/=9%5+\9)[WP&Q\M^TBO%OF2ZVW!)[N
M?]>)<'3\]P!OWR[_6N1H5^9H+73$5\O(B!U]-SMC*WA 7[\G5&&]_*Z##^O?
M]X3DR+/O>W^7O;*U_,Q3S9=6?%5V0]YXH*F&D%+#5)1J;K;(>0XX2V. 4\1X
MG%(<QT[>_-91QD9+E9S11M#**^>SASL'ILON-P!$?6]Z3Z#3)2SC+$P^.]P
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MK;,)(5) @E*@.#>DPHD$C' )1)*S+$<ZAA1YU3>O'NO%' -4+;^S8W0J[];
MY,8&_LKW_,G?MFOL7S)\3\&PA<#K1P];WGM/G:.BW?M_[?:9_<5L76RV:9,E
M<#=_9PR(.B;GLUHNI]71[T3'%.<29X!SI '27 &>DP0PQ)!FN4YPYA4KZS3J
MV)9W*W2TV&933#<RFYW'6FB_K]<-?;>/.SBF/7_[%9P_68E_WLU1V4H=?;Z,
MJC=#>*$4E$#<1AZ47[S .*0?OYO]V*E<+">OBH429C*;8L<JS6R)6 TX(2E
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M;=U7LUQOPD>LM'^.>%5NU%8QD//IE"WJ:ZH_>A8T.(VW(^=>BV+/S'FV4&M
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M8\1M0**D"$DE(*!Q1@&B6 $JLQQHF2BL%4Z8<LKS\!MV;)_TY]7C(UM\KVR
MK0+15H-HK8*G=>DV"8Y687!H^[;FVJ'L*Q#4"Z:PUI';T,-:-5YP'%DC?G=W
MK)NGEI;V/B[F7PNIY(OOOQO3YNULD_5V*Y;%UZHUSR2%AJPR)H#.TQB@3&>
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M/MU&W*[2]M,HC?S1=*V CWUZ#G 7,_\:_ 8RZQL1(R-C9(7<'F>% ,G': \
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M6,,Z]MH5/O+L7;B\0^B%L8%>/SY-Y]^5JJ+QZDU2$V"D%64*&OATSC. <,P
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MU5LY-<TIR4HL#?1, %A2"3@R/^6EI$R*4C/L=\@XCMR3,_P.8B=J*>UI94V
MDRBNZ_HP>##>M)9X1 _;K05S6]K_A<KB>J[9I K@NLK^ERIUZ[D@H8O:^DX_
M["/X=KX1B]7F>:T>=%O.3ZK*_Z\<B&=B;@X55EF185[B$IB/' 00"@U8)A50
M!!>I*BA2N5/H<R!YIO;1JF(*P$]GM.;W<;IUD=P^.B-"_[K'-<GO4>KC!L(O
M*+'?*M.HA!T(P%,B#C5LX+3=JK3*3!"L,I034.99"J#B$%#.%,@P+C5!I1+,
M*^"G?[JIT6.=+/;4F5X:*+.TAMF- <.!%YG@KF275N*.D%]Z!,LX&:;UE-/(
M,3U2WSG+]/BN6YHA5STR-U5RQ<OA8U_DTEAAMOQN40H !3<6&<H4$(1QS5+)
MBPSY]^#MG&MJ=%(+.:3C;C>4;JP1"*#(E+'KI%O+F?Q>2QJG4X #(A'ZXW;/
M]PJ]<'L5[^Y[VW_+P*J89_E7^P-.DAJC VH-.$$%@+FQ/WC!.4"EAA)EN12E
MU^'QY:FF1A&=J94#SX][ '9CCC"P12:.@8CY5X^\"D;8DI"7IQNWSN-5M<^*
M-UZ_XX8#$7[=8\6O=U4]\5BU:B(M*TF?V>*+6C_F,ZUDJ96PW0<) Q +"2C-
M#3%1GBFB<XIR_V:$X^HP-8K;R0U8X_%NUX[;BYXLYEHE/]AVZH/.<4=^3CS.
M3::[^G^A,Y06$AUG*.UJ>X<GRN(1^#SE==8R_-G*R'J,?\[R.@O5>>;R2J(,
M^^:VAGO@B_G7NA('A'F&2PE!7BH$($PA($6* ,%*&=,<8_/)]/DJ=LXRM>]6
MFTI6>RG]/DW=<+I]/&X&*3*]M_%YN(Z/-^'VZA^4$KMG&I6T>I4]I97^BP<&
M=N_\@;^I1Z[6LU(+61*BK=O.O/)I@0%#&@.%1(XYRC!B7H;PR?A3>]G?#7/S
MGZ+F]F;?@$7D=[K5N;.6+614=K?688.Q3^88-P:[6\&ST.L+EP4M+%(')QYJ
M7*1I5M LXR!E*K>UB"A@669>9U8(CDI=:.[53,9MVJF]Y;VE1>YNB"1V6P3'
M36-P:&/O\WHJC>SBD4<L-7(!J#%JC9Q./85B(Q?@<*PV<NGNP4< :S/!Q_5*
MJ\W&&"UL\;/:EUJ:88PS1,PV0R&:F6U&*0&!4 &(>:Z4Y 6&7L$'_=--C9P:
M:6WXP5[<1"O? \0K&#N?! 1"+OYI0 5:6]+$BKHOJ!;T1, !E-"G GU3CGTR
MX*!^Q^F RUT#"N$V(^]JZMXOY</VFUHW([<JN<V*4I:Y*#7(4$',7H::O4R.
M"U!F3 I:"D4A<2EZ[3>M%[^,50G;HUZK.[[]G!(/M9&X92=T8J1.*K'WQ1I_
M]2UPZ8FL1T'<* B/5!=WA_2N.'L50+:JD!;G2(<JD^N-6&^U7/?1QBN:ZZWA
M4>U<_[MO[%)019WLQGV9E<*VUS.,+262 ,JT!%PH K)2%CB52BI<^)B#%^:9
MFAWXT0QFG_COMM"?W:DNK+C[6KHO SL7G( K%>=(4 :D =9:V!+P-+7UM+A@
M)3?_DL%!C2!N '>T=A!1$'6SK /@%/FS=^@+48EXMZ?>RS@-[P_1C4*<+A$G
M<[U.KXANA2]VC+APN7_5I+?-E_S+FBTW\SK?X&FUWLY$P5B)B3W68]C&WD%@
M;LZ XAG!N=*$Y=JU@-*E2:9&L3LYDX.@22VI>UVEBX#V\T HF"*3P "$O"HO
M78-@<!&FBP./5H_IFFKMTDQ7KWV=4@*7XPZ.L\>M4TX0VX3.& P (H0 4Y0
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MF5S\X?&J%GX%@,&EPB^-.UJ=\"N*M8N$7[MT8-QCJY_I<</3G5LQIXHP1C&
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M;)27\I(*NU?PXK_?$&;+KT=N\8N16U72G3UF.P[_S69Y"3.N,@44U!F %"E
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MIQJ[]17'VD7?T*&MGE'T=)"K%R&-P":[NZMM+\RSB_7GQ7+ZGY@G9"FH@CJ
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M!R)V5F(<Q?T17)CO219$0.V!^A*_XFRQZ=!UN:M)-*((58O<HG!5\P<(-FA
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MVS:%TX=0.WA>_8EMO8:R'$_ET5G^7Q>K[3#2][B)$GY<=-VQ%Z+P&#C8XLD
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MQ]<?M@J[F;77 [-'!95;#P 6Z90@,8%[)';X7+._R&/)6;KHHJ&;K5.GP0,
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M.W!6%M#!)4G7A=79MM&I!]/\G*;P[8._@W))CY?J&&[\0^M?#"JF9"TH#LF
M2M9OQV,DM$G(&(G]PV8\'U3#-)*IO,VQ>ZQ$GQ%RKZMC6,@F\PPZ"@05:P=5
MKF4US P94\QJ.Z"ZW;.>J=F+Q_AP>HC\GAL\-U4R1+_-(EE@T3C:H#$0F5;
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MH^/OZZC RY$"@5F130K 5:HC**(G#\P*B$YE$73*60P T$<H'=.\F:$ >JP
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M>7,^@NIA4]Y/@=Z3R73HF,KMUXU/GY;XB4[KU16R,6LFQI7 @Q"0HN/$QA+
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MO/OVE[*-B,]V*G,$6([6EC^'VY#?-[C>=*$S3Y5$HM5"6JV R:A!U20OE)3
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M;ZY^7FP6[P<1_)WBM:%/.4FG<DETYE(;/H-/=3NP@FP4!5<Q&!'W<D;TZQ_
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MW>N=Q=[W'^&M*._\-NH.8N,A!#5=\]J]V!R)6!@G H!)A4?#Y7^-Y*_S!/#
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M13[S06#YZS]/=!]*GOP/4$L#!!0    ( ,^ J526[W!Z/ 4  '\K   6
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MU]A?<7*%81J&Q,>L#N+!2;BI0[IBV0H)?3F%K?##OCR8GA]9QV9/Q2"@#%!
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M+H,6S_QJJKHD>_(/4$L! A0#%     @ SX"I5/\K*;BA:0$ 1:(. !$
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M &MR>7,M,C R,C S,S%?<')E+GAM;%!+ 0(4 Q0    ( ,^ J51%M&2PTP<
M *@I   6              "  >P9" !K<GES+3(P,C(P,S,Q97@S,3$N:'1M
M4$L! A0#%     @ SX"I5$1@^@_%!P  @RD  !8              ( !\R$(
M &MR>7,M,C R,C S,S%E>#,Q,BYH=&U02P$"% ,4    " #/@*E4EN]P>CP%
M  !_*P  %@              @ 'L*0@ :W)Y<RTR,#(R,#,S,65X,S(Q+FAT
7;5!+!08     "@ * )@"  !<+P@    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
